backgroundcas
studi
differ
monoclon
antid
reagent
test
human
shown
equival
efficaci
donor
deriv
polyclon
antid
addit
monoclon
antid
result
paradox
enhanc
alloimmun
effect
also
seen
donor
deriv
antid
case
transgen
mice
express
human
rbc
alloantigen
select
rbc
wildtyp
mice
becom
alloimmun
rbc
expos
either
transfus
pregnanc
latter
lead
hdfn
analog
antid
human
polyclon
mous
serum
deriv
prevent
alloimmun
thu
mous
serv
model
antibodi
mediat
immun
regul
alloimmun
studi
designmethod
igg
subtyp
isol
independ
variabl
engin
panel
igg
subtyp
switch
variant
monoclon
monoclon
isol
murin
igg
subtyp
antigenbind
domain
effect
igg
subtyp
clearanc
alloimmun
transfus
rbc
test
role
fcgriib
inhibitori
fcgr
mice
human
test
use
fcgriib
ko
mice
role
activ
fcgr
afcgr
test
use
novel
condit
knockout
mous
confcgr
common
gamma
chain
requir
express
murin
afcgr
delet
upon
exposur
cre
recombinas
resultsfind
signific
clearanc
rbc
observ
significantli
decreas
wherea
increas
alloimmun
studi
exampl
suppress
enhanc
antibodi
fcgriib
ko
mice
clearanc
unaffect
suppress
elimin
enhanc
alter
afcgr
delet
tissu
clearanc
observ
either
subtyp
enhanc
elimin
suppress
unaffect
tissu
specif
delet
afcgr
demonstr
afcgr
express
dendrit
cell
dc
macrophag
requir
enhanc
conclus
similar
observ
human
monoclon
antirbc
antibodi
prevent
alloimmun
wherea
other
enhanc
igg
subtyp
determin
inhibit
vs
enhanc
inhibit
function
fcgriib
depend
mechan
also
lack
clearanc
mainten
suppress
mice
lack
afcgr
indic
clearanc
requir
suppress
find
consist
data
murin
human
studi
enhanc
requir
express
afcgr
dc
follow
studi
requir
see
find
translat
human
backgroundcas
studi
transfusionrel
acut
lung
injuri
trali
remain
common
caus
death
blood
transfus
therapi
mous
model
trali
reli
administr
mhc
class
mhc
monoclon
antibodi
mab
mice
cognat
mhc
antigen
howev
critic
site
cognat
antigen
express
elucid
hypothes
endotheli
express
mhc
necessari
develop
trali
studi
designmethod
condit
mhc
knockout
mice
background
gener
cross
flox
microglobulin
mice
congen
express
mous
cellspecif
cre
strain
delet
mhc
myeloid
cell
lysmcr
endotheli
cell
platelet
trali
model
inject
mhc
mab
lpsprime
mice
mgkg
ip
lung
injuri
measur
use
extravascular
lung
water
lung
vascular
permeabl
ilabel
albumin
measur
endotheli
express
mhc
within
lung
left
lung
remov
mhc
quantif
use
flow
cytometri
one
week
pneumonectomi
mice
challeng
trali
model
resultsfind
mice
suscept
trali
signific
differ
excess
lung
water
vs
ml
lung
vascular
permeabl
vs
ml
compar
balbc
wildtyp
control
x
x
mice
lack
mhc
express
platelet
fulli
suscept
trali
show
signific
differ
excess
lung
water
vs
ml
lung
vascular
permeabl
vs
ml
lung
neutrophilplatelet
aggreg
format
vs
surviv
hour
vs
logrank
test
compar
x
control
x
x
mice
reduc
mhc
express
lung
endotheli
cell
neonat
tamoxifen
administr
mfi
reduct
vs
x
control
trali
challeng
tamoxifentr
x
x
mice
lowtointermedi
express
mhc
signific
reduct
excess
lung
water
vs
ml
lung
vascular
permeabl
vs
ml
compar
control
high
level
mhc
express
x
x
lysmcremic
lack
mhc
express
neutrophil
experi
suscept
trali
ongo
conclus
trali
result
cognat
antibodi
recognit
endotheli
mhc
vast
endotheli
surfac
area
lung
firstpass
transfus
blood
product
lung
may
explain
pulmonaryrestrict
organ
injuri
transfus
cognat
antibodi
backgroundcas
studi
zika
viru
zikv
associ
sever
neurolog
consequ
fetus
adult
potenti
transfus
transmiss
tt
rna
persist
report
whole
blood
wb
long
clearanc
viremia
plasma
rais
concern
risk
tt
plasma
base
nucleicacid
amplif
test
nat
dynam
zikv
persist
asymptomat
infect
well
understood
need
understand
natur
histori
zikv
infect
sought
character
dynam
infect
prospect
enrol
zikv
blood
donor
studi
designmethod
donor
identifi
investig
zikv
nat
screen
enrol
longitudin
follow
assess
viral
serolog
persist
clinic
outcom
plasma
rbc
obtain
index
donat
blood
urin
saliva
semen
sampl
collect
prospect
week
follow
index
donat
donor
detail
symptom
questionnair
administ
studi
visit
blood
compart
bodi
fluid
test
zika
rna
real
time
rtpcr
plasma
sampl
test
zika
specif
igm
igg
antibodi
resultsfind
percent
zikv
sampl
follow
number
sampl
test
parenthesi
sampl
type
sampl
interv
summar
tabl
plasma
viremia
declin
rapidli
index
donat
wherea
rbcand
wbassoci
viral
rna
persist
month
peripher
blood
mononuclear
cell
pbmc
associ
viru
detect
intermitt
low
level
wane
month
urin
saliva
detect
decreas
significantli
week
undetect
month
donor
enrol
acut
preseroconvers
stage
infect
develop
multipl
zikv
relat
symptom
week
post
index
donat
compar
donor
detect
postseroconvers
conclus
zikv
rna
persist
cellular
blood
compart
sever
month
follow
clearanc
plasma
bodi
fluid
higher
rate
symptom
previous
report
persist
zika
rna
rbc
unknown
implic
blood
screen
current
reli
plasma
test
infect
studi
progress
wb
test
may
valu
extend
detect
acut
infect
diagnost
monitor
pregnant
women
iron
statu
novel
risk
factor
iron
deplet
divers
donor
popul
bryan
r
spencer
yuelong
guo
ritchard
g
cabl
joseph
e
kiss
michael
paul
busch
grier
page
staci
endresdigh
steve
kleinman
simon
glynn
alan
mast
nhlbi
recipi
epidemiolog
donor
evalu
studyiii
redsiii
american
red
cross
rti
intern
american
red
cross
blood
servic
blood
system
inc
blood
system
research
institut
univers
british
columbia
nih
nhlbi
blood
research
institut
nhlbi
backgroundcas
studi
blood
center
regul
unit
state
us
evalu
strategi
minim
iron
deplet
blood
donor
logist
donor
manag
might
differ
across
blood
center
optim
approach
may
also
vari
accord
biolog
behavior
differ
across
subpopul
donor
studi
donor
conduct
predominantli
caucasian
popul
may
differ
racialethn
minor
donor
iron
metabol
capac
undergo
repeat
phlebotomi
studi
designmethod
donor
enrol
us
blood
center
ferritin
test
studi
popul
enrich
racial
minor
africanamerican
aa
asian
hispan
hisp
super
donor
complet
donat
two
year
without
low
hemoglobin
deferr
minor
donor
remain
nonhispan
white
nhw
donor
unselect
popul
specif
elig
criteria
subject
complet
questionnair
risk
factor
iron
deplet
logist
regress
use
identifi
demograph
behavior
predictor
absent
iron
store
ai
ferritin
ngml
low
ferritin
lf
ferritin
ngml
resultsfind
across
subject
ai
lf
high
degre
variabl
base
demograph
factor
donat
behavior
model
stratifi
race
expect
pattern
common
group
includ
sharp
increas
risk
increas
donat
intens
larg
decrement
risk
femal
year
old
model
includ
subject
race
independ
predictor
ai
lf
control
age
sex
bodi
weight
donat
frequenc
factor
tabl
aa
donor
show
decreas
risk
ai
compar
nhw
hisp
donor
higher
risk
daili
use
exogen
iron
reduc
risk
lf
ai
respect
estim
benefit
lessthandaili
use
lower
protect
regular
use
antacid
associ
greater
increment
risk
report
use
hormon
supplement
show
oppos
effect
male
femal
use
oral
contracept
estrogen
femal
reduc
risk
male
report
current
use
supplement
testosteron
twice
estim
risk
ai
conclus
larg
studi
confirm
high
preval
lf
ai
us
donor
princip
risk
factor
age
sex
donat
frequenc
divers
popul
studi
questionnair
data
donor
identifi
addit
demograph
behavior
risk
factor
secondari
import
develop
iron
mitig
strategi
practic
base
age
gender
could
refin
depend
given
blood
center
oper
context
donor
popul
data
report
mean
p
compar
hod
rbc
mfi
median
fluoresc
intens
backgroundcas
studi
storag
red
blood
cell
rbc
undergo
multipl
morpholog
biochem
molecular
modif
collect
call
storag
lesion
proport
clear
rbc
correl
storag
durat
may
respons
rapid
clearanc
transfus
rbc
reduc
transfus
yield
shown
use
imag
flow
cytometri
subpopul
morpholog
alter
rbc
accumul
storag
reduc
surfac
area
small
rbc
srbc
suggest
rapid
elimin
spleen
hour
follow
transfus
hypothesi
remain
clarifi
sinc
physiolog
mechan
rbc
clearanc
remain
precis
identifi
studi
designmethod
murin
young
old
rbc
respect
storag
transfus
differ
model
includ
splenectom
macrophagedeplet
mice
flow
cytometri
use
determin
kinet
clearanc
transfus
yield
quantifi
rbc
retent
organ
accumul
storag
posttransfus
disappear
srbc
analyz
imag
flow
cytometri
resultsfind
use
murin
model
transfus
confirm
posttransfus
yield
decreas
storag
durat
vs
storag
clearanc
storagedamag
rbc
mediat
spleen
macrophag
shown
signific
improv
posttransfus
yield
observ
splenectom
macrophagedeplet
group
human
observ
accumul
subpopul
small
rbc
mous
small
rbc
msrbc
reduc
project
surfac
area
alter
morpholog
msrbc
disappear
rapidli
circul
control
splenectom
mice
decreas
posttransfus
contrast
macrophagedeplet
mice
msrbc
kept
circul
posttransfus
msrbc
complet
disappear
model
suggest
import
elimin
presenc
compens
clearanc
mechan
control
mice
storagedamag
rbc
mostli
retain
spleen
also
bone
marrow
bm
retent
observ
liver
kidney
lung
macrophagedeplet
mice
retent
decreas
spleen
bm
convers
elev
retent
observ
bm
splenectom
mice
associ
transient
retent
kidney
liver
conclus
storag
murin
rbc
damag
rbc
accumul
elimin
follow
transfus
via
spleenmacrophagemedi
mechan
includ
observ
human
subpopul
small
rbc
undergo
rapid
macrophagemedi
clearanc
increas
transfus
yield
absenc
spleen
macrophag
suggest
recipi
function
state
one
determin
factor
age
depend
relaps
remit
autoimmun
hemolyt
anemia
murin
model
andrea
sut
ling
wong
amanda
l
richard
krystalyn
e
hudson
backgroundcas
studi
breakdown
toler
rbc
antigen
may
result
develop
pathogen
autoantibodi
autoab
lead
autoimmun
hemolyt
anemia
aiha
sever
sometim
fatal
diseas
aiha
human
number
known
featur
includ
increas
frequenc
age
tendenc
relaps
remit
howev
mechan
behind
observ
understood
gain
insight
toler
loss
thereof
rbc
autoantigen
util
hod
mous
express
rbcspecif
tripl
fusion
protein
consist
hen
egg
lysosym
hel
ovalbumin
ova
duffi
hod
hod
mice
bred
transgen
mous
express
cell
receptor
specif
ova
peptid
hod
present
mhcii
otii
mice
thu
hod
otii
mice
predispos
autoreact
cell
studi
designmethod
four
cohort
hodxotii
mice
mice
cohort
bled
monthli
month
assess
autoab
product
peripher
rbc
stain
anticompl
mous
immunoglobulin
ab
spleen
weigh
splenocyt
stain
assess
presenc
rbc
progenitor
statist
analysi
hod
otii
autoab
vs
hod
otii
autoabv
hod
otii
perform
use
kruskalw
test
correct
multipl
test
dunn
test
resultsfind
otii
cell
delet
thymu
hod
otii
mice
rather
matur
peripheri
despit
peripher
autoreact
cell
detect
autoab
observ
hod
otii
howev
age
hod
otii
posit
rbc
autoab
month
thereaft
autoab
mice
stop
produc
autoab
within
two
month
onset
remain
autoab
free
throughout
studi
cohort
autoab
mice
femal
hod
otii
autoab
mice
also
enlarg
spleen
compar
hod
otii
autoaband
hod
otii
mice
vs
resp
p
may
due
rbc
consumpt
extramedullari
erythropoiesi
consist
increas
erythropoiesi
elev
number
rbc
progenitor
hi
inter
observ
spleen
hod
otii
autoab
mice
hod
otii
autoaband
hod
otii
vs
resp
p
moreov
autoab
deposit
found
resp
rbc
hod
otii
autoab
mice
analyz
conclus
sever
featur
known
exist
human
aiha
observ
includ
agedepend
autoab
product
relaps
autoimmun
onset
increas
frequenc
femal
model
may
serv
experiment
system
investig
mechan
aiha
reduct
neutrophil
number
risk
factor
rbc
alloimmun
amanda
l
richard
christoph
tormey
krystalyn
e
hudson
backgroundcas
studi
red
blood
cell
rbc
alloimmun
occur
transfus
recipi
exclud
abo
rhd
underli
factor
influenc
alloimmun
poorli
understood
thu
current
reliabl
way
predict
make
alloantibodi
patient
receiv
multipl
rbc
unit
sever
separ
transfus
higher
risk
alloimmun
likewis
certain
diseas
state
higher
rate
alloimmun
myelodysplasct
syndrom
md
sickl
cell
diseas
patient
howev
despit
chronic
transfus
patient
never
develop
rbc
alloantibodi
recent
report
poli
c
elicit
inflamm
lead
enhanc
alloimmun
rate
correl
increas
splenic
neutrophil
pmn
number
addit
rbc
transfus
inflam
recipi
lead
enhanc
erythrophagocytosi
pmn
test
hypothesi
pmn
regul
rbc
alloantibodi
gener
studi
designmethod
mice
mice
treat
pb
deplet
pmn
follow
poli
c
elicit
inflamm
final
transfus
allogen
diolabel
rbc
express
synthet
antigen
hod
helovaduffi
multipl
splenic
cellular
subset
evalu
dio
fluoresc
indirect
measur
rbc
consumpt
hour
posttransfus
antihod
alloantibodi
gener
assess
day
posttransfus
flow
cytometri
human
retrospect
mean
white
blood
cell
wbc
pmn
count
collect
chronic
transfus
md
patient
va
connecticut
healthcar
alloimmun
patient
wbc
pmn
count
assess
day
exposur
alloimmun
rbc
unit
wherea
count
averag
entireti
rbc
therapi
nonalloimmun
patient
patient
match
number
rbc
transfus
resultsfind
mice
mfi
antihod
antibodi
significantli
increas
pmndeplet
mice
compar
control
experi
p
mani
control
mice
made
alloantibodi
nonrespond
pmndeplet
mice
made
detect
antihod
pmn
deplet
also
led
signific
reduct
leukocyt
suggest
lack
compensatori
mechan
rbc
consumpt
absenc
pmn
also
shift
rbc
consumpt
macrophag
immunestimul
dendrit
cell
subset
flow
cytometr
analysi
reveal
pmn
intern
rbc
upregul
express
coinhibitori
molecul
eg
compar
pmn
without
intern
rbc
mous
thu
pmn
may
regul
alloimmun
antigen
present
andor
inhibitori
signal
human
alloimmun
md
patient
signific
decreas
pmn
compar
nonalloimmun
p
signific
differ
detect
mean
wbc
count
two
arm
conclus
data
demonstr
murin
human
set
pmn
may
play
signific
role
regul
rbc
alloimmun
may
provid
key
insight
predict
patient
becom
alloimmun
express
character
respond
rbc
immun
vingert
mari
tamagn
sadaf
pakdaman
anoosha
habibi
philipp
bierl
rachid
djoudi
franc
pirenn
ef
ile
de
franc
laboratori
excel
grex
imrb
aphp
universit
e
pari
est
backgroundcas
studi
posttransfus
alloimmun
induc
lifethreaten
hemolyt
transfus
reaction
human
mechan
respons
rbc
alloimmun
fulli
defin
cell
major
antibodi
product
alreadi
shown
respond
patient
major
antirbc
cell
profil
contrast
whole
blood
nonrespond
patient
unexpect
express
circul
cell
phenotyp
phenotyp
usual
associ
presenc
tfh
cell
special
product
antibodi
suggest
activ
circul
tfh
could
hi
profil
differenti
express
essenti
cell
domicili
lymph
node
encount
b
cell
major
b
cell
differenti
antibodi
product
other
chemokin
receptor
like
also
differenti
circul
tfh
subpopul
studi
interest
phenotyp
function
lymphocyt
paradox
highli
repres
nonrespond
patient
studi
designmethod
membran
function
phenotyp
circul
cell
compar
group
transfus
sickl
cell
patient
alloimmun
nonalloimmun
patient
analysi
also
perform
nontransfus
healthi
control
assay
perform
whole
blood
without
separ
procedur
known
alter
express
chemokin
receptor
resultsfind
hi
subpopul
express
ident
transfus
group
control
express
show
differ
transfus
group
control
howev
nonrespond
patient
express
strong
independ
express
aim
determin
help
circul
cell
product
antibodi
cell
purifi
flow
cytometri
cocultur
day
b
cell
presenc
seb
protein
level
antibodi
seb
stimul
ident
subpopul
transfus
group
control
conclus
paradox
presenc
circul
cell
nonrespond
transfus
patient
appear
particular
function
promot
absenc
humor
respons
howev
respond
patient
high
express
circul
cell
suggest
remark
migratori
properti
toward
secondari
lymphoid
organ
could
facilit
alloimmun
respons
conclus
studi
profil
express
cell
could
help
differenti
respond
nonrespond
patient
rbc
immun
prime
cell
one
rbc
alloantigen
enhanc
subsequ
alloimmun
seema
r
patel
ashley
bennett
kathryn
girardpierc
conni
arthur
amanda
mener
patti
zerra
christoph
tormey
jeann
hendrickson
sean
stowel
emori
univers
yalenew
hospit
yale
univers
emori
univers
school
medicin
backgroundcas
studi
red
blood
cell
rbc
alloantibodi
increas
probabl
transfusionrel
complic
patient
becom
alloimmun
follow
transfus
howev
individu
gener
alloantibodi
appear
experi
increas
rate
addit
alloantibodi
format
follow
subsequ
transfus
howev
immun
one
rbc
alloantigen
prime
immun
complet
distinct
alloantigen
remain
unknown
though
cell
help
classic
occur
direct
recognit
peptid
resid
within
target
b
cell
antigen
individu
develop
antibodi
toward
one
rbc
alloantigen
experi
increas
rate
antibodi
format
complet
distinct
rbc
alloantigen
observ
suggest
cell
respond
one
alloantigen
may
directli
facilit
immun
complet
distinct
rbc
alloantigen
studi
designmethod
recipi
transfus
kel
rbc
presenc
absenc
poli
c
pic
follow
transfus
hod
rbc
kel
rbc
rbc
express
hod
kel
hod
x
kel
mixtur
hod
kel
rbc
hod
kel
examin
role
cell
pickel
prime
recipi
cell
deplet
prior
transfus
addit
recipi
adopt
transfer
cell
pickel
prime
donor
follow
transfus
hod
rbc
hod
x
kel
rbc
antihod
antikel
alloantibodi
format
evalu
use
indirect
immunofluoresc
stain
resultsfind
kel
rbc
transfus
presenc
pic
pickel
enhanc
antikel
antibodi
product
celldepend
process
prime
event
directli
facilit
antihod
antibodi
format
follow
subsequ
hod
x
kel
rbc
transfus
p
pickel
prime
recipi
transfus
hod
kel
rbc
hod
rbc
alon
fail
impact
antihod
antibodi
format
abil
immun
kel
boost
humor
respons
hod
antigen
follow
hod
x
kel
rbc
transfus
requir
kel
prime
presenc
pic
cell
deplet
prevent
pickel
prime
recipi
boost
antihod
antibodi
respons
p
transfer
cell
pickel
prime
recipi
likewis
directli
facilit
antihod
antibodi
format
follow
hod
x
kel
rbc
transfus
p
conclus
result
demonstr
cell
prime
one
rbc
alloantigen
directli
enhanc
immun
respons
complet
distinct
rbc
alloantigen
suggest
mechan
wherebi
alloantibodi
respond
may
exhibit
increas
rate
addit
alloantibodi
backgroundcas
studi
platelet
refractori
remain
signific
clinic
problem
yet
mechan
occur
incomplet
understood
immunemedi
platelet
clearanc
antiplatelet
alloantibodi
play
signific
role
patient
detect
alloantibodi
manag
transfus
hlamatch
platelet
still
mani
patient
refractori
even
receiv
hlamatch
platelet
shown
previous
cell
play
direct
role
platelet
clearanc
allogen
platelet
clear
within
hour
post
transfus
b
celldefici
mmt
recipi
mice
ie
absenc
antiplatelet
alloantibodi
deplet
cell
prevent
clearanc
sinc
minor
antigen
differ
still
exist
donor
hlamatch
platelet
recipi
hypothes
minor
antigen
alon
may
mediat
clearanc
otherwis
hlamatch
platelet
studi
designmethod
test
whether
minor
antigen
stimul
celldepend
platelet
clearanc
examin
platelet
refractori
use
mova
oti
transgen
mice
leukoreduc
donor
platelet
mova
mice
express
membranebound
form
chicken
ovalbumin
thu
present
ovalbumin
peptid
complex
murin
mhc
class
label
vivowith
fluoresc
dye
cfse
transfus
wildtyp
wt
mice
oti
mice
whose
cell
receptor
recogn
specif
ovalbumin
peptid
context
mhc
class
experi
oti
mice
prime
mova
wt
splenocyt
one
week
prior
mova
platelet
transfus
other
wt
mice
adopt
transfer
oti
splenocyt
hour
mova
platelet
transfus
platelet
recoveri
measur
immedi
transfus
well
hour
day
resultsfind
transfus
mova
platelet
oti
mice
result
signific
platelet
clearanc
compar
transfus
wt
platelet
clearanc
kinet
demonstr
platelet
loss
start
hour
peak
hour
similar
whether
oti
mice
previous
prime
mova
splenocyt
specif
mova
platelet
recoveri
oti
recipi
versu
wt
recipi
hour
p
wherea
transfus
wt
platelet
either
oti
wt
recipi
approxim
hour
transfus
adopt
transfer
oti
cell
wt
mice
recapitul
effect
signific
mova
platelet
clearanc
hour
compar
wt
platelet
clearanc
p
conclus
work
extend
abil
cell
mediat
platelet
clearanc
minor
antigen
provid
insight
potenti
etiolog
platelet
refractori
patient
receiv
hlamatch
product
studi
also
hold
implic
clinic
manag
nonantibodymedi
platelet
refractori
patient
therapi
direct
toward
immunomodul
cell
respons
may
prove
benefici
backgroundcas
studi
alloimmun
major
histocompat
mhc
antigen
common
complic
transfus
neg
impact
subsequ
transfus
transplant
previous
demonstr
pathogen
reduct
riboflavin
uv
light
effect
rapidli
kill
donor
white
blood
cell
wbc
block
abil
stimul
allogen
respons
vitro
furthermor
treatment
allogen
platelet
rich
plasma
prp
prevent
alloimmun
mice
provid
partial
antigenspecif
toler
subsequ
transfus
cell
die
differ
pathway
either
toler
inflammatori
sought
determin
cell
death
pathway
trigger
well
evalu
immunogen
prp
contain
wbc
kill
method
studi
designmethod
wbcrich
prp
prepar
mous
blood
treat
wbc
prepar
parallel
blood
treat
known
induc
either
apoptosi
necrosi
membran
integr
phosphatidylserin
exposur
caspas
activ
chromatin
condens
evalu
flow
cytometri
balbc
recipi
transfus
either
treat
wbcrich
prp
treat
wbcpoor
prp
either
alon
ad
untreat
apoptot
necrot
wbc
gener
allogen
donor
blood
second
transfus
untreat
wbcrich
prp
given
week
later
allorespons
compar
mice
given
transfus
second
untreat
transfus
resultsfind
treat
wbc
pattern
phosphatidylserin
exposur
loss
membran
integr
consist
earli
apoptosi
fail
demonstr
signific
caspas
activ
clear
chromatin
condens
alloantibodi
respons
transfus
significantli
higher
mice
previous
expos
untreat
p
necrot
p
wbc
given
treat
apoptot
wbc
ex
vivo
cytokin
respons
stimul
wbc
reduc
recipi
either
apoptot
wbc
enhanc
recipi
untreat
necrot
wbc
conclus
mechan
wbc
death
follow
treatment
share
membran
characterist
earli
apoptosi
distinct
classic
apoptosi
howev
treat
apoptot
wbc
fail
trigger
allorespons
offer
protect
subsequ
alloexposur
backgroundcas
studi
mitochondrialess
red
blood
cell
rbc
oxygen
main
substrat
oxid
reaction
result
oxid
damag
consid
one
major
caus
factor
develop
rbc
storag
lesion
oxygen
satur
venou
blood
gener
assum
around
measur
central
venou
line
howev
recent
investig
level
freshli
prepar
leukocytereduc
red
cell
concentr
lrrcc
reveal
unexpectedli
wide
distribut
mean
yoshida
et
al
blood
transfus
present
studi
undertaken
determin
distribut
lrrcc
produc
mediums
blood
center
use
novel
noninvas
probe
addit
quantit
metabolom
carri
examin
redox
statu
store
rbc
variou
level
studi
designmethod
unit
lrrcc
examin
five
consecut
day
repres
collect
unit
period
region
blood
center
unit
process
room
temperatur
within
hour
blood
collect
measur
noninvas
pvc
bag
immedi
prior
refriger
employ
reson
raman
spectrometri
pendar
microvascular
oximet
pendar
technolog
cambridg
addit
process
method
rcc
volum
blood
type
gender
process
time
record
analys
separ
studi
lrrcc
human
volunt
store
normox
hyperox
hypox
condit
day
rang
prior
uhplcm
metabolom
analys
presenc
c
n
deuter
intern
stableisotop
label
standard
absolut
quantit
resultsfind
measur
carri
noninvas
blood
center
yield
similar
wide
distribut
previou
studi
unit
lrrcc
procur
sampl
invas
within
hour
blood
collect
yoshida
ibid
shape
distribut
appear
near
normal
mean
median
rang
interquartil
rang
iqr
male
donor
show
higher
compar
femal
donor
p
correl
observ
level
process
time
donor
age
blood
type
metabolom
workflow
indic
lower
level
amelior
energi
oxid
metabol
lesion
lower
level
yield
higher
rate
gsh
synthesi
higher
nadph
concentr
higher
gsh
gssg
nadphnadp
ratio
lower
supernat
urat
consumpt
lower
purin
oxid
surprisingli
wide
distribut
start
level
observ
lrrcc
manufactur
blood
center
use
room
backgroundcas
studi
cellular
prion
protein
prp
c
gpianchor
cell
surfac
glycoprotein
express
mainli
brain
also
peripher
organ
includ
blood
bone
marrow
bm
lymphoid
tissu
prp
c
convert
posttransl
scrapieprp
prp
sc
involv
pathogenesi
neurodegen
diseas
includ
creutzfeldtjakob
diseas
kuru
human
scrapi
bovin
spongiform
encephalopathi
anim
howev
biolog
function
prp
c
yet
conclus
elucid
studi
designmethod
studi
prp
c
knockout
mice
ko
util
investig
role
prp
c
hematopoiet
system
control
age
sexmatch
prp
c
transgen
mice
harbor
slightli
augment
prp
c
express
peripher
blood
examin
hematolog
analyz
establish
count
bone
marrow
thymu
spleen
lymph
node
peripher
blood
harvest
analyz
flow
cytometri
use
comprehens
panel
fluorochromeconjug
antibodi
specif
hematolog
cell
precursor
lineag
histolog
bone
marrow
spleen
thymu
lymph
node
evalu
light
microscopi
resultsfind
complet
blood
count
cbc
show
signific
increas
wbc
ko
mice
closer
analysi
wbc
differenti
reveal
elev
number
wbc
ko
mice
due
lymphocytosi
specif
ko
mice
increas
absolut
lymphocyt
count
ko
l
vs
wt
l
p
well
higher
lymphocyt
percentag
compar
control
ko
mice
also
trend
toward
higher
hemoglobin
rbc
hematocrit
compar
wt
mice
addit
platelet
count
ko
mice
higher
control
mice
interest
mean
platelet
volum
indic
platelet
size
significantli
increas
ko
mice
compar
control
ko
fl
vs
wt
fl
comprehens
flow
cytometr
analysi
cell
lineag
reveal
signific
differ
number
rbc
megakaryocyt
bm
lymphocyt
thymu
spleen
lymph
node
histolog
analysi
bm
thymu
spleen
lymph
node
tissu
ko
wt
anim
fail
show
morpholog
differ
two
group
conclus
absenc
prp
c
result
signific
leukocytosi
specif
higher
absolut
count
percentag
lymphocyt
well
larger
platelet
peripher
blood
appear
affect
hematopoiesi
lymphopoiesi
find
indic
prp
c
might
critic
surviv
traffick
lymphocyt
peripher
blood
molecular
mechan
underli
observ
chang
lymphocyt
platelet
whether
involv
function
chang
cell
subject
futur
studi
potenti
role
regulatori
cell
deriv
exosom
immun
modul
yime
yang
rufeng
xie
jie
yang
blood
engin
laboratori
shanghai
blood
center
backgroundcas
studi
exosom
defin
one
type
membran
vesicl
secret
extracellular
space
type
cell
report
involv
intercellular
commun
mediat
biolog
process
human
peripheri
blood
treg
cell
report
stabl
regulatori
cell
greater
inhibit
effect
howev
treg
deriv
exosom
function
involv
treg
mediat
immunemodul
seldom
report
studi
designmethod
cell
freshli
purifi
pbmc
cultur
antibodi
packag
bead
polar
tgfb
rapamycin
treg
cell
harvest
cell
cocultur
bead
stimul
cell
transwel
plate
supernat
deriv
treg
collect
ultrafiltr
centrifug
remain
solut
precipit
peg
harvest
precipit
resuspend
pb
exosom
analyz
sem
nta
exosom
surfac
marker
protein
express
evalu
flow
cytometri
western
blot
microrna
isol
mircut
mirna
kit
measur
qpcr
precipit
exosom
purifi
immunoaffin
captur
cocultur
effector
cell
investig
function
immun
modul
resultsfind
compar
direct
contact
cocultur
separ
treg
cell
could
suppress
prolifer
effector
cell
small
declin
p
mean
noncontact
factor
involv
treg
mediat
immun
modul
total
number
cell
exosom
harvest
electron
microscop
analysi
demonstr
kind
roundshap
membran
vesicl
diamet
nta
express
backgroundcas
studi
regulatori
cell
treg
contain
subtyp
play
essenti
role
immun
regul
autoimmun
diseas
prevent
make
potenti
candid
cell
therapi
autoimmun
diseas
aid
unfortun
due
instabl
natur
regulatori
cell
ntreg
inflamm
condit
includ
instabl
convers
proinflammatori
effector
cell
unabl
modifi
establish
diseas
thu
need
investig
regulatori
cell
stabil
vitro
vivo
previou
work
found
treg
effect
therapeut
function
cia
mice
studi
aim
investig
stabil
induc
polyclon
human
regulatori
cell
inflamm
transfus
studi
designmethod
human
treg
induc
rapamycin
lymphocyt
vitro
collageninduc
arthriti
cia
mice
induc
typetwo
collagen
autoimmun
diseas
model
vitro
stabil
treg
encount
inflamm
test
express
cell
convers
inflamm
condit
vivo
treg
transfus
cia
mice
surviv
mice
express
evalu
reveal
stabil
treg
inflamm
condit
model
addit
also
investig
stabil
mainten
treg
induc
factor
rapamycin
remov
test
express
resultsfind
ex
vivo
induc
human
treg
secret
supernat
cell
express
treg
maintain
induc
factor
rapamycin
remov
vitro
ifnc
express
signific
differ
compar
control
treg
secret
encount
inflamm
condit
vivo
treg
cell
transfus
cia
mice
peak
diseas
onset
day
first
collagen
immun
inflamm
condit
vivo
test
treg
surviv
treg
found
cia
mice
foot
blood
spleen
cell
hour
transfus
remain
conclus
result
reveal
exvivo
induc
expand
human
treg
stabl
inflamm
transfus
maintain
express
induc
factor
remov
make
treg
novel
stabl
cell
potenti
cell
therapi
aid
research
provid
instruct
refer
improv
util
blood
compon
tolerogen
dendrit
cell
induc
mtor
suppress
control
inflamm
ch
model
relat
protein
translat
inhibit
li
gao
shanghai
blood
center
backgroundcas
studi
tolerogen
dendrit
cell
tdc
adopt
cellular
immunotherapi
cut
edg
strategi
treat
hypersensit
respons
diseas
immun
respons
direct
selfantigen
atop
dermat
system
lupu
erythematosu
sle
rheumatoid
arthriti
ra
et
al
howev
tradit
strategi
base
tdc
usual
unstabl
inconspicu
cytokin
induc
process
might
limit
tdc
adapt
cell
therapi
futur
clinic
use
studi
designmethod
human
tdc
deriv
fresh
purifi
monocyt
pbmnc
isol
buffi
coat
induc
mtor
inhibitor
rapamycin
temsirolimu
safe
concentr
confirm
apoptosi
assay
cell
complet
differenti
matur
marker
endocytisi
detect
flow
cytometri
product
cytokin
chemokin
measur
use
elisa
mechan
investig
analysi
realtim
pcr
western
blot
contact
hypersensit
ch
model
atop
dermat
anim
model
treat
tdc
induc
via
mtor
suppress
analyz
ear
thick
tissu
leukocyt
number
calcul
resultsfind
human
tdc
treat
mtor
inhibitor
lower
matur
marker
express
tlr
signal
activ
accompani
set
cytokin
chemokin
remark
downregul
concentr
depend
manner
lp
absent
group
moreov
mtor
suppress
extrem
reduc
capac
lp
treat
human
dc
stimul
autogen
cell
prolifer
one
import
characterist
tdc
beyond
expect
common
signal
transduct
pathway
mapk
nfjb
pathway
signal
target
could
hardli
explan
tolerogen
perform
tdc
exposur
lp
stimul
howev
downstreanm
protein
especi
protein
control
protein
translat
shown
charg
tolerogen
induct
mechan
data
also
support
suggest
rare
differ
mrna
transcript
relat
function
protein
tdc
induc
mtor
inhibitor
exposur
lp
stimul
noninduc
cell
although
transcript
ido
induc
mtor
inhibitor
import
edema
respons
ear
clearli
weaken
ch
model
recruit
less
leukocyt
tissu
cosensit
mtor
inhibitor
tdc
induc
mtor
inhibitor
suggest
tdc
induc
mtor
suppress
abl
control
hypersensit
inflamm
respons
vivo
conclus
accordingli
tdc
induc
mtor
suppress
potent
adopt
cellular
immunotherapi
strategi
treat
hypersensit
respons
diseas
induct
mechan
might
suppress
systemat
effect
function
protein
relat
protein
translat
inhibit
xiaoyun
fu
mikayla
anderson
jame
c
zimr
bloodworksnw
research
institut
univers
washington
school
medicin
backgroundcas
studi
red
blood
cell
rbc
undergo
mani
chang
store
blood
bank
condit
collect
known
storag
lesion
bioactiv
lipid
gener
rbc
storag
implic
certain
advers
outcom
recent
report
bioactiv
lipid
especi
polyunsatur
fatti
acid
pufa
oxid
product
oxylipin
accumul
rbc
storag
despit
leukoreduct
evalu
extent
membran
lipid
degrad
oxid
store
rbc
unit
among
donor
popul
differ
blood
group
quantifi
pufa
lysophospholipid
lpl
leukoreduc
rbc
unit
studi
designmethod
rbc
unit
differ
donor
acquir
process
day
one
day
past
expir
bioactiv
lipid
includ
common
fatti
acid
oxylipin
lpl
analyz
liquid
chromatographytandem
mass
spectrometri
multipl
reaction
monitor
lcmsmsmrm
total
fatti
acid
concentr
select
unit
also
analyz
oneway
anova
test
use
determin
signific
differ
analyt
amongst
differ
blood
group
resultsfind
observ
wide
distribut
concentr
major
pufa
store
rbc
unit
exampl
arachidon
acid
aa
rang
mm
linol
acid
la
mm
dihomoclinolen
acid
dgla
mm
eicosapentaeno
acid
epa
mm
docosahexaeno
acid
dha
mm
alphalinolen
acid
ala
mm
ten
oxylipin
includ
hete
hode
dihom
lpl
includ
lpc
lpss
lpe
show
larg
variat
concentr
among
donor
analyt
quantifi
show
signific
differ
concentr
among
differ
blood
type
oneway
anova
test
fdr
ab
blood
group
consist
exhibit
lowest
concentr
major
pufa
rhblood
group
show
highest
averag
twofold
differ
concentr
rhab
fold
increas
rho
among
pufa
rang
suggest
rh
blood
group
independ
abo
blood
group
correl
donor
donor
variat
lipid
metabol
conclus
wide
distribut
concentr
bioactiv
lipid
among
store
rbc
unit
suggest
lipid
degrad
highli
donorbackgroundcas
studi
ensur
avail
biolog
product
hospit
blood
bank
develop
valid
multipl
storag
condit
product
maxim
shelf
life
qualiti
case
labil
product
metabol
known
remain
activ
storag
lead
storag
lesion
microrna
mirna
level
modul
storagerel
damag
make
mirna
ideal
candid
potenti
biomark
qualiti
monitor
late
nanoparticl
wide
studi
use
biosens
applic
object
work
develop
biocompat
gold
nanosensor
sensit
select
direct
detect
biomark
character
assess
qualiti
blood
product
deliv
hospit
studi
designmethod
gold
nanoparticl
gnp
surround
fluoresc
silica
shell
prepar
use
wet
chemistri
method
chosen
potenti
target
sinc
strongli
express
platelet
concentr
concentr
fluctuat
accord
storag
lesion
custom
rna
dna
molecular
beacon
design
use
probe
specif
detect
target
pb
human
plasma
fluoresc
transduc
probe
conjug
surfac
fluoresc
silica
shellgnp
use
edcnh
crosslink
reaction
hybrid
reaction
target
probe
initi
energi
transfer
mechan
record
fluoresc
resultsfind
gnp
nm
surround
thick
fluoresc
silica
shell
nm
prepar
use
nanosensor
optim
luminesc
properti
longterm
stabil
conjug
probe
onto
nanoparticl
confirm
fluoresc
spectroscopi
microscopi
well
nanoparticl
track
analysi
fluoresc
respons
molecular
beacon
studi
show
reproduc
linear
relationship
r
rnaprob
r
dnaprob
concentr
limit
detect
hybrid
assay
human
plasma
appear
demonstr
denatur
rna
probe
target
conclus
biocompat
fluoresc
gnp
prepar
use
tool
blood
product
character
conjug
molecular
beacon
surfac
nanoparticl
achiev
character
use
spectroscop
microscop
techniqu
function
probe
still
optim
fluoresc
respons
molecular
beacon
character
detect
model
mirna
target
pb
human
plasma
energi
metabol
profil
erythrocyt
storag
supe
ren
qun
yu
yanb
wang
changlan
li
yu
wang
backgroundcas
studi
moment
matur
red
blood
cell
rbc
leav
bone
marrow
optim
adapt
perform
bind
transport
oxygen
deliveri
tissu
red
blood
cell
modul
oxygen
transport
protect
hemoglobin
oxidantinduc
damag
maintain
osmot
environ
cell
glycolysi
energet
metabol
pathway
matur
rbc
obtain
atp
energi
rbc
maintain
number
vital
cell
function
gener
current
method
use
measur
rbc
glycolysi
live
state
realtim
destruct
cell
requir
radioactivityxf
technolog
appli
differ
type
cell
red
blood
cell
suspend
cell
shape
size
differ
cell
importantli
rbc
nucleu
mitochondria
organel
applic
xf
technolog
erythrocyt
explor
assay
condit
necessari
total
atp
lmghb
extracellular
lactat
mm
extracellular
glucos
mm
extracellular
na
mm
extracellular
k
mm
p
pair
ttest
b
intercept
blood
system
red
blood
cell
approv
commerci
use
c
project
fund
whole
part
feder
fund
dhh
aspr
barda
contract
backgroundcas
studi
pathogen
inactiv
method
platelet
concentr
increasingli
use
blood
bank
worldwid
make
transfus
safer
vitro
studi
demonstr
effect
pathogen
inactiv
storag
lesion
littl
routin
qualiti
control
data
blood
bank
outcom
report
studi
designmethod
swirl
distribut
product
monitor
one
year
one
year
implement
intercept
pathogen
inactiv
metabol
paramet
like
ph
glucos
lactic
acid
determin
random
sampl
expir
pathogen
inactiv
product
furthermor
indic
platelet
storag
lesion
measur
apheresi
concentr
prematur
low
swirl
compar
control
normal
swirl
resultsfind
experiment
phase
limit
number
product
valid
intercept
pathogen
inactiv
method
ph
glucos
level
decreas
faster
apheresi
platelet
concentr
high
platelet
content
low
platelet
content
pool
buffi
coat
deriv
product
pathogen
inactiv
implement
routin
product
show
glucos
exhaust
often
prepar
apheresi
compar
buffi
coat
deriv
platelet
concentr
despit
plasma
carryov
former
furthermor
number
apheresi
product
prematur
low
swirl
increas
compar
previou
year
without
pathogen
inactiv
chisquar
contrast
incid
prematur
low
swirl
platelet
concentr
prepar
buffi
coat
method
decreas
vs
note
apheresi
concentr
prematur
low
swirl
significantli
higher
median
platelet
count
unaffect
control
show
sign
increas
storag
lesion
compar
control
expir
day
five
without
swirl
defect
sign
includ
lower
ph
higher
lactic
acid
concentr
increas
mean
platelet
volum
phosphatidylserin
exposur
alphadegranul
conclus
risk
increas
storag
lesion
rate
follow
intercept
pathogen
inactiv
higher
apheresi
buffi
coat
deriv
platelet
concentr
especi
platelet
content
vitro
qualiti
singl
dose
amotosalenuva
treat
platelet
day
storag
crystal
stanley
marguerit
kelher
nero
evero
melissa
vongoetz
betsi
donnelli
anna
erickson
bell
bonfil
memori
blood
center
univers
colorado
ceru
corpor
backgroundcas
studi
interceptv
r
blood
system
platelet
fda
approv
ex
vivo
prepar
pathogenreduc
amicu
apheresi
platelet
compon
pc
reduc
risk
tti
includ
sepsi
potenti
reduc
risk
transfusionassoci
gvhd
registr
studi
clinicaltrialsgov
progress
support
approv
trima
apheresi
platform
collect
platelet
compon
pc
suspend
plasma
object
studi
evalu
vitro
function
platelet
suspend
collect
use
trima
platform
treatment
intercept
blood
system
platelet
studi
designmethod
doubl
dose
apheresi
pc
platelet
ml
collect
trima
apheresi
platform
sampl
taken
donat
prior
divid
donat
produc
intercept
treat
apheresi
pc
use
small
volum
sv
set
untreat
control
pc
c
input
volum
replic
c
dose
c
pc
store
condit
evalu
day
day
physicalmetabol
characterist
resultsfind
day
c
pc
dose
recoveri
day
lower
count
volum
dose
bicarbon
glucos
compar
c
pc
howev
paramet
predict
vivo
function
atp
morpholog
score
hsr
esc
equival
c
tabl
conclus
trima
pc
treat
intercept
blood
system
platelet
use
sv
set
store
day
retain
vitro
metabol
function
properti
consist
vivo
function
induct
pluripot
stem
cellderiv
cardiomyocyt
toxic
supernat
long
termstor
red
blood
cell
vitro
fengyan
fan
yang
yu
lipe
sun
shufang
wang
rui
wang
leiy
zhang
deqe
wang
depart
blood
transfus
pla
gener
hospit
depart
blood
transfus
air
forc
gener
hospit
pla
backgroundcas
studi
recent
multi
research
report
longer
termstor
red
blood
cell
rbc
unit
associ
increas
risk
clinic
advers
event
especi
critic
ill
patient
howev
studi
conclud
neg
result
whether
rbc
storag
durat
associ
increas
risk
clinic
advers
event
uncertain
becom
popular
topic
studi
advers
effect
longer
termstor
rbc
directli
aim
look
pluripot
stem
cellderiv
cardiomyocyt
toxic
induc
supernat
suspend
red
blood
cell
ssrbc
studi
possibl
mechan
studi
designmethod
five
dose
leukoreduc
rbc
prepar
supernat
isol
centrifug
look
cardiotox
ssrbc
humaninduc
pluripot
stem
cellderiv
cardiomyocyt
hipscm
hipscm
treat
ssrbc
final
volum
simul
larg
volum
blood
transfus
use
realtim
cellular
analysi
rtca
technolog
beat
hipscm
record
real
time
detail
level
k
lactic
acid
la
test
use
automat
biochem
k
la
solut
concentr
consist
ssrbc
prepar
cocultur
hipscm
analyz
cardiotox
k
la
solut
hipscm
treat
hipscm
ssrbc
k
cell
cultur
media
nuclear
shape
integr
filament
sarcomer
examin
immunofluoresc
total
rna
hipscm
isol
mrna
analysi
microarray
implement
screen
toxic
effect
relat
signal
pathway
bioinformat
analysi
resultsfind
ssrbc
obviou
influenc
beat
state
hipscmshipscm
treat
ssrbc
stop
beat
beat
pattern
restor
hipscm
treat
ssrbc
stop
beat
beat
pattern
restor
level
k
la
ssrbc
chang
obvious
k
solut
made
hipscm
stop
beat
restor
k
k
la
solut
influenc
beat
pattern
end
treatment
hipscm
treat
ssrbc
show
obviou
shrinkag
end
treatment
cell
treat
k
ssrbc
show
obviou
shrinkag
shrinkag
ssrbc
group
seriou
immunofluoresc
result
show
integr
filament
sarcomer
complet
nuclear
pyknosi
detect
gene
express
array
result
show
total
gene
differenti
express
ssrbc
group
compar
naiv
group
consist
separ
within
k
naiv
group
fifteen
differ
express
gene
select
bioinformat
method
like
play
import
role
cytotox
effect
condit
simul
larg
volum
blood
transfus
ssrbc
long
termstor
rbc
toxic
effect
myocardi
cell
addit
high
potassium
induc
cardiotox
must
element
involv
toxic
effect
studi
appli
signal
pathway
ssrbc
induc
cytotox
larg
volum
transfus
long
termstor
rbc
may
risk
factor
advers
clinic
outcom
clinic
pay
attent
backgroundcas
studi
process
thaw
deglycerol
red
cell
concentr
rcc
function
close
system
allow
prolong
storag
thaw
thaw
cell
better
maintain
compar
sagm
presenc
citrat
seem
necessari
prevent
hemolysi
thaw
cell
storag
atp
level
rapidli
declin
recent
develop
addit
solut
like
shown
better
maintain
atp
level
storag
normal
unfrozen
rcc
howev
probabl
due
absenc
citrat
solut
suitabl
storag
thaw
cell
therefor
design
mannitol
replac
citrat
aim
studi
investig
vitroqu
thaw
deglycerol
rbc
storag
studi
designmethod
leukoreduc
rcc
phosphat
adenin
glucos
guanosin
glucon
citrat
store
day
rcc
glycerol
use
haemonet
v
r
braintre
final
concentr
wv
frozen
store
least
two
week
thaw
deglycerol
use
rcc
resuspend
storag
stabil
hemolysi
atp
level
determin
result
compar
thaw
rcc
prefreez
storag
sagm
resuspend
sagm
resultsfind
prefreez
storag
result
increas
level
day
compar
storag
sagm
resp
mmolg
hb
mmolg
hb
hemolysi
postthaw
storag
remain
day
compar
storag
sagm
hemolysi
remain
day
first
week
postthaw
storag
atp
level
increas
follow
gradual
declin
prolong
storag
whole
postthaw
storag
period
rcc
show
significantli
higher
atp
level
compar
sagm
sagm
level
undetect
day
postthaw
storag
level
decreas
lmolg
hb
day
storag
conclus
prefreez
storag
result
increas
level
compar
postthaw
storag
show
compar
hemolysi
atp
level
much
better
maintain
base
maximum
allow
hemolysi
atp
content
hb
thaw
rcc
store
day
backgroundcas
studi
platelet
plt
vital
effect
treatment
hemorrhag
cold
storag
plt
platelet
addit
solut
pa
promis
altern
convent
storag
room
temperatur
rt
due
lower
risk
bacteri
concern
preserv
plt
function
mitig
plt
activ
current
apheresi
ap
pa
system
fdaapprov
use
us
trima
isoplatepa
iso
terumo
amicu
intersol
int
fenwal
goal
studi
assess
adhes
function
longterm
coldstor
plt
collect
fdaapprov
appa
method
studi
designmethod
plt
collect
iso
use
trima
int
use
amicu
store
day
rt
sampl
test
day
baselin
bl
storag
assess
plt
adhes
shear
flow
bioflux
acd
vacutain
tube
collect
donor
centrifug
obtain
red
blood
cell
rbc
bioflux
run
simul
whole
blood
creat
combin
plt
label
calceinam
rbc
hct
label
blood
perfus
microfluid
channel
fluxion
coat
ugml
collagen
shear
rate
imag
acquir
everi
sec
min
use
fluoresc
microscop
surfac
coverag
report
data
analyz
use
twoway
anova
posthoc
tukey
test
signific
p
resultsfind
rtint
rtiso
plt
show
significantli
decreas
adhes
day
storag
compar
bl
bl
rt
p
sampl
show
differ
adhes
timepoint
compar
blint
significantli
enhanc
adhes
compar
rtint
rtiso
contrast
plt
show
signific
enhanc
surfac
coverag
compar
bliso
day
compar
day
p
conclus
work
suggest
storag
plt
collect
trima
ap
system
iso
day
offer
signific
enhanc
adhes
function
compar
plt
collect
amicu
system
int
store
result
surpris
sinc
shown
express
similar
level
phosphatidylserin
may
suggest
differ
pa
plt
intracellular
signal
expect
storag
plt
collect
either
platform
demonstr
superior
function
rt
storag
plt
product
superior
hemostat
function
shelflif
longer
current
standardofcar
provid
potenti
shipment
product
underserv
area
may
bolster
plt
avail
trauma
care
us
tabl
comparison
white
blood
cell
count
percentag
apoptot
cell
whole
blood
compon
storag
unirradi
irradi
group
n
tang
antiinflammatori
agent
good
safeti
record
clinic
could
reduc
sever
experiment
autoimmun
encephalomyel
eae
asthma
coliti
system
lupu
erythematosu
sle
immun
diseaseshowev
potenti
induc
transfus
toler
remain
exploredth
aim
studi
find
baicalin
could
inhibit
red
blood
cell
rbc
immun
elucid
possibl
mechan
yinchentang
prevent
hdn
studi
designmethod
use
human
red
blood
cell
adjuv
lipopolysaccharid
lp
transfus
mice
induc
antibodi
experiment
system
studi
effect
baicalin
rbc
immun
mice
divid
normal
control
group
human
rbc
transfus
posit
control
group
receiv
human
rbc
lp
intraven
weekli
five
week
control
group
receiv
dexamethason
intraperitoneali
daili
five
week
treatment
group
receiv
baicalin
intraperitoneali
daili
five
week
assess
human
rbc
immun
perform
measur
serum
immunoglobulin
g
igg
immunoglobulin
igm
human
rbc
weekli
lymphocyt
chang
spleen
also
monitor
flow
cytometri
resultsfind
found
baicalin
treatment
decreas
serum
igg
igm
product
significantli
sinc
second
week
concomit
reduct
cell
increas
regulatori
cell
spleen
mesenter
lymph
node
signific
differ
percentag
tfh
tfr
subpopul
among
groupsin
addit
baicalin
treatment
nt
decreas
size
spleen
percentag
posit
cell
spleen
baicalin
treatment
mous
dexamethason
treat
mous
result
indic
baicalin
could
inhibit
rbc
immun
especi
igg
product
without
damag
function
spleen
dexamethason
wildli
use
immunesuppress
drug
blood
transfus
could
damag
function
spleenconsid
good
safeti
record
clinic
may
exploit
suppress
transfus
immun
event
addit
result
elucid
inhibitori
effect
antibodi
product
baicalin
may
possibl
mechan
yinchentang
wide
use
chines
herbal
medicin
prevent
hdn
comparison
immucor
pak
plu
pak
lx
assay
detect
human
platelet
alloantibodi
randi
schuller
sarah
kloss
sara
crew
sandra
j
nanc
american
red
cross
american
red
cross
american
rare
donor
program
backgroundcas
studi
alloantibodi
direct
human
platelet
membran
glycoprotein
gp
ia
iia
iib
iiia
ib
ix
iv
implic
sever
clinic
signific
disord
fetal
neonat
alloimmun
thrombocytopenia
fnait
posttransfus
purpura
ptp
refractori
platelet
transfus
passiv
transfer
antibodi
donor
plasma
polymorph
epitop
gp
give
rise
uniqu
human
platelet
antigen
hpa
identif
specif
platelet
alloantibodi
crucial
diagnos
treat
bleed
disord
current
fda
approv
test
permit
identif
hpa
antibodi
glycoprotein
level
immucor
recent
releas
pak
lx
research
use
ruo
assay
unit
state
abil
identifi
hpa
antibodi
singl
nucleotid
polymoph
snp
compar
perform
pak
lx
fda
approv
immucor
pakplu
studi
designmethod
compar
pakplu
pak
lx
result
plasma
serum
clinic
specimen
group
contain
singl
hpa
alloantibodi
specif
without
hla
antibodi
group
includ
specimen
hla
antibodi
alon
group
consist
patient
sampl
neg
hpa
hla
antibodi
pak
lx
util
luminex
bead
base
assay
allow
user
report
antibodi
platelet
specif
antigen
gpiv
hla
class
pakplu
use
elisa
method
result
report
glycoprotein
locat
gpiibiiia
gpia
iia
gpibix
gpiv
along
hla
class
howev
base
upon
pattern
reactiv
observ
pakplu
pak
lx
assay
possibl
determin
probabl
hpa
antibodi
specif
hpa
snp
resultsfind
conclus
analyz
hpa
antibodi
specif
concord
observ
antibodi
pakplu
assay
difficulti
discrimin
antibodi
antibodi
present
fals
posit
sampl
although
pakplu
signal
od
cutoff
od
ratio
significantli
higher
compar
sampl
discord
hla
class
antibodi
result
assay
isol
weakli
posit
antibodi
within
cutoff
pakplu
adjust
ratio
pak
lx
conclud
pak
lx
easi
use
platelet
alloantibodi
screen
method
abil
differenti
hpa
antibodi
allel
level
histoblood
group
antigen
lewi
promot
cell
migrat
via
regul
microtubul
acetyl
huijun
zhu
ping
lu
shanghai
blood
center
backgroundcas
studi
blood
group
antigen
critic
transfus
practic
antibodi
rais
caus
sever
transfus
reaction
besid
blood
group
antigen
compos
sugar
chain
protein
lipid
etc
may
involv
variou
biolog
process
lewi
histoblood
group
antigen
belong
abh
famili
ley
consist
carbohydr
chain
may
play
import
role
cell
recognit
adhes
well
migrat
critic
step
tumor
progress
thu
attract
wide
research
focus
relev
tumor
biolog
ley
demonstr
affect
cell
mirgrat
via
variou
mechan
howev
although
chang
cytoskeleton
organ
basi
cell
motil
littl
known
associ
cytoskeleton
ley
microtubul
construct
unit
tubulin
particip
variou
step
cell
migrat
aim
explor
role
ley
microtubul
cell
migrat
use
breast
cancer
cell
may
provid
refer
clinic
studi
histoblood
group
antigen
chang
way
think
transfus
practic
studi
designmethod
first
manipul
ley
express
breast
cancer
cell
overexpress
sirna
knockdown
fucosyltransferas
block
ley
activ
cell
use
antiley
antibodi
verifi
effect
ley
cell
migrat
detect
acetylatubulin
level
chang
microtubul
acetyl
sign
stabil
establish
role
ley
cell
migrat
via
microtubul
modif
use
specif
tubacin
nonspecif
tsa
inhibitor
minim
deacetyl
acetylatubulin
test
effect
overexpress
cell
motil
resultsfind
overexpress
increas
ley
express
cell
migrat
knockdown
lead
opposit
ley
activ
blockad
antiley
antibodi
also
significantli
inhibit
cell
migrat
western
blot
immunostain
result
show
atubulin
acetyl
level
neg
relat
ley
express
tubacin
tsa
treatment
increas
acetylatubulin
level
inhibit
cell
migrat
meantim
signific
overexpress
promot
cell
migrat
elimin
conclus
conclud
result
ley
promot
cell
migrat
via
regul
atubulin
acetyl
wherein
ley
may
interact
deacetylas
tumor
promot
becom
target
mani
anticanc
drug
demonstr
potenti
associ
ley
function
studi
mani
blood
group
antigen
also
carbohydr
chain
critic
blood
group
determin
compat
transfus
immunolog
reaction
may
also
effect
initi
develop
diseas
tumor
similar
ley
even
compon
network
import
molecul
contribut
destini
diseas
transfus
blood
product
frequent
need
tumor
patient
attent
focus
search
compat
blood
reduc
transfus
reaction
howev
may
lower
chanc
diseas
advanc
take
account
backgroundcas
studi
reduc
risk
bacteri
contamin
platelet
plt
product
great
concern
sinc
plt
storag
occur
room
temperatur
rt
pathogen
reduct
technolog
prt
develop
inactiv
pathogen
prior
transfus
howev
studi
shown
prt
may
damag
plt
cours
extend
storag
rt
result
greater
loss
function
normal
concomit
platelet
storag
lesion
storag
plt
platelet
addit
solut
pa
help
preserv
plt
function
reduc
risk
contamin
studi
establish
impact
prt
perform
longterm
coldstorag
plt
pa
instead
storag
plt
function
mitochondri
respir
cell
death
paramet
studi
designmethod
plt
unit
collect
pa
store
day
time
period
bag
treat
use
mirasol
prt
riboflavin
uv
sampl
obtain
test
day
collect
baselin
bl
premirasol
pre
postmirasol
post
minut
postmirasol
aggregometri
adp
collagen
trap
rotem
flow
cytometri
pselectin
lactadherin
ps
gpib
highresolut
respirometri
oroboro
imag
flow
cytometri
amni
use
analysi
data
report
pair
student
ttest
use
determin
statist
signific
p
resultsfind
day
pselectin
level
significantli
higher
pre
bl
mirasol
treatment
caus
signific
increas
express
compar
pre
pre
post
remain
incub
signific
drop
collagen
trap
aggreg
observ
post
sampl
compar
pre
adp
aggreg
respons
preserv
differ
pselectin
gpib
express
mitochondri
respir
observ
pre
post
sampl
sampl
display
significantli
less
function
higher
activ
level
lower
mitochondri
respir
compar
pre
post
conclus
prt
treatment
plt
unit
pa
day
storag
present
uniqu
altern
prt
treatment
plt
prior
rt
storag
addit
provid
lower
risk
bacteri
contamin
pa
plt
may
provid
better
preserv
hemostat
function
standardofcar
rt
plt
even
mirasol
prt
treatment
howev
show
mirasol
prt
day
pa
plt
follow
incub
minut
result
widespread
cell
damag
avoid
safeti
evalu
lyophil
canin
platelet
model
coronari
arteri
bypass
graft
cabg
todd
getz
arthur
p
bode
ann
hale
michael
stanton
mark
johnson
g
michael
fitzpatrick
cellphir
bodevet
inc
cellphir
backgroundcas
studi
cellphir
complet
micro
dose
clinic
safeti
trial
use
lyophil
human
platelet
cellphir
also
evalu
safeti
lyophil
canin
platelet
lcp
comparison
liquid
store
canin
platelet
follow
intraven
administr
model
onpump
coronari
arteri
bypass
graft
cabg
canin
safeti
studi
support
futur
phase
ii
human
clinic
trial
cardiac
patient
studi
designmethod
three
group
eight
mix
breed
hound
underw
cabg
creat
anastomosi
administ
lcp
equal
total
circul
platelet
count
tcpc
one
group
four
anim
serv
vehicl
group
receiv
lyophil
plateletformul
buffer
anoth
group
four
anim
receiv
control
old
liquidstor
platelet
safeti
assess
collect
blood
loss
data
evalu
blood
flow
bypass
graft
evalu
develop
acut
thrombosi
mainten
patenc
graft
hr
evalu
period
full
necropsi
complet
tissu
analysi
also
perform
efficaci
signal
evalu
collect
blood
loss
data
coagul
endpoint
pt
aptt
fibrinogen
teg
result
demonstr
administr
test
articl
dose
tcpc
associ
unexpect
mortal
advers
chang
hematolog
coagul
paramet
develop
thrombosi
anastomosi
site
evid
advers
thrombosi
format
either
clinic
microscop
regardless
group
mortal
note
studi
consid
relat
surgic
model
result
test
articl
administr
result
also
demonstr
administr
dose
tcpc
produc
signific
decreas
blood
loss
lcp
tcpc
effect
mitig
blood
loss
old
liquidstor
platelet
trend
toward
effect
appreci
differ
coagul
paramet
observ
group
conclus
result
studi
demonstr
administr
lcp
tcpc
safe
canin
cabg
model
data
also
demonstr
administr
lcp
dose
tcpc
reduc
blood
loss
result
suggest
start
dose
tcpc
may
requir
achiev
effect
dose
futur
human
phase
ii
trial
cardiac
patient
although
studi
power
efficaci
data
indic
level
safeti
tcpc
similar
efficaci
signal
tcpc
observ
sever
advers
event
start
effect
dose
may
vari
depend
clinic
indic
futur
studi
requir
studi
fund
barda
contract
studi
pcrssp
techniqu
genotyp
mutat
genet
polymorph
chines
popul
lilan
li
guoguang
wu
nan
institut
transfus
medicin
backgroundcas
studi
platelet
glycoprotein
iv
import
characterist
platelet
antigen
implic
immunemedi
thrombocytopenia
chines
popul
except
antihla
common
antibodi
clinic
relev
platelet
antibodi
chines
popul
associ
high
frequenc
defici
china
gene
mutat
main
reason
lead
defici
frameshift
mutat
one
mutat
caus
defici
natur
mump
measl
rubella
infect
result
lower
antibodi
level
blood
recommend
may
thu
unfound
outdat
prevent
valuabl
vaccin
opportun
children
frequent
blood
transfus
place
alreadi
highli
vulner
pediatr
popul
risk
acquir
prevent
infect
primari
aim
project
determin
mmr
vaccin
immunogen
patient
chronic
transfus
rbc
studi
designmethod
medic
chart
review
vaccin
transfus
histori
mmrspecif
antibodi
quantifi
pediatr
patient
receiv
dose
mmr
vaccin
month
age
chronic
rbc
transfus
program
sickl
cell
diseas
bthalassemia
major
diamondblackfan
anemia
pyruv
kinas
defici
formal
control
group
longterm
immun
rate
literatur
mmr
compon
resultsfind
tabl
show
immunogen
vaccin
compon
delay
vaccin
serolog
test
averag
year
year
thirteen
patient
chronic
transfus
time
serolog
twentythre
patient
seroconvert
least
one
vaccin
compon
conclus
best
knowledg
first
studi
design
measur
effect
rbc
transfus
mmr
vaccin
immunogen
although
lower
rate
report
literatur
result
suggest
high
rate
immunogen
compon
mmr
vaccin
chronic
transfus
patient
immun
prior
month
posttransfus
weigh
risk
benefit
diseas
prevent
highli
vulner
popul
take
account
aforement
result
reevalu
immun
delay
post
rbc
transfus
call
chronic
transfus
infant
postvaccin
serolog
consid
cold
store
uncrossmatch
whole
blood
safe
administ
pediatr
trauma
patient
christin
leeper
franklyn
cladi
richard
saladino
darrel
triulzi
barbara
gain
mark
yazer
univers
pittsburgh
children
hospit
pittsburgh
upmc
institut
transfus
medicin
backgroundcas
studi
use
uncrossmatch
cold
store
whole
blood
wb
becom
increasingli
popular
initi
resuscit
trauma
patient
without
current
abo
group
wb
advantag
convent
compon
therapi
includ
greater
platelet
factor
concentr
well
less
salin
addit
solut
compar
equival
volum
reconstitut
whole
blood
report
detail
initi
use
wb
pediatr
trauma
patient
studi
designmethod
pediatr
trauma
patient
year
old
kg
evid
hemorrhag
shock
elig
receiv
cckg
cold
store
leukoreduc
group
neg
wb
initi
resuscit
wb
unit
low
titer
antia
b
reduc
likelihood
hemolysi
nongroup
recipi
biochem
marker
hemolysi
measur
day
wb
transfus
follow
two
day
admiss
thromboelastogram
obtain
repeat
necessari
resuscit
receipt
maximum
quantiti
wb
convent
compon
util
resultsfind
approxim
month
trauma
patient
receiv
wb
group
group
recipi
male
median
iqr
age
blunt
trauma
mechan
patient
severelyinjur
median
iqr
injuri
sever
score
mortal
rate
median
iqr
quantiti
wb
transfus
group
recipi
mlkg
versu
mlkg
nongroup
recipi
transfus
reaction
report
mean
standard
deviat
haptoglobin
concentr
nongroup
recipi
mgdl
day
mgdl
day
mgdl
day
correspond
haptoglobin
concentr
group
recipi
mgdl
mgdl
mgdl
respect
p
comparison
similarli
signific
differ
total
bilirubin
ldh
creatinin
potassium
time
point
regard
evalu
cold
platelet
function
compar
subset
patient
receiv
wb
warm
platelet
histor
group
pediatr
trauma
patient
receiv
convent
compon
includ
warm
platelet
mean
standard
deviat
platelet
volum
administ
cc
whole
blood
recipi
versu
cc
warm
platelet
recipi
preand
posttransfus
teg
platelet
count
analyz
differ
median
platelet
count
teg
maximum
amplitud
cold
warm
platelet
group
conclus
use
coldstor
uncrossmatch
whole
blood
resuscit
pediatr
trauma
patient
feasibl
accept
appear
safe
receipt
low
titer
group
wb
lead
detect
hemolysi
amongst
nongroup
recipi
given
find
maximum
quantiti
wb
per
patient
increas
mlkg
identif
red
blood
cell
antibodi
human
breast
milk
novel
adapt
serolog
method
philipp
p
pari
alexi
leonard
lauren
hittson
naomi
lc
luban
deepika
darbari
yunchuan
delor
mo
cyril
jacquot
valli
criss
jennif
webb
children
nation
medic
center
backgroundcas
studi
human
breast
milk
contain
immunoglobulin
present
matern
serum
secret
data
mice
demonstr
potenti
kell
antibodi
absorb
enter
breast
milk
impact
surviv
transfus
kell
posit
cell
howev
method
test
titer
human
breast
milk
red
cell
antibodi
lack
two
week
old
infant
histori
rhd
hemolyt
diseas
fetu
newborn
hdfn
previous
treat
intraven
immunoglobulin
phototherapi
refer
anemia
reticulocytosi
patient
posit
posit
direct
antiglobulin
test
dat
antihuman
igg
posit
antibodi
screen
gel
method
antibodi
identif
show
antid
plasma
eluat
patient
transfus
neg
red
cell
discharg
sever
week
patient
return
twice
persist
anemia
requir
addit
transfus
eight
week
age
evalu
show
persist
dat
igg
reactiv
concern
continu
antibodi
exposur
matern
breast
milk
evalu
potenti
sourc
studi
designmethod
base
similar
properti
human
breast
milk
plasma
test
identifi
igg
antibodi
use
stantard
tube
salin
method
perform
minut
incub
follow
autom
wash
prior
addit
antihuman
igg
reagent
control
breast
milk
posit
antibodi
screen
neg
mother
use
assess
interfer
milk
protein
antibodi
screen
perform
plasma
patient
patient
mother
control
concurr
use
method
antibodi
identif
titer
also
perform
indic
freshli
collect
breast
milk
store
room
temperatur
less
day
found
suitabl
techniqu
resultsfind
patient
mother
show
plasma
antid
titer
breast
milk
show
antid
titer
patient
consist
plasma
antid
titer
patient
mother
chose
stop
breast
feed
week
patient
hemoglobin
improv
week
age
use
method
identifi
two
addit
case
breast
milk
induc
hemolysi
anoth
antid
antijka
conclus
test
show
possibl
identifi
red
cell
igg
antibodi
human
breast
milk
use
standard
tube
salin
method
identifi
implic
antibodi
breast
milk
receiv
infant
persist
anemia
due
hdfn
breast
milk
titer
gener
lower
matern
serum
titer
titer
vari
depend
upon
time
frequenc
breast
feed
cessat
breast
feed
correl
improv
hemoglobin
affect
infant
backgroundcas
studi
red
blood
cell
rbc
transfus
lifesav
patient
sickl
cell
diseas
scd
commonli
complic
rbc
alloimmun
despit
transfus
protocol
serolog
match
c
e
kell
antigen
alloimmun
rh
antigen
continu
scd
patient
often
exhibit
hybrid
rhdced
gene
often
character
product
partial
c
antigen
previous
document
scd
patient
west
indi
west
central
africa
partial
c
risk
alloimmun
c
antigen
transfus
rbc
studi
sought
determin
preval
within
cohort
children
scd
us
comprehens
scd
center
studi
designmethod
rbc
genotyp
result
perform
scd
patient
use
precisetyp
hea
array
immucor
norcross
ga
children
healthcar
atlanta
review
compar
serolog
type
rh
cc
ee
antigen
preval
cantigen
posit
patient
serolog
determin
overal
compar
preval
partial
c
antigen
base
detect
rhce
ce
allel
absenc
rhce
gene
encod
convent
c
antigen
tran
sinc
allel
commonli
link
hybrid
rhd
diiiac
gene
encod
partial
c
antigen
review
blood
bank
inform
system
perform
identifi
number
cantigen
posit
transfus
exposur
frequenc
alloimmun
c
antigen
resultsfind
total
patient
genotyperh
phenotyp
data
avail
c
antigen
posit
serolog
allel
frequenc
rhce
ce
total
patient
possess
rhce
ce
absenc
convent
c
gene
tran
c
antigen
posit
patient
individu
predict
partial
c
base
four
molecular
profil
rhce
ce
rhce
rhce
ce
rh
rhce
ce
rh
ce
rhce
ce
rh
ce
partial
c
patient
antic
alloantibodi
rh
antibodi
detect
transfus
exposur
cantigen
neg
unit
mean
rang
like
placement
cneg
rbc
restrict
upon
detect
rhce
ce
allel
conclus
report
confirm
previou
data
high
preval
partial
c
antigen
scd
patient
histor
type
cposit
serolog
demonstr
benefit
rbc
genotyp
prevent
alloimmun
highli
immunogen
rh
antigen
identifi
individu
receiv
cneg
blood
patient
scd
rbc
genotyp
perform
determin
rbc
phenotyp
prefer
prior
receiv
transfus
investig
detect
zika
viru
rna
us
blood
donor
paula
p
sa
megan
l
nguyen
melani
c
proctor
david
e
krysztof
gregori
foster
erin
k
sash
sandi
dickson
joua
yang
jeffrey
linnen
kui
gao
jay
p
brodski
susan
l
stramer
american
red
cross
grifol
diagnost
solut
inc
grifol
diagnost
solut
inc
qualiti
analyt
inc
backgroundcas
studi
zika
viru
zikv
emerg
flaviviru
primarili
transmit
infect
aed
aegypti
mosquito
recent
outbreak
reveal
nonvector
transmiss
rout
includ
unpreced
sexual
transmiss
arboviru
acut
zikv
infect
mainli
asymptomat
present
selflimit
diseas
also
includ
sever
congenit
defect
neurolog
disord
larg
proport
asymptomat
case
high
number
return
travel
zikvact
area
sever
clinic
consequ
develop
fetus
detect
rna
asymptomat
donor
french
polynesia
epidem
suspect
case
transfus
transmiss
brazil
led
fda
releas
guidanc
document
minim
risk
zikv
transmiss
via
blood
blood
compon
studi
designmethod
investig
test
minipool
mp
nat
use
procleix
zika
viru
assay
tma
implement
collect
five
presum
highrisk
us
state
fl
ga
sc
ms
al
follow
revis
guidanc
test
extend
blood
donat
convers
mpnat
individu
donat
id
nat
implement
phase
complet
travel
histori
question
discontinu
confirmatori
test
includ
repeat
tma
addit
rtpcr
serolog
red
cell
rbc
tma
perform
estim
viral
load
perform
endpoint
tma
plasma
rbc
resultsfind
donat
test
includ
mp
reactiv
donat
identifi
mpnat
idnat
donat
initi
reactiv
ir
confirm
posit
cp
subsequ
test
cp
rate
posit
predict
valu
specif
five
cp
donat
idnat
repeat
reactiv
rr
donat
idnat
ir
igm
posit
rna
posit
rbc
cp
donor
resid
tx
ca
ny
wv
fl
local
transmiss
six
donor
travel
zikvact
area
return
us
day
prior
donat
two
donor
travel
risk
report
clinic
symptom
cp
donor
remain
asymptomat
zikv
rna
detect
rbc
cp
index
donat
estim
level
vari
less
copi
c
ml
cml
time
write
longest
period
detect
rbc
day
vs
day
plasma
tmarr
donor
zikv
rna
level
plasma
obtain
ir
rr
donor
rang
cml
studi
designmethod
plasma
blood
donor
screen
individu
donat
idnat
presenc
zikv
rna
cobasv
r
zika
test
sampl
repeat
duplic
test
second
nat
confirm
infect
estim
vl
antizikv
igm
simul
mp
prepar
dilut
plasma
test
discrimin
idnat
detect
donat
nat
yield
sampl
simul
mp
conclus
igm
result
avail
sort
categori
correspond
sequenti
stage
acut
zikv
infect
igmlow
vl
igmhigh
vl
vl
vl
resultsfind
donat
collect
april
reactiv
zikv
rna
igmindex
donat
higher
vl
mean
x
vs
x
iuml
higher
proport
simul
mpdetect
result
vs
donat
distribut
stage
infect
evalu
epidem
evolv
cours
epidem
rate
idnat
detect
donat
increas
tabl
conclus
studi
demonstr
viral
immunolog
profil
zikv
infect
index
donat
shift
cours
pr
epidem
categor
index
sampl
stage
infect
import
blood
safeti
consider
sinc
infect
util
mp
vs
idnat
screen
like
correl
vl
serolog
stage
infect
stage
infect
also
implic
diagnost
test
understand
durat
zikv
viral
immunolog
marker
blood
persist
zikv
bodi
fluid
tissu
cobasv
r
zika
commerci
avail
blood
screen
data
gener
cobasv
r
zika
ind
preliminari
review
fda
project
fund
whole
part
feder
fund
detect
zika
viru
rna
unit
state
blood
donat
use
coba
v
r
zika
coba
v
r
system
lisa
lee
pate
phillip
c
williamson
michael
paul
busch
susan
rossmann
scott
jone
ann
butcher
john
duncan
jean
stanley
susan
galel
roch
molecular
system
inc
creativ
test
solut
blood
system
research
institut
gulf
coast
region
blood
center
sugar
land
qualtex
laboratori
backgroundcas
studi
februari
us
fda
recommend
blood
donat
area
activ
zika
viru
zikv
transmiss
test
fda
approv
nucleic
acid
test
nat
zikv
rna
treat
fda
approv
pathogen
reduct
technolog
cobasv
r
zika
test
approv
investig
new
drug
applic
march
test
puerto
rico
donat
began
april
precautionari
measur
blood
center
us
state
also
began
nat
test
zikv
august
fda
recommend
univers
screen
blood
donat
aim
studi
describ
detect
zikv
rna
blood
donat
collect
us
state
april
februari
use
investig
cobasv
r
zika
use
coba
v
r
system
studi
designmethod
donat
screen
cobasv
r
zika
individu
donat
test
initi
reactiv
ir
result
repeat
duplic
supplement
test
includ
altern
nat
altnat
assay
less
sensit
cobasv
r
zika
serolog
test
antizika
igm
igg
reactiv
donor
invit
enrol
followup
includ
cobasv
r
zika
serolog
test
donor
consid
zika
confirm
posit
least
one
replic
repeat
test
cobasv
r
zika
reactiv
index
donat
followup
reactiv
altnat
index
donat
posit
antizika
igm
index
followup
ir
donat
also
retest
dilut
simul
minipool
test
resultsfind
total
blood
donat
screen
use
cobasv
r
zika
ir
donat
repeat
reactiv
rr
nonrr
repeat
test
rr
donat
posit
altnat
igm
posit
altnat
neg
donor
igm
posit
one
donor
altnat
equivoc
igm
neg
rr
donor
igm
posit
index
enrol
followup
seroconvert
nonrr
donat
altnat
neg
pend
supplement
test
donor
igm
posit
index
donor
igm
neg
index
enrol
followup
remain
igm
neg
inconclus
donat
without
repeat
test
result
met
criteria
posit
altnat
posit
igm
neg
altnat
neg
igm
posit
donat
pend
addit
test
altogeth
ir
donat
met
criteria
true
posit
index
donat
true
posit
donat
reactiv
retest
simul
minipool
igm
posit
conclus
donat
us
state
screen
zikv
rna
confirm
true
posit
coba
v
r
zika
commerci
avail
blood
screen
use
use
mont
carlo
simul
luiz
amorim
marc
germain
gill
delag
maria
esther
lope
yve
gr
egoir
hemorio
hemaquebec
h
emaqu
ebec
backgroundcas
studi
zika
viru
implic
larg
recent
outbreak
french
polynesia
brazil
follow
outbreak
south
america
central
america
caribbean
four
probabl
transfus
transmit
case
report
brazil
sinc
zika
case
asymptomat
actual
transfus
rate
much
higher
report
studi
use
mont
carlo
simul
risk
estim
brazilian
outbreak
studi
designmethod
data
feed
mont
carlo
simul
collect
januari
st
novemb
th
brazil
whole
countri
rio
de
janeiro
state
one
outbreak
epicent
data
came
brazilian
epidemiolog
bulletin
brazilian
blood
donat
figur
risk
assess
perform
separ
whole
blood
wb
donat
apheresi
platelet
ap
model
took
account
follow
paramet
zika
incid
brazil
rio
lognorm
distribut
symptomat
viremia
period
day
valu
lower
day
infect
donor
symptom
last
day
donationdonoryear
wb
ap
formula
transfus
risk
calcul
incid
x
infecti
period
x
averag
donat
number
per
donor
per
year
wb
xy
aph
zy
x
proport
refus
donor
x
discard
donat
due
post
donat
pd
inform
resultsfind
tabl
show
result
estim
risk
transfus
transmit
zika
import
brazil
rio
de
janeiro
attain
apheresi
platelet
sever
consequ
zika
vulner
popul
pregnant
women
newborn
indic
intervent
reduc
unfavor
outcom
donor
test
pathogen
inactiv
consid
brazil
dengu
denv
arbovirus
popul
avail
brazil
object
studi
assess
contemporan
incid
agent
donor
larg
geograph
dispers
blood
center
locat
southeast
northeast
brazil
studi
designmethod
brazil
public
blood
bank
system
nat
screen
hiv
hcv
hbv
perform
minipool
mp
donat
residu
volum
mp
plasma
ml
routin
discard
begin
april
blood
center
save
mpsweek
retrospect
test
use
triplex
zikv
chikv
denv
transcript
mediat
amplif
tma
assay
develop
grifolsholog
mp
ship
usa
batch
test
grifol
first
two
week
april
combin
pool
donat
thereaft
test
without
addit
pool
estim
percent
posit
donor
denomin
adjust
account
number
donat
includ
pool
month
confid
interv
ci
calcul
use
method
develop
biggerstaff
resultsfind
triplex
assay
perform
shown
high
sensit
limit
detect
copiesml
zikvchikv
denv
accur
discrimin
arbovirus
test
first
month
sampl
complet
mp
compris
donat
collect
april
octob
total
pool
posit
detect
apriljun
tabl
summar
highest
monthli
estim
percent
posit
donor
viru
citi
month
highest
percent
postiv
donor
april
may
peak
donor
belo
horizont
rio
virem
zikv
wherea
zika
evid
donor
recif
donor
citi
virem
chivk
peak
conclus
latter
part
arboviru
outbreak
season
brazil
zikv
chikv
denv
transmit
mosquito
donor
asymptomat
donor
donat
indic
blood
recipi
brazil
extens
expos
virem
blood
compon
use
donor
mp
surveil
may
one
effici
approach
public
health
monitor
onset
magnitud
arboviru
infect
univers
zika
screen
blood
donor
singapor
salli
lam
sze
sze
chua
mar
stone
michael
paul
busch
ai
leen
ang
health
scienc
author
blood
servic
group
blood
system
research
institut
backgroundcas
studi
singapor
report
first
local
transmit
zika
case
august
number
rose
rapidli
case
end
septemb
eight
cluster
hotspot
case
islandwid
zika
viru
zikv
share
mosquito
vector
aed
aegypti
dengu
virus
caus
microcephali
unborn
fetus
infect
pregnant
women
guillanbarr
e
syndrom
hasten
singapor
blood
servic
group
bsg
look
secur
safeti
blood
suppli
zika
threat
aim
assess
assay
perform
usafda
investig
ind
procleix
zikv
nucleic
acid
technolog
nat
assay
univers
blood
donat
screen
singapor
prevent
transfusiontransmit
zika
infect
studi
designmethod
blood
donat
screen
zika
procleix
zikv
nat
assay
sinc
octob
zika
nat
reactiv
sampl
test
blood
system
research
institut
bsri
zika
rna
plasma
red
cell
pcr
zika
dengu
igm
igg
antibodi
zika
confirm
case
defin
presenc
zika
rna
pcr
andor
zika
antibodi
analyt
sensit
evalu
use
blind
frozen
sampl
consist
replic
half
log
dilut
intern
standard
zikv
replic
neg
control
prepar
bsri
probit
analysi
perform
determin
limit
detect
lod
clinic
perform
procleix
zikv
assay
also
assess
local
patient
sampl
obtain
institut
infecti
diseas
epidemiolog
singapor
member
blind
zikv
refer
panel
usafda
resultsfind
total
donat
screen
octob
march
fals
posit
case
zika
confirm
donat
detect
altern
zikv
pcr
test
posit
plasma
red
cell
estim
plasma
viral
load
copiesml
zika
igm
neg
index
donat
sampl
present
postdon
follow
sampl
donor
report
clinic
symptom
analyt
sensit
procleix
zikv
assay
determin
copiesml
lod
copiesml
lod
procleix
zikv
assay
detect
rna
patient
sampl
provid
agreement
result
usafda
zikv
refer
materi
conclus
investig
procleix
zikv
assay
show
good
analyt
sensit
clinic
perform
suitabl
blood
screen
zika
infect
especi
asymptomat
donor
popul
bsg
commenc
univers
zika
nat
screen
individu
donat
test
follow
zika
outbreak
confirm
zika
donat
hightit
seroneg
interdict
translat
risk
incid
donat
singapor
backgroundcas
studi
capaabb
work
group
suggest
step
taken
phase
rhdgenotyp
patient
serolog
weak
phenotyp
weak
type
express
major
rhd
epitop
patient
manag
rhdposit
may
lead
reduct
unnecessari
rh
immunoglobulin
rhig
administr
conserv
rhdneg
rbc
studi
designmethod
rhd
genotyp
perform
patient
sampl
weaker
expect
discrep
rhd
type
result
util
commerci
avail
genotyp
kit
manufactur
immucor
rhd
beadchip
initi
test
perform
refer
lab
rhd
beadchip
valid
implement
institut
serolog
weak
phenotyp
defin
weak
reactiv
initi
gel
test
genotyp
demonstr
weak
type
intent
manag
patient
rhdposit
weak
type
detect
patient
consid
risk
alloimmun
treat
rhdneg
rhd
genotyp
result
pend
rhdneg
rbc
use
pregnant
patient
elig
rhig
result
gener
avail
week
resultsfind
rhdgenotyp
perform
patient
sampl
month
patient
sampl
weak
type
remain
sampl
demonstr
varieti
allel
includ
known
partial
variant
see
tabl
one
patient
identifi
weak
type
requir
multipl
transfus
studi
period
refus
rhdposit
rbc
remain
weak
type
patient
receiv
transfus
institut
sinc
genotyp
four
obstetr
weak
type
patient
receiv
rhig
genotyp
pend
conclus
test
manag
patient
serolog
weak
phenotyp
standard
rhd
genotyp
may
lead
consist
person
patient
care
appropri
manag
resourc
month
studi
period
serolog
weak
patient
identifi
could
manag
rhdposit
howev
result
withhold
dose
rhig
conserv
rhdneg
rbc
genotyp
result
pertain
manag
obstetr
patient
discuss
obstetrician
possibl
inform
may
impact
manag
futur
pregnanc
outcom
highlight
limit
current
genotyp
process
includ
long
turnaroundtim
backgroundcas
studi
rh
blood
group
highli
immunogen
clinic
signific
blood
group
secondari
abo
current
unit
state
blood
donor
type
rhdneg
serolog
undergo
weakd
test
identifi
weak
partial
state
rhd
express
howev
rhd
express
detect
serolog
suggest
investig
serolog
rhdneg
blood
donor
use
genotyp
method
accur
identifi
unit
may
lead
alloimmun
rhdneg
recipi
studi
designmethod
rhd
genotyp
serolog
rhdneg
blood
donor
present
blood
donor
center
implement
identifi
unit
alter
rhd
allel
character
rhdposit
repeat
donat
test
initi
serolog
test
blood
donor
perform
use
fda
approv
antid
reagent
reactiv
reagent
neg
rhd
genotyp
perform
use
commerci
avail
genotyp
kit
manufactur
immucor
rhd
beadchip
assay
detect
rhd
variant
allel
addit
dna
sequenc
perform
select
case
maxim
effici
sampl
batch
test
test
gener
perform
month
rhd
variant
known
suspect
associ
increas
risk
alloimmun
detect
recipi
previou
donat
investig
evid
alloimmun
futur
donat
restrict
rhdposit
recipi
resultsfind
period
month
test
rhdneg
blood
donor
partiald
weak
del
donor
one
donor
sampl
novel
rhd
allel
identifi
dna
sequenc
rhd
phenotyp
associ
allel
variant
unknown
investig
previou
donat
donor
show
rhdneg
recipi
receiv
rbc
donor
five
recipi
underw
antibodi
screen
averag
followup
period
month
antid
detect
sampl
see
tabl
conclus
serolog
test
occasion
fail
identifi
rhdposit
donor
unit
could
place
rhdneg
recipi
risk
alloimmun
dnabas
test
use
identifi
donor
potenti
sensit
rhdneg
individu
limit
studi
period
small
number
serolog
rhdneg
donor
whose
genotyp
indic
potenti
sensit
recipi
found
howev
review
recipi
transfus
record
indic
prior
exposur
donor
rbc
lead
detect
immun
date
futur
potenti
sensit
event
avoid
restrict
unit
rhdposit
recipi
grifol
diagnost
solut
lab
grifol
immunohematolog
center
backgroundcas
studi
pregnant
women
rhd
variant
may
candid
rhig
prophylaxi
molecular
analysi
reveal
genotyp
associ
possibl
antid
format
propos
test
algorithm
advoc
molecular
character
weak
type
patient
type
rhdposit
action
propos
women
partial
variant
may
also
risk
antid
format
includ
algorithm
propos
date
yet
molecular
test
may
unmask
hidden
subpopul
women
type
dposit
may
candid
rhig
prophylaxi
hospit
urban
set
deliveri
africanamerican
patient
initi
routin
fullgen
rhdsequenc
obstetr
patient
whose
serolog
demonstr
weak
also
categor
reactiv
determin
preval
partial
patient
ethnicallymix
popul
may
risk
antid
format
studi
designmethod
octob
march
perform
routin
type
neo
immucor
obstetr
specimen
follow
rhd
sequenc
sampl
either
serolog
weak
phenotyp
antid
test
strength
use
least
antibodi
solid
phase
manual
test
use
seri
seri
reagent
four
addit
antid
reagent
manufactur
grifol
dg
gel
antid
quotient
antid
blend
biorad
antid
blend
ortho
bioclon
antid
also
use
supplement
test
rhd
sequenc
perform
sanger
methodolog
use
routin
clinic
protocol
resultsfind
rhd
polymorph
variat
identifi
sampl
two
rhd
gene
common
known
intron
variant
predict
produc
refer
rhd
protein
two
heterozyg
two
appar
new
rhd
code
variat
confirm
test
four
patient
rhd
allel
known
potenti
make
antid
rhd
rhd
weak
type
one
weak
type
uncertain
suscept
alloimmun
one
weak
type
yet
associ
antid
interestingli
two
variabl
express
associ
appar
new
allel
pend
ongo
confirmatori
test
clone
one
patient
backgroundcas
studi
weak
type
variant
rhd
protein
compris
amino
acid
substitut
locat
transmembran
segment
express
reduc
amount
antigen
variant
known
associ
missens
mutat
g
c
first
nucleotid
exon
rhd
gene
thu
could
implic
exon
skip
mutat
perform
ng
next
gener
sequenc
analysi
fulli
genotyp
known
patient
identifi
addit
variant
studi
designmethod
dna
sampl
studi
beadchip
technolog
immucorbioarray
solut
ng
use
sureselect
human
exon
agil
platform
silico
analysi
differ
bioinformat
tool
use
predict
splice
event
furthermor
function
splice
assay
perform
determin
impact
nucleotid
variat
exon
skip
rhd
gene
studi
complet
compar
model
wild
type
weak
type
rhd
protein
resultsfind
target
analysi
full
exom
sequenc
confirm
blood
group
genotyp
patient
previous
character
beadchip
technolog
interestingli
carri
intron
variat
rhd
gene
alreadi
describ
associ
del
allel
among
last
patient
one
previous
character
rhd
weak
type
carri
c
independ
sanger
sequenc
unrel
rhd
weak
type
sampl
pinpoint
linkag
disequilibrium
c
exac
maf
exac
maf
silico
analysi
mutat
locat
close
splice
acceptor
site
exon
predict
signific
reduct
strength
score
minigen
vector
harbor
rhd
wildtyp
exon
mutant
rhd
c
mutant
rhd
doubl
rhd
mutant
c
plu
show
influenc
skip
exon
due
mutat
compar
model
rhd
protein
point
addit
hydrophob
interact
rhd
weak
type
transmembran
helix
transmembran
helix
hamper
membran
insert
conclus
variat
alway
associ
ci
missens
mutat
c
allel
rhd
weak
type
found
alon
rhd
gene
neutral
polymorph
assess
two
mutat
isol
combin
lead
abnorm
rhd
transcript
result
clearli
demonstr
weak
antigen
reactiv
observ
rhd
type
red
blood
cell
due
substitut
alanin
amino
acid
posit
glycin
topolog
jkweak
jkneg
singlenucleotid
missens
variant
kidd
protein
glenn
ramsey
northwestern
univers
backgroundcas
studi
human
urea
transporterb
hutb
protein
carri
kidd
blood
group
transmembran
tm
tilt
ureapor
ahelic
long
extracellular
connector
segment
cytoplasm
segment
end
numer
singlenucleotid
missens
variant
snmv
weaken
abolish
express
jk
ab
antigen
determin
map
report
jkweak
jkneg
jkneg
snmv
onto
hutb
structur
explor
topolog
correl
jk
antigen
express
studi
designmethod
jk
jk
b
snmv
affect
jk
express
compil
dbrbc
isbt
registri
literatur
search
aabb
isbt
british
blood
transfus
societi
meet
abstract
snmv
locat
correl
human
homolog
xraycrystallograph
structur
mammalian
utb
deriv
analysi
ut
function
levin
ej
resultsfind
seven
snmv
locat
within
amino
acid
aa
exofaci
intern
end
tm
helix
mostli
weak
variant
tabl
exofaci
end
jkweak
two
jkneg
except
intern
end
tm
helix
bear
jk
ab
four
snmv
cytoplasm
ntermin
segment
mostli
weak
variant
contrast
snmv
within
membran
helic
mostli
jkneg
variant
three
jkweak
snmv
associ
alloantijk
ab
antigen
allel
weak
partial
six
jkneg
variant
within
aa
jk
ab
none
snmv
long
extracellular
connector
region
cytoplasm
ctermin
segment
jkneg
variant
adjac
line
part
urea
transport
pore
conclus
transporterstructur
rhd
rhce
protein
snmv
weak
c
c
e
e
express
mostli
within
rbc
membran
noncanon
antigenneg
snmv
unusu
structur
similar
kidd
hutb
jkweak
snmv
end
tm
helic
ntermin
cytoplasm
segment
among
jkneg
snmv
membran
helic
howev
whether
variant
appear
jkweak
jkneg
may
depend
extent
test
nextgener
sequenc
may
provid
complet
structureantigen
correl
backgroundcas
studi
kiddnul
blood
group
often
inherit
recess
genet
trait
due
biallel
mutat
gene
encod
urea
transport
kiddnul
phenotyp
associ
transfus
risk
also
associ
abnorm
abil
concentr
urin
caus
ident
kiddnul
phenotyp
domin
inherit
jk
yet
defin
though
first
describ
contrast
recess
inherit
kiddnul
phenotyp
associ
mutat
gene
aim
studi
identifi
character
caus
gene
domin
kiddnul
red
blood
cell
phenotyp
injk
jkweak
bold
jkneg
express
n
within
aa
tm
ahelix
end
cytoplasm
ntermin
membran
tm
ureapor
ahelic
second
nucleotid
variant
allel
synonym
jkneg
consid
jkweak
isbt
splice
point
studi
designmethod
identifi
sever
famili
domin
inherit
kiddnul
phenotyp
multipl
kindr
spain
perform
wholegenom
linkag
analysi
exom
sequenc
express
rtpcr
western
analys
urea
lysi
use
patient
cell
addit
two
proband
underw
urin
concentr
test
resultsfind
use
molecular
approach
map
affect
locu
mbp
region
lod
score
use
deep
sequenc
identifi
potenti
deleteri
mutat
gene
delet
bp
result
loss
entir
zing
finger
domain
ident
mutat
present
affect
individu
absent
control
test
n
addit
two
adult
individu
homozyg
entir
haplotyp
includ
delet
within
locu
thu
complet
lack
common
allel
identifi
also
obtain
dna
unrel
injk
individu
report
japan
individu
similar
though
ident
none
potenti
genet
variant
identifi
spanish
kindr
present
dna
injk
individu
japan
consist
fact
kidd
antigen
encod
urea
transport
associ
renal
function
found
peopl
spain
inabl
concentr
urin
conclus
predict
zinc
finger
delet
preval
southern
spain
due
founder
mutat
lead
dysfunct
underli
dominantli
inherit
kiddnul
blood
phenotyp
phenotyp
associ
subnorm
urin
concentr
abil
backgroundcas
studi
di
phthalat
dehp
make
pvc
film
flexibl
use
blood
product
storag
dehp
leach
bag
film
solut
metabol
studi
rodent
suggest
exposur
dehp
may
associ
advers
health
effect
albeit
high
dosag
attempt
find
dehp
altern
blood
bag
difficult
due
rbc
membranestabil
effect
dehp
bi
terephthal
deht
nonorthophthal
structur
function
similar
dehp
distinct
metabol
toxicolog
standpoint
deht
undergo
complet
hydrolysi
excel
safeti
profil
classifi
carcinogen
mutagen
reproduct
toxic
endocrin
disruptor
studi
object
evalu
qualiti
fresh
frozen
plasma
ffp
store
deht
contain
versu
ffp
store
dehp
contain
day
year
studi
designmethod
thirtysix
wb
unit
collect
cpd
solut
leukoreduc
centrifug
separ
rbc
plasma
abo
ident
plasma
unit
pool
togeth
group
three
pool
includ
group
group
group
ab
plasma
pool
weigh
mix
sampl
divid
dehp
deht
pair
frozen
less
within
hour
collect
vitro
plasma
test
pt
aptt
factor
v
factor
viii
fibrinogen
protein
c
protein
done
day
pool
day
year
storag
dehp
deht
pair
plasma
thaw
test
time
plastic
concentr
determin
day
day
year
ffp
storag
dehp
deht
monoest
analyz
liquid
chromatographymass
spectrometri
intern
standard
deuterateddehp
mehp
deht
meht
lower
limit
quantif
lloq
dehp
ppm
mehp
ppm
deht
ppm
meht
ppm
resultsfind
mean
standard
deviat
sd
key
clot
factor
plastic
result
summar
tabl
statist
differ
plasma
paramet
dehp
deht
bag
time
period
factor
viii
retain
greater
initi
valu
plasma
store
deht
bag
averag
plastic
content
lower
dehp
bag
backgroundcas
studi
plasma
prevent
dilut
coagulopathi
trauma
victim
replac
coagul
factor
substrat
resuscit
red
blood
cell
rbc
andor
crystalloid
solut
spraydri
plasma
spdp
lightweight
reconstitut
minut
make
ideal
use
combat
prehospit
set
rapidli
provid
plasma
situat
impract
administ
fresh
frozen
plasma
ffp
spraydri
process
preserv
coagul
protein
high
molecular
weight
multim
hmwm
von
willebrand
factor
vwf
decreas
object
studi
compar
spdp
ffp
reconstitut
whole
blood
rwb
test
hypothesi
spdp
inferior
ffp
facilit
platelet
adhes
thrombu
format
studi
designmethod
irbapprov
protocol
whole
blood
healthi
volunt
collect
sodium
citrat
centrifug
g
separ
rbc
plateletrich
plasma
prp
prp
dilut
pipessalin
centrifug
g
platelet
pellet
resuspend
either
spdp
ffp
recombin
pack
rbc
creat
rwb
hematocrit
plateletsml
addit
two
rwb
pair
reconstitut
spdp
dilut
plasma
patient
type
vw
diseas
sampl
fluoresc
label
gpiibiiiaspecif
antibodi
sampl
flow
type
collagenco
microchannel
shear
rate
second
still
imag
adher
platelet
thrombi
captur
order
calcul
surfac
area
coverag
sa
along
length
channel
ratio
pair
ttest
use
compar
sa
sampl
reconstitut
spdp
vs
ffp
margin
noninferior
spdpffp
resultsfind
six
batch
spdpffp
evalu
use
subject
statist
differ
spdpffp
pair
mean
ratio
spdpffp
ci
compar
spdp
vs
differ
median
ratio
rang
sa
twoway
anova
demonstr
batch
significantli
affect
ratio
sa
spdp
vs
ffp
conclus
spdp
despit
decreas
vwf
hmwm
inferior
ffp
abil
support
platelet
adhes
thrombu
format
averag
sa
sampl
reconstitut
spdp
greater
sampl
reconstitut
ffp
lower
limit
th
ci
differ
less
priori
determin
margin
noninferior
even
dilut
plasma
reduct
platelet
adhes
thrombu
format
spdp
rwb
sampl
data
support
develop
inhuman
studi
evalu
efficaci
safeti
spdp
prevent
revers
traumarel
coagulopathi
spraydri
plasma
defici
high
molecular
weight
multim
von
willebrand
factor
retain
hemostat
properti
michael
meledeo
qiyong
peter
liu
grantham
c
peltier
ryan
c
carney
ashley
taylor
colbi
mcintosh
jame
bynum
andrew
p
cap
us
armi
institut
surgic
research
velico
medic
inc
backgroundcas
studi
restor
coagul
factor
key
acut
resuscit
traumat
hemorrhag
blood
product
frequent
unavail
emerg
respons
due
shelflif
restrict
storag
need
singl
unit
spray
dri
plasma
spdp
process
develop
produc
longliv
readili
store
product
reduct
high
molecular
weight
multim
von
willebrand
factor
vwf
increas
low
molecular
weight
multim
vwf
critic
platelet
adhes
thrombu
format
follow
work
demonstr
enhanc
function
use
glycinebas
reconstitut
solut
spdp
studi
examin
two
differ
spdp
pretreat
condit
studi
designmethod
sampl
ffp
ffp
glycin
regular
spdp
without
pretreat
rspdp
rehydr
glycinehcl
glycin
spdp
pretreat
glycinehcl
spdp
pretreat
glycinehcl
glycin
pretreat
rehydr
water
six
donormatch
plasma
type
test
vwf
activ
measur
ristocetin
cofactor
assay
fibrin
polymer
kinet
analyz
turbidimetri
thrombin
gener
tg
observ
thrombogram
chemistri
evalu
istat
residu
cell
materi
quantifi
flow
cytometri
coagul
properti
measur
thromboelastographi
teg
plasma
reconstruct
whole
blood
hct
plateletsnl
typematch
donor
platelet
adhes
collagen
shear
measur
bioflux
resultsfind
pretreat
spdp
show
enhanc
vwf
activ
rspdp
p
fibrin
polymer
densiti
slightli
diminish
rspdp
vs
ffp
vs
od
p
tg
unchang
bicarbonatebas
excess
lower
spdp
sampl
vs
ffp
p
residu
cellular
materi
especi
plateletderiv
reduc
threefold
rspdp
vs
ffp
p
addit
twofold
pretreat
spdp
vs
rspdp
p
teg
result
unchang
plasmaonli
sampl
reconstruct
wb
reduct
amplitud
clot
strength
spdp
sampl
vs
p
platelet
adhes
equival
pretreat
spdp
ffp
rspdp
improv
vs
sampl
surfac
coverag
vs
p
conclus
spdp
longer
shelf
life
easier
storag
requir
ffp
equival
superior
ffp
vitro
assay
spdp
pretreat
glycin
solut
similar
ffp
assay
show
superior
vwf
activ
fewer
residu
cellular
materi
inferior
support
platelet
adhes
collagen
flow
compar
untreat
spdp
clinic
signific
find
unclear
overal
vitro
outcom
suggest
clinic
studi
warrant
interact
red
blood
cell
transfus
lung
injuri
influenc
blood
compon
manufactur
method
mathij
wirtz
anita
tuipd
boer
ruqayyah
almizraq
jason
p
acker
philip
j
norri
jennif
muszynski
nicol
jufferman
academ
medic
center
univers
alberta
canadian
blood
servic
blood
system
research
institut
nationwid
children
hospit
backgroundcas
studi
red
blood
cell
rbc
transfus
associ
acut
lung
injuri
particular
patient
mechan
ventil
caus
factor
known
may
includ
residu
cell
extracellular
vesicl
ev
studi
investig
function
effect
differ
manufactur
method
rbc
product
respons
pulmonari
cell
vitro
model
mechan
ventil
studi
designmethod
group
rbc
product
whole
blood
filter
wbf
red
cell
filter
rcf
apheresi
deriv
ad
whole
blood
deriv
wbd
manufactur
donor
blood
type
b
supernat
prepar
fresh
day
storag
store
measur
thrombin
gener
ev
analysi
type
ii
alveolar
cell
seed
onto
flexibl
membran
incub
rbc
supernat
cell
subject
stretch
use
cellstretch
control
cell
stretch
hour
product
measur
resultsfind
fresh
store
supernat
ad
product
significantli
increas
pulmonari
cell
product
compar
incub
rbc
product
nonincub
control
exacerb
cell
stretch
ad
product
also
significantli
increas
thrombin
gener
abil
compar
rbc
product
well
significantli
increas
number
rbcderiv
ev
compar
rcf
wbd
product
p
incub
stretch
cell
store
wbf
product
result
higher
product
compar
blood
product
stretch
control
rcf
product
activ
pulmonari
cell
absenc
tg
low
level
ev
compar
product
conclus
manufactur
method
markedli
influenc
interact
rbc
product
lung
cell
ad
product
activ
lung
cell
aggrav
cell
stretch
may
part
mediat
rbcbackgroundcas
studi
investig
previous
demonstr
immunosuppress
effect
rbc
supernat
monocyt
vitro
greater
effect
seen
respons
older
unit
recent
clinic
data
suggest
rbc
manufactur
method
may
influenc
immunomodulatori
potenti
directli
measur
use
vitro
model
test
hypothesi
rbc
supernat
obtain
differ
manufactur
method
differenti
effect
monocyt
function
studi
designmethod
rbc
product
manufactur
differ
method
individu
donor
whole
blood
filtrat
wbf
red
cell
filtrat
rcf
apheresi
whole
blood
deriv
wbd
rbc
product
store
sagm
wbf
rcf
adsolcontain
preserv
solut
apheresi
wbd
supernat
obtain
day
fresh
day
expiri
monocyt
cocultur
media
plu
rbc
supernat
media
control
follow
lp
stimul
experi
perform
replic
distinct
monocyt
donor
comparison
group
anova
dunnett
posttest
multipl
comparison
data
mean
sd
control
valu
resultsfind
exposur
apheresi
wbd
rbc
supernat
suppress
monocyt
lpsinduc
tnfa
product
capac
compar
control
tabl
true
fresh
unit
expiri
monocyt
expos
rbc
supernat
alon
without
lp
product
higher
exposur
fresh
wbf
control
p
wbd
expiri
control
p
conclus
manufactur
method
andor
storag
solut
significantli
alter
immunomodulatori
effect
rbc
supernat
monocyt
vitro
may
confound
analys
clinic
effect
rbc
storag
durat
particularli
within
intern
multicent
studi
magnet
levit
system
studi
impact
donor
gender
age
blood
storag
condit
red
blood
cell
densiti
profil
gozd
durmu
alessandro
tocchio
anita
howel
kaushik
sridhar
jason
p
acker
utkan
demirci
stanford
univers
canadian
blood
servic
centr
innov
backgroundcas
studi
amount
hemolysi
red
blood
cell
unit
increas
product
age
shown
lower
femal
blood
donor
male
hypothes
femal
donor
possess
averag
younger
popul
red
cell
result
lower
hemolysi
observ
premenopaus
popul
also
hypothes
differ
donor
popul
mitig
lysi
older
cell
whole
blood
unit
undergo
process
step
produc
red
cell
concentr
rcc
unit
red
blood
cell
rbc
age
circul
undergo
characterist
chang
densiti
membran
composit
allow
separ
younger
cell
studi
designmethod
aim
studi
effect
donor
factor
method
manufactur
store
condit
averag
rbc
age
densiti
red
cell
unit
recent
develop
power
yet
simpl
inexpens
magnet
levitationbas
platform
allow
realtim
highresolut
imag
monitor
variou
cell
popul
labelfre
system
allow
densiti
profil
individu
red
blood
cell
unpreced
resolut
gml
first
determin
effect
rcc
storag
densiti
profil
rbc
levit
singlecel
densiti
profil
measur
day
addit
determin
effect
donor
age
sex
rbc
densiti
profil
blood
sampl
volunt
four
differ
age
sex
categori
male
year
male
year
femal
year
femal
year
profil
resultsfind
first
observ
levit
densiti
profil
well
morpholog
rbc
within
rcc
unit
chang
significantli
storag
addit
rbc
densiti
significantli
differ
young
gml
older
femal
donor
gml
p
moreov
rbc
young
male
gml
significantli
less
dens
compar
rbc
profil
older
femal
donor
gml
p
conclus
develop
magnet
levit
system
pointofcar
realtim
evalu
rbc
red
cell
concentr
rcc
qualiti
envis
result
might
inform
decis
maker
impact
donor
deferr
criteria
may
qualiti
red
cell
concentr
avail
blood
bank
optim
clinic
outcom
cytokin
product
pulmonari
cell
pgml
pgml
backgroundcas
studi
oxid
reduct
potenti
orp
redox
ratio
activ
oxid
reduc
redox
imbal
caus
higher
product
reactiv
oxygen
speci
ro
reactiv
nitrogen
speci
decreas
endogen
protect
antioxid
result
oxid
stress
os
os
caus
cellular
injuri
death
also
import
regul
healthi
immun
respons
injuri
diseas
present
studi
investig
chang
hemoglobin
free
heme
orp
red
blood
cell
rbc
age
effect
red
blood
cell
age
icu
patient
morbid
mortal
studi
designmethod
icu
patient
enrol
prospect
observ
trial
investig
effect
transfus
rbc
age
icu
patient
morbid
mortal
rbc
prestorag
leukoreduc
abo
ident
citrat
blood
sampl
collect
rbc
unit
prior
issu
rbc
supernat
test
free
hemoglobin
heme
orp
patient
follow
prospect
resultsfind
total
rbc
unit
transfus
patient
rbc
characterist
shown
tabl
signific
reduct
detect
orp
valu
storag
durat
p
substanti
correl
also
found
orp
free
hemoglobin
p
orp
free
heme
p
interestingli
statist
signific
differ
averag
orp
valu
transfus
rbc
patient
develop
infect
higher
orp
valu
measur
rbc
unit
given
patient
develop
posttransfus
infect
vs
p
signific
differ
observ
orp
patient
mortal
hospitalicu
day
thrombosi
also
correl
detect
free
hemehemoglobin
rbc
age
infect
develop
conclus
data
demonstr
older
blood
lower
orp
valu
well
increas
free
hemehemoglobin
differ
orp
valu
differ
blood
group
rbc
age
control
statist
signific
differ
patient
mortal
associ
orp
free
hemehemoglobin
rbc
age
decreas
orp
valu
observ
older
blood
like
attribut
storag
lesion
higher
transfus
rbc
orp
valu
associ
subsequ
develop
infect
younger
rbc
found
higher
orp
valu
thu
data
support
youngfresh
blood
may
predispos
subsequ
develop
infect
critic
ill
patient
studi
need
backgroundcas
studi
random
trial
human
address
whether
exposur
red
blood
cell
rbc
store
long
time
associ
harm
explor
effect
inhospit
mortal
transfus
rbc
store
day
compar
rbc
store
day
less
studi
designmethod
data
multin
random
control
trial
use
exploratori
analysi
patient
hospit
adult
requir
transfus
randomli
alloc
receiv
freshest
rbc
inventori
oldest
standard
issu
rbc
provid
larg
cohort
patient
receiv
rbc
storag
durat
along
entir
rbc
storag
continuum
day
use
time
depend
variabl
patient
exposur
defin
maximum
storag
durat
rbc
receiv
use
classifi
individu
day
hospit
one
three
mutual
exclus
exposur
categori
freshest
exclus
expos
rbc
less
equal
day
storag
durat
refer
group
medium
age
least
rbc
day
storag
oldest
least
rbc
greater
day
storag
primari
outcom
allcaus
inhospit
mortal
causespecif
cox
regress
model
inhospit
death
assess
effect
exposur
rbc
categori
exclus
exposur
rbc
store
day
less
effect
fix
timedepend
confound
dealt
stratif
regress
sensit
analys
conduct
weekli
partit
cutpoint
everi
day
b
finer
partit
use
cutpoint
everi
day
resultsfind
patient
receiv
rbc
includ
analysi
exposur
rbc
store
day
associ
increas
risk
inhospit
death
compar
exposur
exclus
freshest
rbc
unit
store
day
less
adjust
sever
fix
timedepend
potenti
confound
hr
ci
p
exposur
blood
store
day
yield
similar
hazard
ratio
hr
ci
p
sensit
analys
use
weekli
partit
exposur
rbc
store
greater
day
compar
exclus
exposur
rbc
store
day
less
signific
hr
ci
p
confid
interv
around
hazard
ratio
interv
includ
similar
find
obtain
partit
exposur
data
day
interv
exposur
rbc
store
day
associ
increas
risk
death
compar
exclus
exposur
rbc
store
day
hr
ci
p
confid
interv
around
hazard
ratio
interv
includ
conclus
individu
expos
rbc
store
day
increas
risk
inhospit
death
compar
individu
expos
exclus
rbc
store
day
less
transfus
anaerob
store
red
blood
cell
improv
recoveri
experiment
rat
hemorrhag
shock
model
alexand
william
cynthia
walser
tatsuro
yoshida
andrew
dunham
pedro
cabral
univers
california
san
diego
new
health
scienc
inc
backgroundcas
studi
hemorrhag
shock
hs
sever
decreas
oxygen
deliveri
induc
cardiovascular
collaps
parallel
control
hemorrhag
clinician
respond
infus
larg
volum
red
blood
cell
rbc
restor
blood
volum
carri
capac
hemodynam
stabil
qualiti
transfus
rbc
determin
recoveri
hs
extent
clinic
sequela
prompt
hs
studi
compar
abil
recov
hs
convent
store
rbc
anaerob
satur
store
rbc
anaerobichypercapn
satur
pco
store
rbc
studi
designmethod
pack
red
blood
cell
prbc
store
leukorfiltr
creat
donor
spraguedawley
rat
prbc
unit
randomli
store
either
convent
anaerob
anaerobichypercapn
condit
rat
hemorrhag
blood
volum
held
hypovolemia
minut
resuscit
recov
blood
pressur
prehemorrhag
prbc
store
either
week
system
hemodynam
cardiac
function
blood
ga
paramet
monitor
shock
resuscit
vital
organ
inflamm
oxygen
function
evalu
post
resuscit
data
analyz
use
twoway
anova
follow
appropri
post
hoc
analys
neg
patient
show
short
term
respons
patient
show
progress
diseas
neg
group
standard
eval
patient
show
respons
progress
diseas
neg
patient
long
term
respons
compar
po
patient
po
short
term
eval
patient
show
respons
patient
progress
diseas
po
group
standard
eval
patient
show
respons
patient
progress
diseas
overal
po
patient
respond
compar
neg
conclus
trend
lower
respons
rate
patient
neg
antibodi
screen
compar
posit
control
find
suggest
neutral
substanc
could
play
role
treatment
respons
altern
reduc
express
may
also
contribut
low
respons
rate
seen
group
may
result
bias
select
need
repeat
presum
repeat
transfus
may
preselect
patient
aggress
diseas
also
small
number
patient
suitabl
review
larger
prospect
studi
control
variabl
need
review
blood
util
provideractiv
critic
administr
thresholdtrigg
massiv
transfus
event
patrick
ramo
john
hess
divis
transfus
medicin
harborview
medic
center
backgroundcas
studi
tradit
definit
massiv
transfus
eg
transfus
ten
unit
red
blood
cell
rbc
period
limit
prospect
identifi
patient
requir
massiv
transfus
exclud
patient
may
surviv
long
enough
meet
criteria
ignor
acuiti
event
address
issu
level
trauma
center
adopt
critic
administr
threshold
cat
addit
indic
activ
massiv
transfus
protocol
mtp
studi
review
blood
util
massiv
transfus
event
base
upon
whether
mtp
provideractiv
versu
cattrigg
studi
designmethod
massiv
transfus
event
januari
april
review
identifi
start
time
termin
time
number
compon
transfus
start
time
compon
transfus
transfus
three
blood
compon
hour
defin
cat
massiv
transfus
event
concern
hemorrhag
shock
either
necessit
provid
activ
mtp
blood
compon
transfus
rate
met
cat
criteria
massiv
transfus
start
time
base
either
time
provid
activ
mtp
time
first
blood
compon
transfus
whichev
came
first
unless
patient
expir
first
termin
massiv
transfus
event
determin
identifi
point
time
patient
went
three
hour
without
transfus
addit
blood
compon
inform
tabul
determin
monthli
number
provideractiv
mtp
cattrigg
mtp
averag
blood
compon
transfus
per
massiv
transfus
conclus
blood
util
lower
within
cattrigg
mtp
even
though
outnumb
provideractiv
mtp
howev
mode
group
suggest
massiv
transfus
requir
less
blood
compon
averag
rate
use
mode
provid
approxim
replac
blood
volum
enough
counter
earli
sign
symptom
hemorrhag
shock
though
studi
review
appropri
provideractiv
mtp
use
cat
indic
ensur
clinician
prepar
potenti
massiv
transfus
investig
need
determin
factor
contribut
downward
trend
averag
blood
compon
transfus
mode
would
suggest
optimist
patient
stabil
faster
resuscit
effici
case
defin
massiv
transfus
includ
rate
compon
transfus
addit
total
volum
transfus
long
term
storag
effect
dithiothreitol
red
cell
antigen
integr
reagent
red
blood
cell
heik
carrel
lauri
sutor
germ
leparc
marjori
doti
william
crew
carter
bloodcar
ut
southwestern
medic
center
oneblood
backgroundcas
studi
drug
daratumumab
pose
problem
transfus
servic
may
caus
number
fals
posit
includ
posit
direct
antiglobulin
test
dat
indirect
antiglobulin
test
iat
panreact
eluat
result
prolong
compat
test
delay
deliveri
blood
product
patient
treat
reagent
red
cell
rrbc
dithiothreitol
dtt
remov
drug
interfer
due
daratumumab
allow
detect
underli
alloantibodi
studi
aim
investig
effect
dtttreatment
rrbc
antigen
integr
day
period
studi
designmethod
twelv
aliquot
human
plasma
contain
antibodi
singl
known
specif
antid
c
e
c
e
fy
fy
b
jk
jk
b
test
untreat
dtttreat
rrbc
immucor
panoscreen
ii
iii
dtt
acro
organ
dtt
treatment
rrbc
perform
use
methodolog
describ
aabb
technic
manual
th
edit
plasma
aliquot
separ
aliquot
store
day
use
fresh
aliquot
thaw
day
avoid
unintend
antibodi
integr
degrad
polyethylen
glycol
immucor
enhanc
techniqu
use
reaction
read
iat
phase
hemolysi
present
observ
diluent
day
prior
mix
cell
suspens
given
grade
base
haemonet
color
compar
chart
serolog
antibodi
reaction
strength
observ
document
day
monthli
breakdown
group
also
display
downward
trend
averag
use
blood
compon
resultsfind
notic
hemolysi
dtttreat
cell
time
compar
untreat
cell
red
cell
antigen
remain
serolog
detect
dtttreat
cell
throughout
studi
despit
greater
degre
observ
hemolysi
minim
differ
reactiv
strength
untreat
dtttreat
cell
antigen
affect
dtt
instanc
dtttreat
cell
react
slightli
strongli
none
antibodi
produc
reactiv
strength
less
untreat
dtttreat
cell
studi
conclus
long
term
storag
dtttreat
rrbc
compromis
antigen
integr
advanc
dtttreatment
storag
larg
aliquot
rrbc
may
serv
increas
effici
transfus
servic
backgroundcas
studi
monocyt
monolay
assay
mma
cellular
bioassay
use
evalu
hemolyt
signific
blood
group
antibodi
aid
select
rbc
alloimmun
patient
requir
fresh
autoallogen
monocyt
mma
highli
restrict
due
tediou
process
fresh
peripher
blood
pb
previou
studi
describ
process
cryopreserv
buffycoat
bc
deriv
fresh
pbmonocyt
mma
assay
aim
evalu
function
properti
cryopreserv
bcmonocyt
substitut
fresh
pbmonocyt
mma
evalu
previous
report
clinic
signific
rbc
alloantibodi
studi
designmethod
peripher
blood
mononuclear
cell
pbmc
isol
buffycoat
pool
suspend
cryopreserv
media
dmso
store
liquid
nitrogen
pbmc
membran
integr
postthaw
determin
trypan
blue
exclus
pbmc
cultur
polyllysinetr
coverslip
co
h
monocyt
monolay
incub
fresh
cryopreserv
antigen
posit
rbc
sensit
either
antid
posit
control
antianwj
lipopolysaccharid
stimul
h
aliquot
sensit
rbc
test
opson
indirect
antiglobulin
test
iat
phagocytosi
index
pi
determin
microscop
number
fulli
phagocytos
monocyt
supernat
analyz
cytokin
use
luminex
techniqu
resultsfind
cryopreserv
pbmc
show
viabil
postthaw
report
signific
differ
phagocytosi
antid
sensit
rbc
cryopreserv
monocyt
vs
fresh
monocyt
show
signific
increas
tnfa
mipa
p
mipb
gro
p
secret
cryopreserv
bc
monocyt
vs
fresh
bc
pbmonocyt
anwjsensitis
rbc
result
pi
respect
vs
antid
sensit
rbc
pi
weak
reactiv
iat
observ
antianwj
sensit
rbc
antid
sensit
rbc
result
iat
reactiv
result
correl
previous
report
result
clinic
signific
mma
use
freshli
obtain
autolog
healthi
donor
monocyt
conclus
studi
show
cryopreserv
preserv
monocyt
viabil
phagocytosi
function
mma
previous
report
fresh
monocyt
mma
assay
two
alloantibodi
test
cryopreserv
bc
monocyt
shown
phagocyt
index
clinic
signific
pi
use
cryopreserv
bcmonocyt
abil
describ
antigen
type
discrep
patient
involv
antigen
c
jk
reveal
serolog
result
differ
phenotyp
predict
dna
test
patient
posit
dat
antiigg
warm
autoantibodi
identifi
plasma
investig
antigen
type
discrep
show
fals
neg
fals
posit
result
use
monoclon
reagent
studi
designmethod
standard
tube
hemagglutin
method
use
antigen
type
rbc
treat
edta
glycineacid
ega
use
gamma
ega
kit
genom
dna
isol
wbc
hea
precisetyp
perform
resultsfind
rbc
patient
type
con
initi
test
immucor
gammaclon
antic
predict
hea
precisetyp
egatr
rbc
gave
reaction
antic
reagent
patient
rbc
gave
variabl
reactiv
biorad
seraclon
ortho
bioclon
antic
patient
rbc
gave
reactiv
antic
reagent
incub
maximum
incub
time
allow
patient
rbc
jk
immucor
gammaclon
antijk
manufactur
state
suitabl
test
predict
jk
hea
egatr
rbc
test
jk
reagent
rbc
patient
test
biorad
seraclon
anti
predict
sbi
hea
test
immucor
gammaclon
anti
show
rbc
patient
egatr
rbc
nonreact
anti
reagent
conclus
commerci
monoclon
reagent
valuabl
resourc
especi
phenotyp
rbc
manufactur
includ
reagent
limit
regard
test
rbc
describ
case
fals
neg
test
monoclon
antic
due
antigen
block
igg
case
fals
posit
test
anti
antijk
type
fals
posit
test
would
potenti
anticip
fals
neg
result
due
antigen
block
unexpect
extend
incub
indic
reagent
insert
may
reveal
weak
reactiv
antigen
block
involv
result
concord
dna
test
obtain
egatr
rbc
gener
accept
necessari
use
directagglutin
monoclon
reagent
case
caution
potenti
fals
neg
fals
posit
result
sampl
posit
dat
support
test
dissoci
igg
rbc
strongli
antigen
type
addit
report
highlight
benefit
dna
test
part
routin
refer
laboratori
workup
backgroundcas
studi
sensit
antigen
express
transfus
cell
trigger
prematur
antibodymedi
clearanc
diminish
therapeut
effect
transfus
may
also
lead
seriou
delay
hemolyt
transfus
reaction
accept
us
clinic
practic
provid
sensit
patient
receiv
cell
lack
offend
antigen
nevertheless
ensur
continu
alloexposur
thu
possibl
sensit
addit
antigen
therebi
complic
patient
manag
mitig
sensit
risk
especi
era
increasingli
costconsci
procur
quantit
assess
immunogen
specif
antigen
desir
giblett
long
ago
introduc
rel
scale
relat
rbc
antigen
immunogen
assum
immunogen
k
http
show
absolut
estim
immunogen
may
extract
directli
observ
antibodi
count
provid
properli
normal
fraction
recipi
risk
name
lack
specif
antigen
expect
fraction
donor
express
antigen
studi
designmethod
defin
immunogen
sensit
risk
r
antigen
ag
interest
condit
probabl
alloantibodi
ab
format
given
alloexposur
ag
ie
r
prob
aballoexp
prob
ab
prob
aballoexp
prob
alloexp
r
rewrit
prob
alloexp
prob
recipi
r
lack
ag
prob
donor
ag
estim
prob
ab
nabnr
nab
denot
number
ab
nr
recipi
obtain
nab
nr
prob
r
lack
ag
r
prob
ag
lefthand
side
repres
observ
sensit
fraction
u
ie
number
observ
ab
relat
number
recipi
risk
conclus
sever
antigen
though
correspond
antibodi
may
rare
eg
jsa
e
u
nevertheless
highli
immunogen
requir
singl
exposur
averag
sensit
contrast
other
averag
requir
mani
exposur
thu
pose
rel
low
risk
conjunct
patient
genotyp
r
scale
facilit
select
patientspecif
cell
minim
risk
prolifer
alloimmun
even
perfectli
match
cell
avail
approach
may
readili
extend
addit
rbc
antigen
antigen
system
backgroundcas
studi
aabb
fda
requir
month
deferr
donor
tattoo
appli
use
nonsteril
needl
reusabl
ink
review
state
regul
ascertain
tattoo
establish
licens
requir
use
steril
singleus
needl
singleus
ink
recent
ad
two
larg
state
collect
blood
accept
state
list
asl
compar
rate
donor
defer
addit
state
determin
potenti
donor
gain
chang
state
tattoo
licens
regul
studi
designmethod
analyz
allogen
interview
respons
screen
question
past
month
tattoo
ye
whether
tattoo
appli
state
regul
entiti
blood
center
state
select
analysi
state
tattoo
regul
state
comparison
period
similar
month
month
select
state
b
similar
month
month
select
frequenc
rate
respons
compar
period
among
respond
tattoo
regul
state
donat
review
presenc
infecti
diseas
marker
includ
hiv
hbv
hcv
resultsfind
higher
proport
donor
present
give
blood
admit
recent
month
tattoo
post
period
state
increas
occur
immedi
follow
addit
state
b
asl
data
shown
among
respond
ye
tattoo
state
b
respect
increas
accept
donor
tabl
absolut
number
accept
donor
tattoo
increas
state
state
b
annual
repres
potenti
gain
state
state
b
addit
donat
donor
tattoo
regul
state
asl
test
neg
hiv
hbv
hcv
conclus
counter
rise
number
inelig
donor
result
recent
ad
deferr
consid
recoveri
donor
defer
tattoo
way
enhanc
donor
base
immedi
rise
number
donor
report
tattoo
follow
addit
state
may
reflect
declin
selfdeferr
base
recent
tattoo
demonstr
increas
potenti
number
donat
without
compromis
safeti
backgroundcas
studi
transgend
donor
repres
small
fraction
blood
donor
determin
elig
donat
challeng
blood
center
assess
behavior
risk
donor
requir
answer
gender
specif
question
true
assess
trali
risk
donor
ask
histori
prior
pregnanc
prior
implement
fda
final
rule
blood
center
ask
donor
birth
gender
determin
elig
base
gender
donor
chang
gender
ask
answer
male
femal
question
final
rule
allow
blood
center
accept
donor
state
gender
determin
elig
base
gender
order
assess
risk
fail
ask
transgend
male
donor
birth
gender
femal
pregnanc
question
review
done
determin
number
transgend
male
activ
donat
larg
blood
center
track
donor
contact
resolv
descrep
donor
chang
gender
femal
male
answer
ye
prior
pregnanc
identifi
hla
antibodi
test
result
review
donor
see
test
whether
test
posit
neg
resultsfind
donor
identifi
chang
gender
birth
gender
femal
donor
chang
gender
male
male
donor
chang
gender
femal
transgend
male
donor
birth
gender
femal
answer
ye
pregnanc
question
one
donat
three
donor
apheresi
donor
test
hla
antibodi
one
test
posit
two
test
neg
hla
antibodi
four
donor
whole
blood
donor
test
hla
test
ad
donor
record
test
could
perform
next
time
present
donat
conclus
transgend
male
donor
may
prior
pregnanc
also
choos
becom
pregnant
transit
femal
male
six
percent
transgend
male
identifi
report
prior
histori
pregnanc
center
donor
request
gender
chang
femal
male
hla
test
request
next
donat
first
time
donor
qualifi
base
state
gender
transgend
donor
histori
pregnanc
identifi
unless
volunt
inform
consider
given
use
educ
materi
prompt
donor
reveal
histori
pregnanc
time
donat
hla
antibodi
test
perform
effect
variabl
volum
scale
introduct
larg
multisit
blood
center
ralph
r
vassallo
marjori
bravo
hani
kamel
blood
system
inc
backgroundcas
studi
regul
allow
whole
blood
donat
wbd
mlkg
estim
blood
volum
ebv
tradit
measuringmix
devic
set
halt
blood
flow
fix
volum
test
sampl
consist
limit
variabl
volum
scale
vv
program
vari
unit
volum
ml
donor
ebv
maxim
transfus
rbc
plasma
recov
plasma
rp
volum
rp
wbd
small
import
sourc
deriv
blood
center
cost
recoveri
report
effect
introduc
hemoflow
vv
donor
reaction
rate
rp
volum
larg
blood
center
compar
previou
fix
set
variabl
collect
volum
expect
decreas
ml
ebv
donor
yo
increas
ml
other
studi
designmethod
donor
vasovag
reaction
vvr
rate
prefaint
prolongedoffsit
reaction
loss
conscious
loc
success
wbd
obtain
center
hemovigil
databas
mo
mo
phase
implement
vv
subsequ
mo
multivari
analysi
mva
period
perform
model
incorpor
donor
sex
age
firsttim
ftd
vs
repeat
statu
ebv
donat
site
volum
number
unit
plasma
sent
fraction
avail
time
period
blood
center
data
warehous
resultsfind
compar
baselin
period
signific
increas
prefaint
reaction
rate
note
preimplement
impl
period
continu
impl
postimpl
period
return
baselin
rate
postimpl
period
tabl
sever
reaction
show
increas
trend
becam
signific
postimpl
period
mva
show
vv
independ
factor
contribut
increas
prefaint
sever
reaction
howev
contribut
measur
odd
ratio
consist
lower
exert
known
donor
determin
reaction
rate
young
age
low
ebv
ftd
statu
collect
site
shown
plasma
unit
volum
increas
averag
ml
postimpl
period
tempor
match
baselin
preimpl
period
conclus
follow
initi
increas
mild
vvr
immedi
implement
vv
vvr
rate
fell
back
baselin
suggest
transient
staff
distract
usual
donor
care
minor
effect
increas
blood
loss
superimpos
improv
trend
subsequ
increas
prolongedoffsit
reaction
loc
prefaint
reaction
alreadi
return
baselin
suggest
staff
train
work
load
donor
complianc
mitig
strategi
determin
donor
reaction
far
greater
effect
small
addit
blood
loss
due
vv
small
signific
increment
rp
volum
improv
deriv
avail
offset
cost
vv
comparison
vasovag
citrat
reaction
rate
donor
accord
type
apheresi
procedur
pierr
robillard
yve
gr
egoir
hemaquebec
h
emaqu
ebec
backgroundcas
studi
apheresi
procedur
expos
donor
variou
volum
citrat
depend
upon
type
length
procedur
type
machin
use
citrat
reaction
cr
result
variou
degre
hypocalcemia
donor
blood
volum
taken
donor
vari
accord
type
procedur
use
volum
replac
loss
blood
volum
part
respons
occurr
vasovag
reaction
vvr
analysi
conduct
estim
incid
cr
vvr
accord
variou
type
apheresi
procedur
perform
blood
center
yfv
report
brazilian
state
rio
de
janeiro
sao
paulo
mina
gerai
santo
mainli
vector
case
mosquito
haemagogu
sabeth
gender
whose
habitat
tropic
forest
sinc
mani
brazilian
urban
area
close
rain
forest
outbreak
risk
area
infect
transmit
aed
mosquito
order
minim
risk
rio
de
janeiro
health
author
decid
promot
mass
vaccin
late
march
vaccin
produc
live
attenu
yfv
circul
least
week
vaccin
individu
vaccin
elicit
viscerotrop
effect
sometim
sever
diseas
due
brazilian
blood
regul
author
establish
week
deferr
period
yfv
vaccin
action
could
dramat
affect
avail
blood
donor
studi
show
measur
taken
rio
de
janeiro
blood
center
circumv
risk
attract
donor
studi
designmethod
strategi
consist
offer
popul
singl
place
blood
center
possibl
donat
blood
immedi
donat
get
vaccin
yfv
financi
advantag
donor
sinc
yfv
vaccin
complet
free
charg
brazilian
citizen
vaccin
administr
train
nurs
offic
close
donor
session
reason
prospect
donor
abl
donat
vaccin
also
offer
provid
contraind
blood
center
annnounc
mass
vacin
campaign
launch
would
vaccin
peopl
came
blood
center
donat
blood
reason
prospect
donor
abl
donat
vaccin
also
offer
provid
contraind
resultsfind
five
day
campaign
receiv
blood
donor
candid
accept
blood
donor
medic
interview
deferr
rate
period
year
prospect
donor
blood
donat
deferr
rate
get
vaccin
yfv
give
blood
campaign
abl
attract
five
day
period
addit
donor
compar
date
repres
increas
number
blood
donat
without
deferr
rate
increment
slight
increas
proport
firsttim
donor
conclus
strategi
success
allow
blood
center
build
blood
inventori
larg
enough
avoid
risk
shortag
due
mass
vaccin
yfv
dose
loss
must
accommod
collect
plt
donat
ensur
us
plt
dose
met
current
tripl
set
kit
pr
approv
europ
plt
loss
adjust
apheresi
target
paramet
may
impact
split
rate
sr
product
per
apheresi
procedur
inventori
suitabl
pr
without
impact
us
blood
center
sr
warrant
evalu
optim
studi
designmethod
apheresi
collect
center
differ
sr
analyz
baselin
sr
convent
pc
calcul
assum
minimum
dose
allow
product
loss
singl
doubl
tripl
convent
pc
ii
concentr
volum
requir
apheresi
devic
manufactur
use
collect
dose
volum
concentr
assess
pr
kit
compat
base
storag
medium
pa
plasma
assum
minimum
dose
allow
product
loss
pr
unit
ii
remov
small
quantiti
unit
excess
volum
dose
meet
pr
spec
iii
part
paramet
collect
could
divid
one
kit
pr
elig
part
undergo
pr
remaind
treat
convent
iv
collect
unsuit
pr
spec
would
decreas
sr
treat
would
count
convent
pc
resultsfind
conclus
blood
center
today
adopt
pr
signific
percent
current
suppli
high
without
affect
sr
compat
increas
divid
larg
donat
percent
achiev
depend
current
proport
collect
practic
chang
collect
paramet
optim
donat
count
accuraci
volum
reduct
improv
pr
compat
individu
analysi
warrant
blood
center
rbc
pltp
plt
pltrbcp
pltrbc
donat
citrat
exposur
ml
studi
designmethod
random
placebocontrol
singl
blind
subject
singlesit
studi
ascend
microdos
autolog
apheresisderiv
thrombosom
conduct
subject
divid
cohort
receiv
increas
dose
rang
lowest
effect
dose
found
rabbit
model
cohort
receiv
dose
cohort
receiv
two
dose
one
hour
apart
primari
end
point
safeti
toler
subject
monitor
inhospit
post
infus
follow
day
advers
event
global
neurolog
assess
abbrevi
physic
exam
laboratori
test
resultsfind
seriou
advers
event
sae
subject
discontinu
postinfus
due
signific
decreas
platelet
count
baselin
total
ae
treatment
emerg
teae
treatmentrel
thrombosom
control
teae
mild
moder
sever
cohort
thrombosom
subject
treatment
relat
advers
event
one
cohort
subject
develop
upper
respiratori
infect
elev
wbc
within
hour
post
infus
resolv
hour
elev
ddimer
hour
post
infus
resolv
day
subject
also
elev
prothrombin
fragment
baselin
increas
post
transfus
peak
hour
resolut
day
one
cohort
subject
develop
nonspecif
twave
chang
hour
follow
infus
resolv
day
without
clinic
symptom
troponin
level
echo
stress
test
normal
ekg
consid
possibl
normal
variant
relat
placement
ekg
lead
anoth
cohort
subject
develop
igg
platelet
autoantibodi
day
undetect
day
chang
platelet
count
thrombosom
autoantibodi
assay
posit
baselin
day
neg
day
backgroundcas
studi
cryopreserv
platelet
plt
could
extend
shelf
life
day
two
year
cryopreserv
plt
cryoplt
appear
greater
vivo
hemostat
effect
liquidstor
plt
plt
shown
requir
protein
synthesi
capabl
certain
function
clot
signal
immun
respons
studi
design
assess
whether
reconstitut
cryoplt
carri
protein
synthesi
upon
thaw
short
term
storag
studi
designmethod
apheresi
plt
cryopreserv
dmso
store
thaw
unit
reconstitut
thaw
ffp
spike
either
lm
puromycin
pm
nm
biotinlabel
pm
plt
store
roomtemperatur
agit
sampl
drawn
immedi
reconstitut
well
hour
assess
pm
incorpor
measur
protein
synthesi
vitro
assay
determin
platelet
activ
bind
phosphatidylserin
exposur
annexinv
bind
microvesicl
count
supernat
plt
microvesicl
pmv
prepar
supernat
ultracentrifug
plt
pmv
lyse
triton
buffer
qualit
proteom
perform
sampl
follow
affinitypurif
streptavidin
bead
resultsfind
vitro
paramet
reconstitut
subsequ
store
platelet
line
previous
publish
result
high
surfac
level
phosphatidylserin
pmv
gener
cryopreserv
count
increas
hour
storag
immunoblot
analys
plt
show
increas
pm
incorpor
hour
storag
respect
massspectrometri
reveal
uniqu
protein
synthes
hour
storag
confirm
gtpase
gtpaseregulatori
protein
rhogdi
immunoblot
analys
analys
pmv
translatom
also
reveal
presenc
synthes
protein
howev
chang
throughout
storag
find
suggest
defin
panel
protein
packag
pmv
upon
freez
thaw
addit
pmv
translatom
profil
compris
smaller
subset
synthes
protein
compar
cryoplt
translatom
includ
protein
rhogdi
conclus
studi
demonstr
cryoplt
synthes
protein
upon
reconstitut
ffp
subsequ
storag
discoveri
subset
protein
pmv
suggest
encapsul
possibl
select
manner
observ
provid
novel
insight
capac
protein
synthesi
cryoplt
potenti
regul
protein
packag
pmv
backgroundcas
studi
author
hospitalbas
blood
bank
receiv
varianc
fda
aabb
use
cold
store
platelet
csp
shelf
life
day
group
csp
store
refriger
emerg
depart
use
support
trauma
program
use
massiv
bleed
patient
placement
csp
air
ambul
store
cooler
next
logic
step
provid
platelet
therapi
sooner
patient
studi
designmethod
eight
doubl
unit
csp
collect
use
trima
accelv
r
two
doubl
csp
pathogen
reduc
use
interceptv
r
pathogen
reduct
system
half
csp
pair
subject
flat
storag
refriger
half
load
credov
r
cooler
unit
ffp
unit
rbc
unit
whole
blood
three
platelet
collect
via
syring
unit
min
storag
cooler
refriger
hour
storag
function
valid
platelet
platelet
count
agonist
thrombin
receptor
agonist
peptid
trap
adenosin
diphosph
adp
collagen
stimul
platelet
aggreg
nonactiv
agonist
activ
platelet
surfac
express
phosphatidylserin
ps
annexinv
bind
pselectin
fibrinogen
receptor
bind
measur
coulter
counter
channel
aggregomet
digit
flow
cytomet
pair
wilcoxon
rank
sum
test
use
analyz
differ
degrad
rate
p
deem
signific
conclus
platelet
includ
pathogen
reduc
store
oxygendepriv
environ
cooler
lose
function
capabl
compar
platelet
store
refriger
adequ
oxygen
hour
therefor
cold
store
platelet
transport
cooler
viabl
option
provid
timeli
platelet
intervent
sever
injur
patient
prior
hospit
arriv
molecular
siev
beyond
genotyp
ghazala
hashmi
reinhard
klemm
michael
seul
biomolecular
analyt
immunoinformatica
backgroundcas
studi
decad
commerci
introduct
http
blood
group
genotyp
though
avail
sever
format
remain
tool
special
task
eg
profil
difficult
patient
sampl
identif
rare
antigen
combin
serolog
remain
tool
choic
routin
antigen
type
introduc
molecular
siev
altern
current
approach
manag
special
donor
unit
inventori
novel
process
dna
analysi
combin
multiplex
marker
offer
exist
genotyp
method
pool
multipl
sampl
manner
permit
step
wise
refin
candid
set
molecular
attribut
pattern
studi
designmethod
molecular
siev
special
format
leansequenc
proprietari
process
permit
simultan
analysi
four
sampl
allel
encod
rbc
antigen
mn
rhce
lu
kel
fy
jk
di
yt
co
includ
identif
rhce
allel
molecular
siev
extend
capabl
analysi
pool
attain
larg
scale
thu
one
format
process
sampl
accommod
singl
run
follow
complet
siev
step
candid
may
directli
assign
request
may
select
enrich
subsequ
profil
step
sampl
rare
otherwis
desir
attribut
molecularsiev
use
identifi
suitabl
donor
unit
sensit
sickl
cell
anemia
sca
patient
http
exclud
le
e
variant
assum
request
per
patient
present
alloantibodi
ab
multipl
combin
proprietari
greedi
algorithm
invok
optim
pair
candid
unit
request
resultsfind
siev
plate
hold
candid
unit
actual
black
donor
follow
profil
sampl
select
enrich
e
neg
c
neg
cekfya
neg
produc
assign
request
indic
color
shown
row
assign
thu
number
assign
substanti
exceed
number
well
process
moreov
remain
pool
sampl
produc
addit
assign
second
set
request
total
assign
well
anoth
scenario
siev
full
plate
sampl
produc
assign
two
success
batch
request
sca
patient
yield
exceed
siev
alon
typic
fill
request
moder
complex
ab
conclus
molecularsiev
widen
funnel
focus
search
candid
donor
unit
attain
new
level
effici
procur
suitabl
unit
patient
hemoglobinopathi
molecular
siev
identifi
red
blood
cell
special
phenotyp
attribut
kristoph
fernandez
monica
kalvelag
ghazala
hashmi
michael
seul
biomolecular
analyt
lifeshar
blood
center
backgroundcas
studi
provid
transfus
support
patient
sickl
cell
anemia
hemoglobinopathi
remain
challeng
logist
task
must
accommod
preexist
alloantibodi
multipl
combin
prefer
minim
risk
continu
transfusionrel
sensit
allel
divers
predominantli
black
patient
popul
especi
rh
locu
encod
varieti
partial
phenotyp
complic
problem
http
bit
studi
designmethod
molecular
siev
proprietari
new
process
order
rapidli
probe
candid
donor
unit
larg
number
multipl
phenotyp
pattern
permit
analysi
pool
pool
pool
sampl
multipl
allel
includ
rhce
locu
encod
mn
rh
lu
kel
fy
jk
di
yt
co
antigen
base
siev
sampl
may
group
molecular
attribut
pattern
rang
singl
eg
specif
combin
eg
combin
allel
encod
partial
rh
phenotyp
siev
option
may
follow
profil
sampl
select
desir
attribut
pattern
genom
dna
predominantli
black
donor
independ
genotyp
one
two
commerci
method
provid
lbc
bmx
pool
prepar
prior
amplif
analyz
novel
leansequenc
method
resultsfind
pool
genotyp
consist
avail
individu
sampl
genotyp
antigen
pattern
particular
interest
includ
two
group
name
sever
pool
homozyg
certain
other
pool
heterozyg
illustr
former
pattern
type
appropri
pool
queri
reveal
siev
alon
identifi
among
sampl
also
among
sampl
also
neg
partial
phenotyp
illustr
latter
pattern
type
pool
identifi
heterozyg
het
allel
encod
antigen
high
low
preval
segreg
het
pool
subpopul
abl
select
specif
ee
pool
demonstr
subsequ
profil
contain
esampl
also
identifi
pool
het
allel
indic
possibl
presenc
rare
donor
exampl
ytab
pool
co
ab
other
conclus
molecularsiev
singl
plate
identifi
mani
desir
antigenneg
phenotyp
permit
select
pool
combin
agneg
pattern
includ
partial
rh
phenotyp
combin
sampl
thu
confirm
ag
neg
avail
assign
siev
also
facilit
enrich
subsequ
refin
molecular
attribut
profil
accord
pend
anticip
demand
antigenneg
pattern
partialc
partial
c
e
sampl
avail
siev
backgroundcas
studi
sequenc
inform
gener
next
gener
sequenc
ng
often
comput
phase
use
haplotypephas
algorithm
util
experiment
deriv
haplotyp
inform
improv
predict
routin
use
hla
type
among
blood
group
system
howev
experiment
deriv
haplotyp
known
short
gene
landsteinerwien
duffi
longer
gene
abo
kb
haplotyp
statist
deriv
recent
establish
larg
dataset
long
ermap
haplotyp
code
scianna
blood
group
system
studi
designmethod
nucleotid
sequenc
kb
use
physic
confirm
ermap
allel
previous
publish
fulllength
sequenc
align
variant
site
extract
manual
bayesian
coalesc
algorithm
implement
beast
use
estim
coalesc
phylogeni
variant
allel
ancestr
state
intern
node
phylogeni
resultsfind
found
least
clade
repres
cluster
allel
clade
one
observ
allel
identifi
ancestr
allel
cluster
allel
use
allel
abl
predict
allel
high
posterior
probabl
ancestr
observ
allel
yet
observ
may
extant
conclus
explor
phylogenet
structur
evolutionari
event
underli
origin
differ
ermap
allel
predict
ancestr
allel
present
studi
show
mean
predict
allel
calcul
distinct
probabl
correct
predict
allel
probabl
instrument
defin
cutoff
valu
determin
comput
predict
allel
worth
confirm
physic
evid
allel
identifi
studi
like
may
util
design
microarray
technolog
imput
genotyp
map
ng
data
new
allel
nucleotid
insert
would
predict
caus
complet
loss
express
correspond
antigen
bioinformat
perspect
encod
group
rather
weak
express
respect
antigen
lack
correspond
antibodi
plasma
found
confirm
repres
subgroup
b
suggest
transcript
slippag
observ
respons
low
level
antigen
express
abo
genotyp
power
serolog
molecular
result
evalu
togeth
studi
need
inform
develop
bioinformat
tool
accur
associ
abo
genotyp
phenotyp
backgroundcas
studi
evolutionarili
relat
abo
gene
encod
b
glycosyltransferas
bt
forssman
glycolipid
synthas
fs
catalyz
biosynthesi
b
forssman
oligosaccharid
antigen
respons
abo
for
blood
group
system
respect
human
bt
possess
leuglygli
metglyala
respect
codon
tripeptid
import
determin
sugar
specif
enzym
nacetyldgalactosamin
galnac
galactos
bt
function
fss
possess
glyglyala
correspond
codon
exhibit
galnac
specif
recent
shown
human
gain
weak
fs
activ
leuglygli
substitut
glyglyala
suggest
tripeptid
involv
recognitionbind
acceptor
substrat
addit
donor
nucleotidesugar
substrat
studi
designmethod
search
addit
mechan
might
enabl
human
express
varieti
amino
acid
substitut
construct
human
prepar
addit
exon
delet
construct
mrna
transcript
also
prepar
dna
express
construct
transfect
cell
cellsurfac
express
antigen
immunolog
monitor
monoclon
antibodi
resultsfind
found
substitut
also
confer
human
weak
fs
activ
also
found
delet
exon
human
transcript
bestow
weak
fs
activ
alter
rna
splice
frequent
cancer
mechan
may
explain
least
partial
appear
antigen
certain
cancer
cell
tumor
forssman
antigenneg
human
speci
furthermor
cointroduct
one
chang
togeth
glyglyala
substitut
synergist
confer
strong
fs
activ
addit
strong
bt
activ
conclus
substitut
glyglyala
tripeptid
codon
catalyt
domain
may
modifi
acceptor
specif
enzym
ser
exon
delet
may
alter
intraglog
local
enzym
mechan
function
synergi
overlap
usag
acceptor
glycosyltransferas
encod
abo
gene
reminisc
common
ancestr
origin
alpha
nac
transferas
gene
find
synthes
implic
boundari
abo
for
system
may
strict
previous
delin
due
crosstalk
inbetween
rh
type
requir
fda
factaabb
ident
test
sinc
antibodi
cb
plasma
matern
origin
aborh
phenotyp
reli
red
cell
type
b
antigen
fulli
develop
birth
present
one
third
b
antigen
express
level
compar
adult
cell
result
indetermin
abo
result
cb
product
evalu
use
dnabas
method
abo
type
aid
resolut
inconclus
indetermin
discrep
serolog
type
result
studi
designmethod
total
cb
unit
cbu
type
aborh
beckman
coulter
pk
system
blood
group
phenotyp
period
abo
genotyp
target
specif
snp
group
b
need
gene
sequenc
conduct
case
indetermin
result
cbu
provid
transplant
abo
discrep
found
transplant
center
resultsfind
sixtytwo
cb
sampl
report
abo
rh
phenotyp
initi
test
therefor
cbu
could
use
clinic
molecular
aborh
type
resolv
one
case
heterozyg
ao
bo
ab
predict
abo
phenotyp
rh
neg
tabl
predomin
donor
race
caucasian
four
cbu
abo
discrep
also
evalu
genotyp
tabl
abo
type
perform
hospit
day
transplant
differ
report
cb
bank
fourth
identifi
posttranspl
abo
type
recipi
molecular
genotyp
resolv
discrep
cbu
ident
alway
verifi
confirmatori
hla
type
conclus
current
fda
approv
dnabas
abo
assay
howev
abo
genotyp
use
method
sampl
antibodi
test
alon
conclus
rescu
cbu
could
use
otherwis
genotyp
help
resolv
abo
discrep
abstract
coba
v
r
hev
use
cobasv
r
system
qualit
pcr
test
detect
hev
rna
human
plasma
purpos
studi
evalu
preval
hev
rna
among
us
blood
donat
collect
midwest
region
report
higher
preval
hev
infect
eastern
us
studi
designmethod
fresh
frozen
edta
plasma
sampl
american
red
cross
donor
collect
februari
deidentifi
screen
individu
donat
test
idnat
use
cobasv
r
hev
use
cobasv
r
system
research
protocol
sampl
primarili
midwestern
eastern
region
us
sampl
reactiv
cobasv
r
hev
test
altern
hev
nat
hev
rna
quantit
hev
genotyp
hev
antibodi
resultsfind
valid
result
total
donat
reactiv
cobasv
r
hev
confirm
posit
confirm
donat
old
male
indiana
old
male
california
old
femal
kentucki
donat
posit
heminest
pcr
altern
hev
nat
howev
kentucki
donat
high
level
hev
rna
iuml
strongli
posit
igm
igg
hev
antibodi
indiana
donat
genotyp
california
donat
genotyp
genotyp
determin
kentucki
donat
see
tabl
clinic
specif
cobasv
r
hev
test
idnat
exact
ci
conclus
base
confirmedposit
donat
test
hev
preval
exact
ci
detect
rate
ci
date
case
tthev
document
us
howev
base
preval
observ
immunosuppress
transfus
recipi
may
increas
risk
transfusiontransmit
hev
backgroundcas
studi
monitor
epidemiolog
tti
within
donor
popul
critic
provid
ongo
assess
infect
risk
associ
fda
polici
chang
msm
deferr
criteria
ttim
multicent
federallyfund
program
intend
deriv
hbv
hcv
hiv
preval
incid
viral
genotyp
donor
risk
factor
greater
blood
collect
us
ttim
support
two
distinct
coordin
center
laboratori
risk
factor
lrcc
donat
databas
ddcc
report
month
preval
along
demograph
trend
ddcc
studi
designmethod
four
blood
provid
respect
test
laboratori
particip
standard
consensusposit
cp
monitor
definit
establish
donor
test
result
hbv
hcv
hiv
result
along
demograph
donor
donat
statu
firsttim
vs
repeat
assembl
singl
data
set
rate
nucleic
acid
test
nat
yield
seroneg
concord
posit
serolog
plu
nat
posit
combin
compris
cp
comput
overal
donor
donat
demograph
geograph
tempor
characterist
appropri
rate
compar
differ
use
confid
interv
analysi
contain
data
resultsfind
among
donat
report
firsttim
repeat
donor
respect
cp
result
hbv
hcv
hiv
correspond
rate
per
pht
donat
preval
among
firsttim
donor
expect
higher
among
donat
repeat
donor
ratio
hbv
hcv
hiv
rate
pht
among
male
higher
among
femal
marker
hbv
vs
hcv
vs
hiv
vs
gener
higher
rate
marker
seen
among
minor
donor
age
group
also
year
hiv
southeast
south
central
hiv
hcv
southwest
hbv
trend
note
time
period
compar
conclus
data
major
us
blood
system
success
combin
baselin
monitor
purpos
demograph
trend
similar
observ
donor
studi
gener
agre
commun
trend
chang
rate
requir
analys
context
potenti
chang
demograph
structur
donor
popul
screen
donat
blood
babesia
endem
region
unit
state
use
transcriptionmedi
amplif
assay
fulli
autom
system
vanessa
bre
melani
c
proctor
deanna
self
moniqu
portug
adrian
gurrola
laura
tonnetti
sonia
bakkour
cheryl
lobo
michael
paul
busch
susan
l
stramer
jeffrey
linnen
grifol
diagnost
solut
inc
american
red
cross
blood
system
research
institut
new
york
blood
center
backgroundcas
studi
procleix
v
r
babesia
assay
procleix
panther
v
r
system
qualit
vitro
nucleic
acid
test
current
develop
assay
base
transcriptionmedi
amplif
tma
detect
four
clinic
relev
babesia
speci
b
microti
b
divergen
b
duncani
b
venatorum
human
whole
blood
specimen
test
intend
screen
blood
donat
individu
pool
donat
whole
blood
sampl
lyse
pool
autom
procleix
xpress
v
r
system
prior
test
procleix
panther
system
studi
evalu
preliminari
analyt
clinic
perform
procleix
babesia
assay
panther
system
studi
designmethod
analyt
sensit
determin
dilut
vitro
synthes
rna
transcript
four
babesia
speci
fresh
b
microtiinfect
hamster
whole
blood
cryopreserv
b
duncaniinfect
hamster
whole
blood
fresh
b
divergensinfect
human
erythrocyt
test
determin
limit
detect
lod
parasitesml
pml
probit
analysi
clinic
sensit
specif
determin
screen
unlink
whole
blood
donat
collect
august
th
april
th
northeastern
unit
state
initi
reactiv
donat
confirm
repeat
test
pcr
andor
igg
immunofluoresc
assay
ifa
reactiv
individu
donor
lysat
test
pool
resultsfind
procleix
babesia
assay
detect
four
babesia
speci
lod
rang
copiesml
preliminari
lod
parasitesml
rang
pml
b
microti
pml
b
duncani
pml
b
divergen
donat
screen
initi
reactiv
confirm
posit
donat
identifi
specif
ci
confirm
posit
specimen
reactiv
ifa
pcr
ifa
pcr
confirm
posit
sampl
reactiv
lysat
pool
donor
reactiv
donat
resid
ct
nj
nh
overal
incid
ct
conclus
procleix
babesia
assay
procleix
panther
system
demonstr
high
clinic
specif
sensit
detect
four
babesia
speci
similar
sensit
confirm
posit
donat
also
detect
pool
thu
demonstr
effect
pool
lysat
screen
conclus
use
lag
avid
assay
show
firsttim
repeat
hivposit
us
blood
donor
newlyacquir
ie
incid
hiv
infect
frequent
younger
donor
use
approach
provid
addit
monitor
tool
assess
chang
characterist
donor
whose
risk
exposur
proxim
date
donat
also
complement
tradit
incid
method
allow
deriv
incid
donor
type
epidemiolog
hepat
b
viru
hepat
c
viru
human
immunodefici
viru
unit
state
blood
donor
lauren
crowder
whitney
r
steel
ed
p
notari
jame
hayn
roger
dodd
susan
l
stramer
american
red
cross
american
red
cross
retir
backgroundcas
studi
preval
hbv
hcv
us
blood
donor
decreas
hiv
rate
remain
constant
howev
incid
recent
calcul
report
preval
incid
residu
risk
rr
hbv
hcv
hiv
larg
us
blood
system
studi
designmethod
preval
calcul
interv
incid
measur
number
posit
among
repeat
donor
divid
total
time
risk
personyear
py
rr
calcul
use
window
period
day
hbv
hcv
hiv
respect
linear
regress
calcul
p
signific
resultsfind
million
donat
donor
femal
firsttim
ft
caucasian
signific
decreas
donat
preval
hbv
hcv
signific
decreas
hiv
year
see
tabl
f
r
valu
signific
decreas
seen
ft
donor
preval
hbv
hcv
preval
ft
donor
significantli
like
male
hbv
hcv
hiv
p
incid
agent
declin
signific
hbv
decreas
hcv
incid
signific
fewer
incid
donor
last
period
vs
hcv
incid
donor
like
male
vs
p
younger
vs
year
overal
incid
donor
like
caucasian
male
p
rr
agent
decreas
time
rr
hbv
hcv
hiv
respect
conclus
preval
incid
rr
hbv
hcv
hiv
gener
decreas
within
blood
system
time
frame
donor
screen
deferr
regul
evolv
import
monitor
risk
critic
note
even
larg
popul
small
chang
number
posit
signific
impact
preval
incid
rate
furthermor
mayv
isol
patient
haiti
suggest
viru
alreadi
circul
caribbean
extent
mayv
transmiss
could
underestim
due
limit
surveil
diagnost
capabl
therefor
necessari
prepar
mayv
emerg
potenti
risk
blood
suppli
case
transmit
blood
transfus
studi
designmethod
platelet
compon
pc
prepar
pa
spike
mayv
treat
amotosalen
uva
illumin
sampl
collect
preuva
postuva
illumin
infecti
titer
determin
rbc
spike
mayv
mix
glutathion
gsh
process
solut
dose
amustalin
incub
room
temperatur
sampl
collect
prior
addit
amustalin
pretreat
follow
incub
posttreat
determin
infecti
titer
infecti
titer
sampl
determin
plaqu
assay
cell
extent
inactiv
determin
compar
infecti
titer
plaqu
form
unit
pfu
ml
prev
posttreat
sampl
resultsfind
mayv
inactiv
limit
detect
pc
rbc
platelet
log
log
pfuml
inactiv
mayv
achiev
rbc
inactiv
mayv
log
log
pfuml
conclus
studi
demonstr
robust
inactiv
mayv
amotosalenuva
treatment
pc
amustalinegsh
treatment
rbc
system
effici
inactiv
alphavirus
demonstr
potenti
transfusiontransmiss
includ
mayv
chikv
rrv
prt
offer
potenti
mitig
strategi
maintain
blood
compon
avail
area
multipl
alphavirus
epidem
endem
test
feasibl
data
submit
fda
review
intercept
red
blood
cell
approv
commerci
use
thrombot
thrombocytopen
purpura
high
inhibitor
may
repres
distinct
diseas
subset
respons
therapi
base
immatur
platelet
count
aipc
dynam
hamza
n
gokozan
holli
reev
robert
w
maitta
case
western
reserv
univers
school
medicin
univers
hospit
cleveland
medic
center
backgroundcas
studi
thrombot
thrombocytopen
purpura
lifethr
consumpt
thrombocytopenia
microangiopath
hemolyt
anemia
caus
diffus
ischem
damag
tissu
earli
therapeut
plasma
exchang
tpe
initi
improv
surviv
absolut
immatur
platelet
count
aipc
found
aid
diagnosi
followup
ttp
patient
aipc
chang
respons
therapi
patient
low
activ
high
inhibitor
analyz
patient
cohort
analyz
aipc
respons
therapi
five
patient
defici
high
inhibitor
larg
tertiari
academ
medic
center
studi
designmethod
patient
activ
high
inhibitor
mean
age
cohort
year
rang
four
patient
femal
one
male
patient
present
microangiopath
hemolyt
anemia
thrombocytopenia
mean
x
l
rang
x
l
low
aipc
mean
x
l
rang
x
l
patient
initi
daili
tpe
prednison
addit
immunosuppress
hospit
stay
cohort
consist
rituximab
mgm
patient
cyclophosphamid
mgm
one
patient
tpe
continu
platelet
count
reach
x
l
least
two
consecut
day
immatur
platelet
fraction
ipf
aipc
ipf
x
platelet
count
obtain
daili
pretp
cbc
aipc
ratio
calcul
baselin
resultsfind
patient
respond
rapidli
daili
tpe
mean
day
rang
day
achiev
threefold
increas
aipc
baselin
mean
x
l
rang
x
l
rapid
improv
platelet
count
howev
improv
platelet
count
accompani
expect
decreas
aipc
suggest
recoveri
diseas
patient
experienc
platelet
mean
x
l
rang
x
l
aipc
mean
x
l
rang
x
l
decreas
occur
concurr
receiv
daili
tpe
mean
day
rang
day
mean
platelet
count
x
l
rang
x
l
mean
aipc
x
l
rang
x
l
patient
initi
either
rituximab
cyclophosphamid
therapi
conjunct
tpe
mean
day
aipc
platelet
count
instabl
aipc
trend
level
indic
restor
neg
feedback
time
conclus
rapid
decreas
platelet
count
good
respons
ttp
patient
may
rais
suspicion
presenc
high
inhibitor
patient
high
inhibitor
similar
aipc
dynam
initi
high
aipc
product
follow
unexpect
decreas
aipc
concurr
platelet
count
recoveri
occur
neg
feedback
platelet
aipc
product
reestablish
patient
high
inhibitor
may
repres
distinct
subset
ttp
suggest
aipc
respons
benchmark
central
urgent
plasma
exchang
servic
patient
admit
diagnosi
thrombot
thrombocytopen
purpura
multihospit
healthcar
system
jansen
n
seheult
michel
n
stram
joan
sevcik
alesia
kaplan
joseph
e
kiss
depart
patholog
univers
pittsburgh
medic
center
blood
system
inc
univers
pittsburgh
backgroundcas
studi
consensu
guidelin
recommend
therapeut
plasma
exchang
tpe
must
start
earli
possibl
within
hour
diagnosi
thrombot
thrombocytopen
purpura
ttp
made
howev
limit
data
document
actual
practic
sever
oper
facet
deliv
central
urgent
tpe
program
multihospit
healthcar
system
includ
central
venou
cv
access
order
releas
deliveri
thaw
plasma
transport
personnel
equip
perform
procedur
studi
analyz
time
elaps
major
step
diagnosi
initi
tpe
patient
admit
ttp
studi
designmethod
retrospect
review
electron
medic
record
laboratori
inform
system
januari
novemb
conduct
identifi
ttp
patient
undergo
urgent
tpe
demograph
comorbid
pertin
laboratori
test
activ
level
complet
blood
count
biochem
marker
hemolysi
coagul
studi
review
identifi
patient
tempor
data
tpe
request
cv
access
placement
plasma
product
releas
usual
happen
cv
access
arriv
tpe
team
initi
procedur
extract
procedur
note
blood
bank
inform
system
descript
summari
statist
gener
use
stata
version
statacorp
tx
group
comparison
made
base
hospit
locat
level
care
histori
ttp
use
wilcoxon
ranksum
test
resultsfind
ttp
patient
identifi
exclud
due
miss
tempor
data
import
variabl
major
patient
treat
central
academ
center
remaind
treat
peripher
site
fifteen
patient
prior
histori
ttp
sever
defici
admiss
median
time
tpe
request
initi
hour
interquartil
rang
hour
nonsignific
trend
shorter
time
interv
request
cv
access
request
tpe
initi
patient
admit
intens
care
unit
icu
versu
nonicu
patient
tabl
treatment
start
within
window
patient
median
time
cv
access
significantli
longer
patient
vs
hour
p
two
patient
prior
histori
ttp
four
patient
sever
defici
major
time
interv
tpe
request
tpe
initi
spent
obtain
cv
access
plasma
product
signific
differ
time
interv
compar
patient
new
diagnosi
ttp
versu
patient
recurr
relaps
diseas
tabl
patient
treat
central
academ
center
versu
peripher
hospit
conclus
consensu
hour
target
window
tpe
request
initi
appear
feasibl
central
tpe
program
servic
transfus
vol
supplement
hospit
healthcar
system
address
limit
avail
cv
access
would
like
yield
greatest
improv
timeli
urgent
tpe
cytoreduct
therapi
cellular
hyperviscos
util
cytapheresi
treatment
chronic
myelogen
leukemia
essenti
thrombocythemia
jan
c
hofmann
dobri
kiprov
california
pacif
medic
center
backgroundcas
studi
sever
retrospect
case
seri
suggest
cytoreduct
therapi
treat
cellular
hyperviscos
prevent
thrombot
event
patient
pt
chronic
myelogen
leukemia
acceler
transform
cmlat
essenti
thrombocythemia
et
may
improv
shortterm
outcom
howev
random
control
trial
rct
assess
efficaci
cytapheresi
treatment
group
pt
perform
studi
designmethod
januari
januari
perform
cytapheresi
cy
treatment
tx
pt
either
cmlat
et
clinic
andor
laboratori
evid
cellular
hyperviscos
pt
cmlat
receiv
leukapheresi
lp
tx
pt
et
receiv
thrombocytapheresi
tc
tx
cmlat
pt
present
median
wbc
x
l
rang
x
l
blast
percent
blast
count
x
l
median
age
year
year
male
cn
symptom
sx
leukostasi
lk
defin
headach
cognit
declin
confus
somnol
visual
abnorm
seizur
pulmonari
pulm
sx
lk
defin
dyspnea
hypoxia
bilater
chest
infiltr
cmlat
pt
sx
lk
pt
sx
either
cn
pulm
lk
sx
pt
sx
cn
pulm
lk
sx
et
pt
present
median
platelet
plt
count
x
l
x
l
pt
sx
thrombosi
evid
cva
tia
mi
dvt
median
age
year
year
pt
male
resultsfind
pt
receiv
cours
cy
tx
follow
object
decreas
risk
thrombot
hemorrhag
complic
relat
hyperviscos
stabil
cmlat
pt
induct
chemotherapi
ind
chemo
wbc
plt
ct
tx
goal
wbc
count
ct
x
l
cmlat
pt
plt
ct
x
l
symptomat
et
pt
x
l
asymptomat
et
pt
cmlat
pt
receiv
median
lp
tx
mean
txspt
rang
tx
et
pt
underw
median
tc
tx
mean
txspt
tx
outcom
evalu
percentag
pt
reach
wbc
plt
ct
tx
goal
receiv
ind
chemo
improv
outcom
defin
pt
reach
wbc
plt
ct
tx
goal
cy
tx
stabil
pt
achiev
reduct
wbc
plt
ct
without
reach
goal
unchang
pt
achiev
neither
cmlat
cohort
pt
improv
pt
stabil
pt
worsen
et
cohort
improv
stabil
unchang
cmlat
pt
median
final
wbc
ct
x
l
rang
x
l
pt
receiv
ind
chemo
et
pt
median
final
plt
ct
x
l
x
l
pt
resolut
thrombot
transfus
vol
supplement
symptom
cmlat
pt
et
pt
expir
within
day
cours
cy
tx
expir
pt
pt
blast
crisi
sx
cn
pulm
lk
pt
intracrani
hemorrhag
cva
pt
hypotens
intub
unabl
toler
ind
chemo
conclus
pt
cmlat
et
evid
impend
thrombosi
may
benefit
cytoreduct
therapi
limit
number
cytapheresi
treatment
median
tx
enabl
high
percentag
pt
receiv
definit
treatment
may
improv
shortterm
clinic
outcom
rct
assess
efficaci
cytapheresi
treatment
versu
induct
chemotherapi
platelet
inhibitor
tx
alon
subset
pt
would
use
backgroundcas
studi
partial
normal
salin
replac
plasma
exchang
procedur
common
practic
benefit
use
normal
salin
replac
fluid
includ
reduc
procedur
cost
possibl
reduct
hypothet
hyperoncot
effect
standard
albumin
formul
howev
use
normal
salin
may
increas
risk
undesir
potenti
costli
advers
event
hypotens
citrat
reaction
goal
studi
compar
frequenc
report
advers
outcom
patient
receiv
albumin
versu
albumin
salin
replac
fluid
plasma
exchang
institut
studi
designmethod
four
year
retrospect
chart
review
done
therapeut
apheresi
procedur
perform
apheresi
servic
use
albumin
normal
salin
replac
patient
receiv
plasma
entir
partial
replac
exclud
procedur
type
order
albumin
vs
percent
normal
salin
actual
use
procedur
age
gender
note
advers
event
procedur
record
case
repeat
procedur
model
use
gener
linear
mix
model
examin
risk
hypotens
andor
citrat
toxic
albumin
use
versu
use
covari
includ
fluid
type
age
gender
odd
ratio
confid
interv
ci
use
measur
risk
use
term
signific
twosid
pvalu
resultsfind
studi
period
procedur
document
subject
femal
age
rang
year
receiv
type
fluid
use
replac
signific
effect
risk
either
hypotens
citrat
toxic
replac
albumin
significantli
lower
risk
either
event
use
ci
also
significantli
lower
risk
caus
hypotens
ci
addit
lower
risk
caus
citrat
toxic
ci
age
signific
effect
hypotens
event
ci
effect
citrat
toxic
combin
outcom
gender
effect
frequenc
event
conclus
partial
salin
use
replac
fluid
albumin
plasma
exchang
significantli
increas
risk
hypotens
citrat
toxic
procedur
age
also
increas
risk
hypotens
use
salin
replac
fluid
plasma
exchang
minim
maxim
patient
safeti
especi
older
patient
backgroundcas
studi
therapeut
apheresi
ta
complex
procedur
mostli
welltoler
rare
associ
advers
event
ae
studi
publish
ae
associ
ta
lack
uniform
data
moreov
common
databas
unit
state
us
report
taassoci
ae
evalu
annual
incid
rate
ae
associ
ta
larg
tertiari
academ
medic
center
year
period
compar
publish
literatur
studi
designmethod
conduct
retrospect
studi
ta
procedur
perform
ae
classifi
accord
criteria
describ
tabl
studi
period
ta
perform
use
cobe
spectra
softwar
version
sinc
spectra
optia
apheresi
system
version
literatur
search
conduct
data
publish
ae
associ
ta
four
studi
us
nonu
studi
canada
europ
japan
analyz
trend
ae
rate
also
analyz
statist
analysi
perform
use
chi
squar
spearman
rho
test
resultsfind
overal
ae
incid
procedur
year
period
frequenc
ae
associ
therapeut
plasma
exchang
tpe
significantli
higher
p
compar
ta
procedur
found
signific
correl
number
tpe
ae
spearman
rho
year
signific
trend
moder
sever
ae
spearman
rho
respect
fatal
studi
period
major
ae
grade
grade
ii
procedur
complet
due
ae
comparison
ae
european
us
studi
show
statist
signific
differ
p
conclus
overal
incid
ae
significantli
lower
current
publish
literatur
incid
ae
publish
countri
significantli
lower
rate
publish
us
differ
incid
ae
literatur
emphas
need
uniform
report
stratif
ae
develop
common
databas
report
taassoci
ae
propos
grade
rational
order
standard
report
ae
tabl
variat
biochem
marker
bone
metabol
plateletpheresi
impact
sociodemograph
lifestyl
factor
marku
dettk
akh
vienna
univers
hospit
backgroundcas
studi
plateletpheresi
associ
shortterm
variat
biochem
marker
bone
turnov
sociodemograph
factor
lifestyl
behavior
recogn
factor
influenc
miner
metabol
bone
health
present
studi
analyz
influenc
demograph
lifestyl
factor
observ
chang
bone
marker
larg
cohort
routin
platelet
donor
studi
designmethod
altogeth
platelet
donor
donat
activ
platelet
donat
particip
studi
detail
anamnesi
particip
underw
standard
question
ask
sever
lifestyl
factor
known
affect
bone
metabol
blood
sampl
plateletpheresi
analyz
bone
format
marker
osteocalcin
oc
bone
resorpt
marker
crosslink
telopeptid
type
collagen
ctx
among
paramet
effect
calcium
supplement
bone
metabol
test
placebocontrol
crossov
studi
involv
ten
donor
resultsfind
plateletpheresi
result
increas
serum
level
bone
resorpt
marker
ctx
bone
format
marker
oc
paramet
return
base
level
within
hour
end
collect
multipl
regress
analysi
includ
paramet
sex
age
posit
famili
histori
bone
diseas
also
individu
factor
like
hormon
contracept
smoke
regular
alcohol
consumpt
sportiv
activ
reveal
influenc
sociodemograph
lifestyl
factor
observ
variat
ctx
oc
associ
individu
donor
career
number
previou
donat
observ
increas
bone
turnov
predict
paramet
could
identifi
amount
citrat
exposur
plateletpheresi
increas
serum
ctx
show
invers
correl
chang
serum
ioniz
calcium
continu
iv
supplement
calciumglucon
throughout
plateletpheresi
reduc
variat
bone
marker
although
effect
pronounc
ctx
compar
oc
conclus
amount
citrat
infus
routin
plateletpheresi
predict
paramet
transient
increas
serum
marker
bone
metabol
known
risk
factor
bone
diseas
includ
sex
age
smoke
alcohol
consumpt
seem
low
impact
observ
citraterel
variat
serolog
biomark
bone
turnov
transfus
optim
blood
product
versu
transfus
standard
product
traumatransfus
rat
model
mathij
wirtz
jordi
jurgen
jacolin
buchnerdoeven
jori
roelof
philip
spinella
jennif
muszynski
carel
gosl
nicol
jufferman
academ
medic
center
washington
univers
school
medicin
nationwid
children
hospit
backgroundcas
studi
transfus
associ
nosocomi
infect
organ
dysfunct
trauma
patient
may
mediat
solubl
bioactiv
substanc
blood
product
hypothes
remov
bioactiv
substanc
improv
host
immun
respons
reduc
organ
dysfunct
studi
designmethod
blood
product
prepar
syngen
rat
blood
accord
blood
bank
standard
solubl
mediat
remov
red
blood
cell
day
old
platelet
day
old
wash
plasma
filter
filter
rat
gram
polytraumat
crush
injuri
small
intestin
liver
lobe
fractur
right
femur
hemorrhag
estim
blood
volum
calcul
hemorrhag
continu
mean
arteri
pressur
reach
rat
random
resuscit
standard
blood
product
washedfilt
blood
product
sham
blood
sampl
taken
trauma
assess
biochemistri
coagul
statu
ex
vivo
whole
blood
stimul
test
lp
perform
sacrific
organ
damag
assess
histopatholog
blood
product
sampl
assess
biochem
chang
comparison
group
done
anova
dunnett
posttest
multipl
comparison
resultsfind
filter
wash
blood
product
significantli
stabil
ph
sodium
potassium
concentr
decreas
lactat
level
product
compar
standard
product
resuscit
group
receiv
averag
blood
product
ratio
howev
use
washedfilt
product
improv
organ
failur
assess
histopatholog
score
level
creatinin
asat
alat
coagul
statu
assess
thromboelastometri
derang
group
normal
transfus
show
signific
differ
washedfilt
product
standard
care
immun
respons
lp
decreas
follow
trauma
compar
healthi
control
differ
group
conclus
filter
wash
blood
product
reduc
aspect
storag
lesion
blood
product
without
affect
hemostat
capac
product
improv
organ
injuri
rat
trauma
transfus
model
improv
immunosuppress
host
respons
result
suggest
wash
filter
blood
product
may
relev
clinic
effect
rat
polytrauma
model
safeti
efficaci
tranexam
acid
cardiovascular
surgeri
singl
center
beforeandaft
studi
takuma
maeda
shigeki
miyata
nation
cerebr
cardiovascular
center
backgroundcas
studi
tranexam
acid
txa
antifibrinolyt
agent
wide
use
cardiovascular
surgeri
sinc
sever
studi
shown
prophylact
use
txa
effect
reduc
blood
loss
cardiovascular
surgeri
howev
concern
risk
thromboembol
event
advers
neurolog
effect
seizur
might
worsen
patient
outcom
consequ
stop
use
txa
april
enabl
us
conduct
beforeandaft
studi
present
studi
aim
examin
associ
txa
advers
effect
seizur
thromboembol
renal
dysfunct
patient
undergo
cardiovascular
surgeri
use
propens
score
match
model
also
assess
associ
txa
clinic
outcom
reoper
bleed
transfus
volum
blood
loss
ventil
time
intens
care
unit
stay
mortal
studi
designmethod
singl
center
retrospect
cohort
studi
involv
patient
underw
cardiovascular
surgeri
cardiopulmonari
bypass
offpump
coronari
arteri
bypass
graft
januari
juli
miss
data
patient
characterist
patient
exclud
incid
advers
effect
associ
txa
clinic
outcom
evalu
januari
march
april
juli
use
propens
score
model
estim
propens
score
use
logist
regress
model
txa
use
function
baselin
variabl
gener
pair
patient
receiv
receiv
txa
also
evalu
advers
effect
txa
use
segment
regress
analysi
resultsfind
propensitymatch
analysi
show
seizur
common
vs
p
ventil
time
longer
h
vs
h
significantli
txa
group
nontxa
group
contrast
transfus
volum
blood
loss
significantli
lower
txa
group
nontxa
group
ml
vs
ml
ml
vs
ml
p
respect
howev
mortal
statist
differ
group
vs
none
outcom
significantli
differ
segment
regress
analysi
yield
similar
result
conclus
even
though
txa
may
associ
increas
rate
seizur
longer
ventil
time
increas
mortal
use
txa
significantli
associ
decreas
blood
loss
transfus
volum
provid
social
benefit
reduc
need
blood
transfus
suppli
blood
compon
limit
age
japanes
societi
seem
advantag
use
txa
decreas
blood
loss
transfus
volum
associ
social
benefit
outweigh
disadvantag
increas
rate
seizur
longer
ventil
time
sustain
impact
blood
manag
strategi
orthoped
continu
qualiti
improv
linda
levinu
michel
deeney
new
england
baptist
hospit
backgroundcas
studi
transfus
one
overutil
treatment
perform
hospit
set
choos
wise
campaign
april
wwwchoosingwiselyorgsocietiesamericanassociationofbloodbank
cost
risk
associ
transfus
high
may
signific
impact
patient
safeti
institut
perform
joint
replac
spine
surgeri
per
year
make
transfusionassoci
cost
high
sinc
last
formal
evalu
metric
use
post
implement
patient
blood
manag
pbm
strategi
question
regard
feasibl
continu
transfus
reduct
sustain
program
rais
administr
key
stakehold
physician
object
studi
determin
sustain
improv
blood
util
dashboard
tabl
data
collect
show
continu
reduct
transfus
rate
blood
expenditur
length
stay
also
shown
continu
reduct
indic
pbm
strategi
implement
compromis
qualiti
outcom
continu
review
monitor
chosen
metric
evalu
chang
polici
practic
relat
transfus
medicin
commun
find
providersadministr
upon
immedi
restrospect
analysi
integr
continu
success
sustain
pbm
program
go
forward
practic
along
investig
use
addit
pbm
strategi
provid
basi
effect
continu
qualiti
improv
program
transfus
medicin
orthoped
safeti
efficaci
prothrombin
complex
concentr
retrospect
review
outcom
academ
hospit
stephani
jalaba
holli
benson
nan
zhang
jill
adamski
theresa
kinard
mayo
clinic
arizona
backgroundcas
studi
prothrombin
complex
concentr
pcc
contain
factor
ii
vii
ix
x
protein
c
use
revers
vitamin
k
antagonist
acut
major
bleed
urgent
invas
procedur
occasion
use
offlabel
plasma
optim
achiev
hemostasi
studi
compar
efficaci
onlabel
offlabel
use
pcc
correct
coagul
paramet
reduc
allogen
blood
transfus
studi
designmethod
retrospect
chart
review
perform
pcc
use
institut
margin
model
gee
method
use
account
within
patient
correl
assess
chang
lab
valu
product
transfus
logist
regress
gee
method
use
evalu
potenti
risk
factor
unsuccess
hemostasi
rate
transfus
pcc
rate
pcc
thrombot
complic
resultsfind
reduct
pt
ptt
significantli
greater
onlabel
offlabel
use
interestingli
transfus
reduct
rbc
plasma
offlabel
use
significantli
greater
onlabel
use
case
onlabel
offlabel
uh
associ
cell
saver
acut
normovolem
hemodilut
anh
cardiopulmonari
bypass
cpb
odd
uh
time
cell
saver
anh
time
cpb
postpcc
thrombos
identifi
case
associ
found
potenti
risk
factor
use
antifibrinolyt
vitamin
k
factor
viia
extracorpor
support
backgroundcas
studi
pregnant
woman
high
risk
pregnanc
diagnos
abnorm
placent
multipl
gestat
admit
inpati
bedrest
obstetr
team
would
like
assur
abil
crossmatch
red
blood
cell
rbc
time
alway
indat
type
screen
specimen
per
current
aabb
standard
necessit
new
sampl
everi
day
lead
excess
iatrogen
blood
loss
increas
difficulti
obtain
intraven
access
patient
point
invas
cathet
picc
line
may
place
order
mitig
issu
chose
extend
type
screen
specimen
expir
day
patient
without
rbc
alloantibodi
passiv
acquir
antid
due
rh
immun
globulin
administr
studi
designmethod
patient
expect
antenat
hospit
least
day
high
risk
transfus
need
identifi
obstetr
servic
submit
request
transfus
servic
extens
pretransfus
specimen
day
transfus
servic
medic
director
review
case
give
final
approv
observ
patient
indat
specimen
extend
outdat
request
thirtyeight
patient
inpati
continu
deliveri
five
patient
discharg
prior
move
anoth
state
admit
later
anoth
local
hospit
three
readmit
later
deliveri
mean
interv
approv
deliveri
day
rang
six
patient
deliv
within
day
approv
approv
mean
number
addit
specimen
per
patient
rang
patient
requir
transfus
prior
deliveri
five
patient
receiv
transfus
least
rbc
time
deliveri
none
evid
transfus
reaction
conclus
sinc
new
antibodi
identifi
prior
discharg
deliveri
transfus
reaction
observ
process
appear
safe
patient
deliv
within
day
approv
extend
specimen
patient
avoid
collect
least
specimen
patient
avoid
least
collect
sinc
new
antibodi
detect
least
day
immun
even
longer
extens
pretransfus
specimen
outdat
may
consid
although
requir
studi
believ
practic
extend
pretransfus
test
sampl
expir
date
day
safe
justifi
weigh
risk
excess
iatrogen
blood
loss
place
invas
line
blood
sampl
pregnant
patient
iron
metabol
critic
ill
patient
develop
anemia
inflamm
margit
boshuizen
jan
binnekad
benjamin
nota
pieter
r
tuinman
kirsten
van
de
groep
olaf
l
cremer
jannek
horn
marcu
j
schultz
robin
van
bruggen
nicol
p
jufferman
academ
medic
center
sanquin
research
landstein
laboratori
vu
univers
medic
center
univers
medic
center
utrecht
backgroundcas
studi
anemia
due
inflammatori
process
anemia
inflamm
ai
frequent
occur
critic
ill
patient
ai
inflammationinduc
hepcidin
decreas
iron
avail
process
thought
regul
erythroferron
impact
erythropoiesi
knowledg
chang
iron
metabol
cours
ai
limit
hamper
develop
strategi
counteract
ai
studi
aim
investig
dynam
paramet
iron
metabol
develop
ai
critic
ill
patient
studi
designmethod
case
control
studi
perform
tertiari
icu
netherland
compar
patient
develop
ai
icu
stay
control
group
nonanem
patient
sepsi
nonanem
patient
without
sepsi
patient
anemia
due
acut
blood
loss
patient
match
age
sex
linear
mix
model
use
assess
differ
paramet
iron
metabol
group
time
resultsfind
patient
ai
level
iron
transferrin
transferrin
satur
decreas
alreadi
prior
develop
anemia
lower
level
compar
control
tabl
ferritin
hepcidin
increas
ai
compar
control
cours
ai
develop
erythroferron
decreas
differ
iron
metabol
group
influenc
diseas
sever
patient
ai
differ
patient
anemia
due
acut
blood
loss
latter
character
high
iron
vs
mmoll
p
transferrin
satur
vs
p
low
ferritin
vs
mgl
p
conclus
critic
ill
patient
ai
iron
metabol
alreadi
alter
prior
develop
anemia
suggest
potenti
window
opportun
therapi
iron
metabol
ai
disturb
nonanem
septic
control
irrespect
diseas
sever
indic
ai
sole
determin
sever
inflamm
iron
metabol
ai
patient
differ
patient
acut
blood
loss
suggest
effort
modul
iron
metabol
anem
icu
patient
take
caus
anemia
account
clinic
oral
abstract
session
novel
approach
process
assess
cell
therapi
product
paradigm
shift
stem
cell
isol
storag
jeffrey
drew
group
llp
backgroundcas
studi
widespread
use
umbil
cord
blood
limit
process
yield
postthaw
recoveri
viabl
nucleat
cell
recommend
therapeut
cell
dose
approxim
x
cell
per
kg
bodi
weight
indic
singl
cord
unit
may
insuffic
treat
larger
individu
cell
isol
method
develop
remov
erythrocyt
whilst
recov
white
cell
fraction
wcf
howev
current
method
result
signific
loss
wcf
whilst
leav
start
volum
erythrocyt
addit
almost
total
loss
potenti
import
low
abund
cellular
subset
use
cord
blood
hematopoiet
reconsititut
regen
medicin
would
widen
process
method
improv
postprocess
postthaw
viabl
cell
recoveri
studi
designmethod
develop
solut
consist
defin
concentr
reagent
routin
use
blood
therapi
combin
blood
solut
result
select
sediment
erythrocyt
graviti
within
minut
wcf
remain
solut
easili
separ
erythrocyt
sediment
wcf
concentr
gentl
centrifug
small
volum
contain
less
origin
erythrocyt
content
addit
dmso
cryogen
storag
control
freez
use
standard
procedur
complet
simpl
process
resultsfind
clearli
demonstr
method
allow
almost
entir
wcf
isol
andor
concentr
modest
loss
cellular
subset
thu
far
examin
addit
improv
prefreez
yield
postthaw
recoveri
viabl
cell
markedli
increas
yield
approxim
fraction
post
separ
freez
thaw
tabl
possibl
import
cfu
assay
result
reproduc
yield
higher
count
cfugm
cfugemm
bfu
coloni
tabl
strong
indic
method
improv
patient
outcom
addit
separ
method
isol
preserv
megakaryocytelik
cell
earli
projenitor
cell
express
nanog
marker
vsel
two
exampl
cellular
subset
usual
lost
use
current
separ
techniqu
conclus
result
demonstr
method
achiev
routin
recoveri
wcf
level
higher
current
method
independ
volum
higher
percentag
recoveri
cell
type
test
achiev
exist
method
markedli
higher
postthaw
recoveri
viabl
nucleat
cell
current
methodolog
almost
complet
remov
hematocrit
result
unit
cord
blood
separ
use
new
method
contain
cell
yield
could
otherwis
achiev
pool
multipl
separ
unit
therefor
new
method
potenti
increas
demand
cord
blood
therapi
expand
larger
individu
adult
suppress
due
limit
cell
yield
deliv
exist
method
effect
implement
absolut
lymphocyt
count
target
addit
target
hematopoiet
progenitor
cell
collect
edwin
burgstal
lui
f
porrata
denni
gastineau
eapen
k
jacob
jeffrey
l
winter
mayo
clinic
backgroundcas
studi
lymphoma
patient
receiv
lymphocyt
lymph
kg
peripher
blood
stem
cell
transplant
superior
surviv
addit
cell
target
kg
lymph
target
also
implement
fifti
patient
alc
alc
implement
retrospect
evalu
studi
designmethod
lymph
yield
number
collect
lymph
target
reach
day
engraft
examin
mobil
gcsf
g
gcsf
plerixafor
consecut
alc
alc
procedur
examin
mannwhitney
chi
squar
test
use
statist
comparison
p
consid
signific
resultsfind
alc
alc
collect
occur
among
patient
fenwal
amicu
use
alc
alc
collect
terumobct
spectra
optia
cmnc
use
remain
diagnosi
hodgkin
nonhodgkin
lymphoma
alc
hodgkin
nonhodgkin
lymphoma
alc
pre
procedur
wbc
lymph
count
significantli
higher
alc
wbc
lymph
l
alc
wbc
lymph
l
equival
whole
blood
correct
ac
process
alc
alc
alc
group
extra
collect
beyond
target
day
day
day
day
day
significantli
patient
mobil
alc
group
alc
group
collect
alc
group
mobil
discontinu
cell
target
reach
signific
differ
g
lymph
compar
mobil
collect
lymph
significantli
higher
collect
mobil
discontinu
lymph
day
wbc
engraft
alc
vs
alc
platelet
engraft
alc
vs
alc
significantli
differ
median
number
collect
alc
alc
significantli
differ
data
median
tabl
conclus
patient
achiev
lymphkg
even
lymphkg
target
implement
lymph
target
increas
patient
obtain
lymphkg
lymph
kg
discontinu
mobil
cell
target
reach
significantli
reduc
lymph
yield
median
increas
one
collect
per
patient
follow
implement
less
expect
extend
preprocess
storag
impair
cord
blood
hematopoiet
stem
cell
activ
suria
jahan
nicola
pineault
canadian
blood
servic
univers
ottawa
canadian
blood
servic
centr
innov
backgroundcas
studi
larg
distanc
collect
process
site
combin
staff
avail
result
long
process
delay
umbil
cord
blood
ucb
unit
current
netcordfact
standard
specifi
unit
store
almost
hour
room
temperatur
rt
long
unit
cryopreserv
postcollect
impact
delay
hematopoiet
stem
cell
hsc
function
unclear
sinc
studi
use
transplant
assay
measur
hsc
key
properti
activ
hypothes
process
delay
reduc
engraft
activ
ucb
unit
set
measur
loss
engraft
activ
associ
preprocess
storag
studi
designmethod
ucb
unit
split
one
half
process
immedi
baselin
hour
second
hour
storag
rt
ucb
process
hetastarch
buffi
coat
maintain
cryopreserv
liquid
nitrogen
use
viabil
assess
postthaw
thaw
ucb
buffi
coat
cell
transplant
nsg
mice
serial
transplant
use
test
selfrenew
differenti
activ
hsc
limit
dilut
ld
assay
poisson
statist
use
estim
frequenc
scid
repopul
cell
src
thaw
unit
resultsfind
storag
process
signific
impact
recoveri
viabl
postthaw
cell
cell
primari
nsg
mice
transplant
ucb
cell
dose
contain
total
annexinv
neg
viabl
cell
latter
done
avoid
bia
toward
one
group
anoth
short
term
platelet
vs
hpltml
leucocyt
vs
p
engraft
significantli
reduc
store
mice
vs
baselin
similar
result
observ
longterm
longterm
human
bone
marrow
bm
engraft
also
reduc
primari
transplant
store
sampl
myeloid
engraft
howev
confirm
group
bm
cell
primari
mice
transplant
secondari
recipi
human
engraft
investig
month
posttranspl
strikingli
frequenc
human
bm
cell
greater
baselin
vs
store
mice
p
henc
storag
rt
ucb
unit
associ
deficit
engraft
activ
like
due
loss
hsc
activ
andor
number
distinct
possibl
net
number
src
baselin
store
sampl
two
unit
calcul
ld
transplant
assay
net
number
src
measur
posttranspl
reduc
unit
unit
conclus
prolong
preprocess
rt
storag
significantli
impair
engraft
activ
ucb
unit
reduc
engraft
secondari
transplant
coupl
result
ld
assay
suggest
engraft
deficit
origin
loss
hsc
number
result
stress
import
rapid
ucb
process
avoid
loss
engraft
activ
acoust
microfluid
separ
blood
compon
charl
lissandrello
ryan
dubay
kenneth
kotz
jason
fier
draper
backgroundcas
studi
new
cell
therapi
requir
effici
autom
method
purif
target
cell
prior
subsequ
process
apheresi
densiti
gradient
centrifug
magnet
separ
achiev
requir
method
current
avail
fulli
meet
clinic
need
close
autom
scalabl
process
continu
acoust
separ
microchannel
emerg
versatil
method
sort
separ
concentr
cell
blood
advantag
centrifug
scalabl
small
larg
quantiti
discrimin
cell
size
well
densiti
meanwhil
unlik
magnet
method
acoustophoresi
label
free
add
reagent
therapeut
cell
shown
previous
acoust
separ
separ
blood
compon
includ
purif
lymphocyt
howev
studi
use
devic
construct
silicon
glass
limit
potenti
scaleup
product
dispos
cartridg
contrast
report
first
ever
demonstr
acoust
lymphocyt
enrich
along
rbc
platelet
deplet
dispos
plastic
chip
present
cartridg
concept
enabl
clinic
scale
throughput
link
microchannel
parallel
studi
designmethod
acoustophoresi
use
ultrason
wave
oscil
rectangular
microchannel
cross
section
scale
ultrason
wavelength
result
acoust
forc
across
channel
drive
cell
toward
axial
center
stream
forc
increas
cell
size
densiti
lymphocyt
experi
weaker
forc
rbc
class
wbc
thu
blood
product
flow
devic
lymphocyt
popul
enrich
side
channel
captur
branch
outlet
likewis
platelet
separ
lymphocyt
initi
output
cell
count
measur
standard
hematolog
analyz
resultsfind
acoust
system
lymphocyt
puriti
total
wbc
enrich
use
leukapheresi
product
start
materi
enrich
achiev
singl
pass
devic
resid
time
total
lymphocyt
recoveri
monocyt
concentr
reduc
furthermor
twopass
process
platelet
reduc
parallel
system
test
rbc
separ
plasma
achiev
separ
conclus
acoust
lymphocyt
enrich
along
platelet
deplet
standard
blood
product
demonstr
first
time
plastic
microchannel
dispos
devic
suitabl
scale
clinic
bioprocess
system
lymphocyt
puriti
compar
exist
method
advantag
monocyt
platelet
deplet
potenti
autom
instrument
backgroundcas
studi
use
natur
killer
nk
cell
cellular
immunotherapi
increas
past
sever
year
specif
use
patient
hematolog
malign
nk
cell
use
institut
past
year
patient
reaction
nk
cell
infus
reaction
quit
sever
retrospect
analyz
reaction
associ
nk
cell
infus
help
address
patient
sever
reaction
other
studi
designmethod
retrospect
chart
review
nk
cell
infus
perform
institut
clinic
protocol
infus
reaction
defin
symptom
time
nk
cell
infus
hour
afterward
sever
reaction
defin
symptom
grade
higher
sever
grade
common
terminolog
criteria
advers
eventsctca
preliminari
data
analyz
use
r
two
major
endpoint
interest
infus
reaction
symptom
sever
infus
reaction
numer
summar
associ
continu
variabl
endpoint
median
rang
interquartil
rang
iqr
use
wilcoxon
test
perform
test
associ
continu
variabl
end
point
chisquar
test
use
test
associ
categor
variabl
endpoint
interest
resultsfind
total
nk
cell
infus
patient
infus
reaction
symptom
patient
sever
reaction
infus
rate
mlmin
similar
among
reaction
sever
reaction
infus
rate
mlminkg
also
similar
among
reaction
sever
reaction
respect
incub
nk
cell
product
overnight
vs
similar
reaction
rate
symptom
reaction
reaction
sever
reaction
sever
reaction
sever
reaction
patient
sever
reaction
higher
calcul
monocyt
dose
monocyteskg
nk
cell
product
x
versu
without
x
conclus
preliminari
data
analysi
reveal
higher
number
monocyt
nk
cell
product
may
contribut
sever
infus
reaction
caus
patient
grade
higher
symptom
limit
studi
includ
retrospect
review
singl
institut
streamlin
mix
lymphocyt
reaction
mlr
assay
evalu
human
mesenchym
stem
cell
immunomodul
activ
christoph
p
delavan
maryann
c
herzig
barbara
christi
jame
bynum
andrew
p
cap
us
armi
institut
surgic
research
us
armi
institut
surgic
research
backgroundcas
studi
mesenchym
stem
cell
msc
investig
treatment
acut
respiratori
distress
syndrom
ard
graft
versu
host
diseas
gvhd
wound
heal
trauma
consensu
build
immunomodul
msc
key
therapeut
potenti
msc
suppress
peripher
blood
mononuclear
cell
pbmc
prolifer
vitro
suggest
correl
suppress
pbmc
inflammatori
respons
vivo
current
mix
lymphocyt
reaction
mlr
assay
gener
reli
either
direct
cocultur
indirect
cultur
use
transwel
system
monitor
prolifer
isol
pbmc
presenc
mitot
inact
msc
studi
detail
msc
analyz
direct
cocultur
pbmc
use
luminesc
atp
assay
studi
designmethod
blood
obtain
hous
blood
bank
pbmc
separ
centrifug
ficollpaqu
leucosep
tube
specifi
manufactur
pool
donor
pbmc
store
msc
deriv
bone
marrow
adipos
tissu
umbil
cord
bmmsc
admsc
ucmsc
respect
human
umbil
cord
endotheli
cell
huvec
serial
dilut
start
cell
well
cultur
well
plate
h
respect
media
day
msc
wash
resuspend
pbmc
media
incub
without
freshli
thaw
pbmcswell
presenc
absenc
phytohemagglutinin
pha
lgml
prolifer
msc
pbmc
assess
triplic
well
quantit
atp
level
use
bioluminesc
reagent
cell
titerglo
promega
resultsfind
pbmc
prolifer
respons
pha
gave
robust
atp
signal
h
fold
increas
control
pbmc
increas
atp
respons
prolifer
seen
absenc
pha
cocultur
msc
inhibit
pbmc
prolifer
depend
upon
msc
passag
sourc
msc
media
addit
intraassay
varianc
triplic
sampl
interassay
variat
msc
prep
run
ident
condit
inhibit
pbmc
prolifer
grade
rang
msc
concentr
therefor
msc
cell
number
result
suppress
pbmc
could
determin
msc
prep
howev
depend
upon
pbmc
donor
pool
conclus
direct
cocultur
live
msc
freshli
thaw
pbmc
give
robust
determin
immunosuppress
msc
grade
respons
determin
allow
comparison
potenc
msc
prepar
streamlin
assay
perform
within
h
without
irradi
cell
minim
equip
outlay
backgroundcas
studi
high
preval
iron
deplet
id
blood
donor
document
recent
studi
none
target
high
school
age
donor
consist
contribut
us
blood
suppli
differ
donor
year
old
yo
adult
baselin
donationalt
iron
statu
import
understand
teenag
need
increas
iron
physiolog
growth
develop
may
suscept
harm
iron
deplet
studi
designmethod
donor
age
elig
ferritin
test
donat
high
school
hs
blood
drive
start
academ
year
two
blood
center
sampl
return
donat
remaind
school
year
also
test
preval
absent
iron
store
ai
ferritin
ngml
low
ferritin
lf
ferritin
ngml
estim
group
separ
gender
linkag
oper
databas
establish
firsttim
ft
vs
repeat
rpt
donor
statu
linear
regress
analysi
test
differ
natur
log
enrol
ferritin
valu
age
multipl
logist
regress
assess
whether
young
age
independ
predict
iron
deplet
control
donat
frequenc
factor
resultsfind
total
donor
contribut
donat
donor
evenli
split
gender
ft
donor
ft
rpt
donor
averag
lower
ferritin
valu
enrol
p
greater
percentag
irondeplet
donor
tabl
repeat
measur
logist
regress
analysi
use
data
visit
femal
sex
greater
number
previou
donat
shorter
interv
sinc
last
donat
lower
bodi
weight
risk
factor
ai
lf
control
covari
donor
age
sharpli
higher
risk
iron
deplet
donor
odd
lf
time
greater
younger
donor
ai
higher
preliminari
statist
model
indic
donor
may
greater
risk
lf
percentag
point
control
factor
conclus
preval
iron
deplet
vari
markedli
age
sex
donat
frequenc
consider
higher
donor
adult
control
logist
regress
analysi
confirm
lower
age
independ
risk
factor
iron
deplet
blood
center
implement
measur
mitig
higher
risk
iron
deplet
potenti
advers
consequ
popul
vulner
donor
mitig
iron
defici
young
donor
preliminari
report
ralph
r
vassallo
marjori
bravo
mari
townsend
hani
kamel
blood
system
inc
backgroundcas
studi
iron
defici
observ
blood
donor
meet
regulatori
hemoglobin
hb
requir
blood
donat
frequent
donat
result
neg
iron
balanc
eventu
lead
anemia
young
donor
may
risk
advers
health
consequ
cognit
dysfunct
pregnancyrel
complic
fatigu
decreas
exercis
endur
pica
even
anemia
occur
studi
designmethod
serum
ferritin
test
implement
larg
blood
collector
test
perform
success
yo
whole
blood
apheresi
donat
low
ferritin
lf
defin
valu
ngml
femal
f
ngml
male
donor
low
ferritin
notifi
deferr
red
blood
cell
rbc
donat
month
f
month
counsel
take
mg
element
iron
daili
day
f
ferritin
ngml
indic
absent
iron
store
ai
ngml
indic
iron
defici
erythropoiesi
ide
ferritin
level
ngml
f
ngml
consid
indic
ironreplet
state
conclus
ferritin
test
young
donor
identifi
individu
lf
would
benefit
risk
mitig
eg
delay
subsequ
rbc
donat
andor
take
iron
supplement
lf
common
f
donor
lf
preval
f
donor
rbc
donat
prior
month
appreci
number
donor
rbc
donat
prior
month
present
lf
data
may
use
conduct
riskbas
decis
make
exercis
establish
recommend
risk
mitig
could
differ
f
eg
univers
iron
replac
teen
male
donor
may
warrant
certain
hb
valu
ferritin
blood
screen
minor
young
adult
donor
jennif
l
ritter
joan
william
michel
humphri
nanci
haubert
ben
reynold
michael
phillip
randal
spizman
ralph
r
vassallo
hani
kamel
salli
caglioti
german
leparc
phillip
c
williamson
abstract
complet
investig
adolesc
growth
spurt
poor
nutrit
onset
mens
increas
risk
iron
deplet
young
donor
new
studi
show
teenag
donor
give
blood
frequent
may
suscept
becom
iron
defici
older
repeat
donor
studi
designmethod
serum
sampl
donor
age
year
analyz
ferritin
level
use
beckman
coulter
instrument
reagent
kit
antiferritin
reagent
suspens
polystyren
latex
particl
uniform
size
coat
polyclon
rabbit
antiferritin
antibodi
immun
complex
form
solut
scatter
light
proport
size
shape
concentr
decreas
light
intens
measur
spectrophotometr
resultsfind
backgroundcas
studi
risk
cardiovascular
cv
diseas
adult
often
identifi
adolesc
year
presenc
even
borderlin
level
multipl
risk
factor
increas
likelihood
cv
event
blood
program
routin
provid
total
nonfast
cholesterol
tc
blood
pressur
bp
measur
blood
donor
ad
glycat
hemoglobin
determin
perform
analys
preval
abnorm
borderlin
elev
level
multipl
risk
factor
among
adolesc
age
femal
donat
blood
studi
designmethod
abnorm
risk
factor
level
defin
sbpdbp
mm
hg
tc
suggest
american
heart
associ
adolesc
presenc
isol
risk
factor
defin
one
singl
abnorm
risk
factor
per
individu
cluster
risk
factor
defin
presenc
abnorm
risk
factor
individu
donor
sex
record
time
donat
resultsfind
tabl
show
preval
isol
abnorm
risk
factor
preval
abnorm
risk
factor
cluster
studi
cohort
overal
adolesc
least
one
abnorm
risk
factor
male
femal
adolesc
isol
abnorm
risk
factor
adolesc
cluster
risk
factor
higher
proport
male
abnorm
bp
alon
backgroundcas
studi
predon
determin
hemoglobin
hb
level
candid
blood
donor
prerequisit
major
blood
servic
use
ensur
donor
safeti
blood
product
qualiti
howev
varieti
hb
test
strategi
use
across
blood
servic
satisfi
select
criterion
studi
aim
identifi
hb
screen
practic
vari
across
blood
donat
servic
extent
influenc
deferr
rate
low
hb
studi
designmethod
onlin
survey
perform
among
member
biomed
excel
safer
transfus
best
collabor
addit
data
literatur
use
extend
dataset
survey
involv
detail
assess
hb
screen
practic
number
donat
low
hb
deferr
male
femal
donor
separ
multivari
negativebinomi
regress
model
built
estim
adjust
effect
minimum
donat
interv
hb
cutoff
highlow
high
defin
gdl
men
gdl
women
iron
monitor
yn
iron
supplement
yn
provid
prescrib
geograph
locat
deferr
rate
due
low
hb
resultsfind
data
includ
blood
servic
worldwid
complet
data
avail
blood
servic
deferr
percentag
low
hb
vari
among
male
donor
among
femal
donor
hb
deferr
rate
notabl
higher
asian
blood
servic
overal
iron
monitor
associ
lower
hb
deferr
rate
men
confid
interv
ci
lower
rate
women
ci
iron
supplement
associ
lower
hb
deferr
rate
among
women
ci
evid
effect
among
men
oneweek
increas
minimum
donat
interv
result
lower
hb
deferr
rate
among
women
ci
among
men
level
signific
higher
hb
cutoff
appear
effect
among
men
women
conclus
variat
hb
deferr
rate
across
blood
donat
servic
particularli
femal
donor
explain
differ
hb
screen
deferr
practic
mitig
strategi
consid
variabl
respons
among
men
women
insight
help
improv
blood
servic
effici
donor
care
characterist
donor
age
sex
size
weight
region
hb
level
date
volum
donat
index
applic
previou
donat
number
previou
donat
previou
year
lifetim
data
analyz
use
logist
regress
stratifi
sex
resultsfind
candid
wb
donat
defer
continent
franc
deferr
significantli
frequent
women
men
due
anemia
defer
women
defer
men
plot
mean
hb
recoveri
time
show
mean
recoveri
time
rang
week
analysi
tabl
identifi
main
factor
associ
higher
likelihood
hb
recoveri
higher
logarithm
time
sinc
previou
donat
lower
level
hb
previou
donat
higher
number
blood
donat
previou
year
conclus
main
factor
associ
higher
likelihood
hb
recoveri
wb
donat
probabl
link
hematopoiesi
stimul
select
bia
among
highfrequ
donor
mean
time
requir
hb
recoveri
long
enough
requir
studi
assess
interdon
interv
franc
backgroundcas
studi
red
blood
cell
rbc
transfus
relat
thromboembol
event
microvesicl
rbc
product
may
support
coagul
part
may
depend
storag
time
microvesicl
procoagul
effect
vitro
amount
microvesicl
increas
storag
durat
studi
designmethod
investig
whether
transfus
rbc
contain
microvesicl
promot
coagul
human
recipi
transfus
mostli
administ
ill
patient
use
model
mild
endotoxemia
eighteen
healthi
volunt
random
receiv
either
salin
day
store
day
store
autolog
rbc
transfus
two
hour
infus
lipopolysaccharid
lp
ecoli
ngkg
blood
sampl
everi
hour
hour
lp
infus
resultsfind
lp
result
mild
increas
thrombin
gener
storag
total
number
microvesicl
increas
iqr
ml
fresh
product
iqr
p
store
product
p
mostli
rbc
deriv
vesicl
transfus
microvesicl
store
rbc
product
fresh
product
could
detect
circul
healthi
volunt
clear
within
hour
howev
infus
store
rbc
microvesicl
augment
thrombin
gener
level
ddimer
thrombinantithrombin
complex
also
unaffect
conclus
transfus
autolog
rbc
contain
high
level
microvesicl
enhanc
coagul
human
volunt
mild
endotoxemia
backgroundcas
studi
transfusionassoci
circulatori
overload
taco
character
hydrostat
pulmonari
edema
relat
blood
transfus
sought
examin
contemporari
risk
factor
outcom
taco
period
patient
blood
manaement
led
declin
blood
util
studi
designmethod
four
academ
hospit
case
taco
detect
activ
surveil
adult
hospit
patient
receiv
blood
transfus
transfus
control
match
case
transfus
intens
taco
incid
calcul
clinic
characterist
compar
control
patient
odd
ratio
calcul
use
multivari
logist
regress
hospit
mortal
length
stay
model
use
cumul
incid
function
proport
hazard
regress
resultsfind
case
taco
match
control
enrol
transfus
patient
receiv
blood
compon
may
juli
taco
incid
case
per
patient
transfus
addit
well
describ
cardiac
renal
comorbid
multivari
analysi
identifi
follow
independ
predictor
taco
number
plasma
unit
emerg
surgeri
pretransfus
diuret
use
higher
posttransfus
hemoglobin
level
see
tabl
compar
control
taco
case
like
requir
mechan
ventil
vs
p
experienc
longer
intens
care
vs
day
hospit
length
stay
follow
transfus
vs
day
p
higher
mortal
vs
conclus
incid
taco
lower
report
prior
activ
surveil
studi
despit
declin
incid
number
blood
compon
transfus
per
case
taco
remain
complic
transfus
signific
associ
morbid
mortal
addit
risk
factor
cardiovascular
kidney
diseas
plasma
transfus
higher
posttransfus
hemoglobin
level
associ
taco
control
covari
model
addit
research
need
examin
util
risk
factor
develop
realtim
predict
algorithm
benefit
reduc
erythrocyt
plasma
exposur
patient
high
risk
taco
backgroundcas
studi
residu
risk
bacteri
contamin
singledonor
apheresi
platelet
ap
recent
address
march
fda
draft
guidanc
enhanc
safeti
platelet
transfus
document
also
describ
exist
pathway
ap
outdat
extens
day
use
fda
clear
rapid
test
rt
hospit
base
transfus
servic
use
rt
enhanc
safeti
ap
transfus
sinc
juli
routin
extend
ap
outdat
day
sinc
februari
studi
report
month
experi
secondari
screen
ap
use
rt
studi
designmethod
ap
obtain
hospitalbas
donor
center
one
four
extern
supplier
ap
screen
cultur
base
method
postcollect
prior
entri
inventori
juli
ap
underw
rt
day
day
unit
transfus
physician
approv
deem
medic
necessari
unit
remain
inventori
day
second
rt
perform
februari
ap
underw
rt
day
routin
outdat
extens
day
perform
second
rt
day
third
rt
day
per
manufactur
instruct
posit
rt
repeat
triplic
repeat
rt
posit
unit
quarantin
cultur
identifi
true
posit
fals
posit
fp
defin
repeat
rt
neg
type
repeat
rt
posit
neg
confirmatori
cultur
type
rt
result
review
studi
period
ap
transfus
outdat
rate
also
summar
resultsfind
sinc
juli
ap
enter
inventori
transfus
prior
rt
test
remain
underw
rt
day
day
rt
posit
type
fp
return
inventori
type
fp
discard
leav
total
avail
inventori
unit
test
rt
origin
inventori
transfus
end
day
remain
origin
inventori
reach
day
outdat
total
origin
inventori
transfus
day
day
underw
second
rt
day
rt
posit
fp
type
one
fp
type
underw
third
rt
day
posit
result
total
origin
inventori
outdat
day
underw
second
rt
day
posit
result
conclus
date
perform
rt
ap
hospit
true
posit
identifi
use
rt
studi
period
decreas
outdat
rate
predict
total
ap
test
twice
rt
day
day
posit
result
deem
fp
repeat
test
cultur
total
unit
test
time
day
day
day
addit
posit
identifi
yet
identifi
unit
initi
neg
rt
result
subsequ
convert
true
posit
low
fp
rate
also
expect
perform
repeat
test
unit
data
suggest
yield
repeat
rt
everi
hour
current
specifi
manufactur
instruct
quit
low
addit
studi
need
clarifi
rt
optim
use
enhanc
detect
ap
bacteri
contamin
surviv
trypanosoma
cruzi
human
blood
compon
laura
tonnetti
aaron
thorp
susan
l
stramer
american
red
cross
backgroundcas
studi
trypanosoma
cruzi
agent
chaga
diseas
associ
million
infect
worldwid
mostli
latin
america
despit
extens
immigr
endem
area
case
transfusiontransmiss
tt
cruzi
report
us
blood
donor
screen
implement
contribut
factor
low
number
tt
case
possibl
associ
parasit
lineag
tt
high
number
unreport
case
platelet
almost
exclus
involv
cruzi
tt
case
howev
prepar
compon
larg
fraction
parasit
found
red
blood
cell
rbc
investig
blood
compon
prepar
storag
time
affect
surviv
parasit
thu
play
role
tt
cruzi
studi
designmethod
whole
blood
wb
unit
spike
cruzi
trypomastigot
final
concentr
parasitesml
parasit
concentr
wb
test
aliquot
contamin
wb
use
prepar
hemocultur
detect
live
parasit
prepar
compon
rbc
separ
half
compon
leukoreduc
lr
filtrat
platelet
plasma
separ
along
one
aliquot
plasma
collect
lr
rbc
store
day
platelet
store
rt
agit
day
plasma
frozen
aliquot
cultur
remov
weekli
rbc
daili
platelet
day
frozen
plasma
sampl
cultur
liver
infus
tryptos
lit
media
detect
live
parasit
week
resultsfind
hemocultur
spikedwb
posit
concentr
parasit
lr
nonlr
rbc
cultur
storag
posit
concentr
storag
rbc
unit
spike
parasitesml
posit
day
time
yield
neg
result
lower
concentr
nonlr
rbc
spike
parasitesml
posit
day
plasma
sampl
cultur
freez
posit
highest
concentr
one
nonlr
sampl
other
neg
platelet
obtain
wb
spike
parasitesml
posit
day
rt
parasit
observ
plasma
platelet
prior
storag
lower
concentr
molecular
analysi
determin
presenc
parasit
dna
compon
ongo
conclus
platelet
storag
condit
offer
suitabl
environ
cruzi
surviv
howev
high
concentr
parasit
also
surviv
rbc
week
leukoreduct
offer
partial
protect
freez
condit
appear
unsuit
cruzi
surviv
hemovigil
monitor
platelet
septic
transfus
reaction
str
treatment
intercept
tm
pathogen
reduct
larg
volum
delay
bactalert
tm
bacteri
cultur
screen
richard
benjamin
marion
lanteri
larri
corash
ceru
corpor
scientif
affair
depart
ceru
corpor
backgroundcas
studi
amotosalenultraviolet
uva
light
intercept
tm
blood
system
ceru
corpor
pathogen
reduct
pr
delay
larg
volum
bacteri
cultur
bactalert
tm
system
dlvbc
biomerieux
inc
repres
respect
bestinclass
system
reduc
risk
str
associ
platelet
concentr
pc
implement
hemovilig
hv
program
continu
receiv
report
suspect
str
low
imput
caus
like
insuffici
inform
avail
imput
system
failur
studi
designmethod
unit
kingdom
french
swiss
belgium
hv
report
ceru
corpor
advers
event
record
review
assess
residu
risk
imput
str
amotosalenuvatr
dlvbcscreen
pc
resultsfind
approxim
million
dlvbcscreen
issu
day
outdat
releas
inventori
day
collect
million
amotosalenuvatr
pc
releas
inventori
day
day
shelflif
septic
fatal
report
either
technolog
french
belgium
swiss
hv
program
monitor
million
convent
nondlvbcscreen
pc
record
str
fatal
concurr
zero
definit
possibl
str
report
amotosalenuvatr
pc
significantli
fewer
convent
pc
tabl
str
per
million
vs
per
million
p
one
definit
possibl
undeterminedindetermin
nonfat
str
contamin
near
miss
pc
report
million
dlvbcscreen
pc
reduc
falseneg
rate
compar
prior
five
year
str
per
million
vs
per
million
p
hv
program
highlight
major
weak
report
str
stringent
criteria
use
determin
definit
imput
includ
evid
patient
infect
pc
contamin
irrefut
evid
donor
sourc
confirm
strain
ident
report
incomplet
investig
consid
undetermin
indetermin
possibl
sepsi
case
almost
certainli
due
bacteri
contamin
pc
suggest
actual
rate
sepsi
consider
higher
report
hv
program
conclus
bestinclass
pathogen
reduct
bacteri
cultur
system
reduc
str
risk
although
underreport
inadequ
clinic
data
may
result
underestim
true
rate
pathogen
reduct
backgroundcas
studi
despit
extant
mitig
measur
eg
divers
pouch
primari
platelet
cultur
collect
facil
bacteri
contamin
platelet
associ
septic
transfus
reaction
remain
lead
caus
transfusionassoci
fatal
unit
state
us
consequ
us
food
drug
administr
recommend
adopt
addit
measur
point
releas
test
port
andor
pathogen
reduct
safeguard
transfusionassoci
sepsi
howev
port
pose
logist
challeng
particularli
institut
highvolum
platelet
util
pathogen
reduct
high
cost
intervent
evalu
second
bacteri
cultur
contend
residu
risk
studi
designmethod
phase
implement
secondari
bacteri
cultur
test
bactalert
tm
biomerieux
inc
durham
nc
initi
octob
platelet
receiv
institut
time
receipt
blood
bank
day
post
collect
product
sampl
use
steril
connect
devic
tscd
tm
terumo
elkton
md
sampl
kit
samplok
tm
sampl
kit
ml
itl
biomed
malaysia
five
ml
product
transfer
asept
bactalert
bpa
aerob
cultur
bottl
use
sampl
devic
inocul
cultur
bottl
load
bactalert
incub
modul
incub
three
day
resultsfind
total
platelet
product
success
cultur
octob
march
respect
period
two
true
posit
cultur
obtain
incid
platelet
product
cultur
grew
acinetobact
speci
case
coagulas
neg
staphylococcu
speci
case
b
posit
result
obtain
four
day
follow
collect
repeat
test
case
b
grew
organ
identifi
initi
cultur
cocompon
inventori
case
neg
initi
repeat
cultur
none
product
releas
transfus
initi
postcollect
product
cultur
remain
neg
collect
facil
time
period
fals
posit
detect
implement
requir
hire
one
addit
dedic
fte
total
cost
technologist
time
equip
relat
suppli
calcul
per
product
test
cost
per
avert
case
conclus
demonstr
feasibl
implement
secondari
bacteri
cultur
test
apheresi
platelet
interdict
bacteri
contamin
unit
prevent
septic
transfus
reaction
present
lowcost
strategi
compar
pathogen
reduct
mitig
risk
septic
transfus
reaction
importantli
offer
viabl
altern
port
high
volum
institut
logist
eg
time
personnel
constraint
imped
practic
adopt
port
increas
case
blood
cultur
posit
transfus
reaction
bcptr
note
hospit
bcptr
defin
bacteri
cultur
posit
transfus
recipi
andor
associ
transfus
blood
product
investig
transfus
reaction
sought
character
risk
clinic
present
bcptr
institut
studi
designmethod
analysi
conduct
report
transfus
reaction
john
hopkin
hospit
jhh
januari
decemb
data
extract
hemovigil
record
evalu
determin
incid
bcptr
sever
symptom
evalu
concord
recipi
data
includ
patient
diagnosi
medic
clinic
manifest
reaction
bacteri
cultur
result
evalu
patient
associ
blood
product
ie
partial
transfus
residu
product
blood
bag
resultsfind
studi
period
total
transfus
reaction
report
bcptr
transfus
reaction
bcptr
associ
apheresi
platelet
red
blood
cell
plasma
recipi
diagnos
span
hematologiconcolog
renal
cardiac
autoimmun
obstetr
organ
identifi
blood
product
recipi
case
case
organ
grown
blood
product
recipi
case
organ
isol
recipi
due
inabl
cultur
product
transfus
recipi
case
isol
organ
recipi
broadspectrum
antibiot
time
transfus
symptom
bcptr
includ
fever
chill
nausea
vomit
pain
dyspnea
blood
pressur
bp
decreas
increas
report
bcptr
chang
bp
conclus
sign
symptom
bcptr
specif
overlap
underli
diseas
well
type
advers
transfus
associ
event
thu
contribut
delay
diagnosi
underreport
furthermor
high
rate
antibiot
use
transfus
recipi
mask
symptom
true
septic
transfus
reaction
hospit
consid
expand
clinic
indic
cultur
blood
compon
implic
transfus
reaction
furthermor
excess
stringent
criteria
cdcnhsn
blood
safeti
surveil
transfusiontransmit
infect
may
contribut
misclassif
septic
event
recipi
particularli
antibiot
clinic
oral
abstract
session
immonohematolog
genet
sickl
cell
diseas
beyond
blindspot
crossreact
antihuman
globulin
specif
igg
subtyp
heather
howi
jenna
lebedev
linda
kapp
xiaohong
wang
meghan
delaney
lay
see
er
jame
c
zimr
bloodworksnw
research
institut
bloodwork
nw
univers
washington
school
medicin
backgroundcas
studi
four
differ
subclass
human
igg
differ
effector
function
essenti
exist
data
effect
igg
subclass
hemolyt
transfus
reaction
hdfn
gener
use
ahg
specif
igg
subclass
recent
decad
becom
appreci
least
natur
human
variant
igg
studi
reactiv
igg
specif
ahg
test
known
variant
studi
designmethod
heavi
light
chain
variabl
region
monoclon
antibodi
sequenc
clone
express
plasmid
fuse
variabl
region
frame
known
igg
variant
plasmid
express
cotransfect
cho
cell
result
panel
antibodi
preincub
rbc
subject
test
current
avail
igg
subtyp
specif
ahg
monoclon
ahg
southern
biotech
sanquin
polyclon
ahg
sanquin
bindingsit
test
carri
flow
cytometri
resultsfind
polyclon
reagent
crossreact
variant
found
igg
subclass
specif
amino
acid
respons
identifi
site
direct
mutagenesi
tabl
titrat
ahg
identifi
dilut
crossreact
lost
authent
target
still
detect
howev
crossreact
could
neutral
preincub
ahg
crossrecogn
igg
form
third
parti
antigen
remain
reactiv
recogn
intend
igg
subtyp
without
detect
crossreact
crossreact
detect
polyclon
monoclon
ahg
test
monoclon
blindspot
due
shorter
hing
region
blindspot
detect
monoclon
polyclon
ahg
conclus
rel
quantit
differ
igg
subtyp
studi
multipl
immun
set
play
import
role
diagnosi
research
human
diseas
includ
immunohematolog
herein
demonstr
reagent
use
gener
bodi
knowledg
suffer
problem
crossreact
blindspot
exist
data
regard
igg
subtyp
biolog
may
inaccuraci
result
defect
igg
specif
ahg
genotyp
match
pediatr
sickl
cell
diseas
patient
nanci
robitail
yve
dominiqu
pastor
marys
stloui
chu
saintejustin
hemaquebec
backgroundcas
studi
among
differ
treatment
modal
avail
sickl
cell
diseas
scd
blood
transfus
frequent
use
howev
alloimmunis
remain
signific
problem
even
prophylact
antigen
match
perform
c
e
kell
antigen
partli
explain
differ
antigen
frequenc
among
caucasian
blood
donor
africanamerican
recipi
variant
rh
blood
group
peopl
africandesc
blood
group
genotyp
propos
potenti
way
allevi
problem
scd
cohort
pediatr
academ
hospit
genotyp
rhd
rhce
fy
gene
primari
object
studi
evalu
whether
compat
genotyp
blood
donor
present
similar
rh
variant
could
identifi
studi
designmethod
sinc
local
blood
provid
intensifi
recruit
africandesc
blood
donor
donor
phenotyp
genotyp
clinic
relev
antigen
differ
mean
genomelab
snp
stream
laboratorydevelop
assay
idcorext
scd
children
genotyp
sequenc
rhd
rhce
fy
cdna
obtain
inform
consent
extend
red
blood
cell
phenotyp
done
diagnosi
hospit
patient
genotyp
compar
h
emaqu
ebec
donor
databas
attribut
blood
donor
specif
patient
resultsfind
diagnosi
septemb
patient
transfus
antibodi
known
blood
group
antigen
specif
antic
anti
antihrb
antifya
antijka
antijkb
anti
antim
antileb
seventeen
patient
either
partial
rhce
result
show
patient
express
normal
c
antigen
express
partial
c
e
antigen
normal
antigen
bore
partial
antigen
weakli
express
fy
phenotyp
found
patient
total
genotyp
blood
donor
africandesc
avail
tabl
indic
compat
donor
conclus
studi
show
sever
patient
rhce
variant
difficult
match
even
avail
genotyp
blood
donor
commun
although
measur
probabl
benefici
decreas
alloimmunis
larger
donor
pool
still
need
fulfil
patient
need
continu
effort
put
toward
recruit
phenogenotyp
improv
situat
use
genet
marker
select
respond
nonrespond
sickl
cell
diseas
scd
patient
transfus
rh
haplotyp
match
red
blood
cell
rbc
unit
tamir
delfino
do
santo
emilia
sippert
mayra
dorigan
de
macedo
sheila
fatima
perecin
menegati
lilian
castilho
hemocentro
unicamp
univers
campina
backgroundcas
studi
rbc
alloimmun
associ
sever
factor
individu
characterist
patient
recent
found
cytokin
polymorph
rhag
allel
may
predict
good
respond
phenotyp
sippert
et
al
transfus
rhag
hladrb
allel
close
link
rh
alloimmun
base
consid
challeng
fulfil
transfus
need
patient
rh
variant
use
genet
marker
select
respond
nonrespond
scd
patient
transfus
rh
haplotyp
match
rbc
unit
evalu
risk
alloimmun
studi
designmethod
studi
includ
nonalloimmun
patient
scd
homozyg
hb
receiv
rang
rbc
unit
rbc
antigen
phenotyp
patient
histori
rbc
antibodi
obtain
medic
record
transfus
servic
computer
databas
rbc
genotyp
perform
use
whea
wrhd
wrhce
beadchip
array
bioarray
solut
immucor
accord
manufactur
instruct
cytokin
gene
polymorph
rhag
gene
polymorph
analys
pcrrflp
taqman
assay
hla
class
ii
genotyp
perform
use
pcrsso
resultsfind
among
nonalloimmun
patient
homozyg
compound
heterozyg
rh
variant
allel
rhag
andor
hladrb
allel
least
one
cytokin
polymorph
associ
risk
alloimmun
transfus
extend
rh
haplotyp
match
rbc
unit
patient
risk
factor
associ
rbc
alloimmun
consid
nonrespond
transfus
extend
rh
match
unit
patient
follow
one
year
develop
rbc
antibodi
conclus
find
contribut
develop
transfus
strategi
nonalloimmun
scd
patient
type
polymorph
could
potenti
help
classif
respond
nonrespond
scd
patient
allow
blood
high
level
compat
five
discrep
sampl
requir
sequenc
id
core
xt
identifi
three
rhce
cear
sampl
encod
partial
c
partial
e
predict
phenotyp
vweak
vs
confirm
sequenc
third
sampl
found
rhce
rhce
cebi
sequenc
predict
phenotyp
sampl
type
ce
e
hea
addit
id
core
xt
accur
identifi
rhce
ce
sampl
snp
link
variou
allel
variant
affect
c
e
antigen
express
sampl
predict
hea
conclus
blood
group
genotyp
platform
vari
depend
specif
snp
includ
assay
variat
may
clinic
signific
genotyp
use
tool
provid
match
blood
discrep
lead
differ
predict
phenotyp
could
affect
unit
select
despit
discrep
method
high
concord
rate
limit
serolog
warrant
reconsider
need
serolog
confirm
extend
phenotyp
backgroundcas
studi
three
decad
ago
two
independ
group
publish
work
suggest
novel
categor
warm
autoimmun
hemolyt
anemia
waiha
basi
dat
score
agefraction
rbc
type
waiha
compris
patient
show
increas
bind
autoantibodi
age
rbc
wherea
type
ii
waiha
autoantibodi
patient
bound
young
old
rbc
appar
prejudic
ubiquit
express
rbc
transmembran
protein
play
vital
role
mainten
rbc
structur
integr
cellular
hemostasi
regul
senesc
suggest
target
autoantibodi
patient
waiha
regul
phosphoryl
key
residu
hyperphosphoryl
hallmark
normal
rbc
senesc
caus
disengag
cytoskeleton
increas
later
diffus
therebi
permit
format
aggreg
form
new
epitop
recogn
natur
igg
autoantibodi
caus
phagocytosi
destruct
senesc
rbc
type
waiha
postul
caus
exacerb
normal
rbc
senesc
studi
designmethod
effort
confirm
character
two
waiha
subtyp
agefraction
whole
blood
sampl
patient
waiha
discontinu
percollv
r
gradient
look
differ
dat
result
less
young
rbc
dens
age
rbc
fraction
fraction
pattern
tyrosin
phosphoryl
resultsfind
confirm
two
distinct
type
waiha
identifi
base
autoantibodi
reactiv
youngest
oldest
autolog
rbc
compar
type
type
ii
patient
found
type
character
percollv
r
fraction
similar
healthi
storagematch
control
increas
tyrosin
phosphoryl
compar
healthi
storagematch
control
phosphoryl
occur
younger
stage
rbc
develop
type
ii
patient
character
percollv
r
fraction
lack
fraction
contain
oldest
rbc
show
complet
lack
dramat
decreas
tyrosin
phosphoryl
compar
healthi
storagematch
control
conclus
result
confirm
two
distinct
type
waiha
type
waiha
increas
bind
autoantibodi
older
rbc
coupl
increas
tyrosin
phosphoryl
suggest
rbc
type
patient
age
faster
rbc
normal
healthi
control
may
repres
acceler
pathogen
form
normal
rbc
senesc
contrast
type
ii
waiha
autoantibodi
bind
strongli
either
young
old
rbc
coupl
lack
fraction
band
repres
oldest
rbc
dramat
diminut
tyrosin
phosphoryl
band
suggest
faster
destruct
rbc
consist
earli
publish
data
metabol
chang
could
affect
rbc
function
microbi
pathogen
primari
sequenc
correl
blood
group
antigen
immunogen
ian
bain
burak
bahar
jeann
hendrickson
krystalyn
e
hudson
christoph
tormey
yalenew
hospit
yale
univers
backgroundcas
studi
known
specif
group
patient
immunolog
respond
readili
other
rbc
antigen
rbc
antigen
differ
donor
recipi
requir
humor
immun
respons
variabl
also
involv
studi
shown
signific
primari
sequenc
ident
common
rbc
antigen
microb
crossreact
possibl
antigen
experiment
model
hypothes
respond
popul
may
immunolog
prime
form
rbc
alloantibodi
via
environment
exposur
crossreact
microbi
antigen
correl
may
link
observ
blood
group
antigen
immunogen
studi
designmethod
perform
peptid
homolog
search
immunogen
rbc
antigen
base
previous
publish
antigen
find
thirteen
amino
acid
peptid
contain
polymorph
residu
k
jk
lu
e
c
c
fy
antigen
queri
ident
microbi
peptid
use
blast
databas
blastp
abstract
algorithm
e
word
gap
cost
search
result
restrict
bacteria
fungi
select
threshold
ident
set
inclus
criteria
corrobor
observ
patient
data
also
examin
preced
cultur
alloimmun
patient
explor
agreement
specif
pathogen
rbc
alloantibodi
resultsfind
signific
peptid
ident
found
rbc
antigen
pathogen
organ
includ
b
fragili
p
aeruginosa
candida
spp
among
other
linear
regress
analysi
number
genus
microbi
kingdom
meet
inclus
criteria
show
statist
signific
invers
trend
predict
degre
immunogen
fy
outlier
remov
r
lower
immunogen
antigen
associ
larger
number
kingdom
kmedoid
cluster
analysi
compar
immunogen
kingdom
show
antigen
cluster
low
c
moder
e
c
high
k
jk
lu
fy
immunogen
group
suggest
antibodi
respons
invers
associ
environment
antigen
preval
alloimmun
patient
review
cultureposit
anticc
group
patient
antik
group
patient
microbeantibodi
agreement
remain
microberbc
antibodi
agreement
rang
overal
patient
demonstr
agreement
interestingli
observ
particularli
strong
agreement
infect
klebsiella
speci
antik
despit
lack
sequenc
ident
patient
review
posit
cultur
klebsiella
speci
patient
demonstr
antik
conclus
studi
highlight
potenti
connect
microbi
infect
rbc
alloimmun
base
share
epitop
specul
lowlevel
antigen
exposur
highli
preval
microbi
antigen
commens
may
promot
immunotoler
provid
model
invers
relationship
rbc
antigen
immunogen
preval
microorgan
longitudin
studi
microbi
carriag
acut
microbi
infect
rbc
alloimmun
respons
larger
patient
cohort
may
inform
backgroundcas
studi
thromboelastogram
teg
incorpor
mani
hospit
armori
manag
transfus
cardiovascular
cv
surgeri
institut
use
welldefin
protocol
teg
util
differ
stage
surgeri
baselin
rewarm
postprotamin
postop
hand
institut
teg
util
driven
mainli
clinic
judgment
teg
order
base
clinic
judgment
clinic
bleed
case
patient
receiv
blood
transfus
teg
perform
publish
literatur
preteg
transfus
impact
teg
result
guid
transfus
requir
cv
surgeri
studi
tri
address
issu
studi
designmethod
retrospect
review
teg
perform
patient
undergo
cv
surgeri
institut
jan
dec
specif
teg
protocol
use
direct
transfus
plasma
platelet
cryoprecipit
period
first
teg
perform
surgeri
includ
analysi
exclud
patient
receiv
red
blood
cell
rbc
transfus
surgeri
rbc
transfus
usual
base
teg
result
teg
analyz
teg
result
divid
three
categori
normal
reaction
time
r
kinet
k
angl
maximum
amplitud
lysi
minut
min
within
refer
rang
hypocoagul
r
min
k
min
degre
mm
hypercoagul
r
min
k
min
degre
mm
fisher
exact
test
zscore
two
popul
proport
use
identifi
statist
signific
differ
teg
result
blood
product
util
resultsfind
teg
analyz
patient
receiv
preteg
transfus
found
significantli
fewer
hypocoagul
teg
result
preteg
transfus
patient
nontransfus
patient
vs
data
also
reflect
trend
suggest
may
normal
teg
result
preteg
transfus
patient
compar
nontransfus
vs
statist
signific
differ
transfus
obtain
teg
result
group
howev
trend
suggest
hypocoagul
state
like
correct
transfus
patient
alreadi
transfus
preteg
compar
nontransfus
versu
conclus
preteg
transfus
impact
teg
result
transfus
correctnorm
coagulopathi
significantli
impact
blood
product
util
cv
surgeri
decreas
threshold
transfus
correct
hypocoagul
state
patient
alreadi
receiv
preteg
transfus
may
due
clinic
signific
bleed
patient
begin
backgroundcas
studi
orthotop
liver
transplant
olt
associ
signific
blood
loss
due
complex
procedur
extens
liver
vascular
demand
blood
transfus
set
cell
salvag
autotransfus
cs
use
altern
decreas
allogen
red
blood
cell
transfus
howev
long
studi
shown
cs
olt
decreas
allogen
blood
transfus
other
report
cs
present
littl
benefit
might
associ
increas
blood
loss
fibrinolysi
studi
evalu
cs
efficaci
reduc
allogen
blood
transfus
intraop
period
studi
designmethod
retrospect
evalu
data
liver
transplant
perform
singlecent
patient
divid
two
group
one
cell
salvag
cs
anoth
without
cs
nc
studi
endpoint
includ
requir
allogen
blood
compon
transfus
intraop
period
group
cs
use
liver
transplant
recipi
patient
malign
sepsi
blood
transfus
indic
base
clinic
hemodynam
criteria
clinic
data
includ
age
gender
diagnosi
bodi
weight
height
warm
cold
ischem
time
model
endstag
liver
diseas
meld
score
statist
analys
perform
use
ttest
chisquar
test
mann
whitney
test
resultsfind
studi
period
olt
perform
total
patient
submit
cs
median
age
year
rang
yo
cirrhosi
caus
chronic
hepat
c
viru
infect
main
etiolog
liver
diseas
hepatocellular
carcinoma
hcc
found
patient
averag
meld
score
slightli
higher
cs
group
vs
p
statist
signific
differ
variabl
bodi
weight
height
cold
ischem
time
mean
salvag
blood
volum
ml
mean
reinfus
blood
volum
ml
allogen
blood
transfus
requir
patient
cs
group
compar
patient
nc
group
howev
averag
red
blood
cell
rbc
fresh
frozen
plasma
ffp
unit
transfus
lower
cs
group
threshold
rbc
transfus
significantli
lower
cs
group
unit
vs
unit
p
backgroundcas
studi
hemorrhag
lead
caus
mortal
trauma
patient
morbid
nontrauma
patientsaddin
encitedata
massiv
transfus
protocol
mtp
reduc
mortal
trauma
nontrauma
set
howev
may
cost
blood
product
wastageaddin
encitedata
blood
product
wastag
benchmark
loos
establish
data
wastag
associ
mtp
especi
spars
redesign
mtp
obstetr
massiv
transfus
protocol
obp
differ
blood
product
prepar
schedul
assess
wastag
deliveri
method
product
util
identifi
differ
wastag
protocol
studi
designmethod
follow
institut
review
board
approv
retrospect
studi
blood
product
wastag
associ
mtp
obp
juli
perform
data
number
product
dispens
wast
manual
collect
transfus
servic
paper
electron
record
autom
data
report
electron
medic
record
resultsfind
mtp
result
higher
total
number
wast
product
obp
product
respect
howev
obp
wastag
occur
frequent
month
period
reflect
automat
thaw
cryoprecipit
first
round
deploy
product
opb
mtptrauma
activ
contribut
higher
wastag
nontrauma
activ
versu
product
skew
one
month
product
wast
due
expir
product
floor
coolerrel
issu
product
dwell
long
control
environ
common
reason
report
wastag
overal
product
wastag
rate
mtp
trauma
mtp
nontrauma
obp
respect
total
exsanguin
protocol
wast
rate
differ
overal
proport
wast
mtp
obp
protocol
insignific
conclus
wastag
associ
protocol
low
statist
differ
mtp
versu
obp
wastag
coolerrel
issu
account
product
wastag
allow
target
wast
reduct
strategi
includ
educ
outreach
improv
product
deliveri
method
better
document
wast
event
identifi
wastag
trend
product
util
optim
protocol
year
old
femal
multipl
gun
shot
admit
level
one
trauma
center
receiv
uncrossmatch
group
rh
neg
red
blood
cell
rbc
rapid
infus
resuscit
transfus
uncrossmatch
product
sampl
collect
lead
error
confus
blood
type
venipunctur
site
use
collect
patient
blood
sampl
current
fda
guidanc
aabb
standard
two
sampl
determin
blood
type
prevent
case
wrong
blood
tube
wbit
electron
identif
system
alway
catch
clarifi
error
studi
designmethod
patient
test
manual
tube
method
two
differ
technologist
use
two
differ
reagent
rack
perform
initi
test
match
result
resultsfind
two
sampl
collect
resuscit
patient
type
patient
transfus
unit
drbc
stabil
two
day
later
anoth
sampl
collect
type
rh
posit
mix
field
seen
antid
weak
test
perform
see
neg
result
antid
could
strengthen
incub
origin
sampl
still
result
tabl
consult
patient
care
team
discov
sampl
collect
iv
site
one
unit
complet
second
unit
transfus
also
discov
clinic
laboratori
sampl
reject
due
possibl
line
contamin
result
sodium
potassium
glucos
appear
inaccur
transfus
servic
laboratori
differ
area
hospit
unawar
sampl
reject
conclus
initi
sampl
collect
iv
site
contamin
dblood
product
rapidli
transfus
resuscit
sampl
collect
initi
trauma
respons
reject
request
made
sampl
drawn
iv
site
sampl
collect
unit
transfus
contamin
use
handheld
barcod
system
would
caught
error
patient
correctli
identifi
futur
prevent
anomali
would
educ
transfus
test
staff
recogn
abnorm
high
hematocrit
secondli
remind
staff
collect
sampl
awar
proper
collect
procedur
laboratori
test
would
includ
type
screen
facil
also
strive
perform
collect
confirmatori
sampl
complet
differ
venipunctur
site
impact
cell
saver
usag
solid
organ
transplant
major
institut
holli
ross
edward
smith
thoma
brown
foek
jeremi
metcalf
suzann
jame
johnson
peter
davi
karafa
sw
badji
abba
zubair
depart
laboratori
medicin
patholog
transfus
medicin
mayo
clinic
depart
anesthesia
mayo
clinic
backgroundcas
studi
institut
perform
averag
solid
organ
transplant
sot
yearli
transfus
support
transplant
tremend
account
larg
percentag
red
blood
cell
rbc
transfus
annual
even
best
practic
allogen
transfus
without
risk
transmiss
pathogen
possibl
even
strictest
screen
method
transfus
increas
risk
alloimmun
advent
intraop
blood
recoveri
reduc
need
allogen
donor
rbc
surgeri
expect
bleed
heavili
cell
saverv
r
haemoneticsv
r
braintre
patient
blood
shed
surgeri
collect
wash
concentr
reinfus
lessen
need
transfus
support
studi
sought
examin
amount
allogen
donor
rbc
unit
save
sot
use
cell
saver
intraop
blood
recoveri
studi
designmethod
data
collect
sot
util
cell
saver
includ
liver
liverkidney
combin
lung
heart
transplant
data
yo
femal
admit
trauma
depart
motor
vehicl
collis
mvc
transfus
rbc
unit
kiosk
blood
type
determin
neg
rbc
antibodi
screen
transfus
unit
rbc
two
month
later
repeat
identifi
two
new
rbc
alloantibodi
antid
anti
antid
format
result
rbc
transfus
kiosk
sourc
anti
undetermin
sinc
e
antigen
express
rh
individu
trauma
depart
staff
notifi
delay
serolog
transfus
reaction
ask
investig
sinc
yo
femal
patient
receiv
rbc
studi
designmethod
investig
plan
develop
trauma
staff
involv
patient
censu
review
chart
kiosk
inventori
obtain
feedback
clinic
provid
review
inform
provid
emerg
servic
em
resultsfind
trauma
unit
busi
admiss
hour
preced
patient
arriv
chart
review
found
follow
physic
attribut
patient
overweight
kg
obviou
facial
deform
mvc
compromis
age
assess
determin
kiosk
fulli
stock
rbc
unit
one
clinic
provid
recal
patient
identif
id
might
unknown
review
em
commun
state
patient
yo
femal
conclus
use
visual
examin
determin
age
signific
select
rbc
patient
trauma
staff
propos
implement
chang
polici
prevent
futur
incid
femal
patient
arriv
without
id
written
confirm
age
transfus
uncrossmatch
rbc
blood
type
determin
notifi
incid
trauma
staff
took
lead
investig
provid
process
improv
resolut
credit
excel
collabor
relationship
transfus
servic
trauma
depart
ensur
patient
safeti
emerg
uncrossmatch
rbc
transfus
rate
aborh
confirm
outpati
pelvic
organ
prolaps
surgeri
alexi
r
peedin
taylor
bruesek
yara
park
jay
raval
univers
north
carolina
backgroundcas
studi
approxim
surgeri
urinari
incontin
pelvic
organ
prolaps
pop
perform
annual
abdomin
pelvic
floor
disord
pfd
surgeri
transfus
rate
histor
rang
wherea
transfus
rate
vagin
robot
pfd
surgeri
rang
respect
sinc
implement
colleg
american
pathologist
cap
requir
abo
rh
confirm
approxim
patient
receiv
transfus
hospit
requir
second
aborh
specimen
drawn
howev
limit
data
avail
regard
impact
new
requir
patient
prepar
undergo
outpati
surgeri
current
requir
preoper
type
screen
primari
object
studi
assess
rate
aborh
confirm
women
underw
outpati
pop
surgeri
studi
designmethod
plan
secondari
analysi
retrospect
cohort
studi
consecut
patient
undergo
pop
surgic
repair
may
may
academ
tertiari
care
institut
among
sampl
patient
exclud
first
drawn
institut
implement
aborh
confirm
requir
fisher
exact
test
use
statist
signific
defin
p
resultsfind
identifi
patient
analysi
preoper
order
two
patient
posit
antibodi
screen
one
patient
antik
one
warmreact
autoantibodi
fiftynin
patient
requir
second
aborh
specimen
per
hospit
protocol
actual
second
specimen
drawn
patient
aborh
confirm
indic
differ
aborh
confirm
compar
age
bodi
mass
index
bmi
preoper
hemoglobin
hgb
surgic
approach
tabl
aborh
discrep
identifi
one
patient
receiv
unit
red
cell
abdomin
pop
surgeri
conclus
rate
requir
aborh
confirm
pop
surgeri
markedli
higher
seen
patient
receiv
transfus
institut
vs
respect
vast
major
women
undergo
vagin
robot
pop
surgeri
transfus
periop
hospit
transfus
servic
consid
elimin
routin
preoper
lowrisk
popul
maximum
surgic
blood
order
schedul
avoid
unneed
test
subsequ
aborh
confirm
volum
reduct
red
cell
reduc
transfusionassoci
advers
event
relat
hyperkalemia
maressa
pollen
laura
knick
linda
van
tol
c
michael
knudson
backgroundcas
studi
one
attribut
older
blood
increas
supernat
potassium
level
contribut
transient
hyperkalemia
problem
exacerb
condit
massiv
transfus
patient
renal
failur
wash
rbc
effect
remov
free
potassium
time
consum
often
perform
one
unit
time
estim
amount
potassium
remov
volum
reduct
red
cell
unit
also
examin
whether
techniqu
would
feasibl
set
massiv
transfus
patient
hyperkalemia
studi
designmethod
expir
temperatur
unit
remov
inventori
util
studi
unit
weigh
volum
reduct
procedur
perform
supernat
weigh
potassium
supernat
measur
use
routin
laboratori
assay
formula
weight
convert
volum
use
specif
graviti
gml
hematocrit
hct
volum
reduc
rbc
measur
use
sysmex
instrument
percentag
supernat
remov
calcul
divid
residu
supernat
volum
reduc
unit
rbc
hct
x
rbc
volum
total
supernat
prior
procedur
residu
supernat
remov
supernat
remain
free
potassium
meq
calcul
concentr
potassium
supernat
mmoll
x
estim
red
blood
cell
residu
supernat
volum
simul
process
would
occur
set
massiv
transfus
protocol
mtp
unit
subject
volum
reduct
record
time
need
process
unit
perform
twice
total
unit
process
manner
resultsfind
volum
reduct
procedur
reduc
supernat
volum
averag
rang
unit
day
estim
mean
residu
meq
rang
two
mock
mtp
trial
time
complet
procedur
approxim
minut
estim
addit
minut
would
requir
modifi
issu
unit
lisemr
conclus
manual
volum
reduct
protocol
red
cell
unit
significantli
reduc
amount
potassium
administ
unit
red
cell
procedur
may
use
older
red
cell
unit
avail
patient
risk
hyperkalemia
procedur
perform
less
one
hour
may
use
condit
massiv
transfus
process
cryopreserv
nonspeci
hospit
collect
preliminari
studi
three
ship
condit
collect
test
use
steril
contain
steril
normal
salin
ns
alon
ns
plu
antibioticantimycot
abam
dri
contain
prolong
exposur
abam
solut
retard
outgrowth
msc
control
microbi
growth
cultur
tissu
sampl
need
find
use
construct
valid
studi
studi
designmethod
valid
studi
design
test
procedur
collect
transport
process
store
umbil
cord
tissu
measur
postthaw
outgrowth
collect
uc
tissu
consent
mother
transport
distant
lab
valid
ship
contain
dri
steril
cup
vagin
caesarian
birth
uc
collect
divid
segment
test
condit
segment
explant
place
gelatinco
grid
tissu
cultur
plate
explant
per
plate
enrich
medium
specifi
msc
outgrowth
contain
antibiot
endpoint
day
growth
score
number
squar
explant
exhibit
outgrowth
compar
total
plant
explant
one
segment
fresh
control
dissect
plant
without
process
remain
tissu
segment
soak
abam
salin
solut
hr
hr
respect
tissu
segment
frozen
cryo
bag
proprietari
dmsolarg
molecular
weight
sugar
solut
backgroundcas
studi
practic
institut
process
time
total
blood
volum
bv
patient
maximum
liter
l
per
procedur
obtain
peripher
blood
stem
cell
consequ
patient
often
would
need
spend
hour
machin
would
desir
abl
specifi
exact
volum
blood
process
achiev
desir
cell
yield
thu
minim
patient
time
machin
nurs
time
perform
procedur
number
bag
submit
cryopreserv
storag
studi
designmethod
institut
recent
implement
new
spectra
optia
cmnc
collect
protocol
continu
flow
continu
collect
procedur
use
autom
interfac
manag
aim
system
precis
manag
separ
interfac
analysi
collect
data
suggest
highli
reliabl
collect
process
predict
algorithm
pa
base
linear
regress
patient
precount
yield
normal
per
liter
blood
process
deriv
util
patient
precount
patient
weight
kilogram
kg
target
dosekg
pa
calcul
exact
volum
whole
blood
process
achiev
request
dose
peripher
stem
cell
initi
equat
modifi
add
addit
predict
volum
account
natur
variabl
process
pa
test
prospect
clinic
set
resultsfind
patient
repres
allogen
autolog
donor
averag
blood
volum
process
l
rang
l
l
target
dose
achiev
patient
previou
practic
patient
would
requir
assum
standard
bv
procedur
process
averag
l
per
patient
rang
l
quantifi
well
new
pa
work
decid
evalu
ratio
actual
predict
volum
vs
ratio
actual
expect
yield
result
high
correl
two
ratio
r
indic
algorithm
produc
consist
result
conclus
predict
collect
process
time
period
analyz
robust
r
confirm
find
first
data
analysi
blood
volum
process
patient
time
machin
decreas
substanti
patient
need
hour
less
achiev
target
dose
nurs
lab
medic
technologist
seen
dramat
chang
workflow
number
bag
process
drop
lab
consequ
freezer
space
save
shorter
collect
time
allow
lab
medic
technologist
finish
work
earlier
day
implement
pa
produc
huge
increas
patient
provid
satisfact
import
factor
like
contribut
success
protocol
includ
precis
consist
aim
system
apheresi
devic
well
small
number
nurs
perform
procedur
result
less
variabl
econom
impact
pa
quantifi
might
interest
area
futur
studi
backgroundcas
studi
zarziov
r
biosimilar
granulocyt
colonystimul
factor
gcsf
recent
introduc
clinic
practic
use
stimul
certain
debat
regard
possibl
less
efficaci
secur
mobil
aim
studi
evalu
differ
good
bad
mobil
assess
need
plerixafor
biosimilar
gcsf
use
studi
designmethod
retrospect
evalu
autolog
mobil
process
perform
june
march
patient
evalu
diagnos
malign
lymphoma
multipl
myeloma
primari
amyloidosi
mobil
accord
standard
protocol
collect
cellular
target
establish
two
group
good
bad
mobil
determin
predictor
unsuccess
mobil
defin
year
old
previou
fludarabin
lenalidomid
bendamustin
treatment
previou
regimen
present
peripher
cytopenia
activ
diseas
previou
mobil
failur
mannwhitney
u
test
use
compar
mean
comparison
median
perform
median
test
count
perform
accord
ishag
protocol
advers
event
ae
analys
accord
ctcae
resultsfind
media
rang
gener
collect
paramet
day
blood
volum
process
exchang
volemia
seventeen
patient
consid
bad
mobil
need
plerixafor
undergon
collect
procedur
twice
statist
signific
differ
group
mobil
characterist
product
cellular
mean
sd
signific
differ
mobil
characterist
product
cellular
group
five
mobil
ae
observ
muscl
pain
fever
flu
syndrom
grade
two
patient
could
undergo
hematopoiet
stem
cell
transplant
due
low
cellular
conclus
differ
product
collect
good
mobil
rich
gm
versu
poor
mobil
plerixafor
rich
cn
cmn
mobil
zarziov
r
could
smaller
expect
sinc
signific
differ
compar
good
mobil
versu
bad
mobil
although
number
case
studi
limit
backgroundcas
studi
mesenchym
stem
cell
msc
wide
studi
shown
benefici
effect
tissu
regener
immunomodul
improv
multipl
organ
failur
caus
infect
sepsi
trauma
howev
msc
express
tissu
factor
may
risk
factor
thrombosi
especi
administr
system
follow
trauma
coagulopathi
common
appli
msc
preclin
anim
model
sought
determin
procoagul
properti
rat
msc
vitro
studi
designmethod
bone
marrow
adipos
deriv
msc
bmsc
amsc
isol
bone
femur
tibia
viscer
fat
tissu
normal
young
spragu
dawley
rat
respect
bmsc
amsc
cultur
passag
use
dmem
medium
fetal
bovin
serum
bmsc
amsc
passag
use
studi
tissu
factor
express
msc
determin
immunohistochemistri
citrat
whole
blood
collect
normal
rat
treat
rat
bmsc
amsc
low
medium
high
dose
ml
ml
ml
respect
prothrombin
time
pt
coagul
properti
platelet
aggreg
respons
adp
collagen
measur
hemostasi
analyz
rotat
thromboelastometri
rotem
imped
aggregometri
multipl
respect
within
incub
resultsfind
tissu
factor
significantli
express
among
bmsc
amsc
passag
vitro
bmsc
amsc
dose
time
treatment
neither
shorten
elong
pt
whole
blood
howev
bmsc
amsc
significantli
shorten
clot
time
ct
none
second
versu
low
medium
high
dose
amsc
second
bmsc
second
p
clot
format
time
cft
p
increas
alpha
angl
p
natem
measur
significantli
affect
ct
cft
alpha
angl
extem
maximum
clot
firm
mcf
fibrinolyt
index
affect
msc
signific
impact
bmsc
amsc
platelet
aggreg
simul
adp
collagen
signific
differ
hemostat
platelet
function
found
treatment
bmsc
amsc
conclus
consist
report
human
deriv
msc
rat
bmsc
amsc
significantli
express
tissu
factor
earli
late
passag
led
signific
decreas
clot
time
variou
dose
time
treatment
howev
msc
direct
impact
platelet
aggreg
vitro
consid
procoagul
capabl
msc
futur
studi
necessari
determin
optim
dose
safeti
use
msc
system
applic
vivo
comparison
terumo
bct
mnc
cmnc
protocol
peripher
blood
stem
cell
collect
lindsey
westbrook
neil
bagamasbad
reynold
dilag
melissa
nasser
nicol
bauer
jennif
wheeler
mari
berg
depart
patholog
univers
colorado
anschutz
medic
campu
depart
medicin
divis
hematolog
univers
colorado
hospit
scientif
support
terumo
bct
backgroundcas
studi
terumo
bct
recent
offer
new
method
peripher
blood
stem
cell
pbsc
collect
use
spectra
optia
apheresi
instrument
new
protocol
continu
mononuclear
cell
collect
cmnc
collect
cell
continu
oppos
older
protocol
mononuclear
cell
collect
mnc
protocol
batch
collect
dual
stage
collect
involv
addit
step
platelet
separ
mnc
within
cell
separ
chamber
institut
use
protocol
purpos
studi
compar
pbsc
product
characterist
run
time
cmnc
mnc
protocol
studi
designmethod
retrospect
review
comparison
paramet
collect
procedur
use
mnc
protocol
collect
procedur
use
cmnc
protocol
done
use
ttest
data
patientsdonor
includ
allogen
donor
well
procedur
detail
includ
run
time
flow
cytometri
marker
stem
cell
posit
throughput
collect
effici
ce
platelet
loss
transfus
per
total
blood
volum
process
plt
losstbv
collect
product
characterist
includ
analysi
resultsfind
numer
result
summar
tabl
mnc
cmnc
donor
group
includ
allogen
donor
respect
donor
weight
significantli
differ
two
group
preprocedur
wbc
valu
also
similar
two
group
run
time
found
significantli
shorter
use
cmnc
protocol
compar
mnc
protocol
product
volum
also
significantli
lower
cmnc
group
compar
mnc
group
although
volum
lower
cmnc
product
significantli
higher
percentag
mononuclear
cell
mono
lymphocyt
lymph
collect
compar
mnc
product
throughput
significantli
higher
cmnc
group
mnc
group
ce
found
slightli
increas
cmnc
group
though
significantli
platelet
loss
significantli
differ
protocol
normal
total
blood
volum
product
hematocrit
hct
significantli
higher
use
cmnc
protocol
howev
red
blood
cell
volum
never
exceed
ml
due
lower
product
volum
cmnc
protocol
cmnc
protocol
collect
smaller
volum
purer
product
compar
mnc
protocol
compar
platelet
red
blood
cell
loss
staff
member
perform
apheresi
procedur
pleas
shorter
run
time
backgroundcas
studi
hematopoiet
stem
cell
hsc
donor
recipi
need
match
blood
type
eventu
hsc
recipi
becom
blood
type
hsc
donor
scenario
becom
quit
conundrum
hsc
recipi
becom
patient
need
organ
transplant
order
patient
receiv
donor
organ
patient
donor
blood
type
hla
type
must
compat
studi
designmethod
blood
type
determin
use
gel
test
card
hla
type
determin
use
sequencespecif
oligonucleotid
sso
sequencespecif
primer
ssp
sequenc
base
type
sbt
technolog
hsc
sourc
bone
marrow
umbil
cord
blood
resultsfind
patient
origin
type
bone
marrow
donor
cord
blood
transplant
one
cord
blood
transplant
success
engraft
engraft
unit
type
donor
patient
type
type
patient
origin
type
receiv
bone
marrow
transplant
type
b
donor
patient
fronttyp
b
backtyp
ab
sinc
patient
abo
front
backtyp
match
note
must
made
confirm
abo
crossmatch
abo
match
patient
hla
abo
ident
kidney
match
father
type
b
previous
patient
father
abo
incompat
abo
hla
result
patient
patient
indic
hsc
transplant
engraft
result
also
indic
abo
hla
match
donor
differ
recipi
origin
abo
hla
type
due
variou
reason
exampl
side
effect
immunosuppress
patient
need
kidney
transplant
patient
enter
unet
system
accord
new
abo
hla
type
uno
regul
requir
patient
list
per
result
two
separ
abo
type
test
patient
antibodi
monitor
per
lab
polici
commun
transplant
center
blood
bank
crucial
backgroundcas
studi
mesenchym
stem
cell
msc
benefici
tissu
regener
immunomodul
improv
multipl
organ
failur
caus
infect
sepsi
trauma
msc
express
tissu
factor
tf
activ
clot
cascad
interfer
hemostasi
hypoxia
condit
occur
trauma
global
shock
site
injuri
known
chang
influenc
phenotyp
cell
includ
msc
studi
want
determin
hypoxia
chang
express
tissu
factor
procoagul
properti
rat
msc
vitro
studi
designmethod
bone
marrow
adipos
deriv
msc
bmsc
amsc
isol
bone
femur
tibia
viscer
fat
tissu
normal
young
spragu
dawley
rat
respect
bmsc
amsc
cultur
use
dmem
medium
fetal
bovin
serum
either
normoxia
hypoxia
msc
growth
curv
measur
cell
counter
tf
express
determin
immunohistochemistri
measur
posit
neg
marker
msc
respect
flow
cytometri
citrat
rat
whole
blood
treat
msc
ml
either
normoxia
hypoxia
coagul
properti
measur
hemostasi
analyz
rotat
thromboelastometri
rotem
resultsfind
hypoxia
potenti
growth
bmsc
depress
growth
amsc
day
comparison
normoxia
bmsc
amsc
equal
express
cultur
condit
tissu
factor
significantli
express
among
bmsc
amsc
normoxia
hypoxia
whole
blood
treat
bmsc
amsc
normoxia
significantli
shorten
clot
time
ct
control
versu
bmsc
amsc
second
natem
hypoxia
also
significantli
shorten
ct
bmsc
amsc
second
p
compar
control
chang
ct
significantli
differ
bmsc
amsc
maximum
clot
firm
mcf
fibrinolyt
index
chang
treatment
bmsc
amsc
regardless
normoxia
hypoxia
condit
conclus
tissu
factor
constitut
express
rat
bmsc
amsc
adjust
msc
cultur
condit
hypoxia
affect
tissu
factor
express
procoagul
properti
msc
bmsc
amsc
studi
also
suggest
procoagul
properti
affect
msc
recruit
injur
tissu
hypox
environ
futur
studi
necessari
determin
optim
dose
msc
whether
safe
use
msc
system
applic
trauma
effect
doubleend
cryopreserv
genetransduc
human
hematopoiet
stem
progenitor
cell
sandeep
k
srivastava
jiaqiang
ren
steven
highfil
narda
theobald
sukse
deravin
andr
larochel
david
f
stroncek
sandhya
r
panch
nation
institut
health
backgroundcas
studi
current
earlyphas
clinic
gene
therapi
trial
use
freshli
collect
cryopreserv
cell
start
fraction
prior
gene
manipul
follow
genetransduct
cultur
end
product
infus
fresh
recipi
wider
applic
scaleup
gene
therapi
manufactur
protocol
would
benefit
doubleend
cryopreserv
dec
cell
manufactur
ie
immedi
postcollect
postgen
modif
dec
help
delink
patient
prepar
condit
phase
cell
manufactur
eas
logist
interfacil
cell
transport
ensur
fulfil
regulatori
product
releas
criteria
infus
object
studi
effect
dec
gene
transduc
mobil
peripher
blood
mpb
cell
studi
designmethod
cryopreserv
cell
healthi
adult
donor
thaw
transduc
tr
retronectin
coat
tissu
cultur
bag
lentiviru
concentr
media
human
serum
albumin
hsa
ngml
cytokin
scf
tpo
day
untransduc
utr
cell
cultur
control
tr
utr
fraction
recryopreserv
standard
freezemix
dmso
pentastarch
hsa
plasmalyt
use
cryopreserv
viabil
hematopoiet
stem
cell
hsc
cell
phenotyp
cfu
assay
done
follow
first
thaw
posttransduct
ptxn
second
cryopreservationthaw
resultsfind
tnc
recoveri
decreas
gradual
donor
sampl
step
transduct
effici
cfu
similar
hsc
rang
cell
arm
compar
rang
cell
viabil
cfu
lower
tr
compar
utr
arm
differ
alter
tabl
conclus
dec
mpb
human
cell
decreas
tnc
recoveri
minim
effect
cell
phenotyp
transduct
effici
cell
function
hsc
number
within
accept
rang
recryopreserv
lower
viabil
tr
arm
compar
utr
arm
like
due
vector
toxic
unaffect
recryopreserv
addit
studi
assess
dec
mediat
chang
cell
earli
apoptot
marker
telomer
length
gene
express
engraft
potenti
nodscid
mice
inform
clinic
trial
backgroundcas
studi
autolog
peripher
blood
stem
cell
pbsc
transplant
use
power
resourc
treatment
hematolog
malign
cryopreserv
cell
routin
perform
allow
patient
adequ
condit
chemotherapi
case
pbsc
harvest
backup
option
remain
store
sever
year
although
effect
storag
lesion
product
still
controversi
work
present
retrospect
data
pbsc
infus
longterm
storag
studi
designmethod
product
harvest
patient
mobil
gcsf
apheresi
cobe
spectra
v
r
flow
cytometri
analysi
cell
perform
prior
cryopreserv
cryoprotect
solut
freshli
prepar
addit
hydroxyethyl
starch
human
serum
albumin
dmso
final
concentr
pbsc
cryopreserv
direct
immers
mechan
freezer
dump
freez
store
transplant
postthaw
viabil
determin
store
cryotub
sampl
trypan
blue
exclus
minut
prior
infus
cell
thaw
infus
bedsid
engraft
defin
first
day
consecut
day
neutrophil
count
l
platelet
count
l
day
gcsf
four
day
patient
gcsf
five
day
use
mozobil
x
cellsl
fourth
day
hpc
collect
perform
fourth
day
mobil
healthi
donor
fifth
day
patient
procedur
realiz
base
predict
algorithm
use
day
collect
estim
wbc
liter
process
obtain
suffici
stem
cell
transplant
algorithm
design
use
linear
regress
peripher
blood
day
collect
versu
collect
per
liter
blood
process
distinct
patient
donor
effici
coeffici
use
collect
materi
sent
analysi
total
calcul
final
laboratori
count
per
kilogram
compar
number
predict
algorithm
spearman
correl
evalu
whether
formula
effect
calcul
made
use
ibm
spss
softwar
resultsfind
among
patient
collect
hpc
autolog
transplant
need
one
day
hpc
harvest
need
two
day
need
three
day
collect
effici
ce
standard
error
mean
sem
compar
predict
valu
collect
final
product
found
strong
correl
p
patient
strong
correl
healthi
donor
p
conclus
use
mathemat
model
predict
algorithm
safe
low
cost
provid
good
tool
estim
wb
liter
process
avoid
unnecessari
procedur
patient
healthi
donor
studi
evalu
phenotyp
characterist
ucmsc
deriv
fresh
cryopreserv
cord
tissu
ct
describ
isct
posit
paper
minim
characterist
mesenchym
stem
cell
plastic
adher
hladr
studi
designmethod
umbil
cord
tissu
wash
blood
vessel
remov
cut
piec
wash
twice
salin
fresh
tissu
immers
salin
day
cultur
frozen
tissu
cryopreserv
least
hour
prior
cultur
coloni
form
unit
cfu
test
tissu
plate
directli
tissu
cultur
flask
follow
wash
pb
antibioticantimycot
tissu
allow
adher
minut
prior
addit
cell
cultur
media
media
chang
sever
time
week
cell
pass
robust
coloni
growth
observ
subsequ
cultur
confluenc
cell
test
msc
flow
panel
passag
prior
confluenc
resultsfind
fresh
cryopreserv
tissu
show
excel
coloni
form
capabl
averag
time
cellular
emerg
day
fresh
frozen
day
total
msc
reach
passag
fresh
frozen
cell
readi
flow
analysi
approxim
week
time
statist
differ
fresh
frozen
tissu
coloni
emerg
p
growth
rate
p
flow
cytometri
show
averag
posit
marker
neg
marker
statist
differ
fresh
frozen
flow
result
p
conclus
ucmsc
show
excel
adher
plastic
fresh
frozen
explant
cultur
consist
fibroblastlik
morpholog
flow
cytometri
analysi
show
strong
msc
phenotyp
fresh
frozen
sampl
data
show
cryogen
process
appear
detriment
effect
abil
obtain
msc
coloni
studi
shown
hsct
improv
surviv
diseasefre
surviv
rate
compar
convent
chemotherapi
treatment
increas
number
hsct
last
year
demand
qualiti
safeti
improv
cell
process
cryopreserv
servic
cell
recoveri
viabil
crucial
paramet
assess
ucb
qualiti
viabl
hsct
graft
sourc
studi
designmethod
twentyf
ucb
unit
cryopreserv
period
year
analyz
unit
underw
red
cell
plasma
deplet
subject
control
rate
freez
subsequ
cryopreserv
use
dmso
dimethylsulfoxid
cryoprotect
concentr
inform
consent
unit
discard
term
unit
obtain
unit
thaw
c
water
bath
aliquot
dilut
proport
human
albumin
solut
plasmin
prepar
enabl
dmso
stabil
concentr
reduct
follow
analysi
perform
nucleat
cell
count
tnc
autom
hematolog
counter
cell
viabil
use
flow
citometri
postprocess
precryopreserv
cell
viabil
test
use
trypan
blue
exclus
dye
postthaw
cell
viabil
assess
use
marker
flow
cytometr
analysi
resultsfind
ucb
storag
period
year
mean
cell
recoveri
mean
statist
signific
correl
storag
period
postprocess
cell
recoveri
p
postthaw
cell
viabil
mean
show
statist
signific
correl
unit
storag
period
p
post
thaw
cell
viabil
result
within
paramet
defin
studi
backgroundcas
studi
umbil
cord
uc
tissu
rich
sourc
mesenchym
stem
cell
msc
collect
noninvas
birth
store
potenti
futur
use
grow
number
stem
cell
bank
establish
uc
storag
program
base
mount
preclin
evid
therapeut
potenti
howev
littl
report
abil
isol
msclike
cell
uc
tissu
extend
period
cryopreserv
work
describ
character
isol
msc
uc
tissu
cryopreserv
composit
materi
famili
stem
cell
bank
year
studi
designmethod
donat
uc
unit
consent
mother
evalu
unit
cryopreserv
composit
tissu
piec
ln
vapor
dmsobas
cryoprotect
unit
rapidli
thaw
rins
dpb
piec
excis
use
biopsi
punch
piec
unit
explant
grid
pattern
mscsupport
medium
incub
day
tissu
discard
media
exchang
cell
isol
th
day
count
subcultur
two
passag
end
passag
cell
collect
count
popul
doubl
time
calcul
isol
cell
unit
also
evalu
msc
immunomark
resultsfind
small
prolif
cell
fibroblast
morpholog
obtain
explant
yield
success
rate
cell
posit
msc
marker
respect
neg
hematopoiet
marker
passag
passag
doubl
time
day
day
respect
line
valu
report
msc
isol
fresh
uc
tissu
conclus
due
immatur
statu
eas
collect
potenti
therapeut
valu
uc
msc
appeal
candid
futur
clinic
transfus
vol
supplement
research
treatment
present
work
demonstr
longterm
cryopreserv
uc
tissu
disrupt
abil
isol
function
msc
tissu
later
date
importantli
growth
characterist
isol
msc
appear
compar
report
msc
fresh
uc
tissu
base
consist
isol
lack
appar
impact
prolifer
kinet
reason
expect
cell
yield
rang
anticip
therapeut
requir
suffici
move
clinic
grade
bioreactor
expans
result
support
feasibl
storag
uc
composit
materi
futur
potenti
cell
isol
expans
clinic
relev
dose
larg
volum
leukapheresi
spectra
optia
cmnc
protocol
adult
pediatr
patient
perform
determin
yield
predict
algorithm
ine
bojan
nelli
besson
ivana
vidov
branka
golub
cepul
depart
transfus
medicin
transplant
biolog
univers
hospit
centr
zagreb
terumo
bct
backgroundcas
studi
larg
volum
leukapheresi
lvl
shown
enhanc
yield
collect
studi
evalu
perform
safeti
spectra
optia
cmnc
protocol
version
adult
pediatr
lvl
predict
algorithm
yield
also
test
studi
designmethod
evalu
retrospect
lvl
perform
adult
patient
lvl
pediatr
patient
treat
uhc
zagreb
march
till
septemb
mobil
regimen
combin
chemotherapi
filgrastim
poor
mobil
receiv
plerixafor
addit
combin
acda
heparin
use
anticoagul
acda
whole
blood
ratio
patient
weight
rbc
prime
perform
lymphocyt
ly
monocyt
mo
collect
effici
ce
calcul
custom
predict
algorithm
determin
linear
regress
count
collect
blood
volum
process
predict
accuraci
evalu
compar
predict
valu
real
yield
result
present
median
iqr
resultsfind
group
ly
mo
ce
high
target
dose
success
reach
procedur
adult
children
procedur
well
toler
advers
reaction
restrict
mild
citrat
toxic
symptom
adult
pediatr
apheresi
went
unev
bleed
episod
occur
transfus
need
product
procedur
characterist
high
correl
collect
blood
volum
observ
group
r
adult
children
respect
p
suggest
yield
could
predict
base
blood
volum
process
linear
regress
equat
serv
predict
algorithm
high
correl
predict
yield
observ
yield
r
adult
children
respect
p
show
accuraci
algorithm
implement
algorithm
could
allow
spare
median
l
blood
adult
procedur
l
pediatr
procedur
conclus
lvl
perform
use
spectra
optia
cmnc
protocol
safe
effici
adult
low
bodi
weight
children
high
ly
mo
observ
group
implement
predict
algorithm
reliabl
minim
blood
volum
process
shorten
procedur
durat
reduc
anticoagul
volum
infus
improv
patient
comfort
mesenchym
stem
cell
therapi
steroid
refractori
graftversushost
diseas
gvhd
emes
molnar
aniko
barta
arpad
batai
zoltan
csukli
zita
farka
laszlo
gopcsa
gabor
tatai
backgroundcas
studi
steroid
refractori
acut
graftversushost
diseas
gvhd
seriou
complic
allogen
hematopoiet
stem
cell
transplant
hsct
experi
accumul
immunomodulatori
effect
mesenchym
stem
cell
msc
infus
numer
immunopatholog
disord
gvhd
signal
msc
hlarestrict
nonimmunogen
natur
studi
designmethod
evalu
efficaci
msc
transfus
case
acut
gvhd
refractori
convent
immunosuppress
treatment
patient
steroidresist
gvhd
receiv
thirdparti
msc
deriv
wharton
jelli
bone
marrow
time
per
case
weekli
dose
million
cellskg
clinic
respons
assess
day
administ
first
dose
complet
remiss
defin
complet
disappear
symptom
partial
remiss
assess
signific
relief
symptomsand
gener
improv
patient
condit
resultsfind
patient
receiv
cycl
msctreatment
dose
per
cycl
median
age
year
old
malefemal
ratio
distribut
origin
malign
n
acut
myeloid
leukemia
acut
lymphoblast
leukemia
myelofibrosi
myelodysplast
syndrom
multipl
myeloma
tcell
lymphoma
nine
patient
undergon
allogen
hsct
match
unrel
donor
three
stem
cell
deriv
hlaident
rel
first
episod
gvhd
hsct
start
median
day
involv
organ
skin
gut
skin
gut
combin
even
lung
case
median
time
msc
first
infus
day
stem
cell
transplant
hsct
day
first
episod
gvhd
cycl
msctreatment
led
complet
remiss
result
inparti
remiss
conclus
evalu
msctherapi
effect
treatment
gvhd
major
observ
case
overal
cumul
respons
rate
applic
thirdparti
msc
offer
promis
altern
therapi
gvhd
gvhdassoci
complic
hsct
research
need
determin
optim
start
treatment
along
issu
longterm
safeti
backgroundcas
studi
stem
cell
collect
leukapheresi
transplant
signific
endeavor
patient
clinic
team
whether
collect
allogen
autolog
patient
undergo
collect
physician
care
patient
alway
concern
whether
abl
harvest
enough
cell
transplant
engraft
typic
goal
adult
procedur
million
cellskg
patient
reach
goal
day
procedur
like
return
follow
day
undergo
second
procedur
reach
desir
goal
given
logist
challeng
plan
transplant
reason
attempt
optim
number
cell
collect
minim
number
collect
measur
patient
cellsml
peripher
blood
leukapheresi
procedur
use
predict
collect
success
reach
million
cellskg
goal
ideal
minimum
cellsml
lead
success
harvest
conclus
identifi
studi
designmethod
analyz
collect
data
patient
evalu
predict
valu
cellsml
level
data
collect
month
everi
patient
underw
stem
cell
collect
four
patient
allogen
donor
autolog
donor
patient
weight
diagnosi
preprocedur
cellsml
level
collect
run
time
amount
volum
process
absolut
viabl
cell
collect
record
collect
effici
cellskg
calcul
patient
resultsfind
data
show
strong
linear
correl
preprocedur
cellsml
postprocedur
cellskg
patient
preprocedur
cellsml
count
greater
collect
least
million
cellskg
patient
preprocedur
cellsml
count
less
collect
less
conclus
preprocedur
cellsml
level
peripher
blood
strong
predict
valu
postprocedur
cellskg
level
confid
know
patient
abl
produc
desir
million
cellskg
preprocedur
cellsml
count
least
obtain
patient
count
counsel
collect
like
take
least
second
day
second
procedur
studi
includ
potenti
lengthen
run
time
volum
process
evalu
handl
patient
fall
cellsml
conduct
heidi
elmoazzen
antonio
giulivi
michael
halpenni
lisa
martin
donna
perron
chri
bredeson
lin
yang
locksley
mcgann
paul
birch
jason
p
acker
canadian
blood
servic
ottawa
hospit
backgroundcas
studi
critic
aspect
hematopoiet
progenitor
cell
process
cryopreserv
method
program
use
dump
freez
method
consist
product
placement
directli
liquid
nitrogen
vapour
addit
cryopreserv
solut
contain
dmso
final
concentr
he
hydroxyethyl
starch
pentastarch
he
sourc
critic
compon
cryoprotect
formul
discontinu
commerci
vendor
requir
altern
cryoprotect
formul
valid
minim
risk
patient
safeti
without
compromis
engraft
qualiti
studi
designmethod
valid
studi
consist
phase
firstevalu
efficaci
four
differ
cryoprotect
formul
second
evalu
full
scale
product
crypreserv
third
concurr
valid
clinic
transplant
phase
sampl
four
differ
cryoprotect
formul
test
tnc
viabil
cfu
three
point
manufactur
fresh
post
process
post
thaw
phase
ii
mock
hpc
apheresi
unit
use
sidebysid
comparison
freez
curv
control
replac
formul
phase
iii
five
clinic
transplant
perform
hpc
apheresi
product
cryopreserv
use
recommend
replac
hetastarch
resultsfind
phase
result
indic
aliquot
cryopreserv
dmso
he
hetastarch
behav
significantli
differ
cell
cryopreserv
control
term
cell
recoveri
viabil
cell
prolifer
assay
cfu
phase
ii
major
freez
profil
display
typic
expect
bulk
freez
profil
formul
phase
iii
transplant
perform
result
mean
engraft
time
day
advers
patient
reaction
observ
engraft
time
use
new
hetastarch
formula
compar
previou
engraft
time
signific
differ
conclus
chang
formul
cryoprotect
solut
repres
major
chang
could
signific
impact
qualiti
addit
maintain
current
dmso
final
concentr
critic
post
thaw
wash
perform
clinic
site
histori
demonstr
low
toxic
rate
exist
formul
studi
demonstr
accept
hetastarch
formul
use
dmso
hetastarch
replac
pentastarch
cryoprotect
formul
use
cryopreserv
hpc
apheresi
product
backgroundcas
studi
autolog
stem
cell
transplant
usual
perform
mobil
peripher
blood
stem
cell
pbsc
tradit
mobil
regimen
includ
granulocyt
coloni
stimul
factor
gcsf
without
chemotherapi
failur
rate
rang
plerixafor
adjunct
agent
use
improv
mobil
mani
clinic
set
howev
high
cost
signific
concern
manufacturerrecommend
dose
mgkg
therefor
patient
weigh
kg
would
requir
second
vial
thu
doubl
drug
cost
implement
polici
cap
plerixafor
mg
patient
weigh
kg
retrospect
studi
compar
mobil
patient
receiv
cap
dose
histor
control
patient
receiv
full
uncap
dose
studi
designmethod
patient
weigh
kg
crcl
receiv
cap
full
dose
plerixafor
identifi
pharmaci
databas
electron
medic
record
use
collect
baselin
characterist
cell
collect
data
resultsfind
total
consecut
patient
includ
cap
full
dose
group
respect
show
compar
baselin
distribut
age
weight
gender
diagnos
plerixafor
given
upfront
rescu
agent
due
suboptim
mobil
group
cap
dose
group
fewer
patient
receiv
chemomobil
plerixafor
upfront
compar
histor
control
use
half
number
vial
plerixafor
collect
similar
number
kg
achiev
compar
collect
success
rate
strategi
dose
cap
plerixafor
mg
patient
kg
costeffect
achiev
compar
mobil
outcom
decreas
drug
cost
half
mean
rang
peripher
blood
calcul
data
show
nonhispan
group
youngest
donor
higher
preapheresi
level
group
reach
statist
signific
compar
preapheresi
youngest
group
yr
oldest
group
yr
hispan
donor
show
statist
similar
preapheresi
level
age
group
moreov
hispan
older
age
group
statist
higher
preapheresi
level
nonhispan
older
age
group
conclus
analysi
sequenti
unrel
pbsc
donor
hispan
donor
maintain
similar
preapheresi
level
even
donor
age
nonhispan
donor
show
decreas
preapheresi
level
age
proven
data
would
suggest
genet
factor
modul
person
abil
mobil
stem
cell
age
genet
factor
differ
ethnic
group
small
data
set
would
suggest
peopl
hispan
ethnic
maintain
robust
quickli
respons
stem
cell
pool
even
age
studi
larger
cohort
need
valid
observ
proven
far
reach
implic
within
stem
cell
research
therapi
arena
backgroundcas
studi
updat
hpc
apheresi
collect
softwar
led
higher
collect
volum
organ
human
progenitor
cell
hpc
product
without
correspond
increas
total
cellular
count
incorpor
volum
reduct
step
therefor
warrant
larger
product
volum
requir
addit
time
transfus
lead
larger
dmso
load
recipi
often
result
need
transfus
sever
day
object
studi
develop
suitabl
mock
hpc
mhpc
product
evalu
effect
biosaf
pericel
volum
reduct
technolog
white
blood
cell
wbc
recoveri
viabil
studi
designmethod
hpc
product
readili
avail
develop
mhpc
creat
whole
blood
buffi
coat
bc
fresh
abo
compat
bc
pool
concentr
use
centrifug
manual
extract
supernat
red
cell
mhpc
product
dilut
plasma
produc
appropri
concentr
volum
hpc
collect
data
last
year
analyz
determin
th
percentil
median
th
percentil
valu
hpc
volum
wbc
concentr
six
mhpc
product
test
three
high
wbc
x
cell
ml
three
low
wbc
x
cell
ml
concentr
high
ml
low
ml
median
ml
volum
unit
process
sequenti
high
median
low
volum
henc
highest
mhpc
volum
process
volum
reduct
first
sepax
pericel
protocol
kit
analyz
reconstitut
volum
adjust
next
volum
target
volum
reduc
forth
one
addit
mock
product
prepar
reproduc
studi
volum
reduc
three
time
wbc
concentr
viabil
determin
volum
reduct
control
sampl
remov
product
prior
process
sat
bench
top
end
protocol
assess
chang
cell
concentr
viabil
time
resultsfind
mock
hpc
product
mean
start
viabil
rang
hematocrit
well
maximum
allow
limit
pericel
signific
differ
wbc
recoveri
chang
viabil
seen
mhpc
product
aggreg
data
show
mean
wbc
recoveri
volum
reduct
process
chang
viabil
recoveri
protocol
use
salvag
product
volum
reduct
gave
recoveri
chang
viabil
input
product
method
found
cv
chang
wbc
concentr
wbc
viabil
test
product
significantli
differ
unprocess
control
sampl
conclus
mock
bc
product
suitabl
altern
hpc
product
avail
develop
good
use
product
otherwis
direct
reject
dispos
volum
reduct
protocol
evalu
minim
impact
wbc
concentr
wbc
viabil
mock
product
found
highli
reproduc
give
confid
valuabl
process
step
hpc
facilit
transfus
hpc
product
recipi
protocol
use
patient
hpc
product
engraft
kinet
track
postimplement
studi
valid
transfus
clinic
assess
first
phase
cryopreserv
pbsc
product
test
two
aliquot
thaw
simultan
product
one
pass
preset
infus
pump
second
control
aliquot
drain
graviti
aliquot
test
baselin
total
nucleat
cell
tnc
count
viabil
final
tnc
recoveri
trypan
blue
tb
viabil
viabil
potenc
cfu
effect
longterm
exposur
dmso
assess
visual
inspect
product
aggreg
measur
viabil
hour
post
thaw
second
vivo
phase
includ
use
infus
pump
consecut
autolog
patient
comparison
infus
transplant
outcom
previou
infus
graviti
drip
comparison
variabl
includ
infus
rate
advers
event
ae
engraft
time
resultsfind
signific
differ
observ
infus
pump
drip
product
test
vitro
includ
tnc
recoveri
cell
viabil
potenc
method
tnc
tb
viabil
decreas
within
hour
cell
viabil
remain
stabl
hour
post
thaw
small
aggreg
appear
hour
method
increas
similar
rate
time
comparison
infus
transplant
outcom
drip
infus
pump
patient
show
signific
differ
measur
variabl
engraft
time
similar
group
anc
day
engraft
pump
drip
respect
platelet
day
engraft
pump
drip
respect
infus
rate
slightli
higher
pump
group
control
patient
requir
transfer
product
syring
due
slow
infus
rate
other
experienc
allerg
hypotens
infus
advers
event
conclus
signific
vitro
clinic
differ
observ
thaw
pbsc
infus
graviti
infus
pump
result
demonstr
use
pump
pbsc
infus
safe
provid
consist
infus
rate
elimin
need
transfer
product
syring
result
compar
engraft
time
donor
racial
distribut
among
zikv
inelig
cbu
caucasian
asian
blackaa
multirac
racial
distribut
clinic
cbu
donor
caucasian
asian
blackaa
multirac
suggest
race
correl
risk
factor
driven
cultur
habit
famili
travel
case
onlyth
sexual
partner
potenti
exposur
determin
donor
inelig
conclus
studi
indic
current
lead
risk
factor
inelig
cb
donor
potenti
exposur
zikv
inelig
cbu
bank
cbu
studi
period
anticip
number
case
decreas
follow
matern
educ
travel
warn
recogn
import
zikv
public
health
potenti
transmiss
via
hctp
product
fda
approv
screen
test
hct
p
donor
becom
time
necess
acknowledg
fund
zimmer
biomet
zimmer
biomet
compani
ibgrl
red
cell
refer
nhsbt
reagent
backgroundcas
studi
storag
red
blood
cell
rbc
becom
less
deform
deplet
adenosin
triphosph
atp
releas
procoagul
phospholipid
accumul
proinflammatori
molecul
free
iron
haemoglobin
increas
potenti
adhes
recipi
vascular
endothelium
longer
rbc
storag
may
impair
transfus
outcom
due
impair
oxygen
deliveri
promot
oxid
stress
increas
proinflammatori
state
coagul
steril
nonpyrogen
rejuven
solut
contain
pyruv
inosin
phosphat
adenin
citra
lab
llc
braintre
approv
us
food
drug
administr
rejuven
store
rbc
solut
act
restor
atp
store
rbc
level
equival
circul
aim
studi
investig
effect
treatment
rejuven
solut
crossmatch
reaction
profil
phenotyp
state
store
rbc
studi
designmethod
ml
aliquot
remov
aborh
group
leucocyt
deplet
rbc
unit
n
store
sagm
day
act
untreat
control
remaind
unit
ml
underw
treatment
rejuven
solut
c
follow
cell
wash
twice
sagm
manual
centrifugebas
process
repres
current
transfus
laboratori
practic
unit
crossmatch
plasma
random
donor
use
diam
gel
column
glass
tube
techniqu
phenotyp
investig
commerci
antisera
perform
identifi
effect
rejuven
solut
treatment
exert
rbc
surfac
antigen
b
c
c
e
e
k
n
p
lu
k
kp
kp
b
le
le
b
fy
fy
b
jk
jk
b
includ
whether
expos
crypt
antigen
tn
tk
th
tx
cad
crossmatch
phenotyp
agglutin
score
observ
untreat
treat
rbc
compar
resultsfind
crossmatch
find
defin
compat
suitabl
incompat
studi
identifi
differ
crossmatch
reaction
profil
untreat
treat
rbc
furthermor
differ
observ
phenotyp
state
untreat
treat
rbc
conclus
treatment
day
old
store
rbc
rejuven
solut
effect
crossmatch
reaction
profil
phenotyp
state
compar
match
untreat
sampl
backgroundcas
studi
cryopreserv
platelet
product
burgeon
worldwid
current
autom
platelet
cryopreserv
method
contrast
red
blood
cell
cryopreserv
use
acp
haemonet
corp
baintre
autom
process
within
close
system
increas
labour
product
provid
high
qualiti
blood
compon
purpos
autom
platelet
cryopreserv
procedur
studi
designmethod
apheresi
platelet
concentr
pc
collect
trima
accel
system
platelet
count
perform
use
abx
micro
pc
centrifug
sorval
centrifug
sorval
usa
min
combin
cryoprotect
cryosur
germani
use
pc
cryopreserv
cryopreserv
pc
cpc
frozen
store
kelvin
chest
freezer
cpc
thaw
degre
c
barkey
plasmatherm
min
cpc
osmol
measur
osmomat
osmomet
resultsfind
stage
platelet
cryopreserv
technolog
develop
platelet
cryopreserv
close
system
patent
ru
first
stage
cpc
spun
separ
plateletrich
plasma
prp
fraction
plateletpoor
plasma
ppp
second
step
resuspend
prp
ad
combin
cryosur
cryoprotect
obtain
final
concentr
dmso
platelet
suspens
injectomat
mc
agilia
npbi
compomix
instrument
autom
phase
pc
frozen
osmol
less
mosml
prp
ppp
frozen
cool
rate
store
chest
freezer
month
pretransfus
defrost
platelet
also
process
close
system
patent
ru
transfer
set
made
possibl
autom
platelet
resuspens
plasma
agenc
exadrop
v
r
postthaw
prp
resuspend
plasma
lower
osmol
mosml
freezethaw
recoveri
platelet
origin
popul
defrost
pc
store
continu
gentl
stir
helmer
platelet
agit
longer
hour
transfus
took
min
cryopreserv
pc
process
pretransfus
thaw
platelet
autom
process
account
bulk
time
min
conclus
autom
techniqu
develop
reduc
workload
offer
reproduc
procedur
high
cpc
qualiti
use
close
system
rule
bacteri
contamin
employ
infus
pump
platelet
stirrer
precis
flow
regul
enabl
adequ
osmol
monitor
bacteri
detect
leukoreduc
apheresi
platelet
day
day
evelyn
c
oyler
suncoast
blood
bank
backgroundcas
studi
recent
publish
fda
draft
guidanc
describ
bacteri
test
enhanc
safeti
avail
platelet
outlin
step
blood
collect
establish
transfus
servic
extend
apheresi
platelet
date
day
evalu
compar
cultur
base
rapid
base
test
method
detect
bacteri
contamin
apheresi
platelet
studi
designmethod
larg
commun
blood
center
transfus
servic
collect
leukoreduc
apheresi
platelet
lrap
use
amicu
separ
system
fenwal
lake
zurich
il
trima
accel
system
terumo
bct
lakewood
co
previouslycultur
lrap
unit
sampl
day
secondari
cultur
use
bactalert
biomerieux
durham
nc
rapid
bacteri
test
use
bactx
immunet
boston
pgd
verax
marlborough
lrap
unit
still
avail
also
sampl
test
rapid
test
day
total
lrap
unit
test
period
cultur
rapid
test
day
rapid
test
day
rapid
test
method
also
evalu
base
cost
eas
use
incub
time
indic
use
resultsfind
lrap
unit
evalu
studi
true
neg
tn
fals
posit
fp
day
test
bactalert
tn
day
bactx
test
result
show
tn
day
tn
day
test
use
pgd
kit
show
tn
day
tn
fp
day
fp
result
confirm
perform
secondari
cultur
found
neg
bactx
requir
specif
analyz
minut
requir
result
interpret
instrument
requir
pgd
reaction
read
within
minut
conclus
result
evalu
make
pgd
best
fit
blood
center
base
transfus
servic
pgd
offer
shorter
time
read
result
need
initi
invest
analyz
indic
lrap
plasma
lrap
pasplasma
eas
use
allow
test
lrap
day
day
night
shift
accomplish
without
addit
staf
allow
extend
outdat
storag
lrap
chang
growth
factor
content
human
serum
use
eye
drop
frozen
storag
year
jo
lorins
pieter
f
van
der
meer
han
van
der
heiden
dirk
de
kort
depart
product
process
develop
sanquin
blood
bank
mudrop
backgroundcas
studi
growth
factor
thought
among
activ
compon
serum
use
treatment
dryey
syndrom
stabil
growth
factor
frozen
storag
mini
contain
ml
unknown
product
store
feasibl
store
product
household
freezer
make
product
avail
patient
need
serum
eye
drop
purpos
studi
demonstr
stabil
growth
factor
content
human
serum
longtim
storag
pack
new
micro
dose
devic
singl
use
eye
drop
studi
designmethod
serum
produc
ml
whole
blood
donat
nonremuner
healthi
donor
quickli
frozen
frozen
storag
month
control
thaw
six
differ
sera
use
fill
larg
number
mini
contain
refrozen
store
either
storag
month
interv
sampl
test
sever
growth
factor
use
magpixv
r
luminex
multiplex
assay
compar
control
sampl
store
growth
factor
test
pdgfaa
abbb
vegf
transfus
vol
supplement
egf
studi
factfind
studi
without
preset
accept
criteria
resultsfind
pdgfabbb
abund
growth
factor
averag
resp
ngml
also
pdgfaa
detect
rel
high
concentr
human
serum
averag
ngml
egf
vegf
detect
rel
low
valu
resp
ngml
ngml
ngml
averag
level
close
detect
limit
ngml
control
store
show
growth
factor
close
initi
valu
sampl
moment
fill
mini
contain
serum
store
month
factor
show
less
decreas
except
pdgfaa
show
resp
lower
valu
serum
store
valu
egf
vegf
stabl
wherea
pdgfabbb
pdgfaa
show
decreas
resp
conclus
human
serum
eye
drop
store
new
micro
dose
devic
household
freezer
profession
freezer
least
one
year
prepar
without
larg
decreas
growth
factor
content
maximum
decreas
found
pdgfaa
serum
store
yet
unknown
test
compon
add
vivo
effect
serum
eye
drop
minim
concentr
ensur
vivo
effect
stabil
test
combin
vitro
vivo
applic
requir
extend
shelflif
beyond
year
ruqayyah
almizraq
heather
ingli
phillip
norri
jennif
muszynski
nicol
jufferman
jelena
holovati
jason
p
acker
univers
alberta
blood
system
research
institut
univers
california
san
francisco
nationwid
children
hospit
academ
medic
center
canadian
blood
servic
backgroundcas
studi
differ
blood
manufactur
method
influenc
residu
cell
number
membran
vesicul
may
affect
qualiti
safeti
blood
compon
aim
identifi
quantifi
character
residu
cell
extracellular
vesicl
ev
store
rbc
product
produc
differ
blood
manufactur
method
studi
designmethod
thirtytwo
rbc
unit
produc
use
whole
blood
filtrat
wbf
red
cell
filtrat
rcf
apheresi
whole
blood
deriv
wbd
method
examin
per
method
residu
platelet
white
blood
cell
wbc
measur
day
use
flow
cytomet
fc
storag
day
number
cell
originsurfac
marker
ev
assess
fc
concentr
sizeprofil
ev
examin
use
tunabl
resist
plu
sens
trp
resultsfind
day
apheresi
wbd
unit
significantli
greater
residu
platelet
comparison
rcf
vs
apheresi
p
wbd
p
wbf
vs
apheresi
p
wbd
p
method
rcf
unit
yield
lowest
count
plateletev
day
highest
number
plateletev
apheresi
day
wbd
day
similarli
signific
differ
among
method
number
wbcev
rcf
contain
smallest
concentr
moreov
trp
fc
show
increas
total
number
ev
day
vs
day
process
method
noteworthi
trp
show
number
small
evsexosom
nm
greater
larg
ev
nm
product
day
highest
level
ev
nm
apheresi
unit
trp
result
also
show
signific
differ
ev
sizeprofil
amongst
rbc
product
p
conclus
studi
show
method
manufactur
significantli
affect
rbc
nonrbc
ev
characterist
throughout
storag
potenti
impact
qualiti
safeti
rbc
product
differ
ev
celloforigin
concentr
sizeprofil
observ
manufactur
method
warrant
examin
potenti
immunomodulatori
effect
clinic
consequ
coagul
complement
assay
whole
blood
store
centigrad
maryann
c
herzig
crystal
lafleur
chriselda
g
fedyk
sherril
j
slichter
andrew
p
cap
us
armi
institut
surgic
research
us
armi
institut
surgic
research
univers
washington
backgroundcas
studi
whole
blood
demonstr
retain
hemostat
activ
includ
platelet
aggreg
function
least
week
storag
without
agit
may
possibl
extend
preserv
platelet
function
agit
wb
order
fulli
character
qualiti
wb
store
without
agit
evalu
complement
activ
marker
inflammatori
potenti
studi
designmethod
subject
donat
one
unit
wb
collect
citrat
phosphat
dextros
anticoagul
adenin
wb
leukoreduc
separ
compon
unit
store
refriger
condit
day
collect
unit
store
day
without
agit
unit
store
day
agit
storag
model
hybrid
incub
set
end
end
rotat
rpm
appropri
time
point
platelet
free
plasma
obtain
wb
sampl
store
frozen
plasma
analyz
elisa
assay
determin
thrombinantithrombin
complex
tat
marker
coagul
solubl
measur
platelet
activ
granul
releas
plasmin
antiplasmin
complex
pap
marker
fibrinolysi
plasminogen
activ
inhibitor
anoth
fibrinolyt
measur
complement
activ
marker
data
analyz
one
way
repeat
measur
anova
resultsfind
platelet
recov
unit
store
day
without
agit
level
meet
fda
requir
x
platelet
per
wb
unit
subsequ
wb
agit
platelet
recoveri
differ
seen
elisa
analysi
agit
nonagit
sampl
chang
seen
tat
pap
level
day
collect
measur
signific
elev
indic
activ
platelet
inhibit
fibrinolysi
p
activ
complement
peptid
elev
time
p
howev
level
normal
refer
rang
time
maximum
refer
respect
conclus
whole
blood
agit
appear
necessari
recov
platelet
fda
requir
whole
blood
store
day
show
activ
complement
protein
contrast
studi
store
red
blood
cell
elev
report
wb
show
elev
complement
gradual
modestli
activ
level
remain
within
refer
rang
whole
blood
shelf
life
meredith
lummer
christian
todd
ceru
corpor
commun
blood
serivc
backgroundcas
studi
interceptv
r
blood
system
platelet
ceru
concord
ca
use
pathogen
reduct
pr
platelet
collect
replac
irradi
cmv
test
bacteri
cultur
point
issu
bacteri
test
better
understand
pr
compat
impact
split
rate
data
analyz
midsiz
blood
center
roughli
rcf
apheresi
wbd
platelet
collect
must
meet
specif
volum
concentr
dose
rang
qualifi
intercept
pr
chang
made
apheresi
devic
includ
ad
follow
collect
target
studi
designmethod
four
month
collect
retrospect
analyz
platelet
collect
evalu
determin
elig
pr
treatment
product
meet
pr
process
specif
unless
intend
hla
match
recipi
hospit
abl
accept
pr
product
underw
pr
treatment
regardless
potenti
impact
split
rate
minimum
posttreat
dose
requir
classifi
collect
singl
doubl
respect
volumedos
mitig
remov
volum
increas
number
product
elig
pr
util
studi
thu
unit
treat
convent
volum
dose
andor
concentr
meet
pr
specif
without
manipul
resultsfind
singl
doubl
collect
elig
underw
pr
treatment
split
rate
singl
doubl
collect
conclus
possibl
treat
singl
doubl
platelet
donat
intercept
pr
blood
center
current
state
slight
impact
split
rate
center
will
make
alter
target
practic
platelet
collect
fall
outsid
specif
pr
process
distribut
convent
product
strategi
increas
elig
toward
minim
impact
split
rate
investig
includ
incorpor
new
collect
set
split
tripl
volumedos
mitig
evalu
need
determin
addit
quantiti
pr
elig
product
result
chang
moniqu
p
gelderman
andrey
skripchenko
fei
xu
ying
li
stephen
j
wagner
pamela
h
whitley
jaroslav
g
vostal
fdacber
obrrdbcdlch
american
red
cross
holland
laboratori
american
red
cross
midatlant
research
facil
backgroundcas
studi
platelet
plt
store
room
temperatur
rt
support
bacteri
prolifer
contamin
unit
therefor
septic
transfus
reaction
may
occur
store
plt
cold
temperatur
c
ct
limit
bacteri
growth
result
rapid
clearanc
upon
transfus
develop
altern
storag
condit
usual
involv
costli
radiolabel
human
studi
success
studi
difficult
predict
base
vitro
studi
thu
anim
model
plt
circul
could
predict
perform
human
plt
human
volunt
would
posit
impact
develop
altern
storag
condit
studi
designmethod
design
immunodefici
scid
mous
model
evalu
recoveri
human
plt
compar
side
side
radiolabel
studi
human
volunt
conduct
evalu
new
plt
storag
condit
thermocycl
plt
hr
ct
hr
c
tc
autolog
apheresi
plt
store
rt
tc
ct
radiolabel
infus
healthi
human
volunt
nonlabel
plt
also
infus
mice
blood
sampl
human
mice
collect
time
gener
surviv
clearanc
curv
plt
circul
flow
cytometri
use
detect
analyz
human
plt
mous
sampl
gener
curv
count
consid
background
resultsfind
mean
recoveri
infus
plt
rt
tc
ct
human
mice
mean
recoveri
plt
rt
ct
ct
compar
perform
plt
human
mice
express
recoveri
percentag
rt
recoveri
human
tc
ct
rt
mice
tc
ct
rt
area
surviv
curv
auc
calcul
individu
mous
studi
human
trial
data
set
result
auc
normal
rt
plt
human
tc
plt
auc
ct
plt
auc
compar
rt
plt
human
comparison
tc
plt
auc
ct
plt
auc
rt
auc
mice
calcul
ratio
auc
tc
plt
ct
plt
human
data
set
mous
model
data
set
respect
conclus
scid
mous
model
differenti
rt
plt
ct
plt
similar
human
base
auc
plt
recoveri
data
howev
mous
model
differenti
ct
plt
tc
plt
occur
human
even
though
mous
model
differenti
ct
plt
tc
plt
may
still
use
tool
screen
novel
storag
condit
human
plt
convert
compon
manufactur
manual
process
autom
nicol
peter
geeta
paranjap
coastal
bend
blood
center
carter
blood
care
backgroundcas
studi
initi
focus
improv
donor
collect
process
drove
us
investig
opportun
compon
manufactur
process
goal
maintain
blood
qualiti
streamlin
manufactur
autom
inprocess
document
compomat
evalu
use
multiteam
approach
includ
compon
manufactur
staff
equip
manag
qa
regulatori
affair
studi
designmethod
comprehens
evalu
team
decid
purchas
compomat
compomast
net
softwar
data
manag
implement
plan
novemb
goliv
central
process
new
work
counter
instal
freseniu
kabi
instal
compomat
compomast
june
train
valid
success
complet
full
launch
occur
midmarch
devic
sop
train
perform
train
qualif
checklist
complet
technician
requir
number
success
unit
process
complet
decemb
valid
complet
sign
march
manufactur
data
collect
use
compomast
net
data
manag
system
qualiti
control
softwar
platelet
plt
paramet
includ
plt
count
plt
weight
plt
yield
implement
bi
implement
ai
compomat
system
data
point
collect
unit
bi
unit
ai
resultsfind
upon
initi
implement
staff
train
use
compomat
found
easi
plt
weight
spread
reduc
averag
averag
gm
actual
plt
weight
reduc
averag
result
averag
increas
recov
plasma
per
unit
plt
count
averag
increas
count
mm
neglig
chang
plt
yield
conclus
plt
weight
spread
reduc
implement
compomat
plt
concentr
increas
averag
abl
consist
produc
smaller
volum
plt
averag
gm
gave
us
plasma
per
unit
recov
plasma
team
intend
review
dryer
cryo
next
step
potenti
addit
plasma
yield
recov
plasma
deglycerol
manual
glycerol
frozen
rcc
use
close
system
cell
processor
anita
howel
angela
hill
brandi
denni
jason
p
acker
canadian
blood
servic
centr
innov
canadian
blood
servic
univers
alberta
backgroundcas
studi
upon
implement
close
system
cell
processor
glycerol
deglycerol
red
cell
concentr
rcc
mani
rare
rcc
frozen
use
current
manual
open
system
glycerol
method
remain
organ
frozen
inventori
studi
undertaken
assess
feasibl
deglycerol
exist
inventori
close
cell
processor
evalu
chang
may
impact
postthaw
red
blood
cell
rbc
vitro
qualiti
close
cell
processor
use
fix
centrifug
bowl
deglycerol
rbc
resuspens
larg
small
unit
assess
determin
impact
cellular
loss
variabl
hematocrit
postthaw
product
studi
designmethod
aborh
match
lr
sagm
rcc
pool
split
produc
larg
ml
small
ml
rcc
rcc
store
glycerol
manual
mix
ml
glycerol
rcc
ml
freez
bag
unit
frozen
h
remov
frozen
storag
thaw
water
bath
larg
rcc
small
rcc
deglycerol
use
organ
current
procedur
cobe
cell
processor
prior
resuspens
salin
dextros
remain
rcc
transfer
bag
spun
allow
remov
excess
glycerol
manual
extract
achiev
hematocrit
deglycerol
ml
centrifug
bowl
resuspens
rbc
qualiti
test
h
postdeglycerol
resultsfind
larg
rcc
significantli
higher
hemoglobin
per
unit
cobe
lower
cell
recoveri
cobe
p
postdeglycerol
smaller
rcc
cell
processor
larg
rcc
deglycerol
cobe
higher
hemolysi
p
supernat
potassium
small
volum
rcc
larg
cobe
rcc
higher
hematocrit
hemoglobin
recoveri
larg
rcc
howev
cobe
rcc
higher
p
hemolysi
level
rcc
cobe
rcc
fail
meet
regulatori
hemolysi
standard
conclus
addit
ml
bolu
dose
glycerol
rcc
differ
volum
result
differ
concentr
glycerol
frozen
rcc
product
may
lead
differ
frozen
rcc
qualiti
addit
size
rcc
impact
qualiti
rcc
process
close
cell
processor
due
centrifug
bowl
volum
limit
result
lower
recoveri
hemoglobin
hematocrit
use
close
cell
processor
resuspens
storag
h
met
vitro
qualiti
standard
recoveri
hemoglobin
hematocrit
drastic
reduc
hemolysi
level
rcc
glycerol
manual
cell
processor
therefor
use
deglycerol
rcc
glycerol
use
manual
open
system
glycerol
method
backgroundcas
studi
wash
platelet
may
indic
thrombocytopen
patient
experi
sever
allergicanaphylact
febril
reaction
convent
platelet
transfus
platelet
wash
process
timeconsum
may
delay
transfus
studi
conduct
evalu
manual
platelet
wash
method
mm
use
salin
centrifug
semiautom
wash
method
sam
use
cobe
cell
processor
studi
designmethod
studi
unit
singl
donor
platelet
evalu
wash
use
mm
wash
use
sam
collect
data
includ
product
weight
preand
postwash
platelet
count
preand
postwash
total
plasma
protein
preand
postwash
presenceabs
platelet
clump
calcul
protein
remov
calcul
platelet
recoveri
rate
platelet
count
measur
sysmex
exn
total
plasma
protein
sampl
measur
roch
coba
resultsfind
tabl
show
averag
platelet
recoveri
sam
significantli
higher
compar
mm
mm
slightli
higher
averag
protein
remov
compar
sam
platelet
clump
observ
either
mm
sam
observ
handson
time
mm
took
minut
longer
sam
backgroundcas
studi
interceptv
r
blood
system
platelet
current
licens
pathogen
reduct
pr
amicu
platelet
intersol
input
platelet
dose
platelet
ml
plasma
pa
new
platelet
process
set
design
three
storag
contain
ts
process
apheresi
platelet
compon
contain
dose
platelet
volum
ml
studi
designmethod
apheresi
pc
amicu
v
r
collect
plasma
one
studi
perform
nomin
dose
platelet
volum
ml
plasma
use
singl
donor
apheresi
collect
two
studi
perform
evalu
high
dose
high
volum
condit
x
platelet
ml
use
either
singl
pool
donat
input
pc
treat
intercept
ts
set
end
day
post
collect
incub
time
compound
adsorpt
devic
cad
contain
rang
hour
intercept
treat
pc
store
contain
day
postdon
pc
evalu
use
panel
vitro
platelet
function
assay
resultsfind
vitro
function
data
apheresi
pc
treat
intercept
ts
set
demonstr
accept
vitro
function
tabl
intercept
treat
pc
ph
platelet
dose
volum
recoveri
posttreat
rang
respect
conclus
pathogen
reduc
platelet
compon
process
use
intercept
ts
set
either
singl
pool
apheresi
donat
maintain
accept
vitro
qualiti
day
storag
intercept
blood
system
platelet
ts
set
current
approv
use
us
backgroundcas
studi
possibl
transmit
infecti
organ
via
blood
product
plasma
deriv
major
public
health
concern
current
screen
measur
consider
improv
transfus
safeti
reduc
risk
associ
known
pathogen
protect
emerg
infecti
threat
pathogen
reduct
technolog
prt
repres
proactiv
strategi
reduc
transfusiontransmit
infecti
risk
howev
scientif
commun
broadli
agre
fact
prt
neg
impact
product
qualiti
marker
studi
aim
evalu
impact
mirasol
prt
platelet
plt
qualiti
plt
process
studi
designmethod
two
abocompat
platelet
concentr
pc
contain
plasma
obtain
either
apheresi
sagm
whole
blood
wb
deriv
process
pair
pool
split
two
equal
unit
one
unit
use
nontreat
control
ctrl
riboflavin
ad
pc
unit
expos
uv
light
accord
manufactur
instruct
mirasol
prt
terumobct
test
numer
invitro
qualiti
marker
plt
concentr
atp
ph
glucos
lactat
sodium
potassium
measur
mirasoltr
nontreat
pc
day
apheresi
pc
day
wbderiv
pc
two
flow
cytometri
assay
use
evalu
express
without
thrombin
activ
measur
percent
annexin
vposit
plt
transfus
vol
supplement
resultsfind
platelet
recoveri
apheresi
wbderiv
pc
respect
mirasoltr
pc
show
higher
level
annexin
vposit
cell
test
vs
ctl
day
higher
rate
express
control
pc
unit
test
vs
ctl
day
mirasol
treatment
gener
chang
ph
glucos
lactat
pc
storag
conclus
mirasol
treatment
induc
loss
net
number
pltsunit
elev
platelet
activ
chang
ph
glucos
lactat
suggest
prt
affect
plt
metabol
final
prt
numer
impact
logist
storag
process
time
constraint
blood
bank
oper
nevertheless
mirasol
prt
routin
use
europ
accept
clinic
outcom
evalu
test
method
detect
bacteri
contamin
platelet
bactx
tm
assay
ji
hye
park
sexton
lorrain
blagg
christi
e
marshal
herman
woodson
sean
eroni
krishna
patel
eric
gehri
john
hopkin
hospit
john
hopkin
hospit
transfus
medicin
dept
john
hopkin
univers
school
medicin
backgroundcas
studi
bacteri
contamin
platelet
plt
lead
infecti
risk
platelet
transfus
therapi
signific
infecti
caus
transmissionassoci
morbid
mortal
therefor
detect
variou
potenti
bacteri
contamin
platelet
time
manner
critic
bactx
assay
rapid
colorimetr
assay
detect
peptidoglycan
cell
wall
compon
gramposit
gramneg
bacteria
report
analysi
bactx
assay
hospit
studi
designmethod
aim
determin
sensit
specif
bactx
assay
intact
leukoreduc
apheresi
plt
lrap
unit
test
bactx
storag
day
control
intact
lrap
also
cultur
autom
bacteri
detect
system
bact
cultur
storag
day
result
bactx
test
compar
result
bact
cultur
system
resultsfind
total
lrap
test
lrap
initi
test
neg
bactx
lrap
initi
test
posit
bactx
initi
posit
bactx
test
neg
subject
repeat
test
contrast
lrap
test
neg
bact
cultur
system
specif
bactx
test
true
posit
test
result
therefor
sensit
bactx
could
determin
conclus
small
studi
platelet
unit
expect
rate
bacteri
contamin
platelet
less
per
unit
initi
posit
rate
therefor
higher
expect
given
small
sampl
size
clear
studi
need
rigor
assess
true
sensit
specif
bactx
assay
vitro
qualiti
rejuven
wash
rbc
alan
gray
matt
landrigan
pamela
whitley
michael
wellington
sherri
sawyer
shalen
hanley
emili
rondeau
louis
herschel
neeta
rugg
patricia
ar
brunker
shawnagay
nestheid
jose
cancelasperez
larri
dumont
zbigniew
szczepiorkowski
fresh
level
object
demonstr
vitro
qualiti
measur
maintain
rbc
store
hour
treatment
fda
approv
rejuven
solut
studi
designmethod
whole
blood
ml
collect
process
site
leukocytereduc
rbc
total
cpd
ml
rejuven
solut
citra
lab
ad
rbc
day
incub
minut
agit
water
bath
helmer
wash
haemonet
store
oc
day
vitro
recoveri
calcul
hemolysi
atp
determin
day
rejuven
wash
postrjv
unit
cultur
postrjv
concentr
centrifug
resultsfind
vitro
rbc
recoveri
respect
bacteri
growth
observ
hemolysi
maintain
unit
unit
unit
hemolysi
follow
concentr
centrifug
morpholog
score
reduc
restor
rejuven
respect
maintain
atp
restor
maintain
fresh
level
rejuven
restor
fresh
level
maintain
fresh
level
valu
significantli
differ
compar
except
note
p
pair
ttest
tabl
conclus
rejuven
store
rbc
restor
atp
fresh
valu
morpholog
near
fresh
level
maintain
improv
vitro
rbc
qualiti
measur
compar
nonrejuven
rbc
studi
fund
zimmer
biomet
storag
hour
fda
approv
use
time
public
liposom
rejuven
new
approach
improv
qualiti
store
red
blood
cell
luciana
da
silveira
cavalcant
jason
p
acker
jelena
holovati
backgroundcas
studi
liposom
shown
minim
rbc
membran
damag
occur
hypotherm
storag
hs
rejuven
solut
shown
restor
rbc
metabol
maintain
atp
level
studi
aim
evalu
effect
combin
liposom
rejuven
qualiti
store
rbc
studi
designmethod
five
leukoreduc
pack
rbc
unit
obtain
pool
split
unit
produc
segreg
four
experiment
group
sham
control
liposometr
l
rejuvesoltr
r
liposom
rejuvesoltr
prbc
incub
h
hepesnacl
sham
liposom
dopc
chol
mol
mm
lipid
rejuvesol
liposom
plu
rejuvesol
vitro
qualiti
access
hemolysi
deform
aggreg
atp
day
hs
resultsfind
hemolysi
significantli
decreas
treatment
compar
sham
control
l
r
ektacytometri
analysi
show
increas
maximum
elong
ei
max
r
treatment
compar
l
rbc
rigid
kei
increas
treatment
compar
sham
l
r
aggreg
amplitud
significantli
increas
r
treatment
au
vs
au
atp
level
significantli
higher
treatment
compar
sham
mmolg
hb
l
mmolg
hb
r
mmolg
hb
mmolg
hb
level
longer
detect
l
treatment
day
combin
treatment
compar
r
mmolg
hb
vs
mmolg
hb
conclus
rejuven
liposom
treatment
improv
qualiti
store
rbc
compar
sham
control
combin
treatment
greater
impact
improv
vitro
qualiti
store
rbc
compar
rejuven
alon
step
toward
uniqu
adapt
thermoregul
system
luci
boyer
eric
duca
patricia
landri
nathali
dussault
jacqu
bernier
danni
brouard
ann
maltai
h
emaqu
ebec
institut
de
technologi
de
emballag
et
du
g
eni
alimentair
backgroundcas
studi
h
emaquebec
hq
face
major
logist
challeng
transport
distribut
blood
compon
larg
geograph
area
collabor
institut
de
technologi
de
emballag
et
du
geni
alimentair
appli
research
group
work
develop
optim
transport
packag
whole
blood
leukotrap
rc
system
haemonet
corp
object
design
packag
system
rapid
cool
one
six
whole
blood
unit
wbu
within
collect
moreov
insul
thermoregul
system
must
maintain
intern
temperatur
wbu
extrem
extern
condit
includ
initi
blood
cool
period
studi
designmethod
propos
packag
design
base
extern
coroplast
box
contain
six
vacuum
insul
panel
vip
increas
insul
effici
preserv
initi
cool
period
extend
thermoregul
properti
ensur
assembl
precondit
phase
chang
materi
pcm
number
pcm
posit
condit
optim
test
order
meet
expect
perform
criteria
precondit
pcm
store
vip
box
test
mimic
worstcas
scenario
remot
blood
drive
experiment
test
wb
bag
fill
ml
salin
mimic
freshli
collect
wb
probe
posit
insid
salinefil
bag
monitor
temperatur
profil
wbu
extrem
winter
summer
condit
ship
box
fill
either
one
six
bag
resultsfind
result
show
thermoregul
box
prototyp
abl
cool
wbu
bag
maintain
intern
temperatur
final
valu
rang
extrem
summer
scenario
similar
result
obtain
extrem
winter
scenario
unit
reach
threshold
valu
bag
intern
temperatur
within
accept
rang
conclus
insul
thermoregul
system
met
hq
perform
criteria
preliminari
result
show
pcm
could
condit
temperatur
higher
without
signific
impact
system
perform
hq
current
valid
ship
box
prototyp
perform
addit
work
reduc
pcm
condit
time
optim
logist
oper
packag
mani
advantag
term
durabl
price
conveni
hq
intend
evalu
system
packag
transport
line
blood
product
stuart
weisberg
christoph
c
c
silliman
beth
shaz
marguerit
kelher
claudia
cohn
new
york
blood
center
bonfil
blood
center
depart
laboratori
medicin
patholog
univers
minnesota
backgroundcas
studi
platelet
collect
store
platelet
addit
solut
pa
reduc
recipi
exposur
donor
plasma
compon
better
defin
effect
pa
platelet
supernat
composit
compar
total
protein
isohemagglutinin
titer
hla
antibodi
vitro
neutrophil
pmn
prime
activ
supernat
pasc
platelet
plasma
platelet
studi
designmethod
apheresi
platelet
group
blood
donor
collect
either
donor
plasma
donor
plasma
within
hour
collect
sampl
product
supernat
frozen
assay
total
protein
concentr
antia
antib
titer
pmn
prime
activ
within
total
lipid
extract
fraction
sampl
screen
hla
antibodi
screenposit
sampl
test
use
luminex
singl
bead
assay
antibodi
strength
specif
solubl
ligand
measur
use
solidphas
elisa
resultsfind
supernat
pasc
platelet
significantli
lower
total
protein
concentr
antia
antib
titer
compar
plasma
platelet
signific
differ
number
hlaantibodi
screen
posit
pasc
product
compar
plasma
platelet
product
howev
hlaantibodi
screenposit
supernat
transfus
vol
supplement
abstract
c
platelet
fewer
hla
specif
specif
compar
plasma
platelet
specif
pmn
prime
activ
significantli
increas
supernat
pasc
platelet
lipid
extract
fraction
affect
howev
level
increas
supernat
pasc
compar
plasma
platelet
tabl
conclus
decreas
plasma
protein
like
underli
lower
rate
allerg
febril
nonhemolyt
transfus
reaction
seen
use
pasc
platelet
decreas
antia
antib
titer
may
prevent
hemolysi
minor
abo
mismatch
lower
hlaantibodi
specif
may
mitig
transfus
relat
acut
lung
injuri
trali
increas
pmn
prime
pasc
platelet
like
due
platelet
membran
releas
bioactiv
lipid
although
associ
trali
pmn
prime
lipid
cytokin
agent
causal
link
trali
mechan
clinic
impact
increas
pasc
platelet
remain
elucid
backgroundcas
studi
current
guidelin
requir
reduct
residu
white
blood
cell
rwbc
wbc
us
wbc
europ
per
unit
establish
refer
method
test
rwbc
platelet
plt
red
blood
cell
rbc
product
flow
cytometri
altern
technolog
develop
includ
hemocytometri
microfluorometri
studi
designmethod
studi
compar
perform
workflow
effici
facsvia
flow
cytomet
simplifi
workflow
autom
loader
adam
automat
microscop
cell
counter
base
imag
technolog
nonfilt
whole
blood
wb
sampl
apheresi
platelet
unit
leukoreduc
lr
rbc
unit
use
gener
spike
sampl
apheresi
platelet
lr
rbc
filter
deplet
wbc
use
diluent
nonfilt
wb
sampl
sourc
wbc
prepar
sampl
wbcul
spike
sampl
wbcul
prepar
sourc
sampl
wbcul
filter
platelet
rbc
unit
evalu
linear
wbc
concentr
wbcul
measur
use
adam
facsvia
sampl
stain
run
triplic
analyz
data
analyz
use
linear
regress
result
proport
wbc
concentr
spike
sampl
reproduc
two
system
measur
run
spike
sampl
wbcul
tube
sampl
stain
run
per
system
cv
diff
calcul
batch
sampl
plt
rbc
run
analyz
repeat
day
workflow
effici
assess
observ
measur
time
task
perform
task
record
instrument
qc
assay
control
sampl
test
analysi
resultsfind
wbc
concentr
result
plt
rbc
sampl
facsvia
correl
well
adam
diffplt
wbcul
respect
diffrbc
wbcul
respect
averag
total
test
time
similar
instrument
min
facsvia
min
adam
total
test
time
adam
requir
continu
handson
time
facsvia
demonstr
min
handsoff
time
conclus
instrument
show
compar
precis
linear
accuraci
averag
total
test
time
similar
instrument
facsvia
offer
signific
workflow
effici
advantag
user
save
averag
handson
time
minut
could
use
task
platelet
rich
plasma
qualiti
control
role
blood
bank
claudia
cohn
mickey
koh
depart
laboratori
medicin
patholog
univers
minnesota
st
georg
hospit
medic
school
backgroundcas
studi
autolog
plateletrich
plasma
aprp
poorli
regul
blood
compon
often
produc
patient
bedsid
use
indic
chronic
acut
orthoped
injuri
wound
incisionh
rheumatolog
diseas
prp
isol
done
apheresi
yield
consist
plateletrich
fraction
howev
aprp
made
use
small
benchtop
centrifug
cartridg
deliv
uneven
platelet
enrich
thu
consist
qualiti
aprp
question
lower
yield
prp
may
decreas
efficaci
studi
designmethod
survey
design
assess
aprp
manufactur
usag
qualiti
control
qc
measur
taken
prior
use
survey
develop
input
content
expert
survey
sent
member
best
isbt
survey
respond
encourag
forward
survey
colleagu
thu
true
denomin
unknown
total
complet
partial
complet
survey
receiv
resultsfind
respons
came
countri
major
respons
came
unit
state
us
respond
report
aprp
use
hospit
aprp
use
predominantli
outpati
though
hospit
also
use
aprp
inpati
set
hospit
aprp
use
md
howev
hospit
md
use
aprp
aprp
use
orthoped
woundincis
repair
rheumatolog
indic
us
aprp
manufactur
outsid
blood
bank
outsid
us
aprp
isol
blood
bank
personnel
nearli
aprp
manufactur
done
qualiti
control
qc
measur
howev
respond
assess
final
product
prior
releas
qc
measur
includ
platelet
count
measur
enrich
platelet
fraction
cultur
product
infecti
serolog
test
case
aprp
fail
qc
could
still
use
pend
md
approv
hospit
conduct
qc
final
aprp
test
done
blood
bank
subset
respond
african
nation
also
use
allogen
prp
allprp
contrast
pattern
use
aprp
allprp
use
primarili
inpati
indic
includ
orthoped
woundincis
repair
allprp
manufactur
blood
bank
donor
center
qc
regular
check
centrifug
use
isol
prp
fraction
conclus
prp
use
hospit
throughout
world
wide
varieti
indic
blood
bank
involv
manufactur
countri
us
aprp
made
outsid
blood
bank
qualiti
control
aprp
product
final
product
done
hospit
improv
consist
efficaci
prp
stringent
qc
measur
need
place
backgroundcas
studi
morpholog
donat
red
blood
cell
rbc
chang
storag
along
loss
deform
increas
surfac
exposur
phosphatidylserin
ps
decreas
intracellular
atp
chang
associ
increas
rbc
clearanc
within
hour
transfus
analysi
morpholog
alter
store
rbc
imag
flow
cytometri
ifc
identifi
subpopul
small
rbc
accumul
upon
storag
rbc
subpopul
reduc
project
surfac
area
undergo
spherocyt
shift
expect
induc
retent
spleen
roussel
dussiot
et
al
storag
alter
revers
rbc
metabol
reestablish
treatment
rejuven
solut
citra
lab
transfus
expect
restor
rbc
properti
thu
potenti
increas
capac
stay
circul
oper
effect
tissu
oxygen
follow
transfus
studi
designmethod
multiparametr
analysi
rbc
alter
perform
evalu
effect
rejuven
rbc
store
sagm
blood
bank
condit
day
day
rejuven
r
rejuven
wash
rw
morpholog
alter
store
rbc
evalu
ifc
imagestream
x
mark
ii
amni
v
r
resultsfind
rejuven
increas
level
intracellular
atp
confirm
metabol
effect
process
popul
distribut
per
rbc
project
surfac
area
measur
ifc
depict
welldemarc
subpopul
small
rbc
increas
storag
rejuven
markedli
reduc
storageinduc
spherocyt
shift
partial
restor
rbc
morpholog
effect
confirm
differenti
interfer
contrast
microscopi
restor
effect
rejuven
process
correct
storagerel
loss
rbc
elong
associ
decreas
ps
exposur
tabl
conclus
multiparametr
analysi
show
storagerel
alter
therefor
correct
metabol
rejuven
impact
effect
gener
posit
cellular
scale
requir
analysi
specif
clinic
studi
assess
transfus
yield
tissu
oxygen
red
cell
concentr
volum
manufactur
method
impact
postthaw
qualiti
cryopreserv
product
process
use
close
cell
processor
anita
howel
angela
hill
tracey
turner
april
xu
brandi
denni
jason
p
acker
canadian
blood
servic
centr
innov
canadian
blood
servic
univers
alberta
backgroundcas
studi
blood
servic
use
toptop
whole
blood
filtrat
wbf
topbottom
red
cell
filtrat
rcf
method
prepar
cpdsagm
lr
red
cell
concentr
rcc
mean
volum
ml
higher
wbf
unit
rcf
unit
similar
hematocrit
close
system
cell
processor
current
implement
cryopreserv
rcc
postdeglycerol
resuspens
addit
solut
perform
oninstru
defin
total
end
volum
dictat
centrifug
bowl
size
impact
result
variat
hematocrit
postthaw
vitrorbc
qualiti
evalu
ensur
regulatori
standard
still
met
rcc
extrem
edg
input
volum
rang
studi
designmethod
small
rcf
ml
larg
wbf
ml
rcc
store
glycerol
frozen
h
larg
rcc
whose
red
cell
mass
exceed
capac
ml
deglycerol
centrifug
bowl
volum
reduc
prior
glycerol
rcc
thaw
water
bath
deglycerol
resuspend
rcc
store
test
vitrorbc
qualiti
resultsfind
small
rcf
rcc
lower
p
hematocrit
specif
graviti
hemoglobin
per
unit
supernat
k
na
concentr
deform
ei
max
higher
p
recoveri
larg
wbf
unit
signific
differ
hemolysi
atp
rbc
indic
rbc
morpholog
residu
glycerol
seen
group
major
unit
met
accept
criteria
tabl
howev
larg
wbf
unit
rbc
recoveri
due
preglycerol
volum
reduct
small
rcf
unit
hemoglobin
valu
g
per
unit
recoveri
hemoglobin
failur
rate
analyz
organ
rcc
product
volum
distribut
mean
recoveri
project
well
hemoglobin
failur
rate
would
unit
test
compliant
regulatori
standard
conclus
differ
group
cryopreserv
rcc
physic
characterist
expect
due
resuspens
method
differ
input
product
red
cell
mass
lack
signific
metabol
differ
group
indic
differ
postdeglycerol
hematocrit
advers
affect
product
qualiti
elong
index
studi
fund
zimmer
biomet
hasan
object
determin
effect
rbc
rejuven
rbc
oxygen
releas
capac
orc
estim
oxygen
consumpt
vo
simul
singl
unit
transfus
either
standard
rejuven
rbc
store
day
studi
designmethod
oxygen
dissoci
curv
odc
hemox
analyz
tc
scientif
gener
fiftytwo
rbc
unit
leukocytereduc
day
day
rejuven
wash
pw
odc
sampl
use
determin
orc
ml
g
hb
total
releas
oxygen
tro
unit
ml
orc
determin
assess
chang
satur
mm
hg
po
eg
lung
mm
hg
po
eg
venou
blood
multipli
ml
g
hb
li
simul
baselin
pretransfus
vo
ml
min
estim
use
day
orc
assum
gdl
transfus
trigger
cardiac
output
lmin
l
blood
volum
pair
student
test
use
compar
statist
analys
resultsfind
rbc
rejuven
day
restor
orc
tro
level
greater
day
tabl
orc
rejuven
unit
time
time
greater
rbc
day
day
respect
p
vo
increas
simul
singl
unit
transfus
rbc
day
day
pw
pre
transfus
vo
respect
p
conclus
result
suggest
transfus
rejuven
rbc
potenti
releas
time
volum
compar
standard
untreat
rbc
store
day
inferior
oxygen
deliveri
tissu
vo
max
observ
exercis
healthi
human
volunt
transfus
two
autolog
rbc
unit
store
day
vs
day
seem
depend
genet
variabl
storag
time
bennettguerrero
therefor
transfus
practic
correct
anemia
may
less
effect
intend
due
variabl
orc
standard
store
rbc
unit
transfus
strategi
consid
whether
use
rbc
increas
orc
may
physiolog
advantag
disclosur
studi
fund
zimmer
biomet
rejuven
solut
adjunct
storag
solut
maintain
physiolog
hemoglobin
oxygen
affin
rbc
unit
storag
andrea
ansari
jay
srinivasan
gustaaf
de
ridder
alan
gray
matt
landrigan
keaton
charl
stoner
angela
crabtre
jessica
poisson
ian
welsbi
duke
univers
school
medicin
duke
health
patholog
citra
lab
zimmer
biomet
compani
zimmer
biomet
duke
univers
depart
patholog
durham
veteran
affair
medic
center
duke
univers
hospit
duke
univers
medic
center
backgroundcas
studi
deleteri
chang
develop
storag
pack
red
blood
cell
rbc
collect
call
storag
lesion
includ
alter
membran
composit
decreas
deform
increas
inbag
posttransfus
hemolysi
loss
atp
snitrosohemoglobin
vasodilatori
capac
cell
surfac
ps
express
deplet
loss
increas
oxygen
affin
hemoglobin
result
lower
partial
pressur
oxygen
hemoglobin
satur
decreas
may
neg
impact
abil
transfus
rbc
releas
oxygen
peripher
tissu
fdaapprov
rejuven
solut
citra
lab
restor
normal
level
atp
normal
membran
function
oxygen
affin
respect
process
requir
incub
hour
impract
step
timesensit
situat
follow
wash
rbc
test
hypothesi
rejuven
without
incub
step
cold
rejuven
could
prevent
revers
chang
oxygen
affin
deform
suscept
hemolysi
rbc
studi
designmethod
eight
unit
group
leukoreduc
prbc
store
obtain
local
blood
center
day
storag
unit
divid
separ
aliquot
control
ctl
wash
w
standard
rejuven
sr
cold
rejuven
cr
rejuven
solut
ad
cr
group
group
store
anoth
day
day
storag
sr
group
incub
hour
rejuven
solut
w
sr
cr
group
separ
wash
cat
v
r
freseniu
kabi
use
high
qualiti
wash
set
hemoglobin
measur
tonometri
use
hemox
analyz
tc
scientif
deform
elong
index
ei
measur
ektacytometri
lorrca
mechatron
supernat
plasma
free
hemoglobin
pfhb
measur
use
visiblelight
spectrophotometri
cell
surfac
ps
express
measur
annexin
v
flow
cytometri
group
result
compar
use
nonparametr
wilcoxon
signedrank
test
resultsfind
signific
differ
notic
group
tabl
ei
pfhb
differ
group
conclus
cold
rejuven
prevent
increas
oxygen
affin
lower
seen
day
rbc
storag
without
advers
effect
deform
hemolysi
offer
altern
incub
rejuven
provid
clinician
readi
access
rbc
highnorm
may
better
releas
oxygen
tissu
caus
transient
potenti
fatal
cardiac
arrhythmia
upon
transfus
particularli
infant
massivelytransfus
patient
compromis
renal
function
reactiv
antibodi
inflammatori
agent
rbc
also
elicit
lifethreaten
reaction
potenti
caus
high
fever
transfusionrel
acut
lung
injuri
trali
anaphylaxi
even
death
studi
multifunct
beadbas
filter
evalu
remov
k
along
free
hemoglobin
hb
prbc
contamin
contribut
transfus
relat
advers
event
studi
designmethod
ten
leukocytereduc
prbc
unit
store
obtain
region
blood
donor
center
expir
day
pass
graviti
sorbentdevic
contain
ml
multifunct
polym
bead
flow
rate
mlmin
supernat
analyz
k
remov
well
free
hb
antibodi
cytokin
biorad
rbc
analyz
viabil
integr
via
flow
cytometri
osmot
fragil
assay
respect
resultsfind
filtrat
age
prbc
unit
sorbent
devic
reduc
k
meql
equival
reduct
free
hb
reduc
mgml
antibodi
specif
igg
iga
igm
decreas
mgml
mgml
mgml
respect
inflammatori
cytokin
significantli
reduc
specif
pgml
pgml
pdgf
pgml
filtrat
signific
impact
cell
surfac
marker
rbc
viabil
decreas
sensit
osmot
chang
valu
list
repres
mean
sem
p
analyt
test
pair
ttest
use
assess
signific
conclus
sorbent
filter
highli
effect
reduc
level
extracellular
k
well
free
hb
antibodi
cytokin
prbc
without
impact
rbc
viabil
integr
studi
demonstr
viabil
multifunct
sorbent
filter
remov
k
along
detriment
compon
store
prbc
readili
incorpor
transfus
practic
minim
advers
effect
backgroundcas
studi
platelet
carri
rh
antigen
residu
red
blood
cell
rbc
platelet
product
immun
neg
recipi
donor
posit
current
recommend
give
rh
immunoglobulin
rhig
rh
neg
patient
receiv
rh
posit
platelet
unit
avoid
potenti
alloimmun
antigen
recent
studi
shown
low
frequenc
alloimmun
rh
mismatch
platelet
transfus
restrict
neg
patient
receiv
neg
platelet
could
creat
shortag
caus
inventori
challeng
higher
yield
platelet
minimum
none
residu
rbc
obtain
new
gener
apheresi
machin
consequ
need
prophylact
rh
immunoglobulin
rhig
may
unnecessari
use
apheresi
deriv
platelet
accur
determin
residu
rbc
platelet
unit
import
patient
safeti
prevent
rh
alloimmun
hemocytomet
consid
gold
standard
cell
count
howev
rapid
conveni
offer
autom
method
result
widespread
use
autom
hematolog
analyz
current
standard
andor
guidelin
advis
system
use
rbc
quantif
platelet
product
studi
designmethod
design
studi
quantifi
residu
rbc
apheresi
platelet
whole
blood
deriv
platelet
compar
hemocytomet
autom
method
measur
amount
red
blood
cell
per
microlit
apheresi
whole
blood
deriv
platelet
unit
use
hemocytomet
two
differ
autom
hematolog
analyz
name
sysmex
sysmex
america
lincolnshir
il
advia
siemen
healthcar
diagnost
tarrytown
ny
whole
blood
deriv
platelet
unit
produc
use
acrodos
tm
system
technolog
conduct
nonparametr
permut
test
base
permut
compar
sysmex
advia
apheresi
whole
blood
deriv
group
abstract
collect
rbc
rbc
store
day
treatment
fda
approv
rejuven
solut
studi
designmethod
addit
rejuven
solut
store
red
blood
cell
rbc
shown
increas
atp
profil
fresh
level
object
compar
hemoglobinoxygen
satur
morpholog
profil
fresh
day
collect
rbc
rbc
store
day
treatment
fda
approv
rejuven
solut
resultsfind
vitro
rbc
recoveri
overal
hemolysi
similar
day
dryair
incub
rejuven
solut
vs
percent
hemolysi
decreas
wash
maintain
unit
storag
averag
atp
restor
averag
fresh
valu
morpholog
score
decreas
day
restor
near
fresh
valu
follow
rejuven
wash
storag
respect
rbc
oxygen
affin
assess
restor
fresh
valu
valu
significantli
differ
compar
day
p
pair
ttest
tabl
conclus
rbc
morpholog
restor
near
fresh
averag
atp
restor
fresh
valu
incub
rejuven
solut
use
dryair
incub
process
rbc
morpholog
atp
maintain
storag
rejuven
refriger
rbc
may
offer
avenu
improv
rbc
qualiti
prior
transfus
vandi
ly
dimath
alyemni
warren
r
korn
matthew
j
brune
juli
katz
karp
thoma
jefferson
univers
hospit
backgroundcas
studi
blood
donor
screen
donor
histori
questionnair
includ
question
regard
behavior
risk
factor
none
specif
screen
use
marijuana
therefor
theoret
possibl
transfer
activ
cannabi
metabolit
transfus
donor
plasma
collect
urban
hospitalbas
blood
donor
center
examin
presenc
activ
cannabi
metabolit
thc
studi
designmethod
deidentifi
donor
plasma
segment
sequest
store
frozen
time
test
test
thc
perform
liquid
chromatographytandem
mass
spectrometri
lcmsm
base
method
modifi
lacroix
saussereau
summari
method
use
dabsyl
chlorid
derivat
thc
produc
sampl
lcmsm
analysi
lc
use
column
postcolumn
detect
msm
use
posit
ion
electrospray
ion
pair
mz
intern
standard
z
thc
mz
quantit
result
thc
obtain
standard
curv
ratio
analyt
integr
integr
intern
standard
rang
ng
ml
thc
limit
quantit
defin
standard
deviat
background
ngml
thc
ngml
resultsfind
total
donor
plasma
sampl
test
thc
sampl
test
posit
either
thc
theoret
calcul
accord
statist
poisson
distribut
indic
would
probabl
one
posit
preval
posit
sampl
probabl
one
posit
preval
posit
sampl
result
thu
indic
boundari
preval
presenc
activ
thcmetabolit
plasma
sampl
less
among
donor
popul
standard
pharmacokinet
cannabi
metabol
previou
studi
indic
like
time
window
less
hour
postexposur
detect
thc
andor
plasma
conclus
test
donor
plasma
sampl
activ
metabolit
cannabi
one
urban
hospitalbas
blood
donor
center
produc
testposit
statist
result
indic
preval
posit
greater
zero
less
probabl
occurr
cannabi
metabolit
blood
donor
sampl
like
highli
variabl
across
donor
center
larg
depend
blood
donor
demograph
elisabeth
maurerspurej
ruqayyah
almizraq
daniel
millar
jason
p
acker
univers
british
columbia
univers
alberta
lightintegra
technolog
inc
canadian
blood
servic
backgroundcas
studi
controversi
around
qualiti
clinic
impact
age
red
blood
cell
concentr
rcc
ongo
current
studi
limit
lack
qualiti
measur
suitabl
routin
screen
rcc
base
evid
fragment
call
microparticl
mp
extracellular
vesicl
marker
cellular
activ
degrad
studi
investig
util
mp
screen
character
effect
rcc
product
method
storag
studi
designmethod
red
blood
cell
concentr
prepar
whole
blood
filtrat
wbf
toptop
red
cell
filtrat
rcf
topbottom
method
centrifug
prepar
supernat
test
mp
content
measur
dynam
light
scatter
tunabl
resist
puls
sens
techniqu
hemolysi
atp
red
cell
deform
day
storag
one
rcf
rcc
test
day
six
ml
aliquot
store
parallel
test
day
sampl
test
mp
content
compar
qualiti
indic
resultsfind
mp
content
show
linear
increas
storag
time
statist
signific
differ
day
p
correl
supernat
hemoglobin
invers
atp
rbc
elast
mp
test
method
agre
respect
total
mp
content
start
level
qualiti
indic
vari
donat
prepar
method
wbf
rcc
contain
much
higher
level
mp
storag
time
mp
content
aliquot
consist
time
point
statist
higher
origin
rcc
day
storag
conclus
mp
content
correl
measur
hemolysi
rbc
qualiti
indic
could
implement
routin
screen
tool
differ
mp
content
donor
process
age
could
monitor
use
inform
compon
product
decis
measur
mp
content
would
allow
screen
rcc
product
studi
pragmat
qc
initi
need
settl
controversi
clinic
effect
rcc
age
singl
donor
spraydri
plasma
futur
plasma
therapi
qiyong
peter
liu
jiha
sohn
ryan
c
carney
sruthi
sundaram
mark
popovski
velico
medic
inc
backgroundcas
studi
frozen
plasma
integr
hemostasi
manag
mani
situat
logist
cumbersom
frozen
storag
long
thaw
time
spraydri
plasma
odp
demand
plasma
potenti
superior
may
store
refriger
near
patient
reconstitut
minut
pointofcar
object
studi
determin
odp
consist
manufactur
blood
center
key
protein
coagul
function
compar
ffp
studi
designmethod
unit
never
frozen
plasma
collect
blood
center
process
onsit
fix
volum
odp
use
velico
spray
dryer
odp
n
pair
ffp
aliquot
store
day
respect
reconstitut
fix
volum
rehydr
fluid
steril
water
inject
extens
character
respect
level
hemostat
protein
coagul
complement
activ
marker
clot
perform
volum
process
plasma
rehydr
fluid
predetermin
ensur
similar
total
protein
concentr
reconstitut
odp
ffp
direct
comparison
resultsfind
compar
ffp
odp
level
function
clot
factor
fibrinogen
factor
ii
v
vii
viii
ix
x
xi
xii
plasminogen
proteas
inhibitor
antithrombin
iii
protein
c
protein
plasmin
esteras
alpha
inhibitor
level
factor
xiii
odp
slightli
lower
ffp
activ
antigen
assay
odp
ident
ffp
level
albumin
immunoglobulin
iga
igg
igm
lipoprotein
calcium
citrat
coagul
protein
evalu
antigen
assay
except
factor
xiii
level
marker
coagul
thrombinantithrombin
prothrombin
fragment
ddimer
complement
activ
odp
remain
similar
ffp
odp
equival
ffp
assess
aptt
pt
thrombelastographi
transfus
vol
supplement
abstract
spraydri
fragment
substanti
number
high
molecular
weight
von
willebrand
factor
vwf
multim
smaller
one
lead
net
increas
vwf
multim
odp
size
redistribut
reduc
vwf
ristocetin
cofactor
activ
vwf
rco
odp
rel
ffp
impact
vwf
antigen
factor
viii
function
stabil
vwf
vwfspecif
studi
shown
odp
retain
hemostat
function
support
platelet
adhes
aggreg
see
abstract
meledeo
et
alu
armi
institut
surgic
research
bercovitz
et
alblood
center
wisconsin
conclus
odp
manufactur
blood
center
qualiti
compar
ffp
futur
studi
determin
product
bioequival
ffp
compar
safeti
efficaci
backgroundcas
studi
collect
time
whole
blood
accord
european
guidelin
limit
minut
addit
donat
collect
time
minut
use
prepar
platelet
plt
concentr
pc
chanc
much
activ
plt
seem
justifi
reevalu
qualiti
plt
donat
new
gener
collect
system
mixer
introduc
includ
effici
needl
aim
studi
investig
vitro
qualiti
pc
prepar
minut
buffi
coat
bc
aim
prevent
unnecessari
discard
bc
simplifi
total
blood
bank
process
studi
designmethod
singledonor
pc
spc
prepar
one
minut
bc
ml
autolog
plasma
ml
pvcdehp
contain
refer
spc
donat
collect
time
minut
prepar
addit
pc
prepar
bc
least
bc
minut
donat
pool
bc
ml
pase
ad
standard
pool
set
pvcbthc
storag
contain
use
storag
pc
pc
store
day
sampl
regular
interv
determin
vitro
qualiti
aggreg
test
perform
chronolog
adp
collagen
multipl
arachidon
acid
aggregomet
thromboelastographi
teg
use
kaolin
activ
appli
assess
overal
clot
capac
valu
express
sd
nonpair
ttest
mannwhitney
u
test
appli
statist
analys
normal
nonnorm
distribut
data
respect
resultsfind
volum
vs
ml
platelet
content
vs
similar
group
end
storag
group
show
compar
vitro
qualiti
day
ph
vs
data
shown
differ
aggreg
respons
stimul
arachidon
acid
adp
collagen
measur
teg
paramet
group
also
compar
fivedonor
pc
fulfil
requir
european
guidelin
asid
occurr
small
aggreg
day
andor
pc
possibl
sometim
incompat
accept
day
plt
show
low
express
phosphatidylserin
exposur
annexin
v
bind
hypoton
shock
respons
platelet
compar
histor
data
conclus
singlepc
plasma
well
fivedonor
pc
pase
prepar
minut
whole
blood
donat
normal
composit
show
good
vitro
qualiti
day
storag
substanti
exclus
minut
donat
pc
prepar
could
stop
studi
perform
effect
pneumat
tube
system
red
blood
cell
unit
ami
mata
jessi
miller
rane
mari
wannarkafarling
sandra
bryant
scott
hammel
sherri
stern
camil
van
buskirk
mayo
clinic
mayo
clinic
rochest
backgroundcas
studi
use
pneumat
tube
system
pt
becom
commonplac
mani
healthcar
facil
throughout
world
purpos
system
transport
product
specimen
result
reduc
turnaround
time
laboratori
test
aid
time
deliveri
patient
care
downfal
ptss
potenti
play
role
increas
hemolysi
sever
studi
publish
effect
ptss
blood
specimen
address
effect
blood
product
specif
red
blood
cell
rbc
object
studi
twofold
determin
pt
use
facil
contribut
increas
hemolysi
rbc
unit
evalu
pt
system
affect
red
cell
microparticl
rmp
level
studi
designmethod
fortyon
unit
rbc
irradi
nonirradi
select
studi
unit
vari
age
rang
day
old
specimen
obtain
unit
prior
transport
pt
run
underground
span
length
mile
half
specimen
spun
plasma
supernat
remov
specimen
evalu
plasma
hemoglobin
hgb
potassium
k
hemolysi
index
hi
rmp
wilcoxon
signedrank
test
p
valu
use
compar
pre
post
valu
addit
statist
analysi
perform
compar
valu
adjust
age
irradi
resultsfind
send
rbc
unit
pt
hgb
hi
rmp
statist
p
higher
adjust
irradi
analyt
remain
statist
higher
howev
adjust
age
pvalu
signific
hgb
hi
k
valu
significantli
chang
rmp
significantli
increas
unit
irradi
tabl
conclus
use
pt
provid
effect
mean
transport
blood
product
howev
contribut
biolog
chang
within
rbc
unit
uncertain
time
chang
affect
outcom
patient
receiv
product
pt
system
differ
specif
valid
prior
use
transport
blood
product
valid
factor
viii
level
thaw
fresh
frozen
plasma
day
storag
pei
lun
karen
lim
erma
sofia
sumardi
isamar
eduardo
ancheta
susan
lim
christina
yip
lip
kun
tan
shir
ying
lee
nation
univers
hospit
singapor
nation
univers
hospit
nation
univers
hospit
singapor
backgroundcas
studi
plasma
transfus
indic
patient
coagul
factor
defici
activ
bleed
undergo
invas
procedur
fresh
frozen
plasma
ffp
place
freezer
within
hour
process
store
colder
order
preserv
coagul
factor
thaw
ffp
expir
period
hour
henc
reduc
wastag
studi
aim
investig
factor
viii
fviii
activ
thaw
plasma
store
day
kept
fviii
chosen
import
coagul
factor
correct
coagulopathi
arbitrari
fviii
level
accept
limit
set
less
iudl
studi
designmethod
randomli
select
unit
ffp
measur
fviii
concentr
base
clot
assay
stav
r
defici
transfus
vol
supplement
viii
diagnostica
stago
fviii
level
measur
five
time
point
prefreez
hour
postthaw
ffp
thaw
use
helmer
plasma
thawer
helmer
scientif
minut
aliquot
thaw
ffp
unit
remov
measur
fviii
refriger
hour
postthaw
thaw
plasma
tp
unit
kept
refriger
day
subsequ
test
resultsfind
result
obtain
list
tabl
unit
test
fviii
post
hour
due
oper
issu
overal
fviii
concentr
decreas
averag
prefreez
post
thaw
hour
storag
tp
post
hour
hour
residu
fviii
level
remain
iudl
except
unit
lower
initi
fviii
concentr
post
hour
unit
test
residu
fviii
activ
within
preset
standard
iu
dl
averag
declin
postthaw
postthaw
respect
observ
trend
blood
group
higher
lower
prefreez
fviii
like
due
small
sampl
size
conclus
decreas
coagul
factor
fviii
ffp
expect
due
diminish
stabil
nevertheless
data
show
major
tp
retain
least
iudl
fviii
typic
patient
factor
level
iudl
may
start
show
abnorm
coagul
profil
tp
use
specif
factor
replac
therapi
may
indic
patient
gener
coagulopathi
activ
bleed
studi
extend
measur
labil
factor
fv
may
add
valu
valid
studi
valid
pathogen
reduct
method
use
amotosalen
uva
compar
pathogenreduc
pool
prpplatelet
convent
singl
prp
platelet
qualiti
bacteri
inactiv
efficaci
lubna
ahm
almenawi
ayman
mohamad
sabri
ali
abdullah
alajeafi
ashwaq
hasan
alhekri
saleem
bin
mahfouz
ali
hasan
alkhodari
rawya
saeed
sheali
marcu
picardmaureau
hussain
bana
almalki
king
abdulaziz
hospit
oncolog
center
ceru
europ
bv
backgroundcas
studi
grow
number
transfusiontransmit
infecti
tti
risk
includ
emerg
endem
pathogen
constant
challeng
blood
center
saudi
arabia
limit
number
pathogen
tti
risk
reduc
use
blood
screen
assay
altern
solut
anticip
pathogen
reduct
pr
technolog
identifi
potenti
solut
valid
amotosalenuva
photochem
treatment
blood
center
perform
compar
platelet
compon
pc
qualiti
standard
control
singledonor
prpconcentr
plasma
day
storag
period
new
test
pathogenreduc
pool
pool
prp
pc
plasma
day
storag
period
efficaci
bacteri
inactiv
also
assess
set
studi
designmethod
qualiti
paramet
leucoreduc
test
pc
assess
day
storag
compar
leucoreduc
control
pc
day
storag
test
pc
pathogenreduc
intercept
blood
system
ceru
corpor
concord
usa
day
process
complet
day
postcollect
sampl
taken
daili
qualiti
analysi
test
control
pc
day
day
respect
bacteri
spike
addit
pc
spike
receiv
ml
mcfarland
cfu
aureu
epidermidi
e
coli
p
aeruginosa
viridan
respect
challeng
pr
efficaci
resultsfind
averag
platelet
loss
test
pc
post
pr
treatment
total
averag
platelet
loss
day
averag
platelet
loss
control
unit
day
averag
ph
test
unit
day
rang
control
pc
ph
glucos
concentr
test
pc
day
mmoll
lower
day
control
unit
mmoll
lactat
level
increas
cours
storag
lactat
level
day
outsid
rang
assay
mmoll
cultur
inocul
pathogen
reduc
bacteri
spike
unit
neg
day
incub
contrast
inocul
nonpathogen
reduc
sampl
control
unit
posit
bacteri
growth
conclus
qualiti
paramet
pathogen
reduc
test
pc
within
specif
compar
convent
control
pc
high
efficaci
bacteri
inactiv
togeth
compar
qualiti
paramet
valu
suggest
use
amotosalenuva
pathogen
reduct
safe
effici
enhanc
pc
transfus
safeti
keaton
charl
stoner
jay
srinivasan
jessica
poisson
ian
welsbi
duke
univers
duke
univers
school
medicin
duke
univers
hospit
duke
univers
medic
center
backgroundcas
studi
coagul
cascad
reli
complex
interact
protein
known
clot
factor
cryoprecipit
cryo
plasmaderiv
blood
product
contain
sever
protein
central
clot
cascad
typic
use
fibrinogen
replac
bleed
patient
howev
cryo
content
tend
variabl
littl
quantit
evid
exist
regard
exact
therapeut
effect
cryo
coagul
studi
aim
better
character
cryo
consist
across
within
sourc
term
function
effect
vitroclot
format
studi
designmethod
duke
proteom
core
conduct
semiquantit
liquid
chromatographymass
spectrometrymass
spectrometri
transfus
develop
vitromodel
coagulopath
patient
use
serial
dilut
pool
normal
plasma
salin
ad
equival
one
two
three
cryoprecipit
dose
tissu
factoractiv
test
rotemv
r
delta
hemostasi
analyz
extem
perform
condit
sourc
doserespons
curv
clot
time
ct
alpha
angl
maximum
clot
format
mcf
gener
use
linear
regress
model
intersourc
unit
variabl
determin
anova
tukey
hsd
posthoc
analysi
rstudio
inc
resultsfind
lcmsm
identifi
protein
cryo
abund
fibrinogen
relev
coagul
notabl
american
red
cross
arc
singl
donor
sourc
steepest
slope
mcf
mmdose
indic
greater
per
dose
potenc
sourc
arc
singl
donor
sourc
highest
mean
mcf
across
dose
level
also
highest
standard
deviat
respons
variabl
arc
singl
donor
sourc
significantli
potent
australian
sourc
conclus
pair
estim
regard
variabl
clot
format
respons
cryo
quantit
doserespons
curv
provid
studi
ct
mcf
alpha
angl
provid
physician
inform
regard
cryo
dose
futur
studi
evalu
therapeut
effect
cryoprecipit
versu
fresh
frozen
plasma
fibrinogen
concentr
would
clinic
import
give
us
insight
rel
util
dose
requir
cryo
correct
dilut
coagulopathi
viral
inactiv
enrich
factor
viii
factor
xiii
fibrinogen
von
willebrand
factor
vwf
multim
fresh
frozen
plasma
ffp
use
vip
plasma
viru
inactiv
treatment
system
backgroundcas
studi
solventdeterg
sd
process
use
plasma
safe
inactiv
lipidenvelop
virus
method
prove
effect
process
coagul
factor
concentr
disrupt
membran
lipidenvelop
virus
cell
protozoa
leav
labil
coagul
factor
intact
studi
done
assess
viral
inactiv
factor
viii
factor
xiii
fibrinogen
von
willebrand
factor
vwf
multim
enrich
capac
vip
plasma
viru
inactiv
treatment
system
studi
designmethod
vip
plasma
viru
inactiv
treatment
system
compris
interconnect
bag
system
sd
reagent
remov
filtrat
final
product
subject
bacteri
lm
filtrat
cryoprecipit
minipool
ml
subject
doublestag
sd
viral
inactiv
follow
one
oil
extract
filtrat
sd
phthalat
di
phthalat
dehp
adsorpt
devic
lm
filter
initi
final
product
compar
visual
appear
blood
cell
count
factor
viii
factor
xiii
fibrinogen
von
willebrand
factor
vwf
multim
initi
final
product
also
check
hiv
hbv
hcv
dengu
malaria
bacteri
contamin
resultsfind
analysi
show
treat
cryoprecipit
clear
neg
blood
count
protein
content
factor
viii
factor
xiii
fibrinogen
von
willebrand
factor
vwf
multim
well
conserv
tabl
kit
ensur
bacteri
steril
tabl
importantli
final
product
free
hbv
hcv
hiv
tabl
conclus
first
time
vip
plasma
viru
inactiv
treatment
system
use
south
asia
product
enrich
viral
inactiv
result
show
effect
product
enrich
viral
inactiv
condit
investig
need
character
function
activ
enrich
compon
irrespect
process
may
offer
one
addit
option
blood
establish
product
viral
inactiv
plasma
compon
especi
low
incom
countri
backgroundcas
studi
buffi
coat
bc
donor
use
pain
medic
like
aspirin
ibuprofen
day
prior
donat
discard
known
side
effect
nonsteroid
antiinflammatori
drug
nsaid
inhibit
platelet
plt
aggreg
nsaid
inhibit
enzym
therebi
block
synthesi
thromboxan
arachidon
acid
howev
qualiti
platelet
concentr
pc
prepar
bc
known
aim
studi
investig
vitro
qualiti
pc
prepar
nsaidbc
autolog
plasma
storag
studi
designmethod
singledonor
pc
spc
prepar
nsaidbc
ml
autolog
plasma
inform
type
pain
medic
extract
anamnes
form
spc
store
day
sampl
regular
interv
aggreg
test
perform
chronolog
adp
collagen
multipl
arachidon
acid
aggregomet
thromboelastographi
teg
kaolin
appli
assess
overal
clot
capac
spc
plasma
normal
control
investig
refer
valu
express
median
iqr
nonpair
ttest
mannwhitney
u
test
appli
statist
analys
normal
nonnorm
distribut
data
respect
resultsfind
volum
vs
ml
plt
content
vs
similar
group
day
group
show
compar
ph
chang
plt
content
data
shown
phosphatidylserin
exposur
day
signific
higher
subset
donor
use
ibuprofen
aggreg
test
arachidon
acid
reveal
gener
low
absent
respons
spc
aspirin
p
diclofenac
naproxen
p
compar
normal
control
differ
detect
aggreg
adp
collagen
teg
slightli
longer
rtime
initi
phase
measur
day
spc
aspirin
diclofenac
naproxen
compar
normal
control
signific
naproxen
differ
disappear
storag
conclus
storag
properti
spc
prepar
nsaidbc
compar
spc
normal
control
main
differ
observ
aggreg
coagul
properti
donor
use
aspirin
diclofenac
naproxen
plt
donor
use
ibuprofen
show
littl
deviat
like
caus
fast
hour
disappear
ibuprofen
blood
circul
revers
bind
plt
use
bc
donor
use
ibuprofen
investig
worst
case
pc
plasma
best
case
pc
addit
solut
scenario
effect
ibuprofen
aggreg
coagul
properti
investig
doserespons
studi
design
ad
differ
level
ibuprofen
plt
backgroundcas
studi
previous
shown
donor
could
classifi
platelet
plt
good
averag
poor
storag
properti
bonteko
transfus
main
differ
good
poor
storag
properti
involv
metabol
activ
result
faster
declin
ph
storag
poor
plt
concentr
pc
might
caus
differ
function
plt
mitochondria
indic
donor
histori
poor
pc
like
health
issu
point
toward
metabol
syndrom
type
diabet
strong
rise
peopl
dutch
popul
aim
studi
character
plt
whole
blood
donor
diagnos
accept
donor
studi
designmethod
twelv
whole
blood
donor
use
insulin
select
buffi
coat
bc
plasma
overnight
hold
use
prepar
singledonor
pc
spc
equival
number
spc
prepar
age
sex
match
control
donor
deriv
collect
session
spc
store
day
sampl
day
diabet
marker
determin
red
cell
cholesterol
triglycerid
level
plasma
group
good
ph
poor
ph
store
spc
select
analys
detail
resultsfind
donor
age
year
primarili
men
donor
higher
mean
bmi
kgm
higher
control
spc
group
volum
vs
ml
plt
content
vs
day
glucos
concentr
higher
diabet
group
vs
mm
p
day
averag
vitro
qualiti
compar
group
data
shown
combin
transfus
vol
supplement
select
good
poor
store
plt
group
larg
differ
lactat
product
observ
vs
mmol
plt
poor
plt
show
faster
declin
mitochondri
membran
potenti
measur
storag
good
plt
remark
differ
triglycerid
level
detect
day
vs
p
conclus
bc
donor
use
insulin
fulfil
donor
criteria
compar
bc
age
sex
match
control
seem
suitabl
prepar
pc
select
good
poor
store
plt
combin
group
result
previou
studi
confirm
signific
differ
glycolysi
rate
function
mitochondria
metabol
syndrom
still
suspect
health
issu
involv
poor
storag
plt
donor
high
mean
age
observ
differ
triglycerid
level
good
poor
store
pc
whole
blood
leukoreduct
failur
follow
manufactur
instruct
may
enough
karen
klinker
nanci
dunbar
zbigniew
szczepiorkowski
backgroundcas
studi
hospit
base
blood
donor
program
use
blood
collect
system
leukoreduc
unit
room
temperatur
prior
centrifug
manufactur
recommend
minimum
wait
time
minut
prior
filtrat
anecdot
vendor
state
wait
hour
improv
leukoreduct
experienc
leukoreduct
failur
januari
februari
detect
routin
qc
initi
investig
caus
unexpect
failur
studi
designmethod
leukoreduct
failur
follow
factor
analyz
collect
time
length
filtrat
length
wait
time
prior
filtrat
platelet
count
staff
perform
process
lot
number
collect
system
bag
whether
unit
collect
donor
fail
leukoreduct
past
hemoglobin
determin
sought
repeat
donor
failur
note
donor
popul
would
suggest
minim
number
donor
would
found
hemoglobin
posit
resultsfind
relationship
establish
length
time
product
rest
wait
prior
filtrat
leukoreduct
failur
found
shorter
wait
time
increas
percentag
leukoreduct
failur
see
tabl
unit
fail
wait
time
less
one
hour
similar
trend
notic
previou
year
investig
show
relationship
length
collect
time
length
filtrat
time
leukoreduct
failur
staff
perform
filtrat
rule
possibl
caus
failur
spread
among
numer
personnel
observ
techniqu
display
sampl
collect
issu
platelet
count
donor
involv
avail
none
outsid
normal
rang
variou
lot
number
collect
set
involv
donor
repeat
failur
conclus
small
studi
found
follow
manufactur
recommend
rest
wait
time
prior
filtrat
insuffici
avoid
excess
leukoreduct
failur
extend
minimum
wait
time
minut
base
data
experienc
leukoreduct
failur
chang
absolut
immatur
platelet
count
diagnost
algorithm
manag
pediatr
thrombot
microangiopathi
hamza
n
gokozan
katharin
down
holli
reev
robert
w
maitta
case
western
reserv
univers
school
medicin
univers
hospit
cleveland
medic
center
backgroundcas
studi
prior
studi
highlight
util
absolut
immatur
platelet
count
aipc
aipc
ratio
therapeut
plasma
exchang
tpe
initi
differenti
thrombot
thrombocytopen
purpura
ttp
thrombot
microangiopathi
help
determin
may
benefit
prompt
initi
tpe
test
readili
avail
report
young
pediatr
patient
present
diarrhea
set
laboratori
result
suggest
microangiopath
thrombocytopenia
suspici
ttp
aipc
measur
clinic
use
studi
designmethod
previous
healthi
month
old
unvaccin
girl
present
histori
diarrhea
day
bloodi
onset
accompani
fever
dehydr
laboratori
result
show
white
blood
cell
count
x
l
platelet
x
l
bun
creatinin
lactat
dehydrogenas
ul
hospit
cours
complic
tonicclon
seizur
episod
stop
anticonvuls
acut
kidney
injuri
requir
hemodialysi
peripher
blood
smear
reveal
schistocyt
third
day
hospit
platelet
count
decreas
x
l
sampl
sent
tpe
initi
clinic
suspicion
ttp
versu
hemolyt
urem
syndrom
atyp
versu
shigatoxin
mediat
immatur
platelet
fraction
ipf
calcul
aipc
ipf
x
platelet
count
obtain
daili
pretp
cbc
aipc
ratio
calcul
baselin
resultsfind
platelet
count
began
increas
prior
tpe
initi
x
l
aipc
x
l
two
consecut
tpe
complet
result
platelet
count
decreas
x
l
aipc
x
l
aipc
ratio
ratio
report
ttp
patient
similarli
aipc
count
x
l
threshold
report
set
ttp
sever
defici
time
stool
cultur
obtain
prior
start
tpe
came
back
posit
e
coli
toxin
test
factor
h
factor
h
autoantibodi
factor
factor
b
normal
activ
patient
treat
infect
platelet
count
improv
within
day
x
l
resolut
renal
failur
bun
mgdl
creatinin
mgdl
addit
seizur
observ
followup
conclus
measur
aipc
use
aid
clinic
decis
pediatr
patient
suspect
ttp
especi
test
etiolog
still
pend
tpe
seem
signific
effect
aipc
decreas
platelet
count
patient
aipc
rapid
obtain
provid
help
inform
set
potenti
overlap
etiolog
set
test
longer
turnaround
time
backgroundcas
studi
thrombot
thrombocytopen
purpura
ttp
thrombot
microangiopathi
character
low
activ
mani
patient
sever
autoantibodymedi
defici
initi
diseas
present
may
suffer
one
recurr
episod
follow
month
year
unclear
diseas
cours
characterist
recurrentrelaps
ttp
may
differ
seen
initi
present
sinc
absolut
immatur
platelet
count
aipc
shown
use
diagnosi
follow
respons
therapi
ttp
patient
proceed
evalu
aipc
pattern
differ
relaps
vers
initi
present
studi
designmethod
studi
cohort
consist
three
patient
two
femal
one
male
acquir
ttp
activ
underw
daili
therapeut
plasma
exchang
tpe
clinic
cours
laboratori
valu
review
platelet
count
plt
immatur
platelet
fraction
ipf
aipc
ipf
x
platelet
count
analyz
treatment
cours
aipc
valu
present
peak
aipc
peak
time
day
plt
count
recoveri
time
day
compar
initi
onset
relaps
episod
patient
aipc
percent
chang
relaps
episod
compar
initi
present
calcul
resultsfind
patient
increas
ipf
decreas
aipc
plt
count
present
initi
recurr
episod
tpe
treatment
initi
aipc
rapidli
increas
reach
peak
valu
day
prior
plt
count
recoveri
consist
previous
describ
ttp
patient
howev
compar
first
onset
recurr
episod
featur
lower
aipc
present
result
shown
percent
decreas
column
increas
peak
aipc
valu
result
shown
percent
increas
column
delay
aipc
peak
delay
plt
recoveri
tabl
moreov
recurr
episod
requir
procedur
compar
initi
present
tabl
conclus
recurrentrelaps
ttp
demonstr
lower
aipc
present
delay
increas
aipc
peak
valu
respons
tpe
compar
initi
present
longer
treatment
cours
observ
recurr
patient
futur
studi
relaps
ttp
patient
need
donor
undergo
frequent
plateletpheresi
effect
hematolog
paramet
sweta
nayak
poonam
coshic
rm
pandey
india
institut
medic
scienc
backgroundcas
studi
frequent
plateletpheresi
donor
asset
blood
bank
wellb
donor
matter
concern
studi
intend
analyz
effect
plateletpheresi
hematolog
paramet
donor
assess
prior
subsequ
procedur
also
tri
compar
effect
cell
separ
use
plateletpheresi
post
donat
hematolog
paramet
studi
designmethod
studi
conduct
februari
march
repeat
plateletpheresi
donor
come
depart
transfus
medicin
nd
time
within
month
first
plateletpheresi
valu
hematolog
paramet
includ
red
cell
platelet
indic
test
prior
plateletpheresi
enter
excel
sheet
gap
donat
calcul
plateletpheresi
done
either
hemonet
separ
hemonet
corpor
braintre
massachusett
usa
fresiniu
separ
comtec
dn
fresiniu
hemocar
gmbh
bad
homburg
vdh
germani
gambro
trima
accel
softwar
version
take
consent
donor
target
collect
procedur
dose
x
platelet
ml
plasma
compar
effect
cell
separ
hematolog
paramet
due
plateletpheresi
paramet
consecut
donat
within
day
consid
data
analyz
stata
within
chang
continu
variabl
assess
pair
ttest
two
group
comparison
done
independ
ttest
wilcoxon
rank
sum
test
comparison
among
cell
separ
done
kruskalw
test
one
way
anova
resultsfind
donor
repeat
plateletpheresi
within
week
group
underw
nd
plateletpheresi
within
day
group
ii
signific
alter
found
red
cell
platelet
indic
within
either
group
signific
differ
variat
platelet
count
group
though
elig
cutoff
lakhsml
platelet
count
lower
baselin
group
donor
wherea
higher
nd
plateletpheresi
group
ii
donor
donor
present
us
rd
time
plateletpheresi
mean
gap
st
rd
plateletpheresi
day
signific
differ
paramet
assess
prior
plateletpheresi
found
except
platelet
distribut
width
plateletpheresi
cell
separ
similar
effect
hematolog
paramet
conclus
signific
chang
hematolog
paramet
plateletpheresi
donor
underw
frequent
plateletpheresi
post
donat
followup
hematolog
paramet
affect
cell
separ
use
plateletpheresi
efficaci
therapeut
plasma
exchang
angiotensin
ii
type
receptor
antibodi
two
kidney
transplant
recipi
chisa
yamada
sila
p
norman
milagro
samaniego
laura
cool
backgroundcas
studi
kidney
transplant
recipi
develop
antibodi
mediat
reject
amr
without
detect
hla
donor
specif
antibodi
dsa
sera
recent
year
angiotensin
ii
receptor
antibodi
report
caus
amr
especi
refractori
amr
possibl
contract
renal
arteri
institut
therapeut
plasma
exchang
tpe
follow
ivig
everi
day
appli
reduc
kidney
transplant
recipi
report
efficaci
tpe
treatment
two
case
studi
designmethod
two
kidney
transplant
recipi
receiv
tpe
treatment
follow
ivig
decreas
ab
review
resultsfind
case
patient
current
femal
focal
segment
glomerulosclerosi
receiv
first
kidney
transplant
live
relat
donor
age
second
deceas
donor
transplant
due
reject
transplant
kidney
age
three
year
posttranspl
creatinin
cr
start
rise
mgdl
biopsi
show
banff
criteria
grade
amr
grade
tcell
mediat
reject
tcmr
grade
interstiti
fibrosi
tubular
atrophi
hla
dsa
neg
serum
high
level
identifi
u
ml
high
uml
intermedi
uml
neg
uml
receiv
tpe
treatment
everi
day
start
losartan
cours
tpe
decreas
uml
histolog
show
improv
amr
tcmr
howev
cr
kept
increas
slowli
mldl
one
month
increas
uml
therefor
receiv
tpe
treatment
decreas
uml
although
level
increas
slightli
uml
month
cr
stabl
mldl
case
patient
mean
p
femal
malign
hypertens
receiv
deceas
donor
kidney
transplant
age
cr
start
rise
week
posttranspl
mgdl
without
detect
hla
dsa
although
biopsi
show
amr
tcmr
focal
sever
arteriopathi
found
high
level
uml
receiv
tpe
procedur
everi
day
decreas
uml
decreas
cr
mgdl
improv
arteriopathi
histolog
level
slightli
increas
uml
next
week
start
weekli
tpe
treatment
weekli
tpe
tpe
treatment
stop
level
remain
rel
unchang
cr
stabl
around
mldl
date
conclus
present
kidney
transplant
recipi
receiv
tpe
treatment
high
level
cours
tpe
procedur
follow
ivig
everi
day
effect
decreas
level
howev
weekli
tpe
effect
reduc
tpe
treatment
may
also
benefici
improv
histolog
amr
clinic
kidney
function
experi
manag
thyroid
storm
plasmapheresi
tatiana
belousova
vanya
jaitli
brian
castillo
hla
tint
kimberli
klein
yu
bai
univers
texa
health
scienc
center
houston
backgroundcas
studi
thyroid
storm
ts
extrem
manifest
thyrotoxicosi
seriou
complic
occur
primarili
patient
grave
diseas
clinic
may
present
wide
rang
hypermetabol
symptom
may
fatal
manag
appropri
report
two
case
ts
sever
cardiac
complic
manag
plasmapheresi
plex
excel
effect
studi
designmethod
year
old
man
patient
medic
histori
hyperthyroid
present
ts
complic
cardiogen
shock
eject
fraction
ef
renal
hepat
dysfunct
well
coagulopathi
patient
persist
tachycard
intub
sedat
requir
tandem
heart
support
year
old
man
patient
b
medic
histori
hypothyroid
synthroid
year
end
stage
renal
diseas
nonischem
cardiomyopathi
ef
present
evalu
dual
kidneyheart
transplant
subsequ
develop
ts
multiorgan
failur
standard
steroid
medic
treatment
show
littl
respons
resultsfind
patient
underw
urgent
plex
along
standard
medic
administr
soon
clinic
suspicion
thyroid
storm
rais
plasma
volum
isovolum
procedur
use
fresh
frozen
plasma
replac
perform
intens
care
unit
procedur
associ
hemodynam
impact
could
easili
manag
patient
show
signific
clinic
improv
within
hour
procedur
complet
total
free
level
trend
normal
near
normal
rang
within
hour
tabl
addit
plex
effect
hormon
associ
antibodi
remov
seem
remain
rebound
phenomenon
observ
case
make
repeat
plex
unnecessari
patient
total
thyroidectomi
week
event
great
clinic
outcom
conclus
case
demonstr
plex
safe
effect
treatment
option
manag
ts
patient
sever
cardiac
dysfunct
procedur
lead
rapid
decreas
thyroid
hormon
associ
antibodi
level
also
lessen
sever
tissu
injuri
moder
inflammatori
process
correct
complic
extracorpor
photopheresi
ezari
syndrom
treatment
hospitalbas
blood
bank
experi
sandra
ortega
anchez
laura
molina
cristina
muniesa
montserrat
octavio
servitj
bedat
silvia
cosano
navarro
maria
isabel
gonz
alez
medina
banc
de
sang
teixit
dermatolog
servic
backgroundcas
studi
extracorpor
photopheresi
ecp
immunomodulatori
therapi
wide
use
sinc
year
cutan
cell
lymphoma
sever
autoimmun
diseas
organ
transplant
reject
last
year
also
use
graft
versu
host
diseas
treatment
use
ecp
cutan
cell
lymphoma
ctcl
mycosi
fungoid
mf
ezari
syndrom
ss
erytroderm
form
recent
categor
american
societi
pheresi
asfa
first
line
treatment
alon
combin
therapi
strong
recommend
grade
ib
categori
sinc
mf
ss
incur
diseas
current
therapi
focu
control
skin
symptom
minim
immunosuppress
object
observ
studi
assess
outcom
patient
diagnos
ss
compar
first
evalu
th
procedur
perform
studi
designmethod
ecp
leukapheresisbas
therapi
ex
vivo
exposit
photosensit
drug
uva
light
subsequ
reinfus
treat
cell
induc
apoptosi
volum
treat
vari
total
bodi
volum
tbv
schedul
ss
diseas
one
cycl
two
daili
ecp
procedur
twice
per
month
venou
access
peripher
case
except
central
cathet
need
procedur
perform
optia
amicu
devic
aphaeresi
extern
uva
irradi
offlin
system
patient
onlin
system
therako
main
paramet
evalu
cutan
respons
rate
number
ezari
cell
previou
treatment
durat
respons
possibl
complic
ecp
treatment
resultsfind
global
respons
rate
partial
remiss
complet
remiss
maintain
respons
sever
side
effect
relat
procedur
found
patient
outcom
analyz
similar
result
publish
literatur
conclus
case
treat
hospit
confirm
efficaci
ecp
ss
treatment
good
safeti
profil
anoth
great
advantag
ecp
rel
lack
immun
suppress
mani
question
remain
still
unansw
ecp
schedul
suitabl
one
must
continu
stop
partial
complet
remiss
achiev
number
leukocyt
treat
techniqu
miniphotopheresi
also
get
good
result
question
make
prospect
studi
necessari
perform
ul
requir
transfus
mild
thrombocytopenia
x
l
acut
kidney
injuri
bun
mgdl
creatinin
mgdl
third
hospit
day
hgb
improv
gdl
howev
worsen
thrombocytopenia
x
l
led
clinic
concern
ttp
peripher
smear
show
mani
red
cell
fragment
patient
transfus
platelet
day
prior
first
tpe
immatur
platelet
fraction
ipf
aipc
ipf
x
platelet
count
obtain
daili
pretp
cbc
aipc
ratio
calcul
baselin
resultsfind
four
tpe
five
day
perform
hospit
day
platelet
count
aipc
improv
x
l
x
l
respect
prior
first
tpe
respons
four
tpe
led
decreas
platelet
count
x
l
aipc
x
l
dynam
resembl
describ
ttp
patient
defici
obtain
prior
tpe
initi
result
time
caus
organ
toxin
identifi
urin
blood
stool
examin
cultur
base
result
tpe
discontinu
led
immedi
increas
aipc
x
l
preced
platelet
count
increas
x
l
three
day
later
patient
discharg
laboratori
valu
time
ldh
ul
hgb
gdl
set
recoveri
renal
function
conclus
time
diagnosi
ttp
essenti
start
tpe
aipc
dynam
differ
ttp
compar
thrombot
microangiopathi
patient
aipc
fail
improv
despit
tpe
improv
procedur
discontinu
follow
increas
platelet
count
three
day
later
ttp
caus
etiolog
aipc
help
adjust
therapi
lead
clinic
improv
research
need
character
immatur
platelet
dynam
nonttp
microangiopathi
infect
role
clinic
cours
idiopath
thrombot
thrombocytopen
purpura
associ
sever
defici
eiman
hussein
jun
teruya
depart
clinic
patholog
cairo
univers
texa
children
hospit
backgroundcas
studi
ttp
life
threaten
diseas
defin
microangiopath
hemolyt
anemia
thrombocytopenia
sever
defici
sinc
introduct
therapeut
plasma
exchang
tpe
treatment
modal
ttp
prognosi
improv
dramat
nonetheless
patient
may
develop
relaps
refractori
potenti
fatal
outcom
despit
notabl
progress
made
studi
emphas
pivot
role
epidemiolog
ttp
remain
uncertain
previou
studi
suggest
mani
factor
appear
influenc
pathogenesi
studi
point
toward
infect
possibl
trigger
may
contribut
develop
ultim
influenc
clinic
cours
one
theori
explain
associ
possibl
cross
reactiv
antibodi
target
infecti
pathogen
direct
aim
studi
prospect
examin
potenti
associ
infect
clinic
outcom
cohort
patient
idiopath
ttp
studi
designmethod
patient
idiopath
ttp
underw
tpe
januari
march
studi
session
perform
daili
platelet
reticulocyt
normal
session
gradual
taper
includ
patient
activ
less
data
infect
occur
within
week
prior
develop
ttp
analyz
resultsfind
thirtytwo
patient
categor
idiopath
ttp
sever
defici
eight
patient
associ
suspect
bacteri
infect
four
patient
show
acut
relaps
coincid
bacteri
infect
central
line
associ
staphylococcu
aureu
infect
occur
three
patient
acinetobact
urinari
tract
infect
report
one
patient
one
patient
symptom
respiratori
infect
develop
ttp
initi
well
relaps
episod
refractori
treatment
demonstr
patient
associ
dental
abscess
one
patient
two
associ
mycoplasma
pneumonia
tpe
session
continu
refractori
patient
death
conclus
patient
idiopath
ttp
refractori
convent
treatment
seriou
consider
given
nonidiopath
caus
particularli
presenc
remot
sourc
infect
addit
trigger
factor
initi
recurr
episod
sandra
sato
kayano
marco
paulo
colella
rafaela
guerra
maciel
ingrid
priscila
ribeiro
pae
ferraz
rafael
colella
c
camargo
cancer
center
backgroundcas
studi
therapeut
leukapheresi
tl
becom
ordinari
procedur
low
bodi
weight
children
cancer
use
time
replac
exchang
transfus
leukodeplet
preced
chemotherapi
help
prevent
leukostasi
hiperviscos
aim
reduc
metabol
renal
complic
associ
cell
lysi
object
studi
evalu
efficaci
safeti
leukapheresi
procedur
pediatr
patient
less
kilogram
use
singl
apheresi
procedur
studi
designmethod
octob
june
two
children
possibl
leukemia
submit
tl
procedur
month
old
weight
kilogram
central
venou
cathet
place
apheresi
perform
use
continu
flow
apheresi
system
devic
prime
ml
abo
rh
kell
compat
leukocytereduc
irradi
hematocrit
pack
rbc
anticoagul
use
acda
plu
heparin
ml
acda
unit
heparin
blood
anticoagul
ratio
complet
blood
count
determin
apheresi
room
heat
avoid
hypothermia
ioniz
calcium
measur
everi
minut
prevent
hypocalcemia
collect
chang
blood
pressur
oxygen
satur
heart
rate
observ
net
fluid
balanc
calcul
sum
volum
anticoagul
cation
nondivert
apheresi
prime
solut
minu
product
volum
procedur
complet
blood
fill
apheresi
tube
discard
patient
intens
care
unit
icu
supervis
pediatr
physician
icu
nurs
awar
potenti
advers
event
procedur
perform
two
hematolog
physician
nurs
practition
resultsfind
white
blood
cell
wbc
blood
count
immedi
apheresi
subject
mm
formula
collect
pump
flow
x
inlet
flow
x
preapheresi
wbc
count
use
goal
remov
x
leukocytesml
singl
leukapheresi
procedur
perform
total
blood
volum
process
per
patient
immedi
procedur
wbc
count
post
tl
wbc
count
respect
net
fluid
balanc
zero
procedur
patient
requir
transfus
conclus
tl
safe
effici
experi
leukodeplet
infant
limit
procedur
children
weigh
kg
less
need
forethought
multidisciplinari
effort
henc
oper
need
custom
procedur
safe
collect
howev
despit
potenti
complic
may
occur
placement
adequ
vascular
access
manag
low
extracorpor
blood
volum
anticoagulantrel
toxic
metabol
hematolog
issu
remain
excel
sourc
leukoreduct
hematolog
malign
diseas
backgroundcas
studi
nationwid
apheresi
registri
give
us
inform
current
statu
trend
regard
apheresi
procedur
data
compar
region
find
understand
differ
perspect
indic
technolog
clinic
practic
korean
societi
apheresi
ksfa
launch
onlin
web
base
registri
system
apheresi
procedur
sinc
report
data
year
studi
designmethod
registri
consist
two
subregistri
one
address
overal
aspect
apheresi
procedur
perform
institut
focus
therapeut
plasmapheresi
procedur
data
regist
voluntarili
particip
hospit
korea
resultsfind
total
apheresi
procedur
perform
hospit
therapeut
plasmapheresi
frequent
procedur
follow
autolog
peripher
blood
stem
cell
pbsc
collect
allogen
pbsc
collect
donor
leukapheresi
therapeut
leukapheresi
cobe
spectra
amicu
wide
distribut
instrument
centrifug
domin
techniqu
therapeut
plasmapheresi
detail
inform
given
therapeut
plasmapheresi
procedur
perform
patient
item
complet
fill
spectra
optia
cobe
spectra
frequent
use
instrument
therapeut
plasmapheresi
fresh
frozen
plasma
ffp
use
frequent
replac
fluid
follow
albumin
albumin
albumin
ffp
procedur
perform
plasma
volum
acd
heparin
use
anticoagul
central
venou
cathet
domin
type
vascular
access
major
clinic
indic
desensit
abo
incompat
renal
transplant
antibodi
mediat
reject
renal
transplant
thrombot
microangiopathi
desensit
abo
compat
renal
transplant
neuromyel
optica
spectrum
disord
hyperviscos
monoclon
gammopathi
advers
reaction
observ
procedur
allerg
reaction
hypocalcem
symptom
hypotens
frequent
report
therapeut
effect
achiev
patient
apheresi
registri
well
run
year
recent
data
reflect
increas
abo
incompat
transplant
korea
revis
updat
registri
plan
year
help
us
achiev
better
understand
apheresi
statu
region
plasma
exchang
may
alway
necessari
patient
sever
hypertriglyceridemia
acut
pancreat
jan
c
hofmann
dobri
kiprov
california
pacif
medic
center
backgroundcas
studi
hypertriglyceridem
pancreat
hp
character
sever
hypertriglyceridemia
shtg
triglycerid
mgdl
acut
pancreat
ap
absenc
caus
hp
potenti
fatal
complic
acut
pancreat
incid
casesyear
complic
shtg
includ
abdomin
pain
nauseavomit
acut
pancreat
hepatosplenomegali
erupt
xanthoma
lipemia
retinali
memori
loss
dementia
peripher
neuropathi
report
effect
use
plasma
exchang
pe
treat
patient
pt
hp
refractori
convent
medic
therapi
lipidfre
diet
plu
pharmaceut
intervent
studi
designmethod
review
medic
record
pt
diagnos
hp
januari
januari
refer
immunotherapi
evalu
pt
receiv
convent
therapi
ct
pe
pe
group
pt
receiv
ct
alon
ct
group
mean
age
year
rang
femal
baselin
mean
triglycerid
level
normal
mgdl
pe
group
mgdl
versu
mgdl
ct
group
baselin
mean
lipas
level
normal
ul
pe
group
ul
versu
ul
ct
group
resultsfind
pt
treat
dietari
restrict
lipidfre
diet
noth
mouth
aggress
lipid
lower
protocol
involv
medic
pe
group
ct
group
receiv
insulin
therapi
manag
symptom
sx
hyperglycemia
andor
diabet
ketoacidosi
pe
group
ct
group
receiv
heparin
therapi
stimul
lipoprotein
lipas
releas
pe
group
underw
averag
pe
treatment
tx
median
rang
daili
tx
use
albumin
requir
ffp
treat
dilut
coagulopathi
case
perform
pe
tx
baselin
triglycerid
level
mgdl
lipas
ul
x
upper
limit
normal
mean
triglycerid
level
pe
tx
mgdl
pe
group
mean
decreas
mean
triglycerid
level
addit
hour
ongo
ct
mgdl
ct
group
mean
decreas
pe
group
achiev
greater
mean
decreas
triglycerid
level
pe
tx
compar
ct
group
hour
ct
group
experienc
mark
improv
clinic
sx
pancreat
hyperglycemia
p
limit
retrospect
cohort
studi
includ
lack
longterm
followup
conclus
small
studi
add
literatur
demonstr
plasma
exchang
effect
rapidli
lower
triglycerid
level
pt
acut
pancreat
hypertriglyceridemia
suggest
may
threshold
rang
triglycerid
lipas
level
convent
therapi
may
nearli
effect
achiev
clinic
resolut
symptom
random
control
trial
would
elucid
appropri
use
adjunct
plasma
exchang
set
hypertriglyceridem
pancreat
role
plasma
replac
therapeut
plasma
exchang
hypertriglyceridemia
singl
patient
studi
geoffrey
wool
angela
treml
univers
chicago
backgroundcas
studi
apheresi
servic
perform
chronic
therapeut
plasma
exchang
tpe
man
chronic
histori
hypertriglyceridemia
mgdl
diabet
mellitu
type
ii
chronic
abdomin
pain
abdomin
pain
sever
persist
overt
evid
chronic
pancreat
imag
fecal
elastas
test
target
sequenc
reveal
pathogen
mutat
explain
patient
hypertriglyceridemia
hypertriglyceridem
pancreat
categori
iii
indic
tpe
asfa
guidelin
patient
unrespons
optim
medic
manag
asfa
guidelin
disord
state
use
plasma
contain
lipoprotein
lipas
could
enhanc
triglycerid
tg
remov
direct
comparison
replac
fluid
report
three
apheresi
physician
servic
use
partial
plasma
replac
variabl
undertook
retrospect
studi
efficaci
partial
plasma
replac
patient
studi
designmethod
perform
tpe
patient
perform
chart
review
captur
replac
fluid
use
preand
posttg
level
drawn
tpe
perform
use
spectra
optia
terumo
lakewood
co
exchang
approxim
one
plasma
volum
use
entir
albumin
exchang
fluid
albumin
procedur
partial
plasma
replac
unit
thaw
plasma
twentysix
tpe
preand
postprocedur
tg
valu
avail
determin
percent
tg
reduct
achiev
tpe
also
determin
daili
rate
tg
increas
next
tpe
appoint
assess
longterm
effect
plasma
prevent
tg
rebound
signific
assess
student
ttest
onetail
heteroscedast
resultsfind
twelv
tpe
perform
partial
plasma
replac
perform
albumin
replac
tabl
show
partial
plasma
replac
associ
significantli
greater
tg
reduct
rate
subsequ
daili
tg
increas
also
lower
partial
plasma
replac
meet
signific
one
mild
allerg
reaction
occur
partial
plasma
replac
respond
quickli
addit
iv
diphenhydramin
conclus
perform
ad
hoc
crossov
studi
efficaci
partial
plasma
replac
tpe
hypertriglyceridemia
patient
without
lipoprotein
lipas
mutat
plasma
significantli
associ
improv
tg
reduct
prevent
posttp
tg
rebound
safeti
efficaci
local
albumin
replac
therapeut
plasma
exchang
phande
watanaboonyongcharoen
metha
apiwattanakul
sompi
santipong
jutaluk
jaipian
jettawan
siriaksorn
ponlapat
rojnuckarin
chulalongkorn
univers
king
chulalongkorn
memori
hospit
prasat
neurolog
institut
backgroundcas
studi
therapeut
plasma
exchang
tpe
albumin
replac
use
treat
varieti
diseas
howev
rise
cost
suppli
shortag
import
albumin
countri
solv
problem
nation
blood
centr
establish
plasma
fraction
plant
manufactur
plasma
deriv
includ
albumin
object
studi
evalu
safeti
efficaci
local
albumin
replac
tpe
studi
designmethod
tpe
use
local
albumin
replac
two
tertiari
care
hospit
perform
june
februari
includ
complet
blood
count
serum
calcium
test
tpe
serum
albumin
test
tpe
local
albumin
avail
solut
use
dilut
albumin
concentr
normal
salin
patient
hospit
receiv
oral
calcium
tpe
prevent
hypocalcemia
advers
effect
record
resultsfind
total
tpe
patient
includ
shown
tabl
neurolog
disord
common
indic
tpe
follow
autoimmun
diseas
median
total
plasma
volum
rang
ml
although
correct
calcium
level
low
mgdl
procedur
clinic
manifest
hypocalcemia
detect
advers
effect
observ
tpe
procedur
patient
first
patient
event
mild
symptomat
hypotens
previous
took
angiotensin
convert
enzym
inhibitor
second
patient
complain
nausea
finish
tpe
reaction
mild
incid
advers
effect
incid
tpe
advers
effect
commerci
albumin
use
differ
statist
differ
p
median
serum
albumin
level
pretp
posttp
gdl
increas
serum
albumin
tpe
statist
signific
p
eightytwo
percent
pretp
serum
albumin
level
lower
gdl
explain
rise
albumin
procedur
demonstr
local
albumin
safe
effect
maintain
albumin
level
patient
undergo
tpe
safeti
effic
costeffect
mononuclear
cell
collect
autolog
immunotherapi
experi
privat
outpati
collect
facil
within
eu
marku
dettk
akh
vienna
univers
hospit
cytocareeu
backgroundcas
studi
within
eu
collect
mononuclear
cell
mnc
start
sourc
manufactur
autolog
cell
therapi
mainli
perform
hospit
hospitalassoci
apheresi
center
report
challeng
perform
leukapheresi
procedur
la
privat
held
medic
practic
specif
emphas
safeti
cell
collect
effici
costeffect
studi
designmethod
review
record
altogeth
outpati
underw
total
la
procedur
cytocar
privat
held
medic
practic
certifi
cell
collect
facil
locat
vienna
austria
patient
particip
variou
industrysponsor
clinic
p
iiii
trial
studi
sponsor
respons
manufactur
activ
cell
product
diseas
entiti
mainli
prostat
cancer
ovarian
cancer
base
differ
studi
protocol
la
perform
either
onetim
twotim
threetim
interv
least
week
repeat
collect
resultsfind
patient
success
complet
apheresi
cours
poor
venou
access
patient
requir
shortterm
femor
cathet
insert
seriou
side
effect
patient
requir
femor
cathet
patient
repeat
la
procedur
side
effect
la
procedur
mainli
consist
mild
hypocalcaemiarel
symptom
patient
followup
survey
one
week
complet
la
reveal
infecti
complic
patient
requir
hospit
median
cell
yield
collect
per
singl
apheresi
wbc
consist
mnc
mnc
cell
yield
remain
stabl
even
repeat
la
collect
cell
product
success
transform
activ
cellular
product
analysi
cost
structur
show
total
cost
care
lower
set
privat
collect
center
compar
hospitalbas
apheresi
center
conclus
leukapheresi
perform
privat
medic
practic
certifi
cell
collect
facil
safe
effect
low
rate
complic
high
level
patient
satisfact
servic
model
costeffect
help
reduc
cost
manufactur
good
product
innov
cellular
product
although
typic
associ
monoclon
gammopathi
eg
waldenstrom
macroglobulinemia
multipl
myeloma
hv
rare
report
patient
disord
immun
system
rheumatoid
diseas
sjogren
syndrom
hiv
diseas
therapeut
plasma
exchang
tpe
indic
hv
due
monoclon
gammopathi
asfa
categori
indic
howev
limit
data
util
tpe
hv
due
polyclon
gammopathi
studi
designmethod
year
old
femal
patient
medic
histori
signific
seroposit
eros
rheumatoid
arthriti
hypertens
diabet
mellitu
cutan
lupu
diffus
parenchym
lung
diseas
present
institut
complaint
progress
fatigu
muscl
weak
poor
appetit
headach
epistaxi
month
fundoscop
examin
show
dilat
tortuou
vasculatur
well
bilater
retin
hemorrhag
mix
flameshap
dotblot
pattern
pertin
laboratori
find
includ
posit
antinuclear
antibodi
screen
antihiston
antibodi
antiro
antibodi
serum
rheumatoid
factor
markedli
elev
iuml
ref
rang
anticycl
citrullin
peptid
antibodi
elev
unit
ref
rang
serum
protein
electrophoresi
immunofix
demonstr
polyclon
hypergammaglobulinemia
protein
precipit
note
point
applic
suggest
circul
immun
complex
serum
igg
igm
iga
mgdl
respect
cryoglobulin
screen
neg
serum
free
kappa
lambda
ratio
peripher
blood
flow
cytometri
identifi
monoclon
bcell
popul
plasma
viscos
note
centipois
cp
admiss
ref
rang
petct
imag
neg
patient
treat
high
dose
steroid
singl
tpe
procedur
perform
use
follow
paramet
volum
treat
total
plasma
volum
replac
fluid
albumin
normal
salin
ratio
replac
fluid
volum
total
volum
process
procedur
toler
without
complic
resultsfind
immedi
posttp
plasma
viscos
level
drop
cp
serum
igg
igm
iga
level
decreas
mgdl
respect
rf
decreas
iuml
patient
report
subject
improv
strength
subsequ
receiv
two
infus
rituximab
separ
two
week
plasma
viscos
remain
less
cp
sinc
tpe
conclus
polycolon
gammomathi
eg
secondari
ra
rare
caus
hv
tpe
provid
transient
relief
symptom
unusu
case
hv
may
facilit
therapi
prevent
recurr
hv
episod
therapeut
plasma
exchang
neuromyel
optica
spectrum
disord
experi
tertiari
care
centr
north
india
ratti
ram
sharma
rekha
han
satya
prakash
naveen
sankhyan
neelam
marwaha
postgradu
institut
medic
educ
research
backgroundcas
studi
neuromyel
optica
spectrum
disord
nmosd
idiopath
inflammatori
demyelin
disord
central
nervou
system
preferenti
involv
optic
nerv
upper
segment
spinal
cord
lead
optic
neuriti
myeliti
tpe
indic
acut
phase
mainten
therapi
treat
prevent
relaps
chronic
phase
studi
designmethod
assess
efficaci
plasma
exchang
patient
nmosd
respond
high
dose
intraven
steroid
retrospect
review
tpe
record
patient
nmosd
period
three
year
jan
dec
tpe
done
use
cobe
spectra
terumo
bct
lakewood
co
usa
replac
one
one
half
patient
plasma
volum
human
serum
albumin
fresh
frozen
plasma
altern
day
improv
clinic
sign
symptom
record
tpe
procedur
end
therapi
advers
reaction
also
record
resultsfind
eleven
patient
nmosd
year
age
f
underw
tpe
procedur
averag
per
patient
patient
high
dose
immunosuppress
therapi
without
much
clinic
improv
three
patient
visual
symptom
visual
well
muscular
symptom
wherea
patient
muscular
symptom
three
seven
test
posit
patient
show
signific
improv
visual
symptom
post
exchang
visionlight
percept
finger
count
two
patient
recoveri
colour
vision
diplopia
six
patient
post
exchang
recoveri
muscl
power
observ
patient
patient
seven
advers
event
observ
procedur
allerg
reaction
replac
fluid
common
event
follow
hypotens
follow
avail
patient
well
immunosuppress
therapi
one
patient
die
due
respiratori
failur
month
anoth
relaps
underw
second
tpe
cycl
continu
well
conclus
tpe
safe
effect
adjunct
therapi
high
dose
immunosuppress
nmosd
trima
accel
softwar
upgrad
platelet
collect
rachel
beck
kimberli
j
duffi
sandra
bryant
audrey
e
traun
mari
benik
jame
r
stubb
justin
kreuter
mayo
clinic
backgroundcas
studi
terumobct
releas
trima
accel
softwar
version
enhanc
allow
collect
platelet
plt
platelet
addit
solut
pa
provid
addit
improv
increas
overal
reliabl
addit
manufactur
identifi
slower
centrifug
speed
low
draw
flow
rate
softwar
expect
function
similarli
version
object
retrospect
studi
identifi
varianc
softwar
upgrad
influenc
plt
product
collect
process
product
collect
studi
designmethod
prior
plt
collect
perform
nine
trima
accel
machin
oper
version
upgrad
valid
nine
machin
version
occur
trima
program
plt
configur
softwar
updat
platelet
collect
data
version
compar
version
incomplet
collect
run
identifi
possibl
leukocyt
contamin
durat
collect
plt
split
rate
evalu
time
period
gener
estim
equat
gee
use
assess
differ
plt
collect
version
adjust
multipl
visit
per
donor
signific
defin
pvalu
resultsfind
follow
upgrad
version
staff
observ
number
chang
includ
increas
centrifug
recoveri
time
donor
low
flow
notabl
increas
possibl
leukocyt
contamin
product
version
trima
accel
show
statist
signific
increas
possibl
leukocyt
contamin
collect
compar
version
durat
collect
plt
split
rate
remain
constant
even
centrifug
speed
adjust
version
conclus
due
fda
limit
allow
implement
trima
accel
pa
plt
current
avail
pathogen
reduct
system
institut
decid
implement
pathogen
reduct
system
time
subsequ
version
softwar
longer
requir
note
slight
increas
possibl
leukocyt
contamin
well
lack
enhanc
plt
collect
upgrad
version
current
provid
ad
valu
version
plt
collect
pulmonari
neurolog
symptom
due
leukostasi
therapeut
leukocytaphersi
tl
use
adjuv
therapeut
modal
patient
symptom
suggest
leukostasi
tl
procedur
perform
use
cell
separ
anticoagul
blood
subject
centrifug
forc
result
separ
layer
cell
plasma
depend
densiti
two
program
cell
separ
mononuclear
mnc
program
greater
centrifug
speed
effici
collect
mnc
polymorphonuclear
pmn
cell
program
lower
centrifug
speed
collect
pmn
hydroxyethyl
starch
he
prefer
collect
granulocyt
transfus
healthi
donor
use
he
facilit
sediment
granulocyt
layer
increas
effici
collect
though
use
he
tl
associ
advers
event
use
volum
expand
pagano
use
tl
vari
report
avail
effici
leukodeplet
use
he
tl
studi
designmethod
receiv
request
leukoreduct
yearold
ladi
chronic
myelogen
leukemia
cml
good
respons
imatinib
week
pregnant
increas
wbc
count
due
discontinu
imatinib
perform
tl
cobe
spectra
use
replac
fluid
ml
albumin
wbc
count
monitor
pre
post
tl
patient
collect
product
modifi
collect
base
result
use
mnc
program
acda
pmn
program
acda
leukodepet
adequ
program
elect
use
he
discuss
patient
physician
tl
perform
use
ml
he
citrat
pmn
program
wbc
pre
procedur
immedi
post
procedur
product
obtain
effici
leukodeplet
differ
program
calcul
resultsfind
effici
wbc
deplet
calcul
product
wbc
patient
wbc
base
blood
volum
also
pre
post
wbc
patient
toler
procedur
well
advers
reaction
patient
fetal
monitor
procedur
conclus
therapeut
leukocytapheresi
cml
patient
safe
effect
reduc
wbc
count
use
ml
hydroxyethyl
starch
anticoagul
post
procedur
patient
wbc
count
sometim
may
provid
data
effici
leucodeplet
backgroundcas
studi
earli
recognit
hypertriglyceridemia
htg
set
acut
pancreat
ap
critic
initi
effect
therapi
role
plasmapheresi
earlyadjuv
approach
acut
htginduc
pancreat
controversi
current
consensu
guidelin
optim
therapi
asfa
categori
iii
report
case
tg
level
well
clinic
symptom
improv
one
therapeut
plasma
exchang
tpe
studi
designmethod
year
old
male
histori
hypertens
htg
diabet
mellitu
dm
present
emerg
depart
excruci
abdomin
pain
patient
diagnos
htg
year
old
treat
initi
diet
lifestyl
modif
howev
clinic
cours
compromis
develop
pancreat
acut
episod
requir
prolong
hospit
admiss
approxim
month
success
treat
medic
howev
recurr
episod
result
chronic
pancreat
complic
pancreat
pseudocyst
pancreat
insuffici
sinc
first
episod
pancreat
medic
manag
fenofibr
lovaza
lisinopril
levemir
novolog
evalu
current
admiss
found
tg
level
mgdl
lipas
ul
glucos
mgdl
bicarbon
mmoll
anion
gap
ct
find
consist
ap
without
evid
necrosi
stabl
pancreat
pseudocyst
medic
therapi
start
omega
fatti
acid
fibrat
statin
hydrat
well
pain
control
statin
therapi
suspend
day
hospit
note
elev
liver
function
test
lft
tpe
request
start
day
admiss
resultsfind
patient
tg
decreas
mgdl
medic
therapi
follow
addit
mgdl
one
volum
tpe
symptom
significantli
improv
discharg
medic
treatment
day
admiss
compar
previou
episod
hospit
stay
significantli
decreas
tg
level
remain
mgdl
day
follow
discharg
conclus
earli
tpe
may
valu
treat
patient
elev
tg
associ
recurr
pancreat
plasmapheresi
might
effect
earli
adjuv
therapi
mitig
length
hospit
stay
improv
costeffect
patient
safeti
backgroundcas
studi
nation
blood
donor
center
southeast
asia
conduct
program
monitor
ferritin
level
platelet
blood
donor
aim
studi
explor
trend
chang
ferritin
studi
designmethod
studi
collect
case
whose
ferritin
level
monitor
twice
interv
detect
day
collect
plasma
sampl
test
ferritin
chemiluminesc
use
commerci
assay
inclus
criteria
includ
apheresi
platelet
blood
donor
two
result
ferritin
first
time
ferritin
test
result
lgl
upper
limit
set
lg
l
male
lgl
femal
describ
manufactur
insert
impact
ferritin
gender
age
blood
donat
frequenc
examin
anova
test
blood
donat
frequenc
categor
five
group
time
time
time
time
time
high
frequenc
time
group
blood
donor
analyz
ferritin
chang
longitudin
data
resultsfind
donor
includ
studi
male
femal
mean
ferritin
lgl
male
ci
lgl
lgl
femal
ci
lgl
result
anova
indic
group
highest
frequenc
time
signific
lowest
ferritin
level
p
averag
chang
ferritin
donat
time
would
lgl
younger
elder
yo
male
lgl
femal
high
frequenc
half
year
time
group
blood
donor
longitudin
analysi
found
longterm
sustain
high
frequenc
blood
donat
caus
signific
declin
ferritin
averag
chang
ferritin
high
frequenc
donor
time
day
reduc
lgl
first
period
lgl
third
period
day
along
period
declin
ferritin
decreas
conclus
analysi
reveal
frequent
apheresi
platelet
donat
would
decreas
ferritin
donor
high
frequenc
platelet
blood
donor
continu
donat
year
declin
ferritin
slow
rare
case
blood
donat
precipit
acut
delirium
joseph
grigg
mari
townsend
lizabeth
rosenbaum
univers
new
mexico
hospit
blood
system
inc
blood
system
inc
backgroundcas
studi
report
case
whole
blood
wb
donat
precipit
transient
agit
delirium
yearold
first
time
male
donor
present
local
blood
center
complet
donor
health
questionnair
miniphys
exam
hemoglobin
check
deem
elig
blood
donat
approxim
minut
uncompl
wb
donat
donor
observ
brief
loss
conscious
postdon
area
fall
injuri
seen
shortli
regain
conscious
donor
becam
agit
confus
orient
month
year
unabl
rememb
name
friend
famili
member
unabl
read
analog
clock
difficulti
word
find
donor
transport
local
univers
hospit
note
comb
deliri
alter
mental
statu
forcibl
restrain
ultim
sedat
intub
transfer
intens
care
unit
studi
designmethod
extens
laboratori
investig
perform
includ
standard
hematolog
chemistri
panel
serolog
pcrbase
studi
multipl
organ
includ
west
nile
herp
hiv
varicella
zoster
syphili
aerob
anaerob
blood
cultur
urin
drug
screen
multipl
drug
abus
radiograph
imag
perform
includ
chest
xray
ct
mri
head
spine
addit
eeg
perform
inpati
neurolog
psychiatri
servic
consult
patient
resultsfind
sedat
discontinu
patient
success
extub
rapidli
improv
complet
return
baselin
within
hour
onset
event
laboratori
investig
reveal
sign
infecti
organ
evid
drug
abus
radiograph
imag
eeg
studi
show
abnorm
addit
infecti
diseas
marker
test
perform
blood
center
laboratori
neg
investig
reveal
donor
experienc
high
level
stress
school
avers
sight
blood
coerc
donat
girlfriend
peer
week
follow
hospit
discharg
blood
center
medic
director
contact
donor
phone
donor
resum
normal
routin
attend
graduat
level
class
conclus
knowledg
first
report
blood
donat
precipit
transient
acut
delirium
time
donat
health
statu
potenti
blood
donor
assess
help
ensur
safeti
donor
recipi
health
questionnair
physic
exam
vital
sign
hemoglobin
level
infecti
diseas
test
help
identifi
overt
sign
medic
ill
may
disqualifi
donor
howev
routin
donor
screen
explicitli
evalu
mental
health
issu
diagnos
undiagnos
although
exceedingli
rare
case
highlight
limit
donor
screen
identifi
donor
may
risk
mental
health
advers
reaction
donat
blood
target
approach
increas
african
american
blood
donor
pool
arnethea
sutton
william
korzun
teresa
nadder
susan
roseff
elizabeth
ripley
virginia
commonwealth
univers
virginia
commonwealth
univers
medic
center
backgroundcas
studi
continu
need
blood
product
requir
frequent
transfus
individu
sickl
cell
diseas
could
benefit
product
collect
african
american
donor
warrant
need
target
intervent
increas
blood
donat
underrepres
popul
one
popul
particular
african
american
account
blood
donor
unit
state
literatur
indic
numer
reason
popul
underrepres
amongst
donor
includ
fear
lack
knowledg
blood
donat
specif
popul
lack
trust
medic
commun
studi
designmethod
african
american
richmond
norfolk
virginia
recruit
church
local
univers
studi
aim
develop
implement
assess
target
educ
approach
incorpor
theori
plan
behavior
variou
teach
method
develop
implement
survey
evalu
particip
feel
attitud
intent
donat
motiv
african
american
nondonor
attempt
donat
blood
particip
attend
educ
session
educ
import
red
blood
cell
donat
african
american
particip
complet
three
survey
one
session
one
directli
session
one
two
month
session
twoproport
ztest
use
compar
known
proport
african
american
present
donat
studi
area
present
donat
studi
regress
analysi
use
estim
relationship
among
survey
variabl
resultsfind
total
subject
includ
data
analysi
sixteen
percent
studi
particip
present
donat
result
attend
educ
session
result
statist
significantli
higher
proport
african
american
present
donat
current
proport
area
state
studi
conduct
result
first
two
survey
indic
subject
norm
attitud
signific
predictor
one
intent
donat
blood
perceiv
behavior
control
factor
educ
session
increas
survey
score
relat
intent
donat
comparison
score
obtain
prior
session
conclus
studi
show
target
educ
program
chang
attitud
toward
blood
donat
african
american
result
increas
new
blood
donor
addit
studi
need
see
behavior
continu
whether
african
american
influenc
commun
increas
awar
motiv
lifelong
blood
donat
femal
basic
traine
conclus
signific
increas
hemoglobin
deferr
basic
train
site
could
result
chang
blood
drive
time
train
schedul
locat
basic
traine
site
schedul
day
januari
blood
drive
date
chang
day
extra
three
day
basic
train
atmospher
associ
diet
chang
increas
physic
activ
may
effect
hemoglobin
level
popul
basic
train
site
b
signific
increas
hemoglobin
deferr
attribut
larger
male
popul
present
site
basic
train
addit
percentag
femal
recruit
donat
blood
drive
decreas
observ
support
hypothesi
increas
hemoglobin
deferr
result
implement
male
hemoglobin
standard
chang
gdl
basic
train
site
b
plan
blood
drive
basic
train
site
b
screen
addit
recruit
must
consid
perform
blood
drive
order
meet
collect
goal
set
prior
implement
chang
male
hemoglobin
standard
blood
donat
donor
spinal
cord
injuri
joanramon
eva
alonso
oscar
monica
romero
teresa
vich
elena
laura
carbonel
eva
paloma
saray
almerg
francesc
carpio
xavier
curia
banc
de
sang
teixit
institut
guttmann
backgroundcas
studi
donat
blood
compon
bc
donor
spinal
cord
injuri
sci
poorli
studi
paralysi
state
diseas
reason
time
sinc
acquisit
peopl
differenti
rest
nonparalyt
popul
term
bc
donat
literatur
review
blood
donat
suitabl
criteria
among
peopl
scarc
veget
labil
may
present
depend
type
sci
obviou
daili
practic
potenti
donor
often
reject
donat
specif
criteria
relat
sci
object
studi
establish
select
criteria
bc
donat
peopl
sci
base
medic
criteria
evalu
rate
advers
donat
blood
reaction
donor
donor
control
group
without
sci
studi
designmethod
organ
regularli
organ
donat
campaign
rehabilit
center
patient
sci
campaign
donor
sci
donor
without
profession
center
rel
etc
donat
blood
januari
decemb
analyz
number
donor
came
give
blood
number
reason
exclus
could
make
donat
whether
sci
number
typolog
advers
reaction
donat
detect
group
donor
sci
higher
due
high
risk
autonom
dysreflexia
exclud
donat
donor
sci
less
one
year
evolut
set
temporari
exclus
criteria
presenc
neurogen
bladder
consid
reason
exclus
resultsfind
analyz
period
donor
came
give
blood
exclud
donat
variou
reason
two
donor
exclud
suffer
sci
higher
exclud
due
high
risk
dysreflexia
anoth
one
donor
exclud
suffer
sci
lower
hemoglobin
level
lower
select
criteria
donor
select
donat
sci
lower
advers
reaction
donat
record
haemovigil
program
none
donor
sci
conclus
accord
experi
donor
sci
lower
type
advers
reaction
blood
donat
select
exclus
criteria
base
donor
paralyt
condit
vagal
syndrom
could
appear
complic
donat
sci
donor
approach
differ
usual
protocol
use
blood
donor
center
experi
chang
manual
autom
blood
pressur
kimberli
j
duffi
sandra
bryant
audrey
e
traun
kristin
borth
mari
benik
jame
r
stubb
justin
kreuter
mayo
clinic
backgroundcas
studi
blood
pressur
bp
import
determin
health
suitabl
blood
donor
manual
method
read
bp
result
variabl
due
minor
varianc
way
staff
perform
manual
procedur
autom
bp
devic
abl
reduc
variabl
bp
determin
decemb
autom
bp
devic
valid
replac
manual
bp
method
blood
donor
center
object
retrospect
studi
determin
chang
manual
autom
bp
process
impact
averag
systol
diastol
pressur
addit
differ
deferr
reaction
rate
observ
studi
designmethod
data
manual
bp
process
accumul
month
period
januari
novemb
inform
assembl
autom
bp
process
month
period
januari
novemb
autom
bp
process
implement
middecemb
decemb
data
exclud
studi
bp
bp
deferr
reaction
donor
weight
demograph
evalu
time
period
donor
may
includ
multipl
time
year
could
set
data
gener
estim
equat
use
assess
differ
autom
manual
bp
signific
defin
p
resultsfind
significantli
peopl
defer
use
autom
bp
compar
manual
bp
read
systol
diastol
bp
measur
significantli
higher
autom
bp
method
manual
method
although
donor
autom
bp
group
experienc
fewer
reaction
manual
bp
group
reduct
larg
enough
reach
statist
signific
even
adjust
gender
weight
age
donat
bp
deferr
systol
diastol
bp
remain
significantli
higher
p
autom
bp
reaction
remain
nonsignificantli
lower
p
conclus
autom
bp
devic
improv
conveni
staff
donor
statist
signific
increas
deferr
margin
decreas
reaction
use
autom
bp
devic
may
play
minor
role
safeti
blood
donor
purpos
studi
hemoglobin
valu
gdl
compar
surrog
deferr
adjust
multipl
visit
per
donor
gener
estim
equat
use
assess
signific
lancet
lancet
b
use
appropri
distribut
data
type
defin
statist
signific
pvalu
resultsfind
averag
hgb
slightli
lower
lancet
b
larger
chang
number
donor
statist
visit
hgb
less
gdl
use
lancet
b
lancet
addit
fewer
first
time
donor
seen
lancet
b
time
lancet
time
adjust
effect
gender
firsttim
donat
use
logist
regress
risk
hgb
higher
lancet
b
lancet
conclus
donor
hgb
slightli
lower
lancet
b
lancet
clinic
differ
slightli
lancet
bs
use
per
visit
lancet
addit
hgb
deferr
obtain
use
lancet
b
lancet
even
adjust
effect
gender
repeat
donor
saw
potenti
deferr
lancet
b
lancet
slight
differ
gaug
lancet
may
associ
freeflow
amount
blood
may
affect
hgb
level
prior
implement
materi
lower
cost
evalu
downstream
consequ
would
recommend
blood
donor
accept
respons
toward
implement
automat
appoint
book
yi
lin
ang
ching
lian
toh
william
choon
hong
sim
health
scienc
author
backgroundcas
studi
surg
demand
blood
due
age
popul
hospit
built
becom
increasingli
import
abl
ensur
donor
return
regular
basi
improv
blood
suppli
blood
stock
manag
dislik
oblig
impos
appoint
singaporean
donor
gener
prefer
walkin
oppos
appoint
book
blood
servic
group
bsg
singapor
made
move
chang
donor
mindset
introduc
automat
appoint
schedul
paper
aim
studi
donor
level
accept
toward
initi
studi
designmethod
determin
donor
accept
rate
data
collect
januari
march
complet
donat
donor
automat
given
next
earliest
elig
date
next
donat
wish
accept
recommend
appoint
either
declin
arrang
log
blood
bank
donor
appoint
book
system
donorcar
make
chang
appoint
offer
remind
sent
phone
via
sm
andor
email
account
three
day
appoint
date
data
collect
donorcar
use
measur
number
appoint
made
declin
three
month
period
donor
declin
appoint
schedul
verbal
interview
reason
resultsfind
total
donor
donat
blood
blood
bank
main
branch
use
baselin
studi
donor
accept
automat
appoint
book
wherea
donor
comfort
declin
still
prefer
walkin
base
time
schedul
rest
decid
variabl
situat
donat
frequenc
choic
prefer
donat
locat
reason
declin
automat
appoint
book
prior
implement
appoint
book
blood
bank
branch
show
donor
book
appoint
donorcar
comparison
made
found
studi
shown
signific
increas
accept
rate
conclus
gener
result
posit
automat
appoint
book
system
enabl
bsg
predict
donor
attend
ensur
better
manpow
manag
reduc
donor
turnaround
time
thu
hope
improv
donor
retent
bsg
still
monitor
automat
appoint
system
futur
studi
still
requir
determin
effect
automat
appoint
book
donor
return
retent
rate
current
bsg
collect
center
manag
appoint
system
eventu
aim
abl
central
appoint
book
system
wherebi
donor
book
appoint
still
abl
donat
collect
site
poisson
distribut
normal
distribut
logist
distribut
lognorm
distribut
transfus
p
donor
refer
popul
except
younger
yr
male
donor
p
donor
refer
mean
donor
sbp
dbp
puls
mmhg
mmhg
bpm
respect
screen
blood
pressur
level
consist
hypertens
male
femal
year
donor
group
significantli
p
higher
refer
popul
male
femal
differ
observ
year
group
conclus
normal
sourc
donor
demograph
physiolog
characterist
often
parallel
refer
usa
popul
howev
differ
includ
lower
cholesterol
level
higher
rate
high
blood
pressur
younger
donor
higher
weight
year
old
femal
develop
blood
donor
educ
materi
gay
wehrli
susan
rossmann
loui
katz
dan
waxman
univers
virginia
health
system
gulf
coast
region
blood
center
sugar
land
america
blood
center
indiana
blood
center
backgroundcas
studi
donor
must
suffici
inform
make
decis
time
consid
option
make
decis
opportun
make
choic
whether
proceed
declin
donat
donor
educ
de
materi
must
address
mandat
set
forth
regulatori
agenc
materi
must
access
understand
gener
popul
goal
nonexperiment
qualit
design
studi
evalu
knowledg
acquir
standard
de
materi
studi
irb
approv
exempt
protocol
studi
designmethod
develop
de
document
written
th
grade
comprehens
level
conveni
sampl
volunt
identifi
twopart
studi
focu
group
fg
incorpor
preand
postquiz
knowledg
acquisit
read
fourpag
de
document
quiz
follow
group
discuss
feedback
preand
postquiz
contain
multipl
choic
question
singl
best
answer
includ
option
answer
nt
know
de
document
revis
base
upon
fg
feedback
quiz
result
revis
page
de
document
test
use
preand
postquiz
individu
interview
ii
resultsfind
demograph
quiz
result
summar
tabl
result
fg
ii
reveal
lack
knowledg
four
area
donor
might
ask
donat
time
donat
process
need
photo
identif
donat
iron
help
increas
low
red
blood
cell
level
donat
sole
purpos
obtain
hiv
test
postquizz
ii
group
reveal
improv
knowledg
acquisit
four
area
feedback
group
reiter
document
long
conclus
develop
de
materi
requir
complic
balanc
provid
critic
inform
concis
appropri
comprehens
level
th
grade
test
de
materi
essenti
step
develop
process
ensur
intend
knowledg
acquir
end
user
popul
next
step
group
pilot
revis
twopag
de
document
donat
site
effect
analysi
rh
blood
suppli
program
establish
hyesung
han
deokja
oh
buja
hur
chulyong
kim
korean
red
cross
blood
servic
backgroundcas
studi
rh
blood
suppli
program
develop
purpos
prompt
stabl
blood
suppli
base
computer
system
program
oper
emerg
contact
commun
program
major
function
request
emerg
blood
recruit
manag
rh
blood
donor
emerg
blood
donat
realtim
blood
suppli
statu
monitor
program
statist
program
aim
research
valid
effect
rh
blood
suppli
program
oper
respons
emerg
blood
suppli
rh
blood
suppli
program
studi
designmethod
research
investig
databas
rh
blood
suppli
program
develop
investig
analyz
compar
recruit
blood
donat
rh
blood
donor
emerg
blood
donat
secur
blood
suppli
upon
request
resultsfind
data
show
number
voluntari
blood
donor
pledg
give
blood
emerg
blood
donat
increas
respect
also
actual
particip
rate
rh
blood
donat
among
group
pledg
give
blood
emerg
blood
donat
increas
moreov
data
indic
blood
suppli
fulli
met
demand
emerg
blood
request
conclus
result
show
rh
blood
suppli
program
effect
recruitmentmanag
rh
blood
donor
emerg
blood
donat
system
contribut
recruit
manag
rh
blood
donor
pledg
donat
blood
secur
rh
blood
emerg
situat
institut
need
meet
demand
rare
blood
type
could
possibl
use
rh
blood
suppli
program
lead
secur
special
type
blood
hanwei
chen
wuhan
blood
center
backgroundcas
studi
china
volunt
blood
donor
donat
platelet
apheresi
ap
time
per
year
howev
awar
knowledg
ap
donat
much
lower
whole
blood
donat
among
chines
popul
approxim
million
dose
ap
transfus
within
billion
peopl
year
china
one
challeng
recruit
new
ap
donor
retent
frequenc
ap
donor
china
studi
designmethod
one
stratifi
recruit
retent
strategi
establish
applic
wuhan
blood
center
sinc
firstli
onetoon
telephon
model
whole
blood
donor
instead
donat
platelet
secondli
group
messag
perman
ap
donor
donat
interv
day
low
inventori
thirdli
specif
recruit
telephon
ap
donor
donat
ap
time
donat
day
less
time
interv
day
last
donat
last
one
prepar
one
letter
thank
ap
donor
gave
time
annual
advis
voluntarili
come
blood
center
ap
donat
avail
resultsfind
past
decad
overal
donat
time
ap
donor
increas
time
dose
ap
increas
time
within
year
ap
collect
fulfil
clinic
need
accord
donat
frequenc
ap
donor
divid
group
donat
ap
donat
time
time
time
donat
time
respect
found
number
perman
ap
donor
donat
ap
time
denot
total
dose
ap
conclus
ap
increas
rapid
steadi
pace
wuhan
blood
center
met
clinic
need
also
suppli
region
outsid
wuhan
addit
perman
ap
donor
gain
attent
donat
greatest
percentag
platelet
conclus
stratifi
recruit
one
effect
approach
meet
clinic
need
platelet
worth
popular
region
year
evalu
site
consecut
donat
finger
stick
fs
hemoglobin
hb
per
site
polici
venou
ven
capillari
cap
zpp
ven
ferritin
fer
perform
per
manufactur
direct
donor
assess
subclin
iron
defici
use
rang
fer
ngml
zpp
level
umolmol
heme
hb
level
particip
complet
onlin
survey
donat
collect
data
symptom
anemia
univari
linear
regress
analysi
use
determin
relationship
test
resultsfind
subclin
iron
defici
present
among
firsttim
repeat
blood
donor
hb
level
gender
age
group
tabl
highli
signific
correl
fs
zpp
ven
zpp
first
second
donat
first
donat
compar
fs
hb
variat
could
explain
variat
fs
zpp
ven
zpp
ven
fer
second
donat
compar
fs
hb
variat
could
explain
variat
fs
zpp
ven
zpp
ven
fer
donat
variat
among
test
fs
hb
ven
fer
ven
zpp
fs
zpp
signific
p
suggest
strong
evid
correl
respond
survey
report
feel
well
donat
note
note
femal
studi
particip
report
feel
unwel
first
donat
ferritin
level
zpp
level
less
umolmol
heme
male
particip
report
feel
well
none
ferritin
level
ngml
ven
fs
zpp
level
umolmol
heme
conclus
subclin
iron
defici
present
hemoglobin
level
insuffici
correl
fs
hb
ven
fer
support
use
fs
ven
zpp
analysi
measur
iron
store
blood
donor
symptom
report
studi
particip
consist
laboratori
result
minimum
male
hb
rais
gmdl
fda
impos
specif
vs
rang
accept
puls
p
blood
pressur
bp
remov
centerbycent
discret
survey
member
america
blood
center
abc
perform
assess
impact
donor
deferr
result
chang
studi
designmethod
onlin
survey
softwar
surveygizmo
boulder
co
use
solicit
collect
deferr
inform
blood
center
two
interv
julydec
julydec
ie
implement
deadlin
final
rule
respect
inform
deferr
present
whole
blood
wb
donat
apheresi
platelet
ap
donat
request
hb
threshold
vs
inform
stratifi
gender
abo
type
statist
analysi
includ
ttest
numer
chisquar
categor
data
minitab
chicago
il
p
consid
signific
resultsfind
data
provid
center
invit
repres
wb
donat
ap
donat
aggreg
two
interv
respect
gender
abo
distribut
appear
repres
us
donor
base
among
wb
donor
rate
deferr
rose
two
interv
among
aggreg
donat
attempt
p
ap
p
mean
center
deferr
rate
tabl
similar
signific
p
mean
center
hb
deferr
rate
among
f
donat
two
interv
wb
ap
respect
absent
chang
accept
hb
threshold
data
vs
deferr
much
sparser
p
deferr
center
could
provid
specif
high
vs
low
vs
irregular
puls
deferr
provid
summari
ie
total
puls
deferr
could
provid
none
bp
provid
detail
high
vs
low
summari
none
p
deferr
increas
success
interv
among
f
wb
donor
center
mean
wb
donor
detail
avail
high
irregular
puls
respons
chang
gender
bp
deferr
significantli
increas
among
wb
donor
regardless
gender
data
set
deferr
rate
vs
ap
donor
quit
small
possibl
reflect
cull
prior
donat
experi
conclus
substanti
addit
donor
deferr
attend
increas
hb
threshold
final
rule
wb
ap
chang
modest
among
femal
donor
consist
absenc
chang
allow
hb
level
modest
signific
chang
attend
stringent
requir
vs
though
data
limit
restrict
aspect
analysi
backgroundcas
studi
diabet
mellitu
reach
potenti
epidem
proport
india
given
diseas
highli
visibl
across
section
societi
within
india
demand
screen
diabet
urgent
research
intervent
region
nation
level
tri
mitig
potenti
catastroph
increas
diabet
predict
upcom
year
due
eas
use
sever
studi
found
test
identifi
patient
commun
might
otherwis
go
undiagnos
took
initi
find
incid
diabet
random
blood
sugar
rb
measur
among
indian
blood
donor
measur
level
among
rb
mgdl
studi
designmethod
prospect
studi
done
depart
transfus
medicin
depart
biochemistri
st
march
st
march
total
blood
donor
test
rb
rb
mgdl
test
gold
standard
hplc
method
use
variant
ii
biorad
blood
donor
mgdl
rb
advis
consult
physician
evalu
resultsfind
donor
test
donor
show
rb
mgdl
forti
two
male
femal
mean
age
year
year
known
case
typeii
diabet
mellitu
dm
oral
medic
exclud
remain
famili
histori
dm
donor
donor
give
consent
test
among
donor
test
level
donor
counsel
refer
physician
manag
overal
incid
donor
dm
popul
donor
conclus
screen
blood
glucos
level
target
blood
donor
go
long
way
curb
diabet
burden
societi
incid
low
ferritin
level
regular
male
blood
donor
accept
hemoglobin
level
singapor
ramir
alcantara
hwee
huang
tan
ai
leen
ang
health
scienc
author
blood
servic
group
health
scienc
author
blood
servic
group
backgroundcas
studi
iron
defici
known
complic
regular
blood
donat
order
protect
donor
health
prevent
iron
defici
aabb
increas
minimum
accept
hemoglobin
level
male
whole
blood
apheresi
donor
gdl
last
may
current
minimum
accept
hemoglobin
male
donor
singapor
gdl
aim
studi
determin
incid
low
ferritin
level
regular
whole
blood
apheresi
male
blood
donor
accept
borderlin
hemoglobin
level
donor
hemoglobin
gdl
studi
designmethod
month
period
serum
ferritin
test
perform
regular
male
whole
blood
regular
male
apheresi
donor
made
least
donat
last
two
year
accept
hemoglobin
level
donor
divid
group
accord
donat
type
hemoglobin
rang
group
whole
blood
hemoglobin
group
b
whole
blood
hemoglobin
group
c
apheresi
hemoglobin
group
apheresi
hemoglobin
serum
ferritin
level
four
donor
group
compar
analyz
ferritin
level
ugl
consid
low
level
ugl
consid
absent
iron
store
resultsfind
donor
studi
ferritin
level
ugl
donor
low
ferritin
group
compar
group
b
respect
p
apheresi
donor
low
ferritin
rate
higher
group
c
donor
compar
group
respect
ferritin
result
group
seen
tabl
conclus
half
donor
studi
low
ferritin
donor
low
ferritin
half
absent
iron
store
donor
low
ferritin
immedi
inform
result
given
iron
supplement
advis
come
back
donat
month
sinc
donor
health
safeti
paramount
import
measur
limit
prevent
iron
defici
blood
donor
must
implement
due
high
incid
low
ferritin
level
whole
blood
apheresi
donor
hemoglobin
gdl
recommend
minimum
hemoglobin
level
cut
male
blood
donor
singapor
increas
gdl
measur
implement
includ
better
donor
educ
risk
iron
defici
need
iron
supplement
use
websit
social
media
backgroundcas
studi
safe
blood
crucial
irreplac
compon
medic
manag
mani
diseas
voluntari
nonremuner
blood
donat
ideal
sourc
qualiti
blood
form
less
demand
blood
pakistan
motiv
among
youth
particularli
student
essenti
make
voluntari
blood
movement
success
assess
knowledg
attitud
practic
regard
voluntari
blood
donat
among
young
student
popul
karachi
effect
approach
made
regard
motiv
enrol
voluntari
non
remuner
blood
donor
futur
pakistan
studi
designmethod
cross
section
prospect
studi
conduct
among
student
differ
univers
colleg
karachi
wellstructur
pretest
questionnair
english
use
access
knowledg
attitud
practic
voluntari
blood
donat
score
mechan
use
understand
overal
knowledg
level
obtain
data
analyz
resultsfind
sampl
popul
consist
male
femal
student
age
group
year
student
heard
voluntari
blood
donat
student
given
blood
lifetim
among
blood
donor
moment
particip
believ
specif
reason
nt
donat
blood
believ
risk
involv
donor
donat
blood
student
want
promot
voluntari
blood
donat
fear
lack
awar
blood
donat
reason
donat
blood
student
gather
inform
voluntari
blood
donat
sever
sourc
mostli
school
colleg
famili
friend
miscellan
effect
report
cours
side
effect
led
interrupt
supplement
instanc
ferritin
level
entri
program
last
visit
mgl
particip
vs
mgl
control
posit
impact
iron
supplement
ferritin
level
observ
took
tablet
ferritin
level
found
particip
control
deferr
low
hemoglobin
group
conclus
iron
supplement
program
drbcd
program
feasiblehowev
take
account
accept
particip
complianc
supplement
donor
obtain
full
benefit
program
use
iron
prepar
better
toler
may
increas
complianc
backgroundcas
studi
hereditari
hemochromatosi
hh
patient
permit
donat
blood
allogen
blood
suppli
long
elig
donat
collect
physicianord
therapeut
phlebotomi
blood
collect
establish
need
except
altern
make
collect
provis
requir
set
forth
met
object
describ
current
hh
donor
longterm
contribut
hospitalbas
donor
center
hospit
blood
suppli
studi
designmethod
irb
protocol
approv
enrol
therapeut
phlebotomi
hh
patientssubject
requir
file
fda
varianc
permit
hh
donor
blood
use
allogen
suppli
without
diseas
label
frequenc
therapeut
bleed
guid
routin
clinic
assess
mcvhemoglobin
serum
ferritin
transferrin
satur
monitor
serum
ferritin
level
ng
ml
target
mainten
phlebotomi
oper
custom
computer
databas
applic
employ
eas
phlebotomi
manag
resultsfind
sinc
incept
cumul
number
hh
subject
enrol
hemochromatosi
protocol
reach
homozygot
without
activ
recruit
accrual
rate
per
quarter
subject
qualifi
allogen
donor
mean
current
age
year
male
caucasian
major
hh
donor
activ
cohort
mainten
phase
therapi
averag
donationsyear
deferr
rate
last
year
hh
donor
contribut
approxim
hospit
allogen
blood
suppli
averag
whole
blood
unit
transfus
per
year
moreov
hh
donor
whole
blood
wb
donat
provid
blood
vitro
research
institut
averag
wb
research
donationsyear
hh
donorderiv
transfusiontransmit
infect
year
sinc
increas
male
hgb
deferr
threshold
hh
male
deferr
blood
donat
conclus
simpl
safe
system
donor
evalu
phlebotomi
manag
transfus
blood
drawn
hh
subject
establish
blood
donat
hh
donor
remain
import
resourc
hospit
hh
donor
benefit
care
medic
followup
iron
statu
mutual
benefici
relationship
feasibl
sustain
test
accuraci
noninvas
blood
hemoglobin
methodolog
blood
donor
set
michel
walker
sharon
garcia
mythili
ram
gulf
coast
region
blood
center
backgroundcas
studi
object
studi
assess
accuraci
hemoglobin
hb
level
measur
orsens
noninvas
occlus
spectroscopi
devic
compar
hb
level
measur
venou
sampl
laboratori
hematolog
analyz
addit
studi
examin
oper
eas
use
donor
satisfact
finger
stickfre
method
studi
designmethod
studi
procedur
protocol
includ
accept
criteria
defin
conjunct
devic
manufactur
determin
standard
deviat
sd
differ
noninvas
sampl
result
sysmex
hematolog
analyz
venou
sampl
result
staff
provid
train
use
noninvas
occlus
spectroscopi
devic
span
day
elig
blood
donor
male
femal
first
screen
noninvas
occlus
spectroscopi
devic
follow
perform
test
util
capillari
blood
screen
method
venou
sampl
collect
blood
donor
perform
hb
measur
sysmex
hematolog
analyz
within
hour
collect
venou
sampl
resultsfind
sd
differ
noninvas
sampl
result
sysmex
hematolog
analyz
venou
sampl
result
exceed
hb
measur
obtain
sysmex
hematolog
analyz
analyz
use
statist
softwar
minitab
sd
differ
report
gdl
precis
yield
coeffici
variat
gdl
standard
deviat
gdl
conclus
oper
found
easi
instal
maintain
oper
minim
train
noninvas
occlus
spectroscopi
technolog
show
accur
perform
compar
venou
sampl
result
compar
capillari
finger
stick
method
deem
suitabl
screen
donor
donor
satisfi
process
appreci
safe
painless
methodolog
ronel
swaneveld
ravi
reddi
dhuli
chowdhuri
brambilla
edward
l
murphi
sanb
rti
intern
ucsfbsri
backgroundcas
studi
maintain
adequ
blood
suppli
south
african
blood
center
need
collect
blood
major
black
african
popul
success
recruit
firsttim
black
blood
donor
temper
lower
suboptim
return
rate
studi
designmethod
perform
prospect
cohort
studi
firsttim
black
blood
donor
donat
fourmonth
period
follow
one
year
within
day
post
donat
questionnair
includ
question
blood
donat
motiv
deterr
administ
telephon
question
use
likert
scale
assess
agreement
statement
relat
domain
altruism
collectiv
selfesteem
market
deriv
local
focu
group
muthivhi
et
al
link
questionnair
blood
donat
databas
allow
logist
regress
analysi
predict
return
second
donat
within
one
year
resultsfind
includ
firsttim
black
donor
median
age
femal
predomin
within
one
year
donor
attempt
least
one
addit
donat
likert
scale
analyz
ordin
variabl
strongli
agre
strongli
disagre
donor
return
associ
follow
motiv
blood
donat
easi
way
make
differ
odd
ratio
likert
increment
ci
donat
respons
advertscampaign
radio
tv
newspap
ci
respons
altruismassoci
statement
associ
return
among
deterr
donor
less
like
donat
agre
statement
afraid
sight
blood
ci
nt
treat
well
blood
center
staff
ci
surprisingli
donor
like
return
agre
statement
afraid
find
hiv
statu
ci
secondari
analysi
treat
likert
scale
categor
variabl
reveal
gener
similar
result
addit
find
donor
disagre
statement
give
blood
blood
avail
need
nt
know
nearest
blood
collect
point
like
return
conclus
novel
design
allow
us
studi
link
donat
motiv
deterr
actual
rather
intend
return
donat
interest
selfesteem
market
predict
return
better
altruism
fear
poor
custom
experi
recogn
deterr
could
address
plan
use
data
construct
black
donor
recruit
intervent
may
test
use
random
trial
design
willing
donat
blood
summer
christoph
bernard
ramya
ghantasala
obhijit
hazarika
nicol
leonard
cori
polonski
zachari
b
wunrow
michel
heleba
jan
k
carney
mark
k
fung
univers
vermont
larner
colleg
medicin
american
red
cross
blood
servic
backgroundcas
studi
year
donat
rate
fall
summer
month
strain
blood
bank
capac
meet
local
demand
hope
identifi
factor
increas
summer
donat
studi
investig
donor
report
barrier
influenc
summer
donat
habit
studi
designmethod
anonym
question
survey
investig
variou
donat
factor
administ
across
multipl
blood
donor
center
statewid
region
question
address
donor
demograph
frequenc
blood
donat
prefer
appoint
make
modal
includ
smartphon
app
use
summer
travel
habit
willing
donat
vacat
factor
deter
donor
donat
vacat
resultsfind
total
survey
receiv
survey
respond
across
multipl
demograph
group
cite
similar
barrier
summer
donat
name
busi
travel
time
relax
respond
travel
summer
report
donat
travel
summer
donat
rate
summertim
travel
nontravel
essenti
equival
prefer
method
schedul
appoint
via
region
blood
donor
center
websit
phone
willing
use
region
blood
donat
smartphon
app
highest
among
respond
age
lowest
among
age
older
respond
prior
knowledg
summer
season
shortag
indic
newfound
motiv
donat
backgroundcas
studi
viral
infect
adenoviru
ebv
cmv
bk
rsv
etc
implic
major
contributor
posttranspl
morbid
mortal
hematopoiet
stem
cell
transplant
hsct
unrel
donor
investig
shown
invitro
expand
viru
specif
cytotox
lymphocyt
ctl
gener
donor
specif
one
virus
safe
effect
treat
viral
infect
hsct
set
recent
clinic
trial
present
clinic
trial
shown
ctl
rapidli
produc
singl
stimul
donor
peripher
blood
mononuclear
cell
pbmc
peptidemixtur
span
target
antigen
presenc
potent
prosurviv
cytokin
other
use
bank
third
parti
epstein
barr
viru
ebv
specif
ctl
gener
third
parti
ebvseroposit
blood
donor
encourag
result
studi
designmethod
elig
consent
blood
donor
test
cmv
antibodi
serolog
cmvseroposit
whole
blood
wb
unit
underw
buffi
coat
process
nonleucocyt
reduc
wb
unit
collect
fenwal
tripl
bloodpack
tm
underw
hard
spin
rpm
minut
separ
spin
compomatev
r
plasma
buffi
coat
separ
red
cell
first
spin
second
spin
lead
separ
buffi
coat
plasma
buffi
coat
submit
gmp
stem
cell
lab
process
cytomegalovirusspecif
ctl
hla
type
high
resolut
loci
obtain
donor
resultsfind
forti
five
elig
healthi
blood
volunt
f
median
age
year
rang
donat
unit
ml
blood
buffi
coat
averag
volum
ml
process
buffi
coat
process
previous
valid
wb
unit
mononuclear
cell
lymphocyt
monocyt
recov
buffi
coat
list
figur
buffi
coat
receiv
gmp
stem
cell
lab
adequ
cell
number
process
process
buffi
coat
whole
blood
viabl
option
concentr
pbmc
specif
product
viral
specif
ctl
third
parti
shelf
product
well
use
research
project
requir
pbmc
healthi
adult
backgroundcas
studi
goal
present
describ
journey
challeng
toward
tjc
patient
blood
manag
pbm
certif
transfusionrel
health
risk
increas
econom
pressur
driven
hospit
recogn
evidencebas
blood
manag
import
costsav
strategi
provid
holi
cross
medic
center
phcmc
provid
california
region
alpha
site
embark
journey
goal
pbm
certif
reduct
number
unnecessari
transfus
within
month
program
launch
improv
patient
outcom
paper
discuss
journey
toward
certif
variou
hurdl
overcom
studi
designmethod
tjc
aabb
societi
advanc
blood
manag
serv
primari
resourc
identifi
current
evidencebas
transfus
practic
manag
method
need
identifi
organiz
gap
data
gather
analysi
could
determin
baselin
perform
set
improv
target
intern
assess
learn
start
scratch
easili
access
data
metric
gap
educ
staff
took
follow
step
develop
pbm
program
form
interdisciplinari
pbm
team
consist
physician
nurs
blood
bank
staff
data
analyst
construct
report
rbc
transfus
help
identifi
outlier
opportun
backgroundcas
studi
maximum
surgic
blood
order
schedul
msbo
list
surgic
procedur
perform
hospit
along
recommend
pretransfus
test
rbc
alloc
surgeri
extent
hospit
msbo
design
explor
survey
studi
designmethod
survey
design
pilot
refin
member
best
collabor
invit
colleagu
encod
onlin
survey
softwar
link
distribut
best
member
colleagu
encourag
respond
distribut
survey
open
day
resultsfind
complet
respons
indic
hospit
msbo
major
hospit
without
msbo
academ
center
oceania
europ
bed
major
hospit
transfus
rbc
per
year
go
implement
msbo
msbo
major
north
america
major
academ
hospit
bed
transfus
rbc
unit
per
year
offer
wide
rang
surgic
servic
averag
procedur
list
msbo
msbo
recommend
pretransfus
test
mean
procedur
list
preoper
type
screen
crossmatch
rbc
unit
procedur
differ
recommend
made
msbo
creat
combin
obtain
consensu
surgic
servic
blood
bank
use
procedurespecif
transfus
data
msbo
creat
sole
use
procedurespecif
data
use
patientspecif
data
make
test
recommend
msbo
updat
less
frequent
annual
hospit
transfus
committe
often
involv
updat
msbo
gener
avail
electron
oper
room
blood
bank
opinion
major
respond
msbo
use
regularli
limit
number
surgeon
anesthesiologist
respond
felt
regularli
use
surgeon
anesthesiologist
felt
use
hospit
respond
conclus
msbo
avail
half
respond
hospit
minor
case
felt
regularli
use
howev
hospit
current
without
one
indic
would
implement
suggest
hospit
perceiv
valu
one
place
implement
follow
msbo
import
step
periop
patient
blood
manag
streamlin
oper
blood
bank
visavi
preoper
test
blood
manag
one
hospit
system
experi
leana
serrano
rahman
mallika
gupta
susan
solometo
ronald
walsh
joan
uehling
montefior
medic
center
backgroundcas
studi
system
pioneer
aco
tertiarycar
referr
center
dedic
serv
patient
across
new
york
citi
area
beyond
compris
four
hospit
see
hospit
admiss
nearli
emerg
depart
visit
annual
activ
program
high
risk
ob
stem
cell
transplant
solid
organ
transplant
heart
liver
kidney
ct
surgeri
ecmo
oncolog
critic
care
transfus
medicin
play
key
role
support
servic
blood
product
spend
approxim
nov
interdisciplinari
committe
creat
effort
improv
patient
care
reduc
blood
product
exposur
reduc
blood
product
expenditur
vice
presidentsponsor
multidisciplinari
committe
compos
repres
surgeri
anesthesia
blood
bank
pediatr
perfus
cardiothorac
surgeri
critic
care
medicin
emerg
depart
studi
designmethod
first
import
step
know
number
although
committe
multipl
sourc
data
one
report
could
display
pertin
inform
baselin
number
imper
committe
abil
effect
chang
home
grown
one
time
report
reveal
servic
clinician
highest
volum
user
initi
plan
target
use
educ
initi
goal
set
reduc
expenditur
journey
continu
regular
bimonthli
meetingsto
brainstorm
strategi
monitor
util
util
analyz
use
home
grown
crystal
report
transfus
patient
locat
report
compar
util
pattern
dollar
spent
total
unit
per
patient
project
manag
use
excel
key
initi
develop
committe
develop
evid
base
transfus
trigger
educ
evid
base
transfus
trigger
across
multipl
campus
specialti
resid
program
clinic
inform
system
ci
soft
stop
order
blood
product
outsid
guidelin
rbc
order
set
default
unit
instead
unit
updat
guidelin
post
easi
find
intern
intranet
spot
resultsfind
despit
higher
patient
volum
complic
patient
mix
still
abl
reduc
blood
product
expenditur
compar
conclus
spite
limit
resourc
committe
abl
effect
chang
capit
current
stakehold
fulli
support
leadership
project
manag
cord
blood
pathway
reduc
iatrogen
blood
loss
neonat
intens
care
patient
traci
shachner
anna
w
rain
christoph
clark
univers
tennesse
graduat
school
medicin
univeristi
tennesse
medic
center
univeristi
tennesse
graduat
school
medicin
backgroundcas
studi
anemia
due
iatrogen
blood
loss
preterm
low
birth
weight
infant
major
contributori
factor
lead
red
blood
cell
transfus
patient
popul
method
reduc
phlebotomi
laboratori
test
reduc
iatrogen
anemia
universitybas
teach
hospit
pathway
collect
cord
blood
sampl
newborn
deliveri
establish
cord
blood
sampl
use
initi
blood
bank
laboratori
test
newborn
patient
transfer
neonat
intens
care
unit
nicu
prevent
need
addit
blood
draw
blood
tube
save
week
postdeliveri
cost
per
deliveri
tray
steril
tube
initi
neg
antibodi
screen
cord
blood
sampl
addit
phlebotomi
requir
blood
product
select
compat
test
popul
four
month
age
studi
designmethod
labor
deliveri
data
facil
analyz
gestat
age
birth
weight
infant
transfer
nicu
collect
data
abl
calcul
total
blood
volum
infant
use
medcalc
system
use
blood
volum
valu
assign
valu
ml
minimum
amount
blood
would
drawn
perform
antibodi
screen
calcul
percent
infant
blood
would
drawn
cord
blood
pathway
establish
transfus
resultsfind
total
infant
deliv
facil
deliveri
infant
transfer
nicu
infant
receiv
least
one
red
blood
cell
transfus
receiv
least
one
platelet
transfus
infant
transfer
nicu
percentag
blood
volum
would
drawn
blood
bank
test
greater
equal
consid
signific
cord
blood
pathway
effect
percentag
blood
volum
preserv
infant
rang
way
infant
birth
weight
rang
gram
gestat
age
rang
week
week
day
conclus
establish
cord
blood
pathway
proven
rel
costeffect
method
prevent
iatrogen
blood
loss
secondari
blood
bank
test
popul
nicu
infant
suscept
iatrogen
anemia
infant
like
benefit
polici
prematur
infant
low
birth
weight
less
gram
develop
standard
respons
team
massiv
hemorrhag
event
outsid
oper
room
set
jame
burner
shannon
davi
suzan
new
vaishali
patel
oren
guttman
univers
texa
southwestern
medic
center
ut
southwestern
medic
center
backgroundcas
studi
manag
massiv
transfus
protocol
mtp
oper
room
rel
frequent
occurr
team
member
well
train
specif
role
howev
event
mtp
activ
outsid
suffici
andor
appropri
train
individu
may
present
lead
scene
confus
chao
potenti
patient
harm
studi
designmethod
failur
mode
effect
analysi
perform
develop
standard
process
manag
mtp
outsid
set
particip
anesthesia
surgeri
transfus
medicin
patient
safeti
qualiti
nurs
everi
step
hospit
mtp
analyz
potenti
error
result
use
creat
code
hemorrhag
team
train
respond
massiv
hemorrhag
nonor
patient
resultsfind
code
hemorrhag
repres
multisystem
team
critic
event
requir
coordin
differ
subteam
primari
resuscit
surgicalintervent
transfus
servic
blood
prepar
equip
manag
medic
manag
lab
requisitionmonitor
code
hemorrhag
protocol
util
critic
care
train
nurs
hospit
rapid
respons
team
play
two
key
new
coordin
role
hemorrhag
coordin
electron
medic
record
emr
coordin
combin
role
serv
reduc
cognit
load
variou
team
prevent
duplic
resourceseffort
mtp
enabl
enhanc
close
loop
task
perform
hemorrhag
coordin
establish
reliabl
commun
primari
resuscit
team
transfus
servic
aid
multiteam
onsit
coordin
emr
coordin
enter
order
emr
sendscommun
laboratori
result
ensur
blood
product
avail
resuscit
team
primari
resuscit
team
includ
team
leader
medic
decis
make
cardiac
lifesupport
manag
proceduralist
establish
venou
andor
arteri
access
event
document
realtim
document
action
medic
event
etc
medic
manag
regist
nurs
prepar
administ
medic
equip
technologist
manag
rapid
blood
product
infus
devic
addit
secondari
role
also
assign
blood
product
checker
verifi
blood
product
prior
transfus
blood
bank
runner
courier
sent
retriev
blood
product
shipment
conclus
code
hemorrhag
protocol
design
ensur
time
effici
deliveri
blood
product
massiv
bleed
patient
outsid
set
futur
work
assess
overal
effect
compar
blood
product
utilizationwastag
patient
outcom
implement
backgroundcas
studi
preoper
anemia
affect
surgic
patient
increas
risk
red
blood
cell
rbc
transfus
preoper
anemia
periop
rbc
transfus
associ
increas
risk
advers
outcom
follow
surgeri
preoper
treatment
anemia
includ
oral
intraven
iv
iron
erythroid
stimul
agent
esa
erythropoietin
epo
howev
optim
treatment
strategi
preoper
anemia
remain
establish
object
evalu
efficaci
safeti
esa
iron
therapi
base
effect
preval
rbc
transfus
advers
thrombot
event
studi
designmethod
search
cochran
central
regist
control
trial
medlin
embas
incept
juli
refer
list
publish
guidelin
review
associ
paper
well
confer
proceed
languag
restrict
appli
includ
random
control
trial
adult
patient
undergo
surgeri
receiv
either
esa
andor
iron
surgeri
versu
iron
intervent
three
author
independ
review
studi
extract
data
includ
trial
risk
bia
assess
includ
studi
applic
pool
risk
ratio
dichotom
outcom
mean
differ
continu
outcom
across
trial
use
randomeffect
model
primari
outcom
number
patient
transfus
red
blood
cell
secondari
outcom
includ
risk
mortal
thrombovascular
event
stroke
myocardi
infarct
deep
vein
thrombosi
pulmonari
embol
resultsfind
total
random
control
trial
conclus
amongst
patient
undergo
surgeri
administr
esa
addit
oral
iv
iron
associ
reduct
patient
requir
rbc
transfus
intraven
iron
less
effect
reduc
rbc
transfus
neither
treatment
associ
clear
increas
risk
advers
thrombot
event
addit
larg
prospect
random
control
trial
requir
determin
optim
manag
strategi
patient
undergo
surgeri
iron
restrict
anemia
evid
base
blood
therapeut
scott
neeley
stephani
roger
digniti
health
st
joseph
medic
center
digniti
health
backgroundcas
studi
million
unit
pack
red
blood
cell
prbc
transfus
annual
unit
state
clinic
basi
mani
half
transfus
random
prospect
trial
ever
demonstr
clinic
benefit
transfus
mild
moder
anem
patient
yet
larg
bodi
evid
shown
due
varieti
reason
includ
immunomodulatori
effect
storag
lesion
blood
transfus
caus
consider
harm
includ
higher
risk
hospit
acquir
bacteri
infect
transfus
relat
acut
lung
injuryacut
pulmonari
edema
acut
myocardi
infarct
higher
recurr
rebleed
higher
cancer
recurr
studi
designmethod
system
wide
goal
launch
across
hospit
decreas
number
prbc
transfus
given
clinic
stabl
patient
hemoglobin
hgb
level
gdl
numer
consist
prbc
unit
transfus
patient
hgb
gdl
greater
prior
transfus
denomin
consist
prbc
unit
transfus
exclus
includ
cardiac
surgeri
nurseri
nicu
pregnanc
postpartum
hemorrhag
massiv
transfus
protocol
transfus
prbc
unit
transfus
one
episod
data
extract
directli
electron
medic
record
hospit
receiv
patient
level
detail
everi
month
prbc
unit
transfus
patient
hgb
gdl
higher
prior
transfus
extens
educ
campaign
evidencebas
transfus
practic
launch
physician
nurs
includ
develop
blood
therapeut
toolkit
develop
standard
digniti
health
blood
therapeut
guidelin
one
day
blood
therapeut
advanc
train
symposium
onsit
visit
hospit
includ
cme
present
onlin
physician
nurs
educ
video
commun
tool
includ
infograph
new
button
develop
patient
educ
resourc
bimonthli
webinar
variou
educ
topic
speaker
addit
ehr
powerplan
revis
ensur
avail
select
transfus
indic
requir
field
align
evid
base
guidelin
facilti
encourag
develop
multidisciplinari
blood
therapeut
committe
review
transfus
given
patient
pretransfus
hgb
gdl
routin
basi
provid
feedback
provid
whose
transfus
deem
accord
current
evidencebas
guidelin
resultsfind
reduct
prbc
unit
transfus
patient
hgb
gdl
start
baselin
repres
annual
save
baselin
unit
per
patient
day
averag
unit
approxim
fewer
unit
transfus
per
month
conclus
blood
transfus
life
save
regard
organ
transplant
carri
consider
risk
transfus
stabl
nonbleed
patient
hgb
level
gdl
accord
evidencebas
guidelin
avoid
due
associ
potenti
harm
furthermor
potenti
harm
dose
depend
decis
transfus
made
one
unit
prbc
transfus
rather
two
three
af
studi
reduc
rbc
unit
two
studi
decreas
percentag
patient
transfus
fortythre
studi
show
intraven
tranexam
acid
reduc
percentag
patient
rbc
unit
transfus
qualitativemetaanalys
translat
recommend
expert
panel
approv
lmbp
workgroup
reduc
rbc
transfus
recommend
earli
assess
effect
rt
hb
alert
cpoecd
reduct
blood
loss
af
assess
percentag
patient
rbc
unit
transfus
across
case
physician
servic
area
discret
period
time
feedback
physician
continu
qualiti
improv
conclus
conclus
lmbp
method
led
evidencebas
recommend
reduc
transfus
critic
laboratori
support
need
achiev
continu
qualiti
patient
safeti
backgroundcas
studi
reduc
inappropri
use
blood
product
via
implement
evid
base
guidelin
main
tenet
patient
blood
manag
use
electron
decis
support
tool
best
practic
alert
bpa
enforc
red
blood
cell
rbc
transfus
threshold
shown
reduc
use
inform
order
provid
transfus
tool
use
date
provid
dose
rbc
transfus
fact
provid
continu
overtransfus
base
number
unit
rbc
given
therapeut
hemoglobinhematocrit
hgbhct
target
approach
rbc
indic
order
allow
calcul
dose
rbc
achiev
desir
target
could
reduc
use
rbc
unit
group
develop
comput
algorithm
calcul
rbc
dose
base
patient
specif
data
drawn
electron
medic
record
emr
use
select
patient
popul
prospect
appli
hospit
wide
clinic
practic
studi
describ
initi
experi
use
algorithm
nonsurg
rbc
transfus
studi
designmethod
blood
util
calcul
buc
mathemat
formula
draw
patient
specif
inform
includ
index
hgb
hct
calcul
dose
number
unit
rbc
transfus
order
achiev
select
target
hgbhct
hgbhct
target
base
indic
rbc
transfus
design
use
basi
rbc
order
set
eth
buc
embed
within
emr
rbc
order
set
provid
recommend
transfus
dose
number
unit
nonsurg
rbc
indic
select
target
hgbhct
indic
number
rbc
unit
order
transfus
track
prospect
order
indic
comparison
unit
transfus
per
month
buc
implement
perform
use
student
ttest
resultsfind
histor
three
nonsurg
rbc
indic
repres
approxim
total
rbc
transfus
prior
buc
mean
number
nonsurg
rbc
unit
transfus
unit
month
first
month
buc
activ
mean
number
unit
unitsmonth
reduct
unitsmonth
nonsurg
blood
use
ttest
nonsurg
rbc
use
repres
approxim
total
rbc
use
hospit
wide
reduct
chang
repres
signific
cost
save
rbc
time
conclus
use
target
base
transfus
indic
electron
decis
support
algorithm
calcul
recommend
transfus
dose
significantli
reduc
nonsurg
rbc
transfus
rate
provid
enhanc
patient
blood
manag
potenti
cost
save
implement
patient
blood
manag
commun
hospit
month
report
card
richard
gammon
oneblood
inc
backgroundcas
studi
collabor
blood
center
bc
consult
three
hospit
bed
healthcar
system
hc
implement
patient
blood
manag
pbm
program
undertaken
review
first
month
studi
designmethod
year
one
pbm
work
group
establish
achiev
includ
physician
engag
program
creation
transfus
committe
provid
nurs
educ
audit
process
implement
nonconform
letter
sent
physician
nurs
complianc
inform
consent
transfus
tag
threshold
discharg
instruct
achiev
year
two
creat
best
practic
alert
bpa
order
meet
transfus
threshold
criteria
bpa
show
first
line
associ
procedur
link
full
procedur
three
recent
lab
result
eg
hemoglobin
hematocrit
red
blood
cell
rbc
allow
order
physician
cancel
order
review
blood
administr
video
creat
mandatori
physician
grant
privileg
complet
within
six
month
low
vital
sign
complianc
requir
action
includ
reduc
requir
five
three
transfus
format
work
group
wg
address
knowledg
practic
gap
year
three
histor
hc
jehovah
wit
patient
jwp
present
pbm
wg
involv
implement
bloodless
medicin
program
step
care
address
includ
identifi
jwp
registr
creat
transfus
special
arm
band
form
bloodless
medicin
physician
group
implement
nurs
bpa
electron
medic
record
creat
advanc
direct
market
public
resultsfind
follow
monitor
complianc
vs
present
complet
consent
vs
present
complet
nurs
flow
sheet
vs
transfus
threshold
support
vs
discharg
instruct
provid
vs
vital
sign
complianc
jwp
increas
cost
save
realiz
decreas
util
implement
bpa
tabl
conclus
pbm
implement
hc
continu
multiyear
process
even
robust
program
challeng
vital
sign
complianc
remain
improv
patient
outcom
goldenhour
beatric
lebeuf
medic
citi
plano
backgroundcas
studi
emerg
medicin
golden
hour
refer
critic
onehour
time
period
follow
traumat
injuri
patient
higher
likelihood
surviv
nearli
half
trauma
relat
death
occur
first
hour
injuri
half
death
result
major
hemorrhag
rapid
administr
blood
product
vital
surviv
patient
implement
bloodtrack
emerg
haemonet
braintre
trauma
emerg
depart
ed
part
qualiti
improv
initi
effici
provid
group
rbc
thawedliquid
plasma
incom
trauma
patient
support
ratiobas
transfus
ensur
proper
handl
traceabl
regul
resourc
studi
designmethod
treat
approxim
trauma
patient
monthli
assess
current
blood
suppli
chain
reveal
multistep
manual
process
took
minut
prepar
physic
transport
cooler
blood
bank
ed
cooler
blood
provid
incom
trauma
patient
whether
end
need
transfus
practic
work
ensur
avail
blood
suppli
critic
moment
result
ineffici
unnecessari
inventori
tieup
percent
cooler
fulli
use
also
consum
valuabl
staff
time
technologist
typic
made
trip
per
month
blood
bank
ed
plu
effect
way
maintain
traceabl
control
access
cooler
monitor
usag
resultsfind
sinc
novemb
implement
bloodtrack
emerg
freed
technologist
perform
import
task
tighten
traceabl
inventori
control
procedur
contribut
medic
citi
plano
verif
level
trauma
center
rather
prepar
cooler
blood
case
may
need
emerg
situat
bloodtrack
emerg
provid
ed
staff
readi
access
emerg
unit
whenev
actual
need
free
estim
hour
tech
time
per
month
perform
task
audio
visual
alert
notifi
blood
bank
emerg
unit
remov
allow
quick
respons
plu
stock
emerg
blood
suppli
ed
blood
bank
nt
unnecessarili
tie
group
rbc
unit
today
blood
bank
stock
maintain
unit
group
rhd
neg
unit
rhd
posit
unit
group
thaw
plasma
liquid
plasma
bloodtrack
emerg
conclus
implement
bloodtrack
emerg
enabl
us
effect
provid
blood
product
incom
trauma
patient
support
ratiobas
transfus
improv
staff
effici
proactiv
respond
emerg
situat
backgroundcas
studi
platelet
limit
resourc
benefit
transfus
must
weigh
risk
aabb
publish
platelet
transfus
guidelin
assist
provid
academ
medic
center
comput
provid
order
entri
cpoe
system
combin
institut
transfus
guidelin
patient
recent
lab
result
guid
transfus
decis
discord
inform
activ
overrid
system
provid
prompt
select
prefix
indic
transfus
eg
count
kml
prophylaxi
option
add
freetext
comment
order
place
data
store
later
review
studi
designmethod
overrid
platelet
order
place
june
review
use
follow
data
prefix
indic
recent
platelet
count
freetext
comment
order
servicedepart
one
five
code
assign
order
iindic
ninot
indic
base
institutionalaabb
guidelin
nmine
inform
pprotocol
eg
liver
transplant
nicnonind
comment
eg
reserv
freetext
comment
categor
assign
one
keyword
order
determin
common
reason
overrid
resultsfind
period
cpoe
overrid
platelet
order
occur
percentag
code
assign
month
provid
tabl
overal
assign
indic
ni
top
keyword
assign
freetext
comment
platelet
count
less
activ
bleed
platelet
count
downtrend
mani
specifi
platelet
count
goal
certain
platelet
count
goal
reason
transfus
eg
downtrend
anticip
drop
per
servic
includ
institut
aabb
guidelin
note
overrid
place
hematologyoncolog
provid
conclus
major
overrid
platelet
order
determin
indic
base
institut
aabb
guidelin
concern
keyword
downtrend
anticip
drop
indic
transfus
expos
patient
unnecessari
transfus
unclear
whether
traine
progress
throughout
year
effect
order
practic
associ
overrid
pattern
review
suggest
potenti
benefit
provid
educ
initi
level
experi
particular
emphasi
hematologyoncolog
order
improv
blood
product
util
practic
backgroundcas
studi
earli
diagnosi
iron
defici
anemia
ida
clinic
laboratori
cl
effect
prevent
treatment
primari
care
may
impact
pack
red
blood
cell
prbc
transfus
well
intraven
iron
therapi
importantli
appli
lower
transfus
trigger
help
avoid
essenti
transfus
also
promot
health
wellb
improv
iron
statu
popul
result
describ
implement
process
prevent
ida
earli
detect
treatment
year
studi
designmethod
perform
measur
educ
organiz
intervent
set
public
integr
healthcar
system
locat
north
africa
border
morocco
isol
km
sea
distanc
nearest
continent
spain
airport
gener
hospit
blood
transfus
servic
establish
blood
donat
compon
product
cl
involv
anemia
detect
diagnosi
receiv
four
primari
care
center
hospit
base
sampl
share
common
leadership
blood
establish
process
guidelin
first
step
cl
diagnosi
ida
call
attent
primari
oral
iron
prevent
treatment
first
level
care
earli
intraven
iron
complex
inpati
sucros
outpati
carboxymaltos
transfus
avoid
stabl
ida
patient
without
activ
bleed
coronari
heart
diseas
safeti
hemoglobin
hb
threshold
sever
anem
patient
close
follow
ass
hb
increas
refer
etiolog
studi
hb
gdl
backgroundcas
studi
bedsid
nurs
critic
safeguard
deliveri
appropri
patient
care
recent
nurs
also
begun
play
import
role
patient
blood
manag
pbm
program
administr
level
although
knowledg
littl
publish
influenc
nurs
may
transfus
practic
bedsid
goal
studi
evalu
impact
nurs
patient
expect
physician
order
practic
studi
designmethod
short
electron
survey
question
prepar
assess
often
bedsid
nurs
discuss
transfus
necess
person
patient
physician
discuss
well
discuss
felt
appropri
lab
threshold
transfus
survey
distribut
regist
nurs
via
email
floor
leader
respons
also
solicit
hospit
volunt
lab
staff
electron
tablet
includ
coverag
night
shift
resultsfind
total
complet
respons
nurs
rang
experi
less
one
year
forti
year
nineti
percent
state
discuss
transfus
necess
patient
physician
report
proactiv
order
place
ninetysix
percent
said
would
discuss
transfus
suggest
patient
requir
blood
product
respond
would
suggest
product
need
nurs
percept
accept
transfus
threshold
wider
distribut
commonli
report
valu
hemoglobin
gdl
platelet
count
inr
greater
conclus
studi
demonstr
nurs
will
discuss
transfus
patient
provid
although
appear
comfort
set
perceiv
transfus
necess
limit
number
survey
respons
suggest
discomfort
level
educ
transfus
practic
along
distribut
perceiv
threshold
reluct
recommend
transfus
present
opportun
educ
empow
nurs
provid
appropri
patient
care
within
guidelin
pbm
program
backgroundcas
studi
use
red
blood
cell
per
inhabit
may
vari
fold
european
countri
reveal
may
substanti
room
blood
optim
strategi
patient
blood
manag
pbm
evidencebas
multidisciplinari
approach
aim
preserv
optimis
patient
blood
order
improv
clinic
outcom
object
studi
assess
effect
nationwid
pbm
program
public
health
portug
studi
designmethod
first
phase
research
project
involv
group
key
opinion
leader
kol
state
prefer
inquiri
assess
rel
valu
specif
pbm
strategi
group
pbm
pillar
highlight
need
strategi
priorit
implement
nationwid
pbm
polici
adapt
conjoint
analysi
techniqu
use
elicit
kol
prefer
second
phase
decis
analysi
model
use
estim
impact
pbm
implement
follow
therapeut
area
surgeri
orthopaed
cardiac
urolog
cardiolog
oncolog
gastrointestin
bleed
abnorm
uterin
bleed
haemodialysi
inflammatori
bowel
diseas
pregnanc
model
input
includ
effect
data
regard
transfus
util
health
resourc
consumpt
mortal
obtain
portugues
nation
health
databas
literatur
review
public
health
valu
pbm
implement
portug
deriv
comparison
two
scenario
current
clinic
practic
pbm
implement
resultsfind
kol
elicit
iron
administr
follow
restrict
transfus
red
blood
cell
prefer
pbm
strategi
remain
strategi
weight
vari
estim
patient
would
elig
pbm
strategi
one
year
time
horizon
result
prematur
death
avoid
reduct
correspond
gain
approxim
life
year
reduct
disabl
adjust
life
year
dali
rel
current
clinic
practic
decreas
inhospit
day
expect
mainli
due
reduct
hospit
length
stay
reduct
readmiss
rate
popul
overal
transfus
rate
could
decreas
current
reduct
impli
blood
transfus
avoid
red
blood
cell
unit
spare
conclus
anticip
implement
nationwid
patient
blood
manag
program
repres
paramount
improv
clinic
outcom
term
morbid
mortal
may
substanti
public
health
impact
contribut
effici
use
health
resourc
resultsfind
adult
liver
transplant
perform
evalu
period
preoper
hemoglobin
creatinin
meld
score
spontan
bacteri
periton
sbp
preoper
hemodialysi
gender
portal
vein
thrombosi
pvt
gave
strongest
model
predict
rbc
usag
model
predict
rbc
case
transfus
captur
time
use
rbc
predict
transfus
use
time
predict
usag
time
exceed
conclus
model
use
specif
preoper
factor
use
predict
intraop
rbc
usag
patient
risk
rbc
transfus
identifi
reason
accuraci
use
model
institut
use
model
might
help
improv
prepar
util
blood
bank
review
blood
order
practic
elect
surgeri
matern
hospit
qi
raymond
fu
kk
women
children
hospit
backgroundcas
studi
preoper
overord
blood
common
result
wast
blood
bank
resourc
blood
unit
withdrawn
pool
lead
constraint
alloc
limit
blood
resourc
meet
need
patient
crossmatch
transfus
ct
ratio
often
use
benchmark
effici
blood
util
within
hospit
blood
transfus
servic
accord
american
associ
blood
bank
aabb
ct
ratio
less
favor
anyth
indic
overord
crossmatch
blood
achiev
necessari
review
presurg
blood
order
practic
matern
hospit
studi
designmethod
data
elect
surgeri
requir
blood
standbi
collect
retrospect
month
period
jan
mar
detail
total
blood
crossmatch
issu
transfus
return
analyz
along
ct
ratio
resultsfind
month
period
patient
undergo
obstetr
gynecolog
procedur
requir
blood
standbi
total
unit
blood
request
unit
crossmatch
unit
sent
oper
theatr
ot
blood
issu
ot
transfus
rest
unutil
observ
ct
ratio
conclus
although
total
blood
request
crossmatch
ct
ratio
remain
recommend
guidelin
almost
crossmatch
blood
unutil
need
improv
standard
blood
order
practic
achiev
costeffect
reduc
unnecessari
workload
establish
adher
maximum
surgic
blood
order
schedul
msbo
could
help
conserv
blood
prevent
overord
blood
backgroundcas
studi
total
knee
arthroplasti
tka
major
orthopaed
procedur
increas
periop
blood
loss
periop
blood
loss
could
signific
patient
undergo
bilater
tka
singl
stage
increas
blood
loss
bilater
tka
often
requir
blood
transfus
result
high
postop
morbid
studi
designmethod
retrospect
studi
patient
receiv
tranexam
acid
txa
studi
group
patient
receiv
txa
surgeri
control
evalu
blood
loss
transfus
requir
studi
group
receiv
singl
bolu
dose
txa
iv
tourniquet
deflat
first
side
knee
statist
backgroundcas
studi
blood
product
util
increas
concern
hospit
system
attempt
reduc
transfusionassoci
risk
one
strategi
optim
util
employ
clinic
decis
support
form
alert
clinician
order
blood
product
investig
whether
alert
target
patient
transfus
indic
could
alter
provid
order
behavior
studi
designmethod
retrospect
observ
studi
cours
seven
month
includ
inpati
adult
medicin
floor
intens
care
unit
larg
academ
hospit
time
crossmatch
pack
red
blood
cell
prbc
order
via
hospit
electron
order
system
indic
eg
hemodynam
stabl
hemoglobin
gdl
must
select
indic
select
contain
threshold
hemoglobin
concentr
patient
recent
hemoglobin
record
greater
threshold
interrupt
alert
display
patient
hemoglobin
activ
order
provid
given
three
option
cancel
order
select
appropri
indic
list
provid
explan
via
free
text
transfus
request
outsid
approv
indic
alert
encount
defin
activ
patient
within
six
hour
period
without
interven
transfus
resultsfind
seven
month
uniqu
alert
encount
led
crossmatch
order
led
order
cancel
provid
like
cancel
transfus
respons
alert
hemodynam
stabl
patient
lower
hemoglobin
threshold
gdl
complic
patient
bleed
cardiovascular
diseas
preoper
higher
hemoglobin
threshold
gdl
backgroundcas
studi
maximum
surgic
blood
order
schedul
msbo
list
surgic
procedur
perform
along
recommend
extent
pretransfus
test
complet
surgeri
begin
improv
patient
data
manag
system
possibl
creat
msbo
base
actual
red
blood
cell
rbc
util
data
perpati
basi
studi
investig
transfus
pattern
academ
hospit
dataderiv
msbo
studi
designmethod
hospit
group
one
share
msbo
group
three
hospit
larg
academ
center
one
children
hospit
center
msbo
recommend
pretransfus
test
patient
transfus
specif
procedur
previou
year
preoper
type
screen
patient
transfus
crossmatch
median
number
rbc
transfus
patient
transfus
data
collect
center
month
period
januari
march
includ
maximum
case
per
hospit
one
month
ensur
equal
represent
center
resultsfind
center
total
case
analyz
frequent
perform
surgeri
includ
orthoped
case
gener
surgeri
cardiac
surgeri
order
case
posit
antibodi
day
surgeri
order
order
accord
msbo
recommend
order
msbo
recommend
one
order
msbo
recommend
one
backgroundcas
studi
peripartum
blood
transfus
common
south
africa
usa
recent
studi
demonstr
antenat
anemia
strong
risk
factor
transfus
odd
ratio
prenat
hemoglobin
hgb
therefor
analyz
etiolog
characterist
antenat
anemia
accord
hiv
statu
larg
hospit
hiv
preval
among
obstetr
patient
studi
designmethod
studi
sampl
anem
hgb
gdl
pregnant
women
refer
antenat
anemia
clinic
larg
hospit
south
africa
clinic
inform
abstract
blood
sent
laboratori
studi
ttest
use
compar
continu
variabl
group
resultsfind
total
women
enrol
median
age
interquartil
rang
year
median
gravida
para
median
gestat
age
week
mean
hgb
referr
gdl
alreadi
take
oral
iron
therapi
total
women
hiv
posit
mean
lymphocyt
count
cellsul
hiv
posit
subject
antiretrovir
therapi
art
prior
pregnanc
art
current
pregnanc
iron
defici
anemia
overwhelmingli
preval
diagnosi
present
women
concurr
chronic
diseas
infect
vitamin
defici
antenat
hemorrhag
otherunknownmiss
caus
anemia
pregnanc
relat
complic
hiv
posit
women
higher
level
creactiv
protein
slightli
lower
level
transferrin
solubl
transferrin
receptor
rbc
folat
hiv
neg
women
tabl
conclus
iron
defici
overwhelm
caus
antenat
anemia
among
south
african
pregnant
women
compar
hivneg
women
hivposit
women
evid
increas
inflamm
rel
littl
differ
iron
studi
earli
treatment
iron
lower
red
cell
folat
high
proport
hiv
posit
women
receiv
art
consist
nation
guidelin
futur
studi
examin
longerterm
respons
iron
therapi
assess
potenti
decreas
incid
peripartum
blood
transfus
backgroundcas
studi
month
old
boy
present
institut
month
hospit
japan
admit
sever
week
unremark
term
birth
ab
rh
posit
woman
lethargi
failur
thrive
bloodi
mucoid
stool
eosinophilia
elev
serum
white
count
found
anem
thrombocytopen
requir
multipl
transfus
also
diffus
scale
erythemat
rash
inner
thigh
studi
designmethod
initi
workup
suspic
allergicnecrot
enterocol
patient
elev
ldh
potassium
concern
rais
leukemia
possibl
tumor
lysi
syndrom
sampl
sent
blood
bank
show
anti
posit
dat
igg
complement
posit
e
e
c
antigen
concern
maternallyinduc
antibodi
rais
possibl
red
cell
antigen
passiv
transfus
blood
product
administ
japanes
hospit
possibl
exclud
workup
reveal
infect
hematolog
prolifer
biopsi
rash
show
spongiot
dermat
clinic
cours
deterior
develop
hepatomegali
jaundic
concern
wiskottaldrich
syndrom
rais
workup
show
normal
immunoglobulin
level
elev
ige
kul
rr
antiplatelet
antibodi
identifi
three
day
admiss
test
sent
genet
alter
japanesespeak
physician
institut
read
prior
flow
cytometri
studi
show
defici
lymphocyt
major
indic
seen
adult
report
plasma
wastag
fortun
pediatr
incid
indic
low
despit
heterogen
patient
popul
util
review
process
primari
pediatr
institut
note
mean
wastag
last
year
recent
chang
clinic
practic
liver
transplant
increas
trauma
recent
evid
faster
plasma
improv
massiv
transfus
protocol
mtp
outcom
facil
decid
implement
use
thaw
plasma
benchmark
mtp
plasma
wastag
studi
designmethod
blood
util
review
reveal
increas
overal
percentag
plasma
wastag
peak
rang
singl
caus
could
readili
identifi
prompt
us
queri
children
hospit
associ
cha
initi
extern
pediatr
benchmark
determin
wastag
compar
children
hospit
addit
review
time
plasma
avail
mtp
resultsfind
mtp
activ
time
case
patient
receiv
blood
product
case
plasma
alreadi
avail
time
rbc
allocationissu
left
case
evalu
median
time
plasma
avail
minut
rang
minut
minut
mean
plasma
wastag
mtp
activ
rang
cha
repli
use
thaw
plasma
wastag
conclus
increas
clinic
evid
support
prompt
transfus
plasma
set
mtp
decreas
morbid
mortal
brief
review
suggest
implement
thaw
plasma
allow
potenti
decreas
plasma
avail
minut
implement
began
thaw
singl
unit
plasma
level
neuro
trauma
alert
keep
singl
unit
ab
plasma
thaw
time
plasma
avail
time
rbc
thu
provid
effect
balanc
blood
product
support
reduc
wastag
preliminari
estim
level
consist
extern
benchmark
prospect
evalu
practic
ongo
institut
includ
collabor
clinic
assess
trauma
team
ultim
prospect
multiinstitut
studi
pediatr
institut
necessari
defin
best
clinic
practic
effect
benchmark
blood
bank
practic
backgroundcas
studi
bacteri
fungal
infect
remain
signific
caus
morbid
mortal
sever
neutropen
patient
hematolog
diseas
receiv
highdos
chemotherapi
hematopoiet
stem
cell
transplant
hsct
granulocyt
transfus
gtx
use
year
although
effect
indic
patient
donor
safeti
remain
debat
particularli
children
contribut
discuss
demonstr
case
gtx
pediatr
patient
age
month
year
old
neutropen
sever
infect
resist
antibiot
andor
antifung
therapi
undergo
hsct
chemotherapi
studi
designmethod
donor
data
concern
total
granulocyt
donat
collect
health
donor
male
femal
donor
match
blood
type
serolog
statu
cytomegaloviru
patient
neg
granulocyt
mobil
singl
dose
rhugcsf
filgrastim
subcutan
donor
maximum
oral
dexamethason
prior
apheresi
apheresi
perform
use
cobe
spectra
v
r
spectra
optia
v
r
citrat
anticoagul
product
irradi
resultsfind
granulocyt
number
increas
time
basal
level
median
cell
collect
rang
gener
donor
report
signific
advers
reaction
donat
report
light
paresthesia
procedur
patient
patient
medic
prior
transfus
diphenhydramin
acetaminophen
product
transfus
within
hour
collect
effort
transfus
soon
possibl
detail
transfus
describ
tabl
advers
reaction
patient
minor
frequent
gtx
includ
vomit
hypotens
headach
resolv
without
seriou
last
complic
assum
gtx
well
toler
conclus
studi
provid
evid
gtx
transfus
safe
perform
pediatr
patient
irina
kumukova
elena
kurnikova
pavel
trakhtman
russian
institut
paediatr
haematolog
oncolog
immunolog
instituteffor
pediatr
hematolog
oncolog
immunolog
backgroundcas
studi
infect
caus
major
mortal
among
person
prolong
neutropenia
relat
hsct
chemotherapi
among
patient
granulocyt
disord
granulocyt
transfus
therapi
logic
approach
treat
patient
infect
refractori
antibiot
want
demonstr
granulocyt
transfus
experi
children
neutropenia
defect
immun
system
sever
infect
studi
designmethod
analyz
retrospect
data
period
donor
underw
granulocyt
mobil
gcsf
dose
mgkg
sc
hr
prior
donat
granulocyt
collect
cobe
spectra
caridianbct
analysi
perform
microsoft
excel
nonparametr
mannwhitney
spearman
test
resultsfind
perform
granulocyt
collect
donor
f
age
mean
increment
wbc
stimul
age
group
year
year
mean
increment
wbc
respect
mean
volum
treat
blood
mean
number
total
wbc
product
l
three
donor
apheresisrel
advers
effect
analysi
includ
granulocyt
transfus
case
infecti
complic
patient
mean
number
transfus
patient
receiv
transfus
mean
donor
granulocyt
transfus
start
mean
day
infect
mean
dose
wbc
transfus
wbc
increment
abl
estim
transfus
wbc
increment
record
transfus
mean
increment
efficaci
determin
number
patient
surviv
infect
episod
amount
case
sever
sepsi
efficaci
transfus
frequenc
posttransfus
reaction
n
febril
nonhemolyt
reaction
n
pulmonari
complic
n
antihla
antibodi
format
n
conclus
signific
differ
mobil
granulocyt
product
volum
men
women
age
group
find
signific
relationship
baselin
wbc
increment
stimul
mean
total
wbc
collect
product
mean
volum
treat
blood
men
women
significantli
differ
perhap
reason
lower
cell
product
women
treat
smaller
blood
volum
lack
increment
wbc
transfus
equival
lack
efficaci
found
signific
associ
transfus
dose
increment
wbc
deliber
estim
data
treatment
patient
sepsi
sever
infect
patient
receiv
receiv
granulocyt
transfus
need
transfus
granulocyt
indic
sever
patient
infect
neutropenia
dysfunct
immun
system
refractori
antibiot
hemolyt
diseas
newborn
due
keegan
barryholson
jennif
andrew
stanford
univers
dept
patholog
stanford
univers
dept
patholog
pediatr
backgroundcas
studi
rare
antibodi
high
incid
red
blood
cell
rbc
antigen
ag
present
peopl
common
rh
phenotyp
ag
miss
individu
rh
null
rh
delet
phenotyp
includ
individu
strongli
express
lack
c
c
e
e
ag
clinic
relev
primarili
report
pregnant
women
caus
mild
fatal
hemolyt
diseas
newborn
hdn
present
rare
case
hdn
due
alloimmun
pregnanc
mother
studi
designmethod
oposit
full
term
infant
born
oposit
mother
neg
st
trimest
antibodi
screen
prior
transfus
two
prior
pregnanc
first
result
normal
term
singleton
second
result
spontan
miscarriag
st
trimest
father
blood
type
unknown
presum
rh
antigen
infant
transfer
institut
hour
life
found
anemia
hemoglobin
gdl
sever
hyperbilirubinemia
total
bilirubin
bili
mgdl
reticulocytosi
posit
direct
antiglobulin
test
igg
admit
neonat
intens
care
unit
potenti
need
exchang
transfus
given
concern
hdn
treat
intraven
immunoglobulin
tripl
phototherapi
day
admiss
temporarili
blunt
hemolysi
bili
rose
maximum
day
life
phototherapi
restart
bili
subsequ
stabil
discharg
home
follow
clinic
meanwhil
mother
donat
blood
given
compat
red
blood
cell
avail
unit
state
via
rare
donor
queri
nine
day
discharg
readmit
worsen
anemia
hemoglobin
gdl
given
steroid
wash
matern
red
blood
cell
discharg
follow
clinic
sever
month
ultim
resolut
anemia
hyperbilirubinemia
resultsfind
deliveri
mother
antibodi
screen
posit
identifi
alloantibodi
detect
antibodi
identif
perform
use
polyethylen
glycol
low
ionic
strength
solut
ficin
enhanc
matern
serum
pan
reactiv
panel
cell
nonreact
cell
sera
react
matern
rbc
phenotyp
mother
reveal
cece
molecular
test
confirm
genotyp
molecular
beadchip
test
yield
type
due
low
signal
e
e
v
vs
ag
genotyp
rh
variant
target
genom
rhce
test
fail
detect
sever
rhce
exon
father
unavail
test
conclus
report
rare
case
hdn
due
antibodi
mother
hope
obtain
laboratori
studi
matern
rel
given
rariti
phenotyp
gener
popul
studi
import
implic
genet
counsel
mother
sister
manag
sever
autoimmun
hemolyt
anemia
case
report
infant
treat
manual
whole
blood
exchang
rapid
clinic
improv
yunchuan
delor
mo
cyril
jacquot
valli
criss
philipp
p
pari
jay
greenberg
naomi
lc
luban
edward
cc
wong
children
nation
medic
center
quest
diagnost
backgroundcas
studi
manag
sever
autoimmun
hemolyt
anemia
aiha
present
lifethreaten
anemia
challeng
particularli
pediatr
popul
mortal
rate
aiha
typic
low
howev
children
rate
may
high
although
corticosteroid
immunomodulatori
therapi
first
line
modal
sever
case
report
describ
use
manual
whole
blood
exchang
wbex
success
treat
aiha
older
children
adult
refractori
first
line
treatment
knowledg
first
case
report
infant
sever
aiha
success
treat
manual
wbex
acut
care
set
studi
designmethod
case
report
format
resultsfind
monthold
previous
healthi
femal
patient
present
emerg
depart
hemodynam
instabl
nadir
hemoglobin
hb
hematocrit
hct
wbc
count
x
l
mildli
elev
platelet
count
x
l
within
normal
limit
histori
notabl
upper
respiratori
tract
infect
day
prior
onset
anemia
laboratori
studi
admiss
show
hyperbilirubinemia
total
mgdl
direct
mgdl
normal
ldh
ul
undetect
haptoglobin
mgdl
indic
ongo
hemolysi
clinic
symptom
includ
diffus
jaundic
hemoglobinuria
lethargi
emesi
admit
pediatr
intens
care
unit
manag
includ
right
intern
jugular
central
venou
cathet
placement
due
poor
peripher
vascular
access
patient
blood
group
rh
neg
posit
antibodi
screen
panel
demonstr
strong
panagglutinin
reactiv
posit
autocontrol
dat
posit
antiigg
neg
despit
posit
cold
antibodi
screen
patient
weigh
kg
estim
total
blood
volum
ml
initi
receiv
simpl
transfus
total
mlkg
least
incompat
group
rh
neg
rbc
increment
respons
manual
wbex
perform
ml
reconstitut
whole
blood
consist
rh
neg
rbc
ab
fresh
frozen
plasma
ffp
hct
util
central
venou
cathet
advers
event
took
place
cours
hour
exchang
one
hour
postexchang
hb
g
dl
subsequ
antibodi
screen
demonstr
reduc
intens
panagglutinin
initi
steroid
therapi
methylprednisolon
mgkgday
continu
improv
clinic
one
week
later
patient
discharg
home
hb
gdl
one
month
later
experienc
recurr
hemolysi
requir
rehospit
time
normal
igm
iga
level
markedli
elev
igg
level
mgdl
subsequ
followup
visit
month
initi
present
anemia
resolv
complet
wean
steroid
conclus
demonstr
case
sever
neonat
aiha
success
treat
manual
wbex
main
advantag
wbex
includ
remov
autolog
rbc
plasma
well
infus
allogen
rbc
case
manual
exchang
transfus
avoid
need
autom
apheresi
procedur
requir
citrat
anticoagul
summari
manual
wbex
potenti
safe
procedur
may
perform
young
children
sever
aiha
abstract
oper
room
experienc
bloodcolor
urin
laboratori
evid
hemolysi
acut
kidney
injuri
cleric
serolog
investig
reveal
caus
hemolysi
mechan
hemolysi
transfus
rate
cathet
gaug
recent
introduc
oneway
valv
consid
studi
designmethod
vitro
simul
transfus
perform
via
syring
measur
includ
hematocrit
hct
free
hemoglobin
visual
hemolysi
index
wash
unwash
red
blood
cell
rbc
test
without
oneway
valv
use
gaug
g
intraven
iv
cathet
oneway
valv
use
test
three
ident
sampl
constant
pressur
appli
manual
rapidli
ml
second
mechan
syring
pump
slowli
mlmin
subset
manual
transfus
time
control
sampl
baselin
measur
collect
graviti
drip
without
pass
oneway
valv
cathet
resultsfind
oneway
valv
increas
hemolysi
markedli
rapid
transfus
use
cathet
well
wash
unwash
rbc
see
tabl
cathet
mean
chang
hct
oneway
valv
without
p
compar
oneway
valv
test
differ
hemolysi
observ
chang
hct
p
rapid
manual
transfus
cathet
unwash
rbc
hemolysi
greater
sampl
took
longer
transfus
use
oneway
valv
chang
hct
versu
time
p
compar
significantli
differ
slight
increas
hemolysi
sampl
took
less
time
transfus
use
oneway
valv
chang
hct
versu
time
correl
time
hemolysi
similar
insignific
use
wash
rbc
iv
cathet
conclus
mechan
hemolysi
consid
investig
possibl
hemolyt
transfus
reaction
especi
high
rate
transfus
use
oneway
valv
rapid
manual
transfus
oneway
valv
greater
resist
associ
increas
hemolysi
backgroundcas
studi
gerbich
ge
antigen
express
glycophorin
c
present
popul
ge
antibodi
caus
delay
hemolyt
transfus
reaction
hemolyt
diseas
fetu
newborn
hdfn
ge
antibodi
also
suppress
erythropoiesi
result
lateonset
anemia
report
case
hdfn
due
studi
designmethod
woman
paraguayan
origin
prior
termin
pregnanc
present
week
gestat
passiv
antid
titer
dand
ge
antigen
type
obstetrician
schedul
matern
blood
collect
near
due
date
possibl
neonat
transfus
woman
went
labor
week
cord
blood
dat
posit
igg
eluat
confirm
antid
birth
hemoglobin
hgb
gdl
reticulocyt
retic
bilirubin
bili
mgdl
infant
discharg
day
life
infant
refer
pediatr
hematolog
lethargi
poor
feed
hgb
gdl
retic
bili
mgdl
avail
blood
center
rare
donor
registri
mother
b
rhand
babi
b
obstetr
author
matern
blood
donat
due
hgb
gdl
matern
blood
collect
rbc
wash
expedit
infant
receiv
matern
rbc
within
hour
time
hgb
gdl
posttransfus
hgb
gdl
one
week
later
infant
symptomat
hgb
gdl
retic
bili
mgdl
nd
aliquot
wash
matern
cell
transfus
two
week
thereaft
infant
hgb
gdl
retic
titer
need
anoth
transfus
matern
blood
store
week
hemolyz
necessit
matern
donat
babi
rd
transfus
week
infant
titer
hgb
gdl
retic
transfus
necessari
week
life
hgb
gdl
retic
babi
thrive
resultsfind
serolog
studi
hospit
refer
blood
center
confirm
antibodi
risk
hdfn
molecular
analysi
reveal
mother
homozyg
ge
father
homozyg
wild
type
ge
infant
heterozyg
ge
conclus
infant
hdfn
due
antibodi
high
preval
antigen
continu
need
transfus
consist
hemolysi
suppress
erythrocyt
product
caus
hemolysi
store
matern
blood
consist
absenc
glycophorin
c
case
demonstr
cooper
multidisciplinari
care
among
blood
bank
donor
center
obstetr
hematolog
rare
case
hdfn
result
success
neonat
outcom
backgroundcas
studi
patient
blood
manag
collabor
approach
optim
transfus
therapi
improv
patient
outcom
pediatr
blood
manag
one
size
fit
given
pauciti
clinic
trial
guid
evidencebas
practic
addit
pediatr
care
encompass
heterogen
patient
popul
appli
one
set
guidelin
difficult
standard
evidencebas
clinic
best
practic
regard
blood
product
usag
children
unnecessari
variat
occur
institut
design
robust
analyt
process
studi
baselin
clinic
practic
examin
blood
product
usag
plan
target
three
pediatr
subspecialti
highest
usag
establish
standard
order
decreas
variationunnecessari
transfus
studi
designmethod
data
base
encompass
admiss
outpati
visit
larg
tertiari
care
academ
children
women
hospit
establish
includ
relev
patient
demograph
diagnost
procedur
code
attend
physician
specialti
visitadmiss
relev
hematologycoagul
laboratori
result
blood
product
order
focus
rbc
order
given
tripicu
random
clinic
trial
result
support
hemoglobin
trigger
gdl
stabl
critic
ill
children
ffp
sinc
anecdot
note
mani
children
receiv
product
minim
elev
intern
normal
ratio
inr
valu
without
bleed
resultsfind
rbc
order
occur
top
three
patient
group
congenit
heart
diseas
patient
hematologyoncolog
patient
neonat
neonat
intens
care
unit
nicu
averag
hemoglobin
everi
patient
gdl
measur
hour
prior
rbc
order
placement
ffp
order
occur
top
three
patient
group
neonat
nicu
congenit
heart
diseas
patient
pediatr
intens
care
patient
averag
inr
everi
patient
measur
hour
prior
ffp
order
placement
conclus
design
robust
data
base
continu
updat
children
larg
tertiari
care
academ
children
hospit
serv
import
benchmark
pediatr
blood
util
plan
leverag
usag
pattern
make
relev
practic
chang
care
children
heterogen
set
ill
backgroundcas
studi
bacteri
contamin
plt
remain
ongo
threat
transfus
recipi
recent
psoralenbas
pr
technolog
reduc
replic
potenti
pathogen
store
plt
fda
approv
describ
approach
phase
prplt
inventori
includ
preliminari
result
ongo
qa
studi
neonat
pediatr
ped
recipi
prplt
studi
designmethod
arriv
prplt
undertook
educ
campaign
hospit
administr
staff
laboratori
staff
clericalclin
aid
nurs
physician
also
contact
risk
manag
hospit
ethic
committe
phototherapi
devic
use
hospit
confirm
compat
psoralenbas
prplt
product
shortli
follow
arriv
prplt
introduc
day
bacteri
safeti
measur
test
convent
cplt
suppli
ped
qa
studi
monitor
plt
util
advers
transfus
event
report
relat
prand
cplt
transfus
studi
evalu
neonat
month
age
infant
month
age
children
year
age
receiv
least
one
transfus
prplt
resultsfind
risk
manag
ethic
committe
agre
prplt
bacteria
test
cplt
would
hospit
standard
care
prplt
phase
transfus
patient
base
abo
compat
expir
date
per
routin
without
regard
patient
age
medic
condit
month
prplt
repres
platelet
inventori
averag
daili
plt
inventori
unit
encount
complic
pr
platelet
phasein
either
clinic
informat
logist
perspect
due
dual
inventori
mani
ped
patient
age
group
transfus
prand
cplt
tabl
two
potenti
transfus
reaction
tr
report
studi
period
teenag
recipi
one
associ
cplt
prplt
case
symptom
ultim
attribut
underli
medic
condit
rash
observ
among
transfus
neonat
receiv
prplt
phototherapi
backgroundcas
studi
pack
red
blood
cell
prbc
transfus
believ
improv
oxygen
deliveri
particularli
vulner
patient
neonat
children
howev
evid
show
hemoglobin
hgb
prbc
increas
oxygen
affin
thu
reduc
oxygen
deliveri
tissu
due
decreas
dpg
level
standard
prbc
transfus
practic
popul
scientif
evid
current
practic
base
limit
addit
due
small
transfus
volum
infant
may
expos
multipl
blood
donor
increas
potenti
advers
event
studi
designmethod
medic
record
pediatr
patient
receiv
prbc
transfus
month
period
retrospect
review
total
patient
identifi
receiv
allogen
prbc
transfus
patient
receiv
autolog
blood
cell
salvag
exclud
patient
characterist
length
stay
prbc
transfus
volum
preand
posttransfus
hgb
advers
event
collect
resultsfind
averag
pretransfus
hgb
gdl
posttransfus
hgb
rise
gdl
mean
prbc
volum
transfus
ml
use
dose
patient
complic
note
volum
overload
thrombosi
feverinfect
hemolysi
necrot
enterocol
nec
death
tabl
conclus
evid
base
transfus
guidelin
lack
neonat
infant
typic
dose
mlkg
kg
patient
instanc
would
translat
full
prbc
unit
ml
averag
size
adult
current
standard
dose
mlkg
yield
high
increas
hgb
may
put
patient
risk
advers
outcom
especi
thrombosi
due
increas
blood
viscos
addit
mani
patient
receiv
volum
reduc
product
deliv
higher
hgb
concentr
per
transfus
dose
base
goal
hgb
patient
condit
rather
weight
base
though
hematocrit
level
benefit
outweigh
risk
remain
unclear
pneumonia
rare
associ
warm
autoimmun
hemolyt
anemia
case
report
suggest
associ
howev
case
confound
find
addit
mycoplasma
infect
describ
uniqu
case
pediatr
patient
clear
evid
sever
hemolysi
strongli
reactiv
warm
autoantibodi
clinic
laboratori
evid
mycoplasma
infect
without
detect
cold
agglutinin
studi
designmethod
patient
previous
healthi
femal
infant
present
hospit
histori
fever
fatigu
decreas
appetit
pallor
treat
acetaminophen
also
develop
clear
rhinorrhea
day
hospit
admiss
time
admiss
laboratori
test
outsid
hospit
reveal
hemoglobin
hematocrit
gdl
respect
platelet
reticulocyt
count
element
complet
blood
count
within
normal
refer
rang
age
complet
metabol
panel
reveal
abnorm
except
total
bilirubin
mgdl
direct
fraction
mgdl
filmarray
respiratori
panel
biofir
diagnost
salt
lake
citi
ut
detect
mycoplasma
pneumonia
pathogen
total
nondetect
patient
start
cours
azithromycin
zithromax
resultsfind
prior
rbc
transfus
blood
bank
evalu
reveal
patient
oposit
stronglyreact
antibodi
screen
test
demonstr
antibodi
reactiv
reagent
red
blood
cell
dat
strongli
reactiv
igg
weakli
reactiv
eluat
reactiv
reagent
red
cell
test
final
cold
agglutinin
studi
neg
undilut
serum
addit
start
azithromycin
patient
given
iv
methylprednisolon
hospit
cours
patient
receiv
rbc
transfus
day
admiss
sever
rbc
transfus
thereaft
see
tabl
despit
transfus
hemolyt
process
persist
infus
dose
iv
immunoglobulin
hospit
day
hemoglobin
rose
gdl
hospit
day
increas
gdl
hospit
day
time
patient
discharg
hospit
instruct
wean
oral
steroid
dose
next
week
follow
close
hematolog
clinic
found
stabl
hemoglobin
gdl
day
hospit
admiss
recurr
hemolyt
process
conclus
pneumonia
infect
typic
caus
cad
rare
associ
warm
autoimmun
hemolyt
anemia
case
demonstr
clear
evid
sever
warm
autoimmun
hemolysi
previous
healthi
infant
increas
use
multiplex
respiratori
viral
bacteri
pathogen
detect
system
rare
phenomenon
pneumonia
infect
associ
warm
autoimmun
hemolyt
anemia
may
becom
recogn
entiti
may
serv
reliabl
reflect
neonat
risk
hyperbilirubinemia
difficulti
elimin
cord
blood
test
neonatologist
relianc
use
abo
incompat
part
neonat
risk
assess
rather
use
point
care
bilirubin
test
current
ts
requir
posit
dat
test
commun
nurs
staff
immedi
given
dat
strength
posit
correl
percentag
neonat
diagnos
hyperbilirubinemia
ts
staff
may
also
consid
notifi
nurs
staff
patient
whose
dat
platelet
leukocyt
immunohematolog
test
genet
tabl
pair
pair
complet
match
pair
partial
match
pair
complet
mismatch
match
rate
studi
conclus
match
rate
hla
match
unrel
hematopoiet
stem
cell
transplant
low
gene
frequenc
unrel
hematopoiet
stem
cell
transplant
obtain
help
studi
relationship
unrel
hematopoiet
stem
cell
transplant
work
sponsor
nation
scienc
foundat
china
backgroundcas
studi
thrombot
thrombocytopen
purpura
ttp
caus
sever
reduc
activ
von
willebrand
factorcleav
proteas
therapeut
plasma
exchang
tpe
well
immunosuppress
minim
morbid
potenti
mortal
present
absolut
immatur
platelet
count
aipc
shown
help
diagnos
follow
ttp
patient
respons
therapi
report
case
man
relaps
ttp
low
high
inhibitor
treat
mycophenol
mofetil
aipcind
unexpect
respons
therapi
studi
designmethod
year
old
male
histori
ttp
present
statu
epilepticu
complic
acut
respiratori
failur
admit
suspicion
relaps
ttp
patient
treat
prior
admiss
tpe
prednisolon
rituximab
cyclophosphamid
clinic
improv
mycophenol
mofetil
mainten
therapi
last
receiv
prior
day
admiss
due
consist
low
platelet
count
inhibitor
day
admiss
platelet
count
x
l
decreas
within
five
day
x
l
lead
initi
daili
tpe
along
mycophenol
mofetil
discontinu
prior
tpe
start
immatur
platelet
fraction
ipf
calcul
aipc
ipf
x
platelet
count
obtain
daili
pretp
cbc
aipc
ratio
calcul
baselin
abstract
resultsfind
aipc
platelet
count
x
l
x
l
respect
count
improv
rapidli
posttp
initi
one
tpe
aipc
tripl
x
l
achiev
ratio
previous
shown
diagnost
ttp
day
aipc
platelet
count
improv
x
l
x
l
respect
absenc
antibodi
rule
heparininduc
thrombocytopenia
time
day
unexpect
decreas
aipc
platelet
count
x
l
x
l
respect
worsen
day
x
l
x
l
respect
despit
daili
tpe
patient
receiv
addit
tpe
fail
improv
aipc
platelet
day
x
l
x
l
respect
aipc
remain
level
day
suggest
observ
decreas
irrevers
activ
remain
low
high
inhibitor
patient
clinic
condit
continu
deterior
famili
place
patient
comfort
care
conclus
ttp
patient
low
aipc
plt
count
present
former
improv
first
posttp
initi
despit
appropri
therapi
lead
earli
improv
platelet
count
patient
count
declin
rapidli
lead
suspicion
platelet
product
suppress
indic
sustain
low
aipc
set
ttp
relaps
ttp
use
immunosuppress
close
follow
aipc
may
aid
establish
earli
therapi
affect
platelet
product
applic
luminex
bead
technolog
detect
antibodi
sudan
tao
ying
liu
yanmin
ji
fame
zhu
blood
center
zhejiang
provinc
key
laboratori
blood
safeti
research
ministri
health
backgroundcas
studi
detect
antibodi
human
platelet
antigen
hpa
crucial
patient
refractori
platelet
transfus
therapi
text
luminex
bead
coupl
antigpiibiiia
antigpiaiia
monoclon
antibodi
impli
detect
antibodi
sensit
luminex
bead
technolog
compar
monoclon
antibodi
immobil
platelet
antigen
maipa
assay
studi
designmethod
monoclon
antibodi
specif
platelet
glycoprotein
gpiibiiia
gpiaiia
separ
coupl
luminex
xmap
bead
four
standard
sera
contain
respect
bought
nibsc
three
neg
sera
without
hpa
antibodi
prepar
ab
type
blood
donor
platelet
contain
collect
react
standard
sera
respect
antigenantibodi
reaction
complex
lyse
lysat
incub
luminex
bead
specif
captur
antigenantibodi
complex
via
epitop
platelet
glycoprotein
beadsantigenantibodi
complex
subject
flow
cytometr
analysi
serum
dilut
serial
dilut
neat
test
sensit
maipa
luminex
bead
assay
two
method
use
test
five
blind
sampl
collect
fmait
patient
resultsfind
luminex
bead
technolog
show
mfi
valu
standard
sera
sampl
react
coupl
bead
significantli
higher
neg
control
vs
impli
luminex
bead
technolog
could
specif
identifi
neg
posit
sera
furthermor
platelet
serum
react
coupl
bead
mfi
compar
neg
control
vs
sera
retest
maipa
result
compar
luminex
bead
technolog
illustr
detect
hpa
antibodi
luminex
bead
technolog
success
sensit
luminex
bead
assay
maipa
detect
respect
crossreact
observ
sampl
contain
hla
abo
platelet
antibodi
result
five
blind
sampl
test
luminex
assay
show
four
sera
posit
gpiibiiia
antibodi
consist
maipa
result
conclus
luminex
bead
coupl
gpiibiiia
gpiaiia
monoclon
antibodi
could
success
use
detect
antibodi
via
epitop
platelet
glycoprotein
sensit
luminex
technolog
higher
maipa
technolog
ahu
thrombot
microangiopathi
tma
character
triad
microangiopath
hemolyt
anemia
thrombocytopenia
renal
failur
absenc
infecti
toxin
literatur
suggest
presenc
pathogen
mutat
complement
protein
case
ahu
lack
welldefin
recommend
regard
test
genet
ahu
complement
pathway
mutat
analysi
expens
test
appropri
util
crucial
prevent
undu
health
care
cost
review
indic
genet
test
understand
physician
order
practic
determin
frequenc
pathogen
mutat
popul
studi
designmethod
perform
retrospect
review
case
refer
complement
pathway
mutat
analysi
nation
refer
laboratori
januari
decemb
clinic
histori
solicit
genet
counselor
case
classifi
author
primari
ahu
tma
renal
failur
without
identifi
caus
secondari
tma
tma
renal
failur
identifi
caus
previous
associ
tma
nontma
test
panel
identifi
variant
complement
protein
cfh
cfi
mcp
factor
b
thbd
dgke
classifi
vu
varianc
uncertain
signific
pathogen
benign
american
colleg
medic
genet
chi
squar
analysisfish
exact
test
use
determin
differ
proport
patient
pathogen
mutat
primari
ahu
versu
secondari
tma
independ
sampl
ttest
use
compar
differ
continu
variabl
primari
ahu
secondari
tma
resultsfind
patient
test
pathogen
mutat
detect
vu
patient
fulfil
criteria
tma
pathogen
mutat
found
group
vu
patient
primari
ahu
pathogen
mutat
vu
patient
secondari
tma
pathogen
mutat
vu
patient
pathogen
mutat
children
posit
famili
histori
ahu
recurr
diseas
patient
primari
ahu
significantli
lower
age
present
vs
yr
pvalu
higher
proport
pathogen
mutat
vs
pvalu
compar
patient
secondari
tma
gender
distribut
hemoglobin
nadir
serum
creatinin
level
similar
two
group
conclus
found
lower
frequenc
patient
pathogen
mutat
compar
report
literatur
data
suggest
patient
secondari
tma
care
evalu
prior
order
genet
test
without
tma
undergo
test
count
platelet
platelet
concentr
hematolog
analyz
sysmex
compar
flow
cytometr
method
farshid
ezligini
kjersti
roen
eriksen
annett
vetlesen
thoma
larsen
titz
geir
hetland
oslo
univers
hospit
univers
oslo
backgroundcas
studi
hematolog
analyz
made
count
whole
blood
sampl
often
use
qualiti
control
blood
compon
platelet
plt
concentr
pc
flow
cytometr
method
count
plt
pc
develop
valid
tool
van
der
meer
et
al
transfus
therefor
pertin
evalu
plt
count
bc
hematolog
analyz
valid
method
flow
cytomet
studi
designmethod
sampl
ten
apheresi
pc
buffi
coatderiv
pc
subject
plt
count
hematolog
analyz
horiba
abx
montpeli
franc
sysmex
toa
kobe
japan
imped
score
addit
dilut
stain
fitc
truecount
tube
bd
bioscienc
intern
bead
standard
measur
gallio
flow
cytomet
beckman
coulter
indianapoli
usa
result
analyz
pair
sampl
test
shown
blandaltmann
plot
resultsfind
mean
plt
valu
l
sd
count
sysmex
toa
gallio
flow
cytomet
respect
sysmex
count
lowest
transfus
vol
supplement
abstract
less
flow
cytometri
plt
count
significantli
differ
p
although
least
pentra
flow
cytometri
conclus
valid
flow
cytometr
method
seem
suitabl
routin
qualiti
control
pc
small
differ
lower
count
compar
flow
cytometr
method
cumbersom
routin
set
much
lower
plt
count
sysmex
may
reflect
optim
plt
count
whole
blood
rather
pc
fast
precis
easi
hpa
type
realtim
pcr
jonathan
down
arishma
lata
roland
russnak
zachari
antovich
heather
dunckley
thierri
viard
new
zealand
blood
servic
linkag
bioscienc
backgroundcas
studi
interact
membranebound
plateletspecif
glycoprotein
extracellular
matrix
play
signific
role
hemostasi
human
platelet
antigen
hpa
found
within
glycoprotein
stimul
product
antibodi
recipi
transfus
platelet
fetu
mother
incompat
hpa
thu
platelet
incompat
associ
variou
form
thrombocytopenia
posttransfus
purpura
blood
disord
new
zealand
blood
servic
perform
hpa
type
pool
platelet
donor
provid
compat
transfus
need
aris
molecular
basi
hpa
character
gener
caus
singlenucleotid
polymorph
snp
hpa
type
typic
perform
use
pcrssp
method
util
timeconsum
post
pcr
analysi
step
aim
studi
evalu
use
realtim
pcrbase
techniqu
transfus
laboratori
set
studi
designmethod
evalu
commerci
avail
solut
consist
reaction
identifi
variant
relev
snp
locat
within
hpa
gene
hpa
genom
dna
purifi
blood
sampl
previous
genotyp
hous
pcrssp
method
use
studi
valid
sampl
resultsfind
result
valid
sampl
concord
type
obtain
pcrssp
realtim
pcr
approach
overcom
major
challeng
hpa
molecular
type
provid
autom
solut
result
increas
laboratori
product
decreas
turnaround
time
analysi
facilit
softwar
gener
result
less
minut
handson
setup
oper
intervent
reagent
complet
molecular
genotyp
result
provid
approxim
minut
sinc
amplifi
product
never
handl
risk
laboratori
contamin
significantli
reduc
realtim
pcr
approach
autom
analysi
implement
new
zealand
blood
servic
tissu
type
laboratori
late
date
test
dna
sampl
blood
donor
donor
test
duplic
concord
sampl
replic
occas
assay
repeat
give
repeat
rate
occasion
reaction
peak
insuffici
trigger
softwar
automat
allel
call
manual
interpret
requir
occur
commonli
assay
conclus
realtim
pcr
autom
analysi
provid
effect
robust
accur
method
molecular
hpa
genotyp
minim
handson
time
workflow
also
easi
implement
offer
cost
effect
altern
classic
method
use
transfus
laboratori
set
genet
variat
antigen
defici
express
jiangsu
chines
han
popul
qing
chen
jianyu
xiao
chengyin
huang
jiangsu
provinc
blood
center
jiangsu
provinc
blood
center
backgroundcas
studi
implic
platelet
refractori
neonat
alloimmun
thrombocytopenia
posttransfus
purpura
especi
noncaucasian
defici
vari
wide
among
differ
ethnic
popul
frequenc
asian
african
american
respect
howev
littl
inform
molecular
basi
individu
defici
jiangsu
chines
han
popul
studi
designmethod
investig
platelet
express
level
determin
molecular
basi
defici
platelet
surfac
han
popul
jiangsu
region
express
level
platelet
detect
flow
cytometri
among
blood
donor
jiangsu
region
donor
without
antigen
express
platelet
surfac
determin
express
antigen
peripher
blood
monocyt
cell
code
exon
gene
adjac
intron
amplifi
sequenc
defici
individu
resultsfind
among
blood
donor
individu
respect
frequenc
type
type
ii
defici
among
studi
popul
respect
among
individu
platelet
express
accord
mean
fluoresc
intens
mfi
valu
individu
show
low
moder
high
express
level
respect
mfi
p
respect
type
defici
individu
heterozyg
g
g
respect
among
type
ii
defici
individu
two
harbor
insert
posit
exon
caus
frameshift
codon
one
c
exchang
posit
exon
result
tryptophan
arginin
substitut
codon
one
insert
bp
start
codon
atg
promot
region
one
heterozyg
c
g
respect
conclus
platelet
surfac
express
level
diversifi
jiangsu
chines
han
popul
frequenc
type
ii
defici
higher
type
studi
find
indic
frequenc
defici
chines
popul
slightli
lower
asian
countri
backgroundcas
studi
phenotyp
immun
pregnanc
transfus
involv
neonat
alloimmun
thrombocytopenia
platelet
transfus
refractori
disord
frequenc
platelet
individu
wide
vari
among
ethnic
group
japanes
subsaharan
african
african
american
caucasian
although
studi
defici
focus
asian
popul
rel
littl
inform
report
chines
popul
investig
express
platelet
larg
sampl
eastern
chines
donor
studi
designmethod
peripher
blood
sampl
collect
unrel
plateletapheresi
donor
eastern
china
express
antigen
platelet
determin
flow
cytometri
use
fluorescein
conjug
monoclon
antibodi
isotyp
control
fitcmous
igg
also
analyz
calcul
refer
rang
phenotyp
donor
platelet
antigen
express
monocyt
analyz
distinguish
type
type
ii
defici
flow
cytometr
paramet
statist
analyz
mannwhitney
test
work
support
nation
natur
scienc
foundat
china
zhejiang
highlevel
innov
health
talent
resultsfind
mfi
mean
fluoresc
intens
platelet
sampl
show
continu
distribut
profil
obviou
fluorescencegap
could
util
distinguish
neg
posit
phenotyp
account
limit
classifi
phenotyp
use
mean
background
mfi
observ
isotyp
control
fortythre
sampl
detect
defici
platelet
one
sampl
neg
platelet
monocyt
frequenc
type
type
ii
defici
eastern
chines
donor
respect
averag
mfi
defici
sampl
significantli
lower
posit
sampl
vs
p
conclus
frequenc
platelet
defici
eastern
chines
donor
close
japanes
african
american
mean
possibl
antibodi
occur
pregnanc
transfus
popul
exist
use
find
regist
donor
largesampl
screen
potenti
immun
thrombocytopenia
patient
antibodi
backgroundcas
studi
gpiv
chromosom
kda
glycoprotein
express
multipl
cell
type
includ
platelet
plt
monocyt
mono
erythroblast
although
rare
among
white
defici
observ
african
classifi
either
type
plt
mono
type
ii
plt
mono
acquir
type
ii
phenotyp
also
observ
set
myelodysplast
syndrom
md
type
individu
develop
alloantibodi
plt
refractori
neonat
alloimmun
thrombocytopenia
report
case
profound
plt
refractori
caus
patient
newli
diagnos
md
studi
designmethod
hla
antibodi
test
perform
commerci
beadbas
fluoresc
assay
phenotyp
plt
mono
patient
famili
member
perform
flow
cytometri
fc
stain
bone
marrow
perform
immunohistochemistri
plt
crossmatch
pltxm
perform
american
red
cross
pltspecif
alloantibodi
test
dna
sequenc
perform
commerci
refer
laboratori
resultsfind
patient
yearold
group
africanamerican
male
present
blurri
vision
lightheaded
complet
blood
count
find
signific
hemoglobin
gdl
plt
count
bone
marrow
biopsi
cytogenet
analysi
reveal
multilineag
dysplasia
blast
complex
karyotyp
del
consist
md
plt
refractori
workup
initi
repeat
plt
transfus
failur
correct
count
increment
cci
hla
antibodi
test
neg
class
panel
reactiv
antibodi
pra
patient
pltxmincompat
donor
trial
group
pltxmcompat
plt
unsuccess
cci
subsequ
test
pltspecif
alloantibodi
identifi
fcphenotyp
show
patient
mono
plt
consist
type
preliminari
dna
result
show
patient
heterozyg
apheresi
plt
unavail
blood
supplier
patient
children
grandson
screen
possibl
donor
show
normal
express
plt
trial
eltrombopag
romiplostim
attempt
improv
plt
count
repeat
hla
antibodi
test
day
demonstr
new
class
alloantibodi
pra
respons
transfus
apheresi
plt
rbc
given
plt
refractori
poor
prognosi
patient
opt
hospic
conclus
describ
patient
sever
plt
refractori
set
new
md
abnorm
absenc
plt
mono
support
congenit
type
although
contribut
patient
underli
md
exclud
rapid
platelet
donor
classif
hla
hpa
profil
leansequenc
without
dna
purif
dipika
patel
kristoph
fernandez
eric
senaldi
pascal
georg
michael
seul
ghazala
hashmi
biomolecular
analyt
central
jersey
blood
center
backgroundcas
studi
prophylact
platelet
transfus
standard
care
manag
thrombocytopenia
emerg
paradigm
person
medicin
select
cellular
product
accord
patient
immunomolecular
signatur
potenti
reduc
rate
antibodymedi
platelet
clearanc
thu
improv
treatment
efficaci
benefit
custom
transfus
therapi
long
recogn
http
routin
realtim
select
platelet
immunogenet
profil
remain
impract
current
method
dna
analysi
address
issu
evalu
process
platelet
donor
classif
use
buccal
swab
sampl
apheresi
platelet
donor
determin
combin
hla
class
hpa
signatur
without
dna
purif
use
novel
leansequenc
process
studi
designmethod
studi
protocol
inform
consent
evalu
process
collect
classifi
buccal
swab
sampl
adult
donor
made
donat
previou
month
sampl
label
studi
barcod
ship
weekli
biomolecular
analyt
bmx
prepar
crude
extract
leansequenc
novel
process
combin
proprietari
sampl
pool
strategi
protocol
elimin
mani
tradit
sampl
cleanup
step
briefli
prepar
crude
extract
sampl
amplifi
pool
analyz
separ
run
hla
class
b
c
latter
use
proprietari
design
limit
analysi
inform
allel
hla
sequenc
informationtheoret
design
permit
direct
allel
haplotyp
reconstruct
use
bmxproprietari
softwar
subset
crude
extract
purifi
analyz
side
side
posit
neg
control
resultsfind
crude
extract
buccal
swab
produc
viabl
profil
hpa
well
hla
class
signific
save
timetoresult
illustr
tabl
report
allel
frequenc
plateletantigen
hpa
consist
predominantli
caucasian
hispan
platelet
donor
popul
http
hw
equilibrium
similarli
hlaclass
haplotyp
frequenc
determin
conclus
leansequenc
lend
rapid
determin
hlaclass
hpa
signatur
platelet
process
streamlin
lean
protocol
achiev
addit
time
cost
save
accommod
crude
extract
produc
buccal
swab
sampl
collect
handl
accord
process
valid
project
process
could
readili
implement
anoth
site
use
element
process
develop
pool
plex
process
earli
donor
recruit
enabl
economi
scale
match
donor
procur
serolog
characterist
heritag
background
novel
hla
allel
hlaa
chuanfu
zhu
yonghong
song
xiangmin
nie
wenben
qiao
blood
center
shandong
provinc
backgroundcas
studi
hla
allel
document
accord
imgt
hla
sequenc
databas
identifi
last
year
besid
sequenc
mani
novel
hla
allel
analyz
serolog
reactiv
hlaa
allel
fist
detect
laboratori
hla
type
china
bone
marrow
donor
program
cmdp
studi
serolog
characterist
heritag
investig
perform
studi
designmethod
routin
hla
tie
potenti
donor
cmdp
perform
biallel
sequencebas
type
method
use
commerci
kit
rose
europ
gmbh
frankfurt
germani
case
full
match
hla
type
result
group
specif
hlassures
sbt
type
kit
texa
biogen
inc
taipei
taiwan
employ
identifi
nucleotid
sequenc
novel
allel
fresh
blood
sampl
collect
proband
famili
member
consent
order
nanalysi
serolog
reactiv
possibl
haplotyp
associ
novel
allel
hla
serolog
specif
indic
one
lambda
hla
kit
resultsfind
full
match
result
obtain
hlaa
locu
hla
type
donor
suggest
possibl
exist
novel
allel
latter
nanalysi
indic
proband
nucleotid
sequenc
hlaa
locu
new
sequenc
close
hlaa
nucleotid
substitut
exon
nt
ca
accaac
result
one
aminoacid
substitut
thrasn
novel
hlaa
allel
offici
name
hlaa
backgroundcas
studi
antid
frequent
caus
hemolyt
diseas
fetu
newborn
hdfn
rule
immun
occur
neg
pregnant
women
occasion
antid
also
observ
carrier
variant
current
matern
plasma
analysi
determin
fetal
rhd
statu
becam
excit
new
tool
manag
dneg
pregnant
women
one
challeng
non
invas
fetal
rhdgenotyp
presenc
variant
pregnant
women
present
case
yearold
pregnant
woman
type
deliv
babi
affect
sever
hdfn
newborn
type
present
posit
direct
antiglobulin
test
dat
antid
identifi
eluat
babi
treat
exchang
transfus
mother
sampl
investig
studi
designmethod
serolog
test
done
hemagglutin
gel
card
genom
dna
extract
whole
blood
spin
column
rhd
exon
sequenc
sanger
sequenc
method
resultsfind
mother
rbc
react
four
monoclon
antid
use
igm
clone
rum
blend
clone
type
antid
identifi
serum
molecular
analysi
show
c
exon
snp
c
chang
exon
g
nucleotid
chang
exon
set
snp
found
similar
molecular
background
except
c
chang
conclus
novel
set
snp
found
mother
relat
novel
rhd
allel
lead
partial
antigen
involv
product
antid
caus
sever
hdfn
find
show
need
elucid
clinic
signific
differ
rhd
genotyp
variou
ethnic
background
erytra
v
r
routin
refer
platform
perform
total
immuno
hematolog
test
abod
group
includ
newborn
sampl
extend
erythrocyt
phenotyp
antibodi
screen
antibodi
identif
dat
crossmatch
perform
patient
whole
blood
sampl
erytra
eflexi
v
r
perform
evalu
accord
protocol
design
simul
routin
workload
use
system
two
differ
configur
concord
system
assess
discrep
analyz
follow
perform
metric
assess
time
first
result
ttfr
turnaround
time
tat
total
workload
first
result
last
result
throughput
resultsh
manual
handson
time
requir
well
walkaway
time
consid
two
differ
configur
system
eas
use
evalu
differ
usabl
featur
rank
number
step
time
follow
activ
track
sampl
sort
load
routin
test
postrun
procedur
consum
use
space
requir
threshold
vitrodetect
antid
gamma
globulin
also
determin
v
r
analyz
refer
method
obtain
abod
test
antibodi
screen
test
antibodi
identif
test
dat
test
discrep
abod
patient
antibodi
screen
antibodi
identif
case
erytra
eflexi
v
r
could
conclud
wherea
erytra
could
due
poor
reaction
use
stat
mode
incub
reserv
urgent
test
prove
use
test
sever
sampl
time
save
min
detect
threshold
antibodi
assess
ngml
uiml
wherea
french
recommend
ngml
possibl
interchang
tray
reagentssampl
make
also
possibl
optim
analyz
oper
impress
technic
staff
posit
regard
esthet
function
design
intuit
easi
use
well
flexibl
v
r
result
demonstr
veloc
sensit
well
abil
easili
perform
routin
workload
medic
analysi
laboratori
erytra
eflexi
v
r
meet
requir
french
regulatori
immunohematolog
iso
accredit
backgroundcas
studi
kell
system
antibodi
inhibit
erythropoiesi
caus
sever
anemia
hemolyt
diseas
fetu
newborn
hdfn
report
case
hdfn
secondari
antikpb
result
multipl
intrauterin
transfus
kp
b
donor
cell
hemolyt
anemia
upon
birth
case
year
old
present
fifth
pregnanc
antikpb
initi
titer
measur
histori
antikpb
develop
third
pregnanc
end
spontan
abort
antibodi
titer
could
initi
patient
antibodi
titer
peak
fourth
pregnanc
result
healthi
male
without
anemia
jaundic
latest
pregnanc
ultrasound
initi
elev
middl
cerebr
arteri
doppler
exam
mom
peak
week
result
three
intrauterin
transfus
due
potenti
labor
find
revers
diastol
flow
middl
cerebr
arteri
doppler
studi
find
associ
impend
intrauterin
fetal
demis
caesarean
deliveri
perform
week
gestat
babi
boy
requir
phototherapi
hyperbilirubinemia
indirect
bilirubin
birth
mgdl
gdl
hemoglobin
babi
type
posit
kp
micro
posit
dat
antibodi
workup
reveal
antikpb
continu
hemolysi
requir
one
transfus
week
age
posit
dat
passiv
acquir
antikpb
longer
detect
week
age
hemoglobin
recov
gdl
indirect
bilirubin
mgdl
week
age
clinic
sign
hemolyt
anemia
resolv
studi
designmethod
serolog
test
includ
peg
iat
tube
method
acid
elut
perform
use
immucor
gamma
elukit
ii
molecular
test
perform
use
immucor
bioarray
hea
platform
resultsfind
antibodi
identif
mother
perform
well
alloadsorpt
studi
rule
underli
alloantibodi
new
weakli
react
anti
detect
day
deliveri
babi
type
posit
howev
anti
detect
eluat
prepar
babi
red
cell
intrauterin
transfus
unit
neg
conclus
knowledg
five
case
report
describ
antikpb
result
moder
sever
hdfn
pregnant
mother
antikpb
detect
monitor
close
backgroundcas
studi
clinic
case
dat
may
insensit
detect
low
signific
level
may
inconclus
due
spontan
red
cell
rbc
aggreg
dat
well
suit
quantifi
number
immunoprotein
molecul
rbc
sinc
reaction
correspond
molecul
cell
number
flow
cytometr
method
detect
rbcbound
publish
howev
mainli
design
quantifi
fraction
rbc
aim
studi
present
flow
cytometr
method
quantif
level
rbcbound
studi
designmethod
ten
microlit
ul
document
experiment
amount
ensur
maximum
bind
mous
monoclon
antihuman
abcam
clone
ad
ul
rbc
suspens
incub
minut
sampl
wash
ul
dilut
antimousef
ab
dako
ad
incub
sampl
wash
resuspend
acquir
flow
cytomet
becton
dickinson
facscanto
ii
enabl
calibr
fluoresc
signal
antibodi
bind
capac
abc
calibr
standard
dako
qifikit
stain
run
parallel
experi
background
fluoresc
abc
subtract
yield
net
abc
valu
correspond
specif
stain
assay
parallel
routin
dat
dcscreen
idcard
gel
card
biorad
appli
seri
rbc
stain
level
dilut
serum
high
titer
antia
estim
normal
rang
rbcbound
edtastabil
sampl
healthi
donor
test
final
assay
appli
sampl
patient
clinic
aiha
inconclus
dat
due
unspecif
dat
polyreact
resultsfind
correl
net
level
rbcbound
valu
rang
abc
level
dilut
use
sensit
rbc
prove
highli
linear
logarithm
vs
logarithm
plot
p
compar
dcscreen
sensit
flow
cytometr
assay
superior
detect
sensit
least
dilut
step
median
normal
level
rbcbound
abc
rang
abc
assay
enabl
demonstr
specif
patient
level
rbcbound
sampl
significantli
elev
abc
conclus
present
flow
cytometr
assay
capabl
quantifi
level
rbcbound
high
degre
linear
analyt
sensit
capabl
quantifi
level
rbcbound
dat
polyreact
sampl
backgroundcas
studi
abo
blood
group
system
red
blood
cell
rbc
consist
b
oligosaccharid
antigen
antia
antib
antibodi
antigen
present
sera
individu
express
antigen
landstein
law
express
antigen
epitheli
endotheli
cell
bodi
abo
match
critic
blood
transfus
also
celltissueorgan
transplant
spite
fact
antigen
antibodi
involv
genet
trait
specifi
singl
genet
locu
abo
forssman
for
system
anoth
rbc
blood
group
system
consist
glycosyl
polymorph
specifi
gene
human
abo
genet
loci
locat
chromosom
function
allel
encod
b
glycosyltransferas
bt
forssman
glycolipid
synthas
fs
catalyz
last
biosynthet
step
b
forssman
oligosaccharid
antigen
molecular
genet
base
allel
two
system
human
wellelucid
abo
gene
also
present
speci
addit
human
howev
presenceabs
functionalitynonfunction
speciesdepend
molecular
mechanismsforc
creat
speci
diverg
includ
human
polymorph
unknown
studi
designmethod
util
genom
inform
avail
genbank
ensembl
databas
gene
map
chromosom
region
surround
abo
gene
construct
vertebr
speci
resultsfind
extens
similar
observ
kind
number
order
gene
well
chromosom
locat
howev
numer
differ
also
identifi
includ
chromosom
rearrang
well
insert
amplif
specif
gene
interestingli
abo
gene
found
locat
boundari
chromosom
fragment
seem
undergon
frequent
inversionstransloc
speci
evolut
conclus
genet
alter
delet
duplic
known
preval
end
rearrang
chromosom
fragment
therefor
speciesdepend
diverg
polymorph
within
speci
clinic
import
glycosyltransferas
gene
may
result
least
partial
unstabl
chromosom
structur
neighbor
gene
alloimmun
despit
phenotyp
match
patient
sickl
cell
diseas
complex
rhce
genotyp
jessica
kneib
emili
coberli
univers
missouri
health
care
backgroundcas
studi
red
blood
cell
transfus
play
import
role
treatment
patient
sickl
cell
diseas
sickl
cell
patient
significantli
increas
risk
alloimmun
compar
gener
popul
standard
care
provid
phenotyp
match
unit
least
c
e
antigen
reduc
risk
unfortun
genotyp
true
alloimmun
risk
may
alway
accur
repres
red
blood
cell
phenotyp
particularli
patient
complex
partial
rhce
variant
studi
designmethod
year
old
femal
histori
sickl
cell
diseas
stroke
iron
overload
present
routin
exchang
transfus
transfus
vol
supplement
patient
blood
type
posit
red
cell
previous
phenotyp
c
e
antibodi
screen
posit
antibodi
c
e
antigen
identifi
plasma
patient
receiv
phenotyp
match
unit
neg
c
e
antigen
previou
transfus
institut
base
known
red
blood
cell
phenotyp
blood
sampl
sent
refer
laboratori
molecular
test
look
partial
rhce
variant
might
explain
antibodi
develop
resultsfind
molecular
test
perform
reveal
presenc
two
differ
partial
rhce
allel
result
predict
phenotyp
c
e
partial
partial
probabl
rhce
genotyp
rhce
cejalrhc
result
partial
express
c
e
antigen
addit
known
risk
alloimmun
absent
c
e
antigen
result
indic
patient
also
capabl
form
alloantibodi
absent
portion
c
e
antigen
base
result
patient
anti
determin
alloantibodi
autoantibodi
conclus
although
phenotyp
match
unit
standard
care
patient
sickl
cell
diseas
red
blood
cell
phenotyp
may
accur
repres
alloimmun
risk
patient
complex
partial
rhce
genotyp
case
molecular
test
confirm
patient
risk
develop
alloantibodi
c
c
e
e
antigen
patient
alreadi
made
alloantibodi
c
e
antigen
determin
would
requir
unit
molecularli
match
rhce
variant
futur
transfus
case
demonstr
phenotyp
match
sickl
cell
diseas
patient
may
adequ
prevent
alloimmun
individu
partial
rhce
variant
alter
splice
rhd
weak
type
allel
associ
skip
exon
pregnant
woman
newborn
carolina
bonet
bub
maria
giselda
aravechia
thiago
costa
marilia
sirianni
eduardo
basto
leandro
santo
lilian
castilho
jo
e
kutner
hospit
israelita
albert
einstein
hemocentro
unicamp
backgroundcas
studi
rhd
weak
type
variant
commonli
found
caucasian
associ
weak
phenotyp
previous
report
vege
et
al
transfus
c
chang
character
rhd
weak
type
allel
splice
variant
induc
skip
whole
rhd
exon
report
alter
splice
rhd
weak
type
allel
associ
skip
exon
pregnant
women
newborn
weak
express
studi
designmethod
antigen
express
evalu
commerci
avail
monoclon
antid
reagent
blend
igmigg
clone
igm
clone
igg
tube
gel
card
c
c
e
e
phenotyp
perform
gel
rhd
genotyp
perform
rhd
beadchip
platform
immucor
direct
autom
sequenc
rhd
exon
flank
intron
region
perform
sanger
dideoxi
method
resultsfind
pregnant
women
newborn
sampl
phenotyp
w
sampl
show
weak
hemagglutin
reaction
antid
clone
use
rhd
beadchip
result
show
ls
signal
indic
possibl
delet
exon
dna
sampl
sequenc
show
c
chang
intron
c
substitut
associ
rhd
weak
type
allel
conclus
result
show
c
associ
c
variat
probabl
function
impact
splice
induc
exclus
exon
dna
mother
newborn
find
import
develop
assay
interpret
genotyp
result
current
guidelin
recommend
antid
igg
prophylaxi
women
weak
type
backgroundcas
studi
sickl
cell
diseas
scd
patient
requir
red
blood
cell
rbc
transfus
minim
diseasespecif
symptomatolog
previou
studi
shown
children
scd
receiv
least
one
rbc
transfus
lifetim
simpl
transfus
erythrocytapheresi
associ
increas
risk
rbc
alloimmun
publish
literatur
lack
frequenc
alloimmun
geograph
associ
pediatr
popul
made
difficult
compar
due
lack
standard
categor
repres
pediatr
patient
popul
across
studi
therefor
look
alloimmun
rate
pediatr
patient
scd
unit
state
us
countri
studi
designmethod
literatur
search
perform
studi
publish
alloimmun
rate
scd
pediatr
patient
includ
hbss
sickl
betathalassemia
hbsc
evalu
overal
alloimmun
rate
number
alloantibodi
per
transfus
patient
alloantibodi
per
transfus
unit
across
world
literatur
compar
use
chisquar
analysi
resultsfind
fourteen
studi
report
data
deriv
alloimmun
rate
pediatr
scd
patient
found
includ
eleven
us
studi
patient
studi
region
brazil
egypt
franc
patient
major
patient
includ
studi
hbss
diseas
patient
receiv
either
episod
chronic
simpl
transfus
erythrocytapheresi
age
rang
us
studi
year
countri
year
avail
data
us
studi
includ
total
alloantibodi
frequent
antibodi
c
e
kell
kidd
antigen
respect
alloimmun
rate
calcul
antibodi
per
patient
studi
antibodi
per
transfus
unit
studi
evalu
rate
use
approach
per
avail
data
us
alloimmun
rate
ci
vs
nonu
studi
ci
transfus
vol
supplement
alloantibodi
per
transfus
patient
vs
similarli
number
alloantibodi
per
transfus
unit
us
evalu
five
studi
higher
compar
larg
french
patient
cohort
vs
averag
number
rbc
unit
transfus
per
patient
us
also
higher
compar
data
franc
vs
conclus
despit
limit
studi
avail
compar
alloimmun
rate
pediatr
scd
patient
us
countri
overal
rate
higher
us
though
definit
reason
could
conclud
avail
data
limit
number
rbc
exposur
ie
unit
transfus
noncrit
condit
could
lead
lower
alloimmun
rate
resultsfind
posttransfus
sampl
refer
irl
trxn
investig
cleric
error
howev
hemolysi
present
posttransfus
plasmaserum
aborh
crossmatch
use
loion
tm
repeat
preand
posttransfus
sampl
discrep
posttransfus
dat
posit
neg
eluat
hospit
request
anoth
unit
investig
complet
antibodi
identif
post
transfus
sampl
loion
tm
neg
suspect
weak
antibodi
addit
investig
use
peg
tm
sampl
reveal
antic
addit
clinic
signific
alloantibodi
detect
preor
posttransfus
sampl
use
peg
tm
conclus
patient
experienc
acut
hemolyt
transfus
reaction
due
anamnest
interact
antic
patient
plasmaserum
c
antigen
transfus
cell
antic
detect
routin
antibodi
identif
techniqu
mma
confirm
anti
c
clinic
signific
laura
bailey
melissa
grohotolski
lisa
deblass
bala
carver
kip
kuttner
health
network
laboratori
miller
keyston
blood
center
backgroundcas
studi
en
antigen
high
preval
antigen
mn
blood
group
system
antigen
mn
system
carri
glycophorin
gpa
glycophorin
b
gpb
antien
rare
immun
igmigg
antibodi
made
individu
lack
part
gpa
protein
antien
implic
fatal
htr
hdfn
en
phenotyp
result
either
rare
delet
gpa
protein
even
rarer
k
phenotyp
individu
k
phenotyp
lack
gpa
gpb
protein
red
blood
cell
type
n
u
en
wr
b
reduc
sialic
acid
studi
designmethod
year
old
white
mennonit
femal
present
midwif
prenat
care
intent
home
deliveri
posit
antibodi
screen
solid
phase
hospit
transfus
servic
antibodi
identif
panel
done
gel
test
antibodi
select
cell
uand
u
var
tube
peg
enhanc
phenotyp
done
base
mn
phenotyp
antien
suspect
specimen
refer
immunohematolog
refer
laboratori
irl
test
includ
phenotyp
unlicens
antisera
ficin
treat
panel
tube
techniqu
allogen
adsorpt
antibodi
exclus
identif
antibodi
titrat
follow
identif
antien
irl
midwif
advis
refer
patient
matern
fetal
medicin
specialist
academ
center
close
patient
home
midwif
also
advis
consid
autolog
blood
donat
test
sibl
resultsfind
test
hospit
blood
bank
demonstr
posit
reactiv
antibodi
screen
gel
antibodi
panel
ahg
phase
result
panagglutin
neg
autocontrol
suggest
high
preval
antibodi
phenotyp
perform
determin
n
u
outdat
u
variant
reagent
cell
react
peg
igg
phase
rule
antiu
antien
suspect
sampl
refer
irl
allogen
adsorpt
perform
rule
antibodi
common
red
cell
antigen
lack
reactiv
ficin
panel
elimin
presenc
antiu
wr
b
phenotyp
unlicens
antiu
neg
unlicens
glycin
soja
demonstr
reactiv
suggest
patient
en
patient
phenotyp
consist
k
phenotyp
base
lack
reactiv
ficin
panel
antibodi
identifi
antien
fs
sinc
antien
extrem
rare
specif
could
confirm
due
lack
en
cell
appropri
antisera
baselin
antibodi
titer
igg
phase
without
enhanc
conclus
case
studi
describ
workup
rare
antibodi
prenat
patient
tertiari
care
hospit
studi
perform
patient
transfer
closer
home
confirm
antien
fs
genotyp
perform
three
titer
perform
remaind
pregnanc
held
although
antien
implic
hdfn
healthi
infant
deliv
without
complic
patient
monitor
close
futur
pregnanc
autolog
donat
andor
sibl
test
consid
order
provid
compat
blood
intrauterin
transfus
transfus
deliveri
backgroundcas
studi
year
old
caucasian
male
diagnos
hemolyt
anemia
previou
transfus
refer
immunohematolog
refer
laboratori
irl
antibodi
identif
rbc
genotyp
initi
serolog
test
refer
facil
irl
demonstr
antid
antic
andor
antig
specif
posit
auto
control
igg
dat
antig
antid
c
specif
frequent
found
rr
individu
expos
r
r
cell
g
antigen
present
rbc
express
either
rhd
andor
c
rare
r
g
r
cell
rhce
c
rhd
gene
encod
determin
g
express
rare
rhd
variant
antigen
lack
g
studi
designmethod
serolog
evalu
includ
tube
test
use
gamma
loion
tm
immucor
inc
norcross
ga
enhanc
elut
studi
gamma
elukitv
r
ii
immucor
inc
edta
glycin
acid
treatment
gamma
ega
tm
kit
immucor
inc
allogen
adsorpt
papain
treat
intact
rbc
reagent
patientderiv
rbc
antisera
molecular
test
perform
bioarray
precis
type
ivd
hea
assay
immucor
inc
resultsfind
molecular
test
reveal
rhce
ce
genotyp
phenotyp
otherwis
unremark
rbc
type
report
serolog
antibodi
i
demonstr
antid
c
g
specif
serum
eluat
use
r
r
r
r
r
r
r
g
r
rr
cell
patient
predict
r
r
dcedc
therefor
antic
possibl
allogen
antid
g
except
unlik
allogen
adsorpt
use
papain
treat
r
r
r
r
cell
exclud
antic
antid
leav
antig
explan
initi
find
reactiv
patient
ega
treat
dat
neg
cell
neat
serum
eluat
antig
antisera
confirm
auto
antig
conclus
warm
autoantibodi
common
find
often
rh
specif
howev
antibodi
usual
demonstr
broad
weaker
specif
eluat
serum
enhanc
use
antig
reactiv
gcell
differenti
antig
antid
antic
gener
academ
transfus
recommend
provid
rhd
cunit
relev
clinic
import
determin
presenc
absenc
antid
rhd
neg
women
childbear
age
present
antig
specif
antid
transfus
vol
supplement
exclud
women
receiv
rhig
part
prenat
care
case
differenti
antid
c
auto
antig
necessari
provid
transfus
recommend
provid
rhdand
cunit
give
serolog
compat
rbc
could
result
format
allogen
anti
autom
eluat
comparison
solidphas
red
cell
adher
gel
autom
eluat
test
jayanna
slayten
christa
voliva
kathi
fletcher
heather
vaught
traci
ingl
indiana
univers
health
indiana
univers
health
iu
health
backgroundcas
studi
acid
eluat
elu
kit
ii
immucor
norcross
ga
test
via
tube
iat
method
parallel
recov
last
wash
per
manufactur
packag
insert
finck
et
al
immunohematolog
demonstr
acid
eluat
may
test
platform
manual
gel
microcolumn
assay
idmtsigg
card
ortho
clinic
diagnost
raritan
nj
autom
solidphas
red
cell
adher
system
echo
immucor
norcross
ga
studi
look
compar
use
autom
gel
microcolumn
analyz
vision
ortho
clinic
diagnost
raritan
nj
solidphas
red
cell
adher
analyz
echo
immucor
norcross
ga
test
acid
eluat
region
midwestern
transfus
servic
studi
designmethod
twenti
patient
sampl
less
day
collect
drawn
edta
use
prepar
acid
eluat
elukit
ii
immucor
norcross
ga
retain
last
wash
test
parallel
two
sampl
dat
posit
weakli
dat
posit
dat
neg
prepar
eluat
observ
color
bluegreenbg
bluebrownbb
bluepurplebp
ph
document
prepar
eluat
whatman
whatman
intern
maidston
england
prepar
eluat
last
wash
test
vision
echo
antibodi
screen
antibodi
screen
posit
sampl
test
antibodi
panel
determin
specificitypanreact
prior
eluat
test
autom
platform
spun
minut
twice
remov
rbc
debri
could
caus
fals
posit
reaction
resultsfind
eluat
prepar
rang
color
bb
bg
bp
ph
eluat
rang
highest
percentag
eluat
ph
sixteen
eluat
test
yield
result
autom
platform
concord
four
eluat
differ
result
summar
tabl
conclus
studi
demonstr
analyz
may
use
eluat
investig
method
yield
appar
fals
posit
result
sampl
initi
dat
neg
echo
sensit
yield
fals
posit
result
vision
neg
vision
fals
posit
one
eluat
echo
neg
appar
associ
noncorrel
eluat
result
relat
color
eluat
age
sampl
eluat
prepar
ph
eluat
larger
studi
may
abl
better
elucid
appar
fals
posit
result
note
studi
echo
vision
eluat
studi
backgroundcas
studi
blood
agglutin
observ
landstein
led
discoveri
human
blood
group
abo
system
allel
describ
glycosyltransferas
encod
result
weaken
express
b
null
group
phenotyp
test
method
reagent
improv
donor
may
appear
chang
abo
type
describ
frequent
group
blood
donor
unit
year
actual
w
studi
designmethod
donat
test
instrument
beckman
coulter
inc
routin
forward
revers
abo
test
use
investig
discrep
molecular
studi
perform
dna
sequenc
abo
intron
exon
specif
primer
locat
flank
intron
region
blood
group
gene
use
amplifi
relev
exon
pcr
templat
use
genom
dna
extract
whole
blood
collect
edta
pcramplifi
exon
subject
bidirect
dna
sequenc
analysi
use
standard
sanger
dideoxi
chemistri
seqscap
softwar
abi
use
analyz
sequenc
data
compar
obtain
sequenc
refer
sequenc
ncbi
resultsfind
serolog
result
shown
tabl
test
antia
b
antia
b
neg
cell
revers
test
result
dna
sequenc
abo
intronsexon
shown
tabl
signific
chang
found
exon
exon
nucleotid
nt
delet
result
shorten
transcript
due
stop
codon
anoth
nt
substitut
lead
amino
acid
chang
mutat
exon
includ
nt
substitut
caus
chang
nt
delet
result
shorten
transcript
conclus
serolog
test
donor
plasma
cell
nonreact
reveal
abo
discrep
molecular
test
confirm
donor
genotyp
heterozygot
ao
abo
predict
w
phenotyp
normal
donor
rbc
test
antia
b
revers
type
confirm
test
b
cell
abo
discrep
caus
presenc
plasma
caus
forward
revers
type
interpret
group
accord
fda
guidelin
donor
technic
group
donat
need
label
group
donor
contact
instruct
ceas
donat
blood
transfus
donat
continu
unit
label
group
would
like
test
group
transfus
facil
result
fda
report
error
numer
report
literatur
rel
insuscept
cell
destruct
antia
howev
one
hemolyt
transfus
reaction
x
blood
transfus
patient
potent
antia
titer
schmidt
nacarrow
et
al
review
transfus
recipi
donor
report
reveal
untoward
reaction
transfus
transfus
vol
supplement
extract
gdna
edtaanticoagul
whole
blood
pilot
tube
deriv
unit
dna
extract
whole
blood
perform
blood
tube
use
biorobot
univers
system
qiagen
inform
maximum
accept
age
blood
purpos
either
vendor
peerreview
literatur
set
assess
blood
day
post
collect
yield
suitabl
gdna
downstream
rbc
genotyp
studi
designmethod
edta
blood
tube
collect
random
blood
donor
use
extract
dna
microlit
whole
blood
day
day
post
collect
blood
sampl
store
extract
tube
brought
room
temperatur
rock
load
biorobot
extract
perform
use
mdx
blood
minikit
qiagen
result
dna
sampl
assess
gdna
yield
absorb
use
nanodrop
thermo
scientif
extract
gdna
test
use
precisetyp
hea
molecular
beadchip
hea
immucor
failur
rate
biorobot
hea
assess
resultsfind
three
extract
success
invalid
biorobot
univers
report
evid
visibl
clot
splatter
extract
note
technologist
sampl
sampl
chosen
random
concentr
measur
use
nanodrop
extract
plate
dna
concentr
rang
ngul
read
except
ul
concentr
interestingli
one
ul
day
yield
day
post
collect
next
month
set
sampl
extract
test
hea
eightythre
fail
extract
fail
hea
none
sampl
fail
extract
day
post
collect
none
fail
hea
day
post
collect
day
post
collect
conclus
base
result
conclud
edta
blood
tube
day
post
collect
use
sourc
gdna
rbc
genotyp
without
neg
effect
concentr
result
dna
sampl
valid
result
genotyp
case
studi
investig
persist
neg
antibodi
screen
patient
receiv
daratumumab
raeann
thoma
carlo
villa
rachel
davisraus
helen
carpent
vrunda
patel
univers
pennsylvania
hospit
univers
pennsylvania
backgroundcas
studi
daratumumab
monoclon
antibodi
therapi
receiv
fda
approv
treatment
multipl
myeloma
commun
suggest
patient
receiv
therapi
would
posit
antibodi
screen
common
antigen
express
red
blood
cell
current
patient
treat
daratumumab
larg
academ
medic
center
wide
variat
reactiv
observ
includ
patient
found
consist
neg
antibodi
screen
sever
potenti
caus
neutral
antibodi
could
easili
test
appli
establish
techniqu
use
neutral
antibodi
reactiv
studi
designmethod
sampl
receiv
drawn
standard
care
indirect
antiglobulin
test
perform
use
solid
phase
red
cell
adher
gel
neutral
perform
ad
equal
volum
neg
daratumumab
treat
patient
plasma
posit
daratumumab
treat
patient
plasma
dilut
control
made
ad
salin
posit
patient
plasma
sampl
incub
hour
room
temperatur
antibodi
screen
repeat
serial
twofold
dilut
also
test
determin
neutral
could
titer
test
repeat
use
variou
posit
patient
sampl
determin
negativeposit
combin
result
differ
reactiv
resultsfind
control
sampl
remain
posit
positiveneg
sampl
neg
solid
phase
test
across
patient
combin
dilut
variabl
reactiv
observ
gel
serial
dilut
show
neutral
neg
patient
observ
dilut
conclus
result
suggest
patient
plasma
may
substanc
neutral
antibodi
possibl
correl
patient
persist
neg
antibodi
screen
patient
respons
daratumumab
addit
studi
necessari
uncov
correl
patient
outcom
studi
use
standard
daratumumabspik
sampl
conduct
backgroundcas
studi
mn
blood
group
red
cell
antigen
system
locat
glycophorin
gypa
glycophorin
b
gypb
individu
lack
gypa
gypa
gypb
red
blood
cell
may
develop
rare
antibodi
en
antigen
en
antigen
highpreval
antigen
locat
gypa
present
case
rare
red
cell
phenotyp
alloimmun
en
antigen
yo
approxim
week
gestat
discov
antien
antibodi
plasma
prenat
type
screen
worrisom
mother
fetu
en
antibodi
igg
isotyp
implic
acut
delay
hemolyt
transfus
reaction
hemolyt
diseas
fetu
newborn
hdfn
test
red
cell
antisera
reveal
patient
lack
n
u
antigen
multiplex
allelespecif
pcr
platform
commonli
use
detect
presenc
absenc
red
cell
gene
sequenc
fail
amplifi
gene
specif
n
u
antigen
find
consist
null
phenotyp
gypa
gypb
antigen
ie
k
k
phenotyp
patient
husband
father
unborn
babi
demonstr
phenotyp
serolog
molecular
mean
given
exceedingli
rare
incid
en
individu
posit
frequenc
clinic
encount
alloantibodi
antigen
limit
experi
literatur
howev
exist
data
give
credenc
associ
transfus
reaction
hemolyt
diseas
fetu
newborn
hdfn
consensu
case
work
highrisk
pregnanc
frequent
intens
monitor
involv
frequent
monitor
antibodi
titer
transfus
requir
mother
fetu
option
either
search
rare
unit
lack
en
antigen
via
rare
blood
donor
registri
direct
donat
famili
member
match
patient
phenotyp
term
patient
underw
induct
labor
success
deliv
health
babi
boy
vagin
rout
deliveri
without
event
transfus
necessari
antepartum
postpartum
studi
designmethod
na
resultsfind
na
conclus
antien
rare
antibodi
limit
data
potenti
clinic
sequela
concern
pregnant
woman
provid
patient
rare
en
neg
red
cell
via
nation
intern
blood
donor
registri
would
arduou
task
need
patient
mani
compat
famili
member
avail
will
donat
blood
k
null
allel
within
famili
like
due
genet
recombin
among
gypa
gype
gene
rather
mutat
gypa
gypb
gene
result
absenc
glycophorin
b
constitut
antigen
mn
blood
group
system
patient
expos
en
present
glycophorin
unborn
babi
red
cell
inherit
father
utero
subsequ
alloimmun
conclus
case
report
demonstr
clinic
approach
identifi
rare
antien
antibodi
prenat
sampl
clinic
find
rare
antibodi
limit
data
requir
leverag
everi
resourc
avail
order
predict
behavior
provid
safe
blood
product
patient
may
requir
backgroundcas
studi
transfus
essenti
patient
scd
thalassemia
maintain
growth
develop
childhood
sustain
good
qualiti
life
adulthood
howev
develop
red
blood
cell
rbc
alloantibodi
autoantibodi
complic
transfus
therapi
patient
routin
phenotyp
blood
recipi
use
phenotypematch
blood
unit
transfus
use
lower
occurr
red
cell
alloantibodi
chronic
transfus
patient
thalassemia
scd
nevertheless
extens
phenotyp
expens
labori
perform
certain
situat
molecular
understand
blood
group
enabl
design
assay
transfus
vol
supplement
use
better
guid
match
red
blood
cell
transfus
maintain
inventori
unit
dna
type
base
aim
evalu
clinic
outcom
molecular
match
perform
differ
level
year
patient
scd
thalassemia
studi
designmethod
blood
group
genotyp
determin
dna
sampl
chronic
transfus
patient
scd
patient
thalassemia
dna
sampl
blood
donor
laboratori
develop
test
ldt
hea
beadchip
tm
rhd
beadchip
tm
rhce
beadchip
tm
sequenc
use
determin
genotyp
among
patient
donor
molecular
match
perform
level
rh
k
match
extend
match
extend
match
includ
rh
variant
consid
total
red
blood
cell
unit
request
patient
number
donat
per
year
compat
donor
resultsfind
accord
patient
need
perform
molecular
match
thalassem
scd
patient
level
scd
patient
patient
thalassemia
level
patient
scd
patient
thalassemia
level
patient
transfus
median
rbc
unit
three
year
molecular
match
observ
transfus
strategi
avoid
new
alloantibodi
develop
hemolyt
transfus
reaction
studi
patient
conclus
molecular
match
shown
clinic
benefit
patient
scd
thalassemia
contribut
significantli
reduc
rate
alloimmun
c
e
k
match
extend
match
improv
clinic
outcom
patient
also
observ
shown
increas
hb
level
reduct
hb
scd
patient
better
vivo
rbc
surviv
diminish
frequenc
transfus
allahna
lilli
elahi
sandra
fazari
hamilton
region
laboratori
medicin
program
backgroundcas
studi
ideal
manual
backup
method
autom
antibodi
detect
system
import
choic
current
backup
method
salin
tube
drop
plasma
minut
incub
chang
either
low
ionic
strength
solut
liss
polyethylen
glycol
peg
method
would
reduc
incub
time
minut
specimen
volum
drop
import
laboratori
consider
object
studi
compar
rel
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
peg
liss
determin
appropri
manual
backup
method
exist
autom
solid
phase
system
studi
designmethod
total
specimen
compar
util
autom
solid
phase
red
cell
adher
assay
sprca
manual
tube
peg
liss
sampl
suffici
quantiti
test
liss
identif
panel
use
determin
clinic
signific
antibodi
warm
autoantibodi
nonspecif
reaction
calcul
base
upon
comparison
sprca
resultsfind
total
clinic
signific
antibodi
detect
use
sprca
techniqu
well
warm
autoantibodi
nonspecif
reaction
peg
demonstr
highest
sensit
lowest
specif
liss
least
sensit
specif
clinic
signific
antibodi
warm
autoantibodi
liss
sensit
peg
specif
reduc
detect
nonspecif
reaction
peg
nonspecif
reaction
versu
identifi
clinic
signific
antibodi
liss
tabl
conclus
ultim
decis
choos
manual
backup
method
must
base
upon
highest
sensit
clinic
signific
antibodi
minim
failur
detect
one
peg
select
backup
manual
method
even
though
peg
higher
sensit
nonspecif
reaction
studi
clearli
demonstr
interplay
tradeoff
method
import
understand
consid
make
method
choic
decis
comparison
thiol
reagent
denatur
rbc
patricia
arndt
anthoni
salazar
regina
leger
american
red
cross
blood
servic
long
beach
memori
medic
center
backgroundcas
studi
monoclon
eg
daratumumab
dara
use
treat
patient
multipl
myeloma
caus
posit
indirect
antiglobulin
test
iat
due
express
red
blood
cell
rbc
serolog
reactiv
remov
adsorpt
method
develop
detectidentifi
underli
alloantibodi
one
popular
method
denatur
antigen
treatment
rbc
thiol
reagent
eg
dithiothreitol
dtt
bromid
aet
chapuy
et
al
describ
valid
aet
ph
per
aabb
technic
manual
ed
treat
untreat
rbc
store
alsev
test
day
two
method
polyethylen
glycol
peg
iat
use
plasma
two
myeloma
patient
receiv
dara
plasma
total
dara
patient
test
reactiv
flow
cytometri
use
phycoerythrin
pe
label
rbc
also
test
day
serum
contain
antik
peg
iat
resultsfind
dtt
ph
pb
final
ph
ph
commerci
dtt
result
tabl
flow
cytometri
result
day
data
shown
similar
day
rbc
treat
dtt
sourc
aet
nonreact
antik
plasma
dara
patient
gave
low
result
posit
event
pe
flow
cytometri
day
treatment
rbc
treat
dtt
react
similarli
untreat
rbc
antik
dara
plasma
show
weaken
reactiv
pe
backgroundcas
studi
clinic
signific
hemolyt
diseas
fetu
newborn
hdn
often
caus
fetomatern
rhd
incompat
discoveri
cellfre
fetal
dna
ccfdna
matern
plasma
becam
possibl
determin
rhd
genotyp
fetu
use
noninvas
techniqu
howev
reliabl
noninvas
prenat
rhd
test
nip
rhd
depend
suffici
amount
cffdna
matern
plasma
sampl
recent
studi
show
fraction
ccfdna
matern
plasma
vari
significantli
pregnant
women
invers
relat
matern
bodi
mass
index
bmi
thu
high
matern
bmi
may
impair
valid
nip
rhd
aim
studi
examin
effect
matern
bmi
correct
nip
rhd
correl
matern
bmi
fraction
ccfdna
total
free
dna
sampl
studi
designmethod
measur
bodi
height
weight
pregnant
rhd
neg
women
gestat
week
obtain
patient
record
use
calcul
matern
bmi
data
bmi
combin
result
nip
rhd
realtim
pcr
target
rhd
exon
sampl
fraction
ccfdna
measur
threshold
cycl
ct
valu
rhd
total
free
dna
measur
ct
gestat
week
correct
nip
rhd
determin
correl
postnat
serolog
rhd
determin
resultsfind
total
pregnant
women
includ
nip
rhd
posit
neg
inconclus
compar
postnat
rhd
type
nip
rhd
result
fals
posit
fp
fals
neg
inconclus
nip
rhd
postnat
rhd
type
posit
mean
bmi
gestat
week
differ
mean
bmi
individu
test
inconclus
fals
neg
nip
rhd
compar
remaind
fraction
ccfdna
calcul
randomli
select
nip
rhd
true
posit
case
median
ccfdna
ratio
distribut
highli
posit
skew
statist
correl
bmi
fraction
ccfdna
total
free
dna
conclus
neither
correct
nip
rhd
test
result
fraction
cffdna
total
free
dna
appear
correl
matern
bmi
regard
matern
plasma
sampl
drawn
gestat
week
delay
hemolyt
transfus
reaction
due
antilan
antibodi
case
report
adla
dh
angelina
suneeti
sapatnekar
suzann
bakdash
cleveland
clinic
backgroundcas
studi
lan
highpreval
antigen
sole
member
lan
blood
group
system
antilan
rare
igg
antibodi
conflict
inform
regard
clinic
signific
potenti
hemolysi
report
case
delay
hemolysi
patient
antilan
antibodi
studi
designmethod
patient
medic
record
avail
literatur
review
resultsfind
year
old
man
oposit
histori
heart
diseas
bladder
cancer
admit
radic
cystectomi
antibodi
screen
panel
panreact
multipl
test
method
gel
liss
peg
neg
autocontrol
dat
salin
antibodi
titer
suggest
antibodi
highfrequ
antigen
antilan
antibodi
identifi
refer
laboratori
donor
lan
two
frozen
rbc
unit
local
avail
transfus
postop
patient
sibl
test
one
oposit
lansibl
identifi
nine
month
later
patient
admit
surgic
manag
metastas
time
antibodi
screen
weakli
reactiv
cell
new
antibodi
rule
blood
conserv
measur
institut
includ
limit
blood
draw
cell
salvag
surgeri
due
bleed
surgeri
lanrbc
unit
transfus
day
includ
rare
donor
unit
unit
sibl
donor
anoth
surgic
procedur
perform
postop
day
patient
symptomat
anemia
hemoglobin
hb
gdl
serial
increas
troponin
lanrbc
unit
avail
four
rbc
unit
untest
lan
transfus
without
advers
event
unit
presum
crossmatch
compat
phenotyp
match
patient
antigen
posttransfus
hb
gdl
maintain
day
antibodi
screen
neg
day
posttransfus
strongli
panreact
day
posit
dat
igg
antilan
antibodi
identifi
plasma
eluat
also
evid
extravascular
hemolysi
includ
progress
decreas
hb
gdl
day
gdl
day
bleed
identifi
increas
total
bilirubin
ldh
peak
mgdl
ul
day
normal
haptoglobin
patient
febril
leukocytosi
neg
cultur
evid
infect
lanrbc
unit
transfus
day
good
respons
hb
gdl
patient
remain
stabl
discharg
skill
nurs
facil
day
later
conclus
transfus
rbc
caus
resurg
antilan
antibodi
delay
hemolyt
transfus
reaction
day
transfus
rariti
lanunit
may
requir
patient
antilan
transfus
unit
close
monitor
delay
hemolysi
necessari
even
antibodi
demonstr
time
transfus
delay
serolog
transfus
reaction
caus
autoantif
karen
yunker
andrea
gerner
lynn
stewart
carol
sostok
molli
bell
gregori
r
halverson
st
elizabeth
healthcar
hoxworth
blood
center
backgroundcas
studi
antif
first
describ
rosenfield
cowork
serum
hemophiliac
multipli
transfus
f
antigen
compris
c
e
antigen
allign
ci
chromosom
antigen
assign
rh
blood
group
system
isbt
capabl
caus
signific
transfus
reaction
mild
hdfn
report
case
year
old
caucasian
male
admit
evalu
suspect
tcell
lymphoma
appear
delay
serolog
transfus
reaction
dstr
due
auto
antif
abstract
studi
designmethod
antibodi
screen
compat
test
perform
autom
solid
phase
echo
neo
lmmucor
inc
red
cell
phenotyp
done
standard
tube
test
commerci
reagent
follow
manufactur
instruct
molecular
genotyp
perform
use
bloodchip
assay
grifol
san
marco
tx
elut
studi
perform
use
elukit
ii
lmmucor
inc
resultsfind
initi
antibodi
screen
neg
patient
transfus
unit
orbc
two
week
later
patient
receiv
addit
orbc
within
day
hgb
decreas
gdl
direct
antiglobulin
test
dat
posit
ounit
incompat
antif
identifi
patient
plasma
eluat
three
addit
unit
request
transfus
due
rariti
ofrbc
patient
transfus
r
r
dcedc
rbc
report
complic
patient
discharg
follow
clinic
molecular
genotyp
show
patient
rhd
delet
rho
del
normal
rhce
rhce
cerhc
ce
gene
predict
phenotyp
rh
phenotyp
repeat
sampl
collect
day
later
c
type
micro
posit
mix
field
minut
incub
rh
antigen
mix
file
non
reactiv
howev
dat
weakli
posit
antilgg
elut
studi
perform
conclus
expect
post
hour
hgb
increment
receipt
standard
unit
blood
near
gdl
hct
throughout
patient
hospit
posttransfus
increment
fulli
achiev
expect
first
transfuion
result
gdl
increas
second
unit
gdl
last
transfus
unit
increas
gdl
less
three
week
later
rhc
antigen
type
microscopicmix
field
extend
incub
indic
remov
r
r
unit
nearli
complet
case
ohto
kariyon
transf
report
cr
studi
rbc
patient
antif
show
initit
surviv
cell
fairli
normal
howev
day
sudden
increas
red
cell
destruct
day
cell
clear
circul
unusu
find
autoantif
mani
report
howev
unusu
find
autoantibodi
caus
clearanc
three
unit
fneg
blood
patient
monitor
see
autoantibodi
recur
determin
still
antif
specif
backgroundcas
studi
use
dithiothreitol
dtt
treat
reagent
red
cell
rrbc
increas
blood
bank
effect
way
negat
interf
panreact
caus
daratumumab
drug
treatment
multipl
myeloma
daili
prepar
dtttreat
rrbc
test
individu
patient
burdensom
laboratori
may
delay
patient
care
evalu
effect
batchprepar
dtttreat
rrbc
store
day
treatment
antibodi
detect
test
studi
designmethod
indat
rrbc
ortho
clinic
diagnost
raritan
nj
select
base
phenotyp
match
antisera
test
rrbc
treat
dtt
sigmaaldrich
st
loui
mo
store
reagent
red
cell
diluent
rrbc
test
commerci
antisera
ortho
clinic
diagnost
raritan
nj
immucor
norcross
ga
per
manufactur
instruct
specif
rh
duffi
kidd
mn
blood
group
see
tabl
patient
sourc
antibodi
antid
antic
also
test
test
perform
dtt
treatment
day
dtt
treatment
day
follow
dtt
treatment
rrbc
reaction
grade
use
standard
serolog
grade
neg
posit
reaction
strength
store
dtttreat
rrbc
also
observ
hemolysi
storag
period
resultsfind
see
tabl
summari
result
commerci
monoclon
human
sourc
antisera
patient
sourc
antibodi
reactiv
dtttreat
rrbc
throughout
storag
period
reactiv
decreas
less
one
reaction
grade
antisera
patient
sourc
antibodi
test
mild
moder
hemolysi
note
dtttreat
rrbc
storag
period
conclus
dtttreat
rrbc
show
adequ
reactiv
variou
red
cell
antisera
storag
day
suggest
dtttreat
reagent
red
cell
store
least
day
use
detect
alloantibodi
minim
effect
detect
abil
batch
prepar
storag
dtttreat
rrbc
increas
test
effici
decreas
turnaroundtim
perform
pretransfus
test
patient
receiv
therapi
interfer
kell
marilyn
stewart
angela
treml
geoffrey
wool
univers
chicago
backgroundcas
studi
daratumumab
dara
antimyeloma
antilymphoma
agent
known
interfer
routin
blood
bank
antibodi
screen
test
dara
igg
monoclon
antibodi
bind
present
red
cell
surfac
univers
chicago
blood
bank
seen
mani
patient
treat
dara
show
interf
reactiv
well
describ
disulfidelink
molecul
immun
epitop
disrupt
reduc
agent
dtt
perform
valid
dtttreatment
reagent
rbc
abrog
dara
interfer
studi
designmethod
valid
done
prove
dtt
treat
red
cell
could
use
screen
patient
receiv
dara
still
detect
clinic
signific
alloantibodi
screen
cell
panel
cell
select
dtt
treatment
rbc
homozyg
clinic
signific
antigen
therefor
allow
ruleout
clinic
signific
antibodi
patient
plasma
sever
patient
receiv
dara
drug
protocol
select
test
well
mani
patient
alloand
autoantibodi
dara
treatment
reagent
screen
cell
panel
cell
treat
dtt
prepar
use
sop
judd
method
immunohematolog
aabb
technic
manual
treat
cell
preserv
test
episod
use
alsev
solut
store
abstract
observ
hemolysi
none
seen
day
immunohematolog
test
use
dtttreat
cell
perform
use
gel
methodolog
untreat
dtt
treat
cell
test
anti
k
patient
test
done
untreat
cell
react
anti
k
treat
cell
neg
control
run
test
time
dtt
treatment
done
thirti
eight
patient
sampl
includ
six
dara
patient
sampl
test
resultsfind
six
patient
dara
interfer
untreat
antibodi
screen
sampl
neg
reaction
dtt
treat
cell
except
one
patient
weak
reaction
one
cell
specimen
repeat
three
time
repeat
weak
posit
reaction
cell
sampl
sent
arc
refer
lab
dtt
treatment
clinic
signific
antibodi
rule
patient
alloantibodi
present
plasma
react
dtt
treat
cell
would
expect
base
underli
alloantibodi
except
newli
form
anti
antibodi
patient
plasma
four
patient
nascent
anti
e
show
reactiv
dtt
treat
cell
plasma
fourteen
patient
long
histori
anti
greater
month
react
dtt
treat
cell
conclus
dtt
treatment
elimin
dara
interfer
previous
describ
also
unexpectedli
lessen
abil
treat
cell
react
nascent
anti
neg
test
alloanti
e
antibodi
daratr
patient
ucm
given
kell
e
neg
blood
immunohematolog
test
perform
use
dtt
reagent
cell
mahboubeh
rahmani
moniqu
scott
garcia
curti
ellic
wong
alexa
j
siddon
christoph
tormey
yalenew
hospit
va
connecticut
healthcar
backgroundcas
studi
benign
ethnic
neutropenia
ben
seen
approxim
person
african
descent
character
neutrophil
count
l
obviou
caus
increas
suscept
infect
advers
effect
present
laboratori
assay
use
identifi
condit
gener
diagnos
clinic
basi
studi
investig
whether
duffi
fy
blood
group
phenotyp
would
potenti
use
modal
help
identifi
patient
ben
test
could
potenti
use
surrog
test
prevent
unnecessari
work
includ
bone
marrow
biopsi
correct
ethnic
clinic
set
studi
designmethod
case
includ
patient
clinic
diagnos
ben
control
chosen
randomli
pool
patient
cbc
type
screen
check
reason
case
control
test
rbc
antigen
fy
fy
b
phenotyp
use
serolog
method
fy
phenotyp
absolut
neutrophil
count
anc
white
blood
cell
wbc
hemoglobin
level
platelet
count
medic
diagnos
extract
medic
record
appropri
data
compar
statist
use
mannwhitney
u
test
signific
set
p
resultsfind
subject
clinic
identifi
probabl
ben
includ
patient
mean
age
selfidentifi
africanamerican
male
control
includ
patient
mean
age
selfidentifi
african
american
male
case
diagnos
ben
fy
ab
phenotyp
mean
anc
ul
wbc
count
ul
significantli
lower
case
ben
fy
ab
phenotyp
respect
compar
control
mean
anc
ul
mean
wbc
count
ul
signific
differ
mean
platelet
count
ul
vs
ul
mean
hemoglobin
level
gdl
vs
gdl
two
group
none
patient
ben
accompani
marrowsuppress
hematolog
disord
base
record
review
howev
subject
control
group
accompani
condit
potenti
marrowsuppress
includ
hepatocellular
carcinoma
acut
myeloid
leukemia
myelodysplast
syndrom
conclus
test
fy
phenotyp
could
potenti
use
surrog
test
patient
chronic
neutropenia
correct
ethnic
clinic
set
diagnosi
ben
studi
regard
fy
phenotyp
compar
control
neutropenia
reason
ben
popul
progress
better
determin
posit
predict
valu
test
compar
provu
concord
addit
sampl
test
antiigg
correl
tube
test
dat
antigen
type
c
c
e
e
k
resultsfind
concord
blood
group
assay
ahg
assay
detect
antifya
warm
antibodi
antibodi
high
incid
antigen
warm
antibodi
miss
provu
identifi
one
addit
anti
identifi
provu
discrep
also
note
noncord
dat
result
five
sampl
posit
antiigg
vs
tube
test
reflect
increas
sensit
gel
methodolog
tube
tabl
summar
result
conclus
studi
demonstr
analyz
associ
ihsystem
tm
gel
card
equival
ortho
provu
random
access
capabl
minim
oper
touchpoint
broad
test
menu
excel
assay
perform
ideal
immunohematolog
system
hospit
transfus
servic
environ
chri
elliott
susan
barn
fiona
lisl
debra
smith
whitehous
natali
backgroundcas
studi
erytra
eflexisv
r
grifol
new
fulli
autom
midsiz
analyz
perform
pretransfus
compat
test
use
dg
gelv
r
technolog
erytra
eflexisv
r
analyz
perform
usabl
adapt
differ
workflow
evalu
routin
environ
larg
uk
acut
hospit
transfus
laboratori
studi
designmethod
comparison
studi
perform
erytra
eflexisv
r
erytra
routin
system
provid
refer
platform
total
test
perform
adult
patient
sampl
donor
red
cell
unit
erytrav
r
eflexi
perform
evalu
accord
seri
scenario
design
simul
routin
workload
use
system
differ
configur
concord
system
assess
discrep
analyz
time
first
result
ttfr
overal
turnaround
time
tat
total
workload
first
result
last
result
throughput
resultsh
manual
handson
time
walkaway
time
record
eas
use
evalu
rank
usabl
featur
number
step
time
activ
includ
sampl
sort
load
routin
test
postrun
procedur
consum
use
space
requir
fault
recognit
messag
assess
simul
failur
eg
reagent
absenc
resultsfind
blood
group
antibodi
screen
antibodi
identif
use
panel
direct
antiglobulin
test
red
cell
phenotyp
serolog
crossmatch
success
test
concord
result
erytra
eflexisv
r
analyz
refer
method
obtain
sampl
test
discrep
antibodi
screen
fals
posit
failur
detect
weak
prophylact
anti
posit
reaction
detect
erytra
panel
system
suggest
genuin
anti
cw
ttfr
tat
depend
significantli
number
factor
includ
number
varieti
test
request
whether
stat
function
activ
analys
seem
prioritis
antibodi
screen
priorit
group
especi
stat
sampl
consid
prefer
laboratori
team
found
softwar
easi
use
improv
exist
ertyra
softwar
physic
design
analys
consid
good
easi
access
almost
area
probe
chang
quick
simpl
analys
success
flag
error
scenario
messag
consid
mislead
could
better
phrase
conclus
result
show
erytra
eflexisv
r
offer
robust
autom
solut
routin
transfus
test
devic
could
comfort
deal
medium
laboratori
process
group
screen
per
day
flexibl
abl
deliv
group
antibodi
screen
identif
dat
phenotyp
serolog
crossmatch
compens
singl
probe
wash
station
clever
use
incub
centrifug
design
featur
allow
compact
design
maximum
flexibl
without
compromis
turnaround
time
evalu
two
monoclon
anti
reagent
detect
rh
e
antigen
variant
gregori
denomm
kathleen
bens
michael
schanen
cindi
piefer
randal
w
velliquett
christin
lomasfr
conni
westhoff
immunohematolog
refer
laboratori
versitibloodcent
wisconsin
immunohematolog
genom
laboratori
new
york
blood
center
backgroundcas
studi
monoclon
antibodi
use
reagent
autom
manual
phenotyp
fals
neg
phenotyp
implic
variant
antigen
eg
alter
c
antigen
mistyp
cblood
unit
stimul
antic
crecipi
develop
new
cecf
rhce
ce
rhce
ce
compound
heterozygot
ce
ceti
ce
cemo
ceek
ceek
var
cern
cemo
ceti
cesceti
cearceek
ceekcej
cemocebi
total
transfus
vol
supplement
reagent
includ
evalu
antigen
variant
confirm
fidel
evalu
two
monoclon
anti
reagent
compar
reagent
use
larg
panel
molecular
confirm
rh
e
variant
studi
designmethod
two
monoclon
anti
clone
licens
compar
anti
diagast
loo
franc
evalu
rbc
sampl
either
recov
frozen
storag
n
edta
blood
donor
n
test
use
manual
tube
method
autom
platform
score
greater
deem
accept
manual
tube
posit
call
autom
test
result
tabul
complex
rhce
ce
allel
tabl
resultsfind
specif
monoclon
anti
confirm
use
common
rhce
haplotyp
r
r
r
r
r
r
rr
twentyon
differ
rhce
ce
allel
includ
extens
panel
rhce
ce
tran
rhce
ce
variou
rhce
ce
plu
rhce
compound
heterozygot
rhce
ce
rhce
ce
homozygot
variou
rhce
ce
rhce
ce
compound
heterozygot
compar
reagent
neg
unaccept
weak
rhce
ce
allel
tran
rhce
ce
rhce
cear
rhce
cemo
rhce
cejal
rhce
cehar
rhce
cearrhc
compound
heterozygot
rhce
cecf
homozygot
rhce
cear
rhce
cemo
rhce
cejal
rhce
cecf
homozygot
detect
use
compar
reagent
fail
e
variant
respect
tabl
failur
detect
e
variant
observ
use
manual
tube
autom
method
compar
clone
none
reagent
detect
e
antigen
variant
express
exampl
rhce
ceharrhc
ce
conclus
anti
react
e
variant
compar
reagent
e
antigen
encod
rhce
jal
rhce
ar
alway
detect
tran
rhce
ce
howev
doubledos
express
detect
suggest
monoclon
reagent
bind
weakli
respect
alter
e
antigen
epitop
e
antigen
encod
rhce
cehar
continu
challeng
detect
meihong
liu
teresita
mercado
orieji
illoh
maria
rio
zhugong
liu
obrr
cber
fda
backgroundcas
studi
extend
molecular
type
larg
number
blood
donor
increas
likelihood
identifi
donor
red
blood
cell
rbc
match
recipi
especi
import
manag
chronicallytransfus
patient
patient
rbc
alloantibodi
sever
highthroughput
multiplex
blood
group
molecular
type
platform
develop
determin
blood
group
antigen
phenotyp
target
nextgener
sequenc
ng
provid
comprehens
sequenc
inform
focus
specifi
genom
region
allow
simultan
detect
genet
variant
multipl
gene
larg
number
sampl
develop
evalu
target
ng
assay
use
two
differ
target
enrich
platform
extend
blood
group
genotyp
studi
designmethod
two
custom
design
platform
sureselect
haloplex
use
independ
prepar
probe
target
entir
gene
blood
group
gene
associ
express
blood
group
antigen
blood
group
system
use
illumina
hiseq
system
perform
next
gener
sequenc
first
sureselectenrich
gene
dna
refer
sampl
averag
target
design
coverag
haloplexenrich
gene
dna
refer
sampl
averag
target
design
coverag
twelv
sampl
enrich
sequenc
method
allow
direct
comparison
refer
sampl
previous
character
blood
group
genet
variant
gene
use
taqman
snp
assay
sanger
sequenc
assay
serolog
data
also
avail
sampl
ng
data
analyz
clc
genom
workbench
sequenc
variant
detect
annot
use
dbsnp
databas
blood
group
genotyp
call
two
target
ng
method
compar
refer
result
resultsfind
two
target
ng
method
evalu
compar
target
enrich
effici
offtarget
enrich
qualiti
ng
sequenc
coverag
genotyp
concord
higher
percentag
haloplex
read
map
target
region
rel
sureselect
read
mean
sequenc
coverag
depth
target
base
around
sureselect
method
haloplex
method
exon
rhd
exon
rhce
exon
ermap
exon
exon
gene
exon
gypb
exon
consist
cover
less
coverag
sureselect
haloplex
target
ng
method
method
detect
rhd
gene
delet
repres
sampl
genotyp
call
concord
blood
group
genet
variant
assess
compar
ng
result
taqman
genotyp
sanger
sequenc
result
concord
obtain
target
ng
method
incorrect
call
restrict
four
complex
blood
group
gene
mn
rhd
rhce
abo
involv
mainli
heterozyg
variant
indel
conclus
use
two
target
ng
method
correctli
detect
blood
group
genet
variant
select
gene
evid
rhce
cehar
encod
hr
b
antigen
debra
j
bailey
trina
horn
paul
mansfield
najmi
qazi
pamela
nickl
jessica
keller
margaret
keller
jan
r
hamilton
backgroundcas
studi
rhce
gene
mani
variant
form
yet
mani
phenotyp
encod
variant
allel
unknown
incomplet
new
inform
elucid
two
alter
allel
haplotyp
express
individu
subsequ
alloantibodi
format
rhce
cehar
allel
first
describ
phenotyp
w
w
hr
w
hr
partial
antigen
express
describ
new
inform
regard
rh
haplotyp
includ
rhce
cehar
allel
appar
hr
b
express
studi
designmethod
rbc
type
perform
standard
tube
method
polyclon
monoclon
antisera
antibodi
identif
studi
perform
standard
tube
hemagglutin
method
publish
techniqu
molecular
immunohematolog
test
perform
genom
dna
extract
whole
blood
includ
hea
rhd
rhce
beadchip
immucor
pcrrflp
analysi
rhce
g
rhd
resultsfind
sampl
african
american
femal
histori
anti
antik
evalu
unexpect
antibodi
red
cell
serolog
rh
phenotyp
untransfus
sampl
plasma
contain
alloanti
antibodi
react
strongli
random
reagent
red
cell
except
unidentifi
reactiv
persist
follow
ficin
dtt
pretreat
reagent
red
cell
red
cell
nonreact
initi
test
differenti
adsorpt
studi
exclud
antibodi
common
antigen
hr
b
except
e
k
subsequ
exampl
red
cell
homozyg
rhd
diiiac
rhce
haplotyp
ie
r
r
rhd
diiia
rhce
rhd
diiiac
rhce
ie
bastiaan
genotyp
found
nonreact
patient
plasma
antibodi
specif
determin
antihr
b
patient
red
cell
antigen
genotyp
identifi
follow
probabl
rh
haplotyp
rhd
rhce
cehar
rhd
diiiac
rhce
addit
antigen
type
patient
red
cell
unlicens
antisera
indic
sourc
hr
b
sourc
phenotyp
conclus
rhd
diiiac
rhce
haplotyp
one
rh
haplotyp
express
origin
hr
b
individu
bastiaan
hr
b
antigen
statu
red
cell
individu
rhce
cehar
allel
describ
report
individu
probabl
rhd
rhce
cehar
rhd
diiiac
rhce
rh
haplotyp
product
alloantihr
b
specif
alloantibodi
produc
red
cell
hr
b
serolog
antigen
type
support
conclus
variant
allel
rhce
cehar
encod
hr
b
antigen
exclud
clinic
signific
alloantibodi
presenc
interf
antibodi
hightit
lowavid
characterist
backgroundcas
studi
hightit
lowavid
antibodi
htla
group
clinic
insignific
antibodi
ab
direct
highpreval
red
cell
antigen
interfer
exclus
clinic
signific
red
cell
ab
crossmatch
test
lead
long
workup
potenti
transfus
delay
often
use
autom
solid
phase
red
cell
adher
assay
antibodi
panel
sp
htla
interfer
seen
method
undertook
studi
determin
efficaci
studi
designmethod
search
laboratori
inform
system
databas
conduct
patient
htla
patient
sampl
avail
record
full
serolog
investig
review
test
method
result
specif
attent
valu
given
test
method
permit
exclus
clinic
signific
ab
rule
resultsfind
approxim
year
patient
htla
establish
least
titrat
studi
serolog
investig
total
sampl
use
combin
gel
sp
peg
liss
tube
method
occasion
dtt
ficin
panel
found
htla
interfer
note
frequent
gel
primari
method
inde
less
often
seen
sp
howev
proport
case
achiev
rule
sp
greater
peg
test
tabl
sampl
rule
could
perform
combin
method
patient
assign
phenotypematch
transfus
test
refer
refer
laboratori
refer
test
sampl
success
rule
case
addit
patient
sampl
neg
antibodi
screen
htla
identifi
upon
workup
incompat
crossmatch
conclus
sp
use
avoid
interfer
htla
conclus
limit
sp
perform
sampl
inabl
use
select
cell
panel
sp
made
difficult
complet
rule
sampl
contain
multipl
ab
peg
test
avail
sampl
least
effect
manual
test
allow
flexibl
select
test
cell
ab
present
sp
peg
test
may
use
alon
combin
avoid
interfer
due
htla
potenti
decreas
number
patient
requir
phenotypematch
unit
due
incomplet
serolog
evalu
backgroundcas
studi
dau
famili
rhd
allel
character
allel
harbor
chang
associ
depress
alter
antigen
express
ancestr
allel
dau
allel
purport
evolv
srivastava
et
al
transfus
recent
summar
serolog
characterist
associ
antid
alloimmun
dau
famili
allel
investig
two
sampl
chang
refer
weak
antigen
express
studi
designmethod
serolog
test
perform
standard
tube
method
use
licens
antid
reagent
albaclon
partial
rhd
type
kit
genom
dna
isol
wbc
use
manual
array
assay
amplif
sequenc
rhd
resultsfind
sampl
yo
multiraci
femal
rbc
react
immedi
spin
iat
immucor
gammaclon
seri
iat
ortho
bioclon
antid
rbc
react
lhm
antid
partial
type
kit
pattern
match
defin
partial
epitop
pattern
rhd
beadchip
found
chang
rflp
detect
characterist
dau
rhd
sequenc
confirm
identifi
two
adjac
chang
exon
encod
sampl
rbc
react
iat
ortho
bioclon
quotient
albaclon
delta
nonreact
immucor
gammaclon
seri
quotient
albaclon
blend
alpha
antid
papain
treat
rbc
iat
ortho
bioclon
result
suggest
el
like
phenotyp
rhd
beadchip
found
chang
rflp
detect
sequenc
confirm
found
new
chang
exon
report
encod
stop
codon
japanes
vox
sang
conclus
report
two
new
allel
rhd
rhd
also
carri
characterist
african
dau
cluster
antigen
associ
partial
antigen
novel
epitop
pattern
chang
associ
dellik
phenotyp
first
observ
knowledg
dau
allel
antigen
rbc
detect
iat
commerci
antid
rhd
nucleotid
chang
report
dbsnp
databas
studi
bring
dau
famili
allel
number
divers
allel
dau
cluster
support
chang
major
ancestr
african
background
allel
wagner
et
al
blood
tae
eun
kim
krc
btri
backgroundcas
studi
case
antid
alloimmun
caus
transfus
serolog
neg
blood
compon
analysi
genotyp
blood
compon
confirm
asian
type
del
reason
applic
genet
analysi
blood
donor
requir
addit
serolog
assay
establish
algorithm
genet
analysi
rhdin
blood
donor
studi
would
introduc
experi
applic
algorithm
result
preliminari
test
studi
designmethod
septemb
present
day
got
sampl
repeat
blood
donor
known
neg
c
posit
andor
e
neg
blood
center
obtain
consent
test
donor
provid
sampl
genet
analysi
accomplish
polymeras
chain
reaction
sequencespecif
primer
pcrssp
region
promot
exon
exon
exon
rhd
gene
base
result
pcrssp
discrimin
result
total
rhd
delet
rhdced
hybrid
rhd
variant
result
discrimin
rhd
variant
addit
analyz
sequenc
exon
confirm
exist
variat
sampl
indetermin
result
perform
sequenc
full
region
exon
result
confirm
rhd
delet
rhdced
hybrid
blood
compon
regard
rhd
neg
result
confirm
rhdvariant
blood
compon
regard
rhd
posit
blood
compon
suppli
final
result
obtain
resultsfind
sampl
identifi
case
total
rhd
delet
case
rhdced
hybrid
case
rhd
variant
rhd
variant
determin
asian
type
del
variat
case
rhdvariant
regard
unknown
variat
conclus
frequenc
rhd
variant
studi
higher
gener
neg
donor
consid
rhce
phenotyp
previou
studi
reason
consid
genet
analysi
rhd
target
donor
neg
c
posit
andor
e
neg
effici
approach
identifi
rhd
variant
better
way
improv
blood
safeti
transfus
medicin
relat
rhd
neg
blood
donor
lei
fang
tsai
ping
chun
wu
shu
hui
feng
yi
wen
tsai
ming
hung
chen
shun
chung
pai
taipei
blood
center
taiwan
blood
servic
foundat
backgroundcas
studi
certain
abo
subgroup
physiolog
condit
may
lead
mixedfield
agglutin
abo
type
among
blood
donor
b
phenotyp
found
common
subgroup
taiwanes
howev
hard
distinguish
b
phenotyp
b
subtyp
also
mixedfield
agglutin
use
routin
serolog
without
genotyp
studi
aim
evalu
flow
cytometr
method
could
altern
differenti
differ
b
subtyp
mixedfield
agglutin
rather
use
molecular
genotyp
studi
designmethod
blood
sampl
taiwanes
blood
donor
exhibit
known
common
abo
phenotyp
includ
establish
normal
flow
cytometr
pattern
genotyp
blood
sampl
b
subtyp
donor
mixedfield
agglutin
routin
serolog
tube
method
gel
card
analyz
flow
cytometri
genotyp
flow
cytometr
method
perform
facscalibur
flow
cytometri
use
gammaclon
antia
b
genotyp
exon
exon
abo
gene
amplifi
sequenc
abo
allel
confirm
pcrrflp
analysi
resultsfind
among
subject
b
ab
phenotyp
genotyp
abo
abo
group
perform
similar
characterist
flow
cytometr
pattern
profil
reproduc
time
pattern
show
main
popul
cell
express
b
antigen
percentag
rbc
exhibit
b
antigen
level
diminish
increas
fluoresc
subject
b
ab
subject
genotyp
abo
abo
abo
abo
abo
display
flow
pattern
differ
abo
group
abo
abo
abo
subject
also
show
main
popul
cell
express
b
antigen
howev
less
percentag
rbc
exhibit
b
antigen
level
abo
abo
subject
abo
subject
abo
abo
display
wedgeshap
pattern
conclus
flow
cytometr
method
detect
b
antigen
rbc
might
use
discrimin
b
subtyp
mixedfield
agglutin
especi
abo
genotyp
approach
could
assist
serolog
abo
subgroup
clinic
refer
laboratori
frequenc
specif
solidphas
detect
erythrocyt
antibodi
solid
phase
test
worth
headach
karen
finegan
karen
gray
jill
adamski
theresa
kinard
qun
lu
backgroundcas
studi
effort
reevalu
autom
test
platform
autom
solidphas
red
blood
cell
adher
vs
autom
gel
column
agglutin
recent
initi
due
percept
excess
equivoc
reaction
solidphas
result
unnecessari
workup
one
site
hospit
system
data
avail
parallel
test
solidphas
gel
peg
perform
anoth
cite
hospit
system
collect
evalu
determin
frequenc
specif
solidphas
detect
erythrocyt
antibodi
see
solidphas
antibodi
workup
necessari
patient
care
studi
designmethod
throughout
transfus
servic
use
autom
solidphas
red
blood
cell
rbc
adher
primari
method
antibodi
screen
identif
solidphas
antibodi
screen
posit
sampl
retest
use
gel
column
agglutin
peg
method
manual
order
determin
method
use
antiglobulin
phase
crossmatch
rbc
product
antibodi
screen
result
three
method
final
antibodi
identif
result
transcrib
spread
sheet
analyz
resultsfind
total
patient
posit
solidphas
antibodi
screen
retest
gel
peg
antibodi
screen
patient
antibodi
reactiv
observ
solid
phase
concurr
gel
peg
test
complet
neg
clinic
signific
rbc
alloantibodi
warm
autoantibodi
clinic
insignific
antibodi
identifi
case
respect
rbc
alloantibodi
identifi
solidphas
includ
anti
antijka
antik
antijkb
anti
antic
see
tabl
conclus
solidphas
rbc
antibodi
clinic
import
signific
portion
case
roughli
case
workup
solidphas
antibodi
unnecessari
workload
transfus
correspond
antigen
neg
rbc
patient
prevent
possibl
hemolyt
transfus
reaction
fulllength
nucleotid
sequenc
allel
encod
duffi
fy
antigen
african
ethiopia
qinan
yin
kshitij
srivastava
addisalem
tayemakuria
willi
flegel
backgroundcas
studi
human
gene
previous
known
darc
compris
two
exon
singl
intron
encod
multipass
transmembran
glycoprotein
express
duffi
blood
group
antigen
fy
duffi
protein
act
chemokin
receptor
variou
proinflammatori
cytokin
malaria
parasit
plasmodium
vivax
p
knowlesi
studi
fy
variant
low
altitud
tropic
gambela
region
import
malaria
endem
endogen
popul
live
region
long
time
present
studi
determin
full
length
nucleotid
sequenc
gene
encod
fy
antigen
donor
ethiopia
southwestern
gambela
region
studi
designmethod
edtaanticoagul
whole
blood
collect
studi
volunt
gambela
region
whole
gene
amplifi
one
reaction
cover
base
pair
bp
primari
amplicon
reamplifi
use
nest
primer
cover
nucleotid
nucleotid
sequenc
obtain
sequenc
reaction
manual
annot
use
ncbi
refseq
sequenc
cover
bp
exon
bp
intron
bp
region
bp
bp
bp
region
encompass
variat
present
dbsnp
nhlbi
esp
databas
resultsfind
among
sampl
total
snp
includ
one
novel
snp
observ
snp
occur
exon
region
intron
individu
carri
snp
indic
common
phenotyp
individu
homozyg
heterozyg
gata
box
mutat
splice
site
mutat
detect
individu
observ
homozyg
heterozyg
snp
could
unambigu
assign
distinct
allel
remain
individu
heterozyg
snp
allel
specif
pcr
requir
identifi
allel
conclus
sequenc
kb
gene
identifi
least
differ
allel
present
studi
found
vast
major
allel
gambela
popul
defin
snp
similar
clinic
relev
fy
allel
turn
defin
snp
posit
c
remain
allel
similar
fy
fy
phenotyp
similar
fy
fy
x
phenotyp
high
frequenc
fy
studi
similar
studi
conduct
western
central
southeastern
region
gambia
mozambiqu
detail
analysi
includ
region
ethiopia
use
support
transfus
care
us
ethiopianamerican
major
may
mix
ethiopian
ethnic
background
judith
aeschlimann
sunitha
vege
christin
lomasfr
conni
westhoff
immunohematolog
genom
laboratori
new
york
blood
center
backgroundcas
studi
homolog
proxim
invert
orient
rhd
rhce
chromosom
favor
gene
convers
event
region
rhd
transfer
rhce
convers
result
hybrid
allel
encod
novel
absenc
high
preval
antigen
rhd
diiiac
common
hybrid
found
african
black
aros
convers
exon
rhce
ce
rhd
diiia
longer
encod
antigen
rather
somewhat
confusingli
encod
partial
c
antigen
rhd
locu
hybrid
allel
ci
rhce
ce
togeth
known
r
haplotyp
investig
atyp
rh
genotyp
result
three
sampl
two
associ
weak
type
one
patient
sickl
cell
diseas
scd
studi
designmethod
serolog
test
standard
method
genom
dna
isol
wbc
sampl
investig
hea
precisetyp
rhd
rhce
beadchip
rflp
rhcdna
sequenc
snpspecif
sequenc
use
establish
linkagephas
resultsfind
sampl
male
sampl
multiraci
femal
presum
present
weaker
expect
type
iat
rhd
beadchip
identifi
common
african
rhd
diiiac
hybrid
encod
partial
c
antigen
appar
convent
rhd
tran
result
provid
explan
weak
antigen
hea
indic
rhce
ce
ce
concord
rh
phenotyp
g
heterozyg
also
detect
rhce
ce
report
rhcdna
analysi
done
transcript
rhce
locu
includ
one
convent
rhce
ce
tran
rhce
ce
exon
replac
rhd
diiia
rhd
locu
one
convent
rhd
hybrid
rhd
diiiac
found
sampl
sampl
scd
male
rh
beadchip
one
convent
rhd
rhd
diii
type
rhce
rhd
diiia
type
never
found
either
rhce
allel
rhcdna
analysi
perform
transcript
repres
uniqu
convers
event
rhd
locu
specif
rhce
ce
exon
replac
exon
common
hybrid
rhd
diiiac
express
partial
c
antigen
lost
uniqu
hybrid
allel
deposit
genbank
report
two
differ
novel
complex
rh
rearrang
two
sampl
thought
uniqu
rhce
locu
repres
gene
convers
rhce
ce
design
rhce
cesdiiia
ce
kind
sampl
genotyp
diii
type
rather
novel
rhd
locu
repres
gene
convers
common
hybrid
design
rhd
diiia
ce
repres
novel
event
r
haplotyp
confound
rh
genotyp
interpret
interestingli
sampl
weaker
expect
antigen
type
despit
presenc
convent
rhd
rhce
ce
haplotyp
dce
import
investig
sampl
unconvent
result
interpret
rh
genotyp
highfrequ
antibodi
antilu
b
antiyt
multitransfus
patient
case
studi
nadia
baillargeon
carol
ethier
cynthia
parent
jessica
constanzoyanez
marys
stloui
marieclair
chevrier
andr
lebrun
hemaquebec
backgroundcas
studi
caucasian
femal
refer
immunohematolog
refer
laboratori
irl
serolog
investig
diagnos
anemia
renal
failur
cardiac
histori
hemoglobin
level
record
pregnanc
histori
provid
receiv
unit
pack
red
blood
cell
rbc
past
includ
unit
within
last
month
none
transfus
unit
phenotypicallymatch
refer
hospit
obtain
panreact
gel
lisssuspend
rbc
ficintr
rbc
neg
direct
antiglobulin
test
dat
autocontrol
studi
designmethod
aborh
dat
antibodi
identif
perform
h
emaqu
ebec
irl
accord
approv
techniqu
addit
lisssuspend
rbc
papaintr
rbc
trypsintr
chemicaltr
reagent
rbc
dithiothreitol
dtt
test
alloadsorpt
done
use
papaintr
allogen
rbc
r
r
r
r
rr
id
core
xt
platform
progenika
biopharm
grifol
vizcaya
spain
use
analys
polymorph
determin
antigen
includ
carthright
lutheran
blood
group
pcrssp
sequenc
specif
primer
pcrrflp
restrict
fragment
length
polymorph
also
perform
verifi
absenc
high
frequenc
antigen
yt
lu
b
sibl
sampl
also
request
conduct
famili
studi
resultsfind
initi
serolog
test
show
strongli
reactiv
panel
gel
liss
suspend
rbc
papaintr
rbc
well
trypsintr
rbc
dtttreat
rbc
neg
media
lead
probabl
antibodi
direct
highfrequ
antigen
alloadsorpt
procedur
allow
identif
antijk
select
panel
high
frequenc
antigen
absent
caucasian
popul
test
patient
sera
react
weakli
one
jk
lu
ab
reagent
cell
meantim
genotyp
result
confirm
probabl
phenotyp
patient
jk
lu
b
yt
addit
test
gel
use
trypsin
dtt
differenti
effect
antigen
lu
b
yt
perform
confirm
antibodi
specif
rbc
unit
jk
lu
b
yt
avail
transfus
select
unit
jk
lu
b
alloantiyt
known
caus
none
moder
transfus
reaction
daughter
sampl
type
yt
lu
conclus
serolog
studi
show
presenc
antijk
addit
two
antibodi
direct
high
preval
antigen
name
antilu
b
antiyt
associ
variou
select
serolog
procedur
combin
ethnic
clue
genotyp
result
serv
solv
uncommon
antibodi
combin
backgroundcas
studi
kel
blood
group
system
consist
antigen
encod
kel
gene
organ
exon
approxim
kel
allel
associ
kell
null
phenotyp
k
kell
antigen
express
allel
associ
kell
mod
phenotyp
k
mod
individu
k
mod
phenotyp
express
weak
amount
antigen
surfac
rbc
express
level
vari
base
allel
present
describ
molecular
serolog
test
perform
case
yearold
hispan
male
blood
donor
whose
rbc
phenotyp
kkj
b
kp
b
studi
designmethod
blood
donor
phenotyp
k
k
kp
b
js
b
antigen
use
standard
tube
agglutin
method
adsorpt
elut
studi
donor
red
cell
perform
use
commerci
antik
antisera
american
nation
red
cross
genom
dna
gdna
isol
edta
blood
tube
use
standard
techniqu
dna
genotyp
human
erythrocyt
antigen
use
precisetyp
tm
hea
molecular
beadchip
immucor
exon
flank
intron
sequenc
amplifi
sequenc
total
rna
extract
use
rneasi
lipid
tissu
mini
kit
qiagen
kel
cdna
amplifi
result
pcr
product
subject
sanger
sequenc
analysi
align
use
sequench
genecod
resultsfind
precisetyp
tm
hea
molecular
beadchip
test
predict
sampl
kp
js
kelcdna
sequenc
analysi
perform
detect
singl
transcript
speci
miss
sequenc
correspond
exon
amplif
exon
gdna
identifi
nucleotid
chang
compar
refer
sequenc
splice
site
intact
cdna
analysi
repeat
aberr
transcript
detect
adsorpt
elut
studi
k
antigen
demonstr
weak
antik
reactiv
incub
pegiggagt
phase
conclus
describ
donor
homozyg
novel
kel
allel
donor
presum
k
phenotyp
base
serolog
molecular
test
reclassifi
k
mod
phenotyp
extrem
weak
express
k
discoveri
aberr
transcript
led
adsorpt
elut
studi
confirm
presenc
weakli
express
k
antigen
red
cell
variant
allel
report
date
http
wwwisbtweborgworkingpartiesredcellimmunogeneticsandbloodgroupterminolog
associ
missens
mutat
contrast
allel
report
associ
aberr
mrna
transcript
propos
allel
name
kel
report
case
possibl
novel
b
subgroup
observ
pregnant
black
femal
patient
specimen
refer
refer
laboratori
investig
possibl
abo
discrep
refer
facil
report
patient
red
blood
cell
nonreact
reagent
antia
antib
patient
plasma
reactiv
cell
nonreact
b
cell
use
autom
gel
methodolog
studi
designmethod
serolog
test
patient
red
blood
cell
perform
use
routin
enhanc
method
molecular
test
pcrrflp
perform
determin
patient
genet
abo
type
predict
abo
phenotyp
resultsfind
serolog
test
patient
red
blood
cell
summar
tabl
similar
result
obtain
multipl
sourc
antisera
enzym
treatment
fail
enhanc
reactiv
patient
sera
strongli
agglutin
cell
fail
agglutin
multipl
sourc
b
cell
phase
test
molecular
test
pcrrflp
result
uncommon
band
pattern
indic
presenc
delet
g
characterist
allel
characterist
uncommon
allel
characterist
b
allel
genom
sequenc
exon
confirm
presenc
allel
abo
g
presenc
b
allel
reveal
chang
associ
previous
report
weak
subgroup
b
conclus
serolog
abnorm
pregnanc
report
due
decreas
antigen
express
unusu
weak
reaction
observ
test
patient
unlik
due
pregnanc
alon
addit
abo
gene
sequenc
requir
determin
specif
allel
mutat
respons
weaken
antigen
express
carin
arnoni
tatian
vendram
muniz
diana
gazito
afonso
cortez
lilian
castilho
flavia
latini
associa
beneficent
de
coleta
de
sangu
hemocentro
de
jo
e
rio
preto
hemocentro
unicamp
backgroundcas
studi
elucid
molecular
basi
vel
molecular
tool
use
explain
reduc
express
vel
antigen
differ
popul
neg
weak
reaction
gener
relat
delet
homozyg
heterozyg
statu
howev
nucleotid
chang
describ
reduc
vel
express
exampl
major
allel
snp
locat
second
intron
gene
regulatori
region
erythroblast
studi
aim
character
genet
chang
relat
atyp
vel
express
brazilian
popul
studi
designmethod
total
blood
donor
sampl
southeast
region
brazil
type
vel
antivel
serum
inventori
geliat
sampl
type
velneg
analyz
adsorptionelut
molecular
studi
perform
sampl
neg
result
sampl
react
sampl
reactiv
dna
isol
peripher
blood
sequenc
resultsfind
donor
sampl
studi
serolog
vel
neg
geliat
posit
adsorptionelut
present
reaction
remain
sampl
show
reactiv
genotyp
result
show
sampl
neg
result
sampl
present
reaction
heterozyg
bp
delet
present
allel
homozyg
statu
remain
sampl
reactiv
allel
allel
contrast
sampl
stronger
reaction
found
allel
sampl
allel
sampl
conclus
molecular
chang
locat
intron
distanc
nucleotid
studi
reinforc
associ
allel
reduct
vel
express
suggest
involv
new
chang
vel
express
conclus
sever
pattern
vel
express
found
differ
popul
influenc
differ
molecular
chang
backgroundcas
studi
antigen
immunogen
antigen
abo
consequ
misclassif
dantigen
patient
donor
sever
person
inherit
mutat
result
quantit
reduct
antigen
cell
surfac
weak
inherit
rh
haplotyp
result
biochem
effect
reduc
avail
antigen
reagent
antisera
ceppellini
effect
other
inherit
gene
qualit
differ
wild
type
latter
individu
often
identifi
form
antid
hypothes
person
risk
form
antid
might
uncov
weak
andor
dispar
type
result
reagent
recogn
differ
epitop
antigen
studi
designmethod
test
perform
use
microtiterwel
direct
agglutin
galileoneo
galileoecho
immucor
norcross
ga
specimen
react
rh
neg
neo
echo
rh
posit
seri
seri
antid
antisera
includ
patient
discrep
histor
type
also
evalu
specimen
meet
inclus
criteria
test
neo
echo
salin
tube
method
use
seri
seri
antid
antisera
genotyp
perform
whole
blood
sampl
sent
immucor
genotyp
laboratori
warren
nj
use
algorithm
rhd
beadchip
rhdxp
prototyp
assay
rhd
zygos
rhce
beadchip
resultsfind
patient
met
inclus
criteria
molecular
test
antigen
weak
rhd
variant
identifi
sampl
ceppellini
effect
ie
c
tran
rhd
result
weak
reactiv
seen
sampl
sampl
result
weak
discrep
reactiv
type
genet
caus
resolv
use
algorithm
test
sampl
result
indic
weakvari
protein
potenti
caus
alloimmun
antigen
remain
sampl
identifi
genet
caus
weak
andor
discrep
test
result
presumpt
classifi
wild
type
conclus
transfus
servic
use
galileoneo
galileoecho
perform
rh
type
consid
molecular
test
patient
whose
rh
type
result
discrep
posit
galileoneo
posit
galileoecho
half
patient
develop
antid
particularli
relev
femal
childbear
potenti
avoid
dposit
transfus
administr
rhig
pregnanc
prudent
type
confirm
molecular
test
carin
arnoni
tatian
vendram
muniz
rosangela
person
lilian
castilho
afonso
cortez
flavia
latini
associa
beneficent
de
coleta
de
sangu
hemocentro
de
jo
e
rio
preto
hemocentro
unicamp
backgroundcas
studi
rhd
rhce
major
protein
constitu
red
blood
cell
membran
compos
complex
togeth
rhag
mani
variant
rh
protein
describ
affect
integr
rh
protein
membran
antigen
express
affect
sever
molecular
chang
also
rhcehaplotyp
present
studi
investig
score
reactiv
sampl
present
strong
reduct
express
studi
designmethod
total
sampl
includ
studi
previous
genotyp
rhd
rhd
rhd
sampl
phenotyp
neov
r
immucor
cc
ee
antigen
direct
agglutinationin
micropl
result
obtain
neov
r
express
score
correspond
reaction
intens
zygos
assay
perform
multiplex
realtim
quantit
pcr
use
set
rhdspecif
primer
rhd
exon
rhce
genotyp
perform
pcrrflp
ssppcr
presenc
dcehybridexon
identifi
amultiplex
pcr
sequenc
identif
rhce
variant
also
perform
necessari
resultsfind
zygos
result
show
sampl
rhd
gene
phenotyp
genotyp
rhce
cerhcec
rhd
rhce
genotyp
sampl
show
presenc
dced
hybrid
gene
rhce
variant
investig
sampl
show
rhce
cearc
genotyp
sampl
rhce
genotyp
sampl
rhce
ce
ce
genotyp
tabl
describ
differ
found
reactiv
among
sampl
carri
c
ce
allel
sampl
homozyg
rhce
ce
result
show
presenc
rhce
c
ce
significantli
reduc
express
antigen
probabl
due
express
partial
c
partial
antigen
tran
rhd
addit
sampl
reduct
express
carri
rhce
variant
alel
phenotyp
use
provid
compat
blood
patient
rarerh
variant
allel
backgroundcas
studi
drug
known
interfer
routin
blood
bank
test
novel
monoclon
human
antibodi
bind
human
enter
clinic
trial
patient
acut
myeloid
leukemia
nonhodgkin
lymphoma
solid
tumor
describ
two
case
patient
treat
abo
discrep
extrareact
revers
type
panaggutinin
plasma
studi
designmethod
retrospect
review
two
case
immunohematolog
workup
show
abo
discrep
plasma
panagglutinin
first
case
year
old
femal
progress
follicular
lymphoma
enrol
phase
trial
combin
rituximab
design
patient
relapsedrefractori
b
cell
nhl
prior
transfus
histori
histor
blood
type
known
two
rbc
unit
request
anticip
surgic
procedur
second
case
year
old
male
refractori
diffus
larg
b
cell
lymphoma
enrol
clinic
trial
histor
blood
type
rh
posit
neg
antibodi
screen
receiv
three
rbc
unit
within
past
month
prior
test
receiv
therapi
resultsfind
abo
type
first
case
show
discrep
forward
type
antia
nonreact
antib
revers
type
cell
b
cell
rhd
type
posit
extend
reagent
rbc
panel
test
patient
serum
react
cell
test
immedi
spin
phase
lisspolyspecif
ahg
pegantiigg
plasma
reactiv
persist
dtt
ficin
treat
red
cell
remov
cold
autoadsorpt
cold
alloadsorpt
rest
adsorpt
repeat
test
avoid
read
nonreact
antihuman
globulin
ahg
phase
use
liss
peg
enhanc
rule
clinic
signific
alloantibodi
direct
toward
common
red
blood
cell
antigen
direct
antiglobulin
test
dat
autocontrol
neg
rbc
unit
issu
patient
crossmatch
compat
c
ahg
phase
abo
type
second
case
perform
administr
show
discrep
forward
antia
revers
b
cell
rhd
type
posit
antibodi
screen
perform
solid
phase
technolog
posit
reagent
red
cell
plasma
react
reagent
red
cell
liss
lisspolyspecif
ahg
dat
autocontrol
neg
genotyp
determin
full
rbc
phenotyp
dna
analysi
obtain
repeat
test
avoid
phase
show
reactiv
pegahg
exclud
alloantibodi
direct
toward
common
red
blood
cell
antigen
conclus
therapi
interfer
blood
bank
test
caus
abo
discrep
panagglutinin
reactiv
plasma
liss
ahg
phase
use
gammaclon
antiigg
unlik
interfer
knowledg
patient
blood
type
phenotyp
start
therapi
critic
provid
safe
blood
backgroundcas
studi
middleag
male
discrep
abo
type
result
investig
initi
forward
type
group
antib
seen
revers
type
unexpect
reaction
note
antia
b
reagent
genotyp
surprisingli
show
abo
consist
group
initi
test
refer
center
sampl
sent
extend
analysi
studi
designmethod
standard
serolog
method
flow
cytometri
use
panel
abo
reagent
lectin
test
nativ
papaintr
red
blood
cell
rbc
lewi
phenotyp
perform
genet
test
abo
papaintr
patient
rbc
use
screen
donor
plasma
two
reactiv
plasma
dtttreat
resultsfind
posit
reaction
obtain
polyclon
antia
b
monoclon
antib
clone
test
patient
papaintr
rbc
panel
lectin
gave
neg
result
genet
test
confirm
predict
group
rule
presenc
antigen
patient
le
thu
secretor
posit
crossmatch
seen
group
plasma
reactiv
obtain
b
plasma
dtt
treatment
crossmatchposit
plasma
indic
antibodi
mainli
igg
type
confirm
posit
flow
cytometri
cross
match
use
antihuman
igg
secondari
antibodi
reactiv
remain
bzyme
treatment
thu
exclud
normal
type
b
antigen
underli
reason
inhibit
lewi
substanc
significantli
decreas
reactiv
enzym
activ
assay
show
patient
plasma
contain
fulli
function
b
glycosyltransferas
suspicion
patient
nonerythroid
cell
produc
breactiv
type
chain
sampl
hematopoiet
stem
cell
transplant
hsct
patient
group
b
secretor
receiv
group
donor
cell
includ
control
gave
type
reaction
conclus
medic
histori
patient
queri
inde
undergon
hsct
year
earlier
reaction
like
due
uptak
recipientderiv
ble
b
type
antigen
isbt
domin
lewi
antigen
recipi
origin
blood
group
b
le
interestingli
bzyme
affect
ble
b
antibl
b
simpli
antib
plu
antil
b
insepar
rare
report
specif
appear
common
among
group
donor
phenomenon
report
unknown
clinic
implic
highlight
complex
carbohydr
blood
group
backgroundcas
studi
provuev
r
visionv
r
ortho
scientif
raritan
new
jersey
autom
analyz
use
mtsgel
tm
card
technolog
perform
immunohematolog
test
benefit
autom
test
includ
improv
effici
enhanc
reliabl
eight
year
use
provuev
r
transfus
medicin
servic
switch
ortho
visionv
r
analyz
januari
shortli
implement
technologist
report
increas
time
spent
perform
manual
resolut
indetermin
design
result
addit
test
column
note
visual
neg
call
posit
analyz
object
studi
investig
caus
appar
fals
posit
result
visionv
r
threecel
antibodi
screen
studi
designmethod
assist
ortho
diagnost
analyz
archiv
queri
identifi
number
gel
card
column
use
screen
number
column
result
gel
card
lot
number
use
test
reactiv
determin
fals
posit
base
supervisori
review
digit
imag
antibodi
panel
result
investig
also
includ
review
daili
qc
record
instrument
mainten
instrument
diagnost
camera
calibr
resultsfind
column
run
part
antibodi
screen
column
gener
result
assum
second
technologist
time
per
estim
hour
need
resolv
updat
result
among
potenti
caus
investig
gel
card
lot
number
associ
number
gener
tabl
case
three
column
visual
neg
analyz
report
reactiv
cell
case
mtsgel
tm
antibodi
identif
panel
perform
also
mtsgel
tm
ficin
panel
yield
panel
perform
two
routin
panel
weak
reactiv
cell
four
ficin
panel
weak
reactiv
appar
specif
fourteen
patient
coincident
subsequ
type
screen
neg
one
patient
newli
demonstr
antijka
fifti
percent
visual
neg
analyz
posit
sampl
test
gel
card
lot
number
lot
lot
conclus
incid
visual
neg
analyz
posit
result
depend
specif
lot
mtsgel
tm
card
use
differ
lot
investig
ortho
diagnost
remain
explain
avoid
unnecessari
wast
technologist
time
resourc
assist
ortho
diagnost
resultsfind
method
evalu
dtt
method
prove
use
mitig
dara
interfer
cord
cell
effect
limit
suppli
alloadsorpt
ineffect
three
differ
dtt
method
evalu
tube
method
initi
fail
led
reevalu
addit
liss
pass
gc
method
sensit
method
follow
releas
dara
sampl
patient
crossmatch
sampl
unit
issu
test
use
liss
tube
gc
iat
method
despit
dtt
treatment
gc
method
remain
posit
iat
patient
test
perform
eight
test
presenc
antibodi
confirm
rouleaux
format
observ
patient
reactiv
detect
transfus
reaction
report
date
alloantibodi
format
observ
date
conclus
previous
report
dtt
method
use
mitig
dara
interfer
observ
interfer
seem
due
rouleaux
andor
cold
reactiv
antibodi
seen
least
liss
tube
iat
may
due
wash
phase
techniqu
dissip
rouleaux
format
reactiv
due
cold
reactiv
antibodi
elimin
perform
strict
practic
use
dtt
iat
method
initi
patient
referr
residu
reactiv
gc
observ
use
liss
tube
prefer
thereaft
patient
observ
investig
panagglutin
could
includ
use
cord
cell
confirmexclud
dara
use
suspect
wendi
bere
sandra
nanc
david
moolten
p
dayand
borg
laboratori
test
random
allogen
blood
donor
autolog
donor
intend
repres
hospit
patient
popul
determin
mean
rang
normal
level
year
retrospect
studi
perform
assess
level
rbcbound
igg
iga
igm
normal
donor
studi
designmethod
residu
edtaanticoagul
aliquot
random
allogen
autolog
blood
donor
sequest
test
per
institut
review
board
approv
protocol
sampl
test
fc
fluorescein
isothiocyan
fitc
label
antihuman
igg
iga
jackson
immunoresearch
lab
west
grove
pa
fitclabel
antihuman
igm
life
technolog
carlsbad
ca
optim
dilut
dulbecco
pb
contain
bsa
becton
dickinson
facscalibur
tm
facscan
tm
san
jose
ca
fc
analyz
rbc
sampl
edtaanticoagul
sampl
ig
coat
control
rbc
test
determin
fc
set
control
valid
crossreact
control
react
expect
less
autolog
donor
test
mean
age
donor
could
older
allogen
donor
mean
age
allogen
donor
captur
despit
rel
small
number
sampl
test
higher
expect
instanc
allogen
donor
elev
rbcbound
iga
igg
igm
level
emphas
need
includ
test
normal
donor
popul
establish
expect
reactiv
thu
normal
abnorm
rang
flow
cytometr
test
long
rang
pcr
reveal
genet
basi
antibodi
pregnanc
high
preval
mn
antigen
judith
aeschlimann
anna
burgo
virginia
lew
sunitha
vege
susan
veneman
christoph
j
gresen
jonathan
hugh
conni
westhoff
immunohematolog
genom
laboratori
new
york
blood
center
blood
center
pacif
bloodsourc
backgroundcas
studi
recombin
event
gener
mani
gypa
gypb
hybrid
give
rise
glycophorin
gp
variant
express
lowpreval
antigen
eg
mia
mini
mur
rare
individu
homozyg
allel
associ
lack
highpreval
antigen
eg
enkt
eneh
enav
complex
hybrid
recombin
event
make
challeng
elucid
specif
allel
present
sampl
particularli
heterozygot
investig
sampl
pregnant
asian
hmong
woman
antibodi
unidentifi
highpreval
mn
antigen
sampl
sister
studi
designmethod
standard
method
use
rbc
type
licens
unlicens
reagent
antibodi
identif
dna
isol
wbc
hea
precisetyp
exonspecif
amplif
sequenc
gypb
exon
long
rang
sequenc
exon
amplicon
perform
snpspecif
primer
use
associ
chang
phase
specif
allel
resultsfind
rbc
pregnant
proband
type
ss
gammaclon
anti
plasma
reactiv
consist
antibodi
high
backgroundcas
studi
rhd
antigen
clinic
signific
immunogen
therefor
individu
develop
antid
risk
haemolyt
transfus
reaction
rhd
polymorph
show
substanti
ethnic
variabl
least
rhd
variant
associ
weak
allel
report
studi
report
two
new
rhd
allel
brazilian
blood
donor
associ
weak
antigen
express
studi
designmethod
statu
evalu
commerci
avail
monoclon
antid
reagent
blend
igmigg
clone
igm
clone
igg
tube
gel
card
c
c
e
e
phenotyp
perform
gel
common
weak
partial
allel
investig
allel
specif
pcr
rhd
beadchip
platform
immucor
direct
autom
sequenc
rhd
exon
flank
intron
region
perform
sanger
dideoxi
method
order
determin
rhd
allel
combin
also
perform
rhcdna
clone
sequenc
backgroundcas
studi
donor
neg
multipl
common
antigen
lack
high
preval
antigen
effici
identifi
use
red
blood
cell
rbc
genotyp
panel
serolog
use
confirm
antigen
neg
statu
discrep
identifi
albeit
rare
investig
discrep
often
lead
identif
variant
antigen
known
set
gyp
variant
associ
express
st
antigen
also
associ
n
type
discrep
meyer
et
al
br
j
haematol
st
allel
also
describ
gyp
hybrid
gypbgypatranscript
crossov
intron
sought
investig
five
n
type
discrep
altern
genotyp
methodolog
perform
found
concord
initi
panel
backgroundcas
studi
sampl
year
old
pregnant
african
american
femal
sent
blood
bank
aborh
antibodi
screen
sampl
analyz
use
provu
analyz
ortho
diagnost
patient
type
po
revers
type
discrep
retyp
sampl
perform
use
tube
method
biorad
reagent
per
hospit
polici
due
previou
aborh
histori
file
retyp
show
patient
subgroup
antia
antibodi
present
plasma
sampl
refer
genotyp
suspicion
like
phenotyp
genet
test
support
serolog
find
subgroup
new
abo
allel
abo
never
report
correl
like
subgroup
detect
studi
designmethod
patient
rbc
type
antia
immucor
antia
b
biorad
grifol
dg
gel
antia
antibodi
work
perform
use
three
differ
lot
cell
three
lot
cell
well
type
screen
cell
auto
control
tube
read
also
incub
rt
patient
initi
antibodi
screen
use
ortho
gel
neg
conclus
patient
deliv
healthi
babi
boy
week
gestat
babi
cord
sent
laboratori
babi
serolog
type
show
b
phenotyp
refer
genet
test
babi
rbc
show
abo
found
mother
previous
report
abo
allel
encod
aspart
acid
asparagin
chang
posit
consist
weak
phenotyp
also
least
five
allel
encod
phenoytp
consist
polymorph
posit
give
special
characterist
new
unreport
abo
allel
data
collect
conclud
aweak
phenotyp
encod
variant
allel
abo
highlight
clinic
relev
confirm
serolog
abo
subgroup
molecular
method
philip
berardi
jacquelin
cote
gwen
clark
vito
scalia
robert
liwski
mindi
goldman
canadian
blood
servic
backgroundcas
studi
elucid
molecular
basi
blood
group
express
led
develop
high
throughput
molecular
method
predict
blood
group
antigen
commonli
use
singl
nucleotid
polymorph
snp
array
requir
nucleic
acid
isol
typic
achiev
extract
genom
dna
whole
blood
method
requir
venipunctur
may
ideal
approach
sever
anem
patient
potenti
donor
unabl
provid
sampl
whole
blood
due
remot
locat
dna
extract
buccal
swab
sampl
offer
noninvas
altern
venipunctur
may
provid
safe
effici
mean
transport
sampl
remot
locat
refer
laboratori
extend
blood
type
predict
canadian
blood
servic
cb
perform
larg
scale
dna
extract
hla
genotyp
onematch
stem
cell
marrow
registri
use
buccal
swab
sinc
buccal
swab
also
use
unrel
donor
stem
cell
registri
us
nmpd
sought
assess
accuraci
reliabl
use
dna
extract
buccal
swab
predict
blood
group
antigen
express
studi
designmethod
perform
parallel
red
cell
genotyp
autom
type
platform
progenikagrifol
idcorext
assay
progenika
biopharmagrifol
bizkaia
spain
use
dna
extract
blood
buccal
tissu
volunt
antigen
system
avail
serolog
reagent
also
compar
result
serolog
type
evalu
three
differ
method
dna
extract
perform
test
regardless
dna
yield
puriti
two
buccal
swab
puritan
medic
product
guilford
main
use
test
swab
store
room
temperatur
dna
extract
perform
within
six
day
collect
initi
phase
studi
buccal
swab
sampl
n
process
autom
biorobot
robot
use
magattract
dna
mini
extract
method
qiagen
venlo
netherland
extract
dna
mean
concentr
puriti
respect
second
phase
studi
n
dna
extract
buccal
swab
perform
use
method
avail
nation
red
cell
immunohematolog
refer
laboratori
qiaamp
dna
mini
kit
use
either
manual
autom
qiacub
robot
workstat
qiagen
venlo
netherland
resultsfind
manufactur
recommend
analyt
rang
dna
concentr
recommend
puriti
absorb
ratio
use
id
corext
platform
dna
extract
buccal
swab
sampl
meet
specif
sever
case
howev
case
lower
concentr
dna
adequ
predict
phenotyp
dombrock
system
suscept
failur
interpret
sampl
low
dna
concentr
call
result
report
concord
genotyp
result
sourc
dna
extract
whole
blood
buccal
tissu
also
concord
predict
phenotyp
serolog
test
result
conclus
studi
support
use
genom
dna
extract
buccal
tissu
id
corext
predict
rbc
phenotyp
high
accuraci
extract
method
may
requir
optim
achiev
dna
yield
within
recommend
analyt
rang
assay
perform
evalu
id
rhd
xt
genotyp
assay
detect
highpreval
rhd
neg
weak
type
araitz
molano
izaskun
apraiz
azcar
miguel
angel
vesga
montserrat
rubia
merced
piedrabuena
fernando
puent
barbera
veldhuisen
ellen
van
der
schoot
onica
l
opez
progenika
biopharma
grifol
compani
centro
vasco
de
transfusi
tejido
humano
banco
de
sangr
tejido
de
arag
sanquin
blood
suppli
research
backgroundcas
studi
well
establish
weak
phenotyp
risk
form
alloantid
wherea
weak
partial
neg
phenotyp
routin
serolog
type
distinguish
among
consequ
rhd
genotyp
recommend
especi
patient
id
rhd
xt
progenika
grifol
qualit
pcrluminex
v
r
xmap
hybridizationbas
genotyp
test
identif
follow
rhd
gene
allel
variant
rhd
weak
type
rhd
weak
type
rhd
weak
type
rhd
delet
rhd
pseudogen
rhd
diiiac
gene
genom
dna
extract
whole
blood
specimen
studi
perform
id
rhd
xt
genotyp
assay
evalu
term
whole
system
failur
rate
call
rate
accuraci
rh
blood
group
type
studi
designmethod
cohort
previous
serotyp
sampl
antigen
obtain
three
european
blood
center
analyz
id
rhd
xt
progenika
sampl
distribut
recommend
annex
common
technic
specif
ivd
product
list
clinic
sampl
neonat
specimen
weak
donor
intend
use
product
weak
serotyp
donor
enrich
commerci
serolog
test
antigen
predict
phenotyp
bidirectionalsequenc
bd
weak
type
confirm
predict
phenotyp
use
comparison
transfus
resultsfind
system
failur
call
rate
inconclus
result
obtain
discrep
found
antigen
serolog
id
rhd
xt
predict
phenotyp
result
although
concord
obtain
analyz
bd
consid
id
rhd
xt
result
correct
concord
id
rhd
xt
bd
result
weak
type
follow
id
rhd
xt
predict
phenotyp
result
obtain
neg
amplif
variant
weak
type
weak
type
heterozyg
weak
type
weak
type
heterozyg
weak
type
weak
type
heterozyg
weak
type
detect
regard
blood
group
predict
phenotyp
result
obtain
id
rhd
xt
concord
bd
result
posit
neg
posit
neg
conclus
id
rhd
xt
genotyp
assay
perform
reliabl
accur
method
predict
genotyp
phenotyp
high
preval
rhd
neg
weak
type
specif
sensit
antigen
antigen
make
use
tool
implement
rhdgenotyp
recommend
patient
blood
transfus
antid
prophylaxi
backgroundcas
studi
scd
patient
form
red
blood
cell
rbc
antibodi
higher
rate
transfus
popul
multipl
predictor
alloimmun
report
well
replic
larg
scd
cohort
investig
clinic
laboratori
genet
predictor
alloimmun
studi
designmethod
larg
scd
cohort
establish
brazil
investig
diseas
outcom
particip
site
patient
current
transfus
abodcceekel
match
rbc
prophylact
extend
phenotyp
match
rbc
first
antibodi
form
polici
match
centerspecif
evolv
increas
level
match
exposur
period
includ
studi
transfus
subject
rbc
alloantibodi
defin
specif
within
cohort
compar
transfus
antibodi
neg
subject
use
chi
squar
compar
categor
variabl
ttest
wilcoxon
ranksum
test
appropri
compar
continu
variabl
backward
elimin
multivari
logist
model
use
gener
odd
ratio
identifi
independ
predictor
alloimmun
use
result
univari
analys
subject
peripher
blood
whole
genom
snp
type
perform
use
affymetrix
array
includ
enhanc
content
blood
relat
snp
genom
wide
associ
gwa
analys
conduct
use
logist
model
identifi
addit
genet
effect
associ
alloimmun
p
valu
clinic
analysi
gwa
consid
statist
signific
resultsfind
cohort
patient
transfus
subject
includ
alloimmun
children
year
alloimmun
adult
multivari
logist
regress
model
age
age
compar
gender
femal
compar
male
transfus
histori
p
transfus
compar
site
hemolysi
log
transform
lactat
dehydrogenas
presenc
autoimmun
disord
p
independ
predictor
alloimmun
gwa
identifi
singl
snp
unclear
biolog
signific
associ
alloimmun
eefsec
gene
respons
incorpor
selenocystein
protein
conclus
rbc
alloimmun
primarili
driven
transfus
burden
scd
cohort
hemolysi
remain
significantli
associ
alloimmun
control
transfus
presenc
autoimmun
diseas
also
associ
rbc
alloimmun
indic
system
immun
dysregul
may
present
scd
patient
develop
rbc
alloantibodi
howev
gwa
identifi
snp
immunoregulatori
gene
significantli
associ
rbc
antibodi
format
studi
popul
backgroundcas
studi
physiolog
anemia
sever
preterm
infant
worsen
blood
loss
requir
laboratori
test
reduc
iatrogen
anemia
placent
blood
otherwis
would
discard
use
laboratori
test
mother
infant
blood
mix
placenta
deliveri
pretransfus
test
result
potenti
alter
due
fetalmatern
hemorrhag
publish
studi
show
pretransfus
test
result
placent
blood
give
result
heel
stick
sampl
standard
practic
studi
designmethod
transfus
servic
test
sampl
pair
newborn
less
gr
birth
weight
one
sampl
collect
newborn
heel
stick
sampl
placenta
follow
test
perform
sampl
pair
abo
rh
antibodi
screen
direct
antiglobulin
test
igg
dat
resultsfind
abo
rh
dat
test
perform
sampl
pair
dat
test
neg
sampl
pair
two
posit
concord
abo
rh
dat
test
perform
sampl
pair
antibodi
screen
perform
placent
blood
sampl
heel
stick
sampl
twenti
eight
sampl
pair
neg
antibodi
screen
test
one
posit
heel
stick
sampl
also
posit
use
placent
sampl
one
heel
stick
sampl
neg
presenc
antibodi
found
posit
placent
blood
sampl
antibodi
detect
placent
sampl
passiv
antid
mother
receiv
pregnanc
discrep
result
indic
placent
blood
sampl
sensit
detect
weak
antibodi
conclus
studi
show
placent
blood
sampl
inferior
heel
stick
sampl
regard
abo
rh
dat
test
base
comparison
studi
placent
blood
use
pretransfus
test
g
birth
weight
newborn
b
among
test
donor
posit
common
rh
phenotyp
kell
blood
group
system
donor
k
posit
k
antigen
found
common
phenotyp
duffi
blood
group
system
fy
ab
fy
found
higher
frequenc
compar
report
black
popul
tabl
commonest
phenotyp
kidd
mn
blood
group
system
jk
respect
le
le
b
allel
seen
donor
respect
lu
b
phenotyp
found
donor
frequenc
rare
phenotyp
jk
ab
le
lu
ab
respect
found
frequenc
antigen
found
similar
report
caucasian
conclus
first
studi
examin
frequenc
rbc
blood
group
phenotyp
among
omani
blood
donor
result
show
higher
frequenc
rare
null
phenotyp
fy
ab
jk
ab
lu
ab
compar
report
caucasian
frequenc
duffi
blood
group
system
resembl
report
black
popul
data
help
understand
influenc
arab
ethnic
background
rbc
blood
group
system
warrant
larg
genotypephenotyp
studi
region
quantit
antid
serum
use
flow
cytometri
amanda
whiteloni
izeki
butler
karen
leighton
scott
jone
anand
srinivasan
qualtex
laboratori
backgroundcas
studi
rh
antibodi
antid
develop
rhneg
individu
expos
antigen
scenario
commonli
observ
alloimmun
antenat
volunt
immun
patient
quantit
antid
serum
import
clinic
set
predict
risk
hemolyt
diseas
newborn
quantit
antid
also
perform
qualiti
control
oper
organ
procur
organ
plasma
fraction
common
practic
report
strength
antid
serum
antibodi
titer
valu
qualiti
control
oper
requir
quantit
valu
develop
screen
assay
use
flow
cytometri
quantit
antid
serum
studi
designmethod
develop
method
quantit
antid
serum
use
flow
cytometri
modifi
protocol
christensson
et
al
hilden
et
al
red
blood
cell
rhposit
blood
sampl
wash
three
time
phosphatebuff
salin
pb
ph
supernat
discharg
dilut
buffer
contain
human
serum
albumin
vv
phosphat
buffer
salin
prepar
serum
sampl
antid
standard
suspend
dilut
buffer
mix
wash
red
cell
cell
suspens
incub
min
follow
incub
fitclabel
antiigg
dilut
buffer
ad
mixtur
incub
addit
min
sampl
analyz
flow
cytometri
use
gate
typic
red
cell
base
forward
sidescatt
signal
green
fluoresc
collect
use
bandpass
filter
set
event
record
frequenc
cell
resultsfind
multipl
dilut
antid
refer
standard
test
rhposit
red
blood
cell
five
differ
donor
reproduc
assay
determin
measur
chang
coeffici
varianc
due
dilut
procedur
machin
variat
sampl
storag
condit
optim
factor
linear
regress
calcul
establish
standard
curv
fluoresc
intens
emit
probe
demonstr
linear
correl
concentr
rh
antigen
refer
standard
serum
thirti
rh
immun
volunt
analyz
concentr
antid
result
benchmark
antibodi
titer
valu
conclus
base
studi
conclud
quantit
rh
antigen
flow
cytometri
use
reliabl
assay
measur
concentr
antid
antibodi
serum
method
reproduc
advantag
report
antibodi
titer
valu
oper
platform
translat
wellplat
base
highthroughput
flow
cytometri
sarah
k
harm
mark
yazer
nanci
dunbar
biomed
excel
safer
transfus
best
collabor
univers
vermont
medic
center
univers
pittsburgh
dartmouthhitchcock
medic
center
backgroundcas
studi
use
emerg
issu
group
plasma
uncrossmatch
group
whole
blood
wb
patient
without
valid
abo
group
becom
increasingli
common
usa
unclear
low
titer
product
provid
situat
inde
univers
agre
upon
threshold
would
qualifi
low
titer
establish
studi
design
determin
rate
high
titer
donor
use
titer
threshold
studi
designmethod
three
academ
hospit
routin
issu
group
plasma
unit
emerg
issu
particip
studi
issu
plasma
patient
dilut
donor
plasma
salin
produc
ad
group
b
reagent
red
blood
cell
rbc
degre
macroscop
agglutin
immedi
spin
observ
unit
consid
high
titer
would
issu
group
recipi
three
center
temperatur
plasma
volum
time
enhanc
perform
titer
procedur
antihuman
globulin
ad
one
center
sampl
taken
plasma
group
wb
unit
procedur
follow
use
b
reagent
rbc
least
one
antibodi
demonstr
macroscop
agglutin
immedi
spin
wb
unit
consid
high
titer
centrifug
rbc
unit
transfus
plasma
platelet
compon
discard
two
center
provid
plasma
test
data
period
respect
one
center
provid
plasma
wb
test
data
period
resultsfind
total
group
plasma
unit
test
high
titer
antib
rang
high
titer
group
plasma
unit
three
center
wb
unit
test
unit
high
titer
unit
high
titer
antia
high
titer
antib
high
titer
antia
antib
backgroundcas
studi
dithiothreiol
dtt
sulfhydryl
reagent
denatur
select
blood
group
antigen
reagent
red
blood
cell
rbc
treat
dtt
use
tool
identifi
antibodi
high
frequenc
antigen
recent
dtt
becom
wide
use
destroy
reagent
rbc
render
free
plasma
drug
interfer
procedur
prepar
dtt
publish
advoc
use
buffer
salin
differ
ph
level
studi
effect
ph
dtt
treatment
time
investig
studi
designmethod
nonbuff
salin
nb
thermo
fischer
scientif
inc
middletown
va
use
prepar
dtt
adjust
ph
ph
use
sodium
phosphat
dibasi
sigma
aldrich
saint
loui
mo
reagent
rbc
immucor
norcross
ga
treat
dtt
solut
parallel
mix
ratio
pack
rbc
dtt
solut
follow
incub
minut
treatment
express
k
antigen
measur
everi
minut
tube
method
use
differ
sourc
antik
assur
uniform
reaction
grade
investig
reaction
grade
rbc
antiserum
convert
semiquantit
score
averag
score
calcul
everi
minut
ph
level
reduct
averag
score
differ
ph
also
calcul
everi
minut
measur
impact
dtt
reagent
ph
rate
k
antigen
destruct
resultsfind
express
k
antigen
measur
agglutin
grade
two
differ
k
antisera
significantli
weaken
minut
dtt
treatment
ph
minut
minut
complet
loss
k
express
seen
minut
dtt
treatment
minut
minut
ph
reactiv
pattern
k
antigen
test
sourc
antik
correl
reduct
averag
score
seen
minut
rang
dtt
treatment
time
ph
rais
rang
rais
minut
rang
rais
conclus
use
higher
ph
buffer
salin
may
shorten
treatment
time
take
weaken
destroy
k
antigen
base
comparison
reaction
score
differ
ph
level
ph
level
impact
dtt
treatment
minut
andor
beyond
minut
incub
ph
dtt
reagent
rel
treatment
time
factor
consid
valid
dtttreatment
process
qualif
dtt
reagent
laboratori
backgroundcas
studi
data
characterist
frequenc
clinic
signific
red
cell
antibodi
within
prenat
popul
well
establish
unit
state
aim
studi
determin
frequenc
red
cell
antibodi
differ
geograph
distinct
region
within
continent
unit
state
studi
design
method
aim
retrospect
studi
evalu
cohort
prenat
patient
n
drawn
juli
june
patient
divid
unit
state
censu
bureau
region
division
categori
accord
place
resid
prenat
blood
work
collect
includ
abo
rh
screen
unexpect
alloantibodi
sampl
found
posit
red
cell
antibodi
sent
one
nine
region
laboratori
identif
result
find
total
patient
found
possess
clinic
signific
red
cell
antibodi
overal
incid
percent
three
commonli
encount
antibodi
antid
n
antim
n
anti
n
frequenc
total
prenat
women
found
possess
two
antibodi
gener
combin
antid
antic
prove
common
instanc
follow
anti
antic
antic
anti
multipl
antibodi
identifi
includ
least
one
antibodi
rh
blood
group
south
region
largest
number
antibodi
identifi
total
west
midwest
northeast
conting
tabl
use
twosid
fisher
exact
test
perform
compar
northeast
south
midwest
west
region
p
valu
antid
calcul
determin
nonrandom
associ
valu
deem
signific
regiontoregion
perspect
regard
antid
pacif
divis
compris
california
oregon
washington
alaska
p
valu
threshold
compar
seven
eight
divis
west
south
central
divis
texa
oklahoma
arkansa
louisiana
show
statist
signific
result
compar
pacif
divis
p
conclus
depend
upon
antibodi
statist
signific
variat
geograph
region
divis
within
unit
state
observ
relationship
antibodi
local
requir
investig
may
attribut
presenc
absenc
red
cell
antigen
among
differ
racial
ethic
popul
reduct
repeat
test
use
gel
technolog
ami
mata
lindsi
rich
sherri
stern
sharon
wangen
camil
van
buskirk
mayo
clinic
mayo
clinic
rochest
backgroundcas
studi
institut
current
use
immucor
neo
immucor
inc
norcross
georgia
perform
aborh
antibodi
screen
absc
test
util
solid
phase
technolog
result
unabl
obtain
immucor
neo
test
repeat
manual
test
bench
use
tube
agglutin
repeat
test
lead
signific
expens
includ
reagent
suppli
technologist
time
decid
leadership
laboratori
would
benefici
observ
methodolog
perform
regard
sidebysid
evalu
perform
immucor
neo
ortho
vision
ortho
clinic
diagnost
rochest
ny
determin
signific
differ
amount
repeat
manual
tube
test
need
perform
evalu
look
aborh
absc
test
test
current
autom
laboratori
studi
designmethod
thirti
specimen
process
immucor
neo
result
type
determin
ntd
aborh
test
select
test
ortho
vision
twentythre
specimen
process
immucor
neo
produc
posit
result
absc
test
select
test
ortho
vision
specimen
edta
tube
collect
within
previou
day
timefram
specimen
test
immucor
neo
ortho
vision
day
resultsfind
ntd
specimen
immucor
neo
result
valid
aborh
type
ortho
vision
three
result
flag
indic
possibl
extra
reactiv
upon
perform
visual
review
result
determin
reactiv
valid
result
present
sampl
requir
manual
tube
test
interpret
aborh
due
mix
field
weak
isoagglutinin
unexplain
extra
reactiv
hemolysi
absc
specimen
result
posit
immucor
neo
specimen
produc
neg
result
ortho
vision
confirm
neg
manual
tube
test
use
peg
enhanc
media
one
specimen
flag
fibrin
upon
perform
visual
review
determin
neg
nine
specimen
posit
immucor
neo
also
posit
ortho
vision
one
specimen
prove
antim
seen
gel
tube
one
specimen
display
unexplain
reactiv
gel
neg
tube
clinic
signific
antibodi
rule
show
discrep
result
monoclon
antic
reagent
similar
pattern
reactiv
reaction
sampl
test
polyclon
antic
show
reactiv
case
test
polyclon
monoclon
anti
show
weaken
reactiv
rhce
sequenc
genom
dna
cdna
show
mutat
exon
predict
encod
substitut
appar
r
r
donor
fneg
type
allow
predict
rhce
ce
genotyp
altogeth
result
consist
presenc
like
rhce
allel
c
e
ci
sampl
individu
reactiv
origin
sourc
slightli
weaker
compar
rhce
ce
rbc
sampl
avail
cryobank
conclus
result
confirm
mutat
alter
conform
properti
rhce
protein
either
ce
ce
background
encod
lowpreval
locr
antigen
locr
reactiv
appear
rather
similar
code
rhce
rhce
allel
quit
unexpect
find
sinc
substitut
close
critic
aminoacid
cc
express
none
case
made
antic
andor
anti
subject
potenti
alloimmun
background
howev
rhce
report
code
partial
c
rh
consid
rhce
like
encod
partial
c
e
also
support
predict
local
chang
second
extracellular
loop
rhce
protein
backgroundcas
studi
weak
genotyp
recommend
transfus
recipi
pregnant
women
newborn
rhd
type
discrep
serolog
weak
phenotyp
determin
carri
weak
genotyp
purpos
studi
analyz
underli
rhd
genotyp
patient
sampl
receiv
weak
genotyp
sinc
publish
recommend
particular
found
carri
weak
genotyp
studi
designmethod
sampl
receiv
weak
genotyp
test
perform
use
pcrrflp
target
sequenc
variant
rhd
gene
previous
defin
sampl
weak
type
genotyp
transfus
vol
supplement
evid
rhd
genet
sequenc
exon
andor
intron
preliminari
test
evalu
sanger
sequenc
rhd
rhce
exon
determin
underli
rh
genotyp
provid
patient
ethnic
presenc
antid
record
resultsfind
major
sampl
obstetr
patient
follow
transfus
patient
clinic
indic
provid
sampl
found
weak
type
sampl
respect
sampl
appear
genet
rhd
neg
genet
sequenc
perform
sampl
rhd
genet
variant
weak
type
tabl
variant
rhd
sampl
also
show
variat
rhce
gene
two
sampl
wild
type
rhd
allel
evalu
ongo
conclus
sampl
test
weak
genotyp
found
weak
type
sampl
evid
rhd
gene
carri
known
weak
type
polymorph
found
rhd
variant
underli
genet
variat
detect
rhd
gene
major
non
weak
type
variant
dar
allel
often
associ
antid
product
backgroundcas
studi
rhd
genotyp
recommend
guid
transfus
dneg
rbc
administr
rh
immunoglobulin
patient
discord
weaker
expect
type
particularli
femal
ob
patient
recommend
base
observ
evid
primarili
europ
flegel
curr
opin
individu
weak
type
risk
clinic
signific
antid
implic
util
approach
divers
us
popul
yet
clear
report
month
experi
rhd
genotyp
sampl
refer
discrep
weak
type
investig
januari
april
studi
designmethod
serolog
test
perform
standard
tube
agglutin
licens
reagent
dna
isol
wbc
use
manual
rflp
rhd
beadchip
assay
rhd
sequenc
ethnic
known
sampl
caucasian
african
americanafrican
multiraci
hispan
asian
resultsfind
rhd
genotyp
identifi
weak
type
allel
known
encod
partial
phenotyp
tabl
uncommon
rare
weak
allel
includ
type
found
partial
allel
found
divers
largest
number
includ
partial
rhd
dar
conclus
multiraci
cohort
individu
weaker
expect
type
due
weak
type
would
consid
risk
clinic
signific
antid
potenti
unknown
risk
studi
import
gain
insight
preval
specif
allel
us
multiethn
popul
continu
evalu
refin
rhd
genotyp
clinic
practic
rhd
allel
caus
discrep
genotyp
result
rhce
small
c
sabin
scholz
sandra
schneider
sabrina
onig
susann
helmig
vicki
van
sandt
innotrain
diagnostik
gmbh
rode
krui
vlaanderen
backgroundcas
studi
human
rh
blood
group
system
c
c
e
e
antigen
express
two
highli
homolog
gene
rhce
rhd
c
immunogen
rh
antigen
differ
c
c
caus
snp
posit
rhce
gene
rhd
allel
also
known
rhd
cat
vii
type
carri
snp
c
rhd
gene
addit
snp
c
rhd
allel
describ
partial
express
rhc
polypeptid
faa
transfus
aim
genotyp
perform
clarifi
caus
weak
c
express
serolog
patient
sampl
male
indic
partial
c
phenotyp
cde
studi
designmethod
rhd
rhce
phenotyp
done
accredit
routin
protocol
monoclon
ab
id
card
diaclon
rh
subgroup
seraclon
antic
genotyp
perform
taqman
probe
assay
rbcfluogen
veryfi
innotrain
diagnostik
gmbh
sso
rbclifecod
genprob
inc
inhous
ssppcr
hila
rode
kruisvlaanderen
commerci
ssppcr
rbcreadi
gene
cde
innotrain
diagnostik
gmbh
sanger
sequenc
rhd
gene
perform
use
inhous
method
innotrain
diagnostik
gmbh
resultsfind
discrep
genotyp
result
gener
differ
test
system
taqman
probe
base
assay
show
repetit
ccee
genotyp
sso
system
rbclifecod
predict
repetit
ccee
phenotyp
ssppcr
sampl
show
weak
c
band
inhous
method
band
visibl
commerci
test
kit
parallel
analysi
rhd
gene
rbcreadi
gene
cde
test
system
reveal
variant
cat
vii
rhd
allel
sequenc
dna
sampl
identifi
two
snp
one
rhd
allel
c
c
confirm
rhd
one
rhd
allel
hispan
femal
prepar
surgeri
result
variabl
reactiv
weakli
posit
reaction
use
microtiterwel
agglutin
versu
tube
test
determin
whether
antigen
express
repres
weak
variant
could
resolv
serolog
test
alon
report
character
novel
rhd
gene
mutat
identifi
rhd
gene
sequenc
studi
designmethod
serolog
type
initi
perform
microtiterwel
agglutin
autom
analyz
platform
galileo
neo
galileo
echo
immucor
norcross
ga
standard
tube
test
use
immucor
seri
antid
reagent
immunohematolog
evalu
perform
standard
tube
test
immedi
spin
indirect
antiglobulin
iat
use
orthobioclon
immucor
gammaclon
immucor
seri
seri
albaclon
antid
reagent
dna
isol
wbc
use
manual
rflp
rhd
beadchip
assay
immucor
bioarray
rhd
sequenc
resultsfind
rbc
reactiv
summar
tabl
dna
test
detect
hybrid
rhesu
box
associ
rhd
gene
delet
indic
patient
hemizyg
rhd
rflp
assay
rhd
beadchip
identifi
chang
rhd
gene
sequenc
identifi
new
g
chang
exon
encod
amino
acid
chang
predict
locat
chang
within
fourth
transmembran
segment
rhd
protein
conclus
identifi
novel
rhd
allel
g
chang
exon
sever
snp
delet
insert
report
chang
exon
phenotyp
genet
variat
result
rh
neg
weak
type
variant
sinc
chang
previous
identifi
unabl
determin
confer
risk
antid
alloimmun
rhd
g
snp
result
serolog
weak
phenotyp
express
antigen
test
microtiterwel
agglutin
neoecho
platform
case
combin
microtiterwel
agglutin
dna
sequenc
help
identifi
new
allel
would
miss
standard
tube
serolog
test
current
commerci
avail
array
assay
serolog
molecular
detect
antibodi
high
incid
antigen
patient
histori
chronic
transfus
georgia
spano
juan
merayorodriguez
christoph
lough
nanci
eckert
lifesouth
commun
blood
center
life
south
commun
blood
center
lifesouth
commun
blood
centerheadquart
backgroundcas
studi
jo
antigen
one
three
high
incid
antigen
dombrock
system
preval
antigen
popul
greater
black
popul
jo
antigen
resist
enhanc
enzym
treatment
ficinpapain
typic
variabl
dithiothreitol
dtt
warm
tm
immucor
zzap
treatment
antijo
igg
antibodi
demonstr
ahg
phase
hemolyt
transfus
reaction
jo
antigen
vari
none
moderatesever
hemolyt
diseas
fetu
newborn
hdfn
observ
antibodi
associ
dombrock
system
two
common
phenotyp
present
black
popul
hy
neg
jo
neg
hy
weakli
expressedjo
neg
studi
designmethod
antibodi
identif
red
blood
cell
rbc
unit
request
posit
year
old
africanamerican
femal
histori
sickl
cell
diseas
histori
pregnanc
patient
recent
transfus
howev
histori
chronic
transfus
last
report
transfus
three
year
prior
current
specimen
known
rbc
antibodi
time
request
facil
report
patient
hemoglobin
gdl
hematocrit
hgbhct
appear
sickl
cell
crisi
request
phenotyp
match
unit
per
hospit
polici
c
e
k
receiv
immunohematolog
refer
laboratori
irl
resultsfind
antijo
detect
patient
plasma
react
liss
peg
tube
method
manual
geliat
antibodi
resist
test
dtt
treat
red
cell
inhous
frozen
reagent
rbc
neg
jo
antigen
posit
hy
use
serolog
prove
presenc
antibodi
high
incid
antigen
allogen
peg
adsorpt
perform
rule
common
clinic
signific
antibodi
antikp
identifi
use
adsorb
plasma
test
molecular
genotyp
grifol
idcor
xt
confirm
patient
genotyp
antigen
neg
jo
kp
posit
hy
conclus
molecular
test
frequent
perform
patient
retain
donor
sampl
local
commun
donor
pool
throughout
florida
georgia
alabama
staff
abl
search
databas
combin
antigen
neg
phenotyp
use
intern
k
blood
establish
comput
softwar
bec
integr
blood
bank
inform
system
ibbi
enabl
us
locat
one
refriger
three
cryogen
preserv
jo
neg
rbc
unit
found
elig
blood
donor
could
recruit
via
automat
gener
call
list
request
rbc
cancel
patient
clinic
symptom
improv
without
transfus
repeat
hgbhct
increas
patient
sibl
histor
neg
jo
antigen
futur
transfus
requir
recommend
direct
donat
made
patient
behalf
order
continu
blood
compon
avail
meet
patient
need
irl
staff
consist
screen
search
inventori
blood
compon
neg
rare
antigen
retain
patient
need
antigen
neg
unit
time
fashion
rbc
two
femal
whose
sampl
refer
rhd
genotyp
previous
report
allel
serolog
reactiv
never
investig
studi
designmethod
serolog
test
perform
autom
analyz
galileo
echo
neo
immucor
norcross
ga
standard
tube
test
licens
antid
reagent
albaclon
advanc
partial
rhd
type
kit
genom
dna
isol
wbc
use
immucor
rhd
beadchip
assay
pcrrflp
rhd
sequenc
resultsfind
patient
yo
femal
whose
rbc
react
echo
neo
test
tube
gave
w
initi
spin
respect
indirect
antiglobulin
test
iat
rbc
nonreact
ortho
bioclon
biorad
seraclon
w
immucor
gammaclon
antid
iat
rbc
react
two
lhm
antid
alba
partial
kit
pattern
match
partial
identifi
clone
rhd
beadchip
detect
inact
rhd
pseudogen
tran
rhd
gene
sequenc
confirm
presenc
pseudogen
rhd
chang
encod
patient
yo
pregnant
femal
whose
rbc
w
iat
immucor
seri
gammaclon
moder
reactiv
iat
alba
alpha
alba
blend
delta
antid
rbc
react
two
lhm
antid
partial
kit
known
partial
pattern
dna
test
predict
rhd
hemizyg
rhd
beadchip
detect
marker
rhd
dar
exon
gave
low
signal
ls
sequenc
found
hybrid
dar
cespecif
nucleotid
exon
encod
amino
acid
chang
conclus
found
two
previous
report
rare
allel
rhd
previous
found
franc
lefloch
et
al
genbank
rhd
dar
part
exon
replac
rhce
report
subsahara
africa
granier
et
al
transfus
design
rhd
dar
allel
frequenc
blood
sampl
avail
test
alter
express
either
allel
provid
serolog
evid
allel
found
two
femal
evalu
rhd
genotyp
inform
transfus
rh
immun
globulin
prophylaxi
encod
partial
phenotyp
novel
epitop
express
pattern
mean
patient
risk
form
allo
antid
backgroundcas
studi
human
monoclon
antibodi
recogn
clinic
trial
treat
hematolog
solid
malign
transmembran
glycoprotein
bind
signalregulatori
protein
sirpa
macrophag
function
regul
phagocytosi
block
thought
enhanc
phagocytosi
promot
antitumor
respons
also
highli
express
rbc
purpos
studi
evalu
drug
interfer
blood
bank
test
studi
designmethod
serolog
test
perform
standard
method
serial
sampl
patient
test
cours
month
treatment
plasma
test
immedi
spin
iat
rr
rh
mod
rh
null
rbc
express
level
vari
depend
rh
phenotyp
dtt
enzym
treat
rbc
also
test
immucor
gammaclon
antiigg
detect
ortho
bioclon
antiigg
total
igg
use
titrat
plasma
dilut
pb
alloadsorpt
perform
papain
treat
rr
rbc
eluat
made
use
gamma
elukit
ii
resultsfind
observ
plasma
soon
hour
post
infus
plasma
react
panel
cell
peg
iat
use
ortho
antiigg
rh
mod
rh
null
rbc
nonreact
weaker
peg
iat
ortho
reagent
reactiv
panel
cell
ortho
igg
gel
card
contrast
iat
reactiv
use
gammaclon
antiigg
w
reactiv
confirm
carryov
agglutin
rh
mod
rh
null
nonreact
peg
iat
use
gammaclon
antiigg
titer
peg
iat
gammaclon
antiigg
ortho
antiigg
plasma
react
dtt
trypsin
papain
achymotrypsin
warm
treat
rbc
somewhat
unexpect
autocontrol
neg
dat
nonreact
microscop
acid
eluat
reactiv
ortho
nonreact
gammaclon
antiigg
plasma
reactiv
remov
alloadsorpt
papain
treat
rr
cell
sampl
low
level
reactiv
remain
peg
adsorpt
invalid
due
precipitationcomplex
antibodi
robust
plasma
reactiv
interf
abo
revers
type
observ
weak
spontan
agglutin
rbc
abo
forward
rh
type
conclus
therapi
interfer
routin
pretransfus
test
antibodi
screen
crossmatch
abo
rh
type
high
level
express
rbc
result
plasma
agglutin
mimick
reactiv
observ
igm
antibodi
although
reactiv
observ
phase
test
method
cleav
rbc
dtt
trypsin
papain
ficin
dtt
ficin
warm
achymotrypsin
treatment
rbc
mitig
interfer
numer
adsorpt
papain
treat
rr
rbc
requir
remov
reactiv
plasma
use
immucor
gammaclon
antiigg
detect
mitig
interfer
iat
although
carryov
reactiv
may
observ
due
block
patient
rbc
dat
autocontrol
weak
nonreact
howev
eluat
prepar
rbc
strong
panreact
use
ortho
antiigg
backgroundcas
studi
caucasian
woman
histori
caesarean
section
rbc
tx
august
admit
hospit
trauma
surgeri
ab
screen
neg
two
unit
transfus
without
transfus
reaction
five
day
later
refer
tertiari
care
trauma
center
due
sever
postop
infect
need
reoper
ab
screen
posit
antibodi
react
panel
cell
detect
urgent
need
rbc
tx
two
weakli
crossmatch
posit
match
unit
transfus
warn
possibl
alloantibodi
patient
got
acut
hemolysi
studi
designmethod
gel
techniqu
use
hospit
transfus
laboratori
addit
variou
antibodi
identif
panel
special
serolog
genotyp
method
use
refer
laboratori
kel
sequenc
done
intern
immunohematolog
center
resultsfind
hospit
transfus
laboratori
result
rhd
neg
dat
neg
ab
identif
untreat
enzymetr
cell
weakli
posit
autocontrol
sampl
submit
refer
laboratori
addit
investig
dat
weakli
posit
ab
identif
result
similar
hospit
result
differ
phenoand
genotyp
method
use
addit
sever
identif
panel
exclud
rare
blood
group
pk
vel
neg
jk
etc
exclud
kphenotyp
reveal
k
phenotyp
total
silenc
mutat
known
kel
gene
genotyp
kit
use
recogn
antiku
antibodi
react
cell
apart
k
phenotyp
presenc
dttsensit
antiku
confirm
dtttreat
panel
cell
antiku
may
caus
immedi
delay
hemolyt
transfus
reaction
sampl
taken
patient
two
sibl
daughter
kel
sequenc
reveal
kel
encod
report
individu
austria
two
known
k
patient
countri
homozyg
daughter
heterozygot
sibl
variant
new
oper
necessari
k
donor
avail
countri
help
isbt
rare
donor
work
parti
k
rhd
neg
donor
found
japan
one
unit
deliv
us
use
next
oper
conclus
alloantibodi
alway
suspect
autocontrol
weaker
panel
cell
reaction
even
direct
coomb
posit
combin
serolog
genotyp
approach
offer
best
solut
problemat
antibodi
case
compat
blood
alway
avail
rare
blood
group
case
intern
cooper
may
help
find
suitabl
donor
transfus
strategi
serolog
weak
phenotyp
tunisia
base
rhd
allel
rh
haplotyp
mouna
ouchari
kshitij
srivastava
houda
romdhan
saloua
jemni
yacoub
willi
albert
flegel
nih
dtmccnih
region
blood
transfus
center
souss
region
blood
transfus
center
souss
tunisia
backgroundcas
studi
antigen
variant
studi
molecularli
mani
arab
popul
includ
gaza
tunisia
egypt
libya
transfus
vol
supplement
sinc
tunisian
popul
largest
known
preval
weak
type
allel
occur
rh
haplotyp
compar
less
europ
systemat
studi
miss
sampl
serolog
weak
phenotyp
routin
found
blood
donor
patient
test
tunisia
studi
design
obtain
data
weak
type
popul
known
harbor
greatest
preval
allel
worldwid
studi
designmethod
total
random
blood
donor
serolog
screen
antigen
use
routin
techniqu
sampl
weak
reactiv
test
panel
monoclon
antid
partial
rhdtype
set
identifi
partial
phenotyp
rhd
gene
sequenc
sampl
serolog
weak
phenotyp
rhce
gene
also
test
molecularli
either
direct
sequenc
use
rhce
beadchip
kit
ascertain
rhce
allel
link
rhd
allel
resultsfind
total
discrep
sampl
observ
express
serolog
weak
phenotyp
among
carri
allel
weak
type
cluster
sampl
show
weak
type
allel
sampl
found
weak
type
dvii
sampl
show
consensu
rhd
sequenc
mutat
rhd
exon
detect
anoth
sampl
molecular
analysi
rhce
gene
show
sampl
serolog
weak
phenotyp
variant
rhce
allel
common
associ
weak
type
link
rhce
weak
type
cear
weak
type
rhce
rhd
allel
link
one
common
rhce
allel
conclus
almost
weak
phenotyp
tunisia
caus
allel
weak
type
cluster
repres
weak
type
allel
base
establish
rh
haplotyp
variant
rhd
rhce
allel
lack
advers
clinic
report
tunisia
recommend
posit
transfus
patient
rhig
administr
pregnant
women
weak
type
tunisia
propos
strategi
pragmat
clinic
decis
even
eventu
rare
alloantid
immun
would
occur
tunisia
associ
weak
type
phenotyp
possibl
rhce
allel
typic
associ
tunisian
individu
may
protect
alloantid
immunizaton
rhce
allel
rhce
ce
often
associ
individu
ethnic
group
may
howev
conclud
conjectur
much
evid
support
time
would
need
corrobor
experiment
clinic
data
use
guid
clinic
recommend
martha
rae
comb
heather
simmon
christin
lomasfr
gayan
shakarian
sunitha
vege
lauren
hutelmy
sandra
nanc
jessica
poisson
nichola
bandarenko
conni
westhoff
duke
univers
hospit
immunohematolog
genom
laboratori
new
york
blood
center
arc
pennjersey
american
red
cross
immunohematolog
refer
laboratori
biomed
servic
backgroundcas
studi
plasma
transfus
year
old
white
femal
post
liver
transplant
rbc
aplasia
react
rt
peg
iat
rbc
sampl
test
except
studi
designmethod
standard
hemagglutin
method
use
antibodi
id
antigen
type
acid
eluat
prepar
use
gamma
elukit
ii
immucor
genom
dna
isol
wbc
use
hea
precisetyp
array
kel
sc
gene
sequenc
sampl
proband
mother
test
applic
resultsfind
patient
dat
neg
plasma
react
dtttreat
papaintr
rbc
avail
rbc
sampl
lack
highpreval
antigen
phenotyp
similar
rbc
sampl
fy
reactiv
detect
titer
remov
prewarm
techniqu
peg
alloadsorpt
adsorb
plasma
react
dtttreat
rbc
extens
rbc
phenotyp
result
unremark
except
follow
js
kp
plasma
react
k
mcleod
rbc
sampl
dtttreat
rbc
rt
peg
iat
dilut
plasma
pretransfus
eluat
show
rel
kp
b
specif
patient
transfus
aliquot
crossmatch
incompat
kp
rbc
posttransfus
dat
antiigg
eluat
react
rbc
sampl
except
kp
sampl
toler
addit
aliquot
phenotyp
similar
rbc
untest
highpreval
kell
scianna
antigen
hea
precisetyp
predict
kp
js
discord
rbc
phenotyp
kel
gene
sequenc
identifi
homozyg
chang
kel
encod
low
preval
antigen
ul
chang
associ
lack
kell
system
antigen
howev
rbc
type
ul
sc
sequenc
found
heterozygos
chang
preval
convent
sc
predict
kel
sc
result
mother
kel
heterozyg
sc
chang
rbc
type
kp
consist
dna
predict
plasma
collect
month
later
nonreact
rt
peg
iat
rbc
type
kp
ul
concord
predict
kell
sc
phenotyp
conclus
report
exampl
kell
scianna
antigen
suppress
block
presenc
autoantibodi
alloantibodi
kel
system
knowledg
first
report
ul
kel
homozygot
rbc
may
lack
highpreval
antigen
antithet
ul
without
dna
test
gene
sequenc
patient
would
presum
kell
null
sc
null
phenotyp
search
k
andor
rbc
unit
would
perform
would
prompt
retyp
rbc
dat
neg
backgroundcas
studi
antijka
common
antibodi
identifi
blood
bank
provid
phenotyp
character
red
cell
lack
antigen
import
avoid
acut
delay
hemolyt
transfus
reaction
nearli
case
antibodi
identifi
context
phenotyp
homozyg
jkb
patient
jk
scenario
quit
rare
present
two
case
antijka
phenotyp
observ
studi
designmethod
patient
multipar
femal
known
transfus
histori
blood
type
posit
posit
antibodi
screen
neg
dat
clearli
identifi
antijka
plasma
patient
phenotyp
jk
ab
genotyp
reveal
presenc
jk
b
allel
jk
allel
complet
sequenc
jk
gene
show
intron
polymorph
homozygos
specif
patient
show
jk
b
genotyp
associ
jkb
null
phenotyp
anti
identifi
conclus
alloantijka
jk
null
patient
patient
receiv
transfus
patient
b
multipli
transfus
old
femal
blood
type
posit
posit
dat
antibodi
screen
plasma
eluat
reveal
antijka
despit
recent
transfus
patient
phenotyp
jk
jk
genotyp
show
presenc
jk
jk
ballel
whole
gene
sequenc
perform
hematolog
biochem
evid
hemolysi
patient
consid
autoantijka
jka
neg
cell
use
transfus
resultsfind
patient
b
develop
antijka
uncommon
phenotypesgenotyp
conclus
common
jk
null
patient
develop
howev
specul
express
kidd
glycoprotein
jkb
epitop
threshold
serolog
detect
enough
prevent
format
antijkb
autoantijka
usual
report
context
activ
hemolyt
process
patient
b
illustr
autoantijka
without
hemolysi
commonli
observ
autoantibodi
exhibit
specif
rh
epitop
rare
case
antijka
requir
phenotyp
genet
analysi
jkb
epitop
jk
b
allel
respect
complex
case
whole
gene
sequenc
backgroundcas
studi
donor
genotyp
red
blood
cell
antigen
becom
common
practic
mani
blood
bank
laboratori
packag
insert
commerci
assay
indic
fals
neg
result
may
gener
unexpect
rare
mutat
affect
primer
probe
bind
caus
allel
dropout
fail
amplif
outcom
may
go
unrecogn
unless
serolog
result
avail
comparison
studi
designmethod
routin
blood
donor
selfidentifi
african
american
select
red
blood
cell
genotyp
dna
extract
genotyp
perform
use
two
commerci
platform
transfus
vol
supplement
precisetyp
bioarray
warren
nj
idcor
xt
grifol
emeryvil
ca
genotyp
result
compar
histor
serolog
result
discrep
resolv
sanger
sequenc
grifol
ih
san
marco
tx
resultsfind
genotyp
result
show
variant
duffi
fy
kell
kel
blood
group
system
donor
genotyp
concord
platform
fy
afi
bgata
kp
akp
predict
phenotyp
fy
kp
genotyp
result
compar
histor
serolog
note
donor
previous
type
fy
separ
donat
previou
kpa
kpb
serotyp
avail
sequenc
fy
exon
reveal
mutat
known
silenc
fya
sequenc
kel
exon
expos
silent
polymorph
exon
c
polymorph
caus
dropout
artifact
yield
fals
neg
kpb
interpret
conclus
discrep
fy
result
well
unlik
kp
b
type
prompt
request
sequenc
rare
mutat
report
peopl
caucasian
descent
first
exampl
fy
mutat
identifi
region
popul
kpb
antigen
present
nearli
popul
howev
kp
b
frequent
seen
peopl
caucasian
descent
date
selfidentifi
african
american
donor
genotyp
kp
akp
b
blood
center
given
divers
region
heterogen
feasibl
identifi
kp
b
donor
selfreport
african
american
red
blood
cell
genotyp
offer
abund
inform
replac
serolog
sole
mean
red
cell
antigen
character
donor
ethnic
continu
play
key
role
select
genotyp
search
rare
unusu
red
cell
type
case
donor
select
genotyp
base
ethnic
initi
thought
genet
variant
previous
report
african
descent
proven
present
case
act
remind
genotyp
limit
must
consid
even
use
licens
methodolog
case
report
present
two
group
pediatr
patient
enter
feed
absentweak
antib
becam
strong
time
patient
studi
designmethod
patient
yearold
male
born
prematur
short
gut
syndrom
underw
small
bowel
liver
transplant
year
age
antib
chang
undetectableweak
strong
age
year
patient
monthold
femal
metabol
urea
cycl
disord
underw
liver
transplant
antib
patient
total
parenter
nutrit
tpn
sinc
birth
strong
antia
normal
immunoglobulin
test
abo
type
enhanc
techniqu
present
tabl
resultsfind
patient
type
group
forward
type
antia
strong
patient
antib
vari
strength
patient
reaction
year
age
thereaft
abo
type
show
mainli
strong
antib
patient
antib
conclus
intestin
bacteria
stimul
product
antia
b
unexpect
chang
antib
caus
abo
discrep
report
children
longterm
tpn
patient
absentweak
antib
sinc
birth
year
age
develop
strong
antib
chang
feed
regiment
medic
patient
consist
strong
antia
absentweak
antib
find
support
notion
normal
colon
gut
import
develop
antia
b
suggest
microflora
gut
patient
prolong
tpn
differ
lead
delay
format
antibodi
compar
individu
normal
enter
diet
differ
strength
antia
andb
could
due
stronger
b
antigen
express
gut
bacteria
resultsfind
daratumumab
protocol
establish
incorpor
use
cord
panel
multipl
myeloma
patient
select
candid
daratumumab
treatment
baselin
test
blood
type
antibodi
screen
dat
genotyp
daratumumab
infus
two
unit
crossmatch
order
precaut
event
patient
develop
reaction
medic
repeat
antibodi
screen
demonstr
panagglutin
serv
posit
control
medic
cord
panel
rule
underli
alloantibodi
select
red
cell
unit
crossmatch
immedi
spin
phase
avoid
expect
indirect
antiglobulin
reactiv
conclus
cord
panel
use
time
five
month
period
rule
underli
alloantibodi
test
daratumumab
protocol
consist
rout
antibodi
screen
follow
cord
panel
resolut
daratumumab
protocol
significantli
reduc
test
time
allow
provis
compat
blood
product
effici
cost
effect
manner
teresa
gorey
elizabeth
hart
brigham
women
faulkner
hospit
univers
massachusettsdartmouth
backgroundcas
studi
purpos
perform
pretransfus
antibodi
screen
detect
clinic
signific
unexpect
antibodi
decreas
probabl
detect
clinic
insignific
antibodi
sever
antibodi
detect
method
polyethylen
glycol
peg
liss
albumin
routin
use
small
transfus
servic
util
peg
enhanc
sensit
detect
clinic
signific
antibodi
indirect
antiglobulin
procedur
code
feder
regul
titl
cfr
part
state
manufactur
instruct
follow
test
unexpect
antibodi
packag
insert
gamma
peg
tm
immucor
inc
norcross
ga
state
neg
reaction
may
examin
optic
aid
base
direct
institut
polici
confirm
neg
reaction
use
microscop
studi
designmethod
oneyear
retrospect
document
review
perform
patient
sampl
posit
antibodi
screen
absc
trigger
antibodi
identif
abid
perform
total
sampl
evalu
abid
subcategor
new
antibodi
facil
patient
share
electron
health
record
within
partnersv
r
healthcar
system
whether
microscop
absc
result
trigger
abid
also
patient
known
antibodi
group
accord
microscop
absc
result
comparison
new
patient
previous
known
antibodi
patient
microscop
result
review
determin
antibodi
clinic
signific
resultsfind
total
abid
perform
new
patient
sampl
new
abid
sampl
microscop
absc
result
previous
known
antibodi
patient
account
total
abid
perform
review
total
abid
workup
total
absc
microscop
result
result
abid
perform
antibodi
identifi
new
antibodi
sampl
conclus
total
new
antibodi
identifi
base
microscop
absc
clinic
insignific
manufactur
direct
follow
state
optic
aid
requir
confirm
neg
result
due
result
studi
decis
made
discontinu
use
microscop
switch
peg
manufactur
whose
direct
indic
observ
macroscop
agglutin
defin
use
agglutin
viewer
optic
aid
decreas
number
abid
save
time
money
provid
potenti
rbc
transfus
time
effici
manner
anton
preval
greater
popul
hereditari
absenc
anwj
describ
singl
famili
howev
red
cell
express
anwj
may
markedli
decreas
near
undetect
level
blood
donor
lu
domin
lutheran
inhibitor
phenotyp
similarli
antianwj
antibodi
format
rare
case
report
literatur
antibodi
develop
context
hereditari
absenc
anwj
ie
true
alloantibodi
one
case
nine
case
antibodi
occur
context
autoimmun
lymphoprolif
diseas
context
believ
develop
secondari
transient
anwj
antigen
suppress
report
case
lack
clinic
laboratori
evid
hemolysi
howev
recent
report
case
involv
woman
aplast
anemia
antibodi
associ
acut
hemolyt
reaction
rbc
transfus
necessit
transfus
support
anwjneg
lu
rbc
case
also
uniqu
antianwj
result
direct
antiglobulin
test
dat
posit
complement
rather
igg
like
previou
case
dat
perform
posit
studi
designmethod
woman
sever
aplast
anemia
experienc
acut
hemolyt
transfus
reaction
ahtr
develop
panagglutinin
indirect
antiglobulin
test
iat
screen
prior
identifi
specif
panreact
antibodi
patient
receiv
rbc
transfus
show
sign
hemolysi
six
first
three
transfus
prior
posit
iat
electron
crossmatch
next
seven
transfus
incompat
antihuman
globulin
ahg
phase
crossmatch
extend
phenomatch
clinic
signific
antigen
patient
ahtr
sign
symptom
includ
fever
rigor
nausea
vomit
dark
urin
flank
pain
impend
doom
anxieti
laboratori
find
includ
hemoglobin
decreas
pretransfus
level
increas
total
bilirubin
ldh
dat
initi
neg
immedi
posttransfus
workup
transfus
reaction
eventu
becam
posit
igg
neg
reagent
antibodi
show
peak
geligg
iat
titer
resultsfind
antibodi
identifi
anwj
specif
patient
pretransfus
sampl
show
weak
anwj
express
altogeth
suggest
autoantianwj
monocyt
monolay
assay
test
use
patient
plasma
rbc
ahtrimpl
unit
yield
monocyt
indic
rang
consist
clinic
hemolysi
observ
given
patient
group
rh
neg
blood
type
continu
transfus
depend
order
avoid
ahtr
intern
collabor
necessari
order
procur
provis
group
rh
neg
rbc
also
serolog
neg
anwj
patient
success
transfus
three
unit
without
incid
conclus
second
document
case
antianwj
patient
aplast
anemia
overal
third
antianwj
case
associ
ahtr
case
also
underscor
import
intern
collabor
cold
autoantibodi
antip
antim
antisd
antil
b
antijk
antik
anti
antic
resultsfind
three
hundr
nineti
weak
genotyp
determin
day
frequenc
type
type
type
type
investig
conduct
determin
molecular
ident
other
sampl
confirm
legitim
serolog
weak
partial
mainli
delet
exon
exon
surpris
amount
sampl
discov
normal
rhd
conclus
along
sandler
et
al
data
find
highlight
difficulti
hospit
face
interpret
serolog
weak
trend
analysi
conduct
regard
reagent
technolog
use
hospit
origin
request
ethnic
concern
patient
signific
correl
could
identifi
point
altogeth
find
allow
share
frequenc
weak
type
obtain
serolog
weak
year
old
quebec
women
also
highlight
need
investig
standard
practic
amongst
hospit
regard
manag
interpret
atyp
type
classifi
fnhtr
taco
incid
trali
happen
period
prophylaxi
use
patient
conclus
fnhtr
describ
common
advers
event
relat
transfus
data
show
higher
incid
allerg
reaction
fnhtr
occur
time
less
allerg
reaction
might
explain
univers
leukoreduct
univers
prophylaxi
adopt
institut
studi
necessari
evalu
benefit
approach
associ
specif
rbc
unit
deem
unrel
transfus
rbc
transfus
ae
analyz
chisquar
test
logist
regress
use
compar
ae
incid
among
transfus
group
resultsfind
univari
multivari
logist
analys
show
irradi
rbc
associ
significantli
increas
incid
transfusionrel
ae
p
signific
differ
febril
nonhemolyt
transfus
reaction
fnhtr
vs
p
ae
nonallerg
type
inflamm
etiolog
vs
p
includ
transfusionrel
acut
lung
injuri
transfusionassoci
dyspnea
transfusionassoci
circulatori
overload
infect
hemolyt
transfus
reaction
irradi
rbc
nonirradi
rbc
contrast
incid
allerg
ae
vs
p
similar
two
group
incid
inflamm
ae
transfus
irradi
rbc
store
week
respect
p
logist
regress
signific
differ
incid
inflamm
ae
caus
irradi
rbc
store
week
longer
week
p
conclus
irradi
rbc
associ
higher
incid
transfus
inflamm
ae
compar
nonirradi
rbc
risk
increas
rbc
store
longer
week
irradi
like
patient
popul
factor
ae
caus
irradi
rbc
also
possibl
rbc
radiat
damag
shown
previou
studi
contribut
increas
ae
incid
list
patient
one
code
gener
emr
search
find
clinic
scenario
trali
mention
patient
record
search
within
laboratori
inform
system
copath
determin
transfus
reaction
report
transfus
medicin
servic
resultsfind
search
electron
medic
record
found
patient
trali
mention
chart
diagnosi
possiblelik
diagnosi
one
patient
exclud
studi
trali
mention
past
medic
histori
outsid
hospit
patient
trali
list
diagnosi
possibl
diagnosi
includ
studi
patient
clinic
scenario
transfus
blood
product
occur
follow
variou
form
respiratori
distress
clinic
team
care
patient
either
give
diagnosi
trali
consid
trali
possibl
diagnosi
case
report
transfus
medicin
servic
transfus
reaction
report
case
one
determin
trali
one
consist
taco
eight
case
never
report
backgroundcas
studi
despit
dilig
effort
transfus
safest
product
avail
patient
undetect
alloantibodi
may
caus
delay
hemolyt
transfus
reaction
dhtr
transfus
reaction
seen
mani
transfus
product
therapeut
plasma
exchang
tpe
may
employ
mitig
ongo
immun
mediat
hemolysi
report
literatur
describ
tpe
clinic
manag
profound
hemolysi
studi
designmethod
case
review
patient
perform
diagnosi
treatment
sever
dhtr
resultsfind
man
histori
gastrointestin
bleed
present
emerg
room
short
breath
hematuria
known
histori
antid
antic
transfus
two
unit
crossmatch
compat
rbc
seven
day
prior
previou
admiss
readmiss
hemoglobin
hb
gdl
declin
gdl
next
day
antibodi
screen
consist
antid
antic
direct
antiglobulin
test
dat
neg
receiv
three
unit
crossmatch
compat
rbc
day
poor
respons
day
routin
lab
could
report
due
mark
hemolysi
worsen
hematuria
creatinin
rose
mgdl
mgdl
refer
mgdl
lactat
dehydrogenas
report
linear
ul
refer
ul
test
reveal
addit
anti
antijkb
dat
plasma
free
hb
mgdl
refer
mgdl
hemoglobinuria
four
five
transfus
rbc
unit
jk
one
also
one
volum
tpe
perform
remov
free
hb
day
use
fresh
frozen
plasma
replac
fluid
haptoglobin
supplement
creatinin
peak
mgdl
day
decreas
mgdl
discharg
day
resultsfind
twenti
three
case
identifi
medic
record
avail
analysi
ten
patient
male
mean
age
year
rang
year
underli
hematolog
malign
bone
marrow
disord
histori
coronari
arteri
diseas
cad
implic
unit
includ
red
blood
cell
platelet
patient
receiv
singl
unit
receiv
two
within
previou
hour
mean
volum
transfus
ml
rang
ml
mean
time
onset
chest
pain
minut
sd
minut
patient
present
within
hour
within
hour
start
transfus
chest
pain
present
symptom
case
case
accompani
symptom
includ
dyspnea
fever
back
pain
hypoand
hypertens
posttransfus
chest
xray
perform
case
show
evid
pulmonari
edema
suggest
possibl
volum
overloadtransfus
associ
circulatori
overload
taco
electrocardiogram
perform
case
show
find
suggest
acut
ischemia
three
patient
minim
increas
troponin
level
although
histori
chronic
elev
troponin
due
stress
cardiomyopathi
fourteen
patient
receiv
form
treatment
includ
increas
oxygen
supplement
metoprolol
acetaminophen
morphin
oral
calcium
carbon
pain
resolv
minut
major
patient
case
result
new
admiss
icu
procedur
cancel
conclus
chest
pain
associ
transfus
infrequ
sever
case
identifi
review
period
symptom
diagnost
criterion
hemovigil
categori
merit
character
determin
whether
blood
product
transfus
could
caus
chest
pain
larger
observ
studi
power
clinic
character
could
help
inform
hypothes
regard
transfusionrel
mechan
could
interrog
translat
research
studi
backgroundcas
studi
thrombot
microangiopathi
tma
children
commonli
seen
form
hemolyt
urem
syndrom
hu
howev
tma
may
seen
presenc
streptococcu
pneumonia
spn
action
bacteri
neuraminidas
spn
result
exposur
normal
hidden
thomsenfreidenreich
antigen
tantigen
found
erythrocyt
tissu
ultim
may
lead
spn
induc
hemolyt
urem
syndrom
phu
subsequ
hemolysi
end
organ
damag
natur
occur
antit
antibodi
expos
antigen
specif
lectin
antisera
confirm
exposur
antigen
phu
altern
phu
identifi
minor
crossmatch
incompat
result
agglutin
expos
antigen
recipi
erythrocyt
antit
antibodi
plasma
portion
blood
product
present
case
suspect
phu
result
compat
minor
crossmatch
lead
concern
eventu
diagnosi
atyp
hu
ahu
studi
designmethod
month
old
boy
present
respiratori
failur
found
blood
cultur
posit
spn
well
hemolyt
anemia
thrombocytopenia
acut
renal
failur
shiga
toxin
neg
normal
level
adamt
base
find
clinic
team
concern
phu
therefor
receiv
wash
erythrocyt
thrombocytopenia
institut
routin
provid
wash
platelet
due
decreas
qualiti
platelet
product
result
minor
crossmatch
suggest
perform
determin
activ
present
resultsfind
minor
crossmatch
perform
patient
erythrocyt
plasma
aboident
platelet
transfus
agglutin
seen
immedi
spin
degre
antihuman
globulin
phase
check
cell
found
find
convey
clinic
team
platelet
issu
without
wash
due
lack
identif
activ
minor
crossmatch
poor
clinic
respons
despit
appropri
antibiot
treatment
addit
studi
perform
primari
team
complement
mutat
found
consist
ahu
patient
treat
eculizumab
clinic
laboratori
improv
present
case
clinic
consist
phu
confirm
diagnosi
done
lectin
antisera
readili
avail
altern
mean
identifi
phu
minor
crossmatch
incompat
demonstr
minor
crossmatch
compat
elucid
definit
diagnosi
ahu
appropri
manag
backgroundcas
studi
orthotop
liver
transplant
olt
complex
technic
challeng
procedur
complic
sever
intraop
bleed
report
case
massiv
transfus
olt
patient
necessit
abo
blood
group
switch
sustain
transfus
support
minimum
group
rbc
inventori
studi
designmethod
type
screen
ts
gel
antia
titer
tube
perform
use
routin
method
chart
review
perform
pertin
medic
laboratori
find
resultsfind
patient
man
cirrhosi
secondari
nonalcohol
steatohepat
antitrypsin
defici
present
olt
donor
olt
patient
endur
substanti
bleed
retroperiton
collater
vessel
complic
posttranspl
coagulopathi
requir
rapid
high
volum
rbc
plasma
support
strain
hospit
inventori
receiv
unit
rbc
unit
plasma
ongo
sever
hemorrhag
switch
group
product
ten
unit
plasma
transfus
wash
antia
antibodi
prior
transfus
rbc
due
difficulti
control
bleed
biliari
reconstruct
fascial
closur
delay
hour
posttranspl
patient
total
estim
blood
loss
receiv
total
unit
rbc
includ
unit
plasma
includ
unit
cryoprecipit
unit
platelet
toward
end
second
procedur
patient
hemorrhag
stabil
final
two
rbc
unit
receiv
postop
day
pod
ts
show
predominantli
rbc
trace
rbc
well
low
antia
igm
igg
titer
tabl
receiv
two
addit
rbc
unit
pod
pod
increas
rbc
ts
rise
antia
titer
blood
type
unequivoc
pod
patient
show
recoveri
liver
synthet
function
pod
factor
activ
complic
cholestasi
conclus
studi
show
success
switch
group
patient
group
set
rapid
hemorrhag
massiv
transfus
pod
patient
revert
recoveri
antia
titer
month
postolt
patient
aliv
sign
improv
biliari
graft
function
new
rfid
transfus
safeti
system
anna
millan
alfr
mingo
maria
isabel
gonzalez
antoni
mena
juan
pedro
benitez
bst
atbiotech
backgroundcas
studi
new
transfus
safeti
system
tss
base
process
technolog
especi
identif
radio
frequenc
rfid
current
implement
two
hospit
gener
one
oncolog
center
tss
fulli
effect
protect
incid
specif
offer
mechan
detect
near
miss
nm
use
procedur
physic
barrier
assur
pretransfusion
sampl
extract
pse
blood
compon
administr
bca
take
place
bed
side
use
locat
control
interact
clinic
transfus
inform
system
ti
tss
allow
analyz
transfusion
activ
inform
real
time
project
organiz
chang
transfus
servic
hospit
unit
creat
new
classif
nm
studi
designmethod
retrospect
analysi
transfus
activ
show
pse
bca
respect
sinc
tss
deploy
retrospect
analysi
classif
secur
event
done
resultsfind
activ
result
hospit
shown
tabl
safeti
event
classifi
pretransfus
sampl
extract
pse
blood
compon
assign
bca
transfus
servic
blood
compon
administr
bca
near
miss
nm
nm
relat
pse
account
mistak
concord
patient
identif
prescript
order
frequent
nm
detect
bca
mostli
occur
patient
inform
ti
match
one
regist
tss
nm
detect
bca
mostli
system
detect
assign
bracelet
nm
relat
pse
account
error
concord
transfus
secur
number
bracelet
pretransfus
sampl
frequent
nm
detect
bca
account
occur
patient
inform
ti
match
one
regist
tss
nm
detect
bca
blood
compon
assign
anoth
patient
analyz
via
commerci
avail
elisa
comparison
adequ
respons
defin
mcgml
serotyp
perform
base
alloimmun
statu
statist
signific
determin
compar
mean
subgroup
use
pair
nonpair
ttest
resultsfind
prevaccin
sp
titer
avail
patient
alloimmun
preand
postvaccin
titer
avail
patient
alloimmun
patient
chronic
transfus
hydroxyurea
surgic
splenectom
patient
histori
surgic
splenectomi
statu
unknown
fortyfour
patient
previou
histori
previou
year
also
report
previou
histori
sp
conjug
vaccin
within
last
year
baselin
prevaccin
titer
show
differ
alloimmun
nonalloimmun
patient
pvalu
group
preand
postvaccin
titer
avail
non
alloimmun
patient
adequ
respons
versu
alloimmun
group
p
backgroundcas
studi
blood
transfus
common
procedur
perform
hospit
set
transfus
process
monitor
ensur
regulatori
complianc
safeguard
safeti
efficaci
regulatori
complianc
transfus
servic
activ
benchmark
transfusionrel
error
tre
occur
veintovein
ie
collect
pretransfus
sampl
final
infus
product
goal
ensur
right
productdos
goe
right
patient
right
time
multipl
overlap
error
document
process
need
captur
report
tre
within
outsid
blood
bank
bb
present
comprehens
error
manag
program
along
data
five
year
benchmark
tre
larg
academ
medic
center
studi
designmethod
tre
detect
captur
report
sampl
suitabl
test
varianc
biolog
product
deviat
addit
tre
observ
report
provid
clinic
staff
ie
blood
delaysundertransfus
transfus
without
consent
infus
wrong
fluid
report
bb
hospit
qualiti
verita
system
hospit
base
report
system
enabl
report
occurr
potenti
caus
patient
harm
seriou
error
review
daili
summat
tre
discuss
monthli
basi
map
tre
within
veintovein
perform
review
fiveyear
transfus
medicin
qualiti
record
patient
harm
event
record
within
verita
system
januari
juli
investig
depth
transfus
reaction
exclud
analysi
resultsfind
averag
tre
per
month
per
year
found
five
year
tre
associ
prebb
activ
occur
within
bb
postbb
event
sampl
collect
handl
repres
total
tre
tre
report
bb
staff
report
nonbb
staff
patient
harm
analysi
reveal
averag
four
level
near
miss
three
level
known
harm
level
patient
harm
per
month
death
relat
tre
detect
seven
month
januari
juli
period
patient
harm
associ
tre
occur
bb
postbb
event
report
extern
bb
staff
conclus
although
tre
detect
prebb
phase
patient
harm
associ
event
indic
effici
captur
prior
caus
patient
harm
tre
caus
patient
harm
includ
near
miss
event
mostli
report
extern
occur
entir
postbb
bb
phase
result
suggest
signific
opportun
qualiti
improv
may
achiev
two
area
prebb
phase
aim
reduct
wast
associ
sampl
collect
handl
postbb
bb
phase
aim
improv
tre
detect
decreas
patient
harm
backgroundcas
studi
uncrossmatch
red
blood
cell
rbc
emerg
issu
platelet
plt
plasma
cryoprecipit
cryo
lifesav
bleed
patient
without
valid
type
screen
collect
term
emerg
issu
product
issu
bridg
pretransfus
test
complet
studi
evalu
util
wastag
rate
blood
product
pregnancyrel
hemorrhag
first
product
issu
emerg
issu
studi
designmethod
list
patient
blood
product
emerg
issu
januari
march
obtain
blood
bank
region
matern
care
hospit
patient
experienc
pregnancyrel
bleed
eg
postpartum
hemorrhag
bleed
relat
complic
pregnanc
ruptur
ectop
pregnanc
bleed
post
spontan
therapeut
abort
exclud
total
number
product
emerg
issu
plu
crossmatch
nonemerg
issu
product
transfus
return
back
blood
bank
inventori
wast
within
hour
first
emerg
issu
product
enumer
apheresi
plt
unit
multipli
ad
number
individu
whole
blood
plt
apheresi
plasma
unit
multipli
ad
number
whole
blood
plasma
unit
resultsfind
seventi
women
receiv
emerg
issu
blood
product
pregnancyrel
hemorrhag
identifi
averag
age
major
patient
pregnancyrel
hemorrhag
receiv
least
one
unit
emerg
issu
blood
product
receiv
least
one
unit
product
issu
unit
wast
plt
wastag
higher
product
like
due
postpool
room
temperatur
shelf
life
keep
wastag
rate
low
meet
clinic
need
patient
ideal
situat
blood
bank
patient
blood
platelet
higher
prophylact
therapeut
transfus
l
vs
l
signific
differ
frequenc
effect
therapeut
vs
prophylact
vs
transfus
prc
find
signific
differ
prc
prophylact
vs
therapeut
vs
transfus
prophylact
vs
therapeut
vs
transfus
signific
differ
prc
also
prophylact
vs
therapeut
vs
pc
transfus
reduct
sever
bleed
obtain
case
prpc
transfus
case
transfus
signific
differ
frequenc
advers
posttransfus
reaction
group
respect
case
backgroundcas
studi
endtoend
electron
transfus
manag
process
includ
bedsid
administr
system
develop
implement
larg
multisit
academ
center
enabl
safe
administr
blood
compon
patient
bedsid
provid
audit
trail
blood
compon
error
identifi
electron
bedsid
transfus
process
report
nation
hemovigil
scheme
categori
error
relat
inform
technolog
error
incorrect
use
emerg
transfus
process
nonemerg
transfus
standard
nonemerg
process
requir
scan
barcod
patient
wristband
contain
identif
detail
verifi
detail
barcod
compat
label
attach
blood
bag
emerg
transfus
option
intend
use
emerg
group
rhd
neg
blood
unit
unlik
nonemerg
unit
alloc
specif
patient
compat
label
emerg
transfus
option
skip
compat
label
barcod
scan
emerg
unit
transfus
patient
need
urgent
transfus
found
emerg
blood
option
misus
nonemerg
transfus
lead
blood
unit
check
ensur
correct
patient
studi
designmethod
center
work
softwar
supplier
develop
solut
correct
weak
process
revis
process
involv
provid
univers
compat
label
emerg
unit
unit
emerg
nonemerg
requir
scan
compat
label
blood
bag
patient
wristband
bedsid
transfus
use
emerg
process
audit
pre
post
implement
new
process
determin
whether
use
correctli
resultsfind
unit
administ
use
emerg
transfus
process
month
chang
implement
found
unit
nonemerg
unit
administ
incorrectli
without
bedsid
compat
check
follow
implement
chang
instanc
incorrect
administr
nonemerg
unit
next
month
compon
administ
emerg
unit
administ
correctli
user
system
report
revis
process
quicker
safer
unifi
function
devic
conclus
improv
process
administr
blood
emerg
prevent
user
follow
incorrect
procedur
nonemerg
transfus
miss
essenti
final
bedsid
electron
check
report
indic
need
continu
vigil
function
electron
transfus
process
correct
weak
compromis
patient
safeti
backgroundcas
studi
recent
recommend
indic
one
red
blood
cell
rbc
unit
transfus
time
reassess
transfus
determin
need
howev
practic
canadian
transfus
medicin
tm
expert
constitut
reassess
unknown
therefor
conduct
survey
tm
expert
across
canada
gather
inform
practic
criteria
reassess
studi
designmethod
tm
expert
identifi
contact
inform
obtain
canadian
nation
advisori
committe
nac
contact
least
one
tm
expert
per
provinc
respond
assign
uniqu
studi
id
consent
survey
allow
anonym
analysi
survey
contain
demograph
gener
practic
question
question
regard
transfus
stabl
anem
inpati
stabl
anem
inpati
discharg
asymptomat
postop
inpati
resultsfind
identifi
canadian
tm
expert
provid
respons
primari
place
practic
laboratori
set
stabl
nonbleed
anem
inpati
respond
recommend
transfus
one
rbc
unit
reassess
recommend
variabl
outpati
set
gener
recommend
transfus
two
rbc
unit
reassess
recommend
reassess
mainli
function
statussymptom
vital
within
short
time
period
hour
repeat
hemoglobin
hour
later
depend
clinic
scenario
search
underli
caus
anemia
outpati
set
lab
practition
emphas
volum
statu
cardiac
examin
transfus
lower
hemoglobin
threshold
asymptomat
patient
discharg
fewer
respond
chose
transfus
compar
inpati
potenti
symptomat
due
anemia
none
respond
suggest
transfus
asymptomat
postop
patient
hemoglobin
trend
conclus
tm
expert
gener
recommend
transfus
one
unit
time
stabl
inpati
assess
transfus
focu
patient
symptom
pertin
physic
exam
hemoglobin
level
underli
caus
topup
transfus
recommend
recommend
may
help
guid
clinician
research
need
gener
higher
qualiti
evid
around
clinic
benefit
cost
effect
practic
backgroundcas
studi
current
evalu
red
blood
cell
rbc
post
transfus
recoveri
base
ex
vivo
label
store
rbc
radioact
cr
method
sever
limit
includ
risk
associ
radioact
inabl
evalu
multipl
rbc
popul
recipi
rbc
label
snhsbiotin
biorbc
overcom
mani
limit
offer
safe
longitudin
track
multipl
transfus
rbc
vivo
purpos
studi
scale
optim
biotinyl
procedur
current
good
manufactur
practic
gmp
environ
studi
designmethod
pack
rbc
unit
divid
two
aliquot
label
select
concentr
snhsbiotin
lgml
cgmp
close
system
averag
biorbc
hematocrit
optim
label
efficaci
determin
flow
cytometr
analysi
biorbc
use
fluorochromeconjug
streptavidin
sa
approxim
million
rbc
measur
triplic
quantum
simpli
cellular
bead
use
quantifi
fluorochrom
molecul
equival
solubl
fluoresc
mesf
infer
number
biotin
molecul
per
rbc
lower
limit
detect
determin
rbc
label
vari
amount
biotin
product
qualiti
safeti
evalu
endotoxin
steril
test
determin
level
spontan
hemolysi
rbc
biotin
label
resultsfind
investig
differ
fluorochrom
laser
excit
wavelength
laser
power
maxim
signal
nois
ratio
label
unlabel
rbc
reveal
excit
phycoerythrin
pe
sa
high
laser
power
provid
best
separ
two
biorbc
popul
label
unlabel
rbc
label
biotin
result
mesfrbc
detect
among
unlabel
rbc
lower
limit
detect
lld
ci
rbc
label
biotin
ml
million
biotinyl
associ
increas
level
hemolysi
label
versu
label
bacteri
contamin
conclus
result
manufactur
process
produc
larg
volum
biorbc
low
risk
contamin
hemolysi
flow
cytometri
assay
detect
biorbc
unlabel
blood
low
frequenc
plan
use
technolog
studi
impact
donor
characterist
rbc
storag
stabil
posttransfus
surviv
backgroundcas
studi
blood
product
offer
resuscit
benefit
trauma
crystalloidcolloid
volum
expand
provid
hemostat
benefit
oxygen
deliveri
usag
often
hamper
suppli
storag
need
hemoglobinbas
oxygen
carrier
hboc
red
cell
replac
may
supplement
oxygen
deliveri
expand
volum
transport
blood
avail
sinc
hemostasi
critic
resuscit
studi
evalu
bovin
hemoglobin
effect
coagul
paramet
alongsid
freezedri
plasma
fdp
vitro
model
hemorrhageresuscit
studi
designmethod
whole
blood
wb
collect
healthi
donor
approv
institut
standard
oper
procedur
first
studi
limit
resuscit
sampl
wb
hboc
volum
model
two
unit
adult
fdp
fdp
sampl
simul
autoresuscit
ad
plasmalyt
suscept
lysi
test
tissu
plasminogen
activ
tpa
followup
studi
perform
sever
resuscit
simul
volum
replac
hboc
andor
fdp
without
prior
plasmalyt
dilut
coagul
paramet
obtain
coagul
analyz
thromboelastographi
teg
rbcshemoglobin
measur
hematolog
analyz
thrombin
gener
quantifi
thrombogram
platelet
aggreg
measur
multipl
adhes
collagen
shear
bioflux
viscos
evalu
rheolog
resultsfind
limit
resuscit
model
hboc
andor
fdp
effect
fibrinogen
pt
aptt
ph
hct
hemoglobin
teg
wb
reduc
clot
strength
dilut
tpa
increas
suscept
tpainduc
lysi
wb
autodilut
simul
mean
lysi
vs
p
hboc
fdp
statist
signific
impact
thrombin
gener
effect
platelet
aggreg
observ
signific
differ
within
dilut
v
undilut
group
seen
platelet
adhes
flow
hboc
significantli
chang
viscos
sever
resuscit
simul
increas
ptptt
reduc
clot
strength
particularli
hboconli
resuscit
howev
even
hboc
volum
replac
produc
clot
accept
teg
paramet
conclus
limit
resuscit
model
signific
vitro
effect
hemostat
paramet
except
increas
suscept
lysi
sever
resuscit
impact
coagul
paramet
prevent
clot
consid
larg
impact
healthi
platelet
coagul
function
vitro
studi
impair
platelet
warrant
alongsid
vivo
studi
initi
resuscit
hemorrhag
shock
therapi
patient
acut
major
bleed
publish
literatur
larg
focus
efficaci
safeti
pcc
actual
usag
practic
less
character
aim
describ
pcc
usag
practic
within
tertiari
care
center
studi
designmethod
conduct
retrospect
review
electron
medic
record
patient
receiv
pcc
addit
institut
formulari
compil
inform
usag
pcc
patient
descript
statist
gener
microsoft
excel
resultsfind
patient
warfarin
pcc
frequent
prescrib
hemorrhag
due
surgeri
pcc
given
warfarin
revers
case
subset
patient
receiv
plasma
within
hour
prior
pcc
hour
pcc
frequent
order
orperiop
servic
conclus
major
pcc
usag
offlabel
term
prescrib
indic
warfarin
revers
frequent
indic
hemorrhag
due
surgeri
pcc
often
order
orperiop
servic
although
guidelin
recommend
use
pcc
plasma
altern
plasma
administ
within
hour
pcc
notabl
subset
patient
backgroundcas
studi
emerg
situat
patient
life
may
jeopard
delay
transfus
physician
may
decid
transfus
blood
emerg
howev
case
poor
commun
lack
clear
expect
blood
bank
patient
care
area
lead
frustrat
delay
time
provis
blood
product
incid
prompt
apprais
emerg
releas
protocol
erp
reveal
gap
commun
expect
blood
bank
nurs
personnel
thu
imper
standard
er
protocol
clear
commun
blood
bank
nurs
personnel
report
outcom
process
improv
result
improv
commun
expect
turnaround
tat
er
protocol
studi
designmethod
sever
meet
conduct
stakehold
critic
care
unit
icu
emerg
depart
ed
intern
medicin
intervent
radiolog
ir
etc
effort
identifi
process
gap
improv
commun
expect
er
episod
goal
design
process
emerg
blood
product
request
releas
life
threaten
situat
simplifi
expedit
process
improv
commun
expect
decreas
tat
improv
patient
safeti
meet
complianc
order
achiev
goal
seri
activ
conduct
includ
meet
stakehold
ensur
process
improv
meet
need
intend
seri
train
session
nurs
educ
icu
ed
ir
surgeri
manag
conduct
meet
commun
goal
expect
defin
agre
upon
train
session
includ
powerpoint
present
educ
staff
member
perform
dri
run
identifi
weak
strength
process
flow
impact
current
process
analyz
result
led
revis
current
sop
addit
prelabel
emerg
pack
blood
unit
neg
rbc
implement
electron
emerg
blood
order
set
resultsfind
ten
month
post
implement
improv
standard
er
pack
protocol
total
er
episod
receiv
averag
tat
order
deliveri
bedsid
reduc
minut
compar
minut
previous
complianc
rate
er
order
physician
document
current
wastag
blood
product
conclus
implement
improv
standard
er
protocol
significantli
improv
commun
expect
decreas
tat
delay
transfus
ensur
patient
safeti
complianc
regulatori
requir
backgroundcas
studi
massiv
transfus
mt
trauma
set
extens
studi
yet
literatur
nontrauma
area
especi
oncolog
rather
spars
follow
studi
conduct
understand
background
outcom
mt
cancer
patient
studi
designmethod
singl
center
retrospect
studi
perform
larg
cancer
center
februari
februari
mt
defin
transfus
rbc
unit
period
follow
data
collect
includ
age
gender
primari
diagnosi
surgeri
acut
care
type
amount
type
blood
compon
transfus
whether
massiv
transfus
protocol
mtp
activ
surviv
day
resultsfind
thirti
mt
occur
one
year
period
total
blood
product
transfus
time
period
gender
distribut
male
averag
age
patient
rang
year
age
surgic
patient
account
mt
critic
care
patient
tumor
categori
includ
carcinoma
sarcoma
leukemia
lymphoma
resect
tumor
follow
complex
reconstruct
caus
major
mt
metastat
renal
cancer
common
diseas
seen
follow
sacral
chordoma
mtp
activ
case
thirtyday
surviv
seen
patient
mortal
surgic
case
periton
mesothelioma
remaind
caus
gi
hemorrhag
perisplen
hematoma
overal
ratio
rbc
ffp
entir
patient
backgroundcas
studi
plasma
strawcolor
supernat
blood
use
type
screen
crossmatch
analyt
phase
test
plasma
examin
prior
process
plasma
occasion
becom
discolor
interf
crossmatch
procedur
time
identif
etiolog
allow
correct
action
minim
delay
transfus
studi
designmethod
analyt
phase
blood
bank
test
sampl
evalu
crossmatch
identifi
three
sampl
discolor
plasma
present
seri
case
illustr
test
process
resultsfind
woman
diagnos
breast
cancer
present
mastectomi
sentinel
lymph
node
biopsi
preoper
specimen
contain
bright
green
plasma
review
preoper
case
reveal
exposur
intraven
methylen
blue
dye
known
alter
color
urin
tear
blood
known
pharmacolog
effect
altern
caus
green
plasma
includ
dye
use
locat
sentinel
node
oral
contracept
use
although
ideal
sampl
could
use
crossmatch
tube
method
autom
gel
techniqu
specimen
drawn
one
week
later
contain
clear
plasma
woman
diagnos
warm
autoimmun
hemolyt
anemia
refractori
blood
transfus
secondari
alloantibodi
administr
synthet
blood
product
result
dark
maroon
color
plasma
common
caus
dark
red
color
hemolysi
sampl
usual
discard
instanc
hemoglobin
color
due
infus
product
experiment
bovin
pegyl
carboxyhemoglobin
affect
colorimetr
evalu
blood
sampl
mind
sampl
discard
test
complet
tube
method
woman
admit
acut
stroke
treat
thrombolyt
reveal
cloudi
white
plasma
could
use
crossmatch
procedur
common
caus
white
plasma
includ
purul
hypertriglyceridemia
sampl
blood
drawn
proxim
administr
radiopaqu
agent
propofol
although
etiolog
could
identifi
repeat
specimen
drawn
sever
hour
later
clear
conclus
case
highlight
import
appropri
evalu
discolor
plasma
discolor
sampl
identifi
repeat
sampl
requir
confirm
chang
color
first
two
case
discolor
persist
prompt
clinic
investig
etiolog
identifi
need
test
elig
transfus
determin
test
tube
method
could
perform
two
case
third
case
repeat
sampl
reveal
clear
sampl
transfus
process
continu
without
delay
decis
regard
analyt
phase
test
must
includ
reevalu
sampl
identif
etiolog
comprehens
regard
proceed
discolor
persist
caleb
weishin
cheng
rebecca
ross
christoph
tormey
amit
gokhal
yale
univers
school
medicin
yalenew
hospit
va
connecticut
healthcar
backgroundcas
studi
daratumumab
dara
monoclon
antibodi
therapi
specif
target
glycoprotein
highli
express
plasma
cell
success
use
patient
refractori
relaps
multipl
myeloma
dara
interfer
blood
bank
test
bind
express
red
blood
cell
caus
pan
reactiv
dara
interfer
overcom
use
dithiothreitol
dtt
treat
reagent
red
blood
cell
minim
alloimmun
provid
crossmatch
compat
blood
treat
patient
institut
dara
protocol
blood
bank
purpos
retrospect
studi
identifi
outcom
protocol
particular
focu
develop
de
novo
alloantibodi
dara
treatment
institut
studi
designmethod
dara
patient
antibodi
workup
complet
use
dtt
pretreat
reagent
red
blood
cell
antibodi
screen
neg
k
antigen
neg
rbc
product
provid
antibodi
identifi
k
neg
along
particular
antigen
neg
blood
provid
electron
medic
record
emr
search
patient
receiv
dara
past
eight
month
studi
subject
examin
see
preexist
alloantibodi
dara
treatment
whether
form
new
alloantibodi
dara
treatment
age
gender
type
screen
predara
treatment
type
screen
postdara
interven
blood
transfus
date
first
dara
treatment
record
resultsfind
overal
subject
identifi
analysi
mean
age
year
male
femal
subject
diagnos
multipl
myeloma
found
alloimmun
rate
prior
administr
dara
patient
transfus
red
blood
cell
rbc
initi
dara
therapi
follow
testingmatch
protocol
none
patient
form
confirm
new
alloantibodi
dara
treatment
patient
underw
least
one
followup
screen
first
rbc
unit
also
found
complic
provid
crossmatch
compat
unit
patient
conclus
knowledg
largest
case
seri
report
result
overcom
dara
interfer
blood
bank
type
screen
test
protocol
implement
laboratori
appear
success
provid
compat
unit
prevent
alloimmun
patient
receiv
dara
therapi
possibl
drug
target
antibodi
form
cell
may
immunosuppress
effect
humor
respons
studi
effect
may
warrant
backgroundcas
studi
multifacil
transfus
servic
began
stock
liquid
plasma
septemb
use
massiv
transfus
trauma
situat
due
infrequ
occurr
incid
liquid
plasma
would
outdat
use
polici
use
liquid
plasma
nonemerg
situat
unit
near
expir
date
implement
studi
evalu
effect
polici
inr
valu
plasma
recipi
studi
designmethod
retrospect
analysi
develop
compar
effect
fresh
frozen
plasma
ffp
liquid
plasma
lqp
chang
inr
valu
recipi
plasma
unit
transfus
within
facil
septemb
april
identifi
follow
data
obtain
hospit
laboratori
inform
system
unit
recipi
primari
reason
transfus
plasma
number
plasma
unit
transfus
type
plasma
transfus
preand
posttransfus
inr
valu
whether
vitamin
k
administ
patient
divid
group
base
type
plasma
unit
transfus
evalu
base
primari
reason
transfus
number
unit
transfus
administr
vitamin
k
chang
inr
recipi
calcul
along
averag
chang
inr
group
backgroundcas
studi
gynaecolog
set
rel
young
anaem
women
iron
defici
due
blood
loss
associ
menstruat
transfus
could
gener
avoid
without
haemodynam
instabl
oral
antifibrinolyt
drug
tranexam
acid
effect
well
toler
treatment
menorrhagia
besid
iron
replac
often
necessari
prolong
period
time
normal
haemoglobin
hb
present
studi
attempt
look
transfus
appropri
use
iron
tranexam
acid
transfus
women
hong
kong
studi
designmethod
anonym
data
gynaeolog
patient
age
retriev
central
databas
public
hospit
includ
age
number
unit
red
cell
transfus
preand
posttransfus
hb
use
iron
andor
tranexam
acid
hospit
upon
discharg
transfus
episod
associ
surgic
oper
admiss
exclud
resultsfind
uniqu
women
receiv
total
unit
red
cell
rc
transfus
episod
identifi
median
age
rang
distribut
preand
posttransfus
hb
unit
rc
transfus
summar
cohort
preand
posttransfus
hb
absent
transfus
episod
associ
use
unit
rc
result
episod
result
post
transfus
hb
parenter
iron
tranexam
acid
uncommon
hospit
given
women
respect
upon
discharg
women
prescrib
oral
iron
alon
oral
tranexam
acid
alon
respect
howev
neither
given
women
conclus
present
studi
observ
transfus
episod
given
hb
substanti
number
episod
transfus
multipl
unit
result
almost
half
post
transfus
hb
level
iron
replenish
bleed
control
transfus
women
given
iron
tranexam
acid
discharg
result
indic
awar
transfus
appropri
iron
defici
anaemia
manag
improv
recommend
indepth
educ
train
provid
better
gynaecolog
patient
blood
manag
backgroundcas
studi
granulocyt
transfus
may
util
boost
immun
respons
patient
lifethreaten
neutropenia
neutrophil
dysfunct
evid
treatmentrefractori
bacteri
fungal
infect
howev
granulocyt
rare
administ
due
uncertainti
regard
efficaci
difficulti
collect
increas
propens
advers
reaction
report
case
granulocyt
transfus
therapi
follow
chimer
antigen
receptor
tcell
cart
therapi
patient
sever
neutropenia
multipl
infect
context
relaps
bcell
acut
lymphoblast
leukemia
ball
studi
designmethod
granulocyt
per
unit
collect
aboident
unstimul
donor
region
blood
center
unit
irradi
gy
transfus
hour
within
hour
time
collect
patient
respons
laboratori
data
review
medic
record
conclus
data
suggest
diagnosi
aml
associ
antihla
antibodi
increas
frequenc
blood
group
patient
aml
report
statist
signific
differ
abo
blood
group
frequenc
found
categori
except
patient
hla
antibodi
blood
group
b
signific
associ
hla
alloimmun
studi
patient
report
larg
studi
femal
blood
donor
differ
hla
antibodi
frequenc
observ
base
abo
blood
group
center
use
flowbas
assay
although
reason
higher
rate
group
b
blood
type
among
patient
antihla
antibodi
hematolog
malign
unknown
could
due
variat
immun
event
pregnanc
vs
transfus
immun
dysregul
relat
hematolog
malign
especi
aml
femal
aml
blood
group
b
appear
like
hla
alloimmun
among
patient
hematolog
malign
implement
electron
solut
reduc
risk
mistransfus
region
transfus
servic
debra
lane
lee
grabner
brenda
herdman
robert
falli
amin
kabani
charl
musuka
canadian
blood
servic
kenora
rainyriv
region
laboratori
program
diagnost
servic
manitoba
backgroundcas
studi
patient
misidentif
improp
sampl
label
ongo
risk
safeti
blood
transfus
rate
mistransfus
remain
unchang
year
attempt
made
reduc
mistransfus
includ
barrier
devic
barcod
rfid
within
region
backgroundcas
studi
role
donor
age
sex
hemoglobin
content
suscept
hemolysi
storag
red
blood
cell
rbc
unit
receiv
increas
attent
howev
impact
donor
characterist
efficaci
rbc
transfus
studi
largescal
donorrecipi
outcom
databas
studi
designmethod
conduct
analysi
use
blood
donor
data
routin
collect
blood
center
transfus
recipi
data
larg
commun
hospit
network
patient
blood
manag
initi
linkag
perform
blood
donor
characterist
hospit
rbc
transfus
recipi
receiv
singl
rbc
unit
studi
exposur
analysi
blood
donor
sex
age
addit
rbc
storag
age
wilcoxon
test
use
examin
chang
hemoglobin
level
follow
rbc
transfus
male
recipi
rbc
male
femal
donor
similar
pretransfus
hemoglobin
level
gdl
howev
transfus
recipi
male
donor
rbc
unit
higher
posttransfus
hemoglobin
level
larger
increment
hemoglobin
compar
femal
rbc
unit
vs
gdl
vs
gdl
femal
recipi
larger
rise
hemoglobin
per
rbc
unit
compar
male
recipi
gdl
vs
gdl
p
femal
sex
recipi
remain
signific
predictor
chang
hemoglobin
account
recipi
age
estim
circul
blood
volum
multivari
analysi
rbc
storag
age
age
donor
signific
factor
chang
hemoglobin
level
multivari
analysi
respect
conclus
rbc
unit
male
donor
result
larger
rise
hemoglobin
level
compar
femal
donor
chang
appar
femal
recipi
even
account
effect
circul
blood
volum
suggest
dose
hemoglobin
lower
femal
male
rbc
unit
analysi
demonstr
feasibl
use
approach
studi
associ
donor
characterist
rbc
efficaci
hemolysi
donorcomponentrecipi
interact
backgroundcas
studi
peopl
identifi
jehovah
wit
jw
compris
less
popul
unit
state
howev
group
present
special
challeng
medicin
due
religi
avers
blood
product
base
biblic
read
degre
religi
refus
vari
individu
individu
institut
polici
conserv
approach
warrant
howev
larg
institut
multipl
team
manag
singl
patient
blood
refus
inform
lost
poorli
commun
provid
provid
system
alert
provid
patient
blood
refus
recent
implement
electron
medic
record
larg
westcoast
institut
studi
designmethod
electron
medic
record
emr
util
studi
institut
modifi
version
epic
ea
best
practic
alert
bpa
design
trigger
time
end
user
attempt
place
order
relat
blood
transfus
transfusionrel
lab
test
humanderiv
pharmaci
item
patient
blood
refus
code
histori
problem
list
religion
jehovah
wit
discret
data
field
alert
constitut
softstop
order
provid
prompt
either
cancel
trigger
order
acknowledg
blood
refusalreligi
histori
overrid
warn
option
select
reason
overrid
data
trigger
automat
collect
emr
system
gener
report
informat
personnel
resultsfind
avail
data
cover
trigger
two
month
postimplement
bpa
bpa
trigger
time
total
affect
patient
user
stratifi
locat
major
trigger
occur
periop
area
time
liver
icu
time
minor
occur
regular
hospit
floor
emerg
depart
nurs
attend
resid
pharmacist
nurs
anesthesiologist
user
affect
order
trigger
bpa
includ
type
screen
human
albumin
iv
solut
human
albumin
iv
solut
immun
globulin
human
solut
conclus
despit
limit
preliminari
data
user
action
find
seem
indic
bpa
effect
halt
half
contraind
order
bloodderiv
product
type
screen
order
given
limit
type
order
bpa
trigger
pattern
suggest
bpa
potenti
alert
previous
unawar
provid
patient
religi
statu
andor
fact
certain
pharmaci
item
bloodderiv
therefor
unaccept
mani
jw
patient
despit
posit
initi
find
ongo
studi
track
efficaci
bpa
data
need
collect
better
metric
institut
sensit
patient
blood
refus
intervent
address
inappropri
cryoprecipitateahf
order
tertiari
medic
center
sirisha
kundrapu
mahmut
akgul
holli
reev
robert
w
maitta
marci
pokorni
ann
capetillo
katharin
down
backgroundcas
studi
although
introduc
manag
hemophilia
cryoprecipit
primarili
indic
low
fibrinogen
level
institut
transfus
medicin
servic
tm
review
make
recommend
clinician
inappropri
cryoprecipit
order
aim
analyz
effect
intervent
reach
target
fibrinogen
level
underestim
overestim
order
studi
designmethod
conduct
retrospect
studi
januaryjuli
adult
cryoprecipit
order
qualiti
assur
form
refer
rang
fibrinogen
mgdl
critic
valu
cryoprecipit
order
massiv
transfus
protocol
oper
room
extracorpor
membran
oxygen
review
tm
studi
period
tm
evalu
order
appropri
dose
agreement
estim
requir
dose
posttransfus
fibrinogen
level
due
intervent
compar
hypothes
intervent
level
statist
analysi
perform
use
chisquar
ttest
resultsfind
adult
year
order
review
tm
approv
approv
order
agreement
tm
estim
dose
order
agreement
tm
estim
underestim
overestim
seventeen
order
posttransfus
fibrinogen
level
without
intervent
would
median
deficit
mgdl
rang
mgdl
median
excess
mgdl
rang
mgdl
fibrinogen
target
median
differ
target
actual
posttransfus
fibrinogen
level
mgdl
target
significantli
higher
intervent
without
could
mgdl
target
p
median
differ
target
posttransfus
fibrinogen
level
group
agreement
approv
request
unit
significantli
differ
possibl
differ
without
intervent
vs
mgdl
median
differ
target
posttransfus
fibrinogen
level
group
nonagr
approv
request
unit
significantli
differ
possibl
differ
without
intervent
vs
mgdl
p
seven
order
critic
low
fibrinogen
mgdl
underestim
request
reach
target
fibrinogen
tm
estim
approv
requir
unit
transfus
overal
frequent
order
unit
ie
pool
frequent
order
disagr
group
unit
signific
differ
agreement
disagr
group
base
clinic
servic
order
unit
tabl
conclus
intervent
tm
review
approv
cryoprecipit
order
associ
increas
accuraci
order
achiev
desir
target
fibrinogen
level
studi
need
develop
multidisciplinari
strategi
accur
cryoprecipit
dosag
patient
characterist
medic
record
vitamin
k
administr
advers
event
collect
tabl
resultsfind
averag
pretransfus
inr
posttransfus
patient
inr
correct
chang
increas
inr
tabl
major
patient
receiv
unit
plasma
mean
plasma
dose
mlkg
transfus
reaction
report
nonhemolyt
transfus
associ
circulatori
overload
reaction
requir
admiss
icu
two
patient
experienc
bleed
ir
procedur
tip
develop
hematoma
tunnel
central
line
median
inr
correct
studi
relationship
number
unit
plasma
transfus
andor
vitamin
k
administ
studi
suggest
may
benefici
may
harm
transfus
plasma
correct
inr
random
trial
need
assess
whether
inr
ration
tool
measur
bleed
risk
whether
prophylact
treatment
plasma
yield
benefit
patient
experienc
bleed
complic
indic
inr
may
consid
safe
lower
risk
procedur
current
practic
may
provid
littl
benefit
substanti
risk
life
threaten
complic
backgroundcas
studi
group
ab
plasma
lack
antia
antib
antibodi
consid
univers
plasma
donor
use
emerg
set
patient
blood
group
avail
approxim
popul
group
ab
limit
avail
inventori
group
ab
plasma
group
ab
popul
plasma
male
donor
consid
suitabl
transfus
sinc
femal
especi
multipar
femal
donor
greater
propens
develop
antibodi
caus
transfus
relat
acut
lung
injuri
trali
make
type
ab
plasma
limit
resourc
hospit
level
one
trauma
center
signific
amount
plasma
transfus
requir
sever
bleed
patient
blood
type
known
group
individu
make
popul
b
antigen
cell
group
second
preval
blood
group
us
popul
b
antigen
cell
group
plasma
compat
group
patient
approxim
patient
popul
patient
blood
type
known
type
red
cell
unit
transfus
plasma
decreas
chanc
hemolysi
conserv
ab
plasma
institut
polici
effect
juli
follow
unit
group
plasma
unit
group
ab
plasma
provid
massiv
transfus
protocol
mtp
along
unit
neg
rbc
patient
blood
type
known
studi
designmethod
prospect
studi
design
monitor
use
group
plasma
mtp
institut
evalu
risk
sever
hemolysi
patient
transfus
incompat
plasma
direct
antiglobulin
test
dat
perform
patient
receiv
incompat
plasma
dat
posit
lactat
dehydrogenas
ldh
haptoglobin
bilirubin
level
obtain
detect
possibl
hemolyt
transfus
reaction
resultsfind
review
mtp
institut
juli
march
twenti
patient
transfus
incompat
group
plasma
group
ab
group
b
patient
five
patient
die
due
sever
injuri
followup
test
patient
could
perform
remain
patient
neg
dat
indic
lack
signific
amount
antibodi
coat
red
cell
could
lead
hemolysi
none
patient
develop
acut
hemolyt
reaction
advers
effect
incompat
plasma
transfus
conclus
studi
add
evid
safeti
group
plasma
transfus
trauma
patient
requir
emerg
massiv
transfus
patient
blood
type
known
base
recent
publish
studi
start
april
institut
provid
group
plasma
emerg
releas
mtp
case
patient
blood
type
known
averag
backgroundcas
studi
bonfil
immunohematolog
refer
lab
irl
sent
approxim
special
platelet
patient
hla
antibodi
hla
platelet
order
increas
dramat
irl
sent
special
platelet
product
purpos
abstract
illumin
method
use
fulfil
increas
client
need
occur
short
period
time
studi
designmethod
bonfil
blood
center
donor
databas
histor
hla
type
howev
approxim
donor
activ
donat
denver
area
one
common
hla
type
donor
type
therefor
fill
hla
platelet
order
request
common
hla
type
donor
system
would
perfect
hla
match
low
number
donor
like
would
platelet
shelf
readi
fill
order
donor
recruit
donat
take
least
two
day
fill
order
less
uncommon
hla
type
like
donor
match
perfectli
case
donor
recruit
fill
order
complic
case
irl
provid
hla
antibodi
list
panel
reactiv
antibodi
test
pra
order
find
product
patient
list
platelet
inventori
correspond
hla
type
print
patient
antibodi
exampl
posit
platelet
cross
list
crossout
process
would
continu
manual
platelet
list
one
posit
hla
antigen
patient
antibodi
platelet
pra
match
patient
order
autom
process
report
link
donor
databas
creat
find
pra
platelet
inventori
donor
recruit
blood
center
medic
director
began
suggest
hospit
client
order
pra
patient
platelet
refractori
pra
test
fast
definit
method
discern
hla
antibodi
mediat
refractori
platelet
refractori
due
caus
resultsfind
complic
case
rare
hla
patient
phenotyp
much
easier
find
pra
patient
match
platelet
shelf
hla
match
donor
approxim
special
order
platelet
pra
match
remain
hla
match
donor
recruit
approxim
special
platelet
sent
pra
match
chang
result
fold
increas
find
product
inventori
fill
order
quickli
conclus
develop
system
provid
pra
match
platelet
faster
altern
find
hla
match
platelet
thu
contribut
better
patient
care
backgroundcas
studi
urgent
case
larg
amount
blood
product
need
quickli
maintain
standard
massiv
transfus
protocol
mtp
critic
time
deliveri
product
mtp
pack
ucm
contain
pack
red
blood
cell
prbc
fresh
frozen
plasma
ffp
unit
plateletpheresi
pack
unit
prepool
cryoprecipit
also
given
patient
labor
deliveri
l
one
request
ucm
blood
product
gener
transport
pneumat
tube
system
pt
undertook
review
mtp
issu
practic
effici
pattern
last
three
half
year
studi
designmethod
electron
archiv
blood
bank
laboratori
inform
system
electron
medic
record
institut
queri
patient
mtp
activ
archiv
correl
paper
copi
activ
collect
data
pertain
relev
inform
order
origin
quickli
first
product
sent
mani
product
transfus
resultsfind
august
march
mtp
activ
ucm
order
could
trace
origin
inpati
floor
includ
icu
oper
room
emerg
depart
labor
deliveri
procedur
room
prbc
issu
transfus
util
unit
ffp
issu
transfus
util
platelet
pack
issu
transfus
util
unit
cryoprecipit
issu
transfus
util
sinc
march
time
first
product
issu
initi
mtp
also
track
event
fall
within
time
period
first
product
issu
minut
less
anoth
issu
minut
result
patient
issu
first
blood
product
within
first
minut
event
initi
time
greater
minut
none
greater
minut
conclus
major
activ
current
come
inpati
floor
primarili
icu
institut
anticip
introduct
adult
level
trauma
center
anticip
balanc
shift
addit
data
show
except
cryoprecipit
util
rate
nearli
ident
among
blood
product
sent
mtp
activ
anticip
util
rate
issu
mtp
product
increas
introduct
new
adult
trauma
center
recent
begun
track
time
last
product
issu
mtp
report
variabl
time
overal
data
show
transfus
servic
gener
perform
adequ
issu
first
product
within
minut
mtp
protocol
activ
data
reflect
time
issu
pt
patient
care
area
experi
addit
minut
delay
pt
deliveri
arriv
product
bedsid
must
continu
collabor
clinic
colleagu
collect
accur
data
provid
best
effici
mtp
care
mehreen
yasin
shailesh
macwan
arlin
stein
jane
fischman
nanci
nikoli
matthew
bank
lennart
logdberg
alexand
indrikov
sherri
shariatmadar
vishesh
chhibber
north
shore
univers
hospit
northwel
health
backgroundcas
studi
massiv
bleed
gener
defin
patient
requir
blood
volum
replac
within
hour
andor
receiv
transfus
greater
equal
unit
one
hour
transfus
vol
supplement
ongo
bleed
mtp
offici
implement
prepar
initi
verif
level
trauma
center
ac
mtp
follow
packag
pack
ratio
rbc
plasma
platelet
subsequ
pack
ratio
mtp
also
includ
prothrombin
time
pt
activ
partial
thromboplastin
time
aptt
fibrinogen
test
pack
transfus
data
use
assess
patient
allow
transfus
servic
clinic
team
identifi
coagulopathi
howev
attempt
supplement
mtp
pack
cryoprecipit
cryo
prothrombin
complex
concentr
pcc
challeng
accomplish
time
manner
studi
designmethod
due
challeng
time
supplement
mtp
packag
cryo
pcc
protocol
modifi
march
add
cryo
pcc
defin
point
mtp
cryo
includ
pack
pcc
pack
order
valid
modif
ad
product
defin
interv
regardless
laboratori
data
decid
review
patient
receiv
rbc
institut
massiv
hemorrhag
patient
would
receiv
pcc
base
current
protocol
review
blood
product
receiv
patient
avail
laboratori
data
resultsfind
patient
receiv
rbc
mtp
activ
patient
patient
receiv
unit
plasma
rbc
unit
transfus
despit
receiv
ratio
blood
product
patient
elev
pt
second
mani
elev
aptt
fibrinogen
level
less
institut
target
mgdl
tabl
anticip
improv
coagul
paramet
note
cryo
pcc
supplement
conclus
data
massiv
hemorrhag
patient
support
role
supplement
mtp
cryo
pcc
patient
requir
transfus
rbc
current
protocol
addit
cryo
pcc
defin
interv
streamlin
process
improv
time
provis
product
bleed
coagulopath
patient
backgroundcas
studi
red
blood
cell
hemolysi
key
find
diagnosi
transplantassoci
passeng
lymphocyt
syndrom
tapl
howev
whether
hematopoiet
stem
cell
organ
transplant
recipi
experi
hemolysi
transplant
contain
unintend
antibodyform
passeng
lymphocyt
depend
chanc
recipi
blood
group
phenotyp
live
donor
liver
segment
transplant
result
case
tapl
donorderiv
antid
potenti
caus
clinic
signific
hemolyt
event
donor
plasma
contain
antid
antid
absent
recipi
pretranspl
plasma
present
recipi
posttranspl
plasma
although
find
establish
diagnosi
tapl
hemolysi
occur
recipi
blood
group
phenotyp
convent
focu
hemolysi
rather
transfer
antibodyform
lymphocyt
divers
primari
pathophysiolog
pl
limit
captur
true
scope
syndrom
studi
designmethod
determin
standard
practic
detect
diagnos
tapl
retrospect
pubm
search
peerreview
englishlanguag
journal
articl
conduct
use
key
word
passeng
lymphocyt
syndrom
case
categor
accord
presenc
absenc
hemolysi
whether
routin
antibodi
screen
detect
donorderiv
passeng
lymphocyteform
blood
group
antibodi
resultsfind
publish
case
report
tapl
report
stem
cell
report
organ
transplant
stem
cell
transplant
organ
transplant
associ
hemolysi
reflect
overwhelm
bia
identifi
tapl
associ
hemolysi
report
stem
cell
tapl
activ
screen
antibodi
immedi
posttranspl
period
report
organ
tapl
activ
screen
antibodi
screen
detect
case
stem
cell
tapl
hemolysi
becam
appar
case
organ
tapl
antibodi
without
hemolysi
infer
tapl
current
underdiagnos
hemolysi
consist
present
andor
antibodi
screen
perform
routin
conclus
new
categori
nonhemolyt
tapl
recommend
captur
otherwis
undiagnos
case
tapasseng
lymphocyt
form
blood
group
antibodi
recipi
hemolysi
occur
aforement
case
ensur
includ
full
scope
tapl
antibodi
screen
perform
routin
one
week
transplant
repeat
clinic
indic
occult
hemolyt
anemia
due
antimur
patient
receiv
blood
region
promin
asian
donor
popul
jean
oak
rosario
mallari
marc
de
asi
elain
shu
jonathan
hugh
tho
pham
stanford
univers
stanford
health
care
stanford
blood
center
bloodsourc
backgroundcas
studi
mur
antigen
present
individu
southeast
asia
taiwan
part
southeastern
china
rare
elsewher
antibodi
mur
antigen
clinic
signific
henc
mani
countri
asia
routin
screen
countri
includ
us
includ
mur
standard
screen
describ
case
occult
antimur
antibodi
caus
anemia
donor
ethnic
distribut
region
blood
center
larg
asian
donor
popul
year
old
hispan
male
chronic
myelomonocyt
leukemia
plasma
cell
dyscrasia
develop
anemia
initi
antibodi
screen
dat
neg
patient
receiv
rbc
unit
everi
week
maintain
hemoglobin
hb
level
gdl
patient
remain
stabl
month
hb
level
acut
drop
gdl
antibodi
screen
remain
neg
addit
month
becam
posit
antijka
antimur
donor
ethnic
data
avail
rbc
unit
receiv
unit
asian
donor
unit
transfus
day
prior
hb
drop
caucasianchines
donor
studi
designmethod
review
ethnic
data
donor
hospitalassoci
blood
center
locat
region
asian
compris
approxim
popul
resultsfind
donor
identifi
chines
vietnames
filipino
southeastern
asian
donor
account
rbc
collect
conclus
identif
antimur
patient
trigger
presenc
concurr
antijka
alloantibodi
sinc
rbc
suppli
local
blood
center
collect
chines
southeast
asian
donor
chronic
transfus
patient
risk
develop
antimurmedi
hemolysi
could
miss
standard
screen
find
rais
possibl
need
blood
bank
locat
region
promin
asian
popul
implement
screen
antimur
brian
adkin
princess
mayni
carol
chandler
shelia
garret
pampe
young
vanderbilt
vanderbilt
univers
medic
center
depart
patholog
microbiolog
immunolog
backgroundcas
studi
antibodi
titrat
test
modal
vital
obstetr
transplant
servic
manual
direct
tube
test
associ
variabl
result
poor
reproducibilityprecis
also
time
resourc
intens
fact
studi
shown
threeto
eightfold
interinstitut
differ
antibodi
titer
sampl
use
manual
tube
method
orthovis
autom
analyz
offer
autom
titer
patient
plasma
use
gel
technolog
although
intens
interest
adopt
autom
test
technolog
titer
wellappreci
titer
obtain
manual
gel
test
much
higher
obtain
manualdirect
tube
test
higher
titer
result
lack
clinic
fetal
anemia
outcom
correl
barrier
implement
moreov
despit
increas
sensit
gel
test
prior
studi
found
variabl
result
regard
reproduc
precis
minim
inform
comparison
tube
titer
orthovis
autom
titer
assess
reproduc
autom
method
studi
designmethod
rh
non
rh
minor
rbc
antibodi
titrat
perform
manual
direct
tube
method
clinic
sampl
sampl
analyz
three
differ
ortho
vision
analyz
assess
precis
interinstru
reproduc
resultsfind
total
sampl
analyz
tabl
rh
nonrh
antigen
titer
via
autom
test
orthovis
result
mean
titrat
rang
time
higher
averag
fold
chang
rhdce
antibodi
titer
wherea
averag
fold
chang
non
rh
titer
rang
rang
anti
titer
particularli
variabl
wherea
ce
overal
reproducibilityprecis
autom
analyz
correl
transfus
vol
supplement
increas
titer
observ
class
antibodi
particularli
anti
perform
parallel
test
obstetr
sampl
correl
pregnanc
outcomefet
test
obtain
valu
conclus
autom
titrat
antibodi
use
orthovis
analyz
result
highli
reproduc
result
differ
instrument
use
sampl
howev
autom
analyz
consist
yield
higher
valu
particularli
rh
result
time
higher
manual
tube
test
interestingli
differ
titer
non
rh
antibodi
manual
tube
autom
test
statist
signific
although
n
thu
far
small
order
leverag
effici
reproduc
benefit
autom
titer
need
establish
critic
titer
rang
requir
activ
monitor
fetu
platelet
addit
solut
reduc
isoagglutinin
titer
apheresi
platelet
unit
maxim
tynuv
elizabeth
j
furlong
willi
flegel
dtmccnih
backgroundcas
studi
isoagglutinin
plasma
apheresi
platelet
concern
transfus
high
titer
antia
andor
antib
may
caus
hemolyt
transfus
reaction
htr
recipi
cognat
antigen
apheresi
platelet
collect
usual
reconstitut
donor
plasma
howev
facil
test
high
titer
isoagglutinin
expos
recipi
risk
htr
due
plasma
incompat
given
base
short
outdat
abo
type
facil
test
perform
apheresi
platelet
cutoff
titer
unit
cutoff
mark
high
titer
given
abo
plasmacompat
recipi
wash
salin
reduc
plasma
howev
wash
platelet
time
consum
process
result
loss
platelet
platelet
addit
solut
pa
use
altern
collect
storag
solut
replac
approxim
donor
plasma
final
product
goal
studi
determin
affect
pa
isoagglutinin
titer
whether
use
pa
could
lead
revis
one
facil
procedur
manag
group
platelet
transfus
studi
designmethod
isoagglutinin
titer
whole
blood
edta
sampl
compar
final
apheresi
platelet
unit
collect
pa
intersol
freseniu
kabi
lake
zurich
il
use
twofold
dilut
step
plasma
test
pool
red
cell
equal
mix
suspens
b
cell
ortho
raritan
nj
gel
matrix
test
mt
buffer
card
ortho
raritan
nj
min
incub
room
temperatur
prior
centrifug
mt
ortho
workstat
fifti
two
donor
group
group
group
b
resultsfind
whole
blood
edta
sampl
test
group
b
exceed
high
titer
threshold
pa
sampl
donor
test
one
group
exceed
threshold
pa
specimen
show
consist
twofold
decreas
titer
compar
whole
blood
specimen
nearli
half
group
donor
exceed
titer
whole
blood
specimen
test
conclus
one
sampl
apheresi
platelet
collect
pa
exceed
clinic
appli
titer
threshold
decreas
number
whole
blood
specimen
exceed
threshold
test
platelet
bag
collect
pa
instead
plasma
whole
blood
specimen
would
lower
number
unit
exceed
high
titer
threshold
reduc
product
need
wash
furthermor
facil
collect
platelet
site
without
access
whole
blood
specimen
donor
could
implement
process
describ
screen
platelet
apheresi
collect
potenti
clinic
advers
isoagglutinin
titer
whether
collect
use
pa
compon
major
blood
compon
israel
collect
distribut
magen
david
adom
mda
main
locat
sever
hospit
israel
also
collect
platelet
inhous
part
effort
understand
plt
util
nationwid
survey
plt
transfus
expir
conduct
studi
designmethod
data
disposit
plt
unit
acquir
mda
collect
inhous
calendar
year
request
hospit
israel
number
plt
distribut
hospit
mda
also
collect
plt
wastag
defin
sum
plt
return
reissu
hospit
blood
bank
plt
expir
blood
bank
shelv
resultsfind
sixteen
hospit
israel
along
mda
particip
survey
list
p
result
present
tabl
along
hospit
distanc
mda
facil
hospit
sum
transfus
wast
plt
slightli
less
number
plt
suppli
mda
like
due
small
number
plt
either
transfus
expir
time
data
collect
period
end
three
largest
hospit
c
b
collect
plt
inhous
addit
acquir
unit
mda
hospit
lower
overal
rate
wastag
includ
donat
hospit
collect
inhous
plt
hospit
wastag
rate
rang
correl
appar
hospit
distanc
mda
facil
number
bed
plt
wastag
rate
conclus
consider
platelet
wastag
israel
larg
hospit
israel
inhous
donat
lowest
overal
wastag
rate
comparison
hospit
factor
known
affect
plt
util
wastag
patient
diagnosi
mix
polici
plt
issu
accept
back
hospit
inventori
plt
inventori
size
time
pool
whole
blood
platelet
rel
time
issu
return
blood
bank
need
investig
optim
order
reduc
wastag
rate
possibl
immunemedi
hemolysi
due
platelet
transfus
mask
underli
hemolysi
patient
blast
crisi
sirisha
kundrapu
christoph
j
gresen
ann
capetillo
holli
reev
katharin
down
case
western
reserv
univers
school
medicin
univers
hospit
cleveland
medic
center
bloodsourc
backgroundcas
studi
transfusionrel
hemolysi
abomismatch
platelet
rare
report
incid
commonli
case
group
platelet
high
titer
antia
result
clinic
signific
hemolysi
transfus
group
ab
recipi
present
patient
possibl
hemolyt
reaction
follow
transfus
abo
mismatch
platelet
present
set
underli
diseas
associ
hemolysi
studi
designmethod
male
chronic
myelogen
leukemia
blast
crisi
evalu
possibl
transfus
reaction
singl
donor
platelet
sdp
two
hour
post
transfus
develop
chill
rigor
increas
blood
pressur
mm
hg
mm
hg
follow
hematuria
ml
chill
rigor
resolv
blood
pressur
stabil
min
diphenhydramin
solumedrol
acetaminophen
neg
patient
abo
group
rh
type
antibodi
screen
preand
posttransfus
specimen
show
discrep
laboratori
indic
hemolysi
summar
tabl
notabl
total
indirect
bilirubin
increas
hemoglobin
decreas
transfus
test
indetermin
hemolyt
transfus
reaction
abnorm
pretransfus
level
despit
underli
diseas
associ
hemolysi
blood
supplier
unit
contact
investig
possibl
high
titer
donor
antia
reveal
donor
antia
titer
result
igm
igg
donor
defer
futur
platelet
donat
conclus
posttransfus
sampl
visibl
hemolysi
neg
dat
increas
total
indirect
bilirubin
transfus
high
titer
donor
antia
support
immun
mediat
hemolyt
transfus
reaction
key
uniqu
aspect
case
baselin
underli
hemolysi
may
mask
need
investig
donor
high
titer
antia
ana
paula
hitomi
yokoyama
leila
patricia
de
sousa
fontenel
isabel
nagl
rei
carolina
bonet
bub
araci
sakashita
raffael
zamper
cristian
nakazawa
tatian
almeida
omura
paula
patricia
silva
batista
marcio
dia
almeida
fernanda
loureiro
de
andrad
orsi
jose
mauro
kutner
hospit
israelita
albert
einstein
hemocentro
unicampuniversidad
estadu
de
campina
backgroundcas
studi
orthotop
liver
transplant
olt
high
complex
procedur
fundament
therapeut
approach
endstag
liver
diseas
despit
improv
hemostat
surgic
anaesthet
techniqu
liver
transplant
still
associ
massiv
blood
loss
high
rate
transfus
requir
peri
intraop
transfus
red
blood
cell
rbc
previous
report
major
predictor
post
oper
mortal
identifi
predict
factor
transfus
requir
may
help
optimis
patient
blood
manag
strategi
olt
conduct
singl
center
retrospect
analysi
case
olt
perform
brazil
order
identifi
predict
factor
red
blood
cell
transfus
studi
designmethod
retrospect
analysi
singl
institut
perform
chart
consecut
patient
submit
liver
transplant
review
follow
variabl
collect
patient
gender
race
primari
diagnosi
presenc
hepatocellular
carcinoma
age
bodi
mass
index
correct
model
endstag
liver
diseas
meld
durat
warm
cold
ischemia
categor
variabl
analys
use
pearson
chisquar
test
continu
variabl
analys
use
tstudent
test
forward
logist
regress
model
use
analys
data
multivari
fashion
identifi
independ
contribut
variabl
previous
found
signific
resultsfind
univari
analysi
femal
patient
absenc
hepatocellular
carcinoma
hcc
primari
diagnosi
correct
meld
warm
ischemia
time
significantli
associ
consumpt
rbc
use
intraop
period
multivari
logist
regress
factor
show
femal
patient
ci
absenc
hcc
cirrhosi
caus
ci
miscellan
diagnosi
autoimmun
metabol
diseas
famili
amyloid
polyneuropathi
vascular
complic
ic
retransplant
due
primari
non
function
graft
ci
p
independ
associ
rbc
transfus
requir
conclus
studi
femal
patient
absenc
hcc
specif
primari
diagnosi
retransplant
due
primari
non
function
graft
significantli
associ
rbc
consumpt
intraop
period
determin
rbc
transfus
predictor
surgeri
might
provid
import
inform
regard
manag
blood
compon
help
optimis
utilis
resourc
blood
conserv
strategi
preval
hightit
group
platelet
product
charl
k
childer
mark
destre
ashley
rose
theresa
nester
madigan
armi
medic
center
bloodwork
northwest
bloodwork
nw
dept
laboratori
medicin
univers
washington
backgroundcas
studi
platelet
substitut
polici
minor
aboincompat
platelet
donor
plasma
may
contain
antibodi
recipi
red
blood
cell
often
issu
effort
best
util
commun
suppli
howev
rare
report
acut
intravascular
hemolysi
report
transfus
attribut
high
antib
titer
typic
group
donor
one
method
reduc
risk
hemolysi
identifi
high
titer
platelet
unit
prior
transfus
subsequ
intervent
percentag
high
titer
group
platelet
product
present
larg
region
blood
center
collect
month
data
prestorag
pool
platelet
unit
pspp
apheresi
deriv
platelet
unit
aplt
shown
studi
designmethod
platelet
compon
sampl
collect
ml
edta
sampl
tube
singl
dilut
plasma
prepar
use
hamilton
microlab
seri
dilutor
use
ml
salin
diluent
ml
platelet
compon
sampl
use
standard
transfer
pipett
two
drop
dilut
sampl
transfer
reaction
tube
along
one
drop
b
red
blood
cell
reagent
reaction
tube
centrifug
immedi
serolog
centrifug
rpm
second
reaction
read
use
light
agglutin
reader
presenc
macroscop
agglutin
weak
greater
either
cell
b
cell
record
posit
reaction
indic
high
titer
antib
retest
sampl
perform
confirm
high
titer
resultsfind
result
indic
titer
cutoff
use
approxim
group
apheresi
platelet
high
titer
commonli
less
half
percent
pspp
unit
high
titer
test
unit
titer
help
chang
abo
outofgroup
platelet
substitut
polici
exampl
bloodwork
transfus
servic
abl
chang
polici
volum
reduc
group
apheresi
platelet
issu
group
ab
patient
give
high
titer
product
group
patient
subsequ
decreas
episod
volum
reduct
help
improv
overal
avail
apheresi
platelet
maintain
day
outdat
month
test
pspp
unit
verifi
product
rare
high
titer
blood
center
stop
perform
test
pspp
unit
start
complain
worsen
back
pain
two
half
hour
receiv
one
unit
rbc
drop
hematocrit
previou
day
hematocrit
increas
ensu
hour
becam
anur
jaundic
cleric
check
confirm
forward
type
posit
also
type
rbc
unit
transfus
reveal
antia
titer
plasma
furthermor
direct
antiglobulin
test
dat
posit
preand
posttransfus
blood
sampl
antia
detect
plasma
collect
three
day
earlier
howev
although
plasma
color
amber
sign
intravascular
hemolysi
undetect
haptoglobin
increas
lactat
dehydrogenas
ldh
total
indirect
bilirubin
resultsfind
posit
dat
pretransfus
sampl
point
ongo
hemolysi
prior
transfus
rbc
unit
set
recent
abomismatch
transplant
pictur
consist
hemolysi
newli
form
antia
prolifer
donor
lymphocyt
pl
perform
emerg
rbc
exchang
use
rbc
goal
hematocrit
reduc
number
rbc
circul
approxim
pain
improv
rapidli
thereaft
complet
recoveri
renal
function
conclus
pl
differenti
diagnosi
suspect
investig
clinic
signific
hemolysi
abomismatch
hpc
transplant
recipi
especi
hpc
sourc
peripher
blood
patient
usual
take
day
antibodi
develop
shortliv
week
due
sever
manifest
perform
emerg
rbc
exchang
success
furthermor
patient
event
expos
vulner
system
issu
proper
blood
type
abomismatch
transplant
recipi
sinc
remedi
electron
backgroundcas
studi
group
rhd
neg
oneg
red
blood
cell
rbc
preciou
resourc
conserv
oneg
inventori
minim
risk
rhd
alloimmun
oneg
femal
childbear
age
transfus
servic
may
automat
provid
group
rhd
posit
opo
rbc
rhd
neg
male
andor
rhd
neg
postmenopaus
femal
bleed
emerg
despit
conserv
strategi
shortag
oneg
rbc
occur
goal
studi
determin
util
oneg
rbc
optim
use
agebas
opo
switch
routin
transfus
oneg
patient
studi
designmethod
recipi
age
aborhd
group
obtain
allogen
rbc
transfus
calendar
year
hospit
addit
hospit
provid
data
augustdecemb
rbc
transfus
patient
year
age
patient
whose
age
abo
group
unknown
exclud
analysi
aborhd
group
rbc
unit
compar
recipi
determin
number
oneg
rbc
transfus
patient
number
rbc
transfus
oneg
patient
number
oneg
rbc
transfus
oneg
patient
number
oneg
rbc
transfus
specif
oneg
patient
year
also
determin
resultsfind
see
tabl
fraction
transfus
rbc
oneg
rang
row
f
percentag
oneg
rbc
transfus
oneg
patient
rang
row
g
thu
nononeg
patient
receiv
oneg
unit
transfus
row
h
hospit
differ
wide
practic
issu
oneg
rbc
oneg
patient
row
overal
use
oneg
rbc
could
reduc
opo
unit
given
oneg
patient
year
old
row
j
conclus
time
oneg
shortag
age
base
opo
switch
rule
may
appli
routin
transfus
would
help
ensur
avail
oneg
rbc
unit
oneg
femal
childbear
age
rasha
eldeeb
moham
nehad
moham
marwa
ali
nashwa
fahmi
nation
blood
transfus
servic
nbt
backgroundcas
studi
sensit
transfus
red
cell
may
complic
transfus
make
increasingli
difficult
find
compat
blood
compon
patient
splenectomi
shown
increas
human
leucocyt
antigen
immun
aim
studi
evalu
effect
splenectomi
occurr
red
cell
alloimmun
human
studi
designmethod
studi
conduct
multitransfus
patient
receiv
blood
transfus
chronic
central
blood
center
thalassemia
patient
bthalassemia
patient
one
patient
thalassemia
sickl
cell
anemia
patient
immun
hemolyt
anemia
patient
auto
immun
hemolyt
anemia
patient
one
paroxysm
nocturn
hemoglobinemia
patient
one
immun
thrombocytopen
purpra
patient
oncolog
patient
chronic
diseas
patient
histori
demograph
data
document
patient
receiv
blood
examin
presenc
spleenour
patient
subject
direct
revers
blood
group
abo
rh
test
alloantibodi
screen
detect
resultsfind
statist
studi
done
determin
effect
splenectomi
increas
rate
red
cell
sensit
chronic
transfus
hemolyt
patient
studi
reveal
alloimmun
patient
non
alloimun
patient
p
statist
analysi
show
high
statist
signific
differ
patient
perform
splectomi
perform
splenectomi
regard
form
conclus
patient
splenectomi
higher
alloimmun
rate
remov
spleen
recommend
patient
period
need
blood
blood
compon
restrict
transfus
trigger
rather
specif
evid
therefor
two
systemat
review
rbc
transfus
guidelin
review
articl
determin
singl
multipl
unit
transfus
strategi
recommend
b
identifi
studi
compar
strategi
perform
studi
designmethod
method
medlin
embas
cinahl
web
scienc
nation
guidelin
clearinghous
trip
databas
search
incept
june
screen
data
abstract
done
independ
two
assessor
review
proport
articl
recommend
articl
recommend
singl
unit
strategi
assess
stratifi
guidelin
systemat
review
review
articl
review
b
primari
outcom
rbc
util
secondari
outcom
includ
proport
unit
transfus
use
singl
unit
strategi
length
stay
mortal
metaanalysi
done
use
mantel
haenszel
random
effect
model
resultsfind
review
identifi
articl
data
abstract
articl
transfus
guidelin
guidelin
made
recommend
singl
unit
multipl
unit
transfus
strategi
tabl
review
b
identifi
retrospect
cohort
studi
elig
data
abstract
perform
util
polici
encourag
singl
unit
transfus
strategi
compar
preimplement
period
postimplement
period
metaanalysi
could
perform
secondari
outcom
proport
unit
transfus
use
singl
unit
strategi
higher
polici
intervent
ci
although
heterogen
high
conclus
systemat
review
demonstr
lack
recommend
amongst
guidelin
pertain
transfus
singl
unit
rbc
retrospect
cohort
studi
support
benefit
use
singl
unit
transfus
strategi
addit
high
qualiti
studi
need
identifi
benefit
singl
unit
transfus
strategi
use
guidelin
group
review
research
area
determin
recommend
made
backgroundcas
studi
platelet
made
platelet
addit
solut
c
pa
c
treat
pathogen
reduct
pr
shown
decreas
post
transfus
platelet
count
platelet
store
plasma
advent
multipl
type
platelet
evalu
whether
mix
platelet
inventori
effect
compon
use
literatur
europ
shown
platelet
red
cell
use
increas
pr
pa
product
use
evalu
rbc
use
institut
shown
chang
number
product
transfus
per
patient
per
month
evalu
whether
mix
inventori
led
platelet
transfus
studi
designmethod
look
occas
patient
receiv
platelet
transfus
singl
day
abl
exclud
refractori
patient
analysi
inform
obtain
routin
qualiti
manag
audit
transfus
decemb
februari
use
analysi
inform
includ
order
servic
product
releas
time
product
code
pre
post
count
statist
analysi
perform
use
minitab
resultsfind
month
unit
platelet
transfus
recipi
month
median
unit
given
patient
rang
overal
distribut
product
use
plasma
pr
pa
f
pa
c
thirti
percent
patient
receiv
product
singl
day
singl
unit
given
patient
receiv
unit
respect
distribut
product
type
plasma
pr
pa
c
pa
f
percentag
present
singl
multipl
product
statist
significantli
differ
overal
distribut
product
given
month
period
distribut
servic
differ
group
receiv
multipl
unit
singl
unit
distribut
hematolog
malign
infus
clinic
no
solid
tumor
medicin
surgeri
pediatr
receiv
multipl
unit
distribut
surgeri
solid
tumor
hematolog
infus
no
chisquar
test
associ
show
increas
multipl
unit
surgic
patient
signific
p
valu
conclus
distribut
type
platelet
given
singl
event
transfus
significantli
differ
overal
distribut
platelet
given
month
period
patient
clinic
servic
better
predictor
use
multipl
product
type
product
given
suggest
surgic
loss
need
higher
platelet
count
procedur
lead
factor
use
multipl
product
transfus
scenario
effect
red
blood
cell
transfus
iron
metabol
critic
ill
patient
margit
boshuizen
yvemari
bo
somsen
maik
e
van
hezel
marleen
straat
robin
van
bruggen
nicol
p
jufferman
sanquin
research
landstein
laboratori
academ
medic
center
backgroundcas
studi
anemia
inflamm
ai
high
preval
critic
ill
patient
ai
iron
metabol
alter
high
level
inflammationinduc
hepcidin
reduc
amount
iron
avail
erythropoiesi
ai
treat
red
blood
cell
rbc
transfus
known
rbc
transfus
increas
iron
level
neonat
thalassemia
patient
effect
rbc
transfus
iron
metabol
inflammatori
process
unknown
sinc
one
unit
rbc
contain
mg
iron
rbc
clear
macrophag
within
hour
follow
transfus
rbc
transfus
could
increas
iron
level
iron
avail
erythropoiesi
investig
effect
rbc
transfus
iron
metabol
icu
patient
addit
compar
effect
septic
patient
nonsept
patient
studi
designmethod
prospect
cohort
studi
icu
patient
receiv
one
rbc
transfus
differ
iron
paramet
measur
hour
transfus
determin
effect
rbc
transfus
period
time
next
impact
rbc
transfus
plasma
iron
paramet
septic
patient
compar
nonsept
patient
analyz
plasma
iron
concentr
transferrin
satur
ferritin
haptoglobin
hepcidin
level
determin
resultsfind
cohort
serum
iron
level
low
chang
follow
transfus
vs
mmoll
also
transfus
effect
transferrin
satur
vs
ferritin
vs
mgl
level
vs
pgml
hepcidin
level
increas
icu
patient
rbc
transfus
vs
ngml
septic
patient
rbc
transfus
induc
decreas
haptoglobin
level
compar
baselin
occur
nonsept
patient
vs
chang
iron
paramet
differ
septic
nonsept
patient
conclus
transfus
one
unit
rbc
increas
iron
level
icu
patient
increas
hepcidin
suggest
rbc
transfus
induc
upregul
hepcidin
despit
absenc
signific
increas
plasma
iron
level
increas
hepcidin
level
transfus
potenti
hamper
iron
avail
erythropoiesi
sepsi
rbc
transfus
decreas
haptoglobin
level
suggest
hemolysi
conclus
rbc
transfus
might
neg
effect
erythropoiesi
due
increas
hepcidin
level
observ
transfus
effect
pa
pr
platelet
use
barbara
mendez
judith
delmont
elizabeth
mccabe
joann
becker
roswel
park
cancer
institut
backgroundcas
studi
anticip
releas
fda
guidanc
bacteri
risk
control
strategi
blood
collect
establish
transfus
servic
enhanc
safeti
avail
platelet
transfus
use
pathogen
reduc
platelet
pr
often
produc
product
made
platelet
addit
solut
pa
may
becom
common
institut
transfus
platelet
made
addit
solut
sinc
pathogen
reduc
platelet
avail
sinc
data
valid
pa
pr
post
count
transfus
pasc
pr
product
statist
lower
platelet
plasma
pp
pa
f
product
studi
look
whether
differ
led
correspond
increas
number
unit
platelet
transfus
studi
designmethod
data
obtain
routin
qualiti
report
produc
blood
util
committe
facil
time
pa
c
pa
f
pr
went
platelet
product
given
recipi
oncolog
diagnosi
data
collect
includ
servic
unit
number
product
code
number
uniqu
recipi
determin
monthli
data
convert
pltmonthrecipi
analysi
statist
analysi
perform
use
two
sampl
ttest
resultsfind
data
normal
pltrecipientmonth
patient
receiv
averag
unitsrecipientmonth
averag
unitsrecipientmonth
interven
data
point
respect
year
averag
slope
graph
point
two
sampl
ttest
show
pltrecipientmonth
statist
differ
p
valu
conclus
implement
pa
pr
platelet
oncolog
environ
increas
number
platelet
transfus
given
addit
analysi
red
cell
use
decreas
data
shown
interpret
indic
patient
increas
episod
bleed
although
post
platelet
count
paspr
platelet
may
lower
evid
platelet
transfus
data
lead
clinic
outcom
necessit
addit
product
given
backgroundcas
studi
report
incid
alloimmun
aml
patient
unrel
number
transfus
patient
receiv
patient
hla
antibodi
exhibit
platelet
refractori
mani
case
also
found
antiplatelet
antibodi
detect
standard
laboratori
test
recent
data
leukemia
hematopoiet
stem
cell
hsct
recipi
transfus
exclus
leukoreduc
product
show
develop
alloimmun
platelet
refractori
object
determin
improv
platelet
count
match
grade
andor
abo
blood
group
hla
match
platelet
highli
alloimmun
patient
concomit
nonimmun
caus
platelet
destruct
studi
designmethod
clinic
document
platelet
refractori
patient
receiv
hla
match
irradi
sda
platelet
hla
type
hlaab
hla
antibodi
identif
review
two
strategi
util
hla
strategi
match
recipi
donor
hlaa
b
type
antibodi
specif
predict
patient
provid
platelet
donor
lack
hla
patient
antibodi
strategi
statist
analysi
one
sampl
ttest
use
minitab
statist
softwar
perform
compar
mean
platelet
increment
hypothet
differ
least
kul
analysi
reveal
mean
kul
percent
lower
bound
confid
interv
platelet
increment
kul
p
resultsfind
median
rang
hla
match
leucoreduc
irradi
sda
platelet
transfus
patient
median
age
year
rang
patient
show
broad
alloimmun
hla
class
iclass
ii
antigen
patient
antihpa
antibodi
gp
iibiiia
gp
iibiiia
gp
iaiia
major
diagnosi
hematolog
malign
amlmdsmpn
cmmlmm
femal
patient
prior
exposur
via
pregnanc
histori
hsct
platelet
abo
identicalplatelet
increment
median
kul
rang
abo
compat
platelet
increment
median
rang
abo
incompat
platelet
increment
median
rang
platelet
count
perform
within
hour
transfus
hla
match
grade
transfus
platelet
follow
use
massiv
transfus
protocol
mtp
commun
hospit
rohini
patel
rene
leblanc
dongfu
xie
alic
cabe
yanyun
wu
overlak
hospit
bloodwork
northwest
use
massiv
transfus
protocol
mtp
commun
hospit
backgroundcas
studi
establish
use
massiv
transfus
protocol
mtp
becom
common
practic
especi
trauma
center
tertiari
hospit
due
signific
number
patient
massiv
bleed
howev
well
establish
use
mtp
also
valu
small
hospit
commun
hospit
mtp
use
fig
set
indic
mtp
blood
product
use
outcom
patient
studi
designmethod
retrospect
review
transfus
data
commun
hospit
bed
size
year
perform
patient
mtp
request
includ
studi
resultsfind
pleas
see
tabl
summari
data
notabl
patient
gi
bleed
ob
bleed
two
common
indic
mtp
patient
surviv
support
mtp
one
case
blood
product
use
establish
readi
mtp
import
support
patient
experi
massiv
bleed
small
hospit
commun
hospit
set
mtp
commonli
use
patient
massiv
gi
bleed
ob
bleed
patient
develop
antibodi
high
incid
antigen
find
compat
unit
may
becom
imposs
includ
mn
system
resid
glycophorin
b
gpb
u
antigen
absent
less
black
popul
alter
form
gpb
known
u
variant
produc
divers
group
antibodi
capabl
caus
mild
sever
hemolyt
transfus
reaction
hemolyt
diseas
fetu
newborn
hdfn
case
illustr
balanc
need
transfus
avoid
complic
thereof
ghanaian
woman
scd
histori
chronic
transfus
present
diffus
pain
hemoglobin
valu
gdl
baselin
gdl
known
e
c
k
fya
jkb
neg
u
variant
anti
c
u
antibodi
elig
famili
donor
nationwid
search
compat
blood
yield
four
crossmatch
compat
u
variant
unit
decis
transfus
made
patient
chang
symptom
vital
sign
transfus
posttransfus
hemoglobin
gdl
transfus
reaction
workup
order
posttransfus
serum
sampl
neg
hemolysi
new
antibodi
identifi
posttransfus
dat
weakli
posit
complement
laboratori
data
reveal
decreas
total
bilirubin
mgdl
two
addit
u
variant
crossmatch
compat
unit
transfus
next
two
day
restor
hemoglobin
gdl
patient
discharg
home
stabl
condit
followup
hemoglobin
level
continu
rise
back
baselin
studi
designmethod
molecular
genotyp
use
donor
unit
select
prior
compat
test
transfus
servic
convent
method
use
monitor
patient
condit
pre
posttransfus
resultsfind
donor
unit
came
differ
donor
gpb
genotyp
patient
patient
experi
acut
delay
hemolyt
transfus
reaction
genotyp
match
success
facilit
donor
unit
select
case
conclus
transfus
u
variant
red
cell
u
variant
patient
undertaken
great
caution
due
epitop
antibodi
heterogen
case
highlight
import
genotyp
compat
select
donor
unit
chronic
transfus
scd
patient
antiu
sound
transfus
manag
patient
requir
plan
good
commun
part
clinician
laboratori
staff
backgroundcas
studi
patient
decompens
waiha
may
requir
transfus
red
blood
cell
rbc
product
crossmatch
incompat
due
free
autoantibodi
feasibl
blood
transfus
waiha
patient
controversi
difficulti
crossmatch
increas
risk
transfus
reaction
sinc
transfus
rbc
may
destroy
rapidli
patient
activ
hemolysi
studi
actual
vs
theoret
risk
increas
hemolysi
waiha
patient
investig
posttransfus
posttfn
hematocrit
hct
chang
waiha
patient
transfus
compat
rbc
compar
receiv
li
blood
hypothes
posttfn
hct
would
invers
relat
degre
ahgphas
incompat
studi
designmethod
review
transfus
patient
quaternarycar
hospit
histori
waiha
octob
march
patient
hct
order
prescrib
physician
clinic
purpos
transfus
episod
defin
unit
releas
interv
posttfn
cbc
ahgphas
crossmatch
tube
test
salin
per
clinic
procedur
transfus
medicin
physician
determin
releas
leastincompat
unit
statist
test
perform
statcalc
epiinfo
cdc
wwwsocscistatisticscom
resultsfind
rbc
product
transfus
waiha
patient
twentythre
patient
receiv
least
incompat
unit
mean
age
year
rang
yr
women
ethnic
composit
africanamerican
caucasian
patient
mixedoth
ethnic
one
hundr
fourteen
product
releas
li
product
compat
ninetythre
li
product
transfus
posttfn
hct
chang
wherea
compat
product
transfus
result
posttfn
hct
chang
v
exact
method
mean
hct
increas
compat
group
per
unit
vs
slightli
lesser
perunit
increas
li
group
ttest
within
li
group
differ
perunit
hct
chang
accord
strength
incompat
tabl
strength
ahg
incompat
avail
unit
unit
incompat
lower
mean
posttfn
hct
rise
compar
li
unit
vs
howev
differ
statist
signific
conclus
posttfn
hct
chang
transfus
li
unit
patient
waiha
less
expect
per
unit
frequent
waiha
patient
receiv
compat
product
vs
howev
like
due
small
sampl
size
mean
differ
statist
signific
interestingli
differ
perunit
posttfn
hct
accord
differ
strength
incompat
sampl
although
mean
increas
li
product
less
li
product
combin
increas
unexpectedli
low
weaklyincompat
unit
studi
futur
work
includ
consider
inpati
vs
outpati
clinic
statu
effect
coincid
alloantibodi
comorbid
medic
transfus
manag
summaris
individu
hospit
type
total
case
inhospit
mortal
adjust
age
sex
comorbid
bleed
context
number
rbc
first
mt
onset
calcul
control
limit
indic
potenti
outlier
data
analyz
use
statist
softwar
stata
resultsfind
mt
case
hospit
tertiarylevel
smallermedium
size
acutecar
specialist
women
number
mt
case
per
hospit
rang
patient
median
age
year
iqr
male
requir
admiss
intens
care
common
clinic
group
cardiac
surgeri
case
trauma
gastrointestin
hemorrhag
howev
mark
variat
hospit
ratio
transfus
product
analyz
accord
bleed
context
vari
hospit
type
pool
averag
adjust
inhospit
mortal
tertiarylevel
hospit
rang
within
control
limit
cb
requir
rbc
within
mt
onset
occur
case
comparison
transfus
manag
subset
mt
case
show
patient
treat
smallermedium
size
acutecar
less
like
receiv
cryoprecipit
patient
treat
tertiarylevel
hospit
versu
conclus
patient
characterist
transfus
practic
vari
hospit
hospit
type
howev
inhospit
mortal
outcom
compar
result
made
avail
particip
hospit
anzmtr
initi
discuss
practic
review
examin
complianc
nation
standard
patient
blood
manag
guidelin
highlight
area
investig
data
also
avail
review
govern
polici
bodi
state
nation
level
support
practic
improv
activ
highlight
prioriti
area
futur
research
backgroundcas
studi
hospit
medic
center
case
big
trauma
often
intraoss
entranc
via
bone
needl
combin
fast
flow
fluid
warmer
infus
fluid
includ
blood
product
administ
pressur
done
vein
trauma
patient
often
suitabl
infus
fluid
supplier
pump
needl
describ
possibl
transfus
blood
product
mainli
limit
plasma
erythrocyt
inform
avail
concern
transfus
platelet
pressur
via
bone
needl
aim
studi
investig
effect
warm
administr
platelet
concentr
pc
pressur
via
bone
needl
vitro
qualiti
platelet
studi
designmethod
pool
bc
ml
platelet
addit
solut
iii
pasiii
use
produc
pc
pc
store
flatb
agit
cyclesmin
temperaturecontrol
cabinet
day
mimic
hospit
condit
pc
warm
use
blood
warmer
transfus
via
bone
needl
transfer
bag
pc
pressur
mm
hg
appli
use
clamp
flow
veloc
mlminut
realiz
platelet
qualiti
pressur
simul
transfus
determin
mean
variou
vitro
paramet
resultsfind
due
prime
transfus
dispos
salin
pc
dilut
result
significantli
increas
pc
volum
decreas
platelet
concentr
simul
transfus
loss
platelet
dispos
set
also
total
number
platelet
decreas
simul
transfus
simul
transfus
pc
still
fulfil
requir
platelet
concentr
l
number
unit
simul
transfus
effect
percentag
annexin
v
posit
cell
indic
activ
induct
apoptosi
ph
influenc
simul
transfus
due
dilut
effect
glucos
lactat
concentr
slightli
lower
simul
transfus
conclus
warm
simul
transfus
pc
high
pressur
via
bone
needl
neg
effect
vitro
qualiti
paramet
platelet
transfus
warm
pc
via
intraoss
entranc
via
bone
needl
expect
neg
effect
vivo
function
platelet
recommend
studi
vivo
effect
limit
clinic
studi
alesia
kaplan
joan
sevcik
joseph
e
kiss
univers
pittsburgh
blood
system
inc
backgroundcas
studi
low
titer
plasma
safe
use
substitut
ab
plasma
trauma
patient
low
inventori
ab
plasma
caus
delay
life
save
therapeut
plasma
exchang
tpe
procedur
ab
patient
need
plasma
replac
ab
nonbleed
patient
present
safe
receiv
ab
low
titer
plasma
tpe
one
ab
patient
receiv
ab
plasma
use
control
compar
hemolysi
laboratori
data
tpe
cours
studi
designmethod
retrospect
review
tpe
procedur
patient
conduct
medic
record
number
procedur
volum
replac
total
number
plasma
unit
number
plasma
unit
quantiti
plasma
hemolysi
laboratori
data
record
averag
quantiti
ml
plasma
plasma
total
volum
plasma
use
calcul
plasma
unit
low
antib
titer
unit
laboratori
plasma
dilut
prepar
test
reagent
b
cell
agglutin
observ
unit
label
low
titer
antib
hemolysi
laboratori
data
trace
linear
graph
trend
compar
patient
control
resultsfind
patient
ab
blood
type
patient
year
old
femal
recurr
defici
ttp
receiv
cours
tpe
total
tpe
procedur
relaps
exacerb
ten
procedur
perform
ab
plasma
averag
ml
plasma
total
plasma
volum
tpe
procedur
patient
year
old
femal
thrombocytopenia
schistocyt
presum
ttp
receiv
total
tpe
procedur
four
procedur
perform
ab
plasma
averag
ml
plasma
total
plasma
volum
tpe
procedur
patient
year
old
femal
defici
ttp
serv
control
receiv
total
procedur
ab
plasma
haptoglobin
ldh
hemoglobin
total
bilirubin
graph
compar
patient
trend
hemolysi
laboratori
data
patient
compar
patient
patient
neg
dat
patient
receiv
rbc
transfus
patient
favor
clinic
outcom
tpe
treatment
adequ
platelet
recoveri
conclus
studi
tpe
effect
perform
without
evid
increas
hemolysi
use
low
titer
plasma
approach
reduc
strain
limit
suppli
ab
plasma
provid
vital
treatment
altern
ab
patient
undergo
tpe
requir
plasma
replac
neg
platelet
unit
avail
patient
antibodi
sameer
khatri
charl
harmon
brian
r
curti
chisa
yamada
backgroundcas
studi
refractori
platelet
plt
transfus
caus
antibodi
ab
human
leukocyt
antigen
hla
class
antigen
ag
less
frequent
plt
specif
ag
psa
glycoprotein
iv
one
identifi
plt
surfac
ag
defici
rare
found
asian
subsaharan
african
also
peopl
mediterranean
descent
two
type
defici
describ
type
defici
complet
lack
plt
monocytemacrophag
wherea
type
defici
lack
plt
variabl
express
monocytemacrophag
transfus
plt
patient
defici
challeng
given
rariti
neg
phenotyp
risk
immun
give
ag
nonmatch
platelet
studi
designmethod
patient
neg
phenotyp
receiv
multipl
plt
unit
review
electron
medic
record
resultsfind
year
old
man
develop
aplast
anemia
follow
liver
injuri
possibl
due
supplement
bodi
build
requir
multipl
plt
rbc
transfus
receiv
unit
apheresi
plt
unit
week
period
without
signific
increas
plt
count
crossmatch
compat
plt
unit
found
unit
hla
match
unit
tri
without
success
point
ab
identifi
serum
patient
type
defici
confirm
flow
cytometri
hla
class
panel
reactiv
ab
pra
due
multipl
plt
transfus
although
ab
low
level
patient
initi
receiv
highdos
prednison
thymocyt
immun
globulin
infus
without
signific
improv
plt
increas
follow
three
dose
ivig
receiv
neg
blood
type
differ
hla
transfus
vol
supplement
unmatch
plt
unit
rel
slight
increas
plt
count
howev
start
respond
nontest
apheresi
plt
receiv
fourth
ivig
two
rituximab
infus
sinc
receiv
ivig
everi
week
medic
includ
filgrastim
eltrombopag
cyclosporin
treatment
aplast
anemia
mean
correct
count
increment
cci
posttransfus
plt
count
avail
shown
tabl
desensit
therapi
antibodi
posit
reactiv
serial
dilut
reduc
dilut
hla
class
pra
decreas
current
receiv
apheresi
plt
unit
twice
week
rbc
unit
period
bone
marrow
bm
slowli
recov
evidenc
increas
wbc
count
zero
kml
slow
increas
reticulocyt
count
current
plan
rbcplt
transfus
support
bm
recov
haploident
transplant
bm
recoveri
fail
conclus
report
case
ab
receiv
multipl
plt
transfus
case
demonstr
decreas
ab
level
immunomodul
altern
option
success
plt
transfus
compat
plt
avail
patient
rare
multipl
ab
plt
tabl
mean
avail
cci
plt
transfus
blood
center
experi
screen
donat
babesia
microti
use
enzymelink
immunoassay
methodolog
nanci
van
buren
jed
gorlin
vanessa
reynold
deborah
anderson
backgroundcas
studi
blood
center
locat
area
consid
moder
endem
babesia
microti
implement
univers
screen
red
cell
collect
minnesota
wisconsin
investig
new
drug
ind
studi
oct
util
immunet
investig
enzymelink
immunoassay
elisa
perform
creativ
test
solut
ct
test
select
costeffect
approach
univers
screen
blood
donor
oppos
investig
ifapcr
test
combin
studi
designmethod
perform
retrospect
analysi
screen
test
result
deferr
rate
evalu
season
donor
abo
bia
deferr
rate
outcom
lookback
investig
sinc
optout
research
test
origin
offer
report
donor
optout
rate
resultsfind
jan
dec
blood
donat
screen
b
microti
immunet
elisa
posit
percent
posit
donat
evalu
monthli
reveal
variabl
reaction
rate
patient
babesia
transmiss
report
sinc
implement
test
document
babesia
ttd
case
donor
previous
test
neg
demonstr
increas
seroconvers
rate
summer
month
consist
histor
season
variat
correspond
tick
season
minnesota
wisconsin
test
perform
characterist
analyz
abo
group
demonstr
differ
posit
rate
optout
rate
donor
chose
test
significantli
decreas
time
reflect
increas
accept
test
posit
test
result
lookback
investig
initi
repres
posit
donat
lookback
perform
donat
within
month
new
posit
screen
test
accord
ind
protocol
confirmatori
test
perform
per
ind
protocol
donor
counsel
true
posit
rate
unknown
prior
ind
trial
unlik
transmit
infect
region
ie
pcr
blood
smear
neg
although
small
number
antibodi
posit
pcr
neg
donor
may
activ
infect
transfusiontransmit
babesia
infect
identifi
lookback
investig
notif
blood
donor
posit
screen
result
also
perform
inform
provid
healthcar
provid
followup
overal
donor
deferr
repres
loss
elig
donor
followup
period
defer
donor
invit
particip
research
collect
requir
volunt
donor
elig
conclus
test
b
microti
may
help
improv
blood
safeti
particularli
endem
region
although
donor
posit
reaction
repres
signific
loss
elig
donor
time
unlik
transmit
infect
direct
test
capabl
detect
babesia
individu
low
level
organ
without
need
concurr
antibodi
test
would
ideal
reinstat
protocol
donor
test
posit
also
consid
nonetheless
current
method
screen
inexpens
compar
pcrbase
method
backgroundcas
studi
human
anellovirus
smallest
particl
size
smallest
genom
size
least
complex
genet
organ
human
pathogen
establish
chronic
persist
infect
infanc
earli
childhood
produc
constantli
detect
load
plasma
thereaft
studi
suggest
ubiquit
present
human
popul
immun
surveil
requir
control
level
viru
load
studi
designmethod
develop
quantit
dna
pcr
assay
conserv
region
anelloviru
genom
detect
known
genotyp
viru
use
assay
examin
viral
load
plasma
us
blood
donor
transplant
recipi
pretranspl
three
month
posttranspl
resultsfind
blood
donor
posit
averag
load
copiesml
plasma
median
valu
copiesml
plasma
rang
copiesml
pretranspl
viral
load
similar
transplant
candid
posit
averag
copiesml
plasma
median
valu
copiesml
plasma
rang
copiesml
posttranspl
viral
load
remark
differ
transplant
recipi
posit
averag
copiesml
plasma
median
valu
copiesml
plasma
rang
copiesml
conclus
result
valid
pcr
assay
develop
confirm
detect
viral
load
around
copi
present
blood
donor
survey
addit
effect
posttranspl
immunosuppress
therapi
caus
increas
viral
load
least
order
magnitud
nonimmunosuppress
individu
backgroundcas
studi
screen
blood
donor
travel
return
endemicepidem
area
highlight
import
multiplex
diagnost
approach
simultan
analysi
variou
pathogen
furthermor
context
similar
clinic
sign
differenti
diagnosi
arbovirus
acut
infect
essenti
discrimin
caus
agent
patient
manag
epidemiolog
surveil
develop
flexibl
diagnost
approach
key
challeng
face
continu
emerg
arbovirus
belong
flaviviru
alphaviru
dengu
viru
denv
west
nile
viru
wnv
zika
viru
zikv
yellow
fever
viru
yfv
usutu
viru
usuv
chikungunya
viru
chikv
studi
designmethod
innov
diagnost
approach
combin
gener
rtpcr
amplif
identif
low
cost
microarray
develop
patent
origin
polythiol
probe
graft
maleimideactiv
micropl
robust
sensit
specif
mean
cci
preivig
plt
postivig
plt
postivig
plt
rel
postivig
singl
donor
apheresi
postivig
crossmatch
compat
postivig
flow
crossmatch
compat
plt
transfus
vol
supplement
detect
viral
genom
analyt
perform
test
evalu
viral
standard
clinic
sampl
denv
wnv
zikv
chikv
forti
human
plasma
blood
donor
histori
contact
arbovirus
use
neg
control
design
two
set
degener
primer
gener
rtpcr
amplif
flavivirus
chikv
biotinyl
amplicon
captur
complementari
graft
polythiol
probe
micropl
addit
streptavidineuropium
label
molecular
hybrid
event
detect
timeresolv
fluoresc
use
micropl
reader
resultsfind
one
origin
gener
probe
denv
specif
probe
design
four
denv
serotyp
wnv
two
zikv
lineag
chikv
valid
use
methodolog
combin
amplif
viral
genom
identif
use
polythiol
probe
show
specif
fals
posit
result
control
sampl
cross
reaction
use
viral
refer
standard
observ
sensit
tcid
ml
chikv
tcid
ml
zikv
final
first
result
obtain
denv
zikv
chikv
clinic
sampl
show
correl
respect
approach
commerci
hous
real
time
rtpcr
method
conclus
innov
strategi
allow
develop
flexibl
highli
sensit
easi
handl
platform
dedic
multiplex
screen
identif
emerg
virus
methodolog
adapt
easi
inclus
addit
molecular
target
improv
surveil
prevent
arbovir
infect
babesia
microti
serolog
test
pool
sampl
feasibl
studi
laura
tonnetti
aaron
thorp
letitia
dixon
susan
l
stramer
backgroundcas
studi
blood
donat
screen
babesia
microti
tickborn
intraerythrocyt
parasit
endem
northeast
upper
midwest
us
perform
investig
studi
use
nucleic
acid
immunofluoresc
assay
ifa
howev
ifa
time
consum
labor
intens
procedur
possibl
fda
licens
screen
assay
near
futur
investig
b
microti
test
ifa
pool
plasma
serum
could
feasibl
screen
approach
studi
designmethod
test
increas
amount
plasma
serum
interfer
background
fluoresc
pool
prepar
plasma
serum
sampl
determin
b
microtineg
individu
ifa
screen
pool
test
ifa
without
block
step
use
bovin
serum
albumin
bsa
goat
serum
minim
background
fluoresc
potenti
interfer
multipl
pool
plasma
serum
sampl
endpoint
titer
posit
sampl
investig
includ
posit
sampl
endpoint
titer
dilut
pool
resultsfind
nonspecif
fluoresc
visibl
pool
higher
elimin
addit
block
step
pool
sampl
show
signific
increas
background
differ
test
pool
serum
plasma
sampl
one
singl
posit
sampl
includ
pool
sampl
pool
test
posit
final
titer
posit
sampl
test
individu
two
posit
sampl
includ
pool
final
titer
pool
equal
sampl
highest
titer
conclus
studi
repres
proof
concept
serolog
test
b
microti
ifa
pool
plasma
serum
sampl
increas
fals
posit
maintain
sensit
test
backgroundcas
studi
rapid
detect
bacteri
contamin
platelet
key
reduc
risk
infect
transfus
blood
compon
bactalert
virtuo
advanc
next
gener
system
improv
autom
connect
data
manag
system
virtuo
new
algorithm
significantli
reduc
time
detect
ttd
microorgan
qualiti
control
test
platelet
prepar
use
bactalert
bta
bpa
aerob
bpn
anaerob
bottl
plasma
known
bactericid
studi
complet
evalu
plasma
susceptibilityresist
organ
consid
virtuo
studi
studi
designmethod
human
plasma
thaw
pool
salin
control
seed
cfuml
organ
associ
platelet
contamin
incub
room
temperatur
hour
coloni
count
perform
initi
incub
plasma
resist
determin
coloni
count
seed
plasma
equival
higher
log
coloni
count
seed
salin
incub
resultsfind
serial
dilut
strain
biobal
tm
strain
except
p
aeruginosa
nctc
determin
plasma
resist
biobal
tm
p
aeruginosa
suscept
antimicrobi
effect
human
plasma
spike
ml
leukocyt
reduc
apheresi
platelet
lrap
inocul
bta
bpa
bottl
load
bta
virtuo
organ
recov
conclus
result
confirm
previous
test
organ
addit
strain
plasma
resist
except
p
aeruginosa
nctc
howev
bpa
bottl
still
recov
p
aeruginosa
presenc
lrap
bpabpn
bottl
inocul
select
organ
panel
presenc
lrap
demonstr
recoveri
load
onto
virtuo
tabl
studi
may
requir
determin
higher
test
volum
lrap
could
affect
recoveri
plasma
sensit
strain
virtuo
fda
clear
platelet
test
notoscriptu
identifi
major
urban
vector
rrv
also
capabl
transmit
dengu
viru
recent
found
lo
angel
illustr
expans
rang
grow
geograph
distribut
aed
speci
mosquito
potenti
rrv
enter
local
transmiss
cycl
outsid
australia
signific
probabl
transfusiontransmiss
tt
confirm
caus
rrv
infect
australia
valid
realiti
rrv
tt
occur
rrv
morbid
lead
clinic
manifest
similar
chikv
infect
vari
degre
arthralgia
becom
debilit
variou
asymptomat
symptomat
infect
ratio
report
increas
risk
addit
tt
endem
area
could
mask
spread
diseas
global
studi
designmethod
platelet
concentr
pc
prepar
pa
inocul
rrv
amotosalen
ad
final
concentr
mm
unit
treat
uva
light
preand
posttreat
illumin
sampl
collect
titrat
rbc
unit
contamin
rrv
mix
process
solutionglutathion
gsh
treat
amustalin
final
mm
concentr
preand
posttreat
sampl
remov
prior
amustalin
treatment
amustalin
addit
respect
titrat
plaqu
assay
cell
log
reduct
calcul
differ
mean
infecti
titer
prev
posttreat
sampl
resultsfind
inactiv
rrv
achiev
limit
detect
pc
rbc
pc
log
log
ml
rrv
achiev
log
log
ml
rrv
inactiv
rbc
conclus
studi
illustr
amotosalenuva
amustalin
gsh
treatment
effect
inactiv
rrv
pc
rbc
respect
data
corrobor
previou
result
achiev
alphavirus
includ
chikv
mayaro
viru
inactiv
high
titer
pc
rbc
demonstr
abil
system
mitig
tt
potenti
maintain
safe
blood
compon
avail
endem
area
data
submit
fda
review
intercept
red
blood
cell
approv
commerci
use
backgroundcas
studi
interceptv
r
blood
system
platelet
design
inactiv
pathogen
contamin
leukocyt
photochem
treatment
process
util
amotosalen
low
energi
ultraviolet
uva
light
current
avail
set
includ
small
volum
sv
ml
larg
volum
lv
ml
dual
storag
contain
ds
ml
design
treat
platelet
dose
new
tripl
storag
ts
set
design
expand
dose
rang
maximum
volum
ml
gener
either
dose
pathogen
reduc
platelet
compon
pc
object
studi
evalu
effect
system
perform
log
reduct
assay
use
repres
gram
posit
neg
bacteria
envelop
nonenvelop
virus
platelet
suspend
pa
plasma
use
ts
set
studi
designmethod
experi
platelet
pool
prepar
either
pa
plasma
final
volum
ml
dose
platelet
condit
repres
inactiv
use
lowest
amotosalen
concentr
mm
highest
concentr
platelet
platelet
unit
inocul
high
titer
virus
bacteria
treat
control
preuva
test
postuva
sampl
serial
dilut
cultur
plate
suitabl
media
use
bacteria
wherea
viral
titer
determin
use
plaqu
assay
log
reduct
calcul
differ
log
titer
control
preuva
test
postuva
sampl
conclus
dromedari
camel
identifi
reservoir
mer
cov
transmiss
human
occur
direct
indirect
contact
mer
cov
detect
high
genom
titer
log
respiratori
secret
mer
patient
lower
genom
titer
log
blood
presenc
viral
particl
blood
acut
patient
give
rise
concern
especi
endem
area
high
mortal
rate
especi
critic
ill
patient
often
requir
blood
transfus
rais
need
method
safe
exclud
mer
cov
contamin
blood
product
pathogen
reduct
amotosalenuva
technolog
wide
establish
technolog
broad
rang
data
support
clinic
efficaci
safeti
amotosalenuva
treat
blood
product
aim
studi
assess
mer
cov
inactiv
efficaci
human
plasma
amotosalenuva
pathogen
inactiv
technolog
safe
exclud
presenc
infecti
viru
human
plasma
unit
preuva
titer
postuva
titer
log
reductionml
log
ml
plasma
pa
e
coli
e
cloaca
k
pneumonia
aureu
blue
tongu
viru
bovin
viral
diarrhea
viru
plasma
k
pneumonia
aureu
transfus
vol
supplement
abstract
studi
designmethod
four
therapeut
human
plasma
unit
spike
fulli
character
mer
cov
clinic
isol
follow
pathogen
inactiv
amotosalenuva
intercept
blood
system
ceru
corpor
four
differ
day
pathogen
reduc
sampl
taken
preand
postpathogen
reduct
variou
process
step
assess
infecti
titer
plaqu
assay
titrat
genom
titer
realtimepcr
sampl
post
pathogen
reduct
passag
time
day
assess
infecti
titer
genom
titer
everi
rd
day
exclud
presenc
lowtit
infecti
particl
resultsfind
viral
particl
plasma
unit
complet
inactiv
averag
efficaci
log
infecti
titer
viral
replic
observ
day
passag
post
inactiv
genom
titer
slightli
affect
pathogen
inactiv
design
target
infecti
titer
physic
titer
conclus
amotosalen
alon
slight
effect
infecti
titer
amotosalenuva
effect
inactiv
infecti
mer
cov
viral
particl
plasma
unit
inactiv
efficaci
log
infecti
titer
give
evid
improv
blood
safeti
amotosalenuva
treat
plasma
mer
cov
endem
region
estim
preval
incid
nation
blood
servic
taiwan
hcv
erad
program
yunyuan
chen
jenwei
chen
chile
chen
shengnan
lu
peijer
chen
depart
research
head
offic
taiwan
blood
servic
foundat
graduat
institut
clinic
medicin
colleg
medicin
nation
taiwan
univers
divis
hepatogastroenterolog
depart
intern
medicin
kaohsiung
chang
gung
memori
hospit
backgroundcas
studi
world
health
organ
set
goal
elimin
hcv
epidemiolog
indic
gener
nation
blood
servic
use
monitor
effect
studi
aim
evalu
preval
incid
hcv
infect
taiwan
studi
designmethod
taiwan
antihcv
sinc
minipool
triplex
nucleic
acid
test
hcv
hbv
hiv
sinc
use
routin
blood
screen
preval
antihcv
hcv
rna
estim
firsttim
donor
respect
agestandard
preval
confid
interv
ci
calcul
adjust
world
standard
popul
incid
studi
donor
donat
blood
two
time
without
histori
antihcv
posit
followup
period
includ
incid
confid
interv
estim
number
new
hcv
rna
posit
case
divid
personyear
followup
resultsfind
crude
preval
antihcv
firsttim
donor
dramat
decreas
per
donor
ci
per
ci
agestandard
preval
also
decreas
per
donor
ci
per
ci
agestandard
preval
antihcv
gener
higher
femal
donor
significantli
higher
male
donor
total
hcv
rna
posit
case
antihcv
neg
identifi
firsttim
donor
crude
agestandard
preval
hcv
rna
per
ci
per
ci
respect
crude
preval
hcv
rna
significantli
higher
femal
donor
p
valu
signific
differ
found
age
standard
p
preval
antihcv
hcv
rna
increas
age
p
trend
incid
studi
total
new
hcv
rna
posit
case
antihcv
neg
found
donor
follow
personyear
incid
hcv
rna
per
personyear
ci
signific
differ
observ
gender
age
group
p
trend
conclus
preval
hcv
infect
dramat
decreas
becom
significantli
higher
male
donor
need
monitor
futur
incid
hcv
rna
low
repeat
blood
donor
need
identifi
incid
case
observ
epidemiolog
characterist
dalia
ashour
sahar
muhmmad
dalia
el
dewi
nation
blood
transfus
servic
azhar
univers
backgroundcas
studi
blood
safeti
challeng
egypt
high
preval
hcv
hbv
nucleic
acid
amplif
test
nat
technolog
potenti
detect
viremia
earlier
current
screen
method
base
seroconvers
primari
benefit
nat
abil
reduc
residu
risk
infecti
wp
donat
estim
reduct
wp
util
nat
hcv
day
hiv
day
hbv
day
studi
designmethod
cross
section
studi
conduct
nation
blood
transfus
center
giza
egypt
total
number
donor
sampl
screen
age
donor
rang
year
sex
f
screen
nat
ulterio
assay
grifol
diagnost
formerli
novarti
diagnost
done
parallel
eia
test
hbsag
hcvab
hiv
ag
ab
use
individu
donat
nat
idnat
multiplex
nat
yield
sampl
test
use
discriminatori
assay
order
ascertain
viral
nucleic
acid
present
donor
sampl
statist
analysi
chisquar
test
use
measur
associ
two
qualit
variabl
resultsfind
nat
screen
detect
total
nat
yield
donat
among
seroneg
donor
among
nat
yield
case
reactiv
hbv
reactiv
hcv
reactiv
stratifi
age
donor
group
group
year
group
b
year
group
c
year
preval
nat
yield
three
virus
significantli
higher
either
group
b
c
compar
group
p
confid
interv
ci
p
ci
respect
preval
nathbv
significantli
higher
age
group
b
compar
group
p
ci
hand
statist
signific
differ
group
c
group
b
c
compar
group
b
c
combin
group
found
significantli
higher
preval
hbv
former
p
ci
nathcv
differ
significantli
three
group
p
ci
group
b
p
ci
group
c
p
ci
group
b
c
nathiv
also
differ
significantli
three
group
p
ci
group
b
p
ci
group
b
c
either
group
c
nathiv
detect
nat
yield
three
virus
significantli
higher
male
femal
p
ci
nat
hbv
significantli
higher
male
p
preval
either
hcv
hiv
differ
significantli
male
femal
p
ci
p
ci
respect
conclus
studi
nat
yield
assum
signific
one
consid
fact
singl
donat
use
gener
compon
use
recipi
henc
effect
nat
yield
becom
time
save
recipi
tti
inde
signific
resultsfind
donor
test
donor
center
repeat
reactiv
season
pattern
preval
observ
highest
number
donor
posit
summer
progress
declin
fall
winter
month
increas
spring
singl
case
transfus
transmit
babesiosi
report
center
period
patient
transfus
two
unit
pack
red
blood
cell
rbc
two
donor
begin
juli
present
august
transfus
found
parasitemia
peripher
blood
smear
subsequ
diagnos
babesiosi
donor
call
back
howev
one
could
track
sampl
sent
state
test
immunofluores
assay
perform
combin
igg
igm
iga
test
posit
titer
screen
elia
sco
donor
donor
indefinit
defer
blood
donor
conclus
data
confirm
decreas
risk
transfus
transmiss
use
screen
assay
prior
implement
screen
transfus
transmit
babesia
case
per
year
tabl
month
implement
pretransfus
babesia
screen
one
break
case
transfus
transmit
babesia
observ
donor
test
thu
babesia
eia
screen
test
effect
prevent
ttb
howev
substanti
loss
donor
due
screen
posit
four
year
experi
idnat
tertiari
care
centr
north
india
implic
transfus
transmiss
donor
screen
jasmeet
singh
amarjit
kaur
gurpreet
kaur
rajesh
kumar
sonia
gupta
dayanand
medic
colleg
hospit
backgroundcas
studi
transfus
transmit
diseas
challeng
transfus
medicin
specialist
patient
care
provid
around
globe
blood
safeti
formid
task
especi
high
popul
countri
like
india
newer
technolog
like
idnat
equip
us
screen
prevent
transfus
transmit
viral
infect
prevent
transmiss
improv
sensit
specif
convent
method
studi
aim
examin
effect
idnat
addit
test
safeti
blood
suppli
studi
designmethod
retrospect
observ
studi
conduct
analyz
data
year
addit
nat
test
blood
bank
dmch
ludhiana
septemb
decemb
resultsfind
result
unit
initi
nat
reactiv
unit
test
discrimin
hiv
hcv
hbv
coinfect
remain
repeat
nonreact
could
discrimin
overal
nat
yield
rate
one
wherea
virusspecif
nat
yield
rate
one
hiv
one
hcv
one
hbv
one
hbvhcv
coinfect
respect
conclus
idnat
screen
blood
donat
institut
past
year
increas
screen
sensit
check
viral
load
prevent
transmiss
probabl
transfus
transmit
viral
infect
assum
compon
prepar
save
transfus
recipi
harm
implement
nat
along
routin
serolog
test
screen
blood
donat
definit
improv
transfus
safeti
mandat
across
transfus
center
min
xu
wei
mao
tao
yashan
yang
zhan
gao
chunhong
zhang
hongmei
liao
jingx
wang
miao
institut
blood
transfus
chines
academi
medic
scienc
peke
union
medic
colleg
sichuan
blood
safeti
blood
substitut
intern
scienc
technolog
cooper
base
chongq
blood
center
backgroundcas
studi
mani
emerg
infecti
pathogen
known
exist
heathi
blood
donat
could
transmit
via
transfus
potenti
hazard
consequ
recipi
conveni
applic
high
put
sequenc
becom
much
easier
investig
uncultur
microbiom
qualifi
blood
donat
therefor
metagenom
analys
use
reveal
emerg
reemerg
infecti
diseas
healthi
donat
might
potenti
threat
blood
safeti
studi
designmethod
pool
plasma
sampl
collect
voluntari
blood
donor
chongq
china
total
dna
rna
extract
amplifi
random
primer
pcr
respect
order
construct
librari
peform
deep
sequenc
illumina
miseq
read
trim
remov
low
qualiti
base
adapt
sequenc
fulli
overlap
pairedend
read
pass
qualiti
filter
concaten
use
pear
classifi
final
read
use
kraken
kraken
databas
made
complet
refseq
bacteri
archaeal
viral
genom
along
human
genom
unclassifi
read
kraken
align
ncbi
nt
databas
use
blastn
cutoff
evalu
best
align
hit
use
classifi
read
krona
use
gener
taxonom
distribut
plot
final
potenti
emerg
reemerg
infecti
pathogen
identifi
classifi
microbiom
experi
abstract
resultsfind
gb
raw
data
read
gener
dna
librari
meanwhil
raw
data
read
gener
rna
librari
clean
human
background
read
bacteria
read
virus
read
parasit
identifi
tabl
hazard
virus
identifi
potenti
threat
blood
safeti
except
virus
bacteria
would
limit
hazard
blood
safeti
plenti
parasit
identifi
alreadi
consid
threat
blood
safeti
develop
countri
also
discov
plasmodium
sp
leishmania
infantum
tabl
conclus
investig
reveal
metagenom
qualifi
blood
donat
chongq
china
result
show
thoughprovok
discoveri
genom
fragment
microb
might
threat
blood
safeti
display
seriou
result
let
us
think
regul
reason
screen
method
well
donor
recruit
strategi
certain
epidem
area
season
ensur
blood
safeti
howev
contrari
result
consid
cautious
exist
genom
fragment
could
repres
exist
infecti
pathogen
valid
metagenom
hint
suggest
go
epidemiolog
investig
specif
test
laboratori
way
bacteria
viru
cultur
ensur
vital
pathogen
backgroundcas
studi
caribbean
becom
endem
region
sever
emerg
virus
last
decad
chikungunya
outbreak
recent
zika
shown
endem
caribbean
island
curacao
effect
provid
safe
blood
product
endem
region
convent
intern
recommend
donor
exclus
test
seem
viabl
option
could
sever
affect
local
blood
suppli
pathogen
reduct
pr
consid
import
new
approach
potenti
benefit
introduct
experi
use
pr
platelet
dutch
caribbean
period
one
year
present
studi
designmethod
pathogen
reduct
thrombocyt
concentr
use
riboflavin
ultraviolet
treatment
mirasol
prt
terumo
belgium
introduc
thrombocyt
concentr
provid
gener
hospit
dutch
caribbean
island
bonair
sint
maarten
pr
data
collect
period
februari
februari
thrombocyt
concentr
prepar
singl
donat
unit
buffycoat
method
resultsfind
period
platelet
concentr
provid
adult
pediatr
patient
includ
patient
intens
care
neonat
intens
care
depart
advers
event
report
cci
transfus
within
expect
outcom
introduct
pr
minim
impact
logist
thrombocyt
concentr
prepar
avail
furthermor
transfus
relat
bacteri
contamin
report
conclus
pr
platelet
concentr
seem
viabl
safe
use
small
scale
caribbean
set
endem
emerg
virus
like
chikungunya
zika
offer
realist
altern
convent
recommend
donor
exclus
test
therebi
help
maintain
suffici
labil
blood
product
avail
michael
phillip
germ
leparc
phillip
c
williamson
lani
palmer
ben
reynold
maria
noedel
lindsey
houghton
creativ
test
solut
oneblood
backgroundcas
studi
due
risk
travel
sexual
transmit
zika
infect
food
drug
administr
issu
guidanc
document
februari
recommend
blood
center
puerto
rico
ceas
distribut
local
collect
blood
product
unless
donor
test
product
pathogen
reduc
march
high
incid
zika
viru
zikv
puerto
rico
uncertainti
impact
continent
us
blood
suppli
intens
pressur
implement
donor
screen
test
zikv
project
initi
februari
includ
clinic
trial
requir
client
onboard
laboratori
oper
stakehold
consist
client
manufactur
institut
review
board
irb
inform
technolog
client
lab
base
food
drug
administr
fda
center
diseas
control
cdc
florida
depart
health
clinic
trial
requir
includ
develop
instrument
assay
valid
sop
creation
result
report
assay
clinic
trial
train
deviat
manag
donor
notif
follow
sampl
handl
client
onboard
began
confidenti
agreement
client
sponsor
zika
base
webinar
creat
provid
overview
sponsor
protocol
lab
test
system
client
respons
complex
project
increas
mosquito
born
zika
transmiss
identifi
two
counti
florida
requir
zikv
test
perform
collect
florida
puerto
rico
zikvnat
perform
singlet
unlik
mpx
wnv
assay
run
minipool
signific
impact
instrument
capac
despit
obstacl
chang
regulatori
requir
zikv
screen
test
implement
within
six
week
studi
designmethod
one
metric
use
measur
client
servic
level
abil
meet
establish
upload
time
goal
individu
client
percentag
sampl
releas
time
evalu
daili
run
monthli
total
upload
time
goal
neg
impact
juli
septemb
due
unexpect
increas
zikv
test
requir
perform
test
singlet
result
instrument
capac
issu
addit
instrument
sourc
octob
oper
stabil
conclus
februari
project
implement
zikv
ind
test
initi
six
week
later
test
perform
first
batch
sampl
despit
chang
regulatori
requir
time
implement
extrem
success
initi
new
ind
test
within
week
unpreced
requir
except
collabor
particip
stakehold
backgroundcas
studi
plasmodium
falciparum
pf
intraerythrocyt
protozoan
parasit
account
nearli
malaria
mortal
africa
report
million
new
case
worldwid
result
death
malaria
preval
highest
subsaharan
africa
home
infect
account
mortal
incid
preval
malaria
africa
significantli
increas
potenti
transfusiontransmiss
tt
littl
screen
product
develop
countri
object
studi
evalu
inactiv
pf
whole
blood
wb
use
system
specif
develop
realiti
develop
world
support
swiss
red
cross
humanitarian
foundat
whole
blood
pathogen
inactiv
africa
inabl
consist
suppli
blood
compon
lead
routin
wb
transfus
transfusiontransmit
diseas
preval
develop
world
establish
robust
wb
pathogen
inactiv
system
desir
approach
use
small
molecul
amustalin
form
coval
adduct
crosslink
within
nucleic
acid
leukocyt
contamin
pathogen
prevent
replic
process
includ
addit
mm
amustalin
mm
glutathion
gsh
room
temperatur
rt
incub
treat
wb
unit
suitabl
storag
day
rt
studi
designmethod
experi
wb
unit
spike
ringstag
pfinfect
red
blood
cell
irbc
pretreat
sampl
remov
prior
addit
amustalin
posttreat
sampl
remov
amustalin
addit
determin
preand
posttreat
titer
calcul
level
inactiv
sampl
serial
dilut
flask
contain
medium
fresh
rbc
dilut
sampl
use
inocul
flask
quadrupl
monitor
parasitemia
count
irbc
blood
smear
flow
cytometri
pretreat
cultur
termin
reach
parasitemia
residu
pf
detect
posttreat
cultur
log
reduct
calcul
differ
mean
titer
preand
posttreat
sampl
resultsfind
robust
inactiv
pf
wb
achiev
limit
detect
log
log
ml
conclus
pf
inactiv
limit
detect
wb
treatment
amustalinegsh
illustr
system
potenti
mitig
risk
pf
transfus
transmiss
endem
region
lack
test
capac
oper
constraint
limit
blood
compon
suppli
reli
wb
transfus
system
wb
approv
commerci
use
increas
patient
safeti
improv
inventori
manag
day
apheresi
platelet
nanci
dunbar
zbigniew
szczepiorkowski
backgroundcas
studi
pathway
current
exist
apheresi
platelet
ap
outdat
extens
day
use
fda
clear
rapid
test
rt
februari
hospit
base
transfus
servic
implement
use
rt
day
routin
extend
ap
shelf
life
day
prior
test
ap
rt
day
transfus
day
day
unit
physician
approv
deem
medic
necessari
report
describ
chang
observ
transfus
practic
platelet
inventori
manag
one
year
follow
routin
use
day
platelet
studi
designmethod
data
obtain
two
studi
period
octob
preimplement
februari
postimplement
interv
transit
period
intent
exclud
studi
period
determin
total
number
ap
transfus
rt
statu
day
transfus
total
number
rt
perform
expir
ap
unit
ap
obtain
supplier
use
adhoc
order
also
obtain
hospit
data
includ
inpati
admiss
surgic
volum
averag
length
stay
case
mix
index
resultsfind
data
shown
tabl
number
ap
transfus
increas
postimplement
compar
increas
inpati
admiss
increas
surgic
volum
hospit
length
stay
case
mix
index
similar
period
averag
number
platelet
transfus
per
patient
statist
differ
pre
post
number
rt
perform
increas
percentag
transfus
unit
test
least
rt
prior
transfus
increas
p
outdat
rate
decreas
p
adhoc
order
decreas
p
conclus
use
approv
rt
routin
ap
outdat
extens
day
associ
increas
patient
safeti
transfus
unit
underw
secondari
test
prior
transfus
increas
cost
rt
offset
reduc
ap
wast
less
frequent
need
adhoc
order
sheila
obrien
vito
scalia
carla
osiowi
michael
carpent
anton
andonov
margaret
fearon
canadian
blood
servic
public
health
agenc
canada
backgroundcas
studi
rate
hepat
b
hbv
hepat
c
viru
hcv
posit
donat
low
per
donat
respect
among
first
time
donor
aim
determin
frequenc
variou
genotyp
hbv
hcv
canadian
blood
donor
confirm
posit
hbv
hcv
studi
designmethod
roch
multiplex
assay
hcvhiv
hbv
implement
minipool
unit
hcv
nat
place
sinc
use
minipool
first
time
donor
screen
hbv
nat
hbsag
antihbc
antihcv
test
use
abbott
prism
assay
confirmatori
test
hbsag
prism
neutral
assay
antihcv
repeat
reactiv
confirm
innolia
hcv
score
line
immunoassay
sinc
march
sampl
test
hbv
nat
posit
confirm
posit
hbsag
hcv
nat
posit
antihcv
confirm
posit
sampl
consid
posit
sampl
sent
phac
sequenc
sampl
posit
donat
aliquot
frozen
c
genotyp
carri
sequenc
phylogenet
analysi
hbv
surfac
antigen
code
region
hcv
viral
rna
extract
subject
revers
transcript
pcr
amplif
region
sanger
sequenc
region
repres
approxim
genom
resultsfind
confirm
posit
donat
whole
blood
donat
hbv
posit
donat
test
hbv
nat
posit
genotyp
type
b
c
e
sampl
hbv
nat
neg
hbsag
posit
antihbc
reactiv
could
sequenc
one
genotyp
also
antihbc
reactiv
sampl
consid
hcv
posit
sampl
hcv
nat
posit
genotyp
type
also
sampl
hcv
nat
neg
antihcv
posit
none
could
sequenc
conclus
first
month
molecular
surveil
show
rang
genotyp
hbv
hcv
sampl
identifi
nat
posit
date
sampl
nat
neg
antihcv
reactiv
could
sequenc
howev
one
nat
neg
sampl
posit
hbsag
antihbc
reactiv
hbv
genotyp
surveil
longer
period
backgroundcas
studi
bactalert
microbi
detect
system
bta
current
fda
clear
qualiti
control
test
leukocyt
reduc
apheresi
platelet
lrap
bactalert
virtuo
microbi
detect
system
virtuo
biom
erieux
st
loui
mo
new
gener
bactalert
instrument
underli
colorimetr
technolog
use
previou
gener
bactalert
use
virtuo
incorpor
new
instrument
architectur
improv
temperatur
stabil
workflow
improv
via
autom
process
current
perform
manual
improv
user
interfac
enhanc
algorithm
shorten
time
detect
object
studi
compar
perform
virtuo
bactalert
bta
instrument
use
bactalert
bpa
aerob
bactalert
bpn
anaerob
bottl
detect
rang
typic
bacteri
contamin
seed
leukocyt
reduc
apheresi
platelet
lrap
studi
designmethod
studi
perform
two
institut
one
us
uk
aliquot
lrap
seed
low
level
cfuml
bacteri
speci
commonli
associ
platelet
contamin
replic
per
instrument
ml
aliquot
per
bottl
inocul
bpa
bpn
bottl
one
set
bottl
load
bta
virtuo
incub
signal
posit
instrument
day
overal
detect
rate
time
detect
bacteri
contamin
instrument
compar
addit
bottl
test
instrument
lrap
organ
evalu
differ
overal
neg
agreement
rate
detect
fals
posit
instrument
serv
steril
control
platelet
prepar
backgroundcas
studi
implement
nucleic
acid
test
nat
blood
screen
still
challeng
resourcelimit
countri
time
countri
higher
similar
proport
replac
voluntari
blood
donor
recruit
higher
preval
infect
observ
relat
develop
countri
consequ
incid
case
infect
expect
countri
hospit
blood
bank
could
afford
nat
due
high
cost
belong
net
central
nat
refer
blood
center
process
consolid
small
blood
bank
region
blood
center
abl
implement
nat
yet
complet
although
effort
reduc
replac
familiar
blood
donat
progress
goal
complet
achiev
aim
compar
preval
hiv
hcv
hbv
nat
screen
blood
center
recruit
voluntari
blood
donor
preval
center
recruit
replac
voluntari
blood
donor
describ
nat
yield
rate
hiv
hcv
hbv
period
three
half
year
experi
studi
designmethod
region
blood
donor
center
rbdc
central
nat
screen
center
differ
region
countri
due
sinc
august
process
requir
achiev
adequ
laboratori
condit
staff
qualif
develop
softwar
assur
sampl
traceabl
interfac
transmiss
result
window
period
suspect
nat
screen
repeat
plasma
unit
second
sampl
blood
donor
requir
confirm
nat
result
rbdc
also
develop
voluntari
donor
program
sinc
center
countri
achiev
goal
resultsfind
total
donat
studi
august
decemb
rbdc
voluntari
blood
donat
recruit
preval
per
donat
hiv
per
hbv
per
hcv
center
togeth
voluntari
replac
blood
donat
recruit
preval
per
donat
hiv
per
hbv
per
hcv
window
period
infect
detect
center
recruit
voluntari
replac
blood
donat
give
nat
yield
rate
hbv
hiv
hcv
conclus
hiv
hbv
hcv
preval
lower
center
task
sustain
voluntari
blood
donor
program
develop
nat
yield
rate
could
reduc
region
program
could
complet
appli
center
mechan
lead
obi
includ
variou
factor
imperfect
host
immun
respons
viral
variat
factor
studi
determin
viral
load
obi
current
recruit
screen
among
blood
donor
five
blood
servic
zhejiang
provinc
china
studi
designmethod
donat
donor
screen
preclud
hbsag
preliminari
test
posit
alt
level
abnorm
follow
sampl
detect
hbsag
twice
use
differ
elisa
reagent
hbv
dna
use
tma
qtpcr
techniqu
sampl
hbv
dna
posit
elisa
neg
test
viral
load
use
taqman
techniqu
coba
system
hbv
region
also
sequenc
resultsfind
obi
found
donat
viral
load
assay
sampl
neg
sampl
viral
load
lower
mean
viral
load
iuml
sampl
mean
viral
load
sampl
iuml
sampl
obi
analyz
hbv
genotyp
b
preval
subtyp
hbv
c
genotyp
compar
sampl
found
two
obi
sampl
carri
c
mutat
could
caus
amino
acid
conclus
studi
viral
load
obi
infect
donor
much
low
uniqu
variat
identifi
obi
individu
transfus
gener
popul
screen
blood
donor
hbv
india
primarili
base
upon
detect
hepat
b
surfac
antigen
hbsag
donor
sera
current
studi
undertaken
determin
preval
occult
hbv
infect
obi
voluntari
blood
donor
analyz
burden
hbv
window
period
donat
studi
designmethod
prospect
observ
monocentr
studi
perform
nation
accredit
board
hospit
nabh
accredit
apex
blood
bank
locat
maharashtra
state
india
monolisa
hbsag
ultra
biorad
franc
sandwich
type
elisa
use
monoclon
polyclon
antibodi
use
hbsag
detect
donor
sera
elisa
nonreact
sampl
also
test
addit
real
time
multiplex
polymeras
chain
reaction
mpxpcr
cobasv
r
taqscreen
mpx
test
donor
found
posit
hbv
dna
follow
upat
th
day
month
month
monolisa
hbsag
ultra
biorad
franc
analyz
interv
window
period
delin
window
period
donat
wpd
true
obi
backgroundcas
studi
occult
hepat
b
infect
obi
character
hepat
b
viru
hbv
dnaposit
hbv
surfac
antigen
hbsag
neg
sinc
may
test
apheresi
donor
hbv
nucleic
acid
improv
laboratori
test
reduc
risk
transfusiontransmit
infect
number
apheresi
collect
increas
significantli
year
year
howev
data
hepat
b
viru
marker
rate
among
donor
continu
lack
aim
studi
evalu
epidem
characterist
incid
estim
risk
factor
obi
among
apheresi
donor
region
central
china
studi
designmethod
apheresi
donor
data
may
dec
retrospect
analyz
sampl
test
hbsag
hbv
dna
marker
nucleic
acid
test
nat
perform
roch
coba
platform
use
pool
serolog
neg
sampl
pool
posit
would
undergo
nat
individu
hbsag
neg
hbv
dna
posit
test
hbv
dna
quantit
pcr
antibodi
hepat
b
surfac
antigen
hbsab
antibodi
hepat
b
core
antigen
hbcab
hepat
b
e
antigen
hbeag
antibodi
hepat
b
e
hbeab
resultsfind
evalu
seroneg
donat
screen
nat
total
hbv
dnareactivehbsagneg
donor
detect
hiv
rna
reactiv
hcv
rna
reactiv
sampl
detect
complet
serolog
screen
index
donat
indic
major
donor
occult
hbv
infect
major
marri
men
fix
donor
mani
whole
blood
apheresi
donat
age
distribut
age
group
year
old
show
larg
proport
account
report
infect
hbv
dna
case
reach
senior
high
school
educ
averag
hbsag
dna
posit
rate
incid
among
apheresi
donor
period
hbsag
dna
estim
compar
among
repeat
whole
blood
donor
develop
pathogen
reduc
pr
cryo
deriv
ffp
day
stabil
studi
designmethod
six
replic
typematch
pool
whole
blood
deriv
wbd
apheresi
aph
plasma
split
produc
convent
control
ml
test
compon
ml
ml
test
compon
pr
amotosalen
uva
light
aph
wbd
ffp
produc
freez
plasma
within
hr
wbd
within
hr
cryo
manufactur
accord
site
sop
frozen
test
ml
control
ml
test
control
cryo
thaw
character
immedi
post
thaw
storag
test
fb
fviii
function
thromboelastographi
rotem
thrombin
gener
cat
resultsfind
pr
cryo
retain
suffici
fb
fviii
activ
post
thaw
tabl
hemostat
capac
rotem
extem
show
retent
fibrin
format
angl
clot
qualiti
mcf
tabl
thrombin
gener
robust
demonstr
multipl
paramet
lag
time
peak
thrombin
endogen
total
thrombin
potenti
etp
time
peak
tt
despit
lower
fviii
level
paramet
maintain
storag
conclus
pr
cryo
process
plasma
sourc
includ
store
rt
day
pr
plasma
provid
adequ
level
fb
hemostat
capac
equival
control
demonstr
rotem
cat
use
stabil
day
increas
avail
cryo
reduc
risk
transfusiontransmit
infect
cryo
produc
psoralentr
pr
plasma
approv
use
us
perform
new
autom
alin
assay
antibodi
cruzi
darwin
smith
ed
bakker
anton
van
weert
jane
bryant
mark
paradowski
lynn
fleischmann
mirjana
sarac
georg
chen
georg
schlauder
gregg
william
abbott
diagnost
sanquin
diagnost
abbott
gmbh
co
kg
backgroundcas
studi
parasit
trypanosoma
cruzi
cruzi
caus
chaga
diseas
endem
america
infect
million
peopl
order
prevent
transfus
mediat
transmiss
parasit
endem
countri
blood
collect
center
requir
high
throughput
antit
cruzi
assay
good
specif
sensit
nonendem
countri
select
test
risk
donor
strategi
avoid
temporari
donor
deferr
addit
continu
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
studi
designmethod
perform
new
autom
chemiluminesc
immunoassay
detect
antibodi
cruzi
evalu
alin
autom
platform
compar
anoth
onmarket
chemiluminesc
immunoassay
precis
assess
day
use
panel
posit
neg
sampl
sensit
evalu
presum
antibodi
posit
specimen
specif
evalu
random
blood
donor
sampl
resultsfind
precis
cv
less
posit
sampl
day
overal
specif
blood
donor
popul
sensit
presum
antibodi
posit
sampl
conclus
result
indic
new
autom
alin
chaga
assay
provid
good
perform
sensit
specif
compar
current
onmarket
antit
cruzi
assay
equal
suitabl
use
univers
screen
endem
select
donor
screen
nonendem
countri
perform
new
autom
alin
assay
hepat
b
surfac
antigen
hepat
b
surfac
antigen
confirmatori
randal
makela
anton
vanweert
ed
bakker
jane
bryant
mark
paradowski
lynn
martin
daniela
kalev
georg
chen
gregg
william
georg
schlauder
abbott
laboratori
sanguin
diagnost
abbott
gmbh
co
kg
abbott
diagnost
backgroundcas
studi
despit
develop
sensit
nat
method
blood
transfus
mani
part
world
reli
serolog
screen
hepat
b
surfac
antigen
hbsag
prevent
transfus
transmit
hbv
infect
sensit
hbsag
assay
must
capabl
cope
wide
rang
mutant
exhibit
uncompromis
specif
addit
continu
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
studi
designmethod
perform
new
autom
chemiluminesc
immunoassay
detect
confirm
hbsag
evalu
next
gener
autom
platform
abbott
alin
precis
assess
day
sensit
evalu
use
known
posit
sampl
commerci
avail
seroconvers
panel
standard
hbsag
mutant
hbsag
genotyp
specimen
h
specif
evalu
random
blood
plasmapheresi
donor
resultsfind
precis
less
cv
posit
sampl
day
blood
donor
specif
sensit
presum
posit
sampl
sensit
genotyp
mutant
detect
vs
compar
assay
seroconvers
detect
equival
compar
assay
reactiv
sampl
detect
alin
assay
reactiv
sampl
detect
compar
assay
analyt
sensit
rang
iuml
alin
hbsag
confirmatori
assay
confirm
known
posit
hbsag
specimen
includ
hbsag
mutant
sampl
confirm
compar
hbsag
confirmatori
assay
conclus
new
autom
alin
hbsag
assay
provid
precis
specif
seroconvers
sensit
compar
current
onmarket
compar
assay
howev
alin
hbsag
assay
demonstr
gain
sensit
compar
assay
detect
confirm
wider
rang
mutant
perform
new
autom
alin
immunoassay
assay
hiv
darwin
smith
ed
bakker
anton
van
weert
jane
bryant
mark
paradowski
kevin
callear
susan
sullivan
georg
chen
georg
schlauder
gregg
william
abbott
diagnost
sanquin
diagnost
backgroundcas
studi
blood
donat
commonli
screen
detect
presenc
antibodi
antibodi
antigen
human
immunodefici
viru
type
blood
center
requir
high
throughput
assay
high
specif
sensit
prevent
unnecessari
donor
deferr
maintain
safe
blood
suppli
addit
continu
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
respons
need
screen
assay
evalu
improv
autom
assay
detect
antibodi
antigen
studi
designmethod
perform
new
chemiluminesc
combin
immunoassay
detect
antibodi
antigen
evalu
abbott
alin
system
precis
assess
day
evalu
posit
sampl
specif
evalu
sampl
obtain
random
blood
donor
plasmapheresi
donor
sensit
evalu
use
presum
posit
sampl
hiv
group
antibodi
antigen
seroconvers
sensit
evalu
commerci
seroconvers
panel
resultsfind
precis
less
cv
posit
sampl
day
blood
donor
specif
sensit
presum
antibodi
posit
sampl
compris
group
n
p
crf
urf
sampl
also
sensit
antigen
posit
viral
isol
sampl
compris
group
n
p
crf
urf
sampl
seroconvers
detect
equival
compar
assay
reactiv
sampl
detect
alin
assay
reactiv
sampl
detect
compar
assay
conclus
result
indic
new
autom
alin
hiv
agab
combo
assay
provid
accept
perform
specif
sensit
precis
provid
similar
seroconvers
sensit
compar
assay
perform
new
autom
alin
immunoassay
detect
antihbc
antibodi
randal
makela
anton
vanweert
ed
bakker
jane
bryant
mark
paradowski
joyc
siregar
angela
vockel
georg
chen
gregg
william
georg
schlauder
abbott
laboratori
sanguin
diagnost
abbott
gmbh
co
kg
abbott
diagnost
backgroundcas
studi
countri
low
preval
hepat
b
blood
donat
commonli
screen
detect
presenc
antibodi
hepat
b
core
antigen
antihbc
alongsid
hbsag
hbv
nat
detect
donor
occult
hepat
b
infect
obi
blood
center
requir
antihbc
assay
high
specif
sensit
prevent
unnecessari
donor
deferr
maintain
safe
blood
suppli
addit
continu
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
respons
need
screen
assay
develop
improv
autom
assay
detect
antihbc
alin
system
studi
designmethod
perform
new
chemiluminesc
antihbc
assay
detect
antihbc
antibodi
evalu
next
gener
autom
abbott
alin
system
precis
assess
day
evalu
posit
sampl
specif
evalu
sampl
obtain
random
blood
donor
sensit
evalu
use
specimen
character
antihbc
posit
mean
serolog
method
analyt
sensit
assess
use
intern
standard
seroconvers
sensit
evalu
use
commerci
seroconvers
panel
resultsfind
precis
less
cv
posit
sampl
day
blood
donor
specif
sensit
sampl
presum
antihbc
posit
analyt
sensit
result
alin
antihbc
assay
rang
iuml
seroconvers
detect
equival
compar
assay
reactiv
sampl
detect
alin
assay
reactiv
sampl
detect
compar
assay
conclus
result
indic
new
autom
alin
antihbc
assay
provid
good
perform
specif
sensit
precis
versu
compar
assay
perform
new
autom
alin
immunoassay
detect
htlv
htlv
ii
antibodi
melani
anderson
anton
vanweert
ed
bakker
mark
paradowski
jane
bryant
tuan
bui
joyc
siregar
georg
chen
georg
schlauder
gregg
william
abbott
laboratori
sanguin
diagnost
abbott
diagnost
backgroundcas
studi
endem
countri
univers
blood
screen
necessari
prevent
transfus
transmit
htlv
infect
antihtlv
ihtlv
ii
nonendem
countri
select
test
may
avoid
unnecessari
tempor
deferr
donor
high
risk
return
travel
donor
born
countri
high
htlv
preval
blood
center
requir
high
throughput
antihtlv
ihtlv
ii
assay
high
specif
sensit
prevent
unnecessari
donor
deferr
maintain
safe
blood
suppli
addit
continu
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
respons
need
assay
high
specif
high
throughput
instrument
develop
new
assay
detect
antibodi
htlviii
antibodi
alin
system
studi
designmethod
precis
assess
day
use
htlv
htlv
ii
posit
sampl
specif
evalu
use
blood
donor
specimen
europ
diagnost
sampl
obtain
unit
state
sensit
evalu
use
preselect
htlv
htlv
ii
posit
sampl
sensit
specif
sampl
split
across
reagent
lot
test
confirm
repeatedli
reactiv
sampl
done
use
mp
diagnost
htlv
blot
resultsfind
imprecis
less
posit
sampl
day
clinic
sensit
preselect
htlv
htlv
ii
posit
sampl
specif
blood
donor
popul
diagnost
sampl
conclus
result
indic
new
alin
autom
htlv
ii
assay
provid
good
perform
specif
sensit
precis
sensit
specif
compar
compar
assay
claudia
ramirez
michel
garcia
fernando
palomino
guillermo
orjuelafalla
nation
blood
bank
colombian
red
cross
universidad
del
rosario
fuat
backgroundcas
studi
current
hepat
c
viru
hcv
supplement
test
algorithm
blood
donat
colombia
requir
immunoblot
assay
perform
everi
hcv
enzym
immunoassay
eia
repeatreact
sampl
higher
proport
indetermin
ind
result
immunoblot
assay
document
nonu
donor
sampl
affect
donor
counsel
eventu
increas
cost
opportun
notif
infect
donor
work
aim
establish
distribut
immunoblot
result
colombian
repeatreact
sampl
well
frequenc
band
detect
posit
indetermin
blot
studi
designmethod
total
antihcvreact
donor
sampl
signaltocutoff
sco
ratio
greater
abbott
architect
underw
supplement
test
immunoblot
either
chiron
riba
hcv
sia
hcv
blot
test
mp
diagnost
neg
neg
indetermin
ind
posit
po
blot
result
group
sco
rang
follow
band
detect
intens
independ
analyz
indetermin
posit
result
resultsfind
immunoblot
result
neg
sampl
indetermin
posit
direct
relationship
observ
posit
immunoblot
increas
sco
proport
ind
result
higher
sco
group
compar
sampl
indetermin
result
frequent
band
detect
contrast
frequent
band
group
posit
result
core
one
sampl
indetermin
group
strong
band
intens
compar
sampl
posit
group
conclus
proport
indetermin
immunoblot
result
sampl
colombian
donor
one
highest
ever
report
twice
much
proport
found
larger
sampl
us
donor
high
proport
ind
result
found
sco
group
suggest
optim
sco
ratio
predict
confirm
antihcv
result
popul
higher
one
recommend
cdc
us
popul
overal
result
suggest
supplement
test
algorithm
blood
donat
colombia
could
improv
use
high
sco
ratio
altern
immunoblot
also
introduc
hcv
genom
assay
instead
immunoblot
least
sampl
intermedi
sco
ratio
crossreact
colombian
popul
warrant
investig
perform
alin
immunoassay
detect
syphili
antibodi
melani
anderson
ivanka
mihaljev
manuela
milet
miljana
stojic
vidov
irena
jukic
jane
bryant
mark
paradowski
angela
vockel
georg
chen
gregg
william
georg
schlauder
abbott
laboratori
croatian
institut
transfus
medicin
abbott
gmbh
co
kg
abbott
diagnost
backgroundcas
studi
blood
donat
commonli
screen
syphili
order
detect
presenc
antibodi
bacterium
treponema
pallidum
addit
continu
pressur
laboratori
oper
demand
full
panel
ttid
assay
perform
singl
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
respons
need
evalu
new
autom
immunoassay
detect
antibodi
pallidum
studi
designmethod
perform
new
autom
chemiluminesc
immunoassay
detect
antibodi
treponema
pallidum
evalu
alin
system
precis
assess
day
use
posit
sampl
specif
evalu
sampl
obtain
blood
plasmapheresi
donor
unit
state
europ
diagnost
sampl
obtain
unit
state
sensit
evalu
use
preselect
posit
sampl
sensit
specif
sampl
split
across
reagent
lot
test
confirm
repeatedli
reactiv
sampl
done
use
test
algorithm
confirmatori
assay
innolia
tm
syphili
score
mikrogen
recomlin
treponema
igg
igm
blot
resultsfind
imprecis
less
cv
posit
sampl
day
clinic
sensit
preselect
syphili
posit
sampl
specif
blood
donor
specimen
diagnost
sampl
conclus
result
indic
new
autom
alin
syphili
assay
provid
good
perform
precis
specif
sensit
line
data
found
compar
assay
perform
new
autom
alin
assay
antihcv
melani
anderson
ed
bakker
anton
vanweert
jane
bryant
mark
paradowski
tuan
bui
lynn
martin
georg
chen
gregg
william
georg
schlauder
abbott
laboratori
sanguin
diagnost
backgroundcas
studi
serolog
screen
antibodi
hepat
c
viru
hcv
often
conjunct
nucleic
acid
test
nat
use
worldwid
prevent
transfus
transmit
hcv
infect
nat
provid
improv
sensit
detect
hcv
preseroconvers
window
serolog
test
provid
continu
detect
hcv
infect
individu
individu
resolv
infect
detect
hcv
rna
blood
plasma
center
requir
high
throughput
antihcv
assay
high
specif
sensit
prevent
unnecessari
donor
deferr
maintain
safeti
blood
plasma
suppli
addit
continu
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
studi
designmethod
perform
new
autom
chemiluminesc
immunoassay
detect
antibodi
hcv
evalu
alin
system
precis
assess
day
evalu
posit
sampl
sensit
evalu
use
preselect
posit
sampl
seroconvers
panel
specif
evalu
sampl
obtain
blood
plasmapheresi
donor
unit
state
europ
diagnost
sampl
obtain
unit
state
sensit
specif
sampl
split
across
reagent
lot
test
confirm
repeatedli
reactiv
sampl
done
use
test
algorithm
consist
innolia
tm
hcv
score
nathcv
discriminatori
nat
assay
resultsfind
imprecis
less
cv
posit
sampl
day
overal
clinic
sensit
preselect
antihcv
posit
sampl
seroconvers
sensit
better
compar
evidenc
new
antihcv
assay
identifi
bleed
compar
assay
specif
blood
donor
specimen
backgroundcas
studi
zika
viru
zikv
outbroken
south
america
unit
state
sinc
middl
declar
public
health
emerg
intern
concern
feb
addit
mosquito
zikv
transmit
via
maternalneonat
relationship
sexual
intercours
blood
transfus
potenti
transfusiontransmit
zika
viru
shown
french
polynesia
asymptomat
blood
donor
test
posit
zika
viru
rna
use
nucleic
acid
test
nat
sever
case
report
confirm
zikv
transmit
transfus
shown
among
blood
donor
zikv
infect
asymptomat
ratio
symptomat
asymptomat
patient
observ
micronesia
approxim
thu
zikv
rais
great
challeng
transfus
safeti
measur
taken
prevent
transfusiontransmit
zikv
includ
temporari
deferr
blood
donor
epidem
locat
donor
selfreport
zikv
symptom
donat
without
quarantin
blood
compon
suppli
blood
collect
nonendem
area
epidem
region
nat
blood
donat
pathogen
inactiv
blood
product
studi
evalu
zikv
inactiv
plasma
use
methylen
blue
photochem
treatment
mbpt
studi
designmethod
plasma
unit
randomli
select
healthi
donor
collect
spike
zikv
sampl
ad
mb
final
concentr
assay
illumin
visibl
light
side
viral
infect
zikv
rna
load
revers
transcript
pcr
measur
spike
plasma
mbpt
confirm
use
repetit
passag
cell
cultur
control
zikv
spike
plasma
without
photochem
treatment
resultsfind
zikv
titer
control
sampl
log
tissu
cultur
infecti
dose
tcid
ml
viral
infect
detect
mb
photochem
inactiv
treatment
loss
infect
demonstr
repetit
passag
cell
cultur
meanwhil
zikv
rna
load
decreas
significantli
initi
treatment
wherebi
ctvalu
jump
control
mbpt
tabl
conclus
show
mb
photochem
treatment
could
effect
inactiv
zikv
plasma
rna
lesion
induc
mbpt
process
nucleic
acid
revers
transcript
amplif
inhibit
mbpt
prove
effici
method
prevent
plasma
transfusiontransmit
zikv
infect
gill
delag
margaret
fearon
susan
l
stramer
megan
l
nguyen
franc
bernier
sheila
obrien
vito
scalia
sakina
smith
yve
gr
egoir
bori
hogema
h
emaqu
ebec
canadian
blood
servic
american
red
cross
sanquin
backgroundcas
studi
hepat
e
viru
hev
known
transfusiontransmiss
part
risk
assess
infect
studi
carri
canadian
blood
donor
subset
donor
sampl
seropreval
howev
donor
sampl
posit
hev
inhous
nucleic
acid
test
hevnat
sinc
studi
suggest
exposur
hev
canada
use
hevnat
limit
detect
iuml
larger
studi
perform
use
sensit
hevnat
assay
studi
designmethod
donor
inform
studi
predon
read
materi
link
sampl
approxim
canadian
whole
blood
donor
includ
canadian
blood
servic
cb
h
emaqu
ebec
hq
collect
clinic
select
ensur
repres
sampl
donor
popul
transfus
vol
supplement
donat
avail
plasma
sampl
test
individu
donat
nat
american
red
cross
laboratori
gaithersburg
md
use
coba
v
r
hev
test
lod
iuml
ci
use
coba
v
r
system
test
current
approv
canada
usa
avail
ce
mark
test
natreact
donor
question
concern
risk
factor
recent
hev
infect
travel
anim
contact
food
water
exposur
undergo
confirmatori
test
altern
nat
viral
load
genotyp
igmigg
serolog
notifi
letter
defer
donat
month
indat
product
collect
donor
frozen
red
blood
cell
plasma
previou
month
destroy
recipi
trace
event
product
transfus
previou
month
resultsfind
april
cb
hq
test
sampl
valid
result
found
hevnat
reactiv
donor
confirm
test
date
confirm
pend
donor
donor
quebec
one
nova
scotia
alberta
male
femal
age
rang
year
two
donor
report
nonspecif
symptom
fatigu
term
risk
factor
ate
pork
includ
ate
pork
liver
ate
shellfish
ate
venison
drank
well
water
one
donor
identifi
risk
factor
viral
load
rang
iuml
iuml
antihev
igm
posit
antihev
igg
posit
index
wantai
assay
conclus
preval
rate
acut
hev
infect
donor
popul
appear
around
data
studi
contribut
ongo
risk
assess
transfusiontransmit
hev
infect
canada
preval
malaria
parasit
donat
blood
nakasero
blood
bank
uganda
gerald
nsubuga
musiisi
ezra
uganda
blood
transfus
servic
backgroundcas
studi
introduct
infect
donat
blood
malaria
signific
health
problem
face
human
uganda
screen
malaria
parasit
neither
routin
done
blood
bank
stipul
current
uganda
nation
blood
transfus
servic
ubt
guidelin
ministri
health
result
proport
donat
blood
infect
malaria
larg
unknown
malaria
infect
place
half
world
popul
risk
major
tropic
subtrop
region
world
million
case
million
death
occur
per
year
howev
studi
aim
determin
preval
malaria
parasit
donat
blood
nakasero
blood
bank
kampala
uganda
studi
designmethod
cross
section
studi
carri
nakasero
blood
bank
kampala
uganda
four
hundr
seventi
randomli
select
donor
sampl
blood
bank
june
august
thin
thick
glass
stain
blood
smear
blood
sampl
giemsa
examin
use
microscop
resultsfind
donat
blood
sampl
test
posit
malaria
parasit
p
falciparum
although
signific
differ
occurr
plasmodium
relat
sex
age
blood
group
p
major
blood
donor
test
posit
belong
blood
group
preval
malaria
parasit
studi
regardless
preval
presenc
malaria
parasit
plasmodium
falciparum
donat
blood
donor
presum
healthi
rais
seriou
concern
safeti
donat
blood
uganda
ministri
health
review
exist
guidelin
screen
malaria
mandatori
univers
blood
donor
screen
polici
malaria
exclus
blood
donor
plasmodia
parasitaemia
use
method
like
pathogen
inactiv
compar
tediou
microscop
procedur
screen
donat
blood
introduc
enhanc
blood
safeti
commun
compon
bactalert
virtuo
virtuo
advanc
next
gener
system
improv
autom
connect
data
manag
system
importantli
virtuo
new
algorithm
significantli
reduc
time
detect
ttd
microorgan
qualiti
control
test
platelet
prepar
use
bactalert
bpa
aerob
bpn
anaerob
bottl
bpa
bpn
bottl
test
virtuo
bact
alert
bta
evalu
repeat
detect
growth
seed
leukocyt
reduc
apheresi
platelet
lrap
without
platelet
addit
solut
pa
throughout
platelet
shelf
life
day
collect
studi
designmethod
pool
lrap
seed
low
level
organ
commonli
associ
platelet
contamin
day
post
collect
seed
lrap
inocul
bpa
bpn
bottl
differ
day
consecut
altern
team
peopl
seed
bottl
load
virtuo
bta
incub
declar
posit
neg
day
addit
bpa
bpn
bottl
inocul
ml
unseed
lrap
test
virtuo
bta
bottl
respect
serv
neg
control
steril
control
evalu
risk
fals
posit
caus
lrap
resultsfind
repeat
virtuo
detect
organ
lrap
demonstr
recoveri
rate
seed
bottl
virtuo
bta
virtuo
demonstr
averag
improv
ttd
hour
compar
bta
presenc
ml
lrap
platelet
lrap
caus
fals
posit
addit
age
lrap
unit
within
day
expiri
impact
ttd
seed
organ
backgroundcas
studi
zika
viru
zikv
emerg
flaviviru
transmit
aed
aegypti
mosquito
sometim
albopictu
mosquito
infect
asymptomat
zikv
nucleic
acid
test
nat
becam
requir
test
blood
donor
per
fda
guidanc
entitl
revis
recommend
reduc
risk
zika
viru
transmiss
blood
blood
compon
base
geograph
locat
implement
test
began
week
guidanc
issu
perform
zikv
nat
donor
whole
blood
blood
compon
investig
new
drug
ind
studi
sponsor
holog
inc
perform
retrospect
analysi
nat
result
potenti
defer
donat
due
fals
posit
screen
result
studi
designmethod
donor
consent
donat
blood
test
zikv
obtain
three
blood
bank
colorado
nebraska
nat
perform
use
procleix
viru
assay
qualit
vitro
nucleic
acid
assay
system
detect
zikv
rna
plasma
specimen
assay
perform
autom
procleix
panther
system
test
perform
accord
manufactur
packag
insert
resultsfind
event
reactiv
result
donor
would
retest
nat
addit
test
igm
antibodi
test
neutral
test
donor
defer
day
bar
continu
zikv
test
nonreact
result
total
donor
screen
zikv
donor
screen
zikv
nonreact
nat
invalid
test
result
obtain
addit
number
fail
test
run
due
instrument
assay
issu
experienc
quit
low
data
indic
assay
instrument
robust
low
frequenc
addit
test
allow
laboratori
publish
time
infecti
diseas
result
blood
bank
custom
conclus
reactiv
rate
data
present
demonstr
lowzero
incid
rate
region
whole
blood
blood
compon
discard
due
reactiv
result
screen
import
continu
ensur
blood
safeti
unit
state
robust
inactiv
yellow
fever
viru
strain
achiev
use
amotosalen
uva
light
pathogen
reduct
treatment
prt
platelet
compon
andrew
laughhunn
felicia
santa
maria
yvett
girard
peter
bringmann
marion
lanteri
adoni
stassinopoulo
microbiolog
depart
ceru
corpor
scientif
affair
depart
ceru
corpor
backgroundcas
studi
yellow
fever
viru
yfv
known
caus
explos
outbreak
one
angola
rapidli
increas
number
infect
brazil
hundr
fatal
sinc
decemb
concern
yfv
flaviviru
transmit
aed
mosquito
could
spread
like
zika
viru
part
america
vector
endem
effect
antivir
support
therapi
avail
best
mitig
strategi
vaccin
live
attenu
vaccin
strain
like
strain
yfv
vaccin
consid
effect
safe
vaccin
howev
major
advers
event
report
includ
neurolog
viscer
advers
effect
addit
transfus
transmiss
tt
live
attenu
yfv
report
sever
clinic
outcom
especi
immunosuppress
patient
order
prevent
tt
yfv
vaccin
strain
aabb
recommend
weekperiod
deferr
yfv
vaccin
yfv
outbreak
vaccin
campaign
may
therefor
reduc
blood
avail
pilot
studi
evalu
abil
inactiv
use
amotosalen
uva
light
prt
platelet
compon
pc
studi
designmethod
pc
pa
plasma
spike
high
titer
treat
prt
sampl
taken
preand
postuva
illumin
infecti
titer
determin
plaqu
assay
use
cell
extent
inactiv
quantifi
compar
titer
inactiv
resultsfind
preprt
infecti
titer
log
pfuml
pc
plasma
log
pfuml
pc
plasma
titer
postprt
sampl
log
pfuml
pc
plasma
log
pfuml
pc
plasma
inactiv
limit
detect
log
inactiv
log
pfuml
achiev
pc
plasma
inactiv
limit
backgroundcas
studi
use
biotin
supplement
increas
recent
year
mani
health
care
profession
may
awar
high
dosag
intak
patient
high
dosag
result
increas
preval
individu
expos
biotin
level
much
greater
recommend
daili
dose
consequ
led
inaccur
lab
result
assay
util
free
captur
biotinstreptavidin
methodolog
although
abbott
alin
assay
util
free
captur
biotinstreptavidin
methodolog
eight
assay
develop
blood
screen
alin
system
evalu
biotin
interfer
ensur
unknown
consequ
high
biotin
level
studi
designmethod
purpos
studi
determin
eight
develop
abbott
alin
assay
would
suscept
biotin
interfer
evalu
perform
presenc
high
concentr
biotin
alin
assay
evalu
hiv
agab
combo
htlv
iii
antihcv
chaga
hbsag
antihbc
syphili
cmv
igg
sampl
spike
concentr
biotin
approxim
ngml
test
control
unspik
sampl
prepar
determin
differ
control
biotin
contain
sampl
two
sampl
one
neg
one
posit
test
assay
except
hiv
htlv
assay
test
two
posit
sampl
antibodi
antigen
htlvi
antibodi
htlvii
antibodi
respect
resultsfind
neg
sampl
sampl
cutoff
sco
differ
biotin
spike
control
hcv
hbc
syphili
cmv
igg
chaga
hiv
agab
htlv
iii
hbsag
posit
sampl
mean
sco
differ
biotin
spike
control
antibodi
sampl
antigen
sampl
hiv
agab
combo
htlv
antibodi
sampl
htlv
ii
antibodi
sampl
antihcv
chaga
hbsag
antihbc
syphili
cmv
igg
conclus
eight
abbott
alin
assay
evalu
determin
suscept
biotin
interfer
result
indic
eight
alin
assay
show
suscept
biotin
interfer
approxim
concentr
ngml
robust
abbott
prism
method
biotin
interfer
c
fischer
r
schneider
w
leonard
cobb
g
schlauder
g
william
zusk
januli
transfus
medicin
abbott
diagnost
wiesbaden
germani
add
diagnost
transfus
medicin
abbott
laboratori
chicago
unit
state
backgroundcas
studi
use
biotin
dietari
supplement
increas
significantli
recent
year
mani
health
care
profession
realiz
patient
take
high
dose
increas
result
increas
preval
peopl
expos
biotin
level
much
higher
recommend
daili
dose
consequ
potenti
inaccur
lab
result
assay
util
free
captur
biotinstreptavidin
methodolog
purpos
studi
identifi
abbott
prism
assay
may
suscept
biotin
interfer
base
assay
design
evalu
perform
assay
high
concentr
biotin
comprehens
review
abbott
current
market
prism
assay
assay
identifi
util
biotinstreptavidin
captur
howev
assay
identifi
subsequ
test
contain
biotin
assay
design
backgroundcas
studi
bacteri
contamin
platelet
highest
residu
infecti
risk
transfus
despit
current
prevent
strategi
bacteri
contamin
may
affect
blood
compon
ambient
storag
temperatur
condit
platelet
make
like
facilit
bacteri
growth
base
precautionari
measur
final
platelet
concentr
includ
worst
case
limit
viabl
bacteria
number
estim
coloni
form
unit
cfu
bag
ie
cfuml
one
major
differ
virus
bacteria
bacteria
abil
grow
concentr
cfuml
day
product
shelflif
moreov
larg
divers
strain
found
contamin
platelet
repres
key
challeng
develop
gener
bacteri
test
aim
studi
develop
econom
easi
diagnost
approach
earli
rapid
sensit
gener
detect
bacteria
platelet
concentr
adapt
process
blood
transfus
servic
requir
major
concern
henc
attent
focus
easi
autom
techniqu
abl
deliv
result
day
collect
studi
designmethod
larg
panel
bacteria
involv
transfus
reaction
includ
clinic
isol
refer
strain
establish
use
mous
immun
antibodi
screen
platelet
spike
step
origin
approach
use
produc
select
monoclon
antibodi
direct
bacteria
develop
gener
immunoassay
recommend
hour
day
collect
sampl
volum
spike
platelet
cfuml
test
short
gener
cultur
lysi
captur
bacteria
magnet
microparticl
micropl
format
immunoassay
perform
detect
captur
bacteria
resultsfind
approach
test
panel
bacteri
strain
involv
transfus
reaction
preanalyt
step
captur
bacteria
microparticl
improv
avoid
fals
neg
result
enhanc
sensit
detect
full
test
develop
studi
combin
preanalyt
cultur
step
follow
mani
stakehold
involv
hcv
erad
program
includ
govern
author
center
diseas
control
prevent
nation
health
insur
health
promot
administr
privat
properti
like
hospit
medic
societi
pharmaceut
vaccin
industri
npo
academia
resultsfind
tbsf
privat
nationwid
singl
blood
servic
program
taiwan
perform
antihcv
screen
test
nat
confirmatori
test
everi
collect
blood
largescal
popul
screen
hcv
taiwan
high
blood
donat
rate
tbsf
confirm
posit
test
result
repeat
blood
donor
identifi
hcv
rna
seroconvers
case
recentlyinfect
hepat
patient
infect
patient
would
refer
physician
medic
care
defer
perman
tbsf
secur
blood
safeti
interview
newlyinfect
case
risk
factor
hcv
patient
studi
help
identifi
elimin
sourc
hcv
infect
tbsf
also
contribut
health
educ
teach
donor
awar
potenti
risk
hcv
infect
keep
monitor
everi
paramet
hcv
epidemiolog
evalu
efficaci
hcv
erad
program
conclus
hcv
erad
program
tbsf
secur
blood
safeti
also
particip
health
educ
diseas
screen
etiolog
find
prevent
surveil
evalu
thu
among
stakehold
tbsf
particularli
import
play
pivot
role
erad
hcv
taiwan
theraflex
uvplatelet
technolog
effici
inactiv
transfusionrelev
bacteria
speci
contamin
platelet
concentr
ute
gravemann
frank
tolksdorf
wiebk
handk
thoma
h
uller
axel
seltsam
german
red
cross
blood
servic
nstob
maco
pharma
intern
gmbh
backgroundcas
studi
theraflex
uvplatelet
system
macopharma
uvcbas
pathogen
inactiv
system
platelet
concentr
pc
inactiv
effici
shown
broad
rang
virus
bacteria
protozoan
previou
studi
first
set
bacteria
speci
intern
repositori
platelet
transfus
relev
bacteri
refer
strain
reveal
high
inactiv
capac
clinic
relev
bacteria
aim
current
studi
investig
bacteria
inactiv
efficaci
theraflex
uvplatelet
system
enterobact
cloaca
pseudomona
fluorescen
staphylococcu
aureu
streptococcu
bovi
recent
ad
intern
repositori
studi
designmethod
pc
produc
buffi
coat
use
addit
solut
macopharma
residu
plasma
content
inactiv
kinet
pc
spike
bacteria
final
concentr
coloni
form
unit
cfu
ml
irradi
increas
dose
full
uvc
dose
achiev
sampl
taken
bacteri
titer
determin
irradi
step
steril
studi
two
pc
pool
inocul
bacteria
final
concentr
approxim
cfuml
bacteria
allow
grow
h
pc
agit
split
one
pc
remain
untreat
growth
control
one
uvctreat
storag
seven
day
sampl
taken
bag
steril
test
bactalert
biomerieux
determin
bacteri
titer
untreat
control
unit
resultsfind
bacteria
pc
inactiv
dosedepend
manner
treatment
use
theraflex
uvplatelet
system
mean
log
reduct
factor
rang
enterobact
cloaca
pseudomona
fluorescen
staphylococcu
aureu
streptococcu
bovi
pc
speci
spike
differ
bacteria
speci
effici
steril
treat
pc
remain
steril
storag
day
bacteria
nontreat
pc
grew
high
titer
cfuml
theraflex
uvplatelet
system
effici
inactiv
broad
rang
differ
bacteria
speci
includ
refer
strain
steril
maintain
storag
period
day
result
suggest
uvcbas
pathogen
inactiv
technolog
significantli
improv
bacteri
safeti
platelet
transfus
transfus
transmiss
infect
among
blood
donor
strategi
direct
laboratori
test
cost
blood
screen
nation
blood
bank
center
addi
ababa
ethiopia
abraham
zewoldi
nation
blood
bank
servic
backgroundcas
studi
blood
compon
life
save
howev
also
associ
life
threaten
hazard
transfus
transmit
infect
tti
hepat
b
viru
hbv
hepat
c
viru
hcv
human
immunodefici
viru
hiv
syphili
seriou
infect
transmit
blood
transfus
seriou
blood
shortag
especi
develop
countri
relianc
unsaf
famili
replac
paid
donor
also
contribut
increas
risk
tti
know
current
preval
tti
among
blood
donor
crucial
donor
program
strategi
develop
cost
effect
altern
strategi
blood
screen
highli
requir
especi
resourc
limit
setup
studi
designmethod
retrospect
analysi
blood
donor
record
cover
period
juli
juli
conduct
data
collect
nation
al
blood
bank
nbb
center
donor
data
base
addit
direct
laboratori
cost
parallel
versu
sequenti
strategi
blood
screen
compar
use
current
price
laboratori
cost
data
first
export
spss
version
softwar
analysi
data
analysi
perform
use
score
odd
ratio
use
softwar
look
associ
depend
independ
variabl
p
valu
less
consid
signific
resultsfind
total
consecut
blood
donor
screen
overal
seropreval
rate
hbv
hiv
hcv
syphili
blood
donor
respect
hivhbv
coinfect
higher
among
blood
donor
follow
hbvhcv
coinfect
whish
account
significantli
increas
seropreval
tti
observ
among
famili
replac
donor
factori
worker
daili
labor
age
group
studi
differ
cost
current
use
strategi
parallel
versu
newli
propos
design
sequenti
test
algor
ethiopian
birr
conclus
signific
percentag
blood
donor
harbor
tti
nbb
center
work
voluntari
blood
donor
mobil
develop
cultur
voluntar
direct
laboratori
cost
analysi
use
current
use
strategi
parallel
higher
newli
design
sequenti
test
algorithm
thu
new
strategi
implement
make
screen
tti
cost
effect
nbb
center
transfus
transmit
malaria
month
old
infant
patricia
davenport
geeta
paranjap
lauri
sutor
carter
bloodcar
ut
southwestern
medic
center
backgroundcas
studi
larg
pediatr
hospit
month
old
infant
support
day
extracorpor
membran
oxygen
ecmo
time
blood
product
transfus
day
end
ecmo
support
routin
blood
smear
examin
reveal
inclus
patient
red
cell
patient
also
intermitt
fever
malaria
confirm
pcr
plasmodium
oval
p
oval
patient
risk
infect
suspect
transfus
relat
report
blood
center
suppli
transfus
product
studi
designmethod
investig
began
focus
donor
red
cell
product
sinc
chanc
apheresi
platelet
product
transmit
malaria
rel
small
frozen
product
remot
identifi
donor
red
cell
product
donor
contact
ask
four
question
addit
question
ask
clarif
need
base
donor
respons
risk
activ
malaria
infect
assess
also
consid
area
p
oval
found
donor
identifi
possibl
risk
test
antibodi
parasit
dna
resultsfind
five
donor
ill
common
cold
bronchiti
like
symptom
donor
travel
went
nonrisk
area
three
donor
former
resid
anoth
countri
may
risk
live
malaria
endem
countri
sinc
birth
came
us
adult
discov
one
three
meet
donor
criteria
donor
fail
disclos
complet
year
stay
us
emigr
cameroon
area
endem
p
oval
travel
anywher
come
unit
state
octob
answer
travel
antibodi
test
donor
posit
p
oval
p
falciparum
pcr
test
neg
anoth
possibl
atrisk
donor
former
resid
iran
test
pcr
antibodi
neg
third
donor
yet
test
countri
resid
p
oval
malaria
conclus
could
definit
proven
donor
antibodi
p
oval
activ
malaria
time
donat
donor
indefinit
defer
refer
outsid
physician
treatment
transfusiontransmit
babesiosi
outsid
endem
area
case
report
german
felix
leparc
oneblood
backgroundcas
studi
yo
male
patient
admit
emerg
room
sever
acut
gastrointestin
bleed
caus
arterioven
malform
later
locat
proxim
jejunum
clip
endoscop
admiss
receiv
total
unit
red
blood
cell
approxim
week
later
readmit
due
anoth
episod
gi
bleed
manifest
melena
part
routin
evalu
cbc
perform
blood
smear
reveal
presenc
intraerythrocyt
parasit
consist
babesia
sp
studi
designmethod
upon
notif
suspect
case
transfusiontransmit
babesiosi
lookback
donor
involv
prior
transfus
event
initi
resultsfind
confirm
presumpt
diagnosi
babesiosi
pcr
perform
babesia
microti
dna
detect
evalu
patient
risk
factor
reveal
prior
gi
bleed
episod
receiv
transfus
eight
month
earlier
also
transfus
open
heart
surgeri
travel
histori
us
midwest
travel
new
england
two
year
ago
spend
time
outdoor
splenectom
mid
donor
lookback
identifi
donor
live
new
london
counti
connecticut
spent
winter
season
central
florida
blood
donat
doubl
rbc
collect
apheresi
took
place
never
diagnos
babesiosi
particip
regularli
outdoor
activ
connecticut
put
risk
tick
bite
although
never
notic
bitten
show
sign
upon
test
found
neg
b
microti
pcr
well
igm
antibodi
igg
antibodi
titer
recipi
rbc
unit
collect
donat
deceas
within
hour
transfus
follow
could
perform
phone
interview
none
remain
donor
risk
factor
babesiosi
four
test
found
serolog
neg
conclus
transmiss
babesiosi
zoonot
rout
confin
region
appropri
host
vector
coexist
peopl
area
endem
may
establish
temporari
resid
donat
blood
nonendem
locat
facilit
transmiss
transfus
illustr
case
licens
assay
babesia
microti
becom
avail
test
scheme
formul
polici
take
issu
consider
transfusiontransmit
stenotrophomona
maltophilia
red
cell
unit
case
report
ashley
c
gamayo
andrea
j
linscott
donni
dumani
backgroundcas
studi
transfusiontransmit
bacteri
infect
ttbi
rare
seriou
complic
blood
product
transfus
transfusionassoci
fatal
report
fda
attribut
bacteri
contamin
red
cell
unit
rare
implic
sever
fatal
ttbi
present
contamin
often
gramneg
rod
gnr
bacteria
psychrophil
properti
present
case
sickl
cell
patient
develop
definit
sepsi
receiv
red
cell
unit
contamin
stenotrophomona
maltophilia
maltophilia
studi
designmethod
femal
sickl
cell
diseas
admit
hospit
possibl
pain
crise
pretransfus
blood
urin
cultur
collect
day
hospit
show
growth
five
day
day
patient
requir
blood
transfus
issu
cmvsafe
irradi
hbsneg
crossmatch
oneg
red
cell
unit
ml
unit
aliquot
via
steril
connect
devic
day
prior
pediatr
patient
ml
pediatr
aliquot
transfus
without
advers
effect
patient
pretransfus
temperatur
within
minut
start
transfus
patient
temperatur
increas
subsequ
reach
maximum
transfus
stop
blood
bank
notifi
immedi
gram
stain
remaind
transfus
compon
reveal
gnr
bacteria
blood
collect
patient
cultur
antibiot
treatment
initi
resultsfind
initi
transfus
reaction
workup
reveal
evid
cleric
error
neg
posttransfus
antibodi
screen
direct
antiglobulin
test
blood
cultur
patient
posttransfus
implic
red
cell
unit
grew
gnr
bacteria
identifi
maltophilia
microbi
test
reveal
cultur
pathogen
abl
prolifer
find
characterist
observ
maltophilia
conclus
first
definit
case
ttbi
maltophilia
bacterium
global
emerg
gnr
wide
spread
environ
caus
communityacquir
nosocomi
infect
immunocompromis
debilit
patient
contamin
unlik
due
asymptomat
donor
laboratori
evid
pathogen
transfus
recipi
transfus
compon
patient
infect
pathogen
prior
transfus
potenti
exposur
could
identifi
patient
recov
follow
appropri
antibiot
treatment
endur
prolong
hospit
transfus
reaction
classifi
definit
sever
tti
definit
imput
valid
commerci
immunoassay
detect
hbsag
hiv
antibodi
product
pool
karen
leighton
izeki
butler
scott
jone
qualtex
laboratori
backgroundcas
studi
plasma
fraction
test
plasma
product
pool
hbsag
hiv
antibodi
qualit
limit
test
control
impur
safeguard
error
donat
test
pool
european
medicin
agenc
ema
publish
guidelin
valid
immunoassay
detect
hbsag
hiv
antibodi
product
pool
aim
valid
commerci
immunoassay
test
product
pool
hbsag
hiv
antibodi
util
ema
guidelin
studi
designmethod
lower
calcul
cutoff
valu
abbott
prism
hbsag
hiv
plu
assay
determin
calcul
mean
signaltocutoff
ratio
sco
plu
standard
deviat
four
differ
type
plasma
product
pool
sampl
calcul
cutoff
valu
util
rest
valid
detect
limit
determin
test
triplic
serial
dilut
hbsag
hiv
antibodi
standard
dilut
plasma
normal
detect
limit
calcul
hbsag
assay
use
product
pool
contain
low
typic
high
antihbsag
titer
intraassay
variabl
determin
test
minimum
determin
low
posit
control
run
interassay
variabl
determin
test
least
repres
neg
product
pool
sampl
least
low
posit
sampl
sco
titrat
seri
standard
spike
plasma
product
sampl
run
perform
six
separ
day
use
two
differ
instrument
two
differ
lot
assay
reagent
resultsfind
lower
calcul
cutoff
valu
hbsag
antihiv
assay
manufactur
cutoff
respect
hbsag
assay
detect
limit
iu
ml
sourc
plasma
iuml
recov
plasma
sampl
normal
detect
limit
studi
demonstr
one
half
hour
maximum
amount
time
pool
sampl
could
sit
c
sampl
still
reactiv
hbsag
antihiv
lowest
posit
dilut
replic
vari
depend
subtyp
group
cv
sco
valu
replic
intraassay
variabl
valid
less
assay
cv
sco
valu
panel
sampl
interassay
variabl
valid
less
conclus
lower
calcul
cutoff
valu
could
determin
commerci
avail
immunoassay
hbsag
antihiv
immunoassay
could
meet
recommend
ema
valid
guidelin
abbott
prism
hbsag
hiv
plu
assay
util
test
product
pool
sampl
perform
donor
day
index
donat
donor
follow
studi
test
doh
donor
test
doh
particip
follow
studi
follow
test
neg
donor
denv
antibodi
neg
donat
equivoc
initi
reactiv
rate
higher
report
date
procleix
zikv
tma
per
p
williamson
et
al
transfus
press
conclus
univers
test
ind
success
implement
incorpor
blood
center
oper
note
initi
reactiv
demograph
analyz
potenti
use
predict
cmv
seroconvers
rate
includ
gender
age
race
ethnic
combin
backgroundcas
studi
grow
geograph
footprint
prioriti
organ
sinc
four
year
period
organ
doubl
number
blood
center
continu
growth
expect
current
challeng
blood
industri
audit
program
need
flexibl
maxim
effici
capac
util
without
increas
complianc
risk
intern
audit
function
central
late
program
consist
type
audit
oper
complianc
audit
support
system
complianc
audit
type
perform
twice
per
year
main
center
model
longer
serv
chang
organ
studi
designmethod
lean
six
sigma
concept
appli
project
survey
result
brainstorm
aid
captur
strength
current
program
opportun
improv
idea
redesign
program
inform
primari
input
swot
analysi
strength
weak
opportun
threat
purpos
understand
perform
current
program
well
element
could
impact
futur
design
potenti
solut
place
pugh
matrix
use
facilit
disciplin
teambas
process
concept
gener
select
potenti
solut
compar
criteria
evalu
select
best
solut
resultsfind
program
redesign
perform
intern
audit
annual
singl
teambas
comprehens
audit
remot
audit
incorpor
requir
less
onsit
time
less
disrupt
improv
auditor
worklif
balanc
cost
save
formula
creat
determin
onsit
audit
time
includ
adjust
risk
factor
audit
report
process
also
autom
simplif
effici
meet
stakehold
need
teambas
approach
leverag
auditor
strength
foster
learn
environ
increas
detect
organizationwid
concern
conclus
comprehens
teambas
approach
program
improv
effect
respond
organiz
growth
without
sacrif
qualiti
increas
complianc
risk
extern
inspect
perform
achiev
record
perform
level
past
year
divers
auditor
skill
led
stronger
skill
presenc
consist
appli
across
system
audit
effici
effect
stronger
collabor
among
audit
team
member
provid
stronger
object
fair
consist
across
system
auditor
audite
increas
knowledg
intern
qualiti
audit
program
improv
backgroundcas
studi
mani
place
blood
bank
use
semiautom
system
perform
fraction
differ
blood
compon
red
blood
cell
platelet
plasma
banc
de
sang
teixit
bst
adopt
fulli
autom
reveo
system
terumo
bct
inc
lakewood
co
year
ago
manufactur
blood
compon
june
bst
start
valid
new
blood
bag
manufactur
terumo
bct
differ
variabl
platelet
volum
process
kit
perform
platelet
pool
new
filter
studi
designmethod
perform
valid
blood
donat
use
differ
condit
see
tabl
current
filter
evalu
platelet
pool
lrfxl
haemonet
corpor
compar
new
filter
terumo
bct
inc
new
blood
bag
manufactur
use
new
vinyl
supplier
portion
process
blood
compon
red
blood
cell
platelet
plasma
use
differ
qualiti
control
qc
test
routin
qc
perform
bst
follow
european
director
qualiti
medicin
healthcar
cytokin
analysi
pselectin
platelet
recoveri
filter
resultsfind
result
similar
bag
current
new
one
well
filter
analysi
done
evalu
qualiti
blood
compon
similar
condit
also
shown
better
perform
platelet
pool
came
bag
centrifug
ml
plasma
vs
ml
plasma
addit
solut
conclus
new
bag
filter
shown
similar
behavior
use
manufactur
blood
donat
reveo
system
blood
bank
regard
new
platelet
pool
kit
better
manipul
oper
observ
although
tube
shorter
meant
difficult
manipul
pool
issu
found
implement
routin
use
plan
start
implement
year
larger
result
order
proper
procedur
qualif
conclus
patient
requir
rare
blood
product
rare
lack
high
preval
antigen
challeng
obtain
antigen
neg
blood
clear
request
exquisit
rare
type
abl
fill
current
donor
molecular
test
larg
number
donor
like
help
identifi
rare
donor
recent
year
recogn
commerci
platform
includ
mani
make
rare
type
even
challeng
find
consider
given
test
donor
ethnic
identifi
rare
donor
recommend
updat
donor
educ
materi
provid
comprehens
inform
risk
iron
defici
recommend
iron
supplement
updat
educ
materi
like
minor
impact
recommend
implement
strategi
iron
supplement
ferritin
test
increas
interdon
interv
donor
group
risk
iron
defici
initi
implement
would
like
either
iron
supplement
ferritin
test
risk
group
implement
either
one
strategi
would
potenti
affect
donor
recommend
limit
number
donat
would
substanti
impact
analysi
focu
year
old
premenopaus
women
age
donor
averag
year
old
donat
time
year
premenopaus
women
donat
time
year
group
limit
donat
year
total
donat
year
old
donat
premenopaus
donor
would
collect
conclus
analyz
impact
aabb
associ
bulletin
bulletin
signific
impact
donor
local
blood
suppli
half
donor
would
receiv
either
ferritin
test
iron
supplement
measur
employ
limit
number
time
donor
could
donat
year
old
premenopaus
women
recommend
would
substanti
impact
abil
provid
blood
product
local
hospit
backgroundcas
studi
transfus
medicin
knowledg
deficit
appar
among
medic
student
resid
practic
physician
defici
may
due
frequenc
type
educ
major
medic
student
unit
state
receiv
four
fewer
hour
transfus
medicin
educ
transfus
medicin
academ
award
group
publish
educ
content
guidelin
medic
school
resid
fellowship
howev
frequenc
educ
method
remain
poorli
evalu
littl
guidanc
investig
effect
differ
educ
techniqu
transfus
medicin
knowledg
acquisit
novic
learner
studi
designmethod
three
educ
pathway
develop
teach
principl
transfus
medicin
allow
learner
recogn
problem
develop
solut
transfus
medicin
complic
simul
group
receiv
educ
activ
within
hour
inperson
highfidel
live
session
hybrid
group
receiv
educ
compon
onlin
also
attend
inperson
highfidel
simul
session
onlin
group
receiv
educ
materi
onlin
includ
prerecordedvideo
simul
session
learner
second
year
medic
student
enrol
one
institut
faculti
member
taught
live
session
develop
onlin
materi
ensur
content
preand
posttest
creat
address
blood
group
blood
donat
blood
test
blood
compon
indic
transfus
complic
educ
session
evalu
likert
scale
survey
rang
zero
poorunsatisfactori
five
outstand
resultsfind
simul
group
student
improv
posttest
score
averag
likert
scale
rate
good
hybrid
group
student
improv
posttest
score
averag
likert
scale
rate
good
onlin
student
improv
posttest
score
averag
likert
scale
rate
good
averag
chang
score
statist
signific
within
train
group
p
valu
addit
simul
group
larger
increas
averag
posttest
score
compar
onlin
group
p
hybrid
group
p
conclus
studi
demonstr
faculti
taught
highfidel
transfus
medicin
simul
curriculum
consist
inperson
didact
session
simul
session
second
year
medic
student
produc
greater
knowledg
acquisit
compar
onlin
hybrid
curriculum
highfidel
simul
curriculum
also
prefer
onlin
educ
indic
likert
survey
result
aaron
j
wybl
yeon
mi
kim
barbara
j
bryant
univers
texa
medic
branch
backgroundcas
studi
diagnost
manag
team
dmt
innov
way
bridg
commun
gap
laboratori
clinic
servic
therebi
facilit
deliveri
improv
patient
care
dmt
employ
multidisciplinari
approach
integr
clinic
laboratori
data
succinct
interpret
recommend
interpret
must
moder
high
complex
order
clinic
valuabl
recommend
made
regard
futur
test
time
test
prior
blood
compon
need
pertin
concern
allow
improv
coordin
patient
care
timeli
dmt
report
vital
patient
manag
inher
design
dmt
also
provid
educ
opportun
traine
academ
center
studi
designmethod
transfus
medicin
servic
larg
universitybas
academ
medic
center
implement
dmt
case
involv
complex
antibodi
identif
workup
transfus
reaction
deviat
standard
oper
procedur
consult
blood
compon
util
massiv
transfus
protocol
juli
januari
evalu
transfus
medicin
resid
electron
medic
record
emr
patient
also
review
determin
relev
clinic
histori
signific
find
present
transfus
medicin
dmt
confer
dmt
compris
physician
transfus
medicin
hematologyoncolog
anesthesiolog
transfus
servic
technic
staff
well
visit
clinic
staff
surgeri
obstetr
gynecolog
transplant
servic
pediatr
dmt
integr
clinic
laboratori
data
formul
relev
interpret
recommend
final
dmt
report
place
emr
access
health
care
provid
financi
benefit
transfus
medicin
dmt
also
evalu
resultsfind
period
case
complex
antibodi
identif
workup
transfus
reaction
consult
blood
compon
util
deviat
standard
oper
procedur
massiv
transfus
protocol
present
transfus
medicin
dmt
confer
placement
dmt
narr
emr
progress
note
laboratori
report
provid
inform
time
commun
resid
particip
dmt
demonstr
improv
clinic
laboratori
correl
skill
result
resid
compet
transfus
medicin
enhanc
revenu
gener
util
standard
profession
compon
cpt
code
conclus
dmt
encompass
multipl
aspect
transfus
medicin
improv
patient
care
enhanc
commun
laboratori
clinic
servic
addit
benefit
dmt
program
includ
resid
clinician
technic
staff
educ
gener
revenu
institut
streamlin
blood
center
hospit
transfus
servic
supplychain
informat
vendormanag
inventori
solut
hamilton
c
tsang
david
lancast
diann
geari
robert
scott
anh
thu
nguyen
adam
garcia
raina
shankar
lesli
buchanan
tho
pham
stanford
health
care
stanford
blood
center
backgroundcas
studi
inventori
manag
major
challeng
integr
part
hospit
transfus
servic
ht
blood
center
bc
oper
current
process
institut
involv
twiceperday
shipment
bc
ht
shipment
predic
upon
current
stock
level
ht
manual
obtain
inventori
level
product
timeconsum
manual
determin
also
errorpron
aim
enhanc
inventori
manag
oper
develop
informat
solut
streamlin
order
process
accur
reflect
inventori
statu
transfus
practic
realloc
valuabl
ht
tech
time
studi
designmethod
ht
gener
inventori
account
product
categori
broken
compon
blood
type
irradi
statu
cmvserolog
statu
therefor
sought
establish
electron
method
reliabl
infer
gener
inventori
level
sinc
raw
electron
inventori
report
compris
gener
inventori
physic
sequest
unit
eg
special
antigen
unit
crossmatch
unit
calibr
period
perform
linear
regress
electron
goldstandard
manual
count
imput
electron
censu
number
unit
product
categori
gener
inventori
reliabl
electron
method
determin
inventori
level
implement
pilot
period
analyz
variou
metric
pre
post
pilot
implement
ensur
noninferior
electron
system
ratio
unit
transfus
per
week
number
stock
number
product
order
stat
number
expir
product
creat
inhous
program
visual
basic
applic
microsoft
redmond
wa
calibr
pilot
period
line
code
written
program
includ
class
modul
distinct
subroutin
resultsfind
pilot
period
investig
system
noninferior
averag
weekli
ratio
cryoprecipit
plasma
rbc
respect
pilot
period
compar
pilot
period
differ
reach
statist
signific
also
monitor
number
stat
order
product
pilot
period
stat
unit
per
week
respect
lastli
also
monitor
number
monthli
wast
product
due
expir
indic
inventori
mismanag
pilot
period
unit
respect
p
estim
hour
per
week
technologist
time
realloc
task
electron
censu
adopt
translat
fte
per
year
save
labor
cost
per
year
perman
adopt
conclus
creat
inhous
electron
order
system
enhanc
inform
fidel
realloc
technologist
time
standard
order
system
show
noninferior
laborintens
manual
system
chang
number
stat
order
ratio
increas
number
expir
product
achiev
free
hour
staff
time
per
year
futur
direct
includ
full
autom
involv
ht
informat
depart
transfus
practic
improv
gain
traction
use
provinci
transfus
qualiti
improv
plan
denis
evanovitch
yulia
lin
troy
thompson
allison
collin
sheena
scheuermann
ontario
region
blood
coordin
network
sunnybrook
health
scienc
centr
backgroundcas
studi
provinci
region
blood
coordin
network
prbcn
held
qualiti
focu
day
qfd
explor
transfus
qualiti
indic
includ
provinc
wide
qualiti
improv
plan
qip
plan
main
goal
reduc
patient
harm
improv
transfus
practic
hospit
reduct
inappropri
use
follow
recommend
made
select
blood
compon
hospit
could
monitor
display
progress
public
forum
hospit
could
compar
peer
strike
provincewid
transfus
qip
committe
guid
develop
plan
support
resourc
ongo
improv
initi
studi
designmethod
provinci
transfus
qualiti
improv
plan
ptqip
committe
form
includ
broad
represent
provinci
patient
blood
manag
coordin
physician
technologist
nurs
administr
clinician
qualityrisk
manag
region
provinc
provinci
blood
advisori
committe
blood
supplier
patient
collabor
organ
provinci
health
qualiti
divis
choos
wise
launch
inform
survey
indic
provinc
hospit
interest
alreadi
adopt
portion
ptqip
assist
hospit
advanc
qip
technologist
prospect
screen
educ
modul
develop
addit
electron
track
tool
hospit
enter
baselin
data
subsequ
audit
data
track
success
hospit
provinci
report
gener
track
tool
formal
survey
conduct
indic
plan
implement
alreadi
implement
ptqip
respond
alreadi
put
prospect
order
screen
technologist
place
conclus
help
hospit
develop
standard
templat
instruct
educ
tool
transfus
qualiti
improv
increas
abil
hospit
uptak
qualiti
improv
initi
take
standard
approach
across
provinc
allow
aggreg
hospit
data
comparison
analys
backgroundcas
studi
militari
civilian
traumabas
studi
demonstr
advantag
transfus
blood
product
prior
patient
hospit
arriv
process
known
prehospit
transfus
pht
helicopt
emerg
medic
servic
hem
worldwid
implement
protocol
great
success
despit
current
lack
guidanc
advisori
public
need
literatur
address
regulatori
requir
logist
challeng
associ
develop
pht
program
herein
report
experi
larg
hospit
system
embark
develop
multist
pht
servic
studi
designmethod
octob
work
group
form
establish
pht
servic
hem
provid
care
thirti
region
hospit
compos
flight
care
staff
emerg
physician
transfus
medicin
specialist
group
identifi
major
task
address
federalst
regul
inventori
structuremanag
product
storagetest
trackingtrac
emerg
releas
protocol
staff
train
specif
regul
govern
pht
regul
pertain
blood
product
storag
valid
monitor
appli
fda
aabb
state
agenc
consult
ensur
complianc
direct
resultsfind
largest
hospit
within
system
alreadi
act
refer
site
design
perform
confirmatori
test
product
suppli
multist
hem
similarli
hospit
task
remot
monitor
blood
refriger
helipad
site
system
fda
licens
blood
supplier
deem
respons
product
consign
transport
four
hem
site
blood
inventori
site
design
contain
group
posit
rbc
group
low
antib
titer
liquid
plasma
fourfactor
prothrombin
complex
concentr
militarytest
inflight
medic
record
system
use
transfer
transfus
inform
nonaffili
hospit
need
valid
inflight
cooler
protocol
product
emerg
releas
inventori
track
system
restock
schedul
also
requisit
plan
staff
compet
regard
emerg
releas
guidelin
transfus
reaction
handlingstorag
product
maintain
hem
medic
director
addit
oversight
provid
transfus
medicin
physician
conclus
work
group
success
identifi
challeng
associ
multist
pht
helicopt
base
servic
span
blood
product
manag
adapt
exist
transfus
procedur
oper
polici
licens
requir
personnel
train
pht
servic
go
live
publish
experi
may
benefit
futur
site
launch
similar
pht
initi
blood
transfus
humanitarian
emerg
yetmgeta
e
abdella
rana
hajjeh
cee
th
smit
sibinga
world
health
organ
region
offic
eastern
mediterranean
intern
qualiti
manag
iqm
consult
backgroundcas
studi
million
peopl
affect
humanitarian
emerg
eastern
mediterranean
region
world
health
organ
affect
countri
world
locat
countri
health
system
weaken
destroy
health
worker
provid
health
servic
difficult
circumst
humanitarian
emerg
increas
demand
blood
transfus
make
deliveri
challeng
complex
despit
obviou
need
across
region
lack
inform
emerg
prepared
respons
capac
blood
transfus
challeng
countri
health
respond
face
meet
need
patient
emerg
studi
designmethod
search
pubm
index
medicu
eastern
mediterranean
region
data
avail
safeti
blood
transfus
humanitarian
emerg
conduct
structur
survey
blood
transfus
servic
bt
countri
region
identifi
follow
type
humanitarian
emerg
current
strategi
ensur
avail
safeti
blood
transfus
emerg
coordin
collabor
countri
gap
challeng
addit
inform
collect
region
consult
eastern
mediterranean
region
held
may
tunisia
resultsfind
found
public
disast
five
countri
region
public
disast
prepared
blood
transfus
casualti
sever
trauma
outsid
region
howev
none
dealt
question
avail
safeti
blood
transfus
emerg
twelv
countri
respond
survey
arm
conflict
terror
commonest
type
emerg
estim
injur
requir
blood
transfus
nine
countri
emerg
prepared
respons
plan
bt
potenti
blood
donor
mobil
public
call
besid
direct
appeal
regular
replac
donor
seven
respond
countri
keep
emerg
blood
stock
collabor
differ
stakehold
exist
seven
countri
lack
adequ
compet
human
resourc
transport
cold
chain
deficit
shortag
suppli
consum
mainten
equip
lack
reliabl
power
suppli
shortag
financ
gap
identifi
conclus
need
integr
bt
overal
nation
emerg
prepared
respons
collect
dissemin
updat
inform
factor
affect
provis
blood
transfus
humanitarian
emerg
provid
technic
financi
assist
affect
countri
strengthen
mechan
coordin
collabor
among
differ
parti
develop
region
emerg
blood
servic
system
manag
expertis
number
collect
per
regist
trt
donor
vari
significantli
rang
therapeut
drawsdonor
per
year
exclud
nt
present
therapeut
blood
collect
averag
number
trt
collectionsdonor
per
year
decreas
conclus
blood
center
experienc
increas
number
therapeut
phlebotomi
well
individu
trt
refer
therapeut
phlebotomi
due
elev
hemoglobin
valu
clear
inform
provid
order
physician
whether
intend
temporari
measur
decreas
hemoglobin
patient
trt
whether
dose
adjust
discontinu
due
known
risk
factor
cardiovascular
diseas
patient
polycythemia
howev
averag
number
donat
per
trt
donor
decreas
timefram
percentag
men
testosteron
present
regular
blood
donor
blood
center
known
sinc
hormon
reason
deferr
find
rais
concern
howev
regular
phlebotomi
necessari
reduc
risk
testosteroneassoci
polycythemia
popul
duti
provid
safe
adequ
blood
suppli
blood
center
also
concern
perpetu
mispercept
repeat
phlebotomi
particularli
requir
frequent
day
suffici
mitig
risk
testosteron
therapi
henc
made
decis
discontinu
offer
phlebotomi
servic
popul
donor
testosteron
meet
donor
elig
requir
approach
involv
use
vein
illumin
devic
blood
donor
center
sara
matheson
kimberli
j
duffi
audrey
e
traun
mari
benik
jame
r
stubb
justin
kreuter
mayo
clinic
backgroundcas
studi
venipunctur
critic
step
blood
collect
locat
suitabl
vein
procedur
challeng
unaccept
vein
select
incorrect
needl
placement
lead
incomplet
collect
infiltr
blood
donor
center
primari
select
vein
done
palpat
within
antecubit
area
prior
needl
insert
skin
site
must
prepar
contact
avoid
needl
place
vein
illumin
vi
devic
avail
aid
visual
display
potenti
suitabl
vein
devic
made
avail
staff
march
initi
test
instruct
period
vi
sinc
use
staff
object
studi
discov
reason
staff
use
vi
identifi
potenti
suitabl
vein
studi
designmethod
staff
survey
develop
distribut
staff
march
inquir
usag
vi
obtain
feedback
devic
time
survey
sent
devic
avail
sever
year
survey
includ
question
involv
frequenc
use
adequaci
train
comfort
use
devic
knowledg
devic
storag
locat
willing
tri
devic
gener
feedback
resultsfind
survey
respons
rate
never
rare
util
vi
selfreport
reason
low
util
focus
two
domin
theme
first
devic
need
second
nt
accur
show
vein
respond
awar
vi
store
access
locat
share
devic
identifi
although
respond
provid
train
use
vi
group
mix
regard
comfort
level
use
devic
independ
group
will
tri
vi
conclus
infiltr
incomplet
collect
account
approxim
unitsyear
qualifi
blood
donor
yet
vi
appear
viabl
solut
blood
donor
program
seem
opportun
challeng
vi
implement
opportun
creat
critic
awar
problem
vein
cannul
challeng
identifi
devic
effect
visual
deeper
vein
necessari
blood
donat
benefit
convert
alyx
penni
schroeder
elizabeth
parker
indiana
blood
center
backgroundcas
studi
apheresi
red
cell
arc
repres
total
red
cell
collect
center
hae
util
collect
arc
due
age
instrument
challeng
collect
mobil
well
need
increas
collect
right
type
product
decis
made
chang
technolog
studi
designmethod
freseniu
kabi
demonstr
fenwal
alyx
technolog
well
busi
case
primari
stakehold
implic
depart
involv
initi
impact
assess
multidepart
kick
meet
held
project
team
form
due
product
demand
decis
made
valid
arc
plasma
apheresi
primari
depart
affect
blood
collect
product
freseniu
kabi
provid
sampl
valid
plan
sop
train
train
materi
use
four
mobilecart
purchas
easi
transport
alyx
quickconnect
feet
instal
mobil
buse
lead
trainer
bc
technic
administr
travel
affili
blood
center
observ
alyx
program
identifi
best
practic
team
blood
collect
trainer
preceptor
initi
group
train
valid
perform
team
also
serv
subject
matter
expert
field
preceptor
freseniu
kabi
return
advanc
alyx
oper
train
train
plan
target
previou
oper
first
oper
new
apheresi
train
goal
mobil
staff
valid
alyx
began
took
approxim
day
complet
time
freseniu
kabi
conduct
alyx
educ
apheresi
recruit
train
collect
recruit
staff
machin
remov
servic
alyx
goliv
occur
addit
oper
train
continu
septemb
resultsfind
due
eas
mobil
use
alyx
reduc
procedur
time
compar
donor
convers
train
increas
compon
collect
alyx
dispos
kit
includ
preattach
solut
contain
reduc
ancillari
item
requir
pack
carri
mobil
decreas
kit
cost
provid
estim
annual
save
conclus
multipl
alyx
donat
type
abl
increas
collect
right
type
procedur
approxim
decreas
kit
cost
alyx
collect
plasma
mobil
blood
drive
possibl
due
eas
use
oper
embrac
technolog
consist
met
monthli
collect
goal
octob
backgroundcas
studi
high
frequenc
donat
risk
factor
iron
defici
femal
iron
store
gener
lower
male
start
donat
career
femal
donat
frequent
particularli
high
risk
minimum
hemoglobin
hb
long
male
femal
male
fall
normal
limit
first
step
mitig
iron
defici
criteria
whole
blood
donor
modifi
male
minimum
hb
increas
gl
femal
minimum
interdon
interv
increas
day
longer
interdon
interv
femal
gradual
implement
start
donor
messag
octob
chang
rebook
donat
appoint
decemb
culmin
eprogesa
criteria
chang
march
chang
expect
initi
result
donat
loss
may
partli
counteract
decreas
hb
deferr
rate
femal
donor
aim
assess
impact
chang
hb
deferr
rate
studi
designmethod
percentag
hb
deferr
calcul
number
donat
attempt
result
hb
deferr
divid
number
success
donat
plu
hb
deferr
multipli
percentag
calcul
male
femal
donor
chang
made
resultsfind
percentag
hb
deferr
increas
male
donor
week
preimplement
week
postimplement
chang
hb
criterion
hb
deferr
rate
femal
donor
septemb
octobernovemb
decemb
march
conclus
hb
deferr
frequent
male
donor
minimum
hb
increas
gl
gradual
implement
increas
interdon
interv
femal
result
reduct
deferr
thu
initi
donat
loss
associ
chang
may
partli
offset
time
decreas
hb
deferr
longer
observ
period
necessari
confirm
find
assess
impact
phenotyp
blood
donor
retent
past
year
blood
product
deriv
procedur
distribut
differ
investig
laboratori
whole
blood
common
product
follow
unmanipul
mononuclear
cell
collect
elutri
monocyt
lymphocyt
less
common
request
includ
platelet
plasma
granulocyt
advers
donor
reaction
infrequ
procedur
conclus
report
feasibl
program
collect
distribut
blood
investig
obtain
blood
compon
vitro
research
use
util
staff
resourc
hospitalbas
blood
bank
research
blood
donat
essenti
support
laboratori
research
maintain
posit
relationship
donor
defer
allogen
transfus
hospitalbas
blood
donor
center
experi
implement
platelet
pathogen
reduct
system
kimberli
j
duffi
mari
benik
jame
r
stubb
justin
kreuter
backgroundcas
studi
safeti
platelet
product
continu
improv
due
test
despit
continu
emerg
microbi
threat
recent
fda
approv
platelet
pathogen
reduct
technolog
protect
transfus
recipi
regardless
new
microbi
danger
order
platelet
product
use
pathogen
reduct
technolog
volum
platelet
yield
dose
concentr
must
collect
within
tight
specif
object
studi
determin
optim
collect
set
enabl
collect
pathogen
reduc
platelet
limit
loss
product
studi
designmethod
collect
instrument
evalu
studi
fda
approv
platelet
suspend
plasma
correspond
pathogen
reduct
system
use
studi
kit
differ
collect
specif
apheresi
collect
occur
fix
site
preplatelet
count
perform
hematolog
analyz
yield
scale
factor
establish
correl
hematolog
analyz
apheresi
collect
devic
order
determin
optim
collect
target
apheresi
collect
instrument
varieti
multipl
yield
volum
establish
collect
staff
instruct
collect
highest
avail
yield
per
donor
collect
volum
platelet
yield
concentr
data
obtain
data
use
determin
product
met
specif
one
avail
kit
actual
platelet
yield
higher
thu
meet
criteria
doubl
product
resultsfind
higher
platelet
concentr
product
ideal
produc
doubl
product
target
product
platelet
concentr
greater
x
ml
like
outsid
specif
pathogen
reduct
kit
platelet
concentr
target
x
ml
result
discard
product
quickli
remov
instrument
set
collect
platelet
yield
low
platelet
concentr
ml
like
produc
product
within
specif
pathogen
reduct
kit
abstract
conclus
loss
tripl
platelet
product
lower
postprocess
platelet
recoveri
requir
collect
platelet
far
precis
goal
platelet
collect
shift
simpli
maxim
platelet
collect
approach
consid
optim
collect
within
limit
kit
specif
final
collect
instrument
configur
platelet
yield
volum
ml
platelet
yield
volum
ml
move
subject
object
donor
elig
screen
platform
blood
center
journey
angela
dirr
steve
cihura
bonfil
blood
center
bbc
bsi
backgroundcas
studi
devic
use
bonfil
blood
center
determin
donor
hemoglobin
donor
elig
reach
end
life
bbc
need
defin
path
forward
reliabl
replac
devic
studi
designmethod
bbc
evalu
devic
follow
criteria
mind
devic
dispos
cost
reagentscontrolsqu
control
object
hgbhct
measur
portabl
durabl
mobil
environ
eas
use
donor
experi
batteri
life
valid
requir
plan
blood
center
suitabl
abil
link
bec
multipl
depart
includ
donor
care
equip
manag
valid
qualiti
regulatori
affair
involv
evalu
product
select
bbc
test
donor
per
devic
fix
mobil
site
bbc
also
consid
donor
feedback
choic
replac
technolog
project
start
februari
target
implement
date
juli
creat
necessari
sop
adopt
exist
sop
bbc
success
complet
valid
devic
chose
compolab
technolog
freseniu
kabi
new
devic
bbc
blood
bank
resultsfind
compolab
select
met
project
scope
select
criteria
import
bbc
reduc
paperwork
daili
task
compolab
elimin
daili
qc
reduc
paperwork
time
improv
error
manag
convert
new
technolog
bbc
donor
deferr
rate
increas
approxim
consequ
increas
bbc
conduct
remind
train
bbc
staff
ensur
proper
sampl
techniqu
higher
sampl
qualiti
time
bbc
deferr
rate
stabil
time
period
bbc
also
success
recruit
new
blood
donor
bbc
program
may
contribut
increas
deferr
rate
deferr
rate
increas
probabl
due
part
fda
final
rule
requir
blood
blood
compon
intend
transfus
manufactur
use
went
effect
may
conclus
evalu
new
equip
bbc
learn
critic
understand
equip
life
cycl
effect
equip
aspect
busi
comprehens
evalu
multipl
donor
elig
screen
platform
compolab
devic
select
bbc
facil
met
major
aspect
project
scope
qualifi
criteria
bbc
also
learn
continu
refresh
train
staff
ensur
optim
devic
perform
extern
factor
chang
regulatori
environ
may
impact
deferr
rate
flowmetri
platelet
apheresi
tetsu
yamamoto
ayumi
araki
hiromi
sanyoshi
hiromi
kanai
hiroya
kikuchi
katsushi
tsukada
kazuhid
mure
hokkaido
red
cross
blood
center
japanes
red
cross
hokkaido
blood
center
backgroundcas
studi
vasovag
reaction
vvr
known
common
advers
reaction
blood
collect
effect
measur
prevent
vvr
yet
develop
effect
time
intervent
apheresi
donat
particular
hold
key
predict
vvr
research
done
topic
studi
designmethod
studi
investig
potenti
predict
vvr
fluctuat
peripher
blood
flow
measur
laser
doppler
flowmetri
platelet
apheresi
donor
popul
highli
like
experi
vvr
data
collect
individu
donat
platelet
period
februari
august
data
donor
experienc
vvr
analyz
calcul
level
issu
vvr
alert
percent
decreas
blood
flow
dbf
percent
decreas
heart
rate
dhr
calcul
time
alert
vvr
estim
three
dbf
level
detect
perform
alert
level
calcul
resultsfind
eight
men
women
experienc
vvr
one
donor
experi
vvr
blood
collect
delay
reaction
rest
afterward
mean
maximum
dbf
donor
vvr
group
significantli
higher
nonvvr
group
maximum
dbf
threshold
sensit
discrimin
vvr
nonvvr
donor
accuraci
dbf
use
alert
level
alert
issu
donor
includ
vvr
group
therefor
sensit
predict
vvr
specif
mean
time
alert
diagnosi
vvr
group
minut
accuraci
alert
vvr
could
predict
even
valu
maximum
dbf
exceed
reason
suppos
differ
donor
suscept
dbf
conclus
investig
whether
vvr
platelet
apheresi
donor
prevent
predict
found
possibl
predict
vvr
earli
enough
onset
interven
monitor
dbf
real
time
blood
collect
use
laser
doppler
flowmetri
futur
research
must
also
investig
whether
incid
vvr
actual
reduc
intervent
adjust
extracorpor
circul
risk
alloimmun
sickl
cell
patient
use
c
e
k
neg
blood
experi
hospit
apheresi
transfus
servic
grace
banez
sese
salam
abdu
shabrina
shah
inova
blood
donor
servic
inova
fairfax
medic
campu
inova
fairfax
medic
campu
transfus
servic
backgroundcas
studi
red
blood
cell
rbc
transfus
often
lifesav
measur
patient
sickl
cell
diseas
scd
critic
manag
scd
complic
splenic
sequestr
stroke
priapism
iron
overload
acut
chest
syndrom
wellrecogn
complic
chronic
transfus
scd
patient
alloimmun
rbc
antigen
prevent
alloimmun
transfus
rbc
neg
c
e
k
antigen
advoc
led
report
reduct
rate
alloimmun
decreas
hemolyt
transfus
reaction
report
summari
three
year
experi
prophylact
transfus
rbc
unit
neg
c
e
k
antigen
scd
patient
red
blood
cell
exchang
transfus
rbcx
studi
designmethod
retrospect
review
scd
patient
histori
stroke
refractori
sickl
pain
crisi
priapism
done
rbcx
perform
everi
week
decemb
march
blood
bank
workup
use
mt
gel
method
antibodi
screen
identif
hospitalbas
donor
center
proactiv
work
hospit
blood
bank
prepar
unit
time
manner
resultsfind
total
patient
femal
male
underw
total
rbcx
octob
march
use
averag
number
rbc
unit
per
rbcx
rbc
unit
neg
c
e
k
antigen
use
rbcx
patient
two
patient
posit
c
antigen
underw
rbcx
use
e
k
antigen
neg
rbc
unit
review
antibodi
screen
test
result
perform
prior
rce
show
new
clinic
signific
alloantibodi
form
exposur
multipl
rbc
unit
conclus
although
consist
standard
care
transfus
practic
relat
extent
antigen
match
scd
patient
studi
suggest
standard
care
transfus
patient
scd
provid
rbc
neg
c
e
k
antigen
abil
find
rare
unit
also
affect
characterist
one
institut
blood
supplier
advantag
hospit
base
donor
center
work
proactiv
collabor
provid
rare
unit
approach
institut
transfus
rbc
unit
neg
c
e
k
studi
designmethod
venou
blood
specimen
healthi
volunt
collect
blood
donat
blood
donat
immedi
day
week
week
week
among
men
week
among
women
immunoglobulin
g
igg
immunoglobulin
igm
immunoglobulin
iga
complement
compon
red
blood
cell
rbc
white
blood
cell
count
wbc
hemoglobin
hb
hematocrit
hct
serum
iron
fe
measur
monitor
dynam
chang
biomark
blood
qualiti
resultsfind
level
igg
slightli
decreas
blood
donat
immedi
iga
decreas
significantli
still
within
normal
rang
igm
chang
blood
donat
level
iga
significantli
decreas
week
among
men
week
among
women
significantli
increas
time
period
igg
rbc
hb
hct
fe
start
recov
week
blood
donat
reach
level
blood
donat
within
week
among
men
week
among
women
conclus
biomark
mutual
chang
cours
week
among
men
week
among
women
donat
ml
blood
significantli
affect
overal
blood
qualiti
util
amicu
dxt
relay
data
manag
solut
increas
platelet
split
rate
improv
amicu
product
janel
wilhelm
jennif
kaluza
memori
blood
center
backgroundcas
studi
increas
platelet
demand
opportun
export
product
set
initi
increas
platelet
product
collect
form
exist
donor
base
also
face
challeng
manag
multipl
collect
site
multipl
state
decis
made
implement
amicu
dxt
relay
data
manag
solut
provid
us
insight
procedur
detail
make
data
driven
decis
day
day
variabl
previous
dip
low
split
forc
reactiv
plan
studi
designmethod
incorpor
dxt
strateg
plan
day
day
oper
dxt
report
monitor
manag
freseniu
kabi
team
product
site
phlebotomist
devic
report
measur
target
vs
actual
yield
donor
paramet
procedur
event
perform
donat
opportun
analysi
allow
us
adjust
configur
set
appropri
improv
accuraci
yield
predict
report
phlebotomist
util
train
optim
donor
gift
donat
addit
platelet
plasma
product
increas
procedur
success
rate
resultsfind
monthli
dxt
report
analysi
result
devic
configur
improv
phlebotomist
center
manag
account
effect
train
donat
optim
increas
overal
platelet
split
rate
percent
increas
concurr
plasma
collect
percent
util
dxt
report
abl
take
proactiv
approach
allow
us
predict
product
avail
day
day
variabl
drop
lower
percent
split
phlebotomist
qn
rate
easili
monitor
regularli
daili
weekli
monthli
result
decreas
overal
qn
rate
consist
percent
conclus
dxt
easi
implement
user
friendli
continu
help
improv
platelet
collect
process
improv
donor
center
dxt
provid
invalu
tool
oper
supervisor
monitor
staff
improv
product
multipl
site
next
step
develop
plan
implement
paperless
document
dxt
healthcareid
abil
immedi
review
data
directli
amicu
key
product
improv
realiz
evalu
impact
backgroundcas
studi
blood
blood
product
limit
expens
resourc
prescrib
handl
store
transfus
accord
hospit
guidelin
establish
ensur
best
practic
standard
maintain
patient
safeti
prerequisit
regist
nurs
rn
involv
blood
blood
product
administr
possess
fundament
knowledg
transfus
practic
aim
aim
studi
evalu
impact
hospitalbas
transfus
practic
train
program
among
regist
nurs
administr
knowledgebas
questionnair
implement
program
result
gather
would
identifi
gap
assimil
knowledg
suggest
improv
design
implement
specif
content
nursel
transfus
train
programm
studi
designmethod
rn
variou
unit
depart
invit
particip
blood
transfus
knowledg
questionnair
octob
formal
transfus
practic
train
programm
introduc
consist
onlin
learn
platform
inservic
train
session
questionnair
administ
rn
one
year
later
septemb
posttrain
programm
evalu
individu
item
score
proport
nurs
perfect
score
compar
preand
postimplement
resultsfind
total
number
rn
rn
complet
questionnair
give
respons
rate
respect
overal
mean
score
point
rang
mean
score
point
rang
percentag
rn
perfect
score
increas
tabl
show
result
question
item
implement
hospitalbas
nursel
transfus
practic
train
programm
led
encourag
improv
blood
transfus
knowledg
amongst
rn
train
may
need
prepar
blood
set
manag
fever
backgroundcas
studi
clinic
use
blood
shown
least
develop
part
veintovein
transfus
chain
global
survey
therefor
carri
order
investig
level
awar
access
util
econtinu
learn
qualiti
blood
use
among
blood
prescrib
clinician
nurs
studi
designmethod
descript
expost
facto
survey
design
use
purpos
select
blood
prescrib
clinician
nurs
hospit
countri
human
develop
index
hdi
group
low
medium
high
high
particip
three
research
question
answer
seven
null
hypothes
test
level
signific
descript
statist
tool
frequenc
count
percentag
use
analyz
demograph
background
inferenti
statist
pearson
productmo
correl
coeffici
ppmc
analysi
varianc
anova
use
analys
hypothes
resultsfind
qualiti
clinic
use
blood
posit
significantli
correl
level
awar
access
econtinu
learn
among
blood
prescrib
cliniciansnurs
signific
differ
level
awar
f
conclus
today
econtinu
learn
becom
conditio
sine
qua
non
effect
qualiti
clinic
use
blood
higher
hdi
level
better
awar
access
util
continu
educ
elearn
convent
program
better
awar
among
clinician
routin
prescrib
blood
compar
other
involv
incident
blood
transfus
access
elearn
depend
highli
presenc
sustain
societ
infrastructur
less
guarante
low
medium
hdi
countri
reliabl
power
suppli
mainten
hardwar
tool
updat
softwar
program
togeth
necessari
knowledg
skill
etechnolog
promin
factor
result
use
polici
strategi
recommend
improv
knowledg
clinic
practic
continu
elearn
program
eg
start
undergradu
medic
nurs
school
continu
postgradu
vocat
medic
special
institut
principl
clinic
transfus
practic
comprehens
includ
appropri
time
curricula
creation
technic
climat
guarante
access
elearn
cours
materi
stimul
nation
intern
exchang
elearn
program
focus
continu
educ
creation
elearn
mentor
network
profession
societi
associ
educ
institut
backgroundcas
studi
transfus
medicin
tm
didact
teach
materi
patholog
resid
wide
avail
share
among
resid
train
program
advanc
blood
knowledg
abo
leader
project
novel
approach
wherein
educ
materi
creat
collabor
commun
practic
cop
educ
theorist
etienn
wenger
defin
cop
group
peopl
share
concern
passion
someth
learn
better
interact
regularli
studi
designmethod
pilot
project
junior
faculti
coinvestig
west
coast
institut
month
creat
minut
powerpoint
present
fundament
tm
topic
member
month
review
edit
therefor
member
creat
review
present
three
total
step
step
member
wrote
multiplechoic
question
particular
topic
end
topic
would
quiz
question
assess
learn
complet
evidencebas
peer
review
present
would
avail
member
use
teach
patholog
resid
three
method
plan
measur
effect
materi
pre
postlectur
abo
leader
exam
use
question
made
topic
assess
learn
pre
postlectur
question
valid
examin
best
collabor
assess
learn
resid
inservic
examin
trend
specif
tm
resultsfind
six
present
develop
abo
leader
member
continu
particip
cop
tm
educ
abo
leader
best
pretest
result
shown
tabl
abo
leader
pretest
data
could
obtain
institut
b
traine
declin
particip
examin
institut
challeng
experienc
cop
includ
heterogen
resid
schedul
balanc
time
dedic
group
given
busi
schedul
difficulti
give
present
defin
institutionspecif
teach
period
posttest
result
includ
assess
complet
conclus
despit
logist
organiz
challeng
feasibl
creat
multicent
cop
tm
educ
impact
group
resid
learn
assess
plan
growth
evalu
backgroundcas
studi
tradit
educ
curriculum
patholog
resid
program
primarili
base
didact
lectur
casebas
present
discuss
oncal
case
use
dramat
vignett
proven
effect
educ
tool
illustr
complex
multidisciplinari
topic
medicin
goal
use
evalu
relev
approach
resid
educ
studi
designmethod
clinic
vignett
base
placenta
accreta
case
written
patholog
resid
transfus
medicin
rotat
twoweek
laboratori
manag
cours
resid
prepar
dramat
vignett
perform
focu
transfus
medicin
laboratori
manag
topic
resid
complet
question
preand
posttest
topic
relat
vignett
sever
meet
review
adapt
script
topic
discuss
rehears
held
sever
commonli
encount
problem
deviat
standard
oper
procedur
resid
audienc
ask
identifi
prior
perform
skit
resid
present
least
one
major
transfus
manag
teach
point
resultsfind
educ
activ
includ
minut
vignett
perform
minut
discuss
complet
focu
commun
oper
room
blood
bank
surgeri
maximum
surgic
blood
order
schedul
pretransfus
test
transfus
safeti
inform
consent
massiv
transfus
protocol
emerg
releas
blood
product
thromboelastometri
interpret
patient
safeti
advers
event
root
caus
analysi
perform
significantli
improv
score
posttest
mean
compar
pretest
score
mean
ttest
p
vignett
discuss
resid
togeth
identifi
intend
nonconform
answer
relat
question
resid
audienc
activ
particip
post
skit
discuss
report
satisfactori
learn
experi
conclus
dramat
clinic
vignett
illustr
multidisciplinari
complex
interact
pivot
import
daili
activ
profession
develop
patholog
resid
specif
structur
goal
clinic
dramat
vignett
use
complementari
educ
tool
illustr
challeng
topic
integr
way
enjoy
easi
understand
rememb
skit
perform
benefit
activ
prepar
extens
studi
topic
deliv
multifacet
coher
present
emphasi
integr
role
laboratori
transfus
medicin
patient
care
hannel
sareneva
susanna
sainio
inna
sareneva
tiia
kivipuro
taru
jask
finnish
red
cross
blood
servic
backgroundcas
studi
finnish
red
cross
blood
servic
frcb
nationwid
blood
servic
provid
finland
respons
collect
test
process
distribut
blood
product
hospit
health
care
provid
frcb
serv
nation
blood
group
refer
laboratori
provid
wide
rang
laboratori
servic
eg
test
hemostasi
tissu
type
possibl
donor
well
patient
wait
organ
stem
cell
transplant
frcb
also
perform
antenat
blood
group
rbc
antibodi
test
cover
whole
countri
sole
nation
oper
provid
educ
servic
ensur
safe
use
blood
product
well
accur
use
laboratori
servic
studi
designmethod
perform
custom
survey
healthcar
profession
assembl
need
educ
base
result
continu
feedback
frcb
provid
hospit
custom
blood
bank
clinic
follow
addit
servic
regular
educ
elearn
applic
transfus
medicin
handbook
blood
product
web
site
report
hospit
use
blood
product
annual
nation
blood
safeti
report
regular
element
educ
program
practic
problem
solv
cours
blood
bank
person
safe
transfus
train
day
clinician
everi
educ
collect
numer
feedback
follow
educ
respond
expect
util
knowledg
practic
also
inquir
like
would
recommend
train
colleg
indic
net
promot
score
np
resultsfind
healthcar
profession
particip
train
day
frcb
annual
addit
expert
give
ten
lectur
hospit
across
finland
feedback
educ
good
vari
rang
np
vari
accord
custom
survey
frcb
provid
appropri
educ
healthcar
profession
score
increas
conclus
feedback
np
score
survey
ensur
educ
train
program
frcb
respons
custom
need
hospit
util
annual
cours
frcb
initi
program
togeth
clinic
contact
person
hospit
aim
ensur
patient
blood
manag
pbm
optim
use
blood
product
also
plan
increas
elearn
applic
cours
transfus
medicin
nurs
medic
student
educ
outreach
effect
report
septic
transfus
reaction
kathleen
grima
ann
eder
beth
dy
mari
oneil
american
red
cross
georgetown
univers
backgroundcas
studi
hemovigil
program
monitor
advers
event
transfus
depend
clinician
abil
recogn
report
reaction
blood
center
apheresi
platelet
donat
implic
septic
transfus
reaction
str
could
underestim
risk
difficulti
recogn
delay
mild
reaction
larg
blood
center
design
educ
outreach
program
increas
awar
str
assess
effect
rate
str
report
nation
hemovigil
program
studi
designmethod
dec
larg
blood
center
develop
web
base
cours
str
cmeceu
credit
letter
sent
hospit
custom
recogn
report
str
alert
avail
cours
blood
center
physician
staff
sale
market
also
engag
hospit
custom
directli
discuss
recogn
report
str
use
onlin
educ
content
physician
track
interact
blood
center
nation
hemovigil
program
compar
number
str
report
month
launch
educ
outreach
resultsfind
web
base
cours
complet
particip
physician
base
review
evalu
cours
highli
valu
particip
rate
excel
good
blood
center
physician
gave
present
hospit
custom
report
suspect
str
increas
compar
prior
year
increas
report
came
specif
region
total
number
str
met
hemovigil
definit
definit
cultureconfirm
probabl
str
nationwid
system
increas
chang
significantli
compar
previou
year
educ
initi
design
deliv
consist
messag
risk
recognit
report
str
number
report
suspect
str
two
region
increas
meaning
chang
overal
report
suspect
confirm
str
across
nation
blood
system
find
could
reflect
hospit
alreadi
recogn
report
medic
signific
reaction
target
audienc
laboratori
personnel
physician
transfus
medicin
clinician
closest
patient
care
bedsid
target
educ
effort
provid
personnel
interfac
hospit
could
use
address
identifi
profession
practic
gap
transfus
medicin
implement
subscriptionbas
cgmp
elearn
lauri
mcgraw
courtney
saphier
helen
belton
salli
bittner
ward
scott
gulf
coast
region
blood
center
backgroundcas
studi
previou
cgmp
elearn
cours
develop
requir
minut
learner
complet
feedback
posit
manufactur
area
struggl
schedul
time
staff
complet
cours
within
assign
schedul
time
shift
design
trend
suggest
subscriptionbas
learn
effect
thalheim
subscriptionbas
elearn
util
minut
modul
deliv
regular
interv
chang
learn
process
singular
event
regular
interact
reinforc
learn
keep
content
top
learner
mind
studi
designmethod
began
develop
cgmp
subscriptionbas
elearn
select
first
five
seri
topic
equip
personnel
label
sop
record
first
topic
equip
divid
modul
select
valid
calibr
qualiti
control
mainten
modul
preand
postquizz
equip
seri
develop
assign
employe
manufacturingrel
job
use
learn
manag
system
prequiz
assign
employe
june
new
equip
modul
assign
month
follow
five
month
seri
conclud
decemb
postquiz
resultsfind
use
survey
assess
incid
report
evalu
train
effect
use
three
four
kirkpatrick
level
previou
cgmp
cours
receiv
good
rate
learner
equip
seri
receiv
highest
rate
scale
employe
complet
version
cgmp
cours
major
prefer
equip
seri
previou
cours
combin
comment
clearli
demonstr
learner
prefer
short
subscript
format
previou
cours
posit
neg
comment
level
learn
averag
score
user
increas
pretest
posttest
greatest
improv
note
score
laboratori
employe
twosampl
ttest
determin
result
statist
signific
tcritic
valu
tstat
valu
level
result
equipmentrel
error
decreas
train
enough
data
demonstr
statist
signific
conclus
level
evalu
data
valid
subscript
approach
effect
knowledg
increas
preto
postquiz
learner
report
appreci
shorter
train
complet
modul
without
special
schedul
requir
result
continu
develop
remain
seri
backgroundcas
studi
interdisciplinari
natur
transfus
medicin
requir
collabor
multipl
work
unit
effici
patient
care
department
silo
imped
collabor
transfusionrel
care
team
hypothes
regular
educ
meet
would
improv
knowledg
awar
depart
role
octob
multidisciplinari
educ
meet
call
friday
blood
confer
fbc
began
collabor
interprofession
forum
involv
frontlin
staff
transfus
practic
monthli
meet
also
broadcast
onlin
unabl
attend
person
present
differ
work
unit
share
background
inform
patient
case
open
floor
construct
discuss
studi
designmethod
survey
sent
fbc
particip
retrospect
captur
effect
fbc
interdepartment
collabor
survey
structur
obtain
form
feedback
use
publish
interprofession
collabor
practic
compet
icpc
guid
core
compet
target
maintain
climat
mutual
respect
commun
within
depart
foster
teamwork
understand
everyon
role
patient
care
resultsfind
survey
respons
rate
endors
fbc
creat
climat
respect
within
transfus
practic
believ
improv
commun
work
unit
feel
fbc
lead
increas
understand
interdepartment
process
notabl
laboratori
scientist
transfus
nurs
highest
attend
rate
furthermor
attend
via
onlin
broadcast
report
lowest
satisfact
respond
posit
main
reason
individu
attend
fbc
increas
knowledg
transfus
medicin
interact
learn
depart
hear
patient
case
studi
understand
big
pictur
one
role
patient
care
suggest
improv
includ
prepar
question
help
initi
discuss
increas
represent
area
broader
perspect
interdepartment
dialogu
post
record
fbc
later
view
conclus
applic
icpc
transfus
medicin
effect
len
assess
valu
interprofession
collabor
although
room
improv
result
support
fbc
contribut
better
commun
transfusionrel
care
team
increas
understand
interdepartment
process
within
transfus
practic
novel
approach
curriculum
develop
demystifi
transfus
medicin
ritcha
saxena
ananya
saxena
saint
univers
school
medicin
backgroundcas
studi
transfus
medicin
essenti
element
educ
requir
futur
physician
variou
disciplin
like
surgeri
intern
medicin
anesthesiologist
work
effect
blood
bank
personnel
transfus
carri
consider
advantag
well
risk
consequ
educ
initi
requir
identifi
particular
knowledg
deficit
transfus
medicin
subsequ
bridg
gap
challeng
updat
undergradu
medic
curriculum
reflect
latest
enhanc
transfus
medicin
studi
designmethod
student
undergradu
semest
student
semest
particip
studi
selfdirect
learn
resourc
combin
modul
interact
instruct
implement
tbl
cours
design
five
educ
modul
focus
qualiti
manag
blood
collect
transfus
reaction
precis
util
blood
product
innov
compon
safeti
design
student
student
reaction
tbl
transfus
medicin
evalu
use
qualit
quantit
assess
tool
analyz
knowledg
attain
critic
think
develop
along
team
continu
particip
first
assess
readi
assur
test
rat
guarante
understood
concept
applic
follow
case
studi
base
test
question
resultsfind
student
reaction
tbl
primarili
posit
student
give
posit
feedback
evalu
readi
assur
test
rat
illustr
improv
team
knowledg
acquisit
implement
effect
qualiti
manag
system
knowledg
acquir
individu
studi
student
grasp
conceptu
knowledg
principl
transfus
medicin
achiev
confid
deal
transfusionrel
complic
anecdot
student
significantli
attain
percept
blood
compon
prepar
storag
optim
util
along
develop
safeti
techniqu
blood
donat
conclus
studi
suggest
reform
medic
curricula
undergradu
medic
student
specif
educ
modul
design
focu
blood
bank
blood
transfus
principl
latest
advanc
transfus
medicin
much
requir
interest
patient
care
safeti
futur
physician
tbl
interest
effici
way
deliv
key
aspect
transfus
medicin
student
resultsfind
open
hous
attende
given
tour
bb
led
bb
attend
bb
resid
bb
supervisor
bb
qualiti
coordin
patient
blood
manag
nurs
also
attend
answer
attende
question
educ
patient
blood
manag
light
refresh
offer
attende
bb
break
room
first
bb
open
hous
held
wednesday
attende
includ
secondyear
medic
student
four
regular
blood
donor
hospit
blood
donor
center
also
employe
facil
manag
univers
offic
admiss
respect
hospit
senior
vicepresid
six
apheresi
nurs
two
clinic
laboratori
staff
two
medic
laboratori
scienc
student
one
addit
staff
member
univers
offic
admiss
second
bb
open
hous
held
thursday
attende
includ
regular
blood
donor
also
employe
offic
intern
affair
suppli
chain
respect
hematologyoncolog
fellow
surgic
resid
backgroundcas
studi
simpl
partial
exchang
transfus
routin
perform
patient
sicklecel
diseas
scd
goal
increas
oxygen
carri
capac
blood
reduc
rel
percentag
sickl
cell
essenti
clinician
abl
rapidli
estim
effect
avail
therapeut
modal
use
clinic
inform
minim
risk
red
blood
cell
exposur
given
formula
calcul
complic
develop
valid
onlin
calcul
assist
physician
task
studi
designmethod
web
applic
gener
wwwphamcalcscom
perform
simpl
transfus
partial
manual
exchang
calcul
valid
compar
predict
clinic
data
perform
autom
deplet
rbcx
calcul
valid
use
terumo
bct
lakewood
co
calcul
fraction
cell
remain
fcr
patient
fcr
may
benefit
delay
procedur
perform
futur
valid
process
includ
deme
regress
global
assess
predict
vs
actual
result
individu
comparison
wherein
valid
conting
predictedexpect
result
expect
result
demonstr
valid
perform
hematocrit
hct
hemoglobin
hgb
level
posttransfus
simpl
partial
manual
exchang
volum
replac
fluid
autom
deplet
rbc
exchang
resultsfind
see
tabl
backgroundcas
studi
focu
new
technolog
modern
medicin
requir
expens
despit
increas
target
impact
patient
still
risk
advers
reaction
medic
treatment
issu
current
discuss
use
standard
person
approach
doctor
multidisciplinari
narrow
special
integr
new
technolog
need
train
result
knowledg
defici
russia
develop
insur
medicin
creat
demand
intens
costeffect
treatment
program
multidisciplinari
approach
pbm
optim
transfus
practic
reduc
risk
advers
effect
improv
financi
perform
health
care
institut
howev
prosper
implement
pbm
also
requir
supplement
medic
compet
provid
harmon
dialogu
logist
administr
clinician
transfusiologist
studi
designmethod
medic
simul
centr
hospit
uniqu
opportun
launch
educ
program
medic
specialist
practic
blood
compon
transfus
main
innov
featur
train
cours
interdisciplinari
approach
intens
learn
perform
comprehens
learn
method
day
academ
hour
traine
attend
lectur
discuss
method
materi
particip
seminar
interact
clinic
discuss
master
class
game
present
model
work
process
sinc
initi
project
june
group
capac
transfus
vol
supplement
peopl
number
medic
specialist
attend
train
nearli
resultsfind
medic
compet
gain
knowledg
modern
recommend
use
blood
compon
abil
interpret
paramet
haemogram
coagulogram
tromboelastogram
abil
unveil
indic
contraind
urgent
schedul
blood
compon
transfus
person
blood
transfus
risk
use
person
approach
select
type
dose
transfus
habitat
predict
efficaci
transfus
correct
anemia
hemostasi
system
malfunct
use
medicin
treatment
perform
macroscop
assess
blood
compon
transfus
procedur
perform
differenti
diagnost
abil
prescrib
advers
effect
treatment
abil
carri
auditori
check
health
card
conclus
launch
program
guidanc
safe
effect
blood
use
adult
patient
multifield
hospit
aim
meet
educ
profession
need
medic
specialist
develop
algorithm
think
rang
use
motiv
case
patient
blood
manag
reach
complianc
practic
effect
emerg
situat
drill
technologist
teamwork
comfort
level
abigail
neil
raeann
stensgard
rebecca
wren
elisabeth
greer
ami
mata
camil
van
buskirk
mayo
clinic
rochest
backgroundcas
studi
teamwork
composur
essenti
technologist
deal
emerg
situat
larg
hospitalbas
blood
bank
multipl
situat
occur
simultan
effort
reduc
error
improv
emerg
respons
group
form
evalu
effect
emerg
situat
drill
esd
esd
base
common
emerg
situat
encount
lab
run
per
month
per
shift
main
goal
esd
improv
teamwork
comfort
level
real
emerg
situat
therefor
reduc
amount
unplan
standard
oper
procedur
sop
deviat
studi
designmethod
prior
esd
implement
survey
sent
technologist
determin
baselin
comfort
level
associ
variou
emerg
situat
one
year
post
esd
implement
survey
sent
technologist
reassess
comfort
level
situat
survey
ask
employe
rate
satisfact
comfort
level
grade
scale
least
satisfiedcomfort
satisfiedcomfort
pre
post
survey
result
evalu
calcul
lab
averag
comfort
level
per
situat
survey
addit
unplan
sop
deviat
relat
emerg
situat
count
one
year
one
year
esd
implement
resultsfind
total
technologist
technologist
took
pre
esd
survey
technologist
took
one
year
post
esd
implement
survey
tabl
show
lab
averag
pre
post
survey
well
percent
differ
employe
respond
post
survey
answer
true
statement
esd
improv
comfort
level
emerg
situat
year
prior
esd
implement
unplan
sop
deviat
year
esd
implement
deviat
conclus
one
area
increas
comfort
level
post
esd
implement
also
technologist
agre
esd
help
improv
overal
comfort
level
emerg
situat
goal
implement
esd
met
base
unplan
sop
deviat
decreas
technologist
satisfact
increas
therefor
esd
deem
effect
monthli
esd
continu
run
hope
continu
improv
teamwork
comfort
level
deviat
level
therapeut
backgroundcas
studi
categori
indic
red
blood
cell
exchang
rbc
exchang
children
sickl
cell
diseas
includ
follow
acut
stroke
stroke
prophylaxi
well
iron
overload
prevent
describ
first
instal
seri
therapeut
plasma
exchang
tpe
challeng
access
volum
manag
instrument
persist
along
need
address
psycholog
emot
well
popul
rbc
exchang
complic
procedur
explain
adult
becom
even
intimid
task
translat
languag
childhood
nevertheless
pretreat
educ
shown
decreas
anxieti
associ
medic
care
provid
age
appropri
specif
treatment
inform
pediatr
patient
decreas
neg
behavior
reduc
stress
promot
faster
recoveri
previou
project
explain
tpe
pediatr
popul
reveal
lack
age
specif
literatur
apheresi
procedur
gener
includ
tpe
rbc
exchang
studi
designmethod
collabor
child
life
specialist
ageappropri
storydriven
explan
rbc
exchang
procedur
adapt
previous
implement
project
relat
tpe
artwork
produc
aid
medic
illustr
complement
storylin
resultsfind
stori
board
address
rbc
exchang
perform
step
involv
prepar
perform
procedur
strategi
cope
procedur
idea
longterm
therapi
also
briefli
address
prepar
children
concept
ongo
therapi
booklet
product
concert
hospit
medic
illustr
avail
hospit
websit
patient
use
conclus
use
previous
illustr
stori
guid
explan
red
cell
exchang
creat
provid
educ
reduc
anxieti
second
instal
continu
pediatr
seri
help
explain
apheresi
procedur
pediatr
popul
hope
reduc
patient
stress
promot
age
appropri
cope
strategi
transfus
safeti
offic
resourc
manual
leonor
de
biasio
also
intend
util
hospit
formal
tso
posit
deleg
respons
staff
resourc
provid
help
inform
assist
educ
transfus
safeti
advers
event
investig
report
product
administr
guidelin
monograph
link
inform
equip
use
infus
blood
resourc
manual
serv
use
refer
tool
assist
healthcar
profession
transit
tso
role
turn
pathogen
reduct
case
flip
switch
kassandra
poffenberg
darla
wendt
jennif
vriez
jame
r
stubb
mayo
clinic
backgroundcas
studi
critic
aspect
implement
new
method
manufactur
blood
product
develop
train
plan
adequ
prepar
staff
nt
interfer
product
caus
delay
patient
care
implement
pathogen
reduct
technolog
prt
use
interceptv
r
blood
system
platelet
understood
would
need
collect
make
loss
product
specif
tripl
collect
institut
collect
major
blood
product
supplement
inventori
major
blood
collect
center
crucial
compon
laboratori
maintain
daili
process
level
learn
new
method
order
sustain
optim
platelet
inventori
level
without
reli
purchas
addit
platelet
extern
vendor
approach
introduc
prt
apheresi
platelet
flip
switch
process
product
new
method
rather
step
wise
roll
dual
inventori
studi
designmethod
essenti
priorit
would
train
first
collect
occur
monday
friday
first
group
train
would
perform
train
two
person
team
product
valid
train
ceru
deploy
team
second
group
would
process
platelet
weekend
even
hour
without
direct
manag
support
last
group
technologist
would
work
normal
hour
direct
manag
support
prt
process
platelet
plasma
broken
two
day
day
platelet
treat
amotosalen
place
compound
adsorpt
devic
remov
residu
amotosalen
hour
day
product
remov
cad
modifi
final
product
code
label
technologist
train
one
one
one
week
period
trainer
altern
train
process
day
day
day
week
follow
train
import
technologist
rotat
back
thru
prt
process
maintain
profici
resultsfind
employe
train
two
month
time
period
prior
flip
switch
daili
averag
product
collect
two
month
train
period
daili
averag
rose
conclus
flip
switch
train
plan
implement
prt
platelet
plasma
highli
success
laboratori
train
implement
new
technolog
creat
bottleneck
process
imper
priorit
would
train
first
insur
complet
coverag
hour
shift
technologist
abl
becom
profici
new
process
maintain
daili
process
expect
sustain
optim
platelet
inventori
accept
depend
individu
conscienc
due
uniqu
medic
challeng
import
caretak
understand
belief
order
provid
optim
care
describ
process
identifi
jw
hospit
commun
treatment
need
staff
studi
designmethod
proper
treatment
jw
requir
abil
identifi
patient
hisher
need
jw
admit
hospit
electron
medic
record
emr
trigger
sever
process
base
patient
list
religion
one
process
creat
order
remind
caretak
complet
declin
blood
consent
dbc
patient
dbc
contain
languag
declin
mabf
review
mibf
patient
identifi
would
accept
emr
order
regard
dbc
provid
educ
link
includ
bloodless
polici
stepbystep
instruct
obtain
dbc
inform
altern
transfus
second
emr
process
trigger
stopgat
prevent
complet
mabf
order
mibf
order
product
patient
declin
third
enrol
patient
minim
blood
volum
lab
protocol
use
microtain
partialfil
vacutain
blood
reservoir
set
reduc
blood
loss
draw
addit
registr
bloodless
packet
ad
patient
paper
chart
packet
contain
dbc
glossari
dbc
term
bloodless
sign
place
patient
bed
bloodless
wristband
worn
patient
two
bloodless
chart
sticker
ad
outsid
chart
step
remind
caretak
patient
special
request
final
patient
blood
manag
pbm
depart
receiv
emr
develop
report
identifi
jw
present
hospit
patient
follow
pbm
nurs
medic
director
durat
care
treatment
plan
optim
hemoglobin
oxygen
carri
capac
hemostasi
discuss
bedsid
caretak
implement
need
resultsfind
nearli
jw
enter
hospit
dbc
complet
result
increas
educ
medic
staff
addit
patient
report
better
commun
caretak
lead
invit
environ
patient
conclus
hospit
found
success
use
educationbas
teamori
approach
involv
emr
pbm
caretak
care
jw
patient
approach
set
foundat
treat
bloodless
medicin
patient
backgroundcas
studi
transfus
servic
provid
safe
blood
compon
vein
vein
donor
act
supplier
patient
final
custom
process
involv
laborintens
activ
critic
materi
human
resourc
facil
highli
coordin
process
cost
manag
great
impact
technic
process
guid
decis
upon
suppli
technic
staff
activitybas
cost
abc
method
determin
cost
driver
within
activ
determin
process
product
final
cost
allow
manag
take
precis
decis
demonstr
effect
abc
approach
result
financi
save
without
compromis
process
qualiti
midsiz
transfus
servic
studi
designmethod
materi
cost
repres
far
activ
central
storag
suppli
satellit
storag
depart
replac
done
independ
residu
stock
purchas
perform
demand
end
perform
suppli
inventori
depart
plan
futur
purchas
control
residu
stock
implement
annual
purchas
satellit
storag
suppli
replenish
program
stock
cost
driver
defin
upon
activ
standard
oper
procedur
sop
result
cost
estim
technic
staff
involv
cost
driver
calcul
indic
possibl
chang
sop
supplier
deliveri
minim
season
fluctuat
compar
last
quarter
last
quarter
work
present
activ
data
blood
collect
illustr
abc
method
resultsfind
blood
bag
use
compar
demonstr
activ
price
negoti
result
readjust
indic
estim
cost
possibl
impact
us
identifi
real
cost
repres
overal
us
r
save
conclus
economi
deterior
countri
higher
inflat
exchang
rate
variat
directli
impact
import
materi
critic
even
advers
economi
abc
show
effect
tool
allow
cost
decreas
without
signific
chang
critic
materi
process
cost
driver
calcul
demand
review
sop
supplier
technic
staff
result
optim
activ
also
staff
involv
reduc
discharg
materi
sinc
cost
wellknown
area
supervisor
satellit
stock
review
briefli
autom
verif
immunohematolog
result
impact
donor
test
barbara
j
bachman
candac
william
carmen
meyer
paul
lamonbi
ann
cleverley
silk
milbradtpohan
biorad
laboratori
diam
gmbh
titl
autom
verif
immunohematolog
result
impact
donor
test
backgroundcas
studi
staf
challeng
today
blood
bank
requir
instrument
minim
oper
intervent
technolog
advanc
develop
everi
immunohematolog
result
necessarili
requir
oper
visual
review
studi
evalu
impact
autom
result
verif
biorad
tm
immunohematolog
system
ihcom
tm
data
manag
system
dm
donor
process
laboratori
studi
designmethod
multicent
studi
perform
donor
sampl
shown
tabl
evalu
two
commonli
use
ihsystem
gel
card
avail
us
workflow
data
analyz
use
process
modellar
app
ipad
studi
focus
postanalyt
step
result
verif
evalu
without
autom
result
verif
determin
impact
qualiti
oper
touchpoint
visual
result
review
occurr
result
accuraci
speed
time
result
interpret
li
data
transfer
oper
touchpoint
postanalyt
phase
requir
visual
result
verif
softwar
defin
speed
metric
analyz
use
minitab
statist
transfus
team
collabor
multipl
user
group
educ
regard
new
process
gap
analysi
perform
determin
optim
deliveri
process
blood
product
key
stakehold
invit
review
option
use
pneumat
tube
system
deliv
blood
throughout
entir
campu
investig
determin
whether
would
viabl
option
given
expand
size
new
campu
resultsfind
user
group
request
addit
train
session
question
aros
regard
use
ehr
blood
order
pneumat
tube
system
would
heavili
use
due
concern
blood
product
could
becom
lost
decid
would
best
rout
deliveri
blood
depart
educ
request
support
creat
job
aid
specif
workflow
chang
impact
depart
order
rh
immun
globulin
cord
blood
workup
etc
conclus
leadership
challeng
provid
stabl
posit
environ
complex
set
chang
simultan
hospit
movemerg
implement
new
ehr
constitut
arduou
task
would
possibl
substanti
prepar
initi
year
advanc
train
essenti
success
scope
chang
big
minim
train
thorough
prior
move
gap
nonetheless
discov
follow
move
abstract
conclus
strateg
develop
partner
fund
support
base
newli
develop
govern
strategi
blood
servic
commit
govern
brought
posit
impact
establish
sustain
safe
nation
blood
servic
program
ethiopia
even
though
identifi
posit
impact
mention
achiev
bt
remain
multipl
challeng
need
continu
fund
partner
support
govern
commit
pilot
implement
comprehens
hybrid
perform
manag
system
nation
blood
servic
zimbabw
bless
mukwada
judith
j
parirewa
tonderai
mapako
nation
blood
servic
zimbabw
backgroundcas
studi
nation
blood
servic
zimbabw
nbsz
introduc
first
perform
manag
system
pm
nbsz
strateg
plan
note
current
pm
lack
objectiviteti
relationship
perfom
remuner
order
revis
pm
nbsz
set
three
member
committe
execut
manag
level
spearhead
revamp
nbsz
pm
aim
new
pm
achiev
share
vision
purpos
object
organ
help
staff
member
understand
recogn
contribut
strateg
plan
paper
share
nbsz
revamp
implement
new
hybrid
pm
deriv
input
establish
pmss
nbsz
monitor
evalu
e
process
link
togeth
oneselect
department
result
one
quarter
share
demonstr
system
work
studi
designmethod
pm
committe
develop
share
execut
manag
pm
conceptu
implement
framework
consult
includ
field
visit
done
three
establish
pm
assess
suitabl
nbsz
adopt
hybrid
pm
adopt
nbsz
pilot
applic
one
quarter
select
depart
done
review
polici
procedur
includ
hybrid
pm
templat
form
done
pm
committe
train
staff
implement
integr
scorecard
conduct
apprais
develop
scorecard
measur
perform
use
new
pm
weight
perform
reward
system
base
layer
perform
bonu
payment
work
use
standardis
tool
throughout
process
risk
assess
done
resultsfind
nbsz
hybrid
pm
base
five
level
plan
name
strateg
department
branch
section
individu
fourcolour
traffic
light
report
system
central
uniformli
assess
perform
level
level
account
properli
defin
level
plan
weight
overal
integr
individu
scorecard
ii
determin
base
individu
four
level
bonu
calcul
base
ii
follow
categori
ii
categori
b
ii
categori
c
ii
categori
ii
pilot
implement
individu
score
staff
rang
ii
number
staff
bonu
categori
categori
categori
b
conclus
new
hybrid
pm
gener
accept
staff
easili
implement
variou
staff
level
provid
basi
full
implement
new
pm
simplifi
pm
easili
adapt
similar
set
ensur
staff
contribut
suffici
object
realis
organis
strateg
vision
rare
donor
engag
american
rare
donor
program
ardp
margaret
c
manigli
deborah
r
fludd
sandra
j
nanc
backgroundcas
studi
rare
donor
defin
blood
type
occur
less
peopl
given
popul
donor
discov
test
new
donor
random
target
way
requir
test
mani
donor
find
one
rare
donor
found
facil
member
american
rare
donor
program
aabb
accredit
american
red
cross
accredit
irl
donor
regist
ardp
databas
rare
donor
activ
rare
donor
ardp
mobil
popul
usa
import
donor
reloc
recogn
rare
donor
donat
unit
identifi
use
patient
rare
blood
need
addit
recruit
need
patient
need
correct
contact
inform
donor
requir
studi
designmethod
ardp
procedur
ardp
member
requir
donor
contact
everi
six
month
ensur
ardp
facil
latest
contact
inform
time
determin
postal
servic
time
limit
six
month
forward
mail
new
address
contact
ensur
recruit
requir
obtain
blood
patient
rare
blood
need
donor
contact
collect
center
donat
contact
achiev
ardp
send
contact
card
postal
mail
twice
yearli
donor
ardp
address
demograph
resultsfind
ardp
report
inform
obtain
contact
card
return
ardp
annual
activ
report
ardp
member
aabb
annual
meet
total
activ
donor
return
contact
card
alert
ardp
chang
calendar
year
donor
move
one
ardp
facil
anoth
donor
longer
elig
donat
addit
address
chang
chang
reactiv
donor
donor
notifi
deceas
want
list
ardp
new
rare
donor
submit
ardp
registr
number
donor
could
potenti
lost
followup
would
new
donor
submit
conclus
nearli
respons
rate
donor
receiv
mail
contact
card
clear
rare
donor
famili
respons
ardp
contact
card
inform
ardp
address
chang
chang
health
statu
affect
abil
donat
evid
import
card
ensur
correct
donor
contact
inform
donor
chang
address
often
known
collect
facil
donor
donat
move
ardp
contact
card
effect
retain
relationship
ardp
regist
donor
keep
address
inform
rare
donor
current
workflow
comparison
two
gel
analyz
larg
transfus
servic
j
peter
pelleti
barbara
j
bachman
mike
leami
susan
olson
candac
william
univers
florida
colleg
medicin
biorad
laboratori
backgroundcas
studi
vendorassist
workflow
studi
becom
popular
analyz
choic
capabl
vari
market
purpos
studi
evalu
provu
ortho
clinic
diagnost
biorad
laboratori
inc
larg
volum
transfus
servic
use
lean
process
flow
studi
designmethod
twentytwo
run
one
six
sampl
per
run
observ
two
ortho
provu
altern
test
larg
transfus
servic
perform
type
screen
type
screen
annual
workflow
pattern
observ
repeat
compar
process
map
detail
direct
observ
use
process
modellar
app
ipad
evalu
start
sampl
centrifug
complet
end
result
sent
analyz
li
lab
inform
system
evalu
qualiti
test
process
step
biohazard
exposur
episod
mainten
task
speed
operatoranalyz
time
cost
testingmainten
personnel
hour
recaptur
time
studi
analyz
use
minitab
statist
signific
assess
use
pair
ttest
p
valu
consid
signific
regardless
qualiti
speed
metric
evalu
demonstr
signific
reduct
improv
process
step
associ
time
compar
ortho
provu
p
process
step
time
studi
address
tabl
account
reagent
storag
capac
realiti
improv
would
greater
display
reallif
oper
evalu
total
number
mainten
task
requir
annual
well
time
associ
mainten
perform
signific
reduct
reduct
differ
hoursyear
conclus
studi
verifi
provid
signific
effici
cost
avoid
ortho
provu
larg
volum
transfus
servic
workflow
comparison
two
high
volum
high
throughput
analyz
aaron
samson
kimberli
monnin
barbara
j
bachman
kyla
warren
susan
olson
candac
william
clinic
patholog
lab
biorad
laboratori
backgroundcas
studi
workflow
studi
perform
high
volum
high
throughput
blood
bank
analyz
larg
volum
test
facil
purpos
studi
evalu
galileo
v
r
neo
immucor
tm
biorad
laboratori
inc
use
lean
process
flow
studi
designmethod
total
separ
test
run
sampl
per
run
observ
three
day
period
galileo
neo
refer
laboratori
annual
perform
approxim
type
screen
workflow
pattern
observ
repeat
compar
process
map
detail
direct
observ
use
process
modellar
app
ipad
evalu
start
sampl
centrifug
complet
dropoff
test
area
end
result
sent
analyz
li
lab
inform
system
evalu
qualiti
process
step
biohazard
exposur
speed
operatoranalyz
time
cost
testingmainten
personnel
hour
recaptur
time
studi
analyz
use
minitab
statist
signific
assess
use
pair
ttest
p
valu
consid
signific
resultsfind
detail
process
step
biohazard
exposur
publish
analyz
mainten
task
evaluatedcompar
tabl
part
time
studi
focus
oper
time
analyz
time
mainten
time
tabl
part
b
regardless
qualiti
speed
metric
evalu
demonstr
signific
reduct
improv
process
step
associ
time
compar
galileo
neo
p
evalu
total
number
mainten
task
requir
annual
well
time
associ
mainten
perform
downtim
significantli
reduc
differ
hoursyear
conclus
studi
verifi
provid
signific
effici
cost
avoid
galileo
neo
high
volumehigh
throughput
test
facil
workflow
impact
autom
result
verif
patient
donor
blood
type
barbara
j
bachman
candac
william
carmen
meyer
paul
lamonbi
ann
cleverley
silk
milbradtpohan
biorad
laboratori
diam
gmbh
backgroundcas
studi
immunohematolog
facil
face
mani
challeng
includ
standard
process
control
product
staf
patient
safeti
allevi
challeng
tm
instrument
complementari
ihcom
tm
data
manag
system
dm
design
provid
lean
autom
enhanc
blood
test
facil
workflow
purpos
studi
focu
lean
function
autom
result
verif
ihcom
dm
determin
impact
workflow
studi
designmethod
intern
extern
studi
use
ihcom
dm
perform
patient
donor
sampl
assay
includ
aborh
blood
group
antibodi
screen
ab
shown
tabl
workflow
data
analyz
use
process
modellar
app
ipad
evalu
focus
postanalyt
step
result
verif
evalu
without
autom
result
verif
determin
impact
qualiti
oper
touchpoint
visual
result
review
occurr
result
accuraci
speed
time
result
interpret
li
data
transfer
oper
touchpoint
postanalyt
phase
requir
visual
result
verif
softwar
defin
speed
metric
analyz
use
minitab
statist
signific
assess
use
pair
ttest
p
valu
consid
signific
resultsfind
use
autom
result
verif
sampl
evalu
aborh
test
would
requir
visual
verif
result
reduct
oper
touchpoint
p
labor
save
minut
hh
mm
aborh
test
antibodi
screen
automat
valid
result
would
result
reduct
oper
touchpoint
p
labor
save
minut
hh
mm
fals
posit
fals
neg
type
result
fals
neg
screen
occur
result
autoverif
rbc
remain
fact
proport
increas
blood
usag
notabl
declin
era
patient
blood
manag
past
year
steadi
increas
demand
neg
rbc
compar
blood
type
observ
blood
center
util
metric
hospit
custom
monitor
monthli
overal
trend
forecast
data
share
regular
visit
despit
heighten
awar
percent
neg
rbc
sale
continu
rise
annual
peak
mid
better
understand
increas
demand
survey
conduct
gather
insight
improv
util
specul
survey
observ
effect
chang
staff
behavior
would
result
reduct
neg
rbc
sale
studi
designmethod
tie
tag
design
survey
tool
attach
neg
rbc
distribut
hospit
custom
period
late
hospit
transfus
servic
staff
ask
record
final
disposit
neg
rbc
transfus
wast
return
tie
tag
inform
survey
object
instruct
tie
tag
complet
commun
via
custom
meet
email
remind
sent
blood
center
driver
complet
tag
return
blood
center
custom
allow
return
rbc
unit
greater
day
shelf
life
remain
unit
tie
tag
attach
hospit
inventori
month
due
shelf
life
rbc
return
rate
percent
net
sale
gross
sale
minu
return
aborh
type
track
monthli
survey
resultsfind
particip
hospit
survey
mean
percent
neg
rbc
gross
sale
month
period
survey
respect
mean
percent
neg
net
sale
survey
fell
compar
averag
month
prior
survey
period
neg
rbc
monthli
return
rate
increas
averag
compar
averag
month
prior
month
survey
averag
neg
rbc
return
rate
increas
mean
percent
neg
rbc
net
sale
trend
slightli
upward
custom
hospit
queri
whether
process
chang
occur
major
chang
polici
inventori
level
report
conclus
survey
percent
neg
rbc
gross
sale
fairli
constant
indic
target
inventori
level
transfus
servic
staff
order
practic
remain
unchang
howev
period
increas
neg
rbc
return
rate
correspond
declin
percent
net
sale
suggest
improv
neg
rbc
util
increas
awar
particip
survey
staff
know
observ
like
play
role
lower
percent
neg
rbc
net
sale
track
monthli
metric
provid
ongo
review
determin
effect
transient
sustain
identifi
opportun
improv
neg
rbc
util
acoustophoret
separ
platelet
whole
blood
relev
practic
altern
centrifug
pierr
bohec
jeremi
gachelin
veroniqu
ollivi
thibaut
mutin
xavier
telot
benoit
ho
tin
noe
sandra
sanfilippo
aeniti
technolog
bichat
inserm
backgroundcas
studi
shearinduc
platelet
activ
unwant
side
effect
centrifugationbas
procedur
current
use
blood
bank
prepar
platelet
concentr
transfus
partli
activ
platelet
could
inde
increas
risk
advers
transfus
reaction
aim
evalu
effect
innov
acousticbas
fraction
devic
carri
qualit
function
vivo
analysi
isol
human
platelet
studi
designmethod
whole
blood
obtain
donor
fraction
use
acousticbas
devic
platelet
recoveri
puriti
determin
quantifi
blood
cell
subpopul
microchannel
outlet
sampl
qualiti
isol
platelet
evalu
use
surfac
express
two
activ
marker
pselectin
use
flow
cytometr
method
procoagul
abil
investig
use
vivo
experiment
platelet
isol
use
softspin
protocol
use
inactiv
control
resultsfind
fraction
use
acousticbas
devic
led
red
blood
cell
clearanc
ratio
whole
blood
greater
p
puriti
platelet
close
find
differ
term
qualiti
function
platelet
donor
isol
use
acoust
devic
versu
softspin
protocol
conclus
acousticbas
blood
process
method
led
excel
preserv
platelet
qualiti
function
provid
novel
promis
techniqu
whole
blood
fraction
clinic
set
autom
blood
bank
process
go
robert
fernandez
llui
puig
pilar
ortiz
joan
ovejo
nuria
martinez
elena
valdivia
susana
g
gomez
banc
de
sang
teixit
backgroundcas
studi
nowaday
blood
bank
requir
new
strategi
manufactur
blood
compon
due
increas
product
banc
de
sang
teixit
bst
implement
last
year
autom
manufactur
includ
lean
manag
method
abl
process
need
blood
donat
area
million
peopl
studi
designmethod
autom
blood
donat
process
bst
done
differ
chang
equip
orbisac
terumo
bct
equip
obtain
buffi
coat
product
got
platelet
concentr
move
equip
atreu
terumo
bct
get
red
blood
cell
buffi
coat
fresh
frozen
plasma
updat
atreu
chang
atreu
terumo
bct
final
move
reveo
system
terumo
bct
sinc
chang
blood
compon
red
cell
concentr
plasma
platelet
leukocyt
residu
chang
process
equip
ad
also
autom
registr
donat
id
weight
temperatur
label
step
implement
two
homemad
robot
final
get
better
result
efficaci
product
bst
incorpor
engin
introduc
lean
manufactur
method
method
base
identif
analysi
problem
chose
activ
add
valu
procedur
resultsfind
chang
updat
evalu
qualiti
blood
compon
red
cell
platelet
also
number
donat
miss
work
hour
necessari
process
blood
donat
evalu
done
process
conclus
result
obviou
autom
blood
bank
make
effici
manufactur
blood
compon
get
better
qualiti
also
cheaper
way
encourag
maintain
lean
philosophi
order
keep
improv
method
identifi
activ
add
valu
process
get
rid
one
necessari
global
industri
world
everyth
chang
fast
improv
necessari
top
field
state
art
blood
bank
backgroundcas
studi
laboratori
envis
autom
blood
product
deliveri
system
extend
blood
access
bedsid
use
remot
blood
alloc
devic
smart
blood
refriger
improv
patient
safeti
provid
time
access
blood
product
potenti
reduc
laboratori
workload
part
initi
bloodtrack
haemobank
hb
haemonet
braintre
instal
interfac
exist
safetrac
tx
haemonet
braintre
laboratori
inform
system
one
hb
instal
methodist
hospit
rmh
campu
includ
busi
outpati
infus
therapi
center
itc
studi
designmethod
assess
current
blood
suppli
chain
reveal
improv
opportun
nurs
blood
bank
staff
frequent
daili
trip
blood
bank
take
nurs
away
patient
besid
creat
congest
blood
bank
window
peak
time
itc
daili
outpati
volum
patient
averag
roundtrip
travel
time
approxim
even
small
delay
wait
line
blood
bank
window
would
produc
profound
rippl
effect
itc
nurs
face
addit
challeng
maintain
nursetopati
ratio
provid
time
patient
care
patient
itc
sameday
transfus
order
ad
blood
bank
workload
creat
unpredict
workflow
often
patient
itc
nurs
repeat
pretransfus
vital
sign
much
time
elaps
gather
vital
obtain
blood
ineffici
result
longer
patient
wait
time
ultim
longer
stay
itc
resultsfind
hb
devic
allow
nurs
staff
access
red
blood
cell
rbc
major
patient
point
care
sinc
implement
novemb
hb
significantli
improv
turnaround
time
rbc
issu
less
help
maintain
nurs
patient
ratio
reduc
traffic
blood
bank
issu
window
prior
hb
implement
blood
bank
staff
rmh
issu
approxim
rbc
per
month
window
nonsurg
patient
reduc
approxim
rbc
per
month
averag
monthli
reduct
conclus
hb
locat
itc
help
expedit
care
patient
easili
manag
blood
product
patient
sameday
order
use
hb
devic
result
reduct
blood
bank
fte
rather
shift
workload
issu
product
monitor
inventori
restock
consist
regist
paramed
pararescu
specialist
helicopt
personnel
combat
squadron
conduct
personnel
recoveri
oper
rescu
down
airmen
station
us
mitig
state
emerg
perform
aeromed
evacu
support
civilian
medic
emerg
patient
need
transfus
field
procur
blood
product
distant
air
forc
base
adjac
medic
facil
debrief
member
st
rescu
squadron
rq
decid
find
local
civilian
blood
supplier
master
sergeant
contact
blood
center
set
contract
blood
suppli
studi
designmethod
blood
center
repres
met
rq
master
sergeant
januari
ask
rq
order
deliveri
expect
said
sporad
use
blood
order
would
rbc
wrote
procedur
consign
packag
use
standard
blood
transport
box
develop
commun
templat
staff
anticip
rq
need
staff
train
base
data
januari
meet
contact
rq
septemb
perform
trial
run
time
learn
master
sergeant
ship
militari
theater
invit
replac
blood
center
pararescu
senior
airman
return
syria
assign
civilian
duti
prior
knowledg
rq
associ
civilian
blood
center
base
field
experi
chang
blood
order
rbc
introduc
blood
transport
contain
use
militari
oper
say
easier
carri
water
land
pararescu
mission
rewrot
procedur
incorpor
transport
contain
made
pictori
job
aid
assist
staff
packag
blood
use
contain
blood
center
rq
perform
mock
run
octob
felt
prepar
futur
event
resultsfind
novemb
rq
deploy
civilian
aeromed
evacu
anticip
rbc
order
actual
order
rbc
ffp
staff
prepar
frozen
ffp
ship
norm
fill
hospit
order
realiz
could
thaw
plasma
flight
contact
rq
offer
liquid
plasma
instead
accept
product
consign
pick
rq
patient
transfus
field
taken
nearbi
hospit
joint
debrief
novemb
th
establish
maximum
blood
order
rbc
liquid
plasma
note
futur
order
may
request
fewer
product
yet
meet
prefer
rbc
plasma
transfus
ratio
conclus
militari
personnel
adapt
instantli
adjust
ever
chang
environ
regul
blood
center
adapt
clear
comprehens
commun
anticip
blood
center
part
suppli
civilian
blood
product
air
nation
guard
tabl
highest
mean
fib
concentr
mgdonor
unit
lowest
mean
fib
concentr
mgdonor
unit
site
mean
fib
concentr
least
mgdonor
unit
fda
minimum
requir
mgdonor
unit
fifteen
blood
center
complet
manufactur
process
survey
one
use
leukocyt
reduct
filter
ahf
destin
plasma
blood
center
manufactur
singl
donor
cryoprecipit
manufactur
pool
donor
cryoprecipit
froze
plasma
colder
blood
bank
freezer
one
froze
plasma
use
dri
ice
one
use
blast
freezer
two
blood
center
method
thaw
frozen
plasma
took
longer
hour
conclus
blood
center
consist
met
overal
fib
minimum
requir
mean
mgdonor
unit
doubl
fda
requir
howev
variabl
fib
level
amongst
blood
center
gener
manufactur
process
similar
except
blood
center
inform
hospit
custom
averag
fib
level
cryoprecipit
order
appropri
care
patient
receiv
product
complianc
product
improv
via
engineeredstaf
schedul
calcul
applic
app
mari
deck
mark
angelelli
kevin
lee
american
red
cross
backgroundcas
studi
healthcar
industri
particularli
blood
bank
industri
continu
experi
tremend
pressur
ensur
patient
safeti
qualiti
daili
manag
maintain
effici
oper
cost
competit
structur
applic
basic
industri
engin
tool
coupl
leansix
sigma
techniqu
time
studi
analysi
bottleneck
elimin
process
standard
transfus
reduc
variat
transform
applic
short
app
util
determin
process
staf
optim
provid
flexibl
dynam
natur
chang
need
blood
bank
studi
designmethod
time
studi
analysi
offer
valuabl
data
process
requir
baselin
establish
translat
data
userfriendli
app
would
enabl
eas
practic
use
facilit
busi
decisionmak
well
effect
manag
daili
oper
import
concept
leanpul
product
system
bottleneck
elimin
workload
balanc
togeth
basic
develop
app
use
ms
excel
softwar
demonstr
resultsfind
success
rollout
implement
staf
schedul
calcul
app
across
pilot
facil
onto
facil
nationwid
yield
improv
product
togeth
sustain
complianc
scorecard
app
interactivebas
approach
program
via
commonli
use
softwar
ms
excel
use
analyz
optim
staf
requir
togeth
staffschedul
ie
match
incom
volumework
content
staf
avail
staffingschedul
calcul
app
util
execut
evalu
whatif
scenario
sensit
analysi
well
plan
toolkit
proactiv
manag
chang
demand
blood
bank
conclus
besid
provid
key
mechan
increas
product
sustain
complianc
top
prioriti
blood
bank
staf
schedul
calcul
app
highlight
continu
improv
opportun
springboard
systemwid
accept
standard
cooler
prepar
walkin
refriger
two
scoop
wet
ice
two
ice
pack
place
bottom
largemedium
small
cooler
respect
rbc
unit
top
ice
qualitycontrol
thermomet
place
top
rbc
unit
control
thermomet
place
interfac
ice
rbc
unit
one
larg
one
medium
cooler
start
temperatur
record
temperatur
record
everi
minut
hour
period
temperatur
exceed
resultsfind
temperatur
record
thermomet
top
unit
five
cooler
reach
minut
shown
tabl
control
thermomet
record
temperatur
maintain
entir
hour
observ
period
larg
medium
cooler
conclus
unit
place
top
ice
cooler
temperatur
reliabl
maintain
minut
data
support
polici
wast
unit
return
blood
bank
rbc
unit
top
ice
backgroundcas
studi
fda
draft
guidanc
highlight
need
reduc
risk
bacteri
contamin
platelet
compon
pc
via
pathogen
reduct
pr
secondari
rapid
test
rt
hospit
must
understand
cost
implic
may
result
object
creat
interact
model
analyz
budget
impact
differ
pc
type
across
rang
exist
us
hospit
studi
designmethod
excel
model
built
popul
base
case
cost
probabl
identifi
literatur
search
well
survey
administ
us
hospit
transfus
servic
director
model
review
refin
panel
seven
transfus
medicin
physician
model
allow
basecas
assumpt
overwritten
valu
specif
institut
three
scenario
gener
compar
annual
cost
plt
acquisit
test
wastag
dispens
transfus
advers
event
ae
shelflif
reimburs
hospit
purchas
pc
convent
cpc
prpc
mix
prpc
model
predict
modest
cost
increas
prpc
compar
cpc
depend
degre
pr
convers
take
account
cost
offset
elimin
bd
irradi
decreas
wast
due
increas
shelflif
outpati
reimburs
effect
pc
shelflif
potenti
increas
pr
due
elimin
bd
depend
nat
turnaround
time
benefit
captur
model
includ
transfusiontransmit
infecti
risk
mitig
emerg
pathogen
may
impact
costbenefit
analys
futur
iter
model
also
enabl
hospit
consid
scenario
rt
use
model
serv
import
tool
hospit
consid
pr
adopt
januari
report
creat
identifi
donor
previous
classifi
rare
accord
american
rare
donor
program
ardp
criteria
donor
classifi
rare
meet
one
follow
highpreval
antigen
neg
multipl
common
antigen
neg
iga
defici
new
process
util
report
involv
send
letter
donor
notifi
rare
donor
statu
encourag
continu
donat
databas
creat
track
letter
sent
rare
donor
august
inventori
reduct
effort
implement
gradual
decreas
number
allogen
red
blood
cell
rbc
collect
minim
unit
age
transfus
inventori
reduct
occur
phase
complet
januari
studi
perform
determin
impact
inventori
reduct
number
rare
donor
donat
studi
designmethod
total
number
allogen
rbc
donat
rare
donor
donat
number
rare
donor
letter
sent
analyz
see
tabl
percentag
rare
donor
donat
per
year
calcul
backgroundcas
studi
blood
center
client
often
carri
low
inventori
blood
blood
compon
laboratori
perform
donor
screen
therefor
limit
time
determin
presenc
absenc
infecti
diseas
within
product
order
measur
ensur
expedit
donor
screen
implement
daili
perform
metric
consist
upload
time
goal
releas
result
client
zkvnat
test
implement
travel
deferr
donor
juli
follow
univers
individu
donor
screen
septemb
novemb
respons
fda
recommend
reduc
risk
zkv
transmiss
blood
blood
compon
per
fda
guidanc
implement
mandatori
zkv
test
client
proxim
area
local
acquir
mosquitoborn
case
zkv
within
week
sept
phase
nationwid
within
week
nov
phase
zkv
test
perform
individu
sampl
unlik
nat
test
perform
minipool
therefor
zkv
test
disproportion
impact
turnaround
time
test
analyz
studi
studi
designmethod
within
two
region
test
lab
particip
clinic
trial
lab
lab
client
requir
univers
zkv
test
evalu
test
result
upload
perform
period
determin
impact
zkv
test
implement
resultsfind
lab
upload
time
perform
rang
januari
juli
upload
time
perform
fell
august
novemb
return
perform
decemb
lab
upload
time
perform
rang
januari
august
perform
fell
septemb
decemb
lab
experienc
low
upload
time
perform
phase
rapid
implement
client
requir
zkv
nat
improv
perform
observ
phase
increas
zkv
client
lab
phase
experienc
modest
declin
upload
perform
rang
client
implement
zkv
nat
perform
phase
addit
client
implement
zkv
test
conclus
unpreced
rapid
implement
zkv
test
laboratori
experienc
short
period
reduc
abil
maintain
upload
time
perform
metric
enhanc
platelet
bacteri
screen
eighthospit
system
robin
larson
colleen
aronson
advoc
lutheran
gener
hospit
acl
laboratori
advoc
hospit
backgroundcas
studi
respons
two
plateletrel
septic
transfus
reaction
draft
fda
guidanc
releas
march
regard
bacteri
risk
control
strategi
transfus
servic
eighthospit
system
implement
verax
pgd
enhanc
platelet
bacteri
screen
test
hospit
transfus
servic
site
implement
test
arrang
fresh
platelet
rotat
blood
supplier
site
implement
verax
pgd
test
perform
test
day
day
platelet
issu
transfus
abstract
summar
data
collect
first
week
test
studi
designmethod
platelet
bacteri
test
log
review
entir
time
period
studi
platelet
test
day
day
test
twice
inventori
report
review
platelet
issu
day
day
requir
test
total
number
platelet
issu
time
period
studi
resultsfind
month
februari
week
perform
test
platelet
issu
particip
transfus
servic
day
day
platelet
march
number
drop
expect
number
level
percentag
data
collect
februari
platelet
test
twice
prior
final
issu
transfus
servic
march
conclus
percent
platelet
issu
fresh
day
day
like
level
number
due
inventori
manag
blood
supplier
individu
transfus
servic
test
platelet
twice
undesir
ideal
platelet
would
test
twice
repres
high
cost
test
reagent
well
staff
time
complet
test
addit
site
perform
test
level
trauma
center
need
test
platelet
avail
time
requir
amount
doubl
test
goal
number
low
possibl
percent
test
vs
issu
platelet
exceed
transfus
servic
staff
becom
comfort
judg
inventori
level
perform
test
expect
amount
doubl
test
decreas
backgroundcas
studi
order
make
defici
apheresi
platelet
clinic
applic
also
improv
comprehens
util
blood
investig
feasibl
prepar
pool
platelet
concentr
pc
provid
reliabl
sourc
clinic
applic
speed
storag
research
pool
pc
china
evalu
chang
platelet
function
filter
leukocyt
leukocyt
filter
pc
qualiti
chang
storag
pvcbthc
blood
bag
studi
designmethod
pc
prepar
ml
viru
free
whole
blood
plateletrich
plasma
prp
method
five
six
bag
abomatch
pc
pool
filter
leukocyt
filter
pc
swirl
phenomenon
ph
automat
blood
count
platelet
aggreg
hypoton
shock
respons
hsr
extent
shape
chang
esc
express
atp
level
platelet
glucos
lactat
concentr
detect
filter
storag
respect
resultsfind
platelet
recoveri
ratio
therapeut
dose
pool
platelet
concentr
filter
leukocyt
rel
chang
rate
hsr
residu
leukocyt
ph
hsr
express
pool
platelet
concentr
filter
vs
vs
vs
signific
chang
wbc
filter
p
storag
pvcbthc
blood
bag
biochem
paramet
pool
platelet
concentr
chang
increas
storag
time
shown
tabl
conclus
storag
pvcbthc
blood
bag
five
day
qualiti
pool
pc
met
requir
chines
standard
gb
complementari
sourc
apheresi
platelet
supplement
china
evalu
samplokv
r
segment
sampler
obtain
measur
sampl
blood
compon
tube
segment
abbejan
blair
ajblair
laboratori
consult
backgroundcas
studi
current
method
use
obtain
sampl
blood
compon
tube
segment
cumbersom
present
signific
risk
exposur
biohazard
sharp
injuri
cross
contamin
itl
biomed
develop
samplokv
r
segment
sampler
ss
devic
obtain
measur
sampl
seal
tube
segment
less
cumbersom
offer
improv
safeti
elimin
need
manual
cut
squeez
tube
segment
ss
evalu
goal
reduc
number
step
requir
obtain
measur
sampl
reduc
biohazard
sharp
exposur
studi
designmethod
ss
obtain
fluid
sampl
seal
tube
segment
needleless
syring
consist
two
chamber
recess
intern
needl
locat
top
devic
femal
port
locat
bottom
devic
needleless
syring
attach
femal
port
seal
tube
end
align
ss
chamber
gentli
push
onto
needl
pierc
end
segment
sampl
segment
withdrawn
syring
studi
perform
rhode
island
blood
center
provid
ri
use
tube
segment
three
bag
manufactur
demonstr
eas
use
follow
process
segment
align
needl
pierc
abil
draw
sampl
syring
abil
expel
air
bubbl
syring
fluid
leak
eas
transfer
sampl
syring
tube
collect
user
feedback
two
length
tube
segment
fill
contain
sampl
volum
two
user
evalu
ss
tube
segment
type
sampl
total
data
point
sampl
collect
attach
syring
measur
sampl
transfer
syring
test
tube
microcentrifug
tube
result
tabul
pass
fail
resultsfind
total
ss
evalu
two
user
sampl
success
collect
transfer
tube
insert
segment
edg
requir
observ
ensur
placement
onto
needl
air
bubbl
collect
syring
could
easili
move
top
backgroundcas
studi
manag
platelet
inventori
crucial
due
number
factor
includ
day
product
outdat
alloc
staff
due
lengthi
donat
process
increasingli
small
donor
pool
high
cost
product
eg
platelet
collect
kit
test
product
process
use
platelet
inventori
manag
tool
potenti
enhanc
understand
unit
transfus
optim
inventori
increas
effici
reduc
wast
object
assess
deciph
platelet
inventori
manag
tool
reduc
amount
outdat
platelet
product
total
cost
platelet
product
full
time
equival
fte
alloc
studi
designmethod
januari
platelet
inventori
manag
process
implement
use
spreadsheet
base
tool
predict
amount
platelet
collect
procedur
need
schedul
day
tool
use
daili
histor
transfus
data
last
five
week
addit
calcul
includ
account
deferr
show
incomplet
collect
product
split
rate
number
gener
calcul
correl
mani
platelet
collect
procedur
schedul
specif
day
week
consid
test
releas
histor
daili
transfus
trend
effect
tool
verifi
compar
platelet
collect
platelet
product
outdat
fte
inform
one
year
period
prior
implement
platelet
inventori
manag
one
year
period
follow
implement
resultsfind
implement
platelet
inventori
manag
tool
collect
lower
shift
accommod
transfus
need
staf
adjust
target
collect
lower
fte
outdat
cost
platelet
outdat
rate
drop
implement
platelet
inventori
tool
unit
unit
decreas
fte
abl
monitor
close
donor
schedul
lower
yearli
averag
fte
fte
lower
fte
conclus
consid
histor
transfus
data
potenti
platelet
demand
posit
impact
schedul
platelet
collect
staf
requir
outdat
product
decreas
sinc
implement
platelet
manag
spreadsheet
tool
lead
less
wast
term
staf
platelet
given
posit
result
begin
develop
similar
tool
whole
blood
collect
identifi
opportun
rightsiz
hospit
inventori
use
compotrac
radio
frequenc
id
inventori
manag
system
nanci
fredrich
jaclyn
mckay
jennif
curn
rowena
punzalan
bloodcent
wisconsin
children
hospit
wisconsin
backgroundcas
studi
abil
track
inventori
blood
compon
real
time
challeng
hospit
transfus
servic
ts
blood
center
bc
use
current
blood
bank
inform
system
bbi
addit
determin
establish
par
level
individu
compon
meet
exceed
daili
transfus
need
difficult
ascertain
pilot
design
track
monitor
blood
compon
distribut
bc
issu
hospit
ts
use
freseniu
kabi
compotrac
radio
frequenc
id
rfid
enabl
inventori
manag
system
object
determin
feasibl
compotrac
system
analyz
compotrac
data
realtim
usag
optim
inventori
level
studi
designmethod
month
pilot
conduct
pediatr
hospit
bc
use
bbi
compotrac
system
track
adults
blood
compon
staff
train
use
compotrac
system
upon
receipt
order
pilot
hospit
bc
staff
appli
rfid
tag
compon
bag
scan
compon
compotrac
system
compon
transport
deliv
ts
follow
establish
procedur
upon
receipt
hospit
compon
scan
inventori
use
ts
bbi
compotrac
system
dual
scan
compon
occur
upon
issu
return
floor
compon
modif
return
bc
product
emerg
use
time
high
demand
rfidscan
priori
pilot
would
stop
compotrac
system
hamper
current
workflow
compon
issu
delay
ts
error
increas
inventori
chang
made
pilot
resultsfind
realtim
data
compotrac
system
provid
actual
usag
blood
compon
includ
compon
dispos
shipment
bc
averag
daili
rbc
inventori
level
usag
select
blood
type
shown
tabl
lesson
learn
relat
equip
workflow
use
smaller
irradi
canist
may
damag
rfid
tag
resolv
reloc
tag
ts
workflow
stat
order
challeng
consist
use
dual
process
track
compon
statu
howev
increas
ts
error
delay
issu
compon
occur
conclus
use
rfid
track
blood
compon
bc
final
disposit
feasibl
realtim
data
compotrac
system
identifi
optim
inventori
level
rbc
pilot
ts
use
realtim
rfid
track
inventori
adjust
target
level
base
actual
daili
usag
time
may
reveal
season
influenc
affect
target
inventori
backgroundcas
studi
physician
expect
blood
avail
time
follow
nation
appeal
juli
donor
base
predict
summer
shortag
high
likelihood
extend
fall
transfus
servic
ts
recogn
potenti
dire
situat
given
institut
patient
acuiti
hospitalbas
ts
support
full
rang
servic
level
trauma
servic
stem
cell
solid
organ
transplant
servic
brisk
cardiothorac
surgic
program
high
risk
obstetr
servic
high
acuiti
medicalsurg
servic
region
donor
center
suppli
blood
product
insur
appropri
respons
patient
need
ts
creat
manag
plan
input
multipl
stakehold
assist
product
manag
time
extrem
shortag
approach
describ
herein
studi
designmethod
direct
transfus
committe
tc
ts
director
present
concern
impend
shortag
hospit
qualiti
director
qd
committe
qd
committe
consist
clinician
nonclinician
train
health
care
qualityregulatori
affair
respons
institut
health
care
qualiti
hcq
activ
qd
recommend
creation
multidisciplinari
team
blood
shortag
task
forc
bstf
analog
exist
task
forc
start
manag
drug
shortag
resultsfind
hcq
tc
support
ts
creat
bstf
blood
shortag
manag
algorithm
bsma
stand
member
bstf
includ
ts
medic
director
chair
senior
vice
presid
svp
hcq
svp
clinic
servic
director
regulatori
affair
legal
counsel
repres
ethic
social
work
pharmaci
patient
referr
commun
ad
hoc
member
includ
whose
patient
would
impact
specif
shortag
bsma
design
bstf
provid
framework
ts
conduct
oper
therapeut
assess
potenti
impact
defin
criteria
conven
bstf
trigger
criteria
includ
mark
ts
concern
essenti
product
high
likelihood
inventori
deplet
broad
patient
impact
conven
bstf
respons
situat
assess
formul
manag
plan
goal
maintain
qualiti
patient
care
conclus
face
potenti
limit
blood
suppli
ts
reach
beyond
laboratori
engag
tc
member
hcq
assembl
robust
multidisciplinari
task
forc
result
inclus
plan
activ
time
address
shortag
assist
manag
impact
patient
abstract
backgroundcas
studi
cryoprecipit
short
cryo
play
critic
role
clot
control
hemorrhag
often
use
treatment
massiv
trauma
major
diseas
includ
metastas
cancer
cardiac
diseas
hepat
failur
organ
transplant
collect
process
cryo
particularli
challeng
due
fact
process
cryo
unit
collect
whole
blood
ship
product
facil
process
within
collect
tight
time
constraint
collect
product
satisfi
precis
collect
plan
extra
courier
servic
make
collect
cryo
unit
costli
product
studi
designmethod
american
red
cross
arc
partnership
research
georgia
institut
technolog
gt
develop
blood
collect
model
increas
amount
whole
blood
process
cryoprecipit
review
blood
collect
process
schedul
collect
locat
factor
arccryo
subject
matter
expert
togeth
gt
research
abl
analyz
problem
structur
sever
analyticdynam
program
properti
develop
near
optim
solut
algorithm
mathemat
model
resultsfind
facilit
implement
decis
support
tool
dst
develop
systemat
select
collect
site
determin
mobil
collect
site
collect
blood
cryo
product
schedul
courier
servic
collect
target
met
total
collect
cost
minim
implement
dst
led
increas
number
whole
blood
unit
satisfi
tight
complet
time
constraint
cryo
product
capac
expans
particular
th
quarter
blood
process
region
abl
process
cryo
unitsmonth
increas
slightli
lower
collect
cost
cost
avoid
result
approxim
reduct
per
unit
collect
cost
cryo
conclus
util
oper
research
toolkit
mathemat
model
nearoptim
algorithm
could
develop
optim
cryoprecipit
collect
process
ensur
time
constraint
product
consist
level
achiev
interdisciplinari
improv
cryoprecipit
collect
collabor
project
select
finalist
franz
edelman
award
recogn
outstand
achiev
practic
oper
research
inventori
manag
transfus
practic
apheresi
platelet
sarah
k
harm
univers
vermont
medic
center
backgroundcas
studi
shelf
life
apheresi
platelet
ap
unit
store
plasma
may
extend
day
usa
use
fda
clear
rapid
test
rt
august
hospit
base
transfus
servic
began
use
rt
day
routin
extend
ap
shelf
life
day
report
describ
chang
platelet
inventori
manag
transfus
practic
six
month
follow
routin
use
ap
studi
designmethod
data
obtain
two
studi
period
septemb
preimplement
septemb
postimplement
studi
period
intent
made
span
month
year
due
season
variabl
platelet
transfus
rate
region
transit
period
ap
inventori
exclud
follow
data
collect
studi
period
total
number
ap
transfus
recipi
ap
unit
transfus
expir
ap
unit
ap
unit
order
adhoc
supplier
inpati
admiss
surgic
volum
averag
length
stay
resultsfind
data
shown
tabl
number
ap
transfus
decreas
postimplement
inpati
admiss
surgic
volum
increas
respect
hospit
length
stay
similar
period
ap
inventori
decreas
postimplement
outdat
rate
decreas
p
adhoc
order
statist
differ
studi
period
averag
number
ap
transfus
per
patient
preand
postimplement
period
statist
differ
respect
furthermor
new
reject
threshold
lipaem
product
implement
threshold
repres
tg
concentr
viral
marker
test
donor
screen
affect
kcbb
abbott
prism
assay
use
hbsag
antihcv
ab
antihiv
ab
antihtlviii
resultsfind
use
data
manag
system
file
record
kcbb
regard
discard
blood
compon
due
lipaemia
last
five
year
demonstr
number
discard
rbc
due
lipaemia
whole
period
unit
number
discard
differ
plasma
platelet
cryoprecipit
compon
last
two
year
due
lipaemia
unit
respect
mean
number
discard
rbc
unit
five
year
studi
exce
test
one
literatur
guidelin
manag
lipaem
donat
review
order
minim
donat
loss
establish
accur
reject
threshold
lipaem
donat
review
sampl
requir
viral
marker
test
kcbb
accept
level
tg
blood
sampl
mgdl
reject
threshold
lipaemia
level
equal
mgdl
conclus
mani
blood
product
unit
discard
needlessli
kcbb
due
lipaemia
last
five
year
includ
rbc
plasma
product
apheresi
platelet
unit
effort
reduc
wast
potenti
lifesav
product
reject
threshold
lipaem
product
recommend
chang
mgdl
mgdl
affect
blood
safeti
follow
studi
recommend
appli
new
threshold
evalu
new
polici
logist
manag
incorpor
pathogen
reduc
singl
donor
platelet
prsdp
inventori
us
tertiari
care
medic
center
eric
gehri
rebecca
ross
debra
mraz
ann
baker
zenna
neal
melani
champion
edward
l
snyder
john
hopkin
univers
school
medicin
yale
univers
yalenew
hospit
backgroundcas
studi
approv
prsdp
fda
provid
opportun
improv
safeti
platelet
inventori
across
patient
demograph
outlin
approach
address
issu
face
first
month
prsdp
avail
studi
designmethod
nurs
educ
team
provid
present
nurs
clinic
unit
support
staff
companysponsor
trainer
staf
session
eveningnight
shift
clinic
ward
present
physician
made
blood
bank
medic
staff
inform
technolog
personnel
creat
new
product
type
blood
bank
comput
system
test
aborh
truth
tabl
ensur
bill
code
place
necess
transient
support
dual
inventori
prsdp
convent
platelet
led
consult
ethic
committe
risk
manag
confirm
prsdp
convent
platelet
cplt
test
bacteria
safeti
measur
test
could
consid
hospit
standard
care
chose
gamma
irradi
unit
prsdp
consist
packag
insert
resultsfind
ethic
committe
risk
manag
confirm
inform
consent
need
transfus
prsdp
prsdp
avail
blood
supplier
increment
monthli
first
four
month
prsdp
avail
prsdp
transfus
hospit
total
platelet
transfus
month
scaleup
prsdp
approxim
inventori
question
receiv
nurs
medic
confer
relat
risk
bacteri
contamin
cplt
vs
prsdp
toxicolog
pr
process
scan
prsdp
label
electron
medic
record
need
irradi
prsdp
use
safeti
measur
address
concern
bacteri
contamin
cplt
publish
prsdp
toxicolog
data
compar
content
psoralen
food
product
grapefruit
mg
per
content
prsdp
ng
per
ml
address
toxicolog
concern
nursingit
allay
concern
scan
issu
simpl
demonstr
final
ensur
parti
awar
fda
requir
irradi
prsdp
present
medic
confer
also
use
opportun
provid
transfusiontransmit
diseas
train
inform
platelet
util
compani
personnel
present
medic
nurs
confer
per
institut
polici
backgroundcas
studi
ensur
platelet
suppli
capabl
repres
challeng
term
donor
recruit
inventori
manag
oper
septemb
apheresi
collect
process
acp
complet
revis
increas
number
product
per
donat
maxim
rate
doubleplatelet
donat
dpd
process
review
led
sever
chang
includ
substitut
predon
platelet
plt
count
measur
donat
type
alloc
favor
use
donor
past
donat
record
multipl
process
step
elimin
evalu
plt
concentr
function
time
deduc
complet
blood
count
cbc
measur
allow
central
analysi
qc
depart
final
introduc
concept
nonoptim
donat
led
increas
proport
dpd
studi
designmethod
donat
center
whole
blood
wb
donor
collect
k
edta
tube
plt
concentr
determin
qc
depart
use
coulter
act
diff
hematolog
analyz
beckman
coulter
sampl
tube
store
measur
hour
postcollect
singl
platelet
donat
spd
dpd
collect
use
trima
accel
unit
pool
split
elp
extend
life
platelet
terumo
bct
storag
bag
mimic
spd
ml
dpd
unit
ml
plt
pool
store
mild
agit
seven
day
except
dpd
split
two
bag
h
sampl
taken
day
ph
po
pco
hypoton
shock
respons
hsr
extent
shape
chang
esc
express
atp
content
lactat
glucos
concentr
use
vitroqu
marker
resultsfind
plt
concentr
function
time
determin
wb
cbc
measur
show
signific
differ
l
l
l
postdon
dpd
store
collect
bag
donat
without
signific
impact
plt
qualiti
marker
plt
concentr
within
manufactur
accept
limit
l
split
day
lactat
pco
concentr
increas
po
decreas
dpd
howev
valu
normal
control
unit
expir
day
conclus
project
approv
health
canada
implement
organ
march
numer
oper
cost
benefit
process
optim
initi
without
signific
impact
safeti
qualiti
postimplant
effici
data
compar
target
increas
target
number
plt
unit
per
donat
ratio
phase
implement
pathogenreduc
platelet
health
system
elizabeth
allen
colleen
vincent
patricia
kopko
univers
california
san
diego
american
red
cross
backgroundcas
studi
pathogen
reduc
platelet
prp
provid
improv
safeti
compar
convent
apheresi
platelet
collect
manufactur
complex
earli
evid
show
doubl
platelet
collect
meet
requir
pathogen
reduct
treatment
blood
center
need
hospit
implement
prp
start
manufactur
hospit
may
wish
use
prp
provid
product
patient
scale
manufactur
blood
center
phase
prp
across
patient
popul
meet
parti
need
evalu
strategi
univers
health
system
transfus
volum
apheresi
platelet
annual
includ
two
hospit
inpati
bed
outpati
cancer
center
studi
designmethod
initi
approv
fund
obtain
hospit
qualiti
council
administr
stakehold
group
hematologyoncolog
educ
consensu
gain
live
train
provid
nurs
outpati
cancer
center
week
bone
marrow
transplant
bmt
ward
week
email
commun
explain
chang
physician
nurs
phase
implement
prp
outpati
cancer
center
patient
immunocompromis
access
immedi
advanc
critic
care
inpati
environ
septic
reaction
occur
phase
expand
usag
includ
inpati
bmt
ward
phase
lift
restrict
prp
could
use
throughout
health
system
goal
reach
prp
within
month
resultsfind
phase
week
request
prp
product
weekli
base
typic
usag
outpati
cancer
center
blood
supplier
provid
averag
prp
weekli
rang
prp
constitut
platelet
transfus
cancer
center
week
excess
prp
inventori
requir
use
prp
inpati
bmt
ward
ahead
schedul
practic
continu
throughout
phase
phase
week
formal
expand
issu
prp
includ
inpati
bmt
ward
request
prp
product
weekli
blood
supplier
provid
averag
prp
weekli
rang
prp
constitut
platelet
transfus
phasedin
area
phase
week
began
issu
prp
throughout
health
system
supplier
provid
averag
prp
weekli
rang
prp
constitut
platelet
transfus
scalingup
ongo
conclus
phase
implement
prp
patient
group
priorit
patient
stand
benefit
product
allow
time
blood
center
scale
manufactur
backgroundcas
studi
maintain
adequ
inventori
platelet
without
signific
outdat
wast
product
constant
challeng
mani
institut
especi
smaller
commun
hospit
health
system
compris
hospit
includ
smaller
commun
hospit
sch
larger
tertiari
care
medic
center
tcmc
sever
year
use
limit
intern
process
platelet
share
institut
success
reduc
platelet
wastag
encourag
us
analyz
platelet
usag
throughout
health
system
devis
expand
novel
concept
platelet
distribut
partnership
blood
supplier
would
allow
us
maintain
inventori
apheresi
platelet
ap
unit
smaller
commun
hospit
without
significantli
increas
platelet
wast
associ
cost
studi
designmethod
round
robin
rr
transport
system
platelet
deliveri
pick
strateg
develop
region
blood
center
align
routin
deliveri
red
blood
cell
rbc
stand
order
effici
deliveri
system
implement
region
blood
center
would
realiz
reduc
supplement
emerg
deliveri
blood
compon
hospit
platelet
transfer
time
rbc
stand
order
deliveri
base
predetermin
rout
schedul
day
ap
deliv
sch
previou
day
platelet
retriev
transfus
pack
blood
center
transport
box
pick
blood
center
driver
platelet
typic
hour
shelf
life
remain
process
occur
next
sch
rout
retriev
platelet
sch
deliv
tcmc
last
stop
rout
thu
sch
adequ
number
unit
avail
regular
transfus
massiv
transfus
protocol
resultsfind
review
rr
process
reveal
signific
benefit
smaller
commun
hospit
abl
routin
maintain
ap
inventori
patient
requir
urgent
platelet
transfus
addit
benefit
decreas
ap
wast
tabl
result
cost
save
addit
cost
save
approxim
note
due
decreas
cost
emerg
platelet
transport
conclus
novel
rr
process
platelet
distribut
result
improv
platelet
avail
smaller
commun
hospit
maintain
reduc
level
ap
wast
health
system
previou
platelet
share
process
anticip
addit
decreas
ap
wast
transfus
vol
supplement
streamlin
process
trend
merg
health
deliveri
system
predict
health
system
adopt
similar
process
improv
platelet
avail
reduc
wast
post
implement
adjust
pathogen
reduct
process
jacquelin
carlson
jame
r
stubb
scott
hammel
manish
gandhi
mayo
clinic
mayo
clinicrochest
backgroundcas
studi
implement
pathogen
reduct
apheresi
platelet
use
cerusv
r
intercept
system
apheresi
platelet
substanti
endeavor
encompass
mani
differ
area
process
chang
adjust
modif
occur
along
way
implement
pathogen
reduct
technolog
prt
apheresi
platelet
made
two
addit
adjust
sampl
process
ensur
accur
labelingcategorizationbrand
final
product
studi
designmethod
prt
valid
consist
apheresi
platelet
product
product
test
preprocess
white
blood
cell
wbc
content
platelet
yield
along
post
process
platelet
yield
data
use
calcul
yield
volum
retent
process
anticip
product
preprocess
yield
may
end
final
storag
bag
would
need
postprocess
sampl
ensur
product
met
criteria
platelet
resultsfind
valid
discov
one
collect
leukoreduc
two
collect
start
yield
end
yield
two
discoveri
led
adjust
prt
platelet
process
wbc
failur
review
wbc
count
sysmex
preprocess
report
see
would
alert
us
potenti
wbc
failur
review
discov
result
mcl
except
wbc
failur
count
monitor
wbc
count
discov
result
test
adam
rwbc
wbc
count
determin
leukoreduc
decid
sysmex
wbc
result
preprocess
sysmex
report
would
review
prior
process
wbc
result
test
adam
confirm
leukoreduc
product
also
discov
preprocess
yield
product
end
post
process
yield
decid
increas
yield
requir
post
process
sampl
includ
conclus
continu
sampl
collect
post
process
yield
confid
releas
product
inventori
yield
platelet
enough
data
accur
determin
volum
yield
loss
process
backgroundcas
studi
univers
kentucki
medic
center
ukmc
larg
academ
hospit
level
trauma
center
suppli
blood
product
kentucki
blood
center
kbc
consign
agreementbas
contract
ukmc
kbc
largest
consum
blood
product
platelet
usag
vari
wide
day
day
platelet
usag
project
provid
kbc
ukmc
blood
bank
therebi
allow
kbc
act
accordingli
given
day
stock
ie
import
vs
export
daili
platelet
project
base
phone
call
ask
clinician
work
highdemand
locat
estim
need
process
easili
confound
multipl
factor
undergon
multipl
adjust
improv
accuraci
studi
designmethod
daili
platelet
project
form
retrospect
review
compar
actual
usag
data
time
predict
system
use
ukmc
bb
time
estim
clinic
need
evalu
effect
base
total
number
day
underpredict
number
day
larg
underpredict
averag
number
unit
underpredict
averag
differ
predict
usag
predict
system
subsequ
chang
base
data
revis
predict
method
estim
clinic
need
evalu
retrospect
use
data
sourc
cover
compar
prior
method
resultsfind
averag
number
platelet
transfus
ud
standard
deviat
ud
predict
amount
ud
differ
predict
amount
number
unit
use
ud
day
underpredict
averag
ud
day
underpredict
u
averag
u
max
u
averag
number
platelet
use
ud
standard
deviat
ud
predict
amount
ud
differ
predict
unit
use
ud
day
month
underpredict
averag
ud
one
day
period
underpredict
u
u
conclus
review
clinic
platelet
usag
time
identifi
rel
stabl
averag
daili
clinic
demand
adjust
predict
system
ensur
possibl
day
project
less
averag
markedli
reduc
catastroph
shortag
reduc
number
day
underpredict
decreas
discrep
underpredict
day
u
u
improv
estim
usag
allow
increas
abil
handl
unpredict
event
without
suddenli
strain
kbc
suppli
flexibl
sever
limit
ukmc
clinic
set
rapid
implement
zika
viru
zkv
nat
blood
donor
screen
joan
dunn
william
maria
noedel
nanci
haubert
kenneth
hudson
larri
morgan
robert
shaw
traci
fickett
jami
jue
valeri
winkelman
salli
caglioti
german
leparc
phillip
c
williamson
backgroundcas
studi
fda
issu
guidanc
document
reduc
risk
zkv
transmiss
blood
blood
compon
respons
plan
implement
mandatori
zkv
test
client
local
acquir
mosquitoborn
case
zkv
within
week
nationwid
week
organ
perform
test
client
blood
center
hospit
across
countri
report
manufactur
sponsor
provid
investig
new
drug
ind
protocol
singl
project
manag
pmo
system
use
control
requir
process
studi
designmethod
project
focu
includ
clinic
trial
requir
client
onboard
lab
oper
lab
object
implement
zkv
test
client
within
week
addit
client
within
week
minim
impact
lab
stagger
implement
use
trackedstreamlin
commun
stakehold
vendor
institut
review
board
irb
client
lab
base
client
servic
lab
resultsfind
clinic
trial
requir
increas
complex
implement
unlicens
test
document
includ
donor
notif
inform
consent
protocol
train
staff
certif
deviat
manag
result
report
multipl
irb
document
requir
ensur
accuraci
ind
commit
principl
investig
assign
lab
client
subinvestig
deliver
multipl
includ
client
requir
vendor
respons
lab
client
onboard
includ
confidenti
agreement
client
sponsor
immedi
zkv
base
webinar
provid
materi
understand
sponsor
protocol
lab
test
system
clientdonor
base
respons
facilit
ensur
effect
commun
twice
weekli
confer
call
held
client
sent
question
facilit
lab
direct
sponsor
specif
client
irb
document
updatesvalid
zkv
test
order
result
receipt
lab
multifacet
vendor
instrument
assay
materi
packag
insert
staff
train
assess
includ
zkv
sampl
volum
throughput
instrument
capabilitycapac
work
requir
includ
vendor
instal
equip
assay
reagent
qualif
staff
train
compet
assess
result
report
client
provid
zkv
test
within
requir
timefram
conclus
success
meet
rapid
implement
zkv
test
larg
due
central
pmo
system
provid
control
process
sponsor
client
vendor
lab
within
lesson
learn
strength
found
multicli
onboard
process
weak
understand
instrument
test
volum
capac
throughput
exceed
period
overcom
cycl
red
blood
cell
babi
unit
traceabl
discard
kuwait
central
blood
bank
five
hospit
marwa
moemen
al
deeb
hala
samuel
boul
fatemah
saleh
al
matroud
rabab
hussien
ali
dashti
hanan
alawadhi
reem
al
radwan
kuwait
central
blood
bank
kuwait
central
blood
bank
kuwait
central
blood
bank
backgroundcas
studi
ill
children
like
receiv
red
blood
cell
rbc
transfus
patient
age
group
rbc
compon
often
transfus
neonat
period
small
volum
aliquot
use
limit
donor
exposur
prevent
circul
overload
decreas
donor
relat
risk
traceabl
abil
trace
individu
unit
donor
recipi
dispos
blood
compon
fulli
traceabl
collect
final
disposit
kuwait
central
blood
bank
kcbb
prepar
babi
unit
distribut
hospit
countri
kcbb
accredit
american
associ
blood
bank
aabb
follow
aabb
regul
trace
everi
compon
studi
designmethod
retrospect
studi
assess
final
deposit
percentag
discard
prepar
pack
rbc
babi
unit
kcbb
five
hospit
blood
bank
hbb
also
assess
level
traceabl
reflect
improv
effici
use
blood
product
method
total
rbc
babi
unit
randomli
chosen
trace
final
deposit
year
till
half
unit
trace
kcbb
tabl
show
number
chosen
unit
distribut
five
government
hbb
unit
year
studi
period
resultsfind
preliminari
result
show
trace
rbc
babi
unit
kcbb
effici
result
hospit
process
statist
analysi
traceabl
done
soon
data
collect
studi
analyz
usag
babi
unit
differ
depart
percentag
discard
unit
traceabl
rbc
babi
unit
kcbb
excel
due
good
manag
train
work
staff
use
electron
system
registr
issu
kuwait
government
hospit
use
electron
system
traceabl
recommend
level
percentag
discard
babi
unit
hospit
high
may
due
practic
use
fresh
blood
day
donat
reserv
babi
unit
donor
babi
reduc
hazard
multipl
donor
exposur
creation
nation
polici
use
rbc
babi
unit
highli
recommend
reduc
discard
unit
also
calcul
number
fals
posit
result
studi
trace
product
midmarch
resultsfind
total
product
test
fifteen
unit
fals
posit
result
could
life
span
extend
fifteen
reactiv
unit
two
repeat
donor
identifi
chart
mark
test
subsequ
donat
crossreact
antibodi
identifi
vendor
none
true
posit
recultur
unit
success
test
test
day
use
day
platelet
transfus
expir
day
cost
test
product
includ
control
calcul
cost
produc
product
would
need
import
product
meet
need
cost
would
roughli
without
ship
cost
estim
averag
expir
platelet
product
per
month
rang
verax
test
rang
implement
conclus
use
verax
pointofcar
test
save
platelet
product
discard
cost
save
import
produc
replac
product
averag
discard
rate
per
month
went
verax
implement
extend
platelet
shelf
life
day
paid
cost
test
ensur
product
avail
patient
need
secur
text
messag
transfus
medicin
text
decreas
wastag
melani
estrella
elsi
lee
georg
washington
univers
hospit
backgroundcas
studi
secur
text
messag
hospit
set
allow
quick
easi
hipaa
compliant
commun
member
patient
care
team
work
mobil
phone
comput
provid
readreceipt
confirm
temporari
record
team
commun
secur
text
potenti
use
manag
tool
transfus
medicin
reduc
blood
product
wastag
exampl
provid
rel
lowburden
mean
busi
clinician
provid
feedback
transfus
servic
scenario
potenti
wastag
inform
use
identifi
area
manag
strategi
could
develop
also
allow
person
educ
opportun
clinician
blood
bank
usag
guidelin
reduc
futur
wastag
goal
studi
use
secur
text
investig
wastag
evalu
respons
clinician
evalu
potenti
effect
reduc
wastag
hope
result
identifi
secur
text
use
manag
tool
transfus
medicin
studi
designmethod
wastag
record
investig
without
assist
secur
text
juli
decemb
review
identifi
common
scenario
prevent
blood
product
wastag
wastag
record
januari
april
review
wast
product
consid
prevent
investig
use
secur
text
commun
order
physician
resultsfind
data
unit
investig
without
use
secur
text
unit
identifi
prevent
wastag
wast
unit
consid
beyond
control
clinician
categori
prevent
wastag
defin
follow
product
releas
procedur
patient
stabil
product
return
outsid
appropri
temperatur
rang
clinician
unawar
product
assign
thu
far
wastag
record
identifi
unit
prevent
wastag
secur
text
use
transfus
servic
physician
investig
twelv
respons
provid
use
feedback
futur
manag
strategi
respons
thank
transfus
servic
inform
instanc
messag
read
repli
conclus
secur
text
messag
potenti
improv
commun
transfus
medicin
easi
use
hipaa
compliant
help
identifi
strategi
reduc
wastag
improv
commun
allow
person
educ
opportun
order
physician
transfus
servic
sequenc
reagent
ad
cryopreserv
freez
solut
guol
chen
xu
zhao
andrew
tiss
sasha
turner
devin
emerson
manijeh
shemirani
sharon
novak
david
garvin
john
eng
wanx
cui
medstar
georgetown
univers
hospit
backgroundcas
studi
dimethyl
sulfoxid
dmso
plasmalytea
plasa
human
serum
albumin
hsa
wide
use
prepar
cryopreserv
freez
solut
use
autolog
plasma
instead
plasa
hsa
studi
identifi
choic
reagent
optim
sequenc
ad
reagent
make
freez
solut
studi
designmethod
materi
dmso
plasa
hsa
autolog
plasma
extract
contain
transfer
pack
bag
polystyren
tube
freez
solut
recip
use
studi
volum
ratio
dmso
plasa
plasa
hsa
kept
room
temperatur
rt
refriger
plasma
rt
simul
endofcentrifug
temperatur
dmso
rt
due
high
freez
point
differ
combin
reagent
choic
storag
temperatur
ad
sequenc
test
photo
taken
total
test
least
minut
cool
dmso
ad
next
reagent
see
tabl
directli
ad
dmso
alon
bag
bag
turn
transpar
white
dmso
add
first
tube
autolog
plasma
first
dmso
next
powderlik
precipit
tube
dmso
first
hsa
next
precipit
instantli
layer
appear
tube
plasa
first
hsa
dmso
last
precipit
form
rt
plasa
hsa
combin
form
thicker
precipit
kept
tube
hsa
first
dmso
next
precipit
form
heavili
sculptur
shape
precipit
group
slightli
milderslow
rt
group
hsa
ad
first
trace
hsa
mix
plasa
bag
tube
hsacontamin
plasa
ad
first
dmso
small
fragment
precipit
form
dmso
add
last
backgroundcas
studi
maintain
robust
blood
product
suppli
essenti
requir
guarante
optim
patient
care
major
hospit
howev
daili
blood
product
use
difficult
anticip
platelet
product
variabl
daili
usag
short
shelf
live
also
one
expens
product
produc
test
store
due
combin
absolut
need
uncertain
daili
demand
short
shelflif
platelet
product
also
frequent
wast
due
expir
sophist
data
analysi
potenti
accur
predict
hospit
wide
platelet
need
therefor
reduc
wastag
studi
designmethod
investig
platelet
usag
pattern
institut
specif
interrog
relationship
platelet
usag
aggreg
hospitalwid
patient
data
recent
consecut
period
use
convex
statist
formul
found
platelet
usag
highli
depend
sever
factor
includ
day
week
number
abnorm
cbc
locationspecif
hospit
censu
data
less
import
factor
exploit
relationship
develop
mathemat
model
guid
collect
order
strategi
resultsfind
model
minim
wast
due
expir
never
allow
shortag
number
remain
platelet
unit
end
day
never
drop
model
compar
histor
expir
rate
period
model
reduc
expir
rate
annual
platelet
usag
approxim
unit
reduct
equat
approxim
unit
save
expir
annual
depend
platelet
price
differ
region
account
annual
save
per
institut
conclus
knowledg
research
first
use
hospit
wide
data
inform
realtim
donor
recruit
strategi
base
anticip
patient
demand
thaw
plasma
implement
signfic
cost
save
decreas
plasma
wastag
morvarid
moayeri
russel
thorsen
rosalin
antonio
g
insign
ami
decourten
florenc
panganiban
patricia
mckean
cyril
jacquot
sara
bakhtari
ashok
nambiar
ucsf
health
children
nation
medic
center
backgroundcas
studi
plasma
ffp
store
outdat
hour
thaw
collect
function
close
system
may
relabel
thaw
plasma
tp
extend
expir
day
thaw
date
although
coagul
factor
level
decreas
period
remain
hemostat
level
tp
safe
use
vast
major
patient
requir
coagul
support
implement
use
tp
multisit
tertiari
care
system
aim
decreas
cost
minim
wastag
studi
designmethod
massiv
transfus
protocol
instiut
alreadi
allow
use
group
ab
tp
follow
review
literatur
practic
larg
center
transfus
committe
extend
approv
tp
patient
neonat
month
patient
undergo
plasmapheresi
factor
defici
disord
also
note
signific
decreas
quantifi
technologist
time
effort
less
time
expend
follow
thaw
unit
print
inventori
report
reportingrecordkeep
discard
unit
conclus
mani
larg
facil
provid
frequent
order
plasma
unit
ultim
transfus
lead
high
plasma
wastag
rate
due
limit
hr
shelflif
tp
extend
shelflif
use
interchang
ffp
patient
implement
tp
multisit
tertiari
health
care
system
result
sustain
decreas
plasma
wastag
save
thousand
dollar
help
conserv
preciou
resourc
merg
immunohematolog
refer
lab
irl
inventoriesus
technolog
creat
advanc
search
function
alexand
delk
richard
gammon
oneblood
oneblood
inc
backgroundcas
studi
immunohematolog
refer
lab
irl
must
maintain
divers
inventori
antisera
aid
antibodi
identif
antigen
type
rbc
unit
meet
regulatori
requir
current
organ
establish
two
irl
site
independ
inventori
manag
system
although
purpos
maintain
antisera
inventori
organ
storag
access
instruct
use
ifu
irl
develop
synergist
method
organ
store
antisera
coupl
inhous
design
custom
excel
spreadsheet
organ
search
antisera
view
ifu
studi
designmethod
list
similar
differ
construct
best
practic
method
identifi
determin
antisera
could
broadli
classifiedorgan
two
main
categori
rare
bulk
screen
sequenti
lab
assign
number
given
antiserum
categori
rare
sera
b
bulk
sera
dynamicstat
freezer
box
storag
system
interbox
static
intrabox
dynam
determin
best
option
combin
two
inventori
conserv
element
allow
librari
growth
antisera
assign
box
remain
box
may
move
within
box
box
may
move
among
freezer
track
box
locat
movement
within
box
custom
excel
spreadsheet
creat
locat
track
featur
allow
two
differ
storag
method
function
one
spreadsheet
spreadsheet
tab
b
antisera
categori
abo
group
desir
unwant
antibodi
filter
allow
quick
search
appropri
antisera
spreadsheet
also
hyperlink
scan
ifu
resultsfind
sequenti
lab
b
number
assign
new
addit
use
dynamicstat
storag
system
excel
spreadsheet
scan
ifu
hyperlink
use
premerg
system
took
averag
minut
choos
antiserum
obtain
appropri
ifu
postmerg
system
reduc
averag
minut
tabl
conclus
merg
two
irl
antisera
inventori
result
need
innov
creat
inventori
manag
system
advanc
search
function
hyperlink
ifu
process
save
valuabl
technologist
time
organ
antisera
effici
abstract
continu
flash
remov
shelf
statu
updat
databas
unit
alloc
tab
includ
truncat
patient
name
protect
privaci
unit
number
compon
type
alloc
expir
datetim
time
sinc
alloc
flash
alert
unit
expir
hour
xmhla
platelet
tab
provid
patient
name
statu
unit
alloc
trxnxmplat
tab
list
pend
transfus
reaction
platelet
cross
match
report
dashboard
elimin
print
sever
timesshift
lengthi
computergener
report
simplifi
thaw
plasma
inventori
manag
help
decreas
plasma
wastag
conclus
use
inhous
talent
minim
capit
expenditur
design
implement
dynam
webbas
dashboard
manag
blood
product
inventori
across
multisit
transfus
servic
dashboard
stabl
customiz
requir
littl
mainten
initi
built
optim
inventori
display
thaw
plasma
implement
dashboard
expand
includ
allogen
blood
product
past
year
tool
replac
manual
process
monitor
rotat
inventori
directli
help
decreas
plasma
wastag
use
deglycerol
red
blood
cell
hospit
transfus
servic
inventori
manag
ronni
l
hill
jason
corley
lizabeth
ostiguin
us
armi
backgroundcas
studi
region
blood
shortag
document
across
unit
state
winter
holiday
timefram
deglycerol
red
blood
cell
drbc
shown
effect
altern
though
expens
manufactur
studi
look
fiscal
inventori
efficaci
use
drbc
meet
need
transfus
servic
time
blood
shortag
studi
designmethod
three
separ
occas
medium
size
dod
donor
center
use
frozen
blood
inventori
produc
type
drbc
meet
need
two
region
transfus
servic
frozen
red
cell
manufactur
offsit
facil
haemonet
use
low
glycerol
freez
method
frozen
within
six
day
collect
thaw
occur
water
bath
follow
order
posit
neg
januari
posit
neg
februari
neg
februari
deglycerol
occur
site
use
unit
pass
intern
qc
requir
drbc
ship
day
hospit
transfus
servic
allow
day
shelf
life
prior
expir
resultsfind
three
event
support
transfus
servic
blood
center
minimum
inventori
requir
standard
type
red
blood
cell
rbc
posit
rbc
avail
nbe
limit
arriv
next
busi
day
collect
process
time
liquid
rbc
take
approxim
two
day
includ
donor
screen
phlebotomi
compon
process
test
label
drbc
cost
dod
averag
per
unit
produc
distribut
drbc
shorter
shelf
life
day
versu
day
rbc
wash
deglycerol
thu
produc
fewer
transfus
reaction
one
tech
oper
four
deglycerol
four
unit
time
januari
februari
took
one
tech
four
hour
per
iter
eight
unit
includ
thaw
label
pack
shipment
conclus
readili
avail
tradit
rbc
drbc
effect
product
bridg
inventori
gap
small
number
unit
need
due
reduc
inventori
collect
process
whole
blood
compon
take
approxim
two
day
produc
greater
number
unit
timefram
base
drbc
readi
faster
freshli
collect
unit
blood
increas
cost
associ
manufactur
frbc
compens
longer
avail
shelf
life
year
small
conting
suppli
frozen
red
cell
deglycerol
equip
effect
three
occas
ensur
avail
type
red
blood
cell
hospit
transfus
servic
valid
human
antitetanu
toxoid
immunoglobulin
assay
perform
abbott
izeki
butler
karen
leighton
scott
jone
rachel
beddard
qualtex
laboratori
biobridg
global
backgroundcas
studi
plasma
fraction
requir
antitetanu
quantit
test
perform
plasma
sampl
collect
individu
donor
plasma
product
pool
test
serv
qualiti
control
test
help
estim
antibodi
potenc
product
bind
site
human
antitetanu
toxoid
immunoglobulin
liquid
reagent
kit
use
turbidimetr
analyz
aim
optim
valid
human
antitetanu
toxoid
immunoglobulin
liquid
reagent
kit
use
photometr
analyz
studi
designmethod
experi
perform
order
determin
optim
amount
requir
reagent
buffer
latex
reagent
antitetanu
toxoid
immunoglobulin
kit
util
abbott
instrument
precis
new
assay
paramet
determin
test
replic
panel
sampl
three
concentr
tetanu
antibodi
singl
test
run
panel
sampl
creat
spike
appropri
amount
tetanu
antibodi
standard
sodium
citrat
plasma
accuraci
determin
test
seri
sampl
rang
iuml
iuml
tetanu
antibodi
sampl
accuraci
studi
creat
dilut
appropri
amount
tetanu
antibodi
standard
sampl
diluent
reagent
kit
linear
regress
determin
use
accuraci
studi
valu
within
rang
iuml
stabil
sampl
determin
test
sampl
store
c
c
triplic
variou
time
interv
resultsfind
cv
optim
antitetanu
assay
antibodi
level
determin
precis
studi
vari
precis
accept
sinc
cv
sampl
test
mean
valu
sampl
test
accuraci
studi
expect
valu
much
lower
accept
criteria
expect
valu
linear
assay
accept
linear
studi
establish
known
tetanu
concentr
statist
signific
predictor
observ
concentr
sampl
stabil
studi
demonstr
abil
quantit
tetanu
antibodi
concentr
sampl
store
day
c
month
c
conclus
data
present
show
success
optim
human
antitetanu
immunoglobulin
reagent
kit
use
photometr
analyz
valid
studi
optim
assay
demonstr
excel
accuraci
precis
linear
use
sampl
store
day
c
store
one
month
c
deep
dive
audit
intraven
immunoglobulin
use
immun
thrombocytopenia
use
inappropri
jiajia
liu
univers
toronto
backgroundcas
studi
intraven
immunoglobulin
ivig
gener
safe
effect
therapi
immun
thrombocytopenia
itp
suggest
scenario
rapid
increas
platelet
count
desir
first
line
therapi
steroid
contraind
due
concern
regard
advers
effect
cost
resourc
avail
ivig
request
form
implement
jurisdict
track
util
appropri
recent
audit
request
form
four
academ
institut
found
lack
complianc
form
requir
inadequ
document
efficaci
led
author
conclud
use
ivig
broadli
inappropri
shih
et
al
aim
conduct
extens
chart
review
patient
receiv
ivig
itp
institut
assess
appropri
use
studi
designmethod
conduct
retrospect
chart
review
patient
itp
receiv
ivig
institut
april
march
local
research
ethic
board
approv
obtain
resultsfind
patient
receiv
ivig
itp
smh
studi
period
total
uniqu
ivig
infus
common
indic
ivig
within
current
accept
guidelin
activ
bleed
preoper
antepartum
care
platelet
count
less
contraind
corticosteroid
addit
indic
still
fell
within
accept
guidelin
recommend
includ
patient
arterialven
thromboembol
risk
thereof
requir
initi
antithrombot
therapi
patient
requir
myelosuppress
chemotherapi
indic
fell
outsid
guidelin
includ
use
ivig
diagnost
challeng
etiolog
thrombocytopenia
unclear
use
prior
intern
travel
patient
difficulttotreat
chronic
itp
despit
platelet
count
x
patient
receiv
ivig
like
diagnosi
itp
transfus
investig
altern
explan
thrombocytopenia
three
patient
refractori
therapi
itp
depend
regular
ivig
infus
infus
consist
day
remaind
infus
consist
receiv
patient
evid
partial
remiss
first
dose
ivig
gener
well
toler
infus
reaction
mitig
use
corticosteroid
antipyret
andor
antihistamin
conclus
found
institut
use
ivig
itp
gener
appropri
care
consid
even
case
meet
current
guidelin
recommend
believ
ivig
remain
import
treatment
itp
particularli
age
popul
preval
condit
complic
bleed
risk
increas
detail
util
knowledg
data
inquiri
requir
develop
tool
polici
enhanc
appropri
ivig
use
multipl
set
believ
opportun
promot
administr
singl
dose
minim
unnecessari
util
ivig
amongst
hematologist
manag
itp
process
improv
crossmatch
bench
ergonom
janet
dornfeld
shengchung
cheng
ann
eggebrecht
beth
greer
savannahsu
rondeau
brian
rognholt
beth
taylor
mayo
clinic
backgroundcas
studi
mission
institut
reduc
risk
workrel
injuri
accordingli
year
ergonom
survey
undertaken
compon
gener
depart
laboratori
medicin
patholog
safeti
audit
survey
identifi
potenti
musculoskelet
risk
suggest
redesign
crossmatch
bench
studi
designmethod
seven
item
ergonom
survey
work
environ
sent
staff
member
earli
februari
twentytwo
technologist
respond
respons
rate
tabl
report
survey
item
respons
resultsfind
problemat
area
avail
workspac
respond
indic
workspac
size
insuffici
chair
fix
height
bench
problemat
problem
note
difficulti
climb
chair
back
chair
hold
chosen
height
laboratori
lean
team
oper
support
group
task
aid
bench
redesign
choos
product
improv
workspac
goal
design
layout
streamlin
test
workflow
better
util
lab
space
includ
plasma
thaw
sink
space
elimin
dead
space
configur
new
workspac
guid
survey
find
adjust
height
workstat
recommend
replac
fix
height
bench
work
facil
design
contactor
purchas
adjust
bench
plan
addon
cabinet
shop
work
bench
assembl
site
allow
bench
top
layout
determin
instal
cabinet
shop
addon
drawer
suppli
pull
breadboard
write
surfac
opportun
assembl
site
streamlin
process
instal
result
minim
disrupt
test
conclus
survey
effect
identifi
work
area
improv
employe
comment
posit
new
workstat
effect
assess
follow
use
origin
survey
assess
success
project
retrospect
studi
emerg
depart
initi
type
screen
test
patient
transfus
test
sandra
lamm
neil
bang
kimberli
sanford
vcu
health
system
virginia
commonwealth
univers
backgroundcas
studi
type
screen
test
often
order
patient
present
emerg
depart
ed
patient
histor
type
second
sampl
drawn
addit
phlebotomi
type
confirm
patient
need
transfus
red
blood
cell
rbc
test
second
phlebotomi
ineffici
use
resourc
time
studi
designmethod
part
perform
improv
initi
transfus
medicin
perform
retrospect
studi
order
initi
ed
determin
test
subsequ
follow
transfus
blood
product
patient
stratifi
ed
depart
time
draw
tsd
transfus
hour
hour
hour
second
sampl
requir
resultsfind
total
order
initi
ed
time
period
patient
subsequ
transfus
type
blood
product
within
hour
tsd
patient
subsequ
transfus
type
blood
product
within
hour
tsd
total
patient
requir
second
sampl
patient
requir
second
sampl
subsequ
transfus
type
blood
product
within
hour
tsd
subsequ
transfus
type
blood
product
within
hour
tsd
conclus
routin
order
test
effici
use
resourc
time
mani
patient
subsequ
transfus
ultim
unnecessari
second
sampl
collect
test
patient
subsequ
transfus
within
hour
tsd
amount
estim
unnecessari
patient
charg
approxim
nurs
hour
phlebotomi
six
month
period
antid
alloimmun
versu
rh
immun
globulin
detect
work
blood
bank
transfus
medicin
servic
bbtm
margaret
diguardo
debra
berri
yunchuan
delor
mo
gay
wehrli
univers
virginia
health
system
children
nation
medic
center
backgroundcas
studi
institut
healthcar
improv
tripl
aim
incorpor
enhanc
patient
satisfact
provid
high
qualiti
safe
care
toward
goal
bbtm
charg
commun
obstetr
physician
ob
patient
antibodi
specif
associ
hemolyt
diseas
fetusnewborn
risk
thu
antid
detect
femal
childbear
age
critic
determin
whether
repres
rh
immun
globulin
rhig
alloimmun
alloantid
review
patient
electron
health
record
ehr
help
quickli
identifi
rhig
administr
document
miss
easi
assum
presenc
alloantid
rhd
alloimmun
impact
mom
fetu
newborn
futur
pregnanc
therefor
without
nation
comprehens
health
inform
exchang
hie
system
imper
investig
beyond
onsit
ehr
whether
patient
receiv
rhig
outsid
hospit
oh
report
irb
approv
exempt
case
seri
detect
work
reveal
rhig
administr
oh
studi
designmethod
two
month
time
period
antid
identifi
four
pregnant
women
review
ehr
reveal
histori
abstract
rhig
administr
subsequ
direct
commun
obstetrician
ob
reveal
histori
rhig
base
patient
home
address
bbtm
nearbi
oh
contact
primari
care
physician
list
ehr
resultsfind
investig
beyond
ehr
ob
reveal
four
patient
receiv
discontinu
prenat
care
present
multipl
site
phone
call
bbtm
oh
histori
one
rhig
administr
within
preced
three
month
found
patient
bbtm
record
ehr
amend
reflect
presenc
passiv
antid
due
rhig
rather
alloantid
chang
also
directli
commun
ob
care
patient
conclus
new
antid
identifi
pregnant
femal
investig
requir
determin
whether
passiv
rhig
versu
alloantid
neither
ehr
patient
histori
ob
reveal
rhig
histori
remain
patient
best
interest
investig
phone
call
oh
reveal
histori
rhig
administr
four
patient
find
commun
critic
inform
help
enhanc
qualiti
safeti
patient
ensur
subsequ
rhig
administr
indic
institut
futur
strategi
avoid
similar
situat
includ
expand
nation
hie
critic
inform
bbtm
histori
allergi
histori
expand
use
wallets
patient
identif
card
rhig
alloantibodi
histori
audit
massiv
transfus
protocol
colleen
aronson
elizabeth
halperin
sharon
brein
mona
papari
acl
laboratori
advoc
hospit
advoc
health
care
itxm
backgroundcas
studi
larg
midwest
hospit
system
level
trauma
site
evalu
audit
massiv
transfus
protocol
mtp
possibl
real
time
audit
impract
due
unpredict
event
search
internet
found
exampl
new
zealand
post
process
evalu
share
team
start
point
adjust
system
specif
prioriti
start
audit
initi
mtp
need
determin
event
often
start
verbal
request
follow
either
downtim
comput
order
studi
designmethod
transfus
servic
ts
determin
sourc
truth
mtp
event
track
sheet
creat
captur
patient
demograph
start
stop
time
number
type
product
issu
wastag
pass
onto
nurs
qualiti
staff
use
track
form
patient
chart
enter
event
error
manag
data
base
focus
event
focus
event
built
includ
patient
demograph
inform
track
form
well
event
call
surgeri
emerg
ed
labor
deliveri
l
etc
type
event
use
tranexam
acid
txa
calcium
chlorid
cacl
temperatur
monitor
pre
post
lab
result
trial
start
month
data
evalu
contain
event
resultsfind
equal
number
event
initi
ed
male
patient
involv
time
time
patient
expir
trauma
type
major
caus
case
involv
gi
bleed
obstetr
case
see
chart
lowest
hemoglobin
hgb
found
averag
post
hgb
averag
ratio
red
blood
cell
rbc
plasma
well
rbc
platelet
plt
cryoprecipit
cryo
also
determin
target
found
rbc
plasma
rbc
plt
rbc
cryo
use
txa
cacl
util
case
conclus
although
data
short
period
time
point
sever
opportun
improv
use
mtp
gi
case
previous
understood
open
new
group
peopl
educ
understand
mtp
process
need
low
use
txa
need
evalu
alreadi
start
convers
drug
store
access
mtp
process
product
ratio
number
suspect
data
avail
much
easier
speak
issu
look
improv
process
expand
level
ii
trauma
site
system
routin
evalu
share
site
autom
report
significantli
reduc
turnaround
time
rbc
antibodi
alert
jessica
l
dillon
jodi
barna
donald
e
ulinski
nanci
dunbar
dartmouth
hitchcock
medic
center
dartmouthhitchcock
medic
center
backgroundcas
studi
clinic
signific
antibodi
promptli
clearli
commun
patient
healthcar
team
avoid
potenti
transfus
delay
blood
avail
complic
incompat
transfus
institut
newli
identifi
clinic
signific
antibodi
immedi
result
electron
medic
record
emr
interpret
comment
also
enter
transfus
medicin
servic
tm
physician
antibodi
workup
review
may
week
antibodi
identifi
comment
describ
antibodi
i
identifi
indic
need
crossmatch
compat
blood
alert
clinician
possibl
delay
provid
crossmatch
unit
sinc
clinician
may
alway
review
result
tm
physician
also
simultan
add
allergi
red
blood
cell
alert
patient
emr
time
interpret
comment
enter
studi
designmethod
juli
implement
autom
report
reduc
turnaround
time
tat
entri
allergi
alert
report
contain
detect
red
cell
antibodi
prior
hour
provid
tm
physician
daili
morn
round
monday
friday
manual
entri
allergi
alert
studi
describ
three
month
comparison
autom
report
intervent
evalu
tat
allergi
alert
entri
emr
age
abstract
resultsfind
august
novemb
preimplement
newli
identifi
clinic
signific
antibodi
result
patient
compar
patient
month
august
novemb
postimplement
tat
allergi
alert
entri
period
shown
tabl
observ
allergi
comment
perform
within
hour
postimplement
period
versu
preintervent
use
new
process
nearli
alert
enter
emr
within
hour
antibodi
result
none
entri
miss
conclus
signific
improv
tat
allergi
comment
entri
follow
implement
autom
report
project
illustr
inform
technolog
leverag
facilit
time
commun
antibodi
identif
blood
bank
verbal
tool
implement
cardiovascular
surgeri
rita
louie
shailesh
macwan
nanci
nikoli
arlin
stein
janel
richardson
manju
bagu
lennart
logdberg
alexand
indrikov
vishesh
chhibber
sherri
shariatmadar
north
shore
univers
hospit
northwel
health
backgroundcas
studi
institut
tertiari
care
facil
perform
cardiovascular
surgeri
cv
increas
healthcar
system
cv
integr
transfus
support
patient
includ
preoper
prepar
prbc
accord
maximum
surgic
blood
order
schedul
addit
blood
compon
issu
order
place
decemb
addit
written
order
submit
blood
bank
via
pneumat
tube
system
without
commun
report
event
result
delay
blood
transfus
examin
process
close
identifi
opportun
improv
collabor
cv
blood
bank
implement
new
workflow
process
enhanc
commun
cv
team
reduc
turnaround
time
improv
patient
safeti
studi
designmethod
open
discuss
collabor
blood
bank
cv
nurs
team
map
process
use
flowchart
addit
blood
order
cv
identifi
bottleneck
brainstorm
solut
verbal
cv
order
process
form
implement
improv
commun
cv
blood
bank
solidifi
commun
includ
time
order
patient
identifi
caller
identif
order
prescrib
staff
receiv
order
quantiti
kind
product
order
mode
order
deliveri
anticip
futur
order
read
back
also
document
verif
order
blood
bank
staff
immedi
process
order
wait
written
order
arriv
upon
receipt
written
order
blood
issu
follow
plandocheckact
transfus
safeti
offic
review
order
follow
paramet
numbertyp
product
turn
around
time
tat
wastagereturn
product
overal
efficaci
sinc
implement
process
resultsfind
signific
improv
note
commun
tat
implement
process
describ
period
blood
bank
receiv
verbal
order
vari
product
combin
tabl
repres
averag
turnaround
time
issu
blood
product
conclus
introduct
verbal
order
tool
cv
streamlin
blood
order
process
lead
increas
effici
lower
tat
effect
commun
team
transfus
servic
key
time
provis
blood
product
critic
patient
challeng
blood
type
test
multipli
transfus
sickl
cell
diseas
patient
jayanna
slayten
traci
ingl
heather
vaught
indiana
univers
health
indiana
univers
health
iu
health
backgroundcas
studi
report
midwestern
univers
transfus
servic
challeng
obtain
correct
blood
type
rbc
exchang
sickl
cell
diseas
scd
patient
test
primari
test
method
solidphas
red
cell
adher
analyz
echo
immucor
norcross
ga
echo
oper
manual
chapter
appendix
state
warn
galileo
echo
reliabl
detect
hemagglutin
reaction
grade
less
tube
methodolog
galileo
echo
gener
interpret
mixedfield
mixedfield
reaction
interpret
posit
neg
equivoc
report
challeng
analyz
limit
impact
assign
correct
blood
type
multipli
transfus
scd
patient
studi
designmethod
two
scd
initi
test
echo
neg
howev
patient
histor
posit
patient
receiv
rbc
exchang
transfus
neg
red
blood
cell
day
previous
repeat
test
sampl
complet
vision
ortho
clinic
diagnost
raritan
nj
neo
immucor
norcross
ga
standard
aborh
manual
test
antia
antib
antid
seri
antid
seri
cell
b
cell
immucor
norcross
ga
repeat
test
compar
verifi
patient
aborh
type
result
enter
comput
system
allow
assign
patient
aborh
type
electron
crossmatch
resultsfind
tabl
summar
initi
repeat
test
two
patient
sampl
although
echo
fail
interpret
flag
blood
type
mixedfield
method
identifi
transfus
neg
blood
detect
mixedfield
type
fail
interpret
aborh
type
determin
ntd
vision
manual
aborh
type
yield
easiest
mixedfield
interpret
macroscop
conclus
result
agre
find
summer
et
al
transfus
report
challeng
detect
mixedfield
use
echo
compar
improv
detect
autom
gel
column
agglutin
sampl
test
multipl
autom
manual
aborh
method
expect
mixedfield
detect
failur
echo
detect
mixedfield
acknowledg
manufactur
risk
facil
may
mistyp
aborh
histor
aborh
compar
avoid
risk
may
appropri
retyp
first
time
scd
patient
method
rather
echo
avoid
challeng
consist
summer
account
region
distribut
mani
larg
hospit
act
region
hub
redistribut
may
appear
optim
inventori
base
odr
bsr
hypothes
crude
key
perform
indic
kpi
requir
redevelop
studi
designmethod
kpi
redevelop
occur
larg
tertiari
care
hospit
blood
bank
canada
respons
transfus
region
provinc
respect
rbc
suppli
inventori
disposit
data
retrospect
assess
februari
baselin
period
demanddriven
inventori
plan
polici
ddip
institut
assess
implement
optim
rbc
reorder
quantiti
base
differ
histor
maximum
minimum
rbc
inventori
weekday
would
lead
blood
shortag
shelflif
inventori
sli
chosen
main
surrog
marker
assess
effici
suppli
chain
process
calcul
differ
age
blood
transfus
abt
receiv
abr
iter
simul
model
r
statist
softwar
perform
optim
sli
postimplement
period
june
resultsfind
model
predict
observ
rbc
disposit
simul
optim
sli
found
occur
optim
set
kpi
abo
blood
group
tabl
led
reduct
observ
overal
sli
day
vs
day
p
odr
vs
bsr
significantli
increas
postimplement
period
conclus
optim
use
simul
model
multipl
factor
bsr
odr
led
effici
gain
larg
tertiari
care
hospit
blood
bank
hospit
blood
bank
use
integr
approach
set
kpi
optim
suppli
chain
approach
requir
valid
blood
bank
jurisdict
requir
hospit
make
reason
attempt
notifi
patient
patient
physician
counsel
patient
offer
test
hospit
must
maintain
record
lookback
notif
part
patient
medic
record
paper
record
lookback
notif
less
access
electron
record
greater
risk
damag
lost
facilit
lookback
process
reduc
paper
document
sought
use
electron
medic
record
emr
perform
document
notif
studi
designmethod
repres
transfus
medicin
tm
inform
technolog
work
togeth
defin
minimum
optim
emr
solut
minim
complet
paper
packet
could
scan
emr
solut
advantag
term
eas
use
process
control
transpar
desir
optim
function
includ
abil
send
letter
emr
document
control
origin
commun
may
alter
opportun
patient
physician
electron
sign
return
respons
letter
form
templat
individu
abil
track
notif
sent
receiv
emr
system
institut
epic
epic
system
corp
verona
wi
function
call
letter
capac
task
seri
five
templat
develop
hiv
hcv
letter
physician
respons
form
physician
return
transfus
servic
blank
letter
templat
use
special
tailor
letter
templat
open
within
patient
emr
demograph
inform
automat
popul
epic
elimin
mani
possibl
cleric
error
blood
product
transfus
eg
rbc
plasma
select
dropdown
menu
date
transfus
manual
enter
sender
complet
letter
rout
patient
physician
show
automat
instantli
electron
basket
well
patient
emr
physician
may
electron
complet
return
respons
form
within
epic
print
return
form
fax
resultsfind
januari
decemb
thirtyf
notif
sent
physician
use
epic
letter
fourteen
respond
epic
notif
five
use
provid
electron
respons
form
case
time
mail
handdeliv
paper
notif
avoid
remain
case
requir
followup
paper
notif
electron
letter
remain
perman
easili
access
document
transfus
servic
first
notifi
physician
conclus
lookback
notif
within
emr
make
complianc
govern
requir
transpar
record
access
caregiv
patient
assessor
secondarili
effici
may
improv
reduc
need
print
maildeliv
letter
evalu
order
practic
oper
room
impact
product
wastag
alexandra
budhai
denden
benabdessadek
annu
georg
alexandra
jimenez
westchest
medic
center
new
york
blood
center
backgroundcas
studi
blood
product
wastag
issu
mani
hospit
aim
address
identifi
highest
rate
wastag
within
hospit
studi
assess
appropri
product
order
util
understand
impact
wastag
studi
designmethod
data
product
order
issu
return
two
month
analyz
hospit
cpoe
product
requisit
form
use
collect
data
surgic
procedur
number
order
unit
compar
hospit
maximum
surgic
blood
order
schedul
msbo
trend
inappropri
order
product
physician
evalu
resultsfind
total
order
review
approxim
product
issu
found
physician
order
within
guidelin
msbo
case
issu
product
return
blood
bank
case
observ
percentag
product
order
use
compar
product
order
return
cardiac
surgeri
nearli
equal
addit
product
order
csection
use
albeit
order
frequenc
significantli
lower
cardiac
case
conclus
data
analyz
demonstr
major
surgeon
adher
institut
msbo
guidelin
note
surgeon
request
product
issu
invas
procedur
rapid
exsanguin
possibl
analysi
reveal
hospit
msbo
allow
excess
blood
order
surgic
procedur
msbo
updat
reduc
suggest
maximum
product
order
gener
data
impli
blood
product
wastag
due
order
practic
surgeon
larger
period
surgic
blood
order
practic
analyz
detect
blood
product
order
util
wastag
trend
subspecialti
backgroundcas
studi
visionv
r
visionv
r
max
ortho
diagnost
raritan
new
jersey
idmt
tm
gel
cardbas
autom
immunohematolog
analyz
market
small
medium
highvolum
type
screen
per
day
blood
bank
respect
laboratori
serv
larg
multispecialti
academ
hospit
receiv
specimen
per
day
need
replac
three
provu
analyz
prior
avail
visionv
r
max
implement
three
visionv
r
analyz
work
exist
neov
r
echov
r
immucor
inc
norcross
georgia
recent
multicent
field
applic
trial
visionv
r
report
mean
turnaround
time
tat
abo
rh
type
aborh
minut
respect
object
studi
determin
visionv
r
tat
routin
daili
highvolum
practic
studi
designmethod
one
visionv
r
oper
fiveweek
period
phase
two
addit
analyz
brought
servic
phase
ii
tat
defin
time
order
receiv
instrument
test
complet
avail
review
threecel
screen
aborh
tat
number
visionv
r
antibodi
panel
collect
nineweek
period
tat
screen
use
tat
screen
rate
determin
step
test
perform
use
inservic
analyz
routin
patient
sampl
train
technologist
sampl
deliber
batch
place
analyz
base
volum
flow
work
time
resultsfind
high
volum
condit
laboratori
three
visionv
r
analyz
mean
tat
longer
larger
standard
deviat
sd
publish
trial
result
transfus
vol
supplement
abstract
phase
visionv
r
perform
panel
phase
ii
visionv
r
perform
visionv
r
panel
conclus
visionv
r
analyz
use
high
volum
condit
suitabl
visionv
r
max
balanc
test
menu
includ
abil
perform
select
cell
panel
tat
use
three
analyz
satisfactori
larg
standard
deviat
indic
opportun
remain
improv
tat
workflow
improv
west
nile
viru
emerg
zika
viru
nationwid
survey
regul
keep
blood
suppli
safe
avail
falisha
atwel
john
roback
ronald
arkin
michael
bartlett
robert
geiger
jaxk
reev
univers
georgia
emori
hospit
backgroundcas
studi
emerg
zikv
unit
state
import
assess
fda
respons
time
provid
guidanc
ensur
safeti
avail
blood
product
face
newli
emerg
infecti
diseas
research
compar
respons
fda
west
nile
viru
wnv
zika
viru
zikv
outbreak
evalu
current
prepared
studi
designmethod
literatur
review
conduct
analyz
fda
respons
time
wnv
crisi
determin
effect
effici
research
survey
perform
determin
donor
histori
questionnair
dhq
adequ
screen
donor
zikv
sole
prevent
method
per
februari
guidanc
industri
recommend
donor
screen
deferr
product
manag
reduc
risk
transfusiontransmiss
zika
viru
determin
current
regulatori
practic
includ
august
guidanc
industri
revis
recommend
reduc
risk
zika
viru
transmiss
blood
blood
compon
perceiv
effect
effici
face
current
zikv
outbreak
survey
monkey
use
particip
anonym
email
weblink
sent
member
aabb
scabb
seabb
person
network
target
respons
rate
particip
selfselect
deselect
base
inclus
exclus
criteria
list
consent
letter
resultsfind
literatur
review
reveal
fda
respons
slow
wnv
outbreak
zikv
respons
effici
thu
far
total
particip
respond
survey
respons
rate
statist
particip
agreement
fda
decis
perform
test
df
null
hypothesi
vs
altern
true
mean
overal
particip
favor
opinion
fda
decis
statist
whether
particip
differ
level
demograph
variabl
region
profess
year
experi
answer
significantli
differ
one
way
anova
model
use
likertscal
question
respons
continu
fstatist
pvalu
null
hypothesi
level
explanatori
variabl
mean
respons
variabl
signific
differ
year
experi
profess
variabl
particip
region
determin
unreli
due
undefin
state
region
list
conclus
research
reveal
industri
expert
conclud
current
system
dhq
fda
guidanc
document
issu
time
adequ
backgroundcas
studi
evalu
new
instrument
solut
pretransfus
test
import
consid
oper
impact
system
lab
varieti
oper
perform
system
metric
evalu
determin
impact
includ
test
workflow
hand
time
autom
time
studi
designmethod
studi
involv
current
state
futur
state
comparison
test
process
instrument
ortho
provuev
r
pv
manual
test
vs
instrument
ortho
visionv
r
ov
data
collect
method
includ
direct
observ
time
studi
interview
pv
bench
perform
type
screen
ts
pv
manual
abidselect
cell
panel
gel
test
test
cord
blood
cb
dat
unit
confirm
uc
patient
type
confirm
pc
crossmatch
xm
etc
done
manual
tube
futur
state
incorpor
ov
ts
abid
uc
evalu
state
cycl
time
ct
averag
base
run
cycl
ct
compris
metric
instrument
time
standbi
time
st
labor
time
lt
st
may
compris
compon
time
could
util
walkaway
time
vigil
time
vt
requir
oper
presenc
oper
action
autom
instrument
vt
cycl
measur
instrument
access
unavail
instrument
daili
mainten
dm
ct
evalu
well
similarli
time
manual
tube
test
process
use
metric
repetit
activ
within
process
uc
xm
time
per
individu
process
captur
multipli
per
unit
resultsfind
tabl
provid
detail
metric
current
state
futur
state
process
tube
base
test
time
follow
pc
xm
cb
dat
implement
futur
state
averag
min
lt
vt
save
sampl
load
ts
equat
labor
reduct
current
state
improv
tat
ts
achiev
futur
state
move
manual
abid
autom
process
result
lt
reduct
averag
min
continu
walkaway
time
achiev
autom
abid
uc
less
impact
labor
time
minim
differ
howev
allow
focu
consist
qualiti
metric
conclus
base
metric
evalu
compar
current
state
futur
state
ov
demonstr
improv
lab
oper
labor
requir
result
tat
deliveri
opportun
exist
autom
workflow
test
still
manual
perform
backgroundcas
studi
high
throughput
effici
autom
serolog
test
crucial
workflow
blood
bank
test
type
screen
sampl
per
day
erytrav
r
grifol
fullyautom
walkaway
analyz
util
gel
card
pretransfus
test
blood
bank
valid
implement
use
erytrav
r
abod
type
antibodi
screen
identif
patient
sampl
replac
solid
phase
test
platform
blood
bank
also
valid
autom
donor
unit
retyp
instrument
bidirect
interfac
blood
bank
lab
inform
system
li
hcll
tm
hemocar
life
line
mediwar
instrument
valid
implement
done
conjunct
softwar
version
upgrad
hcll
tm
interfac
system
chang
maestro
tm
studi
designmethod
correl
test
erytrav
r
result
manual
tube
test
peg
iat
refer
method
perform
patient
sampl
abod
type
antibodi
screen
least
posit
antibodi
screen
known
antibodi
specif
fortytwo
rbc
unit
also
test
abod
confirm
calcul
concord
sensit
specif
perform
precis
studi
also
done
interfac
test
erytrav
r
hcll
hospit
inform
system
use
maestro
tm
interfac
system
perform
valid
resultsfind
concord
result
method
obtain
patient
donor
sampl
test
concord
sampl
posit
antibodi
screen
obtain
method
clinic
signific
antibodi
detect
system
erytrav
r
gave
sensit
specif
precis
studi
show
method
gave
type
screen
result
sampl
differ
test
event
valid
li
upgrad
interfac
system
chang
bidirect
interfac
hcll
tm
establish
instrument
oper
lab
month
conclus
erytrav
r
found
reliabl
accur
handl
high
workload
lab
user
found
instrument
easi
use
henc
train
profici
compet
user
achiev
manag
valid
instrument
straightforward
major
challeng
delay
implement
experienc
blood
bank
attribut
concurr
occur
li
upgrad
migrat
data
integr
system
postimplement
workflow
assess
would
ideal
perform
ensur
instrument
use
full
potenti
implement
systemwid
platelet
inventori
report
optim
platelet
util
reduc
unit
wastag
elli
landolfi
craig
fletcher
peter
millward
beaumont
hospit
beaumont
health
system
backgroundcas
studi
suffici
number
blood
compon
avail
meet
routin
emerg
hospit
need
must
assur
minim
outdat
scarc
expens
blood
compon
inher
challeng
platelet
unit
short
shelflif
report
result
qualiti
improv
project
implement
custom
computer
platelet
inventori
report
design
mitig
common
caus
platelet
wastag
institut
high
platelet
outdat
rate
report
includ
blood
type
product
code
unit
number
respect
product
attribut
supplier
avail
statu
platelet
unit
hospit
locat
system
blood
bank
receiv
morn
fax
report
facilit
transfer
unit
prior
expir
adjust
readili
made
product
order
supplier
studi
designmethod
studi
conduct
hospitalbas
blood
bank
base
avail
platelet
inventori
wastag
qualiti
data
report
went
live
octob
qualiti
data
review
august
decemb
collect
data
analyz
use
descript
statist
method
resultsfind
data
indic
platelet
wastag
compris
total
receiv
platelet
wast
platelet
unit
due
expir
reason
includ
fail
visual
inspect
blood
dispens
use
wast
floor
potenti
tube
station
problem
shortdat
unit
transfer
blood
bank
anoth
facil
mean
monthli
wast
platelet
unit
month
preimplement
report
unit
compar
unit
month
postimplement
unit
month
postimplement
wastag
rate
improv
wast
yearli
plateletstot
receiv
yearli
platelet
unit
year
report
implement
postimplement
rate
see
tabl
importantli
occur
despit
greater
increas
platelet
inventori
result
cost
save
period
conclus
studi
limit
includ
restrict
data
collect
one
campu
option
transfer
expir
platelet
unit
anoth
blood
bank
avail
particip
sister
hospit
would
interest
see
effect
report
hospit
lower
transfus
rate
differ
order
practic
asid
lower
platelet
wastag
within
year
implement
addit
benefit
report
includ
facilit
order
blood
supplier
cornerston
success
inventori
manag
plan
includ
daili
inventori
monitor
ideal
coordin
systemwid
effort
share
platelet
unit
shown
achiev
end
facilit
custom
daili
platelet
inventori
report
efficaci
easili
adapt
tool
demonstr
gain
valeri
hall
lisa
mari
button
lori
scanlanhanson
karen
koch
janet
finley
deepi
goyal
camil
van
buskirk
mayo
clinicrochest
mayo
clinic
mayo
clinic
rochest
backgroundcas
studi
transfus
emerg
depart
level
trauma
center
order
use
handwritten
order
form
transfus
lab
tl
manag
team
medic
director
met
emerg
depart
ed
leadership
resourc
defin
need
success
electron
blood
transfus
system
handwritten
order
form
sever
potenti
error
sourc
could
lead
delay
fill
order
pend
correct
best
circumst
could
lead
transfus
wrong
patient
wrong
product
error
detect
potenti
error
sourc
includ
cleric
error
involv
patient
name
medic
record
number
mrn
write
two
differ
name
order
form
two
locat
record
patient
name
two
product
type
order
one
form
requir
one
product
type
per
order
prioriti
indic
stat
routin
includ
prescrib
callback
inform
number
ed
report
transfus
relat
event
events
transfus
studi
designmethod
electron
order
ed
implement
march
st
transfus
order
gener
ed
electron
unless
case
electron
downtim
system
electron
fill
patient
name
mrn
control
type
blood
product
order
requir
order
prioriti
provid
servic
contact
inform
design
accommod
transfus
order
need
adult
pediatr
patient
pediatr
patient
transfus
order
three
critic
field
identifi
requir
order
process
includ
patient
weight
product
volum
infus
rate
electron
system
design
order
submit
unless
critic
field
complet
resultsfind
electron
order
system
place
year
april
march
time
instanc
blood
order
unintend
patient
previou
patient
medic
record
access
rather
intend
patient
medic
record
instanc
cleric
error
name
misspel
mrn
transposit
etc
miss
servic
contact
inform
miss
order
prioriti
inform
one
product
type
order
singl
order
two
patient
name
one
order
electron
order
also
provid
place
transfusionist
chart
lead
increas
transfus
document
complianc
prior
electron
order
implement
unit
transfus
ed
chart
patient
medic
record
transfus
chart
howev
first
full
year
electron
transfus
order
capabl
transfus
chart
patient
medic
record
conclus
electron
order
ed
essenti
elimin
order
error
area
result
less
rework
technologist
physician
allow
order
process
quickli
tl
result
faster
turnaround
time
improv
overal
qualiti
transfus
order
electron
order
reduc
influenc
human
factor
order
placement
provid
ad
benefit
specif
order
chart
implement
blood
bank
autom
attend
lok
tse
gerald
motta
maria
aguad
brigham
women
hospit
backgroundcas
studi
blood
bank
receiv
numer
nonemerg
phone
call
daili
basi
call
occupi
valuabl
time
also
made
line
unavail
real
emerg
occur
hospit
categor
level
trauma
center
inpati
bed
oper
room
propos
implement
blood
bank
autom
attend
recommend
decreas
phone
call
minim
error
due
distract
phone
call
free
team
member
perform
duti
direct
line
design
request
trauma
cooler
massiv
transfus
protocol
mtp
emerg
releas
blood
product
studi
designmethod
first
step
categor
type
phone
call
receiv
blood
bank
creat
phone
log
data
collect
analyz
four
week
blood
bank
collabor
nurs
hospit
administr
staff
telecommun
team
evalu
possibl
implement
autom
attend
minim
phone
call
import
maintain
patient
safeti
qualiti
servic
time
autom
attend
consist
option
urgent
trauma
emerg
releas
mtp
obstetr
hemorrhag
emerg
releas
option
verbal
verbal
order
cooler
set
option
staff
speak
staff
member
instruct
also
given
specimen
inquiri
product
avail
hospit
inform
system
resultsfind
data
tabl
show
incom
call
fall
three
categori
specimen
inquiri
product
order
inquiri
inquiri
call
nurs
staff
inquir
length
wait
time
blood
product
specimen
avail
overal
decreas
phone
call
implement
autom
attend
conclus
implement
autom
attend
blood
bank
team
abl
identifi
respond
accordingli
effici
urgent
request
verbal
phone
order
decreas
phone
call
freed
team
member
perform
critic
task
depart
improv
detect
wrong
blood
tube
error
implement
twosampl
blood
type
verif
process
ariana
king
steven
zibrat
geoffrey
wool
angela
treml
univers
chicago
medicin
univers
chicago
backgroundcas
studi
organ
use
blood
bank
identif
bbid
band
system
pretransfus
test
detect
wrong
blood
tube
error
wbit
addit
type
screen
result
compar
patient
histor
record
specimen
retyp
second
technologist
histor
result
avail
bbid
band
prone
cleric
error
excess
specimen
reject
believ
miss
wbit
error
blood
bank
account
reject
clinic
laboratori
sampl
yet
compris
total
laboratori
volum
reject
blood
bank
sampl
due
bbid
band
issu
wbit
error
rate
detect
bbidbas
system
studi
designmethod
multidisciplinari
workgroup
form
review
data
best
practic
decis
made
discontinu
bbid
band
implement
twosampl
verif
process
keep
standard
new
laboratori
test
order
creat
emr
system
embed
exist
order
provid
prompt
order
abo
verif
test
previou
aborh
type
result
found
educ
provid
clinic
staff
form
inservic
email
annual
compet
complet
electron
new
process
went
live
septemb
resultsfind
five
month
follow
implement
four
wbit
error
detect
second
sampl
may
miss
use
bbid
band
system
improv
detect
reveal
wbit
error
rate
three
time
nation
averag
new
system
reject
blood
bank
sampl
decreas
averag
reject
laboratori
sampl
decreas
implement
new
process
produc
net
save
conclus
replac
bbid
band
system
twosampl
verif
success
improv
abil
detect
wbit
error
among
patient
lack
histor
blood
bank
result
addit
discontinu
bbid
system
decreas
incid
cleric
error
unnecessari
specimen
reject
also
save
money
organ
next
step
blood
bank
laboratori
qualiti
leader
partner
nurs
leadership
drive
wbit
error
incid
addendum
final
cultur
result
use
student
test
determin
whether
statist
signific
differ
mean
tat
result
addendum
entri
postimplement
period
compar
preimplement
period
resultsfind
preimplement
period
cultur
residu
product
suspect
str
tat
final
cultur
result
entri
patient
emr
day
mean
day
sd
postimplement
period
cultur
residu
product
suspect
str
tat
final
cultur
result
entri
patient
emr
day
mean
day
sd
posit
cultur
either
studi
period
conclus
studi
demonstr
tat
document
improv
use
inform
technolog
notifi
transfus
medicin
physician
result
avail
document
patient
emr
improv
turnaround
time
type
screen
sampl
michaelen
hultman
marcu
holm
johnathan
bakst
gunta
musa
angela
treml
univers
chicago
medicin
univers
chicago
backgroundcas
studi
primari
test
perform
blood
bank
regard
pretransfus
test
type
screen
ty
current
target
institut
blood
bank
minut
turnaround
time
tat
april
blood
bank
forc
move
temporari
locat
due
build
construct
necessit
switch
autom
solid
phase
methodolog
manual
gel
method
averag
number
outlier
increas
tat
analysi
repres
one
week
sampl
per
month
show
increas
outlier
per
month
per
month
averag
monthli
ty
sampl
perform
number
improv
even
upon
return
origin
facil
studi
designmethod
two
ortho
clinic
diagnost
visionv
r
analyz
raritan
nj
purchas
blood
bank
instrument
set
bidirect
interfac
allow
sampl
continu
load
without
manual
order
test
batch
test
elimin
allow
sampl
run
receiv
result
auto
interpret
transmit
laboratori
inform
system
li
base
predetermin
rule
result
need
manual
review
interpret
held
back
final
verif
result
perform
technologist
within
li
reagent
need
consum
could
preload
instrument
elimin
need
repeatedli
load
consum
sampl
run
key
qualiti
indic
includ
tat
continu
monitor
throughout
implement
data
monitor
signific
chang
improv
patient
care
goliv
date
resultsfind
averag
number
outlier
decreas
per
month
benefit
includ
reduct
number
technologist
need
perform
ty
test
addit
reduc
wast
due
better
util
suppli
instrument
along
less
repeat
test
result
project
cost
save
fiscal
year
conclus
use
gel
technolog
combin
two
way
interfac
continu
load
instrument
result
signific
decreas
tat
manual
gel
method
improv
time
report
final
product
cultur
result
patient
emr
barbara
hewitt
dartmouth
hitchcock
medic
center
backgroundcas
studi
certain
transfus
reaction
requir
cultur
return
blood
product
perform
cultur
report
cerner
oper
system
result
cross
patient
emr
final
product
cultur
result
enter
patient
emr
addendum
transfus
reaction
clinic
note
review
transfus
reaction
databas
reveal
occas
final
product
cultur
result
enter
patient
emr
time
manner
import
patient
care
transfus
medicin
servic
patient
primari
provid
know
transfus
reaction
relat
contamin
product
patient
gener
overal
health
inform
also
crucial
supplier
product
determin
other
receiv
compon
affect
unit
possibl
determin
qualiti
control
issu
donor
facil
studi
designmethod
review
specif
month
period
reveal
timefram
final
product
cultur
result
enter
patient
emr
rang
day
mean
day
determin
interest
improv
patient
care
collabor
laboratori
inform
servic
report
creat
product
cultur
result
final
email
would
gener
notifi
medic
director
transfus
safeti
offic
result
avail
resultsfind
data
collect
month
follow
implement
report
note
timeli
final
product
cultur
result
enter
patient
emr
improv
rang
day
mean
day
conclus
improv
patient
care
requir
dilig
time
report
final
cultur
report
determin
potenti
caus
transfus
reaction
process
made
easier
correct
tool
use
omer
ilya
randi
levin
northwel
health
lenox
hill
hospit
backgroundcas
studi
transfus
nonirradi
blood
patient
hematolog
malign
receiv
cytotox
chemotherapi
result
lifethreaten
graft
versu
host
diseas
gvhd
note
sever
instanc
nonirradi
blood
transfus
patient
requir
irradi
blood
design
qualiti
improv
project
educ
session
involv
oncolog
unit
blood
bank
studi
designmethod
project
separ
three
part
first
part
data
transfus
practic
retrospect
collect
four
month
period
oncolog
unit
variabl
collect
includ
date
time
transfus
preand
posttransfus
hemoglobin
patient
diagnos
whether
blood
order
irradi
whether
irradi
blood
issu
blood
bank
patient
hematolog
malign
patient
receiv
cytotox
chemotherapi
candid
irradi
blood
second
part
project
educ
intervent
resid
oncolog
floor
nurs
blood
bank
staff
given
lectur
import
transfus
irradi
blood
oncolog
floor
resid
also
instruct
order
irradi
blood
patient
oncolog
unit
third
part
project
repeat
data
collect
two
month
period
assess
whether
intervent
success
resultsfind
preintervent
unit
transfus
oncolog
floor
unit
requir
irradi
unit
order
irradi
sinc
blood
bank
occasion
issu
irradi
blood
without
specif
order
addit
irradi
unit
issu
postintervent
unit
transfus
oncolog
floor
unit
requir
irradi
unit
order
irradi
specif
prevent
gvhd
eight
addit
irradi
unit
order
requir
irradi
thu
total
unit
order
irradi
addit
irradi
unit
issu
without
specif
order
blood
bank
result
summar
accompani
tabl
conclus
qualiti
improv
project
demonstr
educ
intervent
succeed
chang
clinic
practic
continu
monitor
order
practic
ensur
complianc
continu
plan
expand
qualiti
improv
project
set
includ
emerg
depart
surgic
floor
expect
adher
transfus
guidelin
patient
popul
reduc
incid
advers
event
samantha
ngamsuntikul
charlott
van
dyke
dina
garza
van
hoos
rachel
beddard
biobridg
global
south
texa
blood
tissu
center
backgroundcas
studi
blood
center
apheresi
platelet
red
cell
collect
trima
accel
doubl
red
cell
haemonet
addit
routin
qualiti
control
qc
qc
perform
instrument
flag
collect
instrument
qualiti
control
apheresi
platelet
includ
volum
varianc
rwbc
qualiti
control
apheresi
red
cell
includ
product
volum
volum
varianc
hemoglobin
red
blood
cell
mass
studi
designmethod
period
januari
april
total
collect
flag
addit
qc
trima
accel
haemonet
instrument
qualiti
control
center
track
qualiti
control
softwar
manag
system
hematerra
hemacompli
allow
abil
track
retriev
inform
major
product
flag
instrument
qc
pass
releas
distribut
small
percentag
howev
fail
qc
lead
loss
product
qualiti
control
data
retriev
monitor
trend
use
qualiti
control
softwar
manag
system
backgroundcas
studi
center
medicar
medicaid
servic
cm
roll
plan
implement
iqcp
individu
qualiti
control
plan
new
qualiti
control
option
base
risk
manag
plan
clia
laboratori
perform
nonwaiv
test
plan
meant
clia
approv
test
serv
good
tool
lab
perform
nontradit
tradit
test
nontradit
sampl
studi
designmethod
clia
clinic
laboratori
either
follow
tradit
clinic
clia
qc
requir
accord
regul
implement
iqcp
perfrom
tradit
qc
assess
test
perfrom
cellular
product
decid
implement
iqcp
program
within
qualiti
control
laboratori
follow
iqcp
process
assess
qc
test
use
assess
safeti
puriti
potenc
cell
base
product
one
test
particular
appli
tool
review
qc
steril
test
method
found
use
improv
overal
process
tool
walk
three
process
requir
risk
assess
qualiti
control
plan
qualiti
assess
preanalyt
analyt
post
analyt
phase
test
abstract
conclus
integr
iqcp
qualiti
control
laboratori
determin
success
iqcp
tool
success
identifi
gap
within
steril
test
process
tool
use
addit
qualiti
control
test
manufactur
process
implement
iqcp
program
ensur
regulatori
qc
requir
appropri
test
perform
abl
revis
procedur
reeduc
involv
process
hope
minim
potenti
sourc
error
object
perform
massiv
transfus
protocol
singl
institut
gustaaf
de
ridder
rachel
jug
kimberli
ingersol
nichola
bandarenko
nicol
guinn
jessica
poisson
duke
health
patholog
duke
univers
hospit
duke
health
anesthesiolog
backgroundcas
studi
hemorrhag
lead
caus
mortal
trauma
patient
morbid
nontrauma
patient
use
balanc
transfus
ratio
tr
massiv
resuscit
recommend
base
trauma
data
object
perform
massiv
transfus
protocol
mtp
activ
poorli
studi
may
differ
base
site
medic
servic
mtp
initi
impend
releas
unifi
redesign
exsanguin
protocol
exp
institut
establish
baselin
perform
characterist
exist
mtp
obstetr
massiv
transfus
protocol
obp
studi
designmethod
follow
institut
review
board
approv
perform
retrospect
studi
blood
product
util
outcom
mtp
obp
activ
juli
data
manual
collect
transfus
servic
paper
record
electron
safetrac
record
autom
data
report
electron
medic
record
epic
conclus
observ
consider
variabl
transfus
practic
acut
hemorrhag
depend
servic
locat
activ
trauma
activ
demonstr
sharpest
deficit
platelet
transfus
wherea
group
lag
somewhat
transfus
plasma
rel
pack
red
blood
cell
lo
mortal
vari
among
group
like
reflect
underli
medic
condit
indic
massiv
transfus
identifi
opportun
improv
mtp
transfus
ratio
observ
trauma
case
specif
environ
ratio
deriv
impact
protocoldriven
blood
resuscit
efficaci
patient
identif
improv
strategi
help
reduc
unaccept
specimen
arlin
stein
nanci
nikoli
linda
benison
ruthmir
thelusca
rene
liberti
sherri
shariatmadar
alexand
indrikov
vishesh
chhibber
north
shore
univers
hospit
northwel
health
backgroundcas
studi
blood
bank
bb
process
approxim
specimen
per
year
bb
specimen
unaccept
unlabel
unsign
miss
necessari
document
case
new
specimen
request
drawn
per
protocol
investig
unaccept
specimen
previous
includ
gener
report
blood
bank
staff
subsequ
submit
bb
supervisor
complet
follow
complet
report
sent
nurs
manag
patient
care
unit
pcu
followup
investig
staff
member
involv
process
cumbersom
take
day
staff
member
pcu
alert
deviat
protocol
time
resid
float
staff
involv
difficult
identifi
often
challeng
track
staff
necessari
investig
inservic
studi
designmethod
june
patient
identif
improv
strategi
implement
jointli
depart
nurs
bb
address
mislabel
unlabel
unsign
specimen
part
patient
safeti
initi
current
follow
strategi
unaccept
specimen
receiv
nurs
manag
nm
pcu
immedi
notifi
bb
staff
nm
promptli
initi
debrief
process
staff
involv
draw
specimen
debrief
form
tool
creat
guid
discuss
process
follow
nm
also
engag
avail
staff
huddl
review
incid
reinforc
polici
debrief
form
submit
hospit
qa
bb
prevent
action
includ
believ
use
cultur
model
help
us
understand
reason
staff
label
specimen
accord
polici
cultur
help
promot
share
account
ensur
proper
system
process
place
deliv
high
qualiti
care
resultsfind
tabl
repres
percentag
unaccept
specimen
identifi
bb
sinc
second
quarter
implement
new
process
led
decreas
number
unaccept
specimen
quarterli
follow
implement
opportun
direct
intervent
nm
staff
involv
risen
due
immedi
debrief
process
abstract
conclus
patient
identif
improv
strategi
allow
real
time
engag
bb
pcu
staff
promptli
investig
institut
correctiveprevent
action
deviat
polici
relat
specimen
collect
heighten
awar
correct
patient
specimen
label
error
improv
patient
safeti
patient
experi
platelet
transfus
practic
among
pediatr
oncolog
patient
singl
institut
experi
nicol
crew
morgan
rockwel
joseph
hagan
jun
teruya
shiuki
hui
texa
children
hospit
baylor
colleg
medicin
backgroundcas
studi
despit
advanc
adult
platelet
transfus
ptx
literatur
question
persist
regard
pediatr
transfus
threshold
dosag
respons
therefor
ptx
commonli
guid
local
institut
recommend
ir
aim
studi
determin
degre
adher
ptx
practic
ir
pediatr
tertiari
institut
studi
designmethod
retrospect
review
ptx
practic
includ
transfus
threshold
respons
dosag
collect
platelet
count
within
hour
pre
post
transfus
evalu
patient
year
receiv
prophylact
ptx
juli
decemb
admit
oncolog
acut
care
unit
diagnosi
leukemia
lymphoma
includ
prevent
volum
overload
ir
ptx
patient
one
apheresi
unit
au
patient
therefor
patient
separ
group
kg
kg
signific
proport
order
kg
kg
meet
patient
platelet
threshold
criteria
p
conclus
ptx
threshold
ir
group
kg
kg
common
reason
ir
threshold
invas
procedur
low
molecular
weight
heparin
therapi
greater
ptx
dosag
group
ir
howev
platelet
respons
increas
significantli
p
higher
dose
vs
ir
dose
studi
demonstr
still
consider
deviat
ir
ptx
practic
among
pediatr
oncolog
patient
addit
fals
assumpt
higher
dose
yield
better
respons
put
patient
increas
risk
transfus
relat
advers
event
institut
conduct
qualiti
assur
review
determin
ptx
practic
presurg
sampl
process
improv
enhanc
patient
safeti
complianc
lisa
mari
button
stephani
saathoff
jere
luedk
benjamin
colvin
umalkair
amar
jame
r
stubb
mayo
clinic
backgroundcas
studi
institut
provid
option
presurg
sampl
pss
drawn
day
prior
surgeri
long
patient
report
transfus
blood
blood
compon
contain
allogen
red
cell
pregnant
preced
month
date
pss
collect
pss
patient
return
surgeri
patient
servic
requir
ask
patient
transfus
pregnanc
histori
determin
new
opportun
allogen
red
cell
exposur
howev
process
captur
inform
patient
report
time
pss
draw
day
surgeryposs
transfus
studi
designmethod
electron
fix
design
appli
surgic
intak
process
new
set
question
ad
admit
questionnair
must
complet
prior
patient
surgic
procedur
question
ask
patient
pregnant
transfus
preced
three
month
answer
affirm
comput
system
run
blaze
rule
caus
alert
blood
bank
blood
bank
tech
review
alert
inactiv
patient
pss
base
new
transfusionpregnani
inform
one
year
postimplement
electron
fix
transfus
lab
perform
retrospect
review
pss
alert
gener
threemonth
period
resultsfind
result
review
analyz
display
tabl
determin
patient
pss
alert
activ
sampl
requir
inactiv
conclus
implement
electron
solut
requir
document
pss
elig
upon
return
surgeri
result
estim
pss
alert
blood
bank
year
alert
estim
approxim
patient
per
year
identifi
longer
elig
pss
statu
retrospect
review
perform
share
project
stakehold
determin
electron
questionnair
could
tailor
patient
base
age
gender
pss
statu
benefit
fewer
fals
posit
pss
alert
recogn
ideal
futur
state
compat
institut
current
project
implement
new
electron
medic
record
emr
system
safeti
enhanc
provid
current
electron
fix
remain
improv
suggest
share
team
creat
paramet
new
emr
intent
target
patient
activ
pss
blood
bank
rather
surgic
patient
weill
cornel
medicin
columbia
univers
school
medicin
backgroundcas
studi
blood
order
complex
highrisk
process
multipl
step
potenti
error
delay
risk
associ
process
order
pickup
requir
evalu
strategi
mitig
given
complex
highrisk
natur
blood
order
proactiv
risk
assess
pra
blood
product
order
use
fmea
methodolog
conduct
goal
project
proactiv
assess
effect
redesign
electron
order
set
qualiti
safeti
blood
order
studi
designmethod
evalu
electron
blood
order
redesign
process
pra
complet
use
fmea
methodolog
team
identifi
step
substep
electron
blood
order
process
failur
mode
caus
score
sever
occurr
detect
determin
risk
prioriti
number
rpn
rpn
score
threshold
review
rescor
base
mitig
strategi
design
address
failur
mode
resultsfind
group
score
identifi
failur
mode
categori
use
root
caus
analys
electron
blood
order
process
intern
logic
alert
improv
commun
reduc
risk
score
sever
mitig
strategi
reduc
risk
identifi
failur
mode
includ
type
screen
statu
within
rbc
order
streamlin
alert
order
meet
laboratori
threshold
nurs
task
list
transfus
chang
pickup
process
link
product
readi
statu
laboratori
inform
system
transfus
histori
avail
provid
order
blood
product
reduc
commun
risk
categori
failur
mode
includ
clinic
commun
equip
peopl
process
system
averag
overal
failur
mode
rpn
reduc
commun
categori
averag
rpn
greatest
reduct
conclus
fmea
electron
blood
order
process
proactiv
improv
qualiti
patient
safeti
prevent
transfus
delay
error
blood
product
administr
accur
time
inform
blood
order
process
potenti
reduc
risk
associ
order
prepar
dispens
blood
reduc
turn
around
time
type
screen
blood
bank
kimberli
ouellett
karen
king
joseph
sweeney
rhode
island
hospit
lifespan
academ
medic
center
backgroundcas
studi
expediti
turnaround
time
tat
blood
bank
critic
provid
fulli
test
crossmatch
compat
blood
time
manner
blood
bank
rhode
island
hospit
level
trauma
center
teach
hospit
associ
brown
univers
origin
design
accommod
tube
test
technologist
origin
setup
lab
split
three
section
allow
prepar
issu
unit
first
section
bench
test
second
receipt
compon
third
technolog
chang
blood
bank
adopt
first
manual
gel
station
autom
gel
system
ortho
provuev
r
adapt
space
second
section
blood
bank
contain
manual
subsequ
autom
gel
station
chang
process
sampl
receipt
complet
test
issu
unit
remain
segment
ineffici
averag
tat
type
screen
minut
studi
designmethod
blood
bank
design
remodel
make
open
concept
allow
collabor
amongst
technologist
well
best
use
space
technolog
first
section
tabl
remov
replac
center
consol
allow
movement
entir
front
laboratori
wall
construct
separ
main
work
flow
autom
gel
test
issu
unit
area
complic
workup
inventori
receipt
third
section
remain
repurpos
teach
medic
technolog
student
resid
addit
remodel
blood
bank
retir
ortho
provuev
r
ortho
visionv
r
consid
true
continu
feed
machin
although
interdevic
tat
significantli
differ
minut
provuev
r
visionv
r
visionv
r
built
schedul
effect
handl
system
process
sampl
effici
visionv
r
also
equip
two
centrifug
process
sampl
reduc
tat
multipl
sampl
onboard
bidirect
interfac
design
allow
test
order
type
screen
go
visionv
r
test
result
go
directli
visionv
r
li
without
need
manual
order
test
transmit
result
data
tat
collect
analyz
use
independ
test
chi
squar
resultsfind
mean
tat
preand
postreconfigur
implement
ortho
visionv
r
fraction
sampl
tat
minut
shown
tabl
result
show
reduct
tat
minut
reduct
tat
greater
minut
conclus
combin
new
technolog
space
remodel
lead
signific
reduct
tat
test
blood
bank
caleb
weishin
cheng
lorna
orengo
moniqu
scott
christoph
tormey
yale
univers
school
medicin
yalenew
hospit
va
connecticut
healthcar
backgroundcas
studi
type
screen
fundament
laboratori
test
allow
blood
bank
provid
compat
blood
patient
despit
erron
blood
product
administr
may
occur
much
blood
transfus
prevent
error
adequ
specimen
lack
hemolysi
proper
specimen
label
necessari
otherwis
specimen
reject
lead
second
blood
draw
delay
medicalsurg
manag
hemolysi
rate
specimen
report
high
prior
intervent
may
potenti
reduc
littl
howev
littl
publish
data
nonhemolysisrel
type
screen
reject
initi
undertaken
reduc
reject
rate
blood
bank
sustain
rate
particular
emphasi
nonhemolysisassoci
form
reject
studi
designmethod
root
caus
analysi
rca
perform
preced
month
obtain
baselin
understand
error
involv
submiss
facil
involv
standard
complet
specimen
label
plu
complet
uniqu
wit
form
confirm
ident
patient
specimen
collect
specimen
wit
form
must
submit
simultan
specimen
reject
record
patient
name
medic
record
number
reason
reject
follow
rca
intervent
creat
resolv
common
issu
document
result
reject
approv
intervent
grant
depart
chair
transfus
committe
form
committe
medic
execut
committe
implement
prospect
data
collect
sever
month
manner
determin
effect
intervent
resultsfind
studi
period
reject
rate
averag
reason
specimen
reject
divid
group
hemolysi
blood
bank
wit
collect
form
error
quantiti
suffici
abstract
duplic
sampl
specimen
tube
label
error
highest
percentag
reject
due
improperlyfil
wit
form
tabl
multipl
form
redesign
approv
appropri
committe
new
form
implement
preliminari
data
collect
thu
far
demonstr
reject
rate
reject
relat
wit
form
error
conclus
reject
specimen
impedi
safe
clinic
care
may
delay
medicalsurg
manag
reject
rate
could
reduc
simplif
blood
bank
specimen
collect
form
care
provid
multipl
task
need
perform
short
amount
time
therefor
simplif
often
time
necessari
reduc
human
error
futur
qualiti
initi
aim
simplifi
complex
healthcar
process
without
compromis
patient
care
reduct
fail
whole
blood
donor
test
run
roch
coba
system
christoph
shahan
christina
dejesu
mosi
mccall
fallon
hampton
tangi
her
judi
davi
anjali
patel
sonya
gomillion
bonni
maltbi
qualtex
laboratori
qualtex
laboratori
backgroundcas
studi
part
qualiti
control
program
track
number
technician
relat
fail
run
observ
roch
coba
system
system
use
test
whole
blood
donor
sampl
human
immunodefici
viru
hiv
rna
hepat
c
viru
hcv
rna
hepat
b
viru
hbv
dna
west
nile
viru
wnv
rna
technician
relat
fail
test
run
caus
laboratori
report
result
outsid
contractu
hour
turnaround
time
fail
run
also
caus
retest
increas
reagent
util
system
current
whole
blood
donor
test
turnaround
time
delay
due
issu
fail
run
system
technician
relat
failur
per
week
lean
six
sigma
approach
process
improv
util
identifi
root
caus
develop
countermeasur
order
decreas
number
technician
relat
failur
system
studi
designmethod
number
technician
relat
fail
run
system
track
thru
pareto
chart
use
determin
technician
relat
error
largest
control
factor
caus
run
failur
whi
perform
determin
root
caus
technician
relat
fail
run
gemba
walk
perform
lab
test
process
help
identifi
area
improv
process
improv
team
talk
met
observ
work
directli
staff
oper
system
roch
also
contact
provid
guidanc
help
decreas
technician
relat
failur
resultsfind
main
root
caus
determin
current
process
flow
map
whole
blood
donor
test
use
system
counter
measur
implement
includ
creat
two
phase
process
map
one
phase
relat
process
relat
startup
system
second
phase
relat
process
involv
process
sampl
roch
provid
job
aid
technician
provid
clear
step
technician
take
handl
clean
crash
fail
run
system
counter
measur
implement
number
technician
relat
fail
run
decreas
failur
per
week
decreas
conclus
lean
six
sigma
approach
process
improv
util
identifi
root
caus
develop
countermeasur
order
decreas
number
technician
relat
fail
run
coba
system
lean
six
sigma
approach
counter
measur
significantli
decreas
number
technician
relat
fail
run
patient
transfus
pretransfus
hgb
result
posttransfus
hgb
review
demograph
medic
histori
provid
ident
indic
transfus
complic
abstract
compil
individu
volunt
intern
medicin
resid
group
discuss
case
ensu
determin
transfus
appropri
occur
princip
investigatorattend
physician
made
final
determin
appropri
rbc
transfus
resultsfind
patient
chart
review
exclud
bleed
cardiovascular
instabl
determin
transfus
inappropri
differ
appropri
transfus
respect
age
sex
patient
solid
tumor
vs
anemia
chronic
diseas
vs
like
inappropri
transfus
patient
higher
pretransfus
hemoglobin
like
inappropri
transfus
median
hgb
gdl
vs
gdl
p
inappropri
transfus
patient
also
higher
median
posttransfus
hemoglobin
gdl
vs
gdl
p
moreov
lab
evalut
reveal
associ
lower
folat
level
median
nmoll
vs
nmoll
patient
inappropri
transfus
least
part
receiv
one
unit
without
interv
hemoglobin
check
provid
respons
inappropri
transfus
appropriatelytransfus
patient
experienc
fnhtr
death
unrel
transfus
occur
appropri
inappropri
group
conclus
physician
train
interest
promulg
optim
rbc
transfus
practic
studi
identifi
patient
factor
solid
tumor
anemia
chronic
diseas
correl
higher
likelihood
receiv
inappropri
transfus
beyond
cpoe
educ
intervent
individu
level
design
specif
provid
respons
inappropri
transfus
success
implement
blood
bank
inform
system
smallscal
caribbean
blood
bank
structur
stepwis
approach
luigi
sill
willem
martin
smid
ashley
john
duit
red
cross
blood
bank
foundat
sanquin
consult
servic
backgroundcas
studi
import
tool
compli
gmp
qualiti
standard
effect
use
blood
bank
inform
system
bi
valid
implement
bi
describ
central
larg
blood
bank
literatur
guidelin
lack
nonautom
small
scale
blood
bank
environ
smallscal
blood
bank
face
specif
challeng
computer
relat
economi
scale
exist
process
requir
special
attent
introduct
bi
blood
bank
dutch
caribbean
island
specif
procedur
design
base
exist
guidelin
adapt
local
set
studi
designmethod
red
cross
blood
bank
foundat
sole
provid
labil
blood
compon
dutch
caribbean
island
bonair
sint
maarten
select
bi
provid
implement
isbt
bcsh
guidelin
valid
inform
system
blood
establish
care
analyz
prepar
design
local
procedur
procedur
meant
evalu
valid
featur
bi
edelphyn
hemasoft
america
miami
usa
introduct
outcom
approach
enter
worksheet
evalu
implement
team
manag
implement
plan
design
implement
extern
auditor
sanquin
consult
servic
amsterdam
netherland
invit
evalu
implement
valid
plan
practic
implement
evalu
perform
accord
risk
assess
critic
process
step
resultsfind
base
isbt
bcsh
guidelin
process
flow
chart
describ
relev
phase
critic
step
introduct
valid
bi
design
comparison
current
process
procedur
compar
bi
characterist
make
use
worksheet
worksheet
exist
gap
bi
procedur
care
describ
gap
appropri
procedur
chang
bi
blood
bank
effectu
worksheet
also
provid
basi
staff
train
separ
train
environ
bi
introduct
earli
valid
phase
procedur
process
audit
extern
auditor
feedback
expert
sever
improv
ad
valid
subsequ
implement
process
conclus
use
exist
intern
guidelin
valid
implement
plan
design
prepar
success
introduct
bi
small
scale
caribbean
blood
bank
program
design
seem
well
suit
small
scale
blood
bank
contempl
introduct
bi
time
cost
save
implement
remot
blood
fridg
jessica
peter
dee
dee
cassidi
jed
b
gorlin
nanci
l
van
buren
hennepin
counti
medic
center
innov
blood
resourc
backgroundcas
studi
rapid
deliveri
emerg
releas
group
red
blood
cell
rbc
vital
patient
care
commerci
remot
blood
fridg
packag
avail
larg
upfront
mainten
cost
implement
remot
blood
fridg
directli
emerg
depart
ed
use
counter
fridg
requir
id
access
selfdevelop
io
applic
scan
track
realtim
alert
transfus
servic
ts
product
use
dispens
prior
ed
fridg
implement
rbc
unit
verbal
request
ed
blood
runner
would
pick
return
cooler
given
ed
locat
separ
build
ts
meant
minut
may
requir
transit
unit
often
releas
less
minut
net
effect
provid
would
routin
order
product
ensur
bedsid
patient
arriv
precaut
return
requir
implement
blood
fridg
bedsid
result
predict
outcom
deliv
emerg
releas
rbc
quickli
observ
benefit
decreas
wast
staff
time
studi
designmethod
remot
blood
fridg
implement
juli
data
rbc
request
cooler
rbc
return
rbc
transfus
ed
collect
compar
baselin
data
includ
januari
post
chang
includ
august
juli
data
exclud
includ
pre
post
process
resultsfind
baselin
data
show
ed
request
averag
rbcmonth
cooler
post
chang
drop
rbcmonth
thu
less
blood
request
transfus
servic
cooler
unit
use
fridg
baselin
data
also
show
averag
rbcmonth
return
post
chang
averag
rbc
month
return
repres
absolut
reduct
number
return
product
rbc
dispens
return
take
approxim
minut
complet
paperwork
transport
therefor
chang
save
averag
minut
per
month
also
note
averag
rbcmonth
transfus
baselin
post
chang
confirm
decreas
request
return
due
decreas
patient
volum
sever
fridg
also
success
decreas
deliveri
time
blood
patient
bedsid
baselin
deliveri
time
minut
estim
reduc
minut
conclus
implement
remot
blood
fridg
move
blood
access
closer
patient
bedsid
ensur
faster
deliveri
blood
patient
chang
addit
benefit
decreas
wast
time
henc
cost
decreas
unnecessari
product
request
return
implement
blood
fridg
also
done
reduc
cost
homegrown
process
transfus
everyday
procedur
patentappl
file
relat
transfus
medicin
relat
transfus
alarm
last
year
employ
numer
technic
set
aim
support
autom
supervis
mention
action
aim
contribut
present
develop
lowcost
realtim
individu
intraven
bloodtransfus
monitor
system
base
internet
thing
studi
designmethod
design
system
base
commerci
avail
pantiltzoom
ptz
camera
employ
inch
color
cmo
sensor
provid
effect
mp
mm
len
ircut
daynight
minimum
illumin
luxf
view
angl
camera
focus
droplet
act
visir
detector
hz
samplingr
customdevelop
softwar
support
droplet
ratemonitor
caus
acoust
alarmsign
necessari
eg
clot
blood
transfus
vol
supplement
abstract
suspens
deplet
etc
enabl
necessari
wideangl
imagecaptur
video
imageaudio
set
provid
compress
video
frame
rate
fp
refresh
rate
hz
audio
input
bidirect
builtin
microphon
acquir
ipaddress
connect
mode
wireless
network
interfac
support
protocol
includ
dhcp
tcpip
upnp
http
smtp
provid
typic
powersuppli
size
weigh
g
client
softwar
requir
ir
rang
ircut
filter
remot
access
dual
stream
motion
detect
daynight
ir
night
vision
distanc
offer
twoway
radiolink
provid
well
transflash
tf
record
storag
gb
sdcard
pantilthorizont
pantiltvert
movement
perform
system
facilit
need
also
patient
posit
monitor
read
monitor
display
nibp
ecg
spo
present
resultsfind
system
present
test
laboratori
nonclin
environ
simul
virtual
patient
custommad
phantom
combin
flowrat
neg
pressur
viscos
resist
regul
conclus
system
measur
infusionspe
deviat
lower
develop
iotsystem
take
advantag
exist
hospit
wifi
network
environ
offer
lowcost
solut
monitoringset
allow
even
multiplatform
io
android
window
smartphon
shortrang
connect
particip
exampl
nurs
physician
etc
two
potenti
approach
qualiti
control
bactalertv
r
cultur
media
use
variou
biobal
tm
organ
prepar
patricia
rule
michel
keener
christin
crawford
biomerieux
inc
backgroundcas
studi
bactalertv
r
bpa
bpn
cultur
bottl
use
bactalert
microbi
detect
system
rapid
screen
detect
microbi
contamin
leukocyt
reduc
apheresi
platelet
lrap
recent
chang
clia
qualiti
control
guidelin
aabb
accredit
program
requir
addit
qualiti
control
manufactur
media
lot
specif
shipment
specif
ensur
recoveri
bacteri
growth
studi
conduct
use
commerci
prepar
organ
evalu
comprehens
organ
panel
well
streamlin
method
util
two
organ
panel
studi
designmethod
gener
protocol
consist
three
replic
organ
inocul
two
lot
bpa
bpn
two
differ
analyst
studi
two
part
aspergillu
brasiliensi
candida
albican
bacillu
subtili
subsp
spizizenii
pseudomona
aeruginosa
escherichia
coli
clostridium
sporogen
staphylococcu
aureu
streptococcu
pyogen
prepar
biobal
singleshot
cfu
multishot
cfu
highdos
organ
prepar
low
level
cfu
evalu
day
prepar
method
valid
second
part
studi
util
escherichia
coli
staphylococcu
aureu
prepar
frozen
higher
level
evalut
day
studi
stream
line
approach
routin
qualiti
control
test
bactalert
cultur
bottl
inocul
prepar
enumer
duplic
confirm
level
inocul
time
point
inocul
bpa
bpn
bottl
load
bactalert
microbi
detect
system
c
automat
monitor
growth
neg
bpa
bpn
bottl
includ
duplic
day
test
resultsfind
escherichia
coli
staphylococcu
aureu
streptoococcu
pyogen
bacillu
subtili
subsp
spizizenii
posit
bpa
bpn
cultur
bottl
aerob
aspergillu
brasiliensi
candida
albican
pseudomona
aeruginosa
grew
report
posit
bpa
aerob
cultur
bottl
expect
oblig
anaerob
clostridium
sporogen
posit
anaerob
bpn
cultur
bottl
bacteri
cultur
posit
bactalert
bpa
bpn
bottl
day
fungal
organ
day
overal
agreement
bottl
test
signific
differ
observ
time
detect
differ
lot
differ
analyst
conclus
biobal
prepar
organ
demonstr
reproduc
method
comprehens
streamlin
approach
qualiti
control
bactalert
bpa
bpn
cultur
media
method
simpl
requir
addit
microbi
prepar
storag
live
organ
laboratori
use
electron
patient
identif
system
blood
bank
specimen
label
found
superior
histor
armband
approach
anni
newton
dian
schafer
debra
brown
jess
cox
scott
koepsel
sara
shunkwil
nebraska
medicin
nebraska
medic
center
univers
nebraska
medic
center
backgroundcas
studi
anticip
implement
new
th
addit
aabb
standard
concern
confirm
patient
abo
blood
type
type
screen
crossmatch
specimen
perform
prior
issu
crossmatch
blood
product
laboratori
organiz
leadership
evalu
practic
applic
electron
patient
identif
system
label
blood
bank
specimen
collect
versu
tradit
use
blood
bank
armband
continu
use
armband
would
requir
second
sampl
abo
confirm
patient
histor
blood
type
file
concern
rais
regard
amount
increas
workload
staff
delay
result
avail
base
number
increas
specimen
would
gener
well
potenti
increas
iatrogen
blood
loss
patient
dissatisfact
moreov
nd
sampl
collect
alon
would
improv
rate
mislabel
specimen
observ
supplementari
concern
studi
designmethod
current
organ
employ
electron
patient
identif
system
label
laboratori
specimen
collect
made
feasibl
appli
technolog
blood
bank
well
indepth
evalu
includ
failur
mode
effect
analysi
fmea
span
sever
day
complet
ensur
use
electron
system
would
produc
compar
superior
safeti
result
armband
counterpart
altern
process
specimen
label
abo
confirm
would
satisfi
new
standard
establish
support
care
area
capabl
use
electron
system
extens
educ
provid
staff
physician
advanc
practic
provid
phlebotomist
nurs
ensur
comprehens
well
ration
new
process
alert
congruent
built
electron
health
record
ehr
supplement
inform
regard
crossmatch
test
expir
may
readili
avail
elimin
armband
use
resultsfind
within
day
implement
new
process
septemb
notic
reduct
amount
mislabel
blood
bank
specimen
receiv
total
month
post
implement
compar
month
prior
addit
vast
major
specimen
receiv
blood
bank
henceforth
collect
label
use
electron
system
thu
reduc
amount
potenti
nd
specimen
collect
need
abo
confirm
conclus
use
electron
patient
identif
system
label
blood
bank
specimen
collect
lieu
tradit
blood
bank
armband
proven
improv
patient
safeti
depart
effici
substanti
reduc
occurr
mislabel
specimen
negat
need
nd
specimen
collect
reduc
potenti
iatrogen
blood
loss
improv
patient
satisfact
backgroundcas
studi
base
small
randomis
control
trial
rct
perform
late
earli
intraven
immunoglobulin
ivig
use
suggest
potenti
treatment
avoid
exchang
transfus
et
rh
hemolyt
diseas
newborn
hdn
treatment
modal
routin
use
rhhdn
extend
hdn
caus
abo
incompat
red
blood
cell
antibodi
howev
larger
rct
perform
sinc
shown
prophylact
ivig
reduc
need
et
durat
hyperbilirubinemia
maximum
bilirubin
level
need
topup
red
blood
cell
transfus
primari
object
studi
describ
usag
ivig
hdn
tertiari
academ
referr
hospit
studi
designmethod
retrospect
chart
review
perform
neonat
receiv
ivig
hdn
neonat
intens
care
unit
nicu
januari
june
data
collect
includ
patient
demograph
featur
diagnosi
indic
ivig
neonat
laboratori
result
treatment
detail
advers
event
patient
outcom
resultsfind
ninetyseven
neonat
receiv
ivig
studi
period
femal
less
week
gestat
age
none
coexist
defici
pyruv
kinas
defici
spherocytosi
neonat
receiv
phototherapi
prior
ivig
treatment
indic
ivig
abohdn
rhesushdn
antibodi
often
implic
rhhdn
antid
antid
antic
antic
sixteen
infant
rhhdn
receiv
intrauterin
transfus
mean
cumul
dose
ivig
gkg
rang
gkg
gkg
neonat
receiv
one
four
ivig
administr
tabl
show
number
patient
receiv
ivig
two
time
period
three
advers
reaction
note
ivig
administr
cutan
rash
hypotens
fever
neonat
requir
et
rhhdn
abohdn
fortyf
patient
need
topup
transfus
hospitalis
three
month
age
abohdn
rhhdn
mean
number
transfus
three
conclus
although
initi
describ
rhhdn
abohdn
one
frequent
indic
ivig
neonat
optim
use
ivig
abohdn
need
better
character
studi
show
wide
variat
ivig
dose
signific
proport
neonat
requir
topup
transfus
research
requir
evalu
whether
anemia
abohdn
might
exacerb
hemolysi
ivig
isohemagglutinin
dosedepend
backgroundcas
studi
background
one
seriou
advers
reaction
transfus
develop
graft
versu
host
diseas
symptom
includ
develop
characterist
cutan
rash
enter
often
result
wateri
diarrhea
elev
liver
function
test
ultim
pancytopenia
clinic
cours
rapid
case
fatal
rate
patient
popul
risk
reason
welldefin
includ
patient
immunocompromis
due
diseas
process
therapi
fetu
low
birthweight
neonat
recipi
hlamatch
cellular
blood
product
recipi
cellular
blood
product
donat
blood
rel
basic
etiolog
tagvhd
inabl
transfus
recipi
mount
effect
immun
respons
donor
tlymphocyt
treatment
option
tagvhd
ineffect
make
imper
cellular
blood
compon
irradi
prior
transfus
virtual
elimin
risk
complic
studi
designmethod
transfus
servic
inform
system
mechan
alert
transfus
servic
staff
patient
previous
identifi
need
irradi
blood
compon
howev
patient
identifi
transfus
servic
time
initi
hospit
visit
time
qualifi
diagnosi
patient
erron
receiv
nonirradi
blood
compon
follow
nearmiss
situat
hospit
inform
depart
develop
program
minim
risk
transfus
servic
notifi
patient
newli
requir
irradi
blood
compon
resultsfind
blood
product
order
system
redesign
includ
specif
queri
identifi
patient
requir
irradi
cellular
blood
product
first
physician
notifi
includ
need
blood
product
irradi
patient
problem
list
includ
list
transfus
servic
notifi
need
irradi
subsequ
transfus
order
problem
list
modifi
clinic
staff
second
irradi
blood
compon
ever
request
patient
alert
gener
order
physician
even
requir
irradi
product
includ
problem
list
final
system
automat
default
request
irradi
cellular
product
order
children
less
month
age
compli
local
irradi
polici
conclus
believ
approach
enhanc
includ
list
specif
diagnos
typic
requir
blood
product
irradi
within
comput
algorithm
believ
list
provid
addit
level
safeti
insur
patient
receiv
irradi
blood
compon
appropri
use
lab
inform
system
dynam
dashboard
label
track
cooler
russel
thorsen
rosalin
peter
suslow
gina
giannarelli
sara
bakhtari
ashok
nambiar
morvarid
moayeri
ucsf
health
backgroundcas
studi
tertiarycar
transfus
servic
routin
issu
blood
product
valid
cooler
high
acuiti
area
or
icu
cathlab
etc
cooler
also
use
emerg
releas
massiv
transfus
protocol
ship
product
differ
hospit
site
robot
hold
one
cooler
deliv
product
locat
serv
pneumat
tube
averag
cooler
issu
everi
day
cooler
setup
multistep
laborintens
process
transfus
servic
staff
track
cooler
locat
elaps
timeinus
notifi
clinic
team
returnrecharg
cooler
avoid
product
wastag
develop
lab
inform
system
li
base
solut
manag
cooler
label
track
effici
studi
designmethod
nine
cooler
test
batteri
built
batteri
rbc
plasma
platelet
cryoprecipit
ident
wherea
final
batteri
design
cooler
deliv
robot
contain
plasma
rbc
variabl
expir
time
slightli
differ
second
batteri
pair
built
avoid
duplic
test
cancel
li
second
cooler
compon
type
set
patient
batteri
consist
test
captur
follow
inform
cooler
locat
cooler
id
number
unit
issu
expir
custom
barcod
repres
test
batteri
differ
locat
scan
quickpick
list
avoid
need
manual
entri
cooler
return
final
entri
made
test
batteri
updat
li
dynam
cooler
track
dashboard
livefe
li
display
data
captur
test
batteri
elaps
time
start
cooler
setup
ident
time
cooler
batteri
order
li
captur
automat
color
code
alert
user
cooler
less
hour
expir
flash
alert
pop
cooler
expir
resultsfind
replac
manual
process
handwrit
patient
inform
expir
time
separ
tag
affix
one
tag
cooler
retain
second
one
track
cooler
locat
expir
novel
lisdriven
label
track
system
time
cooler
set
test
batteri
order
result
li
scan
relat
custom
barcod
singl
lisgener
label
print
attach
cooler
cooler
expir
default
hour
per
current
cooler
valid
time
test
batteri
order
cooler
set
tech
pay
attent
expir
product
place
cooler
individu
product
outdat
cooler
expir
time
inform
enter
test
batteri
get
display
dashboard
cooler
expir
time
distinct
systemdriven
countdown
colorcod
visual
display
alert
greatli
simplifi
cooler
monitor
elimin
manual
step
improv
staff
satisfact
conclus
use
li
cooler
setup
deploy
link
dynam
dashboard
display
cooler
locat
expir
time
make
cooler
manag
effici
tool
reduc
manual
step
decreas
likelihood
wastag
aid
cooler
track
